{
  "13734012||0||2": [
    0.10614556819200516,
    0.8783295750617981,
    0.01552482321858406
  ],
  "13734012||1||2": [
    0.0965159460902214,
    0.8878967761993408,
    0.015587292611598969
  ],
  "13734012||2||2": [
    0.10319370031356812,
    0.8895328640937805,
    0.007273480761796236
  ],
  "13734012||3||2": [
    0.019893616437911987,
    0.977959394454956,
    0.002147048246115446
  ],
  "13734012||4||2": [
    0.0985116958618164,
    0.7765727639198303,
    0.12491554021835327
  ],
  "13734012||5||2": [
    0.08127173781394958,
    0.8874476552009583,
    0.031280532479286194
  ],
  "13734012||6||2": [
    0.023367255926132202,
    0.9737953543663025,
    0.002837361767888069
  ],
  "13734012||7||2": [
    0.0071709733456373215,
    0.9913622736930847,
    0.0014668179210275412
  ],
  "13734012||8||2": [
    0.10574155300855637,
    0.8844977617263794,
    0.009760626591742039
  ],
  "13734012||0||5": [
    0.11988881975412369,
    0.8552921414375305,
    0.02481902204453945
  ],
  "13734012||1||5": [
    0.16811126470565796,
    0.8172469735145569,
    0.01464176457375288
  ],
  "13734012||2||5": [
    0.2403278350830078,
    0.743179440498352,
    0.01649278961122036
  ],
  "13734012||3||5": [
    0.06170934438705444,
    0.9343591332435608,
    0.003931532613933086
  ],
  "13734012||4||5": [
    0.3607800006866455,
    0.5902187824249268,
    0.04900122061371803
  ],
  "13734012||5||5": [
    0.50581955909729,
    0.471828430891037,
    0.0223519466817379
  ],
  "13734012||6||5": [
    0.029463447630405426,
    0.9664146900177002,
    0.004121917765587568
  ],
  "13734012||7||5": [
    0.06413676589727402,
    0.9289939403533936,
    0.006869315169751644
  ],
  "13734012||8||5": [
    0.12478885799646378,
    0.8610967993736267,
    0.014114356599748135
  ],
  "13734012||0||48": [
    0.1512478142976761,
    0.8440978527069092,
    0.00465439585968852
  ],
  "13734012||1||48": [
    0.054035723209381104,
    0.9430188536643982,
    0.0029454415198415518
  ],
  "13734012||2||48": [
    0.02929026447236538,
    0.968403697013855,
    0.002306064125150442
  ],
  "13734012||3||48": [
    0.6407184600830078,
    0.3523672819137573,
    0.006914168130606413
  ],
  "13734012||4||48": [
    0.6205917000770569,
    0.3659248948097229,
    0.01348343025892973
  ],
  "13734012||5||48": [
    0.15749794244766235,
    0.8377252817153931,
    0.004776765592396259
  ],
  "13734012||6||48": [
    0.04332491010427475,
    0.9550166130065918,
    0.0016584321856498718
  ],
  "13734012||7||48": [
    0.7265167832374573,
    0.26581236720085144,
    0.007670889142900705
  ],
  "13734012||8||48": [
    0.06782738119363785,
    0.9281859993934631,
    0.003986602649092674
  ],
  "22080671||0||15": [
    0.07435969263315201,
    0.9220542311668396,
    0.0035860815551131964
  ],
  "22080671||1||15": [
    0.1888371706008911,
    0.7950667142868042,
    0.01609610579907894
  ],
  "22080671||2||15": [
    0.006853042170405388,
    0.9922598004341125,
    0.0008871371392160654
  ],
  "22080671||3||15": [
    0.09235794097185135,
    0.8999655842781067,
    0.007676508743315935
  ],
  "22080671||4||15": [
    0.0832238644361496,
    0.9037949442863464,
    0.012981200590729713
  ],
  "22080671||5||15": [
    0.09754785895347595,
    0.8880331516265869,
    0.014418991282582283
  ],
  "22080671||0||139": [
    0.09189871698617935,
    0.8977102041244507,
    0.010391059331595898
  ],
  "22080671||1||139": [
    0.28677117824554443,
    0.6351739764213562,
    0.07805490493774414
  ],
  "22080671||2||139": [
    0.06485210359096527,
    0.9322882890701294,
    0.002859619678929448
  ],
  "22080671||3||139": [
    0.10600727051496506,
    0.8784324526786804,
    0.015560304746031761
  ],
  "22080671||4||139": [
    0.09419173747301102,
    0.841599702835083,
    0.06420855969190598
  ],
  "22080671||5||139": [
    0.16829335689544678,
    0.76105135679245,
    0.07065525650978088
  ],
  "22080671||0||258": [
    0.01106348354369402,
    0.986874520778656,
    0.0020619614515453577
  ],
  "22080671||1||258": [
    0.034388668835163116,
    0.9264969229698181,
    0.039114441722631454
  ],
  "22080671||2||258": [
    0.015692932531237602,
    0.9823216199874878,
    0.0019854502752423286
  ],
  "22080671||3||258": [
    0.5484219789505005,
    0.44128116965293884,
    0.01029678713530302
  ],
  "22080671||4||258": [
    0.00744747556746006,
    0.723423421382904,
    0.26912909746170044
  ],
  "22080671||5||258": [
    0.015589003451168537,
    0.9765784740447998,
    0.00783253088593483
  ],
  "22080671||0||663": [
    0.04181044548749924,
    0.951251208782196,
    0.0069383280351758
  ],
  "22080671||1||663": [
    0.12554971873760223,
    0.8475070595741272,
    0.026943162083625793
  ],
  "22080671||2||663": [
    0.036868054419755936,
    0.9556816220283508,
    0.007450375240296125
  ],
  "22080671||3||663": [
    0.04864976182579994,
    0.9093115329742432,
    0.0420386828482151
  ],
  "22080671||4||663": [
    0.021231910213828087,
    0.9656179547309875,
    0.013150135055184364
  ],
  "22080671||5||663": [
    0.00805972982198,
    0.6691703200340271,
    0.3227699398994446
  ],
  "22080671||0||689": [
    0.02951924316585064,
    0.963166356086731,
    0.007314399350434542
  ],
  "22080671||1||689": [
    0.3241358697414398,
    0.6394527554512024,
    0.036411356180906296
  ],
  "22080671||2||689": [
    0.003909007646143436,
    0.9951325058937073,
    0.000958403164986521
  ],
  "22080671||3||689": [
    0.017457274720072746,
    0.9685020446777344,
    0.014040699228644371
  ],
  "22080671||4||689": [
    0.055282238870859146,
    0.9186771512031555,
    0.026040632277727127
  ],
  "22080671||5||689": [
    0.11166263371706009,
    0.8724470734596252,
    0.015890296548604965
  ],
  "12670680||0||28": [
    0.7529624700546265,
    0.2153385877609253,
    0.03169896453619003
  ],
  "12670680||1||28": [
    0.8913698792457581,
    0.0645541399717331,
    0.04407588765025139
  ],
  "12670680||2||28": [
    0.932904064655304,
    0.05739433318376541,
    0.009701632894575596
  ],
  "12670680||3||28": [
    0.5314497351646423,
    0.40475353598594666,
    0.06379672139883041
  ],
  "12670680||4||28": [
    0.8534254431724548,
    0.1378779262304306,
    0.008696602657437325
  ],
  "12670680||0||172": [
    0.2527483403682709,
    0.41895121335983276,
    0.3283005356788635
  ],
  "12670680||1||172": [
    0.07068131864070892,
    0.4374156892299652,
    0.49190306663513184
  ],
  "12670680||2||172": [
    0.002121011493727565,
    0.11528429388999939,
    0.8825947046279907
  ],
  "12670680||3||172": [
    0.10654854774475098,
    0.881673276424408,
    0.011778191663324833
  ],
  "12670680||4||172": [
    0.003482552943751216,
    0.15646494925022125,
    0.8400524854660034
  ],
  "12670680||0||171": [
    0.8756441473960876,
    0.11876759678125381,
    0.005588196218013763
  ],
  "12670680||1||171": [
    0.9744857549667358,
    0.022191502153873444,
    0.00332274055108428
  ],
  "12670680||2||171": [
    0.9965923428535461,
    0.0027518391143530607,
    0.000655828567687422
  ],
  "12670680||3||171": [
    0.009144369512796402,
    0.9593116641044617,
    0.03154397010803223
  ],
  "12670680||4||171": [
    0.995055079460144,
    0.003943383693695068,
    0.0010014967992901802
  ],
  "24341590||0||30": [
    0.0023850256111472845,
    0.6046803593635559,
    0.3929345905780792
  ],
  "24341590||1||30": [
    0.0023987903259694576,
    0.9807901382446289,
    0.016811100766062737
  ],
  "24341590||2||30": [
    0.002581285545602441,
    0.7675941586494446,
    0.22982454299926758
  ],
  "24341590||3||30": [
    0.003060384886339307,
    0.7062305808067322,
    0.2907090485095978
  ],
  "24341590||4||30": [
    0.00989316962659359,
    0.899219274520874,
    0.09088751673698425
  ],
  "24341590||5||30": [
    0.0031703521963208914,
    0.8005979657173157,
    0.1962316632270813
  ],
  "24341590||6||30": [
    0.00666706170886755,
    0.834471583366394,
    0.15886132419109344
  ],
  "24341590||7||30": [
    0.0033191523980349302,
    0.9867788553237915,
    0.009902006946504116
  ],
  "24341590||8||30": [
    0.017249228432774544,
    0.9351239800453186,
    0.04762677475810051
  ],
  "24341590||9||30": [
    0.013559971004724503,
    0.5455048084259033,
    0.4409352242946625
  ],
  "24341590||10||30": [
    0.002471225569024682,
    0.7912750840187073,
    0.20625364780426025
  ],
  "24341590||11||30": [
    0.0033687972463667393,
    0.8928558230400085,
    0.10377535969018936
  ],
  "24341590||12||30": [
    0.008005211129784584,
    0.7571102380752563,
    0.234884575009346
  ],
  "24341590||13||30": [
    0.009247378446161747,
    0.29521632194519043,
    0.6955363154411316
  ],
  "24341590||0||1260": [
    0.07557978481054306,
    0.9194656610488892,
    0.004954518750309944
  ],
  "24341590||1||1260": [
    0.5048776865005493,
    0.48241719603538513,
    0.012705116532742977
  ],
  "24341590||2||1260": [
    0.8460109233856201,
    0.14833307266235352,
    0.005656010005623102
  ],
  "24341590||3||1260": [
    0.2607005536556244,
    0.729832649230957,
    0.009466765448451042
  ],
  "24341590||4||1260": [
    0.6306112408638,
    0.36226290464401245,
    0.007125868462026119
  ],
  "24341590||5||1260": [
    0.5950911045074463,
    0.3998224139213562,
    0.005086482968181372
  ],
  "24341590||6||1260": [
    0.8185688853263855,
    0.1766444742679596,
    0.0047865984961390495
  ],
  "24341590||7||1260": [
    0.7942348718643188,
    0.19935716688632965,
    0.0064079854637384415
  ],
  "24341590||8||1260": [
    0.2055862694978714,
    0.7849358916282654,
    0.009477821178734303
  ],
  "24341590||9||1260": [
    0.32937386631965637,
    0.5912106037139893,
    0.07941558957099915
  ],
  "24341590||10||1260": [
    0.613004744052887,
    0.35154855251312256,
    0.03544670715928078
  ],
  "24341590||11||1260": [
    0.7195560932159424,
    0.2662334740161896,
    0.01421038806438446
  ],
  "24341590||12||1260": [
    0.6461625099182129,
    0.33114102482795715,
    0.02269643172621727
  ],
  "24341590||13||1260": [
    0.9242965579032898,
    0.07191239297389984,
    0.0037909941747784615
  ],
  "24341590||0||1259": [
    0.02221108041703701,
    0.9757512807846069,
    0.002037585712969303
  ],
  "24341590||1||1259": [
    0.04331294447183609,
    0.9471729397773743,
    0.00951413344591856
  ],
  "24341590||2||1259": [
    0.025433802977204323,
    0.8431874513626099,
    0.13137879967689514
  ],
  "24341590||3||1259": [
    0.027587926015257835,
    0.967384397983551,
    0.005027660168707371
  ],
  "24341590||4||1259": [
    0.052878379821777344,
    0.9222028255462646,
    0.024918822571635246
  ],
  "24341590||5||1259": [
    0.048654649406671524,
    0.9455389380455017,
    0.005806343629956245
  ],
  "24341590||6||1259": [
    0.007851755246520042,
    0.8921064138412476,
    0.10004183650016785
  ],
  "24341590||7||1259": [
    0.0043009365908801556,
    0.9072679877281189,
    0.08843106776475906
  ],
  "24341590||8||1259": [
    0.05756025016307831,
    0.938502848148346,
    0.003936834167689085
  ],
  "24341590||9||1259": [
    0.12432514876127243,
    0.7566024661064148,
    0.11907241493463516
  ],
  "24341590||10||1259": [
    0.0061584338545799255,
    0.7877434492111206,
    0.20609815418720245
  ],
  "24341590||11||1259": [
    0.009299234487116337,
    0.8924721479415894,
    0.09822863340377808
  ],
  "24341590||12||1259": [
    0.041523125022649765,
    0.8677009344100952,
    0.09077594429254532
  ],
  "24341590||13||1259": [
    0.013388431631028652,
    0.8441945910453796,
    0.14241693913936615
  ],
  "13497630||0||39": [
    0.005325058940798044,
    0.6011177897453308,
    0.3935571312904358
  ],
  "13497630||1||39": [
    0.007158335298299789,
    0.6251220107078552,
    0.3677196204662323
  ],
  "13497630||2||39": [
    0.00829195324331522,
    0.6836776733398438,
    0.308030366897583
  ],
  "13497630||3||39": [
    0.01906384527683258,
    0.7062553763389587,
    0.2746807932853699
  ],
  "13497630||4||39": [
    0.04653584584593773,
    0.8619390726089478,
    0.09152509272098541
  ],
  "13497630||5||39": [
    0.06621566414833069,
    0.6893949508666992,
    0.2443893998861313
  ],
  "13497630||6||39": [
    0.009433669969439507,
    0.7595406770706177,
    0.23102566599845886
  ],
  "13497630||7||39": [
    0.003744036890566349,
    0.3538290560245514,
    0.6424269676208496
  ],
  "13497630||8||39": [
    0.0033072668593376875,
    0.41070622205734253,
    0.5859864950180054
  ],
  "13497630||9||39": [
    0.0030147021170705557,
    0.3355887234210968,
    0.6613965630531311
  ],
  "13497630||10||39": [
    0.0025725734885782003,
    0.35339486598968506,
    0.6440325975418091
  ],
  "13497630||11||39": [
    0.0009087169892154634,
    0.09215201437473297,
    0.9069392681121826
  ],
  "13497630||12||39": [
    0.008735695853829384,
    0.394205778837204,
    0.5970584750175476
  ],
  "13497630||0||40": [
    0.8141170740127563,
    0.18216624855995178,
    0.0037166806869208813
  ],
  "13497630||1||40": [
    0.20132684707641602,
    0.7954235076904297,
    0.003249655244871974
  ],
  "13497630||2||40": [
    0.49558955430984497,
    0.49839821457862854,
    0.006012262310832739
  ],
  "13497630||3||40": [
    0.058920975774526596,
    0.9275417923927307,
    0.013537311926484108
  ],
  "13497630||4||40": [
    0.11056894809007645,
    0.8836390972137451,
    0.005791904870420694
  ],
  "13497630||5||40": [
    0.48830410838127136,
    0.4995584785938263,
    0.01213732548058033
  ],
  "13497630||6||40": [
    0.07547660917043686,
    0.9173904061317444,
    0.00713295629248023
  ],
  "13497630||7||40": [
    0.6504549384117126,
    0.3365054428577423,
    0.013039602898061275
  ],
  "13497630||8||40": [
    0.558041512966156,
    0.42528417706489563,
    0.016674388200044632
  ],
  "13497630||9||40": [
    0.5912491083145142,
    0.39203616976737976,
    0.01671472005546093
  ],
  "13497630||10||40": [
    0.8932623267173767,
    0.10325546562671661,
    0.0034821685403585434
  ],
  "13497630||11||40": [
    0.9784947633743286,
    0.01922224834561348,
    0.0022830197121948004
  ],
  "13497630||12||40": [
    0.2017844319343567,
    0.7770309448242188,
    0.021184632554650307
  ],
  "13497630||0||349": [
    0.8198646903038025,
    0.17503944039344788,
    0.0050958301872015
  ],
  "13497630||1||349": [
    0.4029698967933655,
    0.590094268321991,
    0.006935812532901764
  ],
  "13497630||2||349": [
    0.3600514829158783,
    0.6145467758178711,
    0.025401698425412178
  ],
  "13497630||3||349": [
    0.28169479966163635,
    0.6947132349014282,
    0.023591944947838783
  ],
  "13497630||4||349": [
    0.2781403958797455,
    0.7068201899528503,
    0.015039396472275257
  ],
  "13497630||5||349": [
    0.5982438325881958,
    0.37953981757164,
    0.022216377779841423
  ],
  "13497630||6||349": [
    0.16733619570732117,
    0.8140188455581665,
    0.01864500902593136
  ],
  "13497630||7||349": [
    0.41126105189323425,
    0.4841562807559967,
    0.1045827567577362
  ],
  "13497630||8||349": [
    0.4100019037723541,
    0.4933747947216034,
    0.09662329405546188
  ],
  "13497630||9||349": [
    0.4468887746334076,
    0.45671626925468445,
    0.09639496356248856
  ],
  "13497630||10||349": [
    0.7304588556289673,
    0.26058050990104675,
    0.008960648439824581
  ],
  "13497630||11||349": [
    0.9541696310043335,
    0.036083582788705826,
    0.00974674429744482
  ],
  "13497630||12||349": [
    0.8016300797462463,
    0.183721125125885,
    0.014648889191448689
  ],
  "18174210||0||41": [
    0.39357107877731323,
    0.6024510264396667,
    0.003977816551923752
  ],
  "18174210||1||41": [
    0.006781376898288727,
    0.9213513135910034,
    0.07186730951070786
  ],
  "18174210||2||41": [
    0.08106101304292679,
    0.7951154708862305,
    0.12382357567548752
  ],
  "18174210||3||41": [
    0.007350706961005926,
    0.7688636183738708,
    0.2237856686115265
  ],
  "18174210||4||41": [
    0.2606941759586334,
    0.3787490129470825,
    0.36055684089660645
  ],
  "18174210||5||41": [
    0.23949086666107178,
    0.7529643177986145,
    0.007544815540313721
  ],
  "18174210||6||41": [
    0.011267262510955334,
    0.9813298583030701,
    0.007402895949780941
  ],
  "18174210||7||41": [
    0.5596184134483337,
    0.424520343542099,
    0.015861334279179573
  ],
  "18174210||8||41": [
    0.9735401272773743,
    0.02015385404229164,
    0.006306015886366367
  ],
  "18174210||9||41": [
    0.02105141617357731,
    0.8770467042922974,
    0.10190192610025406
  ],
  "18174210||10||41": [
    0.004683888982981443,
    0.07662414014339447,
    0.9186919331550598
  ],
  "18174210||11||41": [
    0.025982443243265152,
    0.8735726475715637,
    0.10044493526220322
  ],
  "18174210||12||41": [
    0.011296396143734455,
    0.8060600161552429,
    0.1826435923576355
  ],
  "18174210||13||41": [
    0.008158503100275993,
    0.970562756061554,
    0.02127869985997677
  ],
  "18174210||0||928": [
    0.023676373064517975,
    0.9474326968193054,
    0.028890879824757576
  ],
  "18174210||1||928": [
    0.00913184229284525,
    0.9798464179039001,
    0.011021736077964306
  ],
  "18174210||2||928": [
    0.21468758583068848,
    0.7761536836624146,
    0.00915869977325201
  ],
  "18174210||3||928": [
    0.9633422493934631,
    0.03259705752134323,
    0.004060728941112757
  ],
  "18174210||4||928": [
    0.28158479928970337,
    0.6728612184524536,
    0.04555391147732735
  ],
  "18174210||5||928": [
    0.1356411725282669,
    0.8378913402557373,
    0.0264674611389637
  ],
  "18174210||6||928": [
    0.09052960574626923,
    0.8977845311164856,
    0.011685816571116447
  ],
  "18174210||7||928": [
    0.18218521773815155,
    0.8070893883705139,
    0.01072536688297987
  ],
  "18174210||8||928": [
    0.03026796504855156,
    0.9291144013404846,
    0.04061764478683472
  ],
  "18174210||9||928": [
    0.9444752335548401,
    0.04632769152522087,
    0.009197065606713295
  ],
  "18174210||10||928": [
    0.9912661910057068,
    0.007237723097205162,
    0.0014961590059101582
  ],
  "18174210||11||928": [
    0.8252870440483093,
    0.15975239872932434,
    0.014960513450205326
  ],
  "18174210||12||928": [
    0.8304532766342163,
    0.16377714276313782,
    0.005769569426774979
  ],
  "18174210||13||928": [
    0.9219657778739929,
    0.0739685595035553,
    0.004065636079758406
  ],
  "18174210||0||929": [
    0.42292577028274536,
    0.5626567006111145,
    0.014417575672268867
  ],
  "18174210||1||929": [
    0.06237876042723656,
    0.9324733018875122,
    0.005147990304976702
  ],
  "18174210||2||929": [
    0.17357474565505981,
    0.7940818667411804,
    0.0323433056473732
  ],
  "18174210||3||929": [
    0.008783258497714996,
    0.9515372514724731,
    0.03967941924929619
  ],
  "18174210||4||929": [
    0.08264733105897903,
    0.8223204612731934,
    0.09503214806318283
  ],
  "18174210||5||929": [
    0.4119775593280792,
    0.5773739814758301,
    0.010648444294929504
  ],
  "18174210||6||929": [
    0.024886952713131905,
    0.9298897385597229,
    0.04522324725985527
  ],
  "18174210||7||929": [
    0.09282010048627853,
    0.8958864808082581,
    0.01129343081265688
  ],
  "18174210||8||929": [
    0.6560582518577576,
    0.3368357717990875,
    0.007105985656380653
  ],
  "18174210||9||929": [
    0.010547010228037834,
    0.7106304168701172,
    0.2788226008415222
  ],
  "18174210||10||929": [
    0.026320423930883408,
    0.9212127923965454,
    0.05246677249670029
  ],
  "18174210||11||929": [
    0.18611861765384674,
    0.7612252831459045,
    0.052656129002571106
  ],
  "18174210||12||929": [
    0.005883064586669207,
    0.9649247527122498,
    0.029192201793193817
  ],
  "18174210||13||929": [
    0.0020233800169080496,
    0.9940491914749146,
    0.0039274911396205425
  ],
  "18174210||0||42": [
    0.01920103281736374,
    0.9077023267745972,
    0.07309668511152267
  ],
  "18174210||1||42": [
    0.01551612839102745,
    0.975666880607605,
    0.008816977962851524
  ],
  "18174210||2||42": [
    0.8105534315109253,
    0.17863982915878296,
    0.010806681588292122
  ],
  "18174210||3||42": [
    0.9644043445587158,
    0.033602550625801086,
    0.001993076177313924
  ],
  "18174210||4||42": [
    0.43882644176483154,
    0.5391873717308044,
    0.021986182779073715
  ],
  "18174210||5||42": [
    0.0641261488199234,
    0.9299324154853821,
    0.005941423587501049
  ],
  "18174210||6||42": [
    0.04781916365027428,
    0.9454447627067566,
    0.006736099720001221
  ],
  "18174210||7||42": [
    0.08079999685287476,
    0.9023721218109131,
    0.016827916726469994
  ],
  "18174210||8||42": [
    0.003577780444175005,
    0.7831236124038696,
    0.21329858899116516
  ],
  "18174210||9||42": [
    0.9455535411834717,
    0.05039846897125244,
    0.0040479786694049835
  ],
  "18174210||10||42": [
    0.9950280785560608,
    0.004034958779811859,
    0.0009369614417664707
  ],
  "18174210||11||42": [
    0.6384355425834656,
    0.35314151644706726,
    0.008422872982919216
  ],
  "18174210||12||42": [
    0.9752633571624756,
    0.021613243967294693,
    0.0031233387999236584
  ],
  "18174210||13||42": [
    0.9456223249435425,
    0.051672615110874176,
    0.002705070422962308
  ],
  "56893404||0||44": [
    0.06866316497325897,
    0.9066324830055237,
    0.024704299867153168
  ],
  "56893404||1||44": [
    0.07904697954654694,
    0.9173873066902161,
    0.0035657163243740797
  ],
  "56893404||2||44": [
    0.019367700442671776,
    0.9729874134063721,
    0.007644880097359419
  ],
  "56893404||3||44": [
    0.006800794508308172,
    0.9869586825370789,
    0.006240468006581068
  ],
  "56893404||0||45": [
    0.038813166320323944,
    0.9475274085998535,
    0.013659416697919369
  ],
  "56893404||1||45": [
    0.0880337581038475,
    0.9085226058959961,
    0.003443657886236906
  ],
  "56893404||2||45": [
    0.024915611371397972,
    0.9674944281578064,
    0.007590000052005053
  ],
  "56893404||3||45": [
    0.007604926824569702,
    0.9870213866233826,
    0.005373639054596424
  ],
  "56893404||0||229": [
    0.15773391723632812,
    0.8380821347236633,
    0.004183976911008358
  ],
  "56893404||1||229": [
    0.20595136284828186,
    0.7789987921714783,
    0.015049814246594906
  ],
  "56893404||2||229": [
    0.4006859064102173,
    0.5934979319572449,
    0.005816157441586256
  ],
  "56893404||3||229": [
    0.3320995569229126,
    0.6517407894134521,
    0.01615959219634533
  ],
  "56893404||0||490": [
    0.0031189254950731993,
    0.993595540523529,
    0.003285506973043084
  ],
  "56893404||1||490": [
    0.01567666232585907,
    0.9825838208198547,
    0.0017395231407135725
  ],
  "56893404||2||490": [
    0.07853427529335022,
    0.7811093330383301,
    0.14035643637180328
  ],
  "56893404||3||490": [
    0.20735585689544678,
    0.30395832657814026,
    0.4886857867240906
  ],
  "56893404||0||1291": [
    0.8454163074493408,
    0.15208761394023895,
    0.00249604694545269
  ],
  "56893404||1||1291": [
    0.9576598405838013,
    0.04074829816818237,
    0.001591893145814538
  ],
  "56893404||2||1291": [
    0.989651620388031,
    0.009717782959342003,
    0.0006306305876933038
  ],
  "56893404||3||1291": [
    0.9980983138084412,
    0.0016649379394948483,
    0.00023679759760852903
  ],
  "56893404||0||491": [
    0.020855901762843132,
    0.9635021090507507,
    0.01564192585647106
  ],
  "56893404||1||491": [
    0.05473649874329567,
    0.9402527809143066,
    0.005010752938687801
  ],
  "56893404||2||491": [
    0.007978334091603756,
    0.9812650084495544,
    0.010756663046777248
  ],
  "56893404||3||491": [
    0.005097391549497843,
    0.9904040098190308,
    0.004498610273003578
  ],
  "56893404||0||1292": [
    0.8454163074493408,
    0.15208761394023895,
    0.00249604694545269
  ],
  "56893404||1||1292": [
    0.9576598405838013,
    0.04074829816818237,
    0.001591893145814538
  ],
  "56893404||2||1292": [
    0.989651620388031,
    0.009717782959342003,
    0.0006306305876933038
  ],
  "56893404||3||1292": [
    0.9980983138084412,
    0.0016649379394948483,
    0.00023679759760852903
  ],
  "45638119||0||52": [
    0.05088100582361221,
    0.836068332195282,
    0.11305062472820282
  ],
  "45638119||1||52": [
    0.7478479743003845,
    0.23989742994308472,
    0.012254503555595875
  ],
  "45638119||2||52": [
    0.12161477655172348,
    0.8138625025749207,
    0.06452266871929169
  ],
  "45638119||3||52": [
    0.11047093570232391,
    0.6264142990112305,
    0.2631148099899292
  ],
  "45638119||4||52": [
    0.0029447004199028015,
    0.07149909436702728,
    0.9255561828613281
  ],
  "45638119||5||52": [
    0.12581820785999298,
    0.8194344639778137,
    0.05474725738167763
  ],
  "45638119||0||51": [
    0.14759832620620728,
    0.7982249855995178,
    0.054176658391952515
  ],
  "45638119||1||51": [
    0.015041562728583813,
    0.919635534286499,
    0.06532292813062668
  ],
  "45638119||2||51": [
    0.09253520518541336,
    0.8611413836479187,
    0.04632342979311943
  ],
  "45638119||3||51": [
    0.05916934832930565,
    0.8178313374519348,
    0.12299935519695282
  ],
  "45638119||4||51": [
    0.9989823698997498,
    0.0006241198279894888,
    0.00039342796662822366
  ],
  "45638119||5||51": [
    0.05072370171546936,
    0.9177966117858887,
    0.03147963806986809
  ],
  "45638119||0||53": [
    0.0663454607129097,
    0.8221033215522766,
    0.11155123263597488
  ],
  "45638119||1||53": [
    0.8058649301528931,
    0.18573500216007233,
    0.008400014601647854
  ],
  "45638119||2||53": [
    0.11671076714992523,
    0.8322191834449768,
    0.05107008293271065
  ],
  "45638119||3||53": [
    0.16846394538879395,
    0.6496540904045105,
    0.18188196420669556
  ],
  "45638119||4||53": [
    0.0009094160050153732,
    0.007243035826832056,
    0.9918476343154907
  ],
  "45638119||5||53": [
    0.12216634303331375,
    0.8251755237579346,
    0.05265810713171959
  ],
  "4709641||0||58": [
    0.19100748002529144,
    0.765595018863678,
    0.0433974489569664
  ],
  "4709641||1||58": [
    0.9979932308197021,
    0.0015280772931873798,
    0.00047876217286102474
  ],
  "4709641||2||58": [
    0.056086860597133636,
    0.9170274138450623,
    0.02688571996986866
  ],
  "4709641||3||58": [
    0.40991324186325073,
    0.5836890935897827,
    0.006397682707756758
  ],
  "4709641||4||58": [
    0.022473439574241638,
    0.9714880585670471,
    0.006038508843630552
  ],
  "4709641||5||58": [
    0.06218225881457329,
    0.9304156303405762,
    0.0074021173641085625
  ],
  "4709641||0||286": [
    0.4323149025440216,
    0.5639671683311462,
    0.0037179822102189064
  ],
  "4709641||1||286": [
    0.10559432208538055,
    0.8920202851295471,
    0.002385350177064538
  ],
  "4709641||2||286": [
    0.04773259907960892,
    0.9500244855880737,
    0.0022428680676966906
  ],
  "4709641||3||286": [
    0.007406473159790039,
    0.9498273134231567,
    0.042766179889440536
  ],
  "4709641||4||286": [
    0.6508965492248535,
    0.34609395265579224,
    0.0030094177927821875
  ],
  "4709641||5||286": [
    0.005237226840108633,
    0.9603795409202576,
    0.034383244812488556
  ],
  "4709641||0||287": [
    0.17461368441581726,
    0.8211778998374939,
    0.004208413418382406
  ],
  "4709641||1||287": [
    0.047344934195280075,
    0.9472648501396179,
    0.00539026316255331
  ],
  "4709641||2||287": [
    0.12414523214101791,
    0.8732013702392578,
    0.002653418807312846
  ],
  "4709641||3||287": [
    0.976593017578125,
    0.021094705909490585,
    0.002312327269464731
  ],
  "4709641||4||287": [
    0.014276674948632717,
    0.7755579948425293,
    0.2101653516292572
  ],
  "4709641||5||287": [
    0.9960232973098755,
    0.0034105400554835796,
    0.0005660854512825608
  ],
  "4709641||0||56": [
    0.27347898483276367,
    0.6740105152130127,
    0.052510544657707214
  ],
  "4709641||1||56": [
    0.002986838109791279,
    0.407987117767334,
    0.5890260934829712
  ],
  "4709641||2||56": [
    0.024935396388173103,
    0.9639204144477844,
    0.011144197545945644
  ],
  "4709641||3||56": [
    0.33904749155044556,
    0.6525681018829346,
    0.00838430318981409
  ],
  "4709641||4||56": [
    0.0030136480927467346,
    0.9906508922576904,
    0.006335464771836996
  ],
  "4709641||5||56": [
    0.013151168823242188,
    0.9794197678565979,
    0.007429064251482487
  ],
  "4709641||0||57": [
    0.4532760977745056,
    0.5164749026298523,
    0.03024899773299694
  ],
  "4709641||1||57": [
    0.9913023710250854,
    0.007111730054020882,
    0.0015858603874221444
  ],
  "4709641||2||57": [
    0.006993943825364113,
    0.9831489324569702,
    0.009857112541794777
  ],
  "4709641||3||57": [
    0.6741819977760315,
    0.31690698862075806,
    0.00891098938882351
  ],
  "4709641||4||57": [
    0.5917453169822693,
    0.4045965373516083,
    0.0036581638269126415
  ],
  "4709641||5||57": [
    0.029213473200798035,
    0.9649098515510559,
    0.005876690614968538
  ],
  "40349336||0||63": [
    0.08645103126764297,
    0.9003058671951294,
    0.013243068009614944
  ],
  "40349336||1||63": [
    0.10691921412944794,
    0.8790613412857056,
    0.014019413851201534
  ],
  "40349336||2||63": [
    0.18560783565044403,
    0.8087109923362732,
    0.0056811426766216755
  ],
  "40349336||3||63": [
    0.26350870728492737,
    0.7242383360862732,
    0.012252907268702984
  ],
  "40349336||4||63": [
    0.32102999091148376,
    0.6411246061325073,
    0.037845440208911896
  ],
  "40349336||5||63": [
    0.1934044510126114,
    0.7295879125595093,
    0.07700759917497635
  ],
  "40349336||0||64": [
    0.9092519879341125,
    0.08739204704761505,
    0.0033558751456439495
  ],
  "40349336||1||64": [
    0.9432374835014343,
    0.05499789118766785,
    0.0017646957421675324
  ],
  "40349336||2||64": [
    0.6598214507102966,
    0.33510956168174744,
    0.005068930797278881
  ],
  "40349336||3||64": [
    0.6557834148406982,
    0.33793067932128906,
    0.006285944487899542
  ],
  "40349336||4||64": [
    0.8468897938728333,
    0.14846199750900269,
    0.0046482086181640625
  ],
  "40349336||5||64": [
    0.9274513125419617,
    0.06950506567955017,
    0.0030436604283750057
  ],
  "40349336||0||325": [
    0.9373577833175659,
    0.059937406331300735,
    0.002704785205423832
  ],
  "40349336||1||325": [
    0.8925337791442871,
    0.10381020605564117,
    0.0036560825537890196
  ],
  "40349336||2||325": [
    0.9372602701187134,
    0.06024252623319626,
    0.0024971147067844868
  ],
  "40349336||3||325": [
    0.9071127772331238,
    0.08954774588346481,
    0.00333948596380651
  ],
  "40349336||4||325": [
    0.9520266056060791,
    0.044416286051273346,
    0.0035571677144616842
  ],
  "40349336||5||325": [
    0.6253835558891296,
    0.3698001801967621,
    0.004816283006221056
  ],
  "40349336||0||326": [
    0.06917402893304825,
    0.8922402262687683,
    0.03858578950166702
  ],
  "40349336||1||326": [
    0.08994898945093155,
    0.8510467410087585,
    0.05900424346327782
  ],
  "40349336||2||326": [
    0.004769016522914171,
    0.9734696745872498,
    0.021761322394013405
  ],
  "40349336||3||326": [
    0.0015545935602858663,
    0.9839940071105957,
    0.014451378025114536
  ],
  "40349336||4||326": [
    0.008736759424209595,
    0.7158426642417908,
    0.27542057633399963
  ],
  "40349336||5||326": [
    0.0972597599029541,
    0.8926252126693726,
    0.010115057229995728
  ],
  "4387784||0||74": [
    0.08096679300069809,
    0.9065700769424438,
    0.012463114224374294
  ],
  "4387784||1||74": [
    0.06536351144313812,
    0.900850772857666,
    0.03378571942448616
  ],
  "4387784||2||74": [
    0.109944649040699,
    0.8749963045120239,
    0.01505906879901886
  ],
  "4387784||3||74": [
    0.043761394917964935,
    0.9476882815361023,
    0.008550352416932583
  ],
  "4387784||4||74": [
    0.38552311062812805,
    0.22738167643547058,
    0.387095183134079
  ],
  "4387784||5||74": [
    0.41354188323020935,
    0.35931408405303955,
    0.22714407742023468
  ],
  "4387784||6||74": [
    0.3283222019672394,
    0.61745685338974,
    0.05422103404998779
  ],
  "4387784||7||74": [
    0.25759947299957275,
    0.7204766869544983,
    0.021923774853348732
  ],
  "4387784||8||74": [
    0.1975894272327423,
    0.7394022941589355,
    0.06300821155309677
  ],
  "4387784||9||74": [
    0.11755265295505524,
    0.847733199596405,
    0.03471412882208824
  ],
  "4387784||10||74": [
    0.3583885431289673,
    0.4313164949417114,
    0.2102949172258377
  ],
  "4387784||0||75": [
    0.07599829137325287,
    0.9127753376960754,
    0.01122631411999464
  ],
  "4387784||1||75": [
    0.45671531558036804,
    0.5093109607696533,
    0.033973727375268936
  ],
  "4387784||2||75": [
    0.22766001522541046,
    0.7451421022415161,
    0.027197908610105515
  ],
  "4387784||3||75": [
    0.17095141112804413,
    0.815972626209259,
    0.01307593286037445
  ],
  "4387784||4||75": [
    0.6220107674598694,
    0.3216753304004669,
    0.05631382018327713
  ],
  "4387784||5||75": [
    0.6436147093772888,
    0.29087233543395996,
    0.0655129998922348
  ],
  "4387784||6||75": [
    0.42217040061950684,
    0.5223885774612427,
    0.055440984666347504
  ],
  "4387784||7||75": [
    0.5757032632827759,
    0.4000759422779083,
    0.024220764636993408
  ],
  "4387784||8||75": [
    0.504916787147522,
    0.42016446590423584,
    0.07491875439882278
  ],
  "4387784||9||75": [
    0.3723049759864807,
    0.5770419836044312,
    0.050653062760829926
  ],
  "4387784||10||75": [
    0.6188122630119324,
    0.3164772093296051,
    0.06471055746078491
  ],
  "4387784||0||1280": [
    0.27792420983314514,
    0.3819262683391571,
    0.34014949202537537
  ],
  "4387784||1||1280": [
    0.6355969905853271,
    0.33254387974739075,
    0.031859055161476135
  ],
  "4387784||2||1280": [
    0.17878998816013336,
    0.7456032633781433,
    0.07560671120882034
  ],
  "4387784||3||1280": [
    0.08564583957195282,
    0.8735676407814026,
    0.04078654199838638
  ],
  "4387784||4||1280": [
    0.49652600288391113,
    0.4654594361782074,
    0.038014572113752365
  ],
  "4387784||5||1280": [
    0.2771430015563965,
    0.6121827363967896,
    0.11067425459623337
  ],
  "4387784||6||1280": [
    0.3208729922771454,
    0.6240741014480591,
    0.05505296587944031
  ],
  "4387784||7||1280": [
    0.33755749464035034,
    0.6231480240821838,
    0.03929450735449791
  ],
  "4387784||8||1280": [
    0.18534357845783234,
    0.7118031978607178,
    0.1028531938791275
  ],
  "4387784||9||1280": [
    0.1896333396434784,
    0.6846472024917603,
    0.12571950256824493
  ],
  "4387784||10||1280": [
    0.3847196102142334,
    0.5654109716415405,
    0.04986945539712906
  ],
  "4387784||0||1281": [
    0.655489981174469,
    0.33049893379211426,
    0.014011034741997719
  ],
  "4387784||1||1281": [
    0.7625580430030823,
    0.22627882659435272,
    0.01116317417472601
  ],
  "4387784||2||1281": [
    0.32394877076148987,
    0.6406302452087402,
    0.03542095795273781
  ],
  "4387784||3||1281": [
    0.766139805316925,
    0.225271537899971,
    0.008588695898652077
  ],
  "4387784||4||1281": [
    0.7036131024360657,
    0.28886744379997253,
    0.0075194016098976135
  ],
  "4387784||5||1281": [
    0.3210964798927307,
    0.6316014528274536,
    0.04730210453271866
  ],
  "4387784||6||1281": [
    0.41678762435913086,
    0.5668401122093201,
    0.016372237354516983
  ],
  "4387784||7||1281": [
    0.49862003326416016,
    0.4926428496837616,
    0.008737151511013508
  ],
  "4387784||8||1281": [
    0.36399519443511963,
    0.6107528805732727,
    0.025251923128962517
  ],
  "4387784||9||1281": [
    0.8853626251220703,
    0.10854192078113556,
    0.0060954331420362
  ],
  "4387784||10||1281": [
    0.36964738368988037,
    0.6199839115142822,
    0.010368669405579567
  ],
  "5531479||0||76": [
    0.007586142513900995,
    0.9658073782920837,
    0.026606466621160507
  ],
  "5531479||1||76": [
    0.9636586308479309,
    0.02148730680346489,
    0.014854023233056068
  ],
  "5531479||2||76": [
    0.9259548187255859,
    0.06687652319669724,
    0.007168630138039589
  ],
  "5531479||3||76": [
    0.0037594903260469437,
    0.08039865642786026,
    0.915841817855835
  ],
  "5531479||4||76": [
    0.2954884469509125,
    0.6517030000686646,
    0.052808478474617004
  ],
  "5531479||5||76": [
    0.17080596089363098,
    0.7641679644584656,
    0.06502603739500046
  ],
  "5531479||6||76": [
    0.004368460737168789,
    0.13890421390533447,
    0.8567273616790771
  ],
  "5531479||0||77": [
    0.96694415807724,
    0.031039947643876076,
    0.002015927340835333
  ],
  "5531479||1||77": [
    0.9714854955673218,
    0.016936227679252625,
    0.01157836988568306
  ],
  "5531479||2||77": [
    0.24578751623630524,
    0.2984171509742737,
    0.4557953476905823
  ],
  "5531479||3||77": [
    0.9971404075622559,
    0.0021630392875522375,
    0.00069651153171435
  ],
  "5531479||4||77": [
    0.3895927369594574,
    0.5577626824378967,
    0.05264455825090408
  ],
  "5531479||5||77": [
    0.4554316997528076,
    0.5152484774589539,
    0.02931986004114151
  ],
  "5531479||6||77": [
    0.9968000650405884,
    0.0023827021941542625,
    0.0008172343368642032
  ],
  "5531479||0||724": [
    0.022948717698454857,
    0.9696988463401794,
    0.007352398242801428
  ],
  "5531479||1||724": [
    0.006638570223003626,
    0.9635024666786194,
    0.029858943074941635
  ],
  "5531479||2||724": [
    0.35626113414764404,
    0.40818092226982117,
    0.23555797338485718
  ],
  "5531479||3||724": [
    0.022035755217075348,
    0.9420943856239319,
    0.03586988151073456
  ],
  "5531479||4||724": [
    0.24428929388523102,
    0.6523683071136475,
    0.10334241390228271
  ],
  "5531479||5||724": [
    0.004379757214337587,
    0.7728064060211182,
    0.22281379997730255
  ],
  "5531479||6||724": [
    0.001113784615881741,
    0.02287791483104229,
    0.9760082960128784
  ],
  "5531479||0||723": [
    0.01346982829272747,
    0.9815976619720459,
    0.0049325586296617985
  ],
  "5531479||1||723": [
    0.005793184507638216,
    0.9686338901519775,
    0.0255728829652071
  ],
  "5531479||2||723": [
    0.9752379655838013,
    0.018171807751059532,
    0.006590129341930151
  ],
  "5531479||3||723": [
    0.010395375080406666,
    0.9080022573471069,
    0.08160240203142166
  ],
  "5531479||4||723": [
    0.16372309625148773,
    0.7621100544929504,
    0.07416687160730362
  ],
  "5531479||5||723": [
    0.004419759847223759,
    0.9877617359161377,
    0.007818473502993584
  ],
  "5531479||6||723": [
    0.0009164008661173284,
    0.03134700655937195,
    0.9677366018295288
  ],
  "1084345||0||91": [
    0.057930801063776016,
    0.9228287935256958,
    0.019240371882915497
  ],
  "1084345||1||91": [
    0.3563048839569092,
    0.6280674338340759,
    0.015627674758434296
  ],
  "1084345||2||91": [
    0.03613464534282684,
    0.9349228143692017,
    0.02894255705177784
  ],
  "1084345||3||91": [
    0.34175044298171997,
    0.6502798199653625,
    0.007969741709530354
  ],
  "1084345||4||91": [
    0.18038398027420044,
    0.7846195697784424,
    0.03499643877148628
  ],
  "1084345||5||91": [
    0.0031217087525874376,
    0.957941472530365,
    0.03893684595823288
  ],
  "1084345||0||92": [
    0.027259059250354767,
    0.9556317329406738,
    0.017109224572777748
  ],
  "1084345||1||92": [
    0.00818636640906334,
    0.9567863345146179,
    0.03502731770277023
  ],
  "1084345||2||92": [
    0.004447268322110176,
    0.9827969074249268,
    0.012755784206092358
  ],
  "1084345||3||92": [
    0.00917714275419712,
    0.9827837944030762,
    0.008039036765694618
  ],
  "1084345||4||92": [
    0.030664075165987015,
    0.9374686479568481,
    0.03186725452542305
  ],
  "1084345||5||92": [
    0.4303383529186249,
    0.5647946000099182,
    0.004867082927376032
  ],
  "1084345||0||148": [
    0.04138714447617531,
    0.9562782049179077,
    0.0023346322122961283
  ],
  "1084345||1||148": [
    0.4992147982120514,
    0.2683783769607544,
    0.2324068248271942
  ],
  "1084345||2||148": [
    0.8275994062423706,
    0.12883366644382477,
    0.04356699436903
  ],
  "1084345||3||148": [
    0.038238655775785446,
    0.5320237874984741,
    0.42973756790161133
  ],
  "1084345||4||148": [
    0.14353449642658234,
    0.4330577850341797,
    0.4234076738357544
  ],
  "1084345||5||148": [
    0.9926432967185974,
    0.006181633565574884,
    0.001175045152194798
  ],
  "6540064||0||98": [
    0.31741878390312195,
    0.6059813499450684,
    0.07659994065761566
  ],
  "6540064||1||98": [
    0.16428986191749573,
    0.794737696647644,
    0.040972426533699036
  ],
  "6540064||2||98": [
    0.1594478040933609,
    0.8149437308311462,
    0.02560841105878353
  ],
  "6540064||3||98": [
    0.0197082981467247,
    0.8916500210762024,
    0.0886417031288147
  ],
  "6540064||4||98": [
    0.21830326318740845,
    0.3714301884174347,
    0.41026654839515686
  ],
  "6540064||5||98": [
    0.015929047018289566,
    0.9788361191749573,
    0.005234844051301479
  ],
  "6540064||6||98": [
    0.0019214098574593663,
    0.9856062531471252,
    0.012472382746636868
  ],
  "6540064||7||98": [
    0.012063916772603989,
    0.9864892959594727,
    0.001446732203476131
  ],
  "6540064||8||98": [
    0.03482627123594284,
    0.9612641334533691,
    0.003909566439688206
  ],
  "6540064||9||98": [
    0.1809016764163971,
    0.32629185914993286,
    0.49280640482902527
  ],
  "6540064||10||98": [
    0.022930053994059563,
    0.9619469046592712,
    0.015123071148991585
  ],
  "6540064||11||98": [
    0.13827583193778992,
    0.8554319739341736,
    0.006292205769568682
  ],
  "6540064||12||98": [
    0.4316854476928711,
    0.5627526640892029,
    0.005561877973377705
  ],
  "6540064||13||98": [
    0.5704575777053833,
    0.402911901473999,
    0.026630554348230362
  ],
  "6540064||14||98": [
    0.2722961902618408,
    0.25383079051971436,
    0.4738730192184448
  ],
  "6540064||15||98": [
    0.5448288917541504,
    0.4412016272544861,
    0.013969454914331436
  ],
  "6540064||16||98": [
    0.9850244522094727,
    0.008294331841170788,
    0.006681229919195175
  ],
  "6540064||17||98": [
    0.02898872271180153,
    0.9340583682060242,
    0.036952901631593704
  ],
  "6540064||18||98": [
    0.04760201275348663,
    0.9066237807273865,
    0.04577425867319107
  ],
  "6540064||0||603": [
    0.29255521297454834,
    0.6951028108596802,
    0.012341911904513836
  ],
  "6540064||1||603": [
    0.026743251830339432,
    0.4335002601146698,
    0.5397565364837646
  ],
  "6540064||2||603": [
    0.0996641218662262,
    0.8875854015350342,
    0.012750498950481415
  ],
  "6540064||3||603": [
    0.09391576051712036,
    0.8998590111732483,
    0.006225232966244221
  ],
  "6540064||4||603": [
    0.014348088763654232,
    0.6837472915649414,
    0.3019045889377594
  ],
  "6540064||5||603": [
    0.03343619778752327,
    0.9124508500099182,
    0.05411297455430031
  ],
  "6540064||6||603": [
    0.08316875249147415,
    0.8658605813980103,
    0.050970617681741714
  ],
  "6540064||7||603": [
    0.07664026319980621,
    0.9097257256507874,
    0.013634000904858112
  ],
  "6540064||8||603": [
    0.03646409884095192,
    0.9596529006958008,
    0.00388296484015882
  ],
  "6540064||9||603": [
    0.03797891363501549,
    0.958763599395752,
    0.0032575002405792475
  ],
  "6540064||10||603": [
    0.04244866222143173,
    0.5605009198188782,
    0.3970504105091095
  ],
  "6540064||11||603": [
    0.6181633472442627,
    0.3589423894882202,
    0.022894253954291344
  ],
  "6540064||12||603": [
    0.15931732952594757,
    0.831850528717041,
    0.008832145482301712
  ],
  "6540064||13||603": [
    0.08613797277212143,
    0.8890728950500488,
    0.024789106100797653
  ],
  "6540064||14||603": [
    0.03628271818161011,
    0.8362032771110535,
    0.12751401960849762
  ],
  "6540064||15||603": [
    0.004385072272270918,
    0.8506776690483093,
    0.14493727684020996
  ],
  "6540064||16||603": [
    0.0010976848425343633,
    0.026003165170550346,
    0.9728990197181702
  ],
  "6540064||17||603": [
    0.03291292116045952,
    0.9011932611465454,
    0.06589382141828537
  ],
  "6540064||18||603": [
    0.0433395653963089,
    0.9029604196548462,
    0.053699977695941925
  ],
  "6540064||0||901": [
    0.08974511921405792,
    0.22469061613082886,
    0.6855642199516296
  ],
  "6540064||1||901": [
    0.0883139818906784,
    0.45305919647216797,
    0.4586268663406372
  ],
  "6540064||2||901": [
    0.1755199432373047,
    0.8156071901321411,
    0.008872860111296177
  ],
  "6540064||3||901": [
    0.002259736182168126,
    0.010980198159813881,
    0.986760139465332
  ],
  "6540064||4||901": [
    0.24091127514839172,
    0.5984947681427002,
    0.16059400141239166
  ],
  "6540064||5||901": [
    0.029507549479603767,
    0.9287319779396057,
    0.04176044464111328
  ],
  "6540064||6||901": [
    0.020388610661029816,
    0.8169546723365784,
    0.1626567840576172
  ],
  "6540064||7||901": [
    0.24445562064647675,
    0.7266301512718201,
    0.028914229944348335
  ],
  "6540064||8||901": [
    0.07933804392814636,
    0.9119928479194641,
    0.008669042959809303
  ],
  "6540064||9||901": [
    0.21002034842967987,
    0.5573904514312744,
    0.23258920013904572
  ],
  "6540064||10||901": [
    0.2188647985458374,
    0.7402512431144714,
    0.040883924812078476
  ],
  "6540064||11||901": [
    0.0934801697731018,
    0.8711165189743042,
    0.035403378307819366
  ],
  "6540064||12||901": [
    0.21691997349262238,
    0.7690467238426208,
    0.01403328962624073
  ],
  "6540064||13||901": [
    0.19890591502189636,
    0.7631974816322327,
    0.03789662942290306
  ],
  "6540064||14||901": [
    0.6008381843566895,
    0.3612719774246216,
    0.03788990154862404
  ],
  "6540064||15||901": [
    0.11465403437614441,
    0.5203884243965149,
    0.3649575412273407
  ],
  "6540064||16||901": [
    0.020105209201574326,
    0.6772001385688782,
    0.3026946187019348
  ],
  "6540064||17||901": [
    0.03690659999847412,
    0.8804463744163513,
    0.08264707773923874
  ],
  "6540064||18||901": [
    0.07080663740634918,
    0.819566011428833,
    0.1096273735165596
  ],
  "36606083||0||105": [
    0.021451180800795555,
    0.9620712399482727,
    0.016477622091770172
  ],
  "36606083||1||105": [
    0.01407566200941801,
    0.947253406047821,
    0.03867097198963165
  ],
  "36606083||2||105": [
    0.09927792102098465,
    0.783193051815033,
    0.11752899736166
  ],
  "36606083||3||105": [
    0.02391256019473076,
    0.952381432056427,
    0.023705990985035896
  ],
  "36606083||4||105": [
    0.0828746110200882,
    0.8729869723320007,
    0.044138435274362564
  ],
  "36606083||0||807": [
    0.033370133489370346,
    0.9646437764167786,
    0.001986078917980194
  ],
  "36606083||1||807": [
    0.003050826722756028,
    0.9960976839065552,
    0.0008514818036928773
  ],
  "36606083||2||807": [
    0.019357997924089432,
    0.9761438369750977,
    0.004498196300119162
  ],
  "36606083||3||807": [
    0.844989538192749,
    0.1483433097600937,
    0.00666711525991559
  ],
  "36606083||4||807": [
    0.6590798497200012,
    0.33368346095085144,
    0.007236704230308533
  ],
  "36606083||0||808": [
    0.05293536186218262,
    0.9450851678848267,
    0.0019794723484665155
  ],
  "36606083||1||808": [
    0.003573835361748934,
    0.9953287839889526,
    0.0010973524767905474
  ],
  "36606083||2||808": [
    0.280989408493042,
    0.7141395807266235,
    0.004870988428592682
  ],
  "36606083||3||808": [
    0.951102077960968,
    0.045200515538454056,
    0.003697457490488887
  ],
  "36606083||4||808": [
    0.52315753698349,
    0.46721264719963074,
    0.009629838168621063
  ],
  "10582939||0||144": [
    0.32848209142684937,
    0.6683415174484253,
    0.0031763887964189053
  ],
  "10582939||1||144": [
    0.003311815205961466,
    0.956060528755188,
    0.04062765836715698
  ],
  "10582939||2||144": [
    0.0031796745024621487,
    0.9921604990959167,
    0.0046598175540566444
  ],
  "10582939||3||144": [
    0.1061142310500145,
    0.7132493257522583,
    0.180636465549469
  ],
  "10582939||4||144": [
    0.0017431034939363599,
    0.9964442849159241,
    0.00181266525760293
  ],
  "10582939||5||144": [
    0.02573738992214203,
    0.9609122276306152,
    0.01335038710385561
  ],
  "10582939||6||144": [
    0.04464785382151604,
    0.949337899684906,
    0.00601422693580389
  ],
  "10582939||7||144": [
    0.09378214180469513,
    0.8991740942001343,
    0.007043750956654549
  ],
  "10582939||8||144": [
    0.028496846556663513,
    0.9535664319992065,
    0.01793668419122696
  ],
  "10582939||9||144": [
    0.013102056458592415,
    0.9519268870353699,
    0.03497103601694107
  ],
  "10582939||10||144": [
    0.021251024678349495,
    0.7846797704696655,
    0.19406923651695251
  ],
  "10582939||11||144": [
    0.06889089196920395,
    0.7875460386276245,
    0.14356310665607452
  ],
  "10582939||12||144": [
    0.008895914070308208,
    0.37639984488487244,
    0.6147042512893677
  ],
  "10582939||13||144": [
    0.044649478048086166,
    0.9029140472412109,
    0.0524364672601223
  ],
  "10582939||0||142": [
    0.07279662042856216,
    0.9184772372245789,
    0.00872612651437521
  ],
  "10582939||1||142": [
    0.9299394488334656,
    0.06812376528978348,
    0.0019368118373677135
  ],
  "10582939||2||142": [
    0.40208545327186584,
    0.594391942024231,
    0.0035225702449679375
  ],
  "10582939||3||142": [
    0.32929614186286926,
    0.5414294600486755,
    0.1292743980884552
  ],
  "10582939||4||142": [
    0.13361814618110657,
    0.8629103899002075,
    0.0034715058282017708
  ],
  "10582939||5||142": [
    0.14351603388786316,
    0.8449365496635437,
    0.011547358706593513
  ],
  "10582939||6||142": [
    0.044982414692640305,
    0.9343118667602539,
    0.020705731585621834
  ],
  "10582939||7||142": [
    0.5442938208580017,
    0.44044357538223267,
    0.01526262704282999
  ],
  "10582939||8||142": [
    0.1140376627445221,
    0.8157190680503845,
    0.07024326175451279
  ],
  "10582939||9||142": [
    0.7436478734016418,
    0.24739129841327667,
    0.008960830979049206
  ],
  "10582939||10||142": [
    0.5998134613037109,
    0.38800472021102905,
    0.01218182872980833
  ],
  "10582939||11||142": [
    0.236285001039505,
    0.6525135040283203,
    0.11120152473449707
  ],
  "10582939||12||142": [
    0.9971681237220764,
    0.0019664710853248835,
    0.000865363166667521
  ],
  "10582939||13||142": [
    0.21538184583187103,
    0.7446519732475281,
    0.03996617719531059
  ],
  "10582939||0||143": [
    0.21805930137634277,
    0.7691770792007446,
    0.012763665057718754
  ],
  "10582939||1||143": [
    0.09608123451471329,
    0.8918400406837463,
    0.012078797444701195
  ],
  "10582939||2||143": [
    0.01899091526865959,
    0.9746814966201782,
    0.006327534094452858
  ],
  "10582939||3||143": [
    0.1676718145608902,
    0.6506499648094177,
    0.18167825043201447
  ],
  "10582939||4||143": [
    0.005004311446100473,
    0.9918943047523499,
    0.0031013530679047108
  ],
  "10582939||5||143": [
    0.051995899528265,
    0.9238272309303284,
    0.02417687326669693
  ],
  "10582939||6||143": [
    0.11580874025821686,
    0.8517029285430908,
    0.032488346099853516
  ],
  "10582939||7||143": [
    0.07367356866598129,
    0.8850153088569641,
    0.04131108149886131
  ],
  "10582939||8||143": [
    0.12175697088241577,
    0.8387396931648254,
    0.03950338065624237
  ],
  "10582939||9||143": [
    0.029336940497159958,
    0.8417288064956665,
    0.12893423438072205
  ],
  "10582939||10||143": [
    0.1121087372303009,
    0.7905915379524231,
    0.09729970246553421
  ],
  "10582939||11||143": [
    0.1740601807832718,
    0.6872951984405518,
    0.13864460587501526
  ],
  "10582939||12||143": [
    0.004591206554323435,
    0.17958761751651764,
    0.8158211708068848
  ],
  "10582939||13||143": [
    0.107683464884758,
    0.8217608332633972,
    0.07055564224720001
  ],
  "10582939||0||146": [
    0.7116931080818176,
    0.26322636008262634,
    0.025080569088459015
  ],
  "10582939||1||146": [
    0.007262817118316889,
    0.9803935289382935,
    0.0123435752466321
  ],
  "10582939||2||146": [
    0.004627198446542025,
    0.9933284521102905,
    0.002044385066255927
  ],
  "10582939||3||146": [
    0.10275392979383469,
    0.6282693147659302,
    0.26897674798965454
  ],
  "10582939||4||146": [
    0.0019449886167421937,
    0.996309220790863,
    0.0017457434441894293
  ],
  "10582939||5||146": [
    0.021648384630680084,
    0.9426183104515076,
    0.035733286291360855
  ],
  "10582939||6||146": [
    0.08635301887989044,
    0.9101321697235107,
    0.0035148330498486757
  ],
  "10582939||7||146": [
    0.015551814809441566,
    0.9325685501098633,
    0.05187966674566269
  ],
  "10582939||8||146": [
    0.08910880237817764,
    0.8382460474967957,
    0.07264521718025208
  ],
  "10582939||9||146": [
    0.018084589391946793,
    0.8073472380638123,
    0.17456823587417603
  ],
  "10582939||10||146": [
    0.03733508661389351,
    0.7865317463874817,
    0.1761332005262375
  ],
  "10582939||11||146": [
    0.06459922343492508,
    0.688544750213623,
    0.2468559890985489
  ],
  "10582939||12||146": [
    0.0038134546484798193,
    0.23052100837230682,
    0.7656655311584473
  ],
  "10582939||13||146": [
    0.06243858113884926,
    0.8541393876075745,
    0.08342201262712479
  ],
  "37549932||0||155": [
    0.0774187371134758,
    0.9148426651954651,
    0.007738560438156128
  ],
  "37549932||1||155": [
    0.25885456800460815,
    0.7327901124954224,
    0.008355299010872841
  ],
  "37549932||2||155": [
    0.2155923843383789,
    0.7765647768974304,
    0.007842856459319592
  ],
  "37549932||3||155": [
    0.09168535470962524,
    0.8909140825271606,
    0.017400572076439857
  ],
  "37549932||4||155": [
    0.5006875991821289,
    0.46312427520751953,
    0.036188092082738876
  ],
  "37549932||5||155": [
    0.07000076770782471,
    0.9242650270462036,
    0.005734240636229515
  ],
  "37549932||0||156": [
    0.8068562150001526,
    0.1881222128868103,
    0.005021617282181978
  ],
  "37549932||1||156": [
    0.2624974846839905,
    0.7298368215560913,
    0.007665670942515135
  ],
  "37549932||2||156": [
    0.6391513347625732,
    0.3564646244049072,
    0.004384052008390427
  ],
  "37549932||3||156": [
    0.0919370949268341,
    0.8974831700325012,
    0.010579760186374187
  ],
  "37549932||4||156": [
    0.04184675216674805,
    0.9221059679985046,
    0.03604733571410179
  ],
  "37549932||5||156": [
    0.015541693195700645,
    0.9812204837799072,
    0.0032377985771745443
  ],
  "37549932||0||1088": [
    0.5879170298576355,
    0.3920970559120178,
    0.019985999912023544
  ],
  "37549932||1||1088": [
    0.44486910104751587,
    0.47284752130508423,
    0.08228334784507751
  ],
  "37549932||2||1088": [
    0.2871181070804596,
    0.7011772990226746,
    0.011704573407769203
  ],
  "37549932||3||1088": [
    0.9701324105262756,
    0.022920748218894005,
    0.006946757435798645
  ],
  "37549932||4||1088": [
    0.6122093796730042,
    0.3291071057319641,
    0.05868355557322502
  ],
  "37549932||5||1088": [
    0.8586385846138,
    0.1347009241580963,
    0.00666050473228097
  ],
  "5824985||0||164": [
    0.6934464573860168,
    0.3029509484767914,
    0.003602549433708191
  ],
  "5824985||1||164": [
    0.21578697860240936,
    0.7795736789703369,
    0.004639339633285999
  ],
  "5824985||2||164": [
    0.08447320759296417,
    0.9112427234649658,
    0.004284121096134186
  ],
  "5824985||3||164": [
    0.09382878243923187,
    0.8930516242980957,
    0.013119615614414215
  ],
  "5824985||4||164": [
    0.05228138715028763,
    0.94411700963974,
    0.003601625096052885
  ],
  "5824985||5||164": [
    0.06723245233297348,
    0.9238331317901611,
    0.008934477344155312
  ],
  "5824985||6||164": [
    0.12599331140518188,
    0.8650737404823303,
    0.008932962082326412
  ],
  "5824985||7||164": [
    0.3387461304664612,
    0.6557571887969971,
    0.005496687721461058
  ],
  "5824985||8||164": [
    0.3132735788822174,
    0.6818345785140991,
    0.0048918831162154675
  ],
  "5824985||9||164": [
    0.47378987073898315,
    0.5139908194541931,
    0.01221928745508194
  ],
  "5824985||10||164": [
    0.8688867688179016,
    0.12859416007995605,
    0.00251906574703753
  ],
  "5824985||11||164": [
    0.8936337828636169,
    0.10322587192058563,
    0.003140424145385623
  ],
  "5824985||12||164": [
    0.5359624624252319,
    0.45997169613838196,
    0.0040658521465957165
  ],
  "5824985||13||164": [
    0.1891808658838272,
    0.7895945310592651,
    0.021224642172455788
  ],
  "5824985||14||164": [
    0.7779703140258789,
    0.21911513805389404,
    0.0029146072920411825
  ],
  "5824985||15||164": [
    0.9936740398406982,
    0.005390943493694067,
    0.0009350409382022917
  ],
  "5824985||16||164": [
    0.9940295219421387,
    0.005498741753399372,
    0.00047179704415611923
  ],
  "5824985||0||165": [
    0.6279927492141724,
    0.36763858795166016,
    0.00436862837523222
  ],
  "5824985||1||165": [
    0.1910291314125061,
    0.8049514293670654,
    0.004019472748041153
  ],
  "5824985||2||165": [
    0.13325858116149902,
    0.8620510697364807,
    0.004690301604568958
  ],
  "5824985||3||165": [
    0.075701043009758,
    0.9121752381324768,
    0.012123743072152138
  ],
  "5824985||4||165": [
    0.0637158676981926,
    0.9318466186523438,
    0.004437523894011974
  ],
  "5824985||5||165": [
    0.057841453701257706,
    0.929801344871521,
    0.012357257306575775
  ],
  "5824985||6||165": [
    0.08055052161216736,
    0.9096992611885071,
    0.009750223718583584
  ],
  "5824985||7||165": [
    0.48243632912635803,
    0.5129006505012512,
    0.004663065541535616
  ],
  "5824985||8||165": [
    0.256336510181427,
    0.7387941479682922,
    0.004869300406426191
  ],
  "5824985||9||165": [
    0.4193129539489746,
    0.5663771629333496,
    0.014309876598417759
  ],
  "5824985||10||165": [
    0.8362392783164978,
    0.16084371507167816,
    0.0029170082416385412
  ],
  "5824985||11||165": [
    0.9149397611618042,
    0.081563800573349,
    0.0034964794758707285
  ],
  "5824985||12||165": [
    0.6862930059432983,
    0.30946052074432373,
    0.004246443510055542
  ],
  "5824985||13||165": [
    0.1765747368335724,
    0.7969272136688232,
    0.026498030871152878
  ],
  "5824985||14||165": [
    0.733756959438324,
    0.26301562786102295,
    0.003227428300306201
  ],
  "5824985||15||165": [
    0.9897769689559937,
    0.008934799581766129,
    0.001288262428715825
  ],
  "5824985||16||165": [
    0.9868432879447937,
    0.012409971095621586,
    0.0007468070834875107
  ],
  "5824985||0||168": [
    0.49564024806022644,
    0.4948952794075012,
    0.009464455768465996
  ],
  "5824985||1||168": [
    0.10701365023851395,
    0.888674259185791,
    0.004312093369662762
  ],
  "5824985||2||168": [
    0.1182563528418541,
    0.87688809633255,
    0.0048555354587733746
  ],
  "5824985||3||168": [
    0.08866140991449356,
    0.8804909586906433,
    0.030847618356347084
  ],
  "5824985||4||168": [
    0.016143791377544403,
    0.9814746379852295,
    0.0023815555032342672
  ],
  "5824985||5||168": [
    0.11338509619235992,
    0.8731579184532166,
    0.013456941582262516
  ],
  "5824985||6||168": [
    0.03066997602581978,
    0.9547813534736633,
    0.014548640698194504
  ],
  "5824985||7||168": [
    0.013375798240303993,
    0.9757875204086304,
    0.010836716741323471
  ],
  "5824985||8||168": [
    0.12320160865783691,
    0.8696039915084839,
    0.007194385398179293
  ],
  "5824985||9||168": [
    0.041360270231962204,
    0.9216371774673462,
    0.0370025709271431
  ],
  "5824985||10||168": [
    0.2750743627548218,
    0.7119836211204529,
    0.012942006811499596
  ],
  "5824985||11||168": [
    0.03951596841216087,
    0.9546598792076111,
    0.005824148189276457
  ],
  "5824985||12||168": [
    0.11329495161771774,
    0.8828501105308533,
    0.0038548633456230164
  ],
  "5824985||13||168": [
    0.09905785322189331,
    0.8623360991477966,
    0.03860604017972946
  ],
  "5824985||14||168": [
    0.05576780438423157,
    0.938788890838623,
    0.005443343427032232
  ],
  "5824985||15||168": [
    0.10491307079792023,
    0.7886514067649841,
    0.10643556714057922
  ],
  "5824985||16||168": [
    0.0053862230852246284,
    0.9912059903144836,
    0.003407801501452923
  ],
  "5824985||0||169": [
    0.30007338523864746,
    0.6856128573417664,
    0.014313760213553905
  ],
  "5824985||1||169": [
    0.13425999879837036,
    0.8618742823600769,
    0.0038657125551253557
  ],
  "5824985||2||169": [
    0.13078317046165466,
    0.8640051484107971,
    0.005211677867919207
  ],
  "5824985||3||169": [
    0.05882113426923752,
    0.9104321599006653,
    0.03074677102267742
  ],
  "5824985||4||169": [
    0.015756547451019287,
    0.9806734323501587,
    0.0035699992440640926
  ],
  "5824985||5||169": [
    0.11492973566055298,
    0.8640568852424622,
    0.021013397723436356
  ],
  "5824985||6||169": [
    0.024509131908416748,
    0.961606502532959,
    0.013884395360946655
  ],
  "5824985||7||169": [
    0.009989416226744652,
    0.9675753116607666,
    0.022435305640101433
  ],
  "5824985||8||169": [
    0.12758761644363403,
    0.8662587404251099,
    0.006153605412691832
  ],
  "5824985||9||169": [
    0.02596270479261875,
    0.923146665096283,
    0.050890643149614334
  ],
  "5824985||10||169": [
    0.10308035463094711,
    0.8807926177978516,
    0.01612699404358864
  ],
  "5824985||11||169": [
    0.03191068395972252,
    0.9579242467880249,
    0.010165028274059296
  ],
  "5824985||12||169": [
    0.22318220138549805,
    0.7711613178253174,
    0.005656514782458544
  ],
  "5824985||13||169": [
    0.08220754563808441,
    0.8607445359230042,
    0.05704789236187935
  ],
  "5824985||14||169": [
    0.02207711711525917,
    0.9708973169326782,
    0.007025603670626879
  ],
  "5824985||15||169": [
    0.05244371294975281,
    0.8041508197784424,
    0.14340543746948242
  ],
  "5824985||16||169": [
    0.010361645370721817,
    0.9845770001411438,
    0.005061364267021418
  ],
  "18872233||0||166": [
    0.8988130688667297,
    0.09954024851322174,
    0.0016466093948110938
  ],
  "18872233||1||166": [
    0.05106138437986374,
    0.896034836769104,
    0.05290384963154793
  ],
  "18872233||2||166": [
    0.050916969776153564,
    0.9330452084541321,
    0.016037805005908012
  ],
  "18872233||3||166": [
    0.07815660536289215,
    0.8923174142837524,
    0.02952602319419384
  ],
  "18872233||4||166": [
    0.10674665123224258,
    0.8606070280075073,
    0.0326463058590889
  ],
  "18872233||5||166": [
    0.022786207497119904,
    0.9631924629211426,
    0.014021304436028004
  ],
  "18872233||6||166": [
    0.006013222970068455,
    0.5762766599655151,
    0.4177100658416748
  ],
  "18872233||7||166": [
    0.06712298840284348,
    0.9071967601776123,
    0.02568024769425392
  ],
  "18872233||8||166": [
    0.09554622322320938,
    0.891152560710907,
    0.013301249593496323
  ],
  "18872233||9||166": [
    0.9604833722114563,
    0.028129246085882187,
    0.011387396603822708
  ],
  "18872233||10||166": [
    0.0025353392120450735,
    0.20331044495105743,
    0.7941542267799377
  ],
  "18872233||11||166": [
    0.09336280077695847,
    0.8823036551475525,
    0.02433355525135994
  ],
  "18872233||12||166": [
    0.9976335763931274,
    0.001852908288128674,
    0.0005135678220540285
  ],
  "18872233||0||167": [
    0.7733045220375061,
    0.20323407649993896,
    0.02346138469874859
  ],
  "18872233||1||167": [
    0.6186894774436951,
    0.37737590074539185,
    0.003934602253139019
  ],
  "18872233||2||167": [
    0.1122731938958168,
    0.8837746977806091,
    0.00395211111754179
  ],
  "18872233||3||167": [
    0.12097650021314621,
    0.8514145612716675,
    0.02760889381170273
  ],
  "18872233||4||167": [
    0.15574118494987488,
    0.8196000456809998,
    0.02465881034731865
  ],
  "18872233||5||167": [
    0.1408051997423172,
    0.8529350757598877,
    0.006259671878069639
  ],
  "18872233||6||167": [
    0.5158987045288086,
    0.47944411635398865,
    0.004657209850847721
  ],
  "18872233||7||167": [
    0.34760260581970215,
    0.6468340158462524,
    0.005563346203416586
  ],
  "18872233||8||167": [
    0.2992870807647705,
    0.6975610256195068,
    0.003151920158416033
  ],
  "18872233||9||167": [
    0.002218206413090229,
    0.1653824746608734,
    0.8323993682861328
  ],
  "18872233||10||167": [
    0.8958379030227661,
    0.10132179409265518,
    0.002840364119037986
  ],
  "18872233||11||167": [
    0.39551401138305664,
    0.5996168851852417,
    0.004869051277637482
  ],
  "18872233||12||167": [
    0.0029242669697850943,
    0.2784160375595093,
    0.7186596393585205
  ],
  "18872233||0||163": [
    0.6636607646942139,
    0.30761781334877014,
    0.028721453621983528
  ],
  "18872233||1||163": [
    0.9578135013580322,
    0.03985060378909111,
    0.0023359088227152824
  ],
  "18872233||2||163": [
    0.3867805004119873,
    0.6092873215675354,
    0.003932164050638676
  ],
  "18872233||3||163": [
    0.12346743792295456,
    0.8422043323516846,
    0.03432822227478027
  ],
  "18872233||4||163": [
    0.11068526655435562,
    0.8267892599105835,
    0.06252548098564148
  ],
  "18872233||5||163": [
    0.4778960645198822,
    0.5179295539855957,
    0.004174372181296349
  ],
  "18872233||6||163": [
    0.6450498700141907,
    0.34967470169067383,
    0.005275423172861338
  ],
  "18872233||7||163": [
    0.357771635055542,
    0.6348965764045715,
    0.007331731729209423
  ],
  "18872233||8||163": [
    0.25389721989631653,
    0.7423409223556519,
    0.003761881496757269
  ],
  "18872233||9||163": [
    0.004051358439028263,
    0.3434108793735504,
    0.6525377631187439
  ],
  "18872233||10||163": [
    0.937315046787262,
    0.05907875671982765,
    0.0036061350256204605
  ],
  "18872233||11||163": [
    0.41656145453453064,
    0.5763707756996155,
    0.00706779770553112
  ],
  "18872233||12||163": [
    0.004577220883220434,
    0.3115711212158203,
    0.6838517189025879
  ],
  "2177022||0||197": [
    0.2157905250787735,
    0.6977629065513611,
    0.08644656836986542
  ],
  "2177022||1||197": [
    0.2643687129020691,
    0.5642939209938049,
    0.17133739590644836
  ],
  "2177022||2||197": [
    0.9755182266235352,
    0.01858074590563774,
    0.00590108847245574
  ],
  "2177022||3||197": [
    0.4321798086166382,
    0.5617007613182068,
    0.0061194151639938354
  ],
  "2177022||4||197": [
    0.008688627742230892,
    0.013522234745323658,
    0.9777892231941223
  ],
  "2177022||5||197": [
    0.30806076526641846,
    0.6175487637519836,
    0.07439049333333969
  ],
  "2177022||6||197": [
    0.3312077522277832,
    0.47673365473747253,
    0.19205860793590546
  ],
  "2177022||0||199": [
    0.01691870391368866,
    0.9784753322601318,
    0.004605934955179691
  ],
  "2177022||1||199": [
    0.09580916166305542,
    0.8963881134986877,
    0.007802770007401705
  ],
  "2177022||2||199": [
    0.5525321960449219,
    0.44143691658973694,
    0.006030908785760403
  ],
  "2177022||3||199": [
    0.20128792524337769,
    0.7941916584968567,
    0.004520461428910494
  ],
  "2177022||4||199": [
    0.03207682445645332,
    0.9648348689079285,
    0.0030883322469890118
  ],
  "2177022||5||199": [
    0.49645352363586426,
    0.4926842749118805,
    0.0108622582629323
  ],
  "2177022||6||199": [
    0.10780718922615051,
    0.7974200248718262,
    0.0947728380560875
  ],
  "2177022||0||198": [
    0.6632140874862671,
    0.3245624601840973,
    0.012223540805280209
  ],
  "2177022||1||198": [
    0.7659893035888672,
    0.22363118827342987,
    0.010379471816122532
  ],
  "2177022||2||198": [
    0.40509265661239624,
    0.5845654010772705,
    0.010341919027268887
  ],
  "2177022||3||198": [
    0.20186343789100647,
    0.7803428173065186,
    0.01779373735189438
  ],
  "2177022||4||198": [
    0.8205623626708984,
    0.1690148562192917,
    0.010422776453197002
  ],
  "2177022||5||198": [
    0.3634183704853058,
    0.6120542883872986,
    0.02452731691300869
  ],
  "2177022||6||198": [
    0.8839274048805237,
    0.10897015035152435,
    0.00710243359208107
  ],
  "18231807||0||200": [
    0.3501744568347931,
    0.6464626789093018,
    0.0033628931269049644
  ],
  "18231807||1||200": [
    0.7733901739120483,
    0.22314895689487457,
    0.0034609290305525064
  ],
  "18231807||2||200": [
    0.8972625136375427,
    0.085691437125206,
    0.017046034336090088
  ],
  "18231807||3||200": [
    0.22550973296165466,
    0.7658693194389343,
    0.00862092338502407
  ],
  "18231807||4||200": [
    0.12220117449760437,
    0.7526971101760864,
    0.1251017451286316
  ],
  "18231807||5||200": [
    0.10033770650625229,
    0.8970744013786316,
    0.0025879014283418655
  ],
  "18231807||0||1307": [
    0.47810569405555725,
    0.4933657944202423,
    0.02852841652929783
  ],
  "18231807||1||1307": [
    0.28659486770629883,
    0.5983725190162659,
    0.11503268033266068
  ],
  "18231807||2||1307": [
    0.8675398230552673,
    0.10847792774438858,
    0.023982252925634384
  ],
  "18231807||3||1307": [
    0.010890579782426357,
    0.9855000376701355,
    0.0036093720700591803
  ],
  "18231807||4||1307": [
    0.8625668883323669,
    0.11480320990085602,
    0.02262989617884159
  ],
  "18231807||5||1307": [
    0.3049471080303192,
    0.6664890050888062,
    0.028563831001520157
  ],
  "18231807||0||1308": [
    0.24509772658348083,
    0.734134316444397,
    0.020767901092767715
  ],
  "18231807||1||1308": [
    0.09761936962604523,
    0.8546127080917358,
    0.04776795208454132
  ],
  "18231807||2||1308": [
    0.1628778874874115,
    0.8049559593200684,
    0.03216616064310074
  ],
  "18231807||3||1308": [
    0.06570177525281906,
    0.9051331877708435,
    0.029165012761950493
  ],
  "18231807||4||1308": [
    0.5466035008430481,
    0.39975932240486145,
    0.05363721400499344
  ],
  "18231807||5||1308": [
    0.16913779079914093,
    0.7949633002281189,
    0.035898882895708084
  ],
  "18231807||0||1309": [
    0.6769618391990662,
    0.31743863224983215,
    0.005599486641585827
  ],
  "18231807||1||1309": [
    0.7305328845977783,
    0.2567291855812073,
    0.012737911194562912
  ],
  "18231807||2||1309": [
    0.7849587798118591,
    0.17892077565193176,
    0.0361204519867897
  ],
  "18231807||3||1309": [
    0.6002731919288635,
    0.3936096429824829,
    0.006117112468928099
  ],
  "18231807||4||1309": [
    0.7092636823654175,
    0.253198504447937,
    0.03753777965903282
  ],
  "18231807||5||1309": [
    0.6331496834754944,
    0.35815417766571045,
    0.008696099743247032
  ],
  "19205437||0||220": [
    0.3863527774810791,
    0.5923293232917786,
    0.02131793089210987
  ],
  "19205437||1||220": [
    0.015270069241523743,
    0.690468966960907,
    0.29426097869873047
  ],
  "19205437||2||220": [
    0.31084492802619934,
    0.3569765090942383,
    0.33217859268188477
  ],
  "19205437||3||220": [
    0.08967679738998413,
    0.4494541883468628,
    0.4608689844608307
  ],
  "19205437||4||220": [
    0.6580770611763,
    0.21131601929664612,
    0.13060694932937622
  ],
  "19205437||5||220": [
    0.002204301068559289,
    0.0057167066261172295,
    0.992078959941864
  ],
  "19205437||0||221": [
    0.28242337703704834,
    0.6758256554603577,
    0.0417509600520134
  ],
  "19205437||1||221": [
    0.935204029083252,
    0.0144112603738904,
    0.05038478970527649
  ],
  "19205437||2||221": [
    0.8363841772079468,
    0.11416374891996384,
    0.04945207014679909
  ],
  "19205437||3||221": [
    0.9909424185752869,
    0.003847365966066718,
    0.005210171919316053
  ],
  "19205437||4||221": [
    0.7207050323486328,
    0.12826767563819885,
    0.15102723240852356
  ],
  "19205437||5||221": [
    0.16342894732952118,
    0.814971387386322,
    0.021599626168608665
  ],
  "19205437||0||222": [
    0.6569637060165405,
    0.33657047152519226,
    0.006465747952461243
  ],
  "19205437||1||222": [
    0.0040677268989384174,
    0.01677083969116211,
    0.9791614413261414
  ],
  "19205437||2||222": [
    0.6553632616996765,
    0.24061544239521027,
    0.1040213406085968
  ],
  "19205437||3||222": [
    0.013868915848433971,
    0.03155110403895378,
    0.9545799493789673
  ],
  "19205437||4||222": [
    0.346269428730011,
    0.16303607821464539,
    0.49069443345069885
  ],
  "19205437||5||222": [
    0.10450899600982666,
    0.741084098815918,
    0.15440692007541656
  ],
  "2014909||0||223": [
    0.12210805714130402,
    0.8665019273757935,
    0.011389940045773983
  ],
  "2014909||1||223": [
    0.16612732410430908,
    0.7107933163642883,
    0.12307930737733841
  ],
  "2014909||2||223": [
    0.10225439816713333,
    0.2676313817501068,
    0.6301142573356628
  ],
  "2014909||3||223": [
    0.6353702545166016,
    0.29023364186286926,
    0.07439611852169037
  ],
  "2014909||4||223": [
    0.018267592415213585,
    0.6990897059440613,
    0.282642662525177
  ],
  "2014909||5||223": [
    0.21806207299232483,
    0.4940733313560486,
    0.2878645360469818
  ],
  "2014909||6||223": [
    0.05905722454190254,
    0.8643919229507446,
    0.07655085623264313
  ],
  "2014909||7||223": [
    0.3516708016395569,
    0.5362273454666138,
    0.11210181564092636
  ],
  "2014909||0||323": [
    0.2401035577058792,
    0.7564054131507874,
    0.003491019131615758
  ],
  "2014909||1||323": [
    0.3809565007686615,
    0.5946363210678101,
    0.024407191202044487
  ],
  "2014909||2||323": [
    0.4366883635520935,
    0.5588594079017639,
    0.0044521763920784
  ],
  "2014909||3||323": [
    0.24395354092121124,
    0.7484208941459656,
    0.0076255956664681435
  ],
  "2014909||4||323": [
    0.2526938021183014,
    0.6800077557563782,
    0.06729841977357864
  ],
  "2014909||5||323": [
    0.4783948063850403,
    0.48910343647003174,
    0.03250173106789589
  ],
  "2014909||6||323": [
    0.2762058675289154,
    0.6665523052215576,
    0.057241834700107574
  ],
  "2014909||7||323": [
    0.27351143956184387,
    0.6919713616371155,
    0.034517209976911545
  ],
  "2014909||0||441": [
    0.05424505099654198,
    0.942359983921051,
    0.0033949294593185186
  ],
  "2014909||1||441": [
    0.19595834612846375,
    0.8005902767181396,
    0.0034514288417994976
  ],
  "2014909||2||441": [
    0.005669105798006058,
    0.4473075568675995,
    0.5470232963562012
  ],
  "2014909||3||441": [
    0.0018883568700402975,
    0.9706326127052307,
    0.027478989213705063
  ],
  "2014909||4||441": [
    0.061832789331674576,
    0.9127388000488281,
    0.02542848140001297
  ],
  "2014909||5||441": [
    0.06113721430301666,
    0.9240109920501709,
    0.014851842075586319
  ],
  "2014909||6||441": [
    0.08089053630828857,
    0.9086623191833496,
    0.01044717337936163
  ],
  "2014909||7||441": [
    0.03257085010409355,
    0.9414336681365967,
    0.025995442643761635
  ],
  "2014909||0||324": [
    0.24245420098304749,
    0.7527137398719788,
    0.004831998609006405
  ],
  "2014909||1||324": [
    0.31159651279449463,
    0.6480031609535217,
    0.04040038585662842
  ],
  "2014909||2||324": [
    0.1685255467891693,
    0.828330397605896,
    0.0031440858729183674
  ],
  "2014909||3||324": [
    0.19225752353668213,
    0.7953292727470398,
    0.012413266114890575
  ],
  "2014909||4||324": [
    0.13835303485393524,
    0.8588707447052002,
    0.002776139182969928
  ],
  "2014909||5||324": [
    0.36762404441833496,
    0.5671674013137817,
    0.06520852446556091
  ],
  "2014909||6||324": [
    0.2770150303840637,
    0.63259357213974,
    0.0903913602232933
  ],
  "2014909||7||324": [
    0.24214716255664825,
    0.7006099224090576,
    0.057242944836616516
  ],
  "6944800||0||224": [
    0.007082990370690823,
    0.6746492981910706,
    0.31826773285865784
  ],
  "6944800||1||224": [
    0.5282456278800964,
    0.3333086669445038,
    0.13844574987888336
  ],
  "6944800||2||224": [
    0.08615680038928986,
    0.5813694596290588,
    0.3324737846851349
  ],
  "6944800||3||224": [
    0.7447453141212463,
    0.22624969482421875,
    0.029005005955696106
  ],
  "6944800||4||224": [
    0.1878720223903656,
    0.5646971464157104,
    0.24743083119392395
  ],
  "6944800||0||225": [
    0.9602460861206055,
    0.037557315081357956,
    0.0021965736523270607
  ],
  "6944800||1||225": [
    0.6324669718742371,
    0.3500050902366638,
    0.017527934163808823
  ],
  "6944800||2||225": [
    0.9588742852210999,
    0.037875205278396606,
    0.0032505381386727095
  ],
  "6944800||3||225": [
    0.9777650237083435,
    0.020631486549973488,
    0.0016035394510254264
  ],
  "6944800||4||225": [
    0.9493727087974548,
    0.04778406023979187,
    0.0028432284016162157
  ],
  "6944800||0||226": [
    0.04841294139623642,
    0.936316967010498,
    0.01527009904384613
  ],
  "6944800||1||226": [
    0.6538968682289124,
    0.3263247311115265,
    0.01977841556072235
  ],
  "6944800||2||226": [
    0.2954237461090088,
    0.40523767471313477,
    0.29933854937553406
  ],
  "6944800||3||226": [
    0.09827648848295212,
    0.8885053396224976,
    0.013218213804066181
  ],
  "6944800||4||226": [
    0.40475335717201233,
    0.4540221691131592,
    0.1412244588136673
  ],
  "4388470||0||235": [
    0.19278666377067566,
    0.7297748923301697,
    0.07743840664625168
  ],
  "4388470||1||235": [
    0.25130850076675415,
    0.6673681139945984,
    0.08132339268922806
  ],
  "4388470||2||235": [
    0.16059494018554688,
    0.8048588037490845,
    0.03454623371362686
  ],
  "4388470||3||235": [
    0.0730806514620781,
    0.9026015400886536,
    0.024317873641848564
  ],
  "4388470||4||235": [
    0.44505661725997925,
    0.46487149596214294,
    0.09007196128368378
  ],
  "4388470||5||235": [
    0.3697867691516876,
    0.43627461791038513,
    0.19393858313560486
  ],
  "4388470||6||235": [
    0.11686767637729645,
    0.8241084218025208,
    0.05902385339140892
  ],
  "4388470||7||235": [
    0.032744478434324265,
    0.9463989734649658,
    0.020856522023677826
  ],
  "4388470||0||233": [
    0.5162359476089478,
    0.4496993124485016,
    0.03406473621726036
  ],
  "4388470||1||233": [
    0.5652143359184265,
    0.413519948720932,
    0.02126569300889969
  ],
  "4388470||2||233": [
    0.701396107673645,
    0.28166747093200684,
    0.016936367377638817
  ],
  "4388470||3||233": [
    0.36801737546920776,
    0.623153567314148,
    0.008829033933579922
  ],
  "4388470||4||233": [
    0.700859546661377,
    0.27301591634750366,
    0.026124607771635056
  ],
  "4388470||5||233": [
    0.22054198384284973,
    0.3809688091278076,
    0.39848920702934265
  ],
  "4388470||6||233": [
    0.7853294610977173,
    0.20301075279712677,
    0.011659777723252773
  ],
  "4388470||7||233": [
    0.13352231681346893,
    0.8600602746009827,
    0.006417378783226013
  ],
  "4388470||0||236": [
    0.08133961260318756,
    0.8742475509643555,
    0.044412799179553986
  ],
  "4388470||1||236": [
    0.26517757773399353,
    0.6839090585708618,
    0.05091334879398346
  ],
  "4388470||2||236": [
    0.08715525269508362,
    0.9012686014175415,
    0.011576169170439243
  ],
  "4388470||3||236": [
    0.07852563261985779,
    0.9103460907936096,
    0.011128291487693787
  ],
  "4388470||4||236": [
    0.46718502044677734,
    0.47081178426742554,
    0.06200314685702324
  ],
  "4388470||5||236": [
    0.3846781551837921,
    0.4928585886955261,
    0.12246321141719818
  ],
  "4388470||6||236": [
    0.1795482188463211,
    0.7717136740684509,
    0.04873806983232498
  ],
  "4388470||7||236": [
    0.013744105584919453,
    0.975028932094574,
    0.011226890608668327
  ],
  "4388470||0||303": [
    0.004301890265196562,
    0.9928580522537231,
    0.0028400965966284275
  ],
  "4388470||1||303": [
    0.13904248178005219,
    0.8345857262611389,
    0.0263717882335186
  ],
  "4388470||2||303": [
    0.021578095853328705,
    0.9723854660987854,
    0.0060364860109984875
  ],
  "4388470||3||303": [
    0.016998538747429848,
    0.9729413390159607,
    0.010060121305286884
  ],
  "4388470||4||303": [
    0.08599773049354553,
    0.8924997448921204,
    0.021502507850527763
  ],
  "4388470||5||303": [
    0.20653095841407776,
    0.7738855481147766,
    0.019583484157919884
  ],
  "4388470||6||303": [
    0.006947780027985573,
    0.9828760027885437,
    0.010176184587180614
  ],
  "4388470||7||303": [
    0.011559193953871727,
    0.9797908663749695,
    0.008649867959320545
  ],
  "1568684||0||250": [
    0.6901428699493408,
    0.30521824955940247,
    0.004638855345547199
  ],
  "1568684||1||250": [
    0.5145654678344727,
    0.47251829504966736,
    0.01291617751121521
  ],
  "1568684||2||250": [
    0.4042833149433136,
    0.5707007646560669,
    0.025015980005264282
  ],
  "1568684||3||250": [
    0.8992511034011841,
    0.09128858894109726,
    0.00946034025400877
  ],
  "1568684||4||250": [
    0.6253623366355896,
    0.33776089549064636,
    0.03687681630253792
  ],
  "1568684||5||250": [
    0.9940018057823181,
    0.004634839482605457,
    0.0013633916387334466
  ],
  "1568684||6||250": [
    0.6151811480522156,
    0.3754630982875824,
    0.009355760179460049
  ],
  "1568684||0||251": [
    0.005224829073995352,
    0.9889784455299377,
    0.005796762648969889
  ],
  "1568684||1||251": [
    0.44489797949790955,
    0.538263738155365,
    0.016838232055306435
  ],
  "1568684||2||251": [
    0.3796091377735138,
    0.6081094145774841,
    0.012281399220228195
  ],
  "1568684||3||251": [
    0.31374362111091614,
    0.27476638555526733,
    0.41148999333381653
  ],
  "1568684||4||251": [
    0.056349679827690125,
    0.8793988823890686,
    0.06425147503614426
  ],
  "1568684||5||251": [
    0.011982440017163754,
    0.25871846079826355,
    0.7292991280555725
  ],
  "1568684||6||251": [
    0.22436249256134033,
    0.7371985912322998,
    0.038438841700553894
  ],
  "1568684||0||248": [
    0.01814926043152809,
    0.9755310416221619,
    0.006319679785519838
  ],
  "1568684||1||248": [
    0.16219061613082886,
    0.5282540917396545,
    0.309555321931839
  ],
  "1568684||2||248": [
    0.03914748132228851,
    0.9466812610626221,
    0.014171205461025238
  ],
  "1568684||3||248": [
    0.006167109124362469,
    0.2714309096336365,
    0.7224019765853882
  ],
  "1568684||4||248": [
    0.01197442039847374,
    0.3398459851741791,
    0.6481795907020569
  ],
  "1568684||5||248": [
    0.06464335322380066,
    0.8458579182624817,
    0.08949870616197586
  ],
  "1568684||6||248": [
    0.048049427568912506,
    0.8945822715759277,
    0.05736831575632095
  ],
  "1568684||0||249": [
    0.015413261950016022,
    0.9764066338539124,
    0.008180072531104088
  ],
  "1568684||1||249": [
    0.507854163646698,
    0.48884353041648865,
    0.0033023396972566843
  ],
  "1568684||2||249": [
    0.019157763570547104,
    0.9520623683929443,
    0.028779862448573112
  ],
  "1568684||3||249": [
    0.621708869934082,
    0.25434499979019165,
    0.12394620478153229
  ],
  "1568684||4||249": [
    0.9966933727264404,
    0.002292138524353504,
    0.0010144845582544804
  ],
  "1568684||5||249": [
    0.05252879485487938,
    0.9073017239570618,
    0.04016948118805885
  ],
  "1568684||6||249": [
    0.05643640458583832,
    0.9174585342407227,
    0.02610500529408455
  ],
  "11614737||0||272": [
    0.001406730618327856,
    0.9965069890022278,
    0.0020862596575170755
  ],
  "11614737||1||272": [
    0.002245415234938264,
    0.9969403743743896,
    0.0008142862352542579
  ],
  "11614737||2||272": [
    0.007582413963973522,
    0.9797108769416809,
    0.012706748209893703
  ],
  "11614737||3||272": [
    0.011256812140345573,
    0.9707886576652527,
    0.017954587936401367
  ],
  "11614737||4||272": [
    0.0039031547494232655,
    0.9524187445640564,
    0.043678104877471924
  ],
  "11614737||5||272": [
    0.006969342473894358,
    0.9785822629928589,
    0.014448320493102074
  ],
  "11614737||6||272": [
    0.016368336975574493,
    0.9237345457077026,
    0.059897106140851974
  ],
  "11614737||7||272": [
    0.01564391702413559,
    0.8534143567085266,
    0.13094179332256317
  ],
  "11614737||8||272": [
    0.00522830942645669,
    0.45094048976898193,
    0.5438311696052551
  ],
  "11614737||9||272": [
    0.0660269558429718,
    0.7325534224510193,
    0.20141960680484772
  ],
  "11614737||10||272": [
    0.07562445849180222,
    0.8049737215042114,
    0.11940178275108337
  ],
  "11614737||11||272": [
    0.2157125473022461,
    0.7796854972839355,
    0.004602030850946903
  ],
  "11614737||12||272": [
    0.003610791638493538,
    0.18429946899414062,
    0.8120898008346558
  ],
  "11614737||13||272": [
    0.3443215787410736,
    0.635097086429596,
    0.020581362769007683
  ],
  "11614737||14||272": [
    0.04554750397801399,
    0.9522579908370972,
    0.0021945007611066103
  ],
  "11614737||15||272": [
    0.010030796751379967,
    0.8823971152305603,
    0.10757210850715637
  ],
  "11614737||0||1360": [
    0.0632663145661354,
    0.9343146085739136,
    0.0024191036354750395
  ],
  "11614737||1||1360": [
    0.007823951542377472,
    0.9913358688354492,
    0.0008401390514336526
  ],
  "11614737||2||1360": [
    0.016428807750344276,
    0.979158341884613,
    0.004412864800542593
  ],
  "11614737||3||1360": [
    0.016959168016910553,
    0.97504061460495,
    0.008000212721526623
  ],
  "11614737||4||1360": [
    0.07135380059480667,
    0.9222782850265503,
    0.006367966067045927
  ],
  "11614737||5||1360": [
    0.022800017148256302,
    0.9715626835823059,
    0.005637351889163256
  ],
  "11614737||6||1360": [
    0.017799589782953262,
    0.9758437871932983,
    0.006356618832796812
  ],
  "11614737||7||1360": [
    0.010160821489989758,
    0.9779174327850342,
    0.011921700090169907
  ],
  "11614737||8||1360": [
    0.3115532398223877,
    0.6772109270095825,
    0.011235849931836128
  ],
  "11614737||9||1360": [
    0.17090503871440887,
    0.36016878485679626,
    0.46892616152763367
  ],
  "11614737||10||1360": [
    0.4199487864971161,
    0.48921382427215576,
    0.09083735197782516
  ],
  "11614737||11||1360": [
    0.015041975304484367,
    0.9812657237052917,
    0.0036923198495060205
  ],
  "11614737||12||1360": [
    0.718254029750824,
    0.19876429438591003,
    0.0829816609621048
  ],
  "11614737||13||1360": [
    0.5117382407188416,
    0.48174166679382324,
    0.006520089227706194
  ],
  "11614737||14||1360": [
    0.09034615010023117,
    0.907170832157135,
    0.002483024960383773
  ],
  "11614737||15||1360": [
    0.01847180165350437,
    0.9532611966133118,
    0.028267009183764458
  ],
  "11614737||0||274": [
    0.0017033226322382689,
    0.9973115921020508,
    0.000985112157650292
  ],
  "11614737||1||274": [
    0.006630266550928354,
    0.9926648736000061,
    0.0007048273109830916
  ],
  "11614737||2||274": [
    0.010321115143597126,
    0.9873908162117004,
    0.002288037445396185
  ],
  "11614737||3||274": [
    0.02454550936818123,
    0.9724574089050293,
    0.002997106406837702
  ],
  "11614737||4||274": [
    0.006639779079705477,
    0.990724503993988,
    0.002635674085468054
  ],
  "11614737||5||274": [
    0.021905746310949326,
    0.9744611382484436,
    0.0036331014707684517
  ],
  "11614737||6||274": [
    0.005178516265004873,
    0.9891156554222107,
    0.005705852527171373
  ],
  "11614737||7||274": [
    0.025150246918201447,
    0.9360316395759583,
    0.03881809487938881
  ],
  "11614737||8||274": [
    0.41772258281707764,
    0.4673914909362793,
    0.11488599330186844
  ],
  "11614737||9||274": [
    0.6549887657165527,
    0.2892298400402069,
    0.05578140169382095
  ],
  "11614737||10||274": [
    0.38483214378356934,
    0.36331069469451904,
    0.25185713171958923
  ],
  "11614737||11||274": [
    0.5673703551292419,
    0.4284106194972992,
    0.004219024907797575
  ],
  "11614737||12||274": [
    0.28085198998451233,
    0.6409184336662292,
    0.07822953909635544
  ],
  "11614737||13||274": [
    0.7039623260498047,
    0.2916540503501892,
    0.004383549559861422
  ],
  "11614737||14||274": [
    0.12575165927410126,
    0.8722862601280212,
    0.0019620852544903755
  ],
  "11614737||15||274": [
    0.030269762501120567,
    0.9188888669013977,
    0.05084139108657837
  ],
  "11614737||0||1359": [
    0.06784624606370926,
    0.9293641448020935,
    0.0027896305546164513
  ],
  "11614737||1||1359": [
    0.006467039696872234,
    0.9926503300666809,
    0.0008826207485981286
  ],
  "11614737||2||1359": [
    0.011516083963215351,
    0.9854298830032349,
    0.003054035361856222
  ],
  "11614737||3||1359": [
    0.01921195536851883,
    0.9700114727020264,
    0.010776587761938572
  ],
  "11614737||4||1359": [
    0.06175940856337547,
    0.9310117959976196,
    0.007228838745504618
  ],
  "11614737||5||1359": [
    0.007403988856822252,
    0.9900426864624023,
    0.0025533142033964396
  ],
  "11614737||6||1359": [
    0.03289724513888359,
    0.9260050058364868,
    0.04109780117869377
  ],
  "11614737||7||1359": [
    0.009912543930113316,
    0.9801762104034424,
    0.009911201894283295
  ],
  "11614737||8||1359": [
    0.28672224283218384,
    0.42141881585121155,
    0.2918589115142822
  ],
  "11614737||9||1359": [
    0.1622827798128128,
    0.7342960238456726,
    0.10342114418745041
  ],
  "11614737||10||1359": [
    0.15459249913692474,
    0.7713485360145569,
    0.07405900955200195
  ],
  "11614737||11||1359": [
    0.01502419076859951,
    0.9788954257965088,
    0.006080443970859051
  ],
  "11614737||12||1359": [
    0.5575750470161438,
    0.28944164514541626,
    0.15298330783843994
  ],
  "11614737||13||1359": [
    0.42432376742362976,
    0.5691502690315247,
    0.006525983102619648
  ],
  "11614737||14||1359": [
    0.07681789249181747,
    0.9206458330154419,
    0.0025362924207001925
  ],
  "11614737||15||1359": [
    0.017808610573410988,
    0.9475914239883423,
    0.03459995239973068
  ],
  "14376683||0||277": [
    0.07777880877256393,
    0.9094414710998535,
    0.012779741548001766
  ],
  "14376683||1||277": [
    0.9228498339653015,
    0.06909886002540588,
    0.008051319047808647
  ],
  "14376683||2||277": [
    0.8360224962234497,
    0.15753750503063202,
    0.006440005265176296
  ],
  "14376683||3||277": [
    0.13594360649585724,
    0.7176907062530518,
    0.1463656723499298
  ],
  "14376683||4||277": [
    0.018574312329292297,
    0.7049081921577454,
    0.27651742100715637
  ],
  "14376683||5||277": [
    0.12599432468414307,
    0.7908716797828674,
    0.0831340104341507
  ],
  "14376683||6||277": [
    0.3018423914909363,
    0.5808348059654236,
    0.11732282489538193
  ],
  "14376683||7||277": [
    0.13849130272865295,
    0.7538406252861023,
    0.10766805708408356
  ],
  "14376683||8||277": [
    0.1418008655309677,
    0.7869688868522644,
    0.07123029977083206
  ],
  "14376683||9||277": [
    0.12463008612394333,
    0.8428748846054077,
    0.03249495103955269
  ],
  "14376683||0||278": [
    0.06463520228862762,
    0.9245879650115967,
    0.01077684573829174
  ],
  "14376683||1||278": [
    0.8635664582252502,
    0.1262730062007904,
    0.010160515084862709
  ],
  "14376683||2||278": [
    0.6416438817977905,
    0.30374664068222046,
    0.054609525948762894
  ],
  "14376683||3||278": [
    0.10540755838155746,
    0.8593291640281677,
    0.035263314843177795
  ],
  "14376683||4||278": [
    0.7560489177703857,
    0.1902741938829422,
    0.05367681384086609
  ],
  "14376683||5||278": [
    0.3235373795032501,
    0.5226250886917114,
    0.15383756160736084
  ],
  "14376683||6||278": [
    0.37412044405937195,
    0.580636203289032,
    0.04524337127804756
  ],
  "14376683||7||278": [
    0.023761894553899765,
    0.9532161355018616,
    0.02302190661430359
  ],
  "14376683||8||278": [
    0.08358294516801834,
    0.903788149356842,
    0.012628943659365177
  ],
  "14376683||9||278": [
    0.6691526770591736,
    0.3192574977874756,
    0.01158978883177042
  ],
  "14376683||0||279": [
    0.05158519372344017,
    0.9407300353050232,
    0.007684832904487848
  ],
  "14376683||1||279": [
    0.8664243817329407,
    0.12262497842311859,
    0.01095066498965025
  ],
  "14376683||2||279": [
    0.46135082840919495,
    0.49003854393959045,
    0.0486106276512146
  ],
  "14376683||3||279": [
    0.11089494079351425,
    0.8517700433731079,
    0.03733498975634575
  ],
  "14376683||4||279": [
    0.019776923581957817,
    0.8173472285270691,
    0.16287581622600555
  ],
  "14376683||5||279": [
    0.34967806935310364,
    0.481142520904541,
    0.16917948424816132
  ],
  "14376683||6||279": [
    0.34394338726997375,
    0.6135510802268982,
    0.04250553622841835
  ],
  "14376683||7||279": [
    0.028453709557652473,
    0.945642352104187,
    0.025903914123773575
  ],
  "14376683||8||279": [
    0.07165142148733139,
    0.9107500314712524,
    0.01759849116206169
  ],
  "14376683||9||279": [
    0.6717893481254578,
    0.3158618211746216,
    0.012348920106887817
  ],
  "7821634||0||306": [
    0.3113689720630646,
    0.5796504020690918,
    0.10898064821958542
  ],
  "7821634||1||306": [
    0.12374523282051086,
    0.8544647693634033,
    0.021790022030472755
  ],
  "7821634||2||306": [
    0.14852726459503174,
    0.7475606799125671,
    0.10391207039356232
  ],
  "7821634||3||306": [
    0.19551724195480347,
    0.757321834564209,
    0.04716087132692337
  ],
  "7821634||4||306": [
    0.7054805159568787,
    0.26153767108917236,
    0.03298178315162659
  ],
  "7821634||5||306": [
    0.08384069800376892,
    0.8810954093933105,
    0.03506391495466232
  ],
  "7821634||6||306": [
    0.8718480467796326,
    0.034312181174755096,
    0.09383981674909592
  ],
  "7821634||7||306": [
    0.0737435594201088,
    0.8782188892364502,
    0.0480375662446022
  ],
  "7821634||8||306": [
    0.17453086376190186,
    0.7235605120658875,
    0.10190864652395248
  ],
  "7821634||9||306": [
    0.5241327285766602,
    0.415986567735672,
    0.05988067761063576
  ],
  "7821634||0||308": [
    0.25010961294174194,
    0.7194305658340454,
    0.03045983798801899
  ],
  "7821634||1||308": [
    0.3551177680492401,
    0.6253237724304199,
    0.019558535888791084
  ],
  "7821634||2||308": [
    0.3438605070114136,
    0.6394157409667969,
    0.01672377437353134
  ],
  "7821634||3||308": [
    0.39803439378738403,
    0.5832607746124268,
    0.01870482787489891
  ],
  "7821634||4||308": [
    0.08563362061977386,
    0.9083429574966431,
    0.006023421883583069
  ],
  "7821634||5||308": [
    0.9385928511619568,
    0.05795929208397865,
    0.0034479110036045313
  ],
  "7821634||6||308": [
    0.10879164189100266,
    0.884489119052887,
    0.006719275843352079
  ],
  "7821634||7||308": [
    0.040653325617313385,
    0.9563905000686646,
    0.0029562111012637615
  ],
  "7821634||8||308": [
    0.5184932947158813,
    0.4686351418495178,
    0.012871503829956055
  ],
  "7821634||9||308": [
    0.9989466071128845,
    0.0006488504004664719,
    0.00040454414556734264
  ],
  "7821634||0||309": [
    0.17350277304649353,
    0.7413715124130249,
    0.08512574434280396
  ],
  "7821634||1||309": [
    0.3043053448200226,
    0.6881749629974365,
    0.007519679144024849
  ],
  "7821634||2||309": [
    0.19154243171215057,
    0.7762619256973267,
    0.03219561651349068
  ],
  "7821634||3||309": [
    0.13701944053173065,
    0.824698269367218,
    0.03828233852982521
  ],
  "7821634||4||309": [
    0.9840223789215088,
    0.013523831032216549,
    0.0024538016878068447
  ],
  "7821634||5||309": [
    0.3051633834838867,
    0.676730215549469,
    0.01810639351606369
  ],
  "7821634||6||309": [
    0.012277323752641678,
    0.014963868074119091,
    0.9727588295936584
  ],
  "7821634||7||309": [
    0.3650687634944916,
    0.6185340881347656,
    0.01639711670577526
  ],
  "7821634||8||309": [
    0.32976865768432617,
    0.642553985118866,
    0.027677297592163086
  ],
  "7821634||9||309": [
    0.8487431406974792,
    0.1388935148715973,
    0.01236339658498764
  ],
  "6173523||0||310": [
    0.10565673559904099,
    0.6922992467880249,
    0.2020440250635147
  ],
  "6173523||1||310": [
    0.07270584255456924,
    0.8177130818367004,
    0.10958103090524673
  ],
  "6173523||2||310": [
    0.19999372959136963,
    0.677541196346283,
    0.1224651113152504
  ],
  "6173523||3||310": [
    0.0870482325553894,
    0.8340567946434021,
    0.07889493554830551
  ],
  "6173523||4||310": [
    0.04483705013990402,
    0.9237053394317627,
    0.03145758435130119
  ],
  "6173523||5||310": [
    0.037410955876111984,
    0.9494178295135498,
    0.0131711820140481
  ],
  "6173523||6||310": [
    0.16907662153244019,
    0.7432981133460999,
    0.08762535452842712
  ],
  "6173523||7||310": [
    0.03291327878832817,
    0.9508645534515381,
    0.016222113743424416
  ],
  "6173523||8||310": [
    0.07035328447818756,
    0.9165191054344177,
    0.013127545826137066
  ],
  "6173523||9||310": [
    0.05139673873782158,
    0.8821218013763428,
    0.06648147106170654
  ],
  "6173523||10||310": [
    0.11767639964818954,
    0.7808263301849365,
    0.10149728506803513
  ],
  "6173523||11||310": [
    0.061875347048044205,
    0.8597506880760193,
    0.07837401330471039
  ],
  "6173523||12||310": [
    0.09802417457103729,
    0.8623406291007996,
    0.039635226130485535
  ],
  "6173523||13||310": [
    0.15484607219696045,
    0.7000821232795715,
    0.1450718343257904
  ],
  "6173523||14||310": [
    0.08566058427095413,
    0.6753460168838501,
    0.23899343609809875
  ],
  "6173523||0||313": [
    0.09780480712652206,
    0.5974991917610168,
    0.3046959936618805
  ],
  "6173523||1||313": [
    0.10542692244052887,
    0.6197872161865234,
    0.2747858166694641
  ],
  "6173523||2||313": [
    0.08432228863239288,
    0.8127475380897522,
    0.10293020308017731
  ],
  "6173523||3||313": [
    0.06580298393964767,
    0.8341764807701111,
    0.10002052783966064
  ],
  "6173523||4||313": [
    0.025322064757347107,
    0.9496917128562927,
    0.024986201897263527
  ],
  "6173523||5||313": [
    0.013450580649077892,
    0.979861855506897,
    0.00668759411200881
  ],
  "6173523||6||313": [
    0.1365130990743637,
    0.7848288416862488,
    0.07865806668996811
  ],
  "6173523||7||313": [
    0.016320908442139626,
    0.9723278880119324,
    0.011351260356605053
  ],
  "6173523||8||313": [
    0.02117791213095188,
    0.9607691168785095,
    0.01805289275944233
  ],
  "6173523||9||313": [
    0.02881019562482834,
    0.9248766303062439,
    0.04631313681602478
  ],
  "6173523||10||313": [
    0.062400754541158676,
    0.8817927241325378,
    0.05580649897456169
  ],
  "6173523||11||313": [
    0.037738945335149765,
    0.8897461891174316,
    0.07251490652561188
  ],
  "6173523||12||313": [
    0.018784448504447937,
    0.9481345415115356,
    0.03308102488517761
  ],
  "6173523||13||313": [
    0.0896969735622406,
    0.7012917995452881,
    0.20901119709014893
  ],
  "6173523||14||313": [
    0.11850991100072861,
    0.6755940914154053,
    0.20589599013328552
  ],
  "6173523||0||312": [
    0.043759945780038834,
    0.6225213408470154,
    0.33371874690055847
  ],
  "6173523||1||312": [
    0.11714078485965729,
    0.8210312128067017,
    0.061827994883060455
  ],
  "6173523||2||312": [
    0.03430100157856941,
    0.6927615404129028,
    0.2729374170303345
  ],
  "6173523||3||312": [
    0.019366567954421043,
    0.8583306670188904,
    0.12230277061462402
  ],
  "6173523||4||312": [
    0.008716531097888947,
    0.9650309681892395,
    0.02625253051519394
  ],
  "6173523||5||312": [
    0.003929583355784416,
    0.9649831056594849,
    0.031087318435311317
  ],
  "6173523||6||312": [
    0.029671339318156242,
    0.817011833190918,
    0.15331678092479706
  ],
  "6173523||7||312": [
    0.01092089805752039,
    0.9677176475524902,
    0.021361419931054115
  ],
  "6173523||8||312": [
    0.005399348679929972,
    0.9580068588256836,
    0.0365937314927578
  ],
  "6173523||9||312": [
    0.011073215864598751,
    0.8909730911254883,
    0.09795363247394562
  ],
  "6173523||10||312": [
    0.015721824020147324,
    0.7916656732559204,
    0.19261251389980316
  ],
  "6173523||11||312": [
    0.01830253377556801,
    0.8895580768585205,
    0.09213938564062119
  ],
  "6173523||12||312": [
    0.00714511051774025,
    0.9112949967384338,
    0.08155985921621323
  ],
  "6173523||13||312": [
    0.038264527916908264,
    0.7407222390174866,
    0.22101324796676636
  ],
  "6173523||14||312": [
    0.06678440421819687,
    0.6880748271942139,
    0.24514071643352509
  ],
  "2097256||0||336": [
    0.13822253048419952,
    0.8162698149681091,
    0.045507702976465225
  ],
  "2097256||1||336": [
    0.19567403197288513,
    0.6886795163154602,
    0.11564649641513824
  ],
  "2097256||2||336": [
    0.10376717150211334,
    0.7889742851257324,
    0.10725857317447662
  ],
  "2097256||3||336": [
    0.05971183255314827,
    0.700191855430603,
    0.240096315741539
  ],
  "2097256||4||336": [
    0.03955580294132233,
    0.899124264717102,
    0.061319999396800995
  ],
  "2097256||5||336": [
    0.10974770784378052,
    0.5953116416931152,
    0.29494068026542664
  ],
  "2097256||6||336": [
    0.08040545880794525,
    0.8144014477729797,
    0.10519307106733322
  ],
  "2097256||7||336": [
    0.06484412401914597,
    0.7885240912437439,
    0.14663174748420715
  ],
  "2097256||8||336": [
    0.06755603849887848,
    0.8467081785202026,
    0.08573579788208008
  ],
  "2097256||9||336": [
    0.08021341264247894,
    0.8134949803352356,
    0.10629159957170486
  ],
  "2097256||10||336": [
    0.09162245690822601,
    0.8070049285888672,
    0.1013726219534874
  ],
  "2097256||11||336": [
    0.049584224820137024,
    0.7946702241897583,
    0.15574553608894348
  ],
  "2097256||0||337": [
    0.4802362322807312,
    0.44209060072898865,
    0.07767320424318314
  ],
  "2097256||1||337": [
    0.2887663245201111,
    0.5690796375274658,
    0.1421540081501007
  ],
  "2097256||2||337": [
    0.13933494687080383,
    0.6986725926399231,
    0.16199254989624023
  ],
  "2097256||3||337": [
    0.11539744585752487,
    0.7173336148262024,
    0.16726893186569214
  ],
  "2097256||4||337": [
    0.12867821753025055,
    0.8090781569480896,
    0.06224365532398224
  ],
  "2097256||5||337": [
    0.20330746471881866,
    0.5705738663673401,
    0.22611872851848602
  ],
  "2097256||6||337": [
    0.26108282804489136,
    0.6322131752967834,
    0.10670392215251923
  ],
  "2097256||7||337": [
    0.14033599197864532,
    0.6894392967224121,
    0.17022469639778137
  ],
  "2097256||8||337": [
    0.16059628129005432,
    0.759550929069519,
    0.07985282689332962
  ],
  "2097256||9||337": [
    0.2664693295955658,
    0.6308412551879883,
    0.10268943011760712
  ],
  "2097256||10||337": [
    0.19298666715621948,
    0.6882451176643372,
    0.11876829713582993
  ],
  "2097256||11||337": [
    0.16433869302272797,
    0.723734438419342,
    0.11192689090967178
  ],
  "2097256||0||890": [
    0.16048955917358398,
    0.7707661986351013,
    0.06874416768550873
  ],
  "2097256||1||890": [
    0.25507286190986633,
    0.6733867526054382,
    0.07154034078121185
  ],
  "2097256||2||890": [
    0.12045195698738098,
    0.8377617597579956,
    0.0417863167822361
  ],
  "2097256||3||890": [
    0.07091309130191803,
    0.7811822295188904,
    0.14790470898151398
  ],
  "2097256||4||890": [
    0.12056265771389008,
    0.8549347519874573,
    0.024502558633685112
  ],
  "2097256||5||890": [
    0.11809652298688889,
    0.8162335157394409,
    0.0656699687242508
  ],
  "2097256||6||890": [
    0.1697382628917694,
    0.8010920286178589,
    0.029169686138629913
  ],
  "2097256||7||890": [
    0.08998438715934753,
    0.8452978134155273,
    0.06471780687570572
  ],
  "2097256||8||890": [
    0.08122485131025314,
    0.8906437158584595,
    0.02813139744102955
  ],
  "2097256||9||890": [
    0.07711739093065262,
    0.8702085018157959,
    0.052674081176519394
  ],
  "2097256||10||890": [
    0.15300285816192627,
    0.8116240501403809,
    0.035373102873563766
  ],
  "2097256||11||890": [
    0.04764251783490181,
    0.8719573616981506,
    0.08040019869804382
  ],
  "2097256||0||891": [
    0.4403001368045807,
    0.5000198483467102,
    0.059679992496967316
  ],
  "2097256||1||891": [
    0.4967648684978485,
    0.4431987404823303,
    0.06003636121749878
  ],
  "2097256||2||891": [
    0.18712346255779266,
    0.7588720321655273,
    0.05400453135371208
  ],
  "2097256||3||891": [
    0.15760333836078644,
    0.7416980862617493,
    0.10069862753152847
  ],
  "2097256||4||891": [
    0.42998161911964417,
    0.5496900081634521,
    0.02032836712896824
  ],
  "2097256||5||891": [
    0.293671578168869,
    0.6519659161567688,
    0.05436251312494278
  ],
  "2097256||6||891": [
    0.452789306640625,
    0.5106679201126099,
    0.03654278442263603
  ],
  "2097256||7||891": [
    0.34665167331695557,
    0.6083966493606567,
    0.04495171830058098
  ],
  "2097256||8||891": [
    0.2678631842136383,
    0.705862820148468,
    0.026273945346474648
  ],
  "2097256||9||891": [
    0.3962298631668091,
    0.5607209801673889,
    0.04304913803935051
  ],
  "2097256||10||891": [
    0.4976779818534851,
    0.47230425477027893,
    0.0300177913159132
  ],
  "2097256||11||891": [
    0.17179881036281586,
    0.749461829662323,
    0.07873935997486115
  ],
  "14658685||0||351": [
    0.020547091960906982,
    0.9445256590843201,
    0.03492732346057892
  ],
  "14658685||1||351": [
    0.024643078446388245,
    0.779297411441803,
    0.19605958461761475
  ],
  "14658685||2||351": [
    0.0186159685254097,
    0.937212347984314,
    0.044171664863824844
  ],
  "14658685||3||351": [
    0.0613388828933239,
    0.878496527671814,
    0.060164615511894226
  ],
  "14658685||4||351": [
    0.010014756582677364,
    0.903803288936615,
    0.08618191629648209
  ],
  "14658685||5||351": [
    0.02090730331838131,
    0.8015652298927307,
    0.17752742767333984
  ],
  "14658685||6||351": [
    0.01566152088344097,
    0.9003035426139832,
    0.08403497189283371
  ],
  "14658685||0||352": [
    0.0176737941801548,
    0.6482402682304382,
    0.33408594131469727
  ],
  "14658685||1||352": [
    0.07743344455957413,
    0.8935933709144592,
    0.028973136097192764
  ],
  "14658685||2||352": [
    0.19511082768440247,
    0.7990040183067322,
    0.005885133985430002
  ],
  "14658685||3||352": [
    0.07045061141252518,
    0.5187526941299438,
    0.4107966125011444
  ],
  "14658685||4||352": [
    0.08757508546113968,
    0.9005852937698364,
    0.011839593760669231
  ],
  "14658685||5||352": [
    0.042800772935152054,
    0.7214598059654236,
    0.23573942482471466
  ],
  "14658685||6||352": [
    0.24045011401176453,
    0.7074273228645325,
    0.052122604101896286
  ],
  "14658685||0||704": [
    0.04023582860827446,
    0.9137411713600159,
    0.046023011207580566
  ],
  "14658685||1||704": [
    0.08966825157403946,
    0.5127311944961548,
    0.39760056138038635
  ],
  "14658685||2||704": [
    0.15205858647823334,
    0.5714815258979797,
    0.2764599323272705
  ],
  "14658685||3||704": [
    0.09996119886636734,
    0.471627801656723,
    0.42841094732284546
  ],
  "14658685||4||704": [
    0.01990836299955845,
    0.6250209212303162,
    0.35507068037986755
  ],
  "14658685||5||704": [
    0.02944638766348362,
    0.6275878548622131,
    0.3429657816886902
  ],
  "14658685||6||704": [
    0.013558387756347656,
    0.8878158330917358,
    0.09862570464611053
  ],
  "14658685||0||1074": [
    0.9554476737976074,
    0.04225091636180878,
    0.0023014473263174295
  ],
  "14658685||1||1074": [
    0.08434883505105972,
    0.8690129518508911,
    0.04663825407624245
  ],
  "14658685||2||1074": [
    0.3879193961620331,
    0.5494232177734375,
    0.06265738606452942
  ],
  "14658685||3||1074": [
    0.244980588555336,
    0.691188395023346,
    0.06383104622364044
  ],
  "14658685||4||1074": [
    0.014600898139178753,
    0.8815767168998718,
    0.10382242500782013
  ],
  "14658685||5||1074": [
    0.0069652944803237915,
    0.9203541874885559,
    0.0726805329322815
  ],
  "14658685||6||1074": [
    0.03302780166268349,
    0.9471820592880249,
    0.019790159538388252
  ],
  "14658685||0||1075": [
    0.02596127614378929,
    0.8408369421958923,
    0.13320185244083405
  ],
  "14658685||1||1075": [
    0.4952574372291565,
    0.49671638011932373,
    0.00802622176706791
  ],
  "14658685||2||1075": [
    0.017777973785996437,
    0.797023594379425,
    0.18519845604896545
  ],
  "14658685||3||1075": [
    0.18613332509994507,
    0.7100347876548767,
    0.10383187979459763
  ],
  "14658685||4||1075": [
    0.37030503153800964,
    0.6020107865333557,
    0.027684159576892853
  ],
  "14658685||5||1075": [
    0.805907666683197,
    0.18946132063865662,
    0.004631063435226679
  ],
  "14658685||6||1075": [
    0.796227753162384,
    0.19792935252189636,
    0.005842935293912888
  ],
  "1550937||0||364": [
    0.0499751903116703,
    0.7107986211776733,
    0.23922613263130188
  ],
  "1550937||1||364": [
    0.05150223150849342,
    0.8479424118995667,
    0.10055530071258545
  ],
  "1550937||2||364": [
    0.02294088341295719,
    0.9240161776542664,
    0.05304292216897011
  ],
  "1550937||3||364": [
    0.09748633205890656,
    0.8573181629180908,
    0.045195482671260834
  ],
  "1550937||4||364": [
    0.020935311913490295,
    0.9670546054840088,
    0.012010094709694386
  ],
  "1550937||5||364": [
    0.03701380640268326,
    0.7160518169403076,
    0.24693438410758972
  ],
  "1550937||0||370": [
    0.06589090079069138,
    0.8649970293045044,
    0.06911203265190125
  ],
  "1550937||1||370": [
    0.349631130695343,
    0.6403011083602905,
    0.010067769326269627
  ],
  "1550937||2||370": [
    0.8925262689590454,
    0.07956713438034058,
    0.02790657989680767
  ],
  "1550937||3||370": [
    0.9167453050613403,
    0.06560898572206497,
    0.017645716667175293
  ],
  "1550937||4||370": [
    0.0827299952507019,
    0.8553329110145569,
    0.061937082558870316
  ],
  "1550937||5||370": [
    0.010752877220511436,
    0.008217161521315575,
    0.9810299873352051
  ],
  "1550937||0||371": [
    0.06353770941495895,
    0.8624601364135742,
    0.07400213181972504
  ],
  "1550937||1||371": [
    0.3407483398914337,
    0.6489987969398499,
    0.010252920910716057
  ],
  "1550937||2||371": [
    0.8368817567825317,
    0.1272977888584137,
    0.035820506513118744
  ],
  "1550937||3||371": [
    0.8399271965026855,
    0.12732480466365814,
    0.03274799883365631
  ],
  "1550937||4||371": [
    0.03087637946009636,
    0.9100992679595947,
    0.05902436003088951
  ],
  "1550937||5||371": [
    0.0032741944305598736,
    0.009402763098478317,
    0.987322986125946
  ],
  "24922825||0||372": [
    0.6749598383903503,
    0.31260475516319275,
    0.012435424141585827
  ],
  "24922825||1||372": [
    0.06033898890018463,
    0.9103116989135742,
    0.029349347576498985
  ],
  "24922825||2||372": [
    0.78194659948349,
    0.20478391647338867,
    0.01326946821063757
  ],
  "24922825||3||372": [
    0.002693095011636615,
    0.993553638458252,
    0.00375322881154716
  ],
  "24922825||4||372": [
    0.2569113075733185,
    0.7104774117469788,
    0.03261129558086395
  ],
  "24922825||5||372": [
    0.2854861915111542,
    0.698101282119751,
    0.016412479802966118
  ],
  "24922825||6||372": [
    0.31220898032188416,
    0.6705669164657593,
    0.017224077135324478
  ],
  "24922825||7||372": [
    0.04931052029132843,
    0.18688639998435974,
    0.7638030648231506
  ],
  "24922825||8||372": [
    0.20963728427886963,
    0.6748367547988892,
    0.11552596092224121
  ],
  "24922825||9||372": [
    0.012236550450325012,
    0.9725689888000488,
    0.015194418840110302
  ],
  "24922825||0||772": [
    0.6974223852157593,
    0.29807737469673157,
    0.004500205162912607
  ],
  "24922825||1||772": [
    0.915583074092865,
    0.0817478597164154,
    0.0026690850500017405
  ],
  "24922825||2||772": [
    0.46309444308280945,
    0.5211300253868103,
    0.01577547751367092
  ],
  "24922825||3||772": [
    0.6892387866973877,
    0.30599161982536316,
    0.004769633989781141
  ],
  "24922825||4||772": [
    0.7414823174476624,
    0.25034448504447937,
    0.008173185400664806
  ],
  "24922825||5||772": [
    0.919625461101532,
    0.07593756914138794,
    0.004436981864273548
  ],
  "24922825||6||772": [
    0.7756022810935974,
    0.2122562676668167,
    0.012141435407102108
  ],
  "24922825||7||772": [
    0.9900642037391663,
    0.008815557695925236,
    0.0011202782625332475
  ],
  "24922825||8||772": [
    0.8949034810066223,
    0.10178877413272858,
    0.003307715291157365
  ],
  "24922825||9||772": [
    0.7079172134399414,
    0.28671061992645264,
    0.005372184328734875
  ],
  "24922825||0||853": [
    0.7883725762367249,
    0.20556087791919708,
    0.006066545844078064
  ],
  "24922825||1||853": [
    0.9192404747009277,
    0.07662313431501389,
    0.004136391915380955
  ],
  "24922825||2||853": [
    0.789579451084137,
    0.18984456360340118,
    0.020575927570462227
  ],
  "24922825||3||853": [
    0.8388599753379822,
    0.15465138852596283,
    0.006488558370620012
  ],
  "24922825||4||853": [
    0.8203561305999756,
    0.16966494917869568,
    0.009978871792554855
  ],
  "24922825||5||853": [
    0.9344642758369446,
    0.06142337620258331,
    0.004112280905246735
  ],
  "24922825||6||853": [
    0.7879994511604309,
    0.19518707692623138,
    0.016813477501273155
  ],
  "24922825||7||853": [
    0.9750729203224182,
    0.02318246103823185,
    0.0017445867415517569
  ],
  "24922825||8||853": [
    0.993610680103302,
    0.005721892695873976,
    0.0006674931501038373
  ],
  "24922825||9||853": [
    0.6884708404541016,
    0.29512447118759155,
    0.016404729336500168
  ],
  "19005293||0||379": [
    0.0009715771884657443,
    0.995928943157196,
    0.0030994550324976444
  ],
  "19005293||1||379": [
    0.005795456934720278,
    0.9892673492431641,
    0.0049371980130672455
  ],
  "19005293||2||379": [
    0.9975276589393616,
    0.0019732273649424314,
    0.0004991010646335781
  ],
  "19005293||3||379": [
    0.5792132616043091,
    0.4142952561378479,
    0.006491462234407663
  ],
  "19005293||4||379": [
    0.8428415656089783,
    0.1491403877735138,
    0.008018065243959427
  ],
  "19005293||0||1347": [
    0.8454945683479309,
    0.1517113745212555,
    0.0027941125445067883
  ],
  "19005293||1||1347": [
    0.04516737163066864,
    0.9536827802658081,
    0.0011498283129185438
  ],
  "19005293||2||1347": [
    0.999180018901825,
    0.0005886125145480037,
    0.0002312700089532882
  ],
  "19005293||3||1347": [
    0.03026849776506424,
    0.9665151238441467,
    0.0032163304276764393
  ],
  "19005293||4||1347": [
    0.010691349394619465,
    0.9873437881469727,
    0.0019648324232548475
  ],
  "19005293||0||1348": [
    0.20450851321220398,
    0.7853118181228638,
    0.010179716162383556
  ],
  "19005293||1||1348": [
    0.045174192637205124,
    0.9524531364440918,
    0.0023726343642920256
  ],
  "19005293||2||1348": [
    0.0016661400441080332,
    0.02487432211637497,
    0.9734594821929932
  ],
  "19005293||3||1348": [
    0.05929432436823845,
    0.9357936978340149,
    0.004911966156214476
  ],
  "19005293||4||1348": [
    0.0014638188295066357,
    0.9963794350624084,
    0.0021567516960203648
  ],
  "19005293||0||380": [
    0.41888704895973206,
    0.5784497857093811,
    0.0026631634682416916
  ],
  "19005293||1||380": [
    0.027853524312376976,
    0.9694501161575317,
    0.0026964202988892794
  ],
  "19005293||2||380": [
    0.0005854463670402765,
    0.03145935386419296,
    0.9679551124572754
  ],
  "19005293||3||380": [
    0.0038067020941525698,
    0.9811404943466187,
    0.015052848495543003
  ],
  "19005293||4||380": [
    0.0008685308275744319,
    0.9907160997390747,
    0.008415368385612965
  ],
  "1148122||0||389": [
    0.08621422201395035,
    0.8396679162979126,
    0.07411787658929825
  ],
  "1148122||1||389": [
    0.12759961187839508,
    0.8281868696212769,
    0.04421348124742508
  ],
  "1148122||2||389": [
    0.5101257562637329,
    0.4777153432369232,
    0.012158860452473164
  ],
  "1148122||3||389": [
    0.037280939519405365,
    0.943494975566864,
    0.019224151968955994
  ],
  "1148122||4||389": [
    0.14288583397865295,
    0.8259769678115845,
    0.03113720938563347
  ],
  "1148122||5||389": [
    0.09090617299079895,
    0.8074055910110474,
    0.10168829560279846
  ],
  "1148122||6||389": [
    0.07649261504411697,
    0.8674700260162354,
    0.05603737384080887
  ],
  "1148122||7||389": [
    0.08466754853725433,
    0.8335733413696289,
    0.08175911754369736
  ],
  "1148122||0||390": [
    0.07495054602622986,
    0.8759507536888123,
    0.049098752439022064
  ],
  "1148122||1||390": [
    0.1173776164650917,
    0.8425441384315491,
    0.04007824510335922
  ],
  "1148122||2||390": [
    0.5732815861701965,
    0.4160366356372833,
    0.01068184245377779
  ],
  "1148122||3||390": [
    0.03204454109072685,
    0.9519690871238708,
    0.015986403450369835
  ],
  "1148122||4||390": [
    0.10895995795726776,
    0.8724609017372131,
    0.018579142168164253
  ],
  "1148122||5||390": [
    0.10747025907039642,
    0.8498390913009644,
    0.04269067198038101
  ],
  "1148122||6||390": [
    0.0716177225112915,
    0.8968905210494995,
    0.031491801142692566
  ],
  "1148122||7||390": [
    0.07500968873500824,
    0.8512359261512756,
    0.07375437766313553
  ],
  "1148122||0||391": [
    0.0758306160569191,
    0.8855704665184021,
    0.0385989174246788
  ],
  "1148122||1||391": [
    0.12992604076862335,
    0.834688127040863,
    0.0353858508169651
  ],
  "1148122||2||391": [
    0.758583128452301,
    0.23211990296840668,
    0.009296986274421215
  ],
  "1148122||3||391": [
    0.06462708860635757,
    0.9047533273696899,
    0.03061959706246853
  ],
  "1148122||4||391": [
    0.12613463401794434,
    0.8544390797615051,
    0.019426263868808746
  ],
  "1148122||5||391": [
    0.04467396065592766,
    0.8924174308776855,
    0.06290855258703232
  ],
  "1148122||6||391": [
    0.08468865603208542,
    0.873100221157074,
    0.042211104184389114
  ],
  "1148122||7||391": [
    0.07679902017116547,
    0.8663558959960938,
    0.056845128536224365
  ],
  "1148122||0||392": [
    0.04236561432480812,
    0.8778792023658752,
    0.07975523918867111
  ],
  "1148122||1||392": [
    0.04883540794253349,
    0.8948283791542053,
    0.05633620172739029
  ],
  "1148122||2||392": [
    0.3135360777378082,
    0.6394583582878113,
    0.04700556397438049
  ],
  "1148122||3||392": [
    0.011417068541049957,
    0.9518744945526123,
    0.03670840710401535
  ],
  "1148122||4||392": [
    0.04084230214357376,
    0.9027837514877319,
    0.05637393146753311
  ],
  "1148122||5||392": [
    0.10726041346788406,
    0.798681378364563,
    0.09405816346406937
  ],
  "1148122||6||392": [
    0.11007517576217651,
    0.8342139720916748,
    0.05571087449789047
  ],
  "1148122||7||392": [
    0.08958055824041367,
    0.8207752108573914,
    0.08964423090219498
  ],
  "1148122||0||393": [
    0.04003756865859032,
    0.8913295269012451,
    0.06863287836313248
  ],
  "1148122||1||393": [
    0.049562979489564896,
    0.9053816199302673,
    0.04505538195371628
  ],
  "1148122||2||393": [
    0.40468740463256836,
    0.549304187297821,
    0.04600836709141731
  ],
  "1148122||3||393": [
    0.007809668779373169,
    0.8850296139717102,
    0.10716072469949722
  ],
  "1148122||4||393": [
    0.031016886234283447,
    0.90884929895401,
    0.060133885592222214
  ],
  "1148122||5||393": [
    0.1799827516078949,
    0.7551383376121521,
    0.0648789256811142
  ],
  "1148122||6||393": [
    0.11690567433834076,
    0.8190310001373291,
    0.06406329572200775
  ],
  "1148122||7||393": [
    0.11460116505622864,
    0.8297165036201477,
    0.055682338774204254
  ],
  "1148122||0||388": [
    0.05497670918703079,
    0.8298956751823425,
    0.11512763798236847
  ],
  "1148122||1||388": [
    0.05592924728989601,
    0.893634021282196,
    0.050436753779649734
  ],
  "1148122||2||388": [
    0.26333728432655334,
    0.6965029835700989,
    0.040159717202186584
  ],
  "1148122||3||388": [
    0.012132593430578709,
    0.9578123688697815,
    0.03005501627922058
  ],
  "1148122||4||388": [
    0.041819408535957336,
    0.878376305103302,
    0.07980430871248245
  ],
  "1148122||5||388": [
    0.2071855366230011,
    0.6881498098373413,
    0.1046646386384964
  ],
  "1148122||6||388": [
    0.13303488492965698,
    0.7831990718841553,
    0.08376603573560715
  ],
  "1148122||7||388": [
    0.1272512525320053,
    0.7926729917526245,
    0.08007575571537018
  ],
  "6309659||0||413": [
    0.10634270310401917,
    0.48821160197257996,
    0.40544575452804565
  ],
  "6309659||1||413": [
    0.2014138549566269,
    0.7869284152984619,
    0.011657774448394775
  ],
  "6309659||2||413": [
    0.05035535246133804,
    0.8279072642326355,
    0.12173742800951004
  ],
  "6309659||3||413": [
    0.04189164564013481,
    0.8764297366142273,
    0.08167863637208939
  ],
  "6309659||4||413": [
    0.02735404670238495,
    0.963033139705658,
    0.009612827561795712
  ],
  "6309659||5||413": [
    0.046094901859760284,
    0.9500144124031067,
    0.00389067898504436
  ],
  "6309659||6||413": [
    0.09645083546638489,
    0.8843434453010559,
    0.019205721095204353
  ],
  "6309659||7||413": [
    0.1800527125597,
    0.8168889880180359,
    0.003058263100683689
  ],
  "6309659||8||413": [
    0.07255808264017105,
    0.9180428385734558,
    0.009399102069437504
  ],
  "6309659||9||413": [
    0.1866765022277832,
    0.8070990443229675,
    0.006224462296813726
  ],
  "6309659||10||413": [
    0.11582157015800476,
    0.7196882963180542,
    0.164490208029747
  ],
  "6309659||11||413": [
    0.0878182053565979,
    0.9067047238349915,
    0.005477112717926502
  ],
  "6309659||12||413": [
    0.5498411655426025,
    0.4335949718952179,
    0.016563856974244118
  ],
  "6309659||13||413": [
    0.5309368968009949,
    0.453642874956131,
    0.015420233830809593
  ],
  "6309659||0||414": [
    0.7529298067092896,
    0.23194631934165955,
    0.015123826451599598
  ],
  "6309659||1||414": [
    0.05401463806629181,
    0.8155214190483093,
    0.13046400249004364
  ],
  "6309659||2||414": [
    0.6516335606575012,
    0.339232474565506,
    0.009133975021541119
  ],
  "6309659||3||414": [
    0.03967277333140373,
    0.8734968900680542,
    0.08683035522699356
  ],
  "6309659||4||414": [
    0.06927550584077835,
    0.9148311018943787,
    0.015893368050456047
  ],
  "6309659||5||414": [
    0.015010684728622437,
    0.9622078537940979,
    0.02278149500489235
  ],
  "6309659||6||414": [
    0.014940096996724606,
    0.9504677653312683,
    0.03459208831191063
  ],
  "6309659||7||414": [
    0.003315103007480502,
    0.983141303062439,
    0.0135435676202178
  ],
  "6309659||8||414": [
    0.27083417773246765,
    0.7171596884727478,
    0.012006206437945366
  ],
  "6309659||9||414": [
    0.012294313870370388,
    0.8464308381080627,
    0.1412748098373413
  ],
  "6309659||10||414": [
    0.048590440303087234,
    0.8150632381439209,
    0.13634635508060455
  ],
  "6309659||11||414": [
    0.015170098282396793,
    0.958886444568634,
    0.025943422690033913
  ],
  "6309659||12||414": [
    0.026740141212940216,
    0.46669891476631165,
    0.5065609216690063
  ],
  "6309659||13||414": [
    0.1028636023402214,
    0.8765690326690674,
    0.02056736871600151
  ],
  "6309659||0||416": [
    0.005113999824970961,
    0.9919688105583191,
    0.0029172308277338743
  ],
  "6309659||1||416": [
    0.0026895664632320404,
    0.9961073994636536,
    0.001203019986860454
  ],
  "6309659||2||416": [
    0.006501682568341494,
    0.9313920140266418,
    0.06210629269480705
  ],
  "6309659||3||416": [
    0.04155498743057251,
    0.7713620066642761,
    0.18708296120166779
  ],
  "6309659||4||416": [
    0.02092263661324978,
    0.9641722440719604,
    0.01490516122430563
  ],
  "6309659||5||416": [
    0.10618538409471512,
    0.6267299652099609,
    0.26708468794822693
  ],
  "6309659||6||416": [
    0.017936835065484047,
    0.9528459310531616,
    0.029217183589935303
  ],
  "6309659||7||416": [
    0.012811924330890179,
    0.9859824776649475,
    0.0012055597035214305
  ],
  "6309659||8||416": [
    0.211608424782753,
    0.7770406007766724,
    0.011350978165864944
  ],
  "6309659||9||416": [
    0.012540196068584919,
    0.9260832071304321,
    0.06137661263346672
  ],
  "6309659||10||416": [
    0.026773879304528236,
    0.862589418888092,
    0.11063674837350845
  ],
  "6309659||11||416": [
    0.08293119817972183,
    0.6846641898155212,
    0.2324046790599823
  ],
  "6309659||12||416": [
    0.007600649259984493,
    0.6856486201286316,
    0.3067507743835449
  ],
  "6309659||13||416": [
    0.019733333960175514,
    0.9713025689125061,
    0.008964105509221554
  ],
  "6309659||0||417": [
    0.003980537876486778,
    0.9912790656089783,
    0.004740341566503048
  ],
  "6309659||1||417": [
    0.011045929044485092,
    0.9879412055015564,
    0.001012827386148274
  ],
  "6309659||2||417": [
    0.9838733077049255,
    0.013491183519363403,
    0.0026355721056461334
  ],
  "6309659||3||417": [
    0.055845972150564194,
    0.7523552775382996,
    0.19179876148700714
  ],
  "6309659||4||417": [
    0.035597413778305054,
    0.9528806805610657,
    0.011521875858306885
  ],
  "6309659||5||417": [
    0.12006641179323196,
    0.5926960110664368,
    0.28723764419555664
  ],
  "6309659||6||417": [
    0.0337371863424778,
    0.9304363131523132,
    0.035826534032821655
  ],
  "6309659||7||417": [
    0.03716248273849487,
    0.960915207862854,
    0.0019222891423851252
  ],
  "6309659||8||417": [
    0.2095714658498764,
    0.7726464867591858,
    0.017782088369131088
  ],
  "6309659||9||417": [
    0.28363972902297974,
    0.6825170516967773,
    0.03384324908256531
  ],
  "6309659||10||417": [
    0.0871562510728836,
    0.7668116092681885,
    0.1460321545600891
  ],
  "6309659||11||417": [
    0.13140009343624115,
    0.6846873760223389,
    0.18391253054141998
  ],
  "6309659||12||417": [
    0.8616936206817627,
    0.10544081032276154,
    0.03286556527018547
  ],
  "6309659||13||417": [
    0.7468599081039429,
    0.2483561486005783,
    0.004783887881785631
  ],
  "6309659||0||415": [
    0.753829300403595,
    0.23511959612369537,
    0.01105115469545126
  ],
  "6309659||1||415": [
    0.053146593272686005,
    0.8636369109153748,
    0.08321652561426163
  ],
  "6309659||2||415": [
    0.699604868888855,
    0.29250234365463257,
    0.007892734371125698
  ],
  "6309659||3||415": [
    0.04477866739034653,
    0.8774732947349548,
    0.07774800807237625
  ],
  "6309659||4||415": [
    0.07651002705097198,
    0.913988471031189,
    0.00950152799487114
  ],
  "6309659||5||415": [
    0.010283851996064186,
    0.984091579914093,
    0.005624552257359028
  ],
  "6309659||6||415": [
    0.02220400609076023,
    0.9386166930198669,
    0.03917933627963066
  ],
  "6309659||7||415": [
    0.0027018063701689243,
    0.9925984144210815,
    0.004699737764894962
  ],
  "6309659||8||415": [
    0.24693407118320465,
    0.7464368343353271,
    0.006629088893532753
  ],
  "6309659||9||415": [
    0.006037448532879353,
    0.9477230906486511,
    0.0462394580245018
  ],
  "6309659||10||415": [
    0.06693626940250397,
    0.8180508017539978,
    0.11501290649175644
  ],
  "6309659||11||415": [
    0.01821652054786682,
    0.9579145312309265,
    0.023868942633271217
  ],
  "6309659||12||415": [
    0.012835376895964146,
    0.38018882274627686,
    0.606975793838501
  ],
  "6309659||13||415": [
    0.1269557923078537,
    0.8595084547996521,
    0.013535775244235992
  ],
  "9315213||0||420": [
    0.027935495600104332,
    0.9640224575996399,
    0.00804207380861044
  ],
  "9315213||1||420": [
    0.1149921864271164,
    0.8163166046142578,
    0.0686912089586258
  ],
  "9315213||2||420": [
    0.4362019896507263,
    0.558976411819458,
    0.0048216464929282665
  ],
  "9315213||3||420": [
    0.8287630081176758,
    0.1665056049823761,
    0.004731453023850918
  ],
  "9315213||4||420": [
    0.7427161931991577,
    0.24458244442939758,
    0.012701420113444328
  ],
  "9315213||5||420": [
    0.003108468372374773,
    0.23454803228378296,
    0.7623434662818909
  ],
  "9315213||6||420": [
    0.2094639390707016,
    0.7650877237319946,
    0.025448322296142578
  ],
  "9315213||7||420": [
    0.93317711353302,
    0.06129085272550583,
    0.005532037001103163
  ],
  "9315213||8||420": [
    0.1035195142030716,
    0.8579705357551575,
    0.03850989788770676
  ],
  "9315213||0||680": [
    0.38221651315689087,
    0.6143408417701721,
    0.003442647634074092
  ],
  "9315213||1||680": [
    0.38996490836143494,
    0.5994817614555359,
    0.010553387925028801
  ],
  "9315213||2||680": [
    0.4075401723384857,
    0.5877621173858643,
    0.004697753116488457
  ],
  "9315213||3||680": [
    0.7749125361442566,
    0.22113986313343048,
    0.003947653342038393
  ],
  "9315213||4||680": [
    0.9911483526229858,
    0.0074696592055261135,
    0.001381980604492128
  ],
  "9315213||5||680": [
    0.8900945782661438,
    0.10477301478385925,
    0.0051324148662388325
  ],
  "9315213||6||680": [
    0.8579959869384766,
    0.13773806393146515,
    0.004265910945832729
  ],
  "9315213||7||680": [
    0.29138803482055664,
    0.7043926119804382,
    0.004219362046569586
  ],
  "9315213||8||680": [
    0.8136736154556274,
    0.1831657886505127,
    0.0031605830881744623
  ],
  "9315213||0||681": [
    0.03828045725822449,
    0.9595523476600647,
    0.0021671613212674856
  ],
  "9315213||1||681": [
    0.22050875425338745,
    0.7728367447853088,
    0.0066545396111905575
  ],
  "9315213||2||681": [
    0.056625477969646454,
    0.9401233792304993,
    0.0032511611934751272
  ],
  "9315213||3||681": [
    0.011326050385832787,
    0.7262498140335083,
    0.2624240815639496
  ],
  "9315213||4||681": [
    0.0011923892889171839,
    0.0056886933743953705,
    0.9931188821792603
  ],
  "9315213||5||681": [
    0.09089608490467072,
    0.8045574426651001,
    0.10454646497964859
  ],
  "9315213||6||681": [
    0.10056321322917938,
    0.3561526834964752,
    0.5432840585708618
  ],
  "9315213||7||681": [
    0.10638552159070969,
    0.8853894472122192,
    0.00822504609823227
  ],
  "9315213||8||681": [
    0.22885575890541077,
    0.76217120885849,
    0.00897304993122816
  ],
  "9315213||0||682": [
    0.0025712833739817142,
    0.9961624145507812,
    0.001266289153136313
  ],
  "9315213||1||682": [
    0.06869358569383621,
    0.9173731803894043,
    0.013933274894952774
  ],
  "9315213||2||682": [
    0.04665721580386162,
    0.9503855109214783,
    0.0029572502244263887
  ],
  "9315213||3||682": [
    0.006544829811900854,
    0.9807153940200806,
    0.012739776633679867
  ],
  "9315213||4||682": [
    0.00800906028598547,
    0.22664859890937805,
    0.7653422951698303
  ],
  "9315213||5||682": [
    0.031051283702254295,
    0.9483993053436279,
    0.020549455657601357
  ],
  "9315213||6||682": [
    0.00875544361770153,
    0.9775974154472351,
    0.013647114858031273
  ],
  "9315213||7||682": [
    0.056409627199172974,
    0.9383503198623657,
    0.00524006737396121
  ],
  "9315213||8||682": [
    0.03416948765516281,
    0.962152361869812,
    0.003678139066323638
  ],
  "9315213||0||683": [
    0.25494515895843506,
    0.7380051612854004,
    0.007049723528325558
  ],
  "9315213||1||683": [
    0.15838393568992615,
    0.7932287454605103,
    0.04838729277253151
  ],
  "9315213||2||683": [
    0.43777593970298767,
    0.5578833222389221,
    0.004340703133493662
  ],
  "9315213||3||683": [
    0.27144306898117065,
    0.7201440334320068,
    0.008412890136241913
  ],
  "9315213||4||683": [
    0.9979825019836426,
    0.0011722464114427567,
    0.0008452470065094531
  ],
  "9315213||5||683": [
    0.9000334739685059,
    0.08141699433326721,
    0.018549570813775063
  ],
  "9315213||6||683": [
    0.3443000614643097,
    0.31333619356155396,
    0.34236377477645874
  ],
  "9315213||7||683": [
    0.4958678185939789,
    0.4926374852657318,
    0.011494621634483337
  ],
  "9315213||8||683": [
    0.83956378698349,
    0.15210935473442078,
    0.008326822891831398
  ],
  "10165258||0||444": [
    0.022635772824287415,
    0.9377343654632568,
    0.039629895240068436
  ],
  "10165258||1||444": [
    0.05065957456827164,
    0.9108359813690186,
    0.03850444406270981
  ],
  "10165258||2||444": [
    0.1341385543346405,
    0.7491419315338135,
    0.11671949177980423
  ],
  "10165258||3||444": [
    0.0850299745798111,
    0.8758208155632019,
    0.03914918005466461
  ],
  "10165258||4||444": [
    0.006692271679639816,
    0.9501147866249084,
    0.043192990124225616
  ],
  "10165258||5||444": [
    0.5786404013633728,
    0.3487650156021118,
    0.07259450852870941
  ],
  "10165258||6||444": [
    0.014661584049463272,
    0.5986603498458862,
    0.3866780400276184
  ],
  "10165258||0||445": [
    0.01286059059202671,
    0.9678459167480469,
    0.01929353177547455
  ],
  "10165258||1||445": [
    0.05704190582036972,
    0.8716229200363159,
    0.07133518159389496
  ],
  "10165258||2||445": [
    0.3693830072879791,
    0.5562312602996826,
    0.07438570261001587
  ],
  "10165258||3||445": [
    0.04009311646223068,
    0.9439879059791565,
    0.015918929129838943
  ],
  "10165258||4||445": [
    0.011335308663547039,
    0.9392212629318237,
    0.04944336414337158
  ],
  "10165258||5||445": [
    0.2900860607624054,
    0.529241144657135,
    0.1806727796792984
  ],
  "10165258||6||445": [
    0.04271407797932625,
    0.6619299650192261,
    0.29535597562789917
  ],
  "10165258||0||443": [
    0.007305195089429617,
    0.9400085210800171,
    0.05268622562289238
  ],
  "10165258||1||443": [
    0.03359818458557129,
    0.815163254737854,
    0.1512385606765747
  ],
  "10165258||2||443": [
    0.1046971008181572,
    0.5923286080360413,
    0.30297431349754333
  ],
  "10165258||3||443": [
    0.01084569375962019,
    0.6419657468795776,
    0.3471885919570923
  ],
  "10165258||4||443": [
    0.010411919094622135,
    0.9086610674858093,
    0.08092699199914932
  ],
  "10165258||5||443": [
    0.2938639521598816,
    0.5011663436889648,
    0.20496973395347595
  ],
  "10165258||6||443": [
    0.004709628876298666,
    0.2695941627025604,
    0.7256962656974792
  ],
  "4200695||0||453": [
    0.9409703612327576,
    0.034075021743774414,
    0.024954544380307198
  ],
  "4200695||1||453": [
    0.28555670380592346,
    0.6935497522354126,
    0.02089347317814827
  ],
  "4200695||2||453": [
    0.25594818592071533,
    0.7378397583961487,
    0.006211999803781509
  ],
  "4200695||3||453": [
    0.37258487939834595,
    0.62177973985672,
    0.00563545199111104
  ],
  "4200695||4||453": [
    0.31851544976234436,
    0.6787434816360474,
    0.002741110511124134
  ],
  "4200695||5||453": [
    0.015452586114406586,
    0.9772588014602661,
    0.0072886454872787
  ],
  "4200695||6||453": [
    0.042652565985918045,
    0.9554811716079712,
    0.001866281614638865
  ],
  "4200695||7||453": [
    0.0024119685404002666,
    0.9964794516563416,
    0.0011085980804637074
  ],
  "4200695||8||453": [
    0.009268755093216896,
    0.9898848533630371,
    0.0008464272250421345
  ],
  "4200695||9||453": [
    0.13210445642471313,
    0.8617295622825623,
    0.006165968719869852
  ],
  "4200695||10||453": [
    0.23726296424865723,
    0.7343383431434631,
    0.028398752212524414
  ],
  "4200695||11||453": [
    0.13408879935741425,
    0.8072658777236938,
    0.05864529311656952
  ],
  "4200695||12||453": [
    0.22097857296466827,
    0.7532234787940979,
    0.025797918438911438
  ],
  "4200695||13||453": [
    0.005718738306313753,
    0.8736017346382141,
    0.12067951261997223
  ],
  "4200695||14||453": [
    0.9656786322593689,
    0.03283414617180824,
    0.0014871786115691066
  ],
  "4200695||15||453": [
    0.026551447808742523,
    0.8376784920692444,
    0.13577011227607727
  ],
  "4200695||16||453": [
    0.31354665756225586,
    0.6745178699493408,
    0.011935465037822723
  ],
  "4200695||0||454": [
    0.9698336124420166,
    0.01849503442645073,
    0.011671390384435654
  ],
  "4200695||1||454": [
    0.1893167793750763,
    0.7689699530601501,
    0.041713278740644455
  ],
  "4200695||2||454": [
    0.2021789848804474,
    0.7909294962882996,
    0.006891454569995403
  ],
  "4200695||3||454": [
    0.34901314973831177,
    0.6467002034187317,
    0.004286620300263166
  ],
  "4200695||4||454": [
    0.22627823054790497,
    0.7714139819145203,
    0.0023077840451151133
  ],
  "4200695||5||454": [
    0.016780270263552666,
    0.9769200086593628,
    0.006299707572907209
  ],
  "4200695||6||454": [
    0.010642239823937416,
    0.9883390665054321,
    0.0010186745785176754
  ],
  "4200695||7||454": [
    0.001271913992241025,
    0.9976840019226074,
    0.0010440521873533726
  ],
  "4200695||8||454": [
    0.006280805915594101,
    0.9929693341255188,
    0.0007498560007661581
  ],
  "4200695||9||454": [
    0.1259540170431137,
    0.8698325157165527,
    0.004213448613882065
  ],
  "4200695||10||454": [
    0.16779786348342896,
    0.7895863652229309,
    0.04261581599712372
  ],
  "4200695||11||454": [
    0.02300834283232689,
    0.876969039440155,
    0.10002263635396957
  ],
  "4200695||12||454": [
    0.05570424720644951,
    0.9042007923126221,
    0.04009493440389633
  ],
  "4200695||13||454": [
    0.00494670495390892,
    0.8717966675758362,
    0.12325660139322281
  ],
  "4200695||14||454": [
    0.9574306607246399,
    0.040553607046604156,
    0.0020157229155302048
  ],
  "4200695||15||454": [
    0.01572992652654648,
    0.7641392350196838,
    0.22013084590435028
  ],
  "4200695||16||454": [
    0.20061299204826355,
    0.7742248177528381,
    0.02516225539147854
  ],
  "4200695||0||1056": [
    0.019408676773309708,
    0.7069382071495056,
    0.2736530900001526
  ],
  "4200695||1||1056": [
    0.06209582835435867,
    0.8882594108581543,
    0.04964478686451912
  ],
  "4200695||2||1056": [
    0.02293788082897663,
    0.9697203040122986,
    0.007341868244111538
  ],
  "4200695||3||1056": [
    0.3467095196247101,
    0.6496407389640808,
    0.003649720223620534
  ],
  "4200695||4||1056": [
    0.001394985942170024,
    0.997648298740387,
    0.0009567438974045217
  ],
  "4200695||5||1056": [
    0.020582154393196106,
    0.978228747844696,
    0.0011890437453985214
  ],
  "4200695||6||1056": [
    0.0019639749079942703,
    0.997072696685791,
    0.0009633178706280887
  ],
  "4200695||7||1056": [
    0.0014156409306451678,
    0.9976669549942017,
    0.0009173803846351802
  ],
  "4200695||8||1056": [
    0.006244190968573093,
    0.9930042624473572,
    0.0007515569450333714
  ],
  "4200695||9||1056": [
    0.06645680218935013,
    0.9225699305534363,
    0.010973259806632996
  ],
  "4200695||10||1056": [
    0.12908917665481567,
    0.7746800184249878,
    0.09623081982135773
  ],
  "4200695||11||1056": [
    0.005406991112977266,
    0.9394353628158569,
    0.055157676339149475
  ],
  "4200695||12||1056": [
    0.002657580655068159,
    0.974748969078064,
    0.02259342558681965
  ],
  "4200695||13||1056": [
    0.00552339619025588,
    0.9171870946884155,
    0.07728952914476395
  ],
  "4200695||14||1056": [
    0.0012963460758328438,
    0.99275803565979,
    0.005945650860667229
  ],
  "4200695||15||1056": [
    0.006999645847827196,
    0.9713525176048279,
    0.021647820249199867
  ],
  "4200695||16||1056": [
    0.06248984858393669,
    0.9024237394332886,
    0.03508642688393593
  ],
  "4200695||0||1069": [
    0.03212105482816696,
    0.6122869253158569,
    0.35559195280075073
  ],
  "4200695||1||1069": [
    0.07853685319423676,
    0.8476077914237976,
    0.07385535538196564
  ],
  "4200695||2||1069": [
    0.03356937691569328,
    0.9523060917854309,
    0.014124606736004353
  ],
  "4200695||3||1069": [
    0.4305383563041687,
    0.5658947825431824,
    0.003566868370398879
  ],
  "4200695||4||1069": [
    0.0015004788292571902,
    0.9975624084472656,
    0.0009370804764330387
  ],
  "4200695||5||1069": [
    0.033826153725385666,
    0.9646068811416626,
    0.0015669554704800248
  ],
  "4200695||6||1069": [
    0.0017856501508504152,
    0.9973616003990173,
    0.0008527842001058161
  ],
  "4200695||7||1069": [
    0.0014285671059042215,
    0.9976626634597778,
    0.0009087506914511323
  ],
  "4200695||8||1069": [
    0.007268632762134075,
    0.9918770790100098,
    0.0008542880532331765
  ],
  "4200695||9||1069": [
    0.06057450547814369,
    0.9300053119659424,
    0.009420187212526798
  ],
  "4200695||10||1069": [
    0.15171431005001068,
    0.7385891675949097,
    0.10969649255275726
  ],
  "4200695||11||1069": [
    0.007932513020932674,
    0.9135364890098572,
    0.07853105664253235
  ],
  "4200695||12||1069": [
    0.003677320433780551,
    0.9687336683273315,
    0.0275889802724123
  ],
  "4200695||13||1069": [
    0.005175692494958639,
    0.8810341358184814,
    0.1137901321053505
  ],
  "4200695||14||1069": [
    0.002589727519080043,
    0.9913434982299805,
    0.006066728848963976
  ],
  "4200695||15||1069": [
    0.010471389628946781,
    0.9072705507278442,
    0.08225808292627335
  ],
  "4200695||16||1069": [
    0.09476001560688019,
    0.862998902797699,
    0.04224105551838875
  ],
  "40096222||0||461": [
    0.0028480777982622385,
    0.19749952852725983,
    0.7996523976325989
  ],
  "40096222||1||461": [
    0.07809107005596161,
    0.8929647207260132,
    0.02894425019621849
  ],
  "40096222||2||461": [
    0.4499884247779846,
    0.5429829359054565,
    0.007028657477349043
  ],
  "40096222||3||461": [
    0.4156131148338318,
    0.5610493421554565,
    0.02333751507103443
  ],
  "40096222||4||461": [
    0.8178067207336426,
    0.16593682765960693,
    0.016256513074040413
  ],
  "40096222||5||461": [
    0.5734871625900269,
    0.3892337679862976,
    0.037279050797224045
  ],
  "40096222||6||461": [
    0.517391562461853,
    0.4719832241535187,
    0.010625191032886505
  ],
  "40096222||0||609": [
    0.008413161151111126,
    0.49624529480934143,
    0.4953414797782898
  ],
  "40096222||1||609": [
    0.013861652463674545,
    0.39371851086616516,
    0.5924198627471924
  ],
  "40096222||2||609": [
    0.27382463216781616,
    0.4107801020145416,
    0.3153952956199646
  ],
  "40096222||3||609": [
    0.10145621001720428,
    0.7948894500732422,
    0.10365430265665054
  ],
  "40096222||4||609": [
    0.007004485931247473,
    0.3352753520011902,
    0.657720148563385
  ],
  "40096222||5||609": [
    0.06568195670843124,
    0.769120991230011,
    0.16519702970981598
  ],
  "40096222||6||609": [
    0.01552830170840025,
    0.889436662197113,
    0.09503500908613205
  ],
  "40096222||0||610": [
    0.21683093905448914,
    0.6754336953163147,
    0.10773542523384094
  ],
  "40096222||1||610": [
    0.7860273718833923,
    0.18497419357299805,
    0.02899840846657753
  ],
  "40096222||2||610": [
    0.004722642246633768,
    0.6696953773498535,
    0.32558202743530273
  ],
  "40096222||3||610": [
    0.7152733206748962,
    0.27451467514038086,
    0.0102120041847229
  ],
  "40096222||4||610": [
    0.47965067625045776,
    0.4461873173713684,
    0.07416192442178726
  ],
  "40096222||5||610": [
    0.021299324929714203,
    0.8813291192054749,
    0.09737151861190796
  ],
  "40096222||6||610": [
    0.7557672262191772,
    0.23783659934997559,
    0.006396165117621422
  ],
  "40096222||0||560": [
    0.09878847002983093,
    0.8961830735206604,
    0.005028437357395887
  ],
  "40096222||1||560": [
    0.0036192908883094788,
    0.9949005246162415,
    0.0014802230289205909
  ],
  "40096222||2||560": [
    0.17203320562839508,
    0.82309490442276,
    0.0048718685284256935
  ],
  "40096222||3||560": [
    0.9216371774673462,
    0.07373209297657013,
    0.004630679730325937
  ],
  "40096222||4||560": [
    0.16179053485393524,
    0.7186837792396545,
    0.11952567845582962
  ],
  "40096222||5||560": [
    0.07336270809173584,
    0.9127954840660095,
    0.013841837644577026
  ],
  "40096222||6||560": [
    0.02129462920129299,
    0.9759829044342041,
    0.0027224437799304724
  ],
  "14706752||0||481": [
    0.29345130920410156,
    0.6970241665840149,
    0.009524472989141941
  ],
  "14706752||1||481": [
    0.3016824722290039,
    0.6208727955818176,
    0.07744476944208145
  ],
  "14706752||2||481": [
    0.21589556336402893,
    0.695825457572937,
    0.08827898651361465
  ],
  "14706752||3||481": [
    0.08451825380325317,
    0.8846771717071533,
    0.030804522335529327
  ],
  "14706752||4||481": [
    0.15380319952964783,
    0.7935090065002441,
    0.052687790244817734
  ],
  "14706752||0||1047": [
    0.2542850971221924,
    0.7392241358757019,
    0.006490806117653847
  ],
  "14706752||1||1047": [
    0.13507626950740814,
    0.7785992622375488,
    0.08632444590330124
  ],
  "14706752||2||1047": [
    0.07552909106016159,
    0.8880613446235657,
    0.03640959784388542
  ],
  "14706752||3||1047": [
    0.02553636208176613,
    0.9514947533607483,
    0.022968867793679237
  ],
  "14706752||4||1047": [
    0.03205827623605728,
    0.9512330889701843,
    0.016708627343177795
  ],
  "14706752||0||1400": [
    0.41852253675460815,
    0.5585147738456726,
    0.02296276018023491
  ],
  "14706752||1||1400": [
    0.3346799910068512,
    0.5065672993659973,
    0.1587526500225067
  ],
  "14706752||2||1400": [
    0.3216717839241028,
    0.561818540096283,
    0.11650969088077545
  ],
  "14706752||3||1400": [
    0.306880384683609,
    0.555378258228302,
    0.13774137198925018
  ],
  "14706752||4||1400": [
    0.370457261800766,
    0.5629764199256897,
    0.06656632572412491
  ],
  "14637235||0||484": [
    0.09175097197294235,
    0.8836496472358704,
    0.02459939755499363
  ],
  "14637235||1||484": [
    0.7195772528648376,
    0.27293720841407776,
    0.007485513109713793
  ],
  "14637235||2||484": [
    0.7148046493530273,
    0.27647197246551514,
    0.008723357692360878
  ],
  "14637235||3||484": [
    0.4952736496925354,
    0.4967646300792694,
    0.007961656898260117
  ],
  "14637235||4||484": [
    0.6946582198143005,
    0.26642853021621704,
    0.03891323134303093
  ],
  "14637235||5||484": [
    0.20963166654109955,
    0.7745948433876038,
    0.015773534774780273
  ],
  "14637235||0||485": [
    0.8341654539108276,
    0.1598772257566452,
    0.005957361776381731
  ],
  "14637235||1||485": [
    0.03753228858113289,
    0.9034180641174316,
    0.05904962867498398
  ],
  "14637235||2||485": [
    0.5378381013870239,
    0.3792705833911896,
    0.0828913077712059
  ],
  "14637235||3||485": [
    0.4477260112762451,
    0.5360639095306396,
    0.016210105270147324
  ],
  "14637235||4||485": [
    0.7752218842506409,
    0.21358861029148102,
    0.01118940208107233
  ],
  "14637235||5||485": [
    0.05306049808859825,
    0.9388952255249023,
    0.008044270798563957
  ],
  "14637235||0||486": [
    0.40967339277267456,
    0.5643597841262817,
    0.02596678026020527
  ],
  "14637235||1||486": [
    0.2006528079509735,
    0.7742615342140198,
    0.025085633620619774
  ],
  "14637235||2||486": [
    0.5856545567512512,
    0.4055668115615845,
    0.008778628893196583
  ],
  "14637235||3||486": [
    0.5355831980705261,
    0.45583537220954895,
    0.008581404574215412
  ],
  "14637235||4||486": [
    0.8908711671829224,
    0.09785345196723938,
    0.011275378055870533
  ],
  "14637235||5||486": [
    0.15314333140850067,
    0.8304597735404968,
    0.016396930441260338
  ],
  "14637235||0||487": [
    0.022651689127087593,
    0.9677978157997131,
    0.00955049879848957
  ],
  "14637235||1||487": [
    0.8517501354217529,
    0.11654892563819885,
    0.03170089051127434
  ],
  "14637235||2||487": [
    0.5966752767562866,
    0.32205528020858765,
    0.08126941323280334
  ],
  "14637235||3||487": [
    0.6761707663536072,
    0.31934285163879395,
    0.004486399237066507
  ],
  "14637235||4||487": [
    0.702564537525177,
    0.28597864508628845,
    0.011456772685050964
  ],
  "14637235||5||487": [
    0.01810077577829361,
    0.9766801595687866,
    0.005219061393290758
  ],
  "14637235||0||436": [
    0.7715756893157959,
    0.21550728380680084,
    0.01291697472333908
  ],
  "14637235||1||436": [
    0.013805168680846691,
    0.9600057601928711,
    0.026189038529992104
  ],
  "14637235||2||436": [
    0.16092367470264435,
    0.826820969581604,
    0.012255413457751274
  ],
  "14637235||3||436": [
    0.06457521766424179,
    0.9294060468673706,
    0.006018708925694227
  ],
  "14637235||4||436": [
    0.3594222664833069,
    0.6362958550453186,
    0.004281874746084213
  ],
  "14637235||5||436": [
    0.08173029869794846,
    0.9132378101348877,
    0.005031936336308718
  ],
  "17077004||0||495": [
    0.006967621389776468,
    0.686992347240448,
    0.306039959192276
  ],
  "17077004||1||495": [
    0.07912582904100418,
    0.9068475961685181,
    0.01402656827121973
  ],
  "17077004||2||495": [
    0.07068658620119095,
    0.852428674697876,
    0.07688481360673904
  ],
  "17077004||3||495": [
    0.004464860539883375,
    0.9659609794616699,
    0.029574168846011162
  ],
  "17077004||4||495": [
    0.016466684639453888,
    0.9692995548248291,
    0.014233742840588093
  ],
  "17077004||5||495": [
    0.002544619608670473,
    0.9959778189659119,
    0.001477542333304882
  ],
  "17077004||6||495": [
    0.006867954041808844,
    0.973901629447937,
    0.01923045516014099
  ],
  "17077004||7||495": [
    0.009540317580103874,
    0.8201476335525513,
    0.1703120768070221
  ],
  "17077004||8||495": [
    0.050352804362773895,
    0.8464689254760742,
    0.1031782403588295
  ],
  "17077004||9||495": [
    0.0019323771120980382,
    0.06734097748994827,
    0.9307267069816589
  ],
  "17077004||0||498": [
    0.9583927989006042,
    0.04016700014472008,
    0.0014401762746274471
  ],
  "17077004||1||498": [
    0.017036108300089836,
    0.9748890995979309,
    0.00807478278875351
  ],
  "17077004||2||498": [
    0.1633610725402832,
    0.7974070310592651,
    0.03923185542225838
  ],
  "17077004||3||498": [
    0.034872930496931076,
    0.9535266757011414,
    0.011600377038121223
  ],
  "17077004||4||498": [
    0.13439448177814484,
    0.8604445457458496,
    0.005161010194569826
  ],
  "17077004||5||498": [
    0.050799623131752014,
    0.9444363117218018,
    0.004764064680784941
  ],
  "17077004||6||498": [
    0.15201395750045776,
    0.8394904732704163,
    0.00849558599293232
  ],
  "17077004||7||498": [
    0.04958963021636009,
    0.791386604309082,
    0.15902379155158997
  ],
  "17077004||8||498": [
    0.03277340531349182,
    0.9099913835525513,
    0.057235222309827805
  ],
  "17077004||9||498": [
    0.9985364675521851,
    0.0012054265243932605,
    0.0002580449800007045
  ],
  "17077004||0||923": [
    0.010126682929694653,
    0.9867532253265381,
    0.0031201750971376896
  ],
  "17077004||1||923": [
    0.007009139284491539,
    0.9920334219932556,
    0.0009574191644787788
  ],
  "17077004||2||923": [
    0.036924634128808975,
    0.943952202796936,
    0.019123172387480736
  ],
  "17077004||3||923": [
    0.004924665205180645,
    0.9848796725273132,
    0.010195684619247913
  ],
  "17077004||4||923": [
    0.01090383529663086,
    0.9878811836242676,
    0.0012149389367550611
  ],
  "17077004||5||923": [
    0.002585537265986204,
    0.9965046644210815,
    0.0009098747395910323
  ],
  "17077004||6||923": [
    0.011913321912288666,
    0.9859914183616638,
    0.0020952573977410793
  ],
  "17077004||7||923": [
    0.0035637759137898684,
    0.27495959401130676,
    0.7214766144752502
  ],
  "17077004||8||923": [
    0.049216631799936295,
    0.9403018951416016,
    0.010481423698365688
  ],
  "17077004||9||923": [
    0.0020174668170511723,
    0.005843102466315031,
    0.9921393990516663
  ],
  "17077004||0||925": [
    0.5773019194602966,
    0.42034050822257996,
    0.002357569057494402
  ],
  "17077004||1||925": [
    0.2565303146839142,
    0.736596941947937,
    0.006872734986245632
  ],
  "17077004||2||925": [
    0.5743934512138367,
    0.4120667576789856,
    0.013539810664951801
  ],
  "17077004||3||925": [
    0.2355422079563141,
    0.7606863975524902,
    0.003771362826228142
  ],
  "17077004||4||925": [
    0.21266183257102966,
    0.7829284071922302,
    0.00440980913117528
  ],
  "17077004||5||925": [
    0.03702109679579735,
    0.9612273573875427,
    0.0017515551298856735
  ],
  "17077004||6||925": [
    0.12455668300390244,
    0.8723958730697632,
    0.0030474935192614794
  ],
  "17077004||7||925": [
    0.8659133911132812,
    0.1215885728597641,
    0.012498069554567337
  ],
  "17077004||8||925": [
    0.29661861062049866,
    0.6914218068122864,
    0.011959564872086048
  ],
  "17077004||9||925": [
    0.9534059166908264,
    0.04395369067788124,
    0.0026402934454381466
  ],
  "17077004||0||922": [
    0.3860093653202057,
    0.610030472278595,
    0.003960154484957457
  ],
  "17077004||1||922": [
    0.007523005828261375,
    0.9911631345748901,
    0.0013138403883203864
  ],
  "17077004||2||922": [
    0.13592658936977386,
    0.8397358059883118,
    0.0243376474827528
  ],
  "17077004||3||922": [
    0.06940039247274399,
    0.9251955151557922,
    0.00540410028770566
  ],
  "17077004||4||922": [
    0.09881120175123215,
    0.8984880447387695,
    0.002700742334127426
  ],
  "17077004||5||922": [
    0.034088294953107834,
    0.9640258550643921,
    0.0018858361290767789
  ],
  "17077004||6||922": [
    0.1136140525341034,
    0.8838216066360474,
    0.002564339665696025
  ],
  "17077004||7||922": [
    0.6476392149925232,
    0.32920601963996887,
    0.023154770955443382
  ],
  "17077004||8||922": [
    0.21731938421726227,
    0.7736053466796875,
    0.009075339883565903
  ],
  "17077004||9||922": [
    0.9983443021774292,
    0.0009012705413624644,
    0.000754444336052984
  ],
  "14803797||0||523": [
    0.00885599385946989,
    0.9887945652008057,
    0.002349437214434147
  ],
  "14803797||1||523": [
    0.21462254226207733,
    0.7536748647689819,
    0.03170255199074745
  ],
  "14803797||2||523": [
    0.14525796473026276,
    0.8414705991744995,
    0.013271408155560493
  ],
  "14803797||3||523": [
    0.05814617872238159,
    0.9343066811561584,
    0.007547155022621155
  ],
  "14803797||4||523": [
    0.5441023707389832,
    0.3401110768318176,
    0.1157865896821022
  ],
  "14803797||5||523": [
    0.40534430742263794,
    0.5070644021034241,
    0.08759123086929321
  ],
  "14803797||6||523": [
    0.06069638952612877,
    0.9351068735122681,
    0.004196702502667904
  ],
  "14803797||7||523": [
    0.02029513753950596,
    0.7126374840736389,
    0.2670673727989197
  ],
  "14803797||0||524": [
    0.011851910501718521,
    0.9857670068740845,
    0.002381148748099804
  ],
  "14803797||1||524": [
    0.242485910654068,
    0.7334116101264954,
    0.02410251647233963
  ],
  "14803797||2||524": [
    0.16776734590530396,
    0.8173813819885254,
    0.014851225540041924
  ],
  "14803797||3||524": [
    0.08887249231338501,
    0.9029861092567444,
    0.008141390979290009
  ],
  "14803797||4||524": [
    0.7337532639503479,
    0.1515018790960312,
    0.11474484205245972
  ],
  "14803797||5||524": [
    0.6057882308959961,
    0.3577865958213806,
    0.03642519563436508
  ],
  "14803797||6||524": [
    0.16584262251853943,
    0.8300005197525024,
    0.004156856797635555
  ],
  "14803797||7||524": [
    0.03406757488846779,
    0.7681905627250671,
    0.19774186611175537
  ],
  "14803797||0||881": [
    0.03177618607878685,
    0.9666918516159058,
    0.00153198535554111
  ],
  "14803797||1||881": [
    0.29528316855430603,
    0.7006745934486389,
    0.004042300395667553
  ],
  "14803797||2||881": [
    0.9856365919113159,
    0.008025609888136387,
    0.006337776780128479
  ],
  "14803797||3||881": [
    0.11881843954324722,
    0.8130512237548828,
    0.06813036650419235
  ],
  "14803797||4||881": [
    0.16710828244686127,
    0.8195741176605225,
    0.013317660428583622
  ],
  "14803797||5||881": [
    0.44409453868865967,
    0.5276855826377869,
    0.028219887986779213
  ],
  "14803797||6||881": [
    0.1004178449511528,
    0.8133252859115601,
    0.08625680953264236
  ],
  "14803797||7||881": [
    0.15914186835289001,
    0.7826094031333923,
    0.05824870243668556
  ],
  "14803797||0||883": [
    0.00801520049571991,
    0.9910916686058044,
    0.0008930986514315009
  ],
  "14803797||1||883": [
    0.1237405389547348,
    0.8709390759468079,
    0.005320461001247168
  ],
  "14803797||2||883": [
    0.14769934117794037,
    0.1256125420331955,
    0.7266881465911865
  ],
  "14803797||3||883": [
    0.06392603367567062,
    0.90474933385849,
    0.031324587762355804
  ],
  "14803797||4||883": [
    0.11197642236948013,
    0.8774950504302979,
    0.010528543032705784
  ],
  "14803797||5||883": [
    0.18539036810398102,
    0.7899209260940552,
    0.024688757956027985
  ],
  "14803797||6||883": [
    0.08782587945461273,
    0.8910147547721863,
    0.021159421652555466
  ],
  "14803797||7||883": [
    0.09727143496274948,
    0.8525128364562988,
    0.05021575465798378
  ],
  "14803797||0||884": [
    0.005473392549902201,
    0.9937204122543335,
    0.0008061667322181165
  ],
  "14803797||1||884": [
    0.11935152113437653,
    0.875812828540802,
    0.004835622385144234
  ],
  "14803797||2||884": [
    0.14300939440727234,
    0.11178626120090485,
    0.7452043294906616
  ],
  "14803797||3||884": [
    0.06532062590122223,
    0.909318208694458,
    0.025361089035868645
  ],
  "14803797||4||884": [
    0.1085154116153717,
    0.8781695365905762,
    0.013315060175955296
  ],
  "14803797||5||884": [
    0.17208918929100037,
    0.803191065788269,
    0.024719757959246635
  ],
  "14803797||6||884": [
    0.07467778772115707,
    0.9087615609169006,
    0.016560636460781097
  ],
  "14803797||7||884": [
    0.09033127129077911,
    0.8746858239173889,
    0.034982867538928986
  ],
  "14803797||0||882": [
    0.016787927597761154,
    0.9820318222045898,
    0.0011802730150520802
  ],
  "14803797||1||882": [
    0.22663956880569458,
    0.7693709135055542,
    0.003989506047219038
  ],
  "14803797||2||882": [
    0.9841341376304626,
    0.008816876448690891,
    0.007048981264233589
  ],
  "14803797||3||882": [
    0.10423842817544937,
    0.8351383209228516,
    0.060623202472925186
  ],
  "14803797||4||882": [
    0.1649487167596817,
    0.8137256503105164,
    0.021325668320059776
  ],
  "14803797||5||882": [
    0.3302108943462372,
    0.6341031193733215,
    0.035685956478118896
  ],
  "14803797||6||882": [
    0.0846673771739006,
    0.8537825345993042,
    0.06155003607273102
  ],
  "14803797||7||882": [
    0.1291271150112152,
    0.8150413632392883,
    0.05583149939775467
  ],
  "16056514||0||537": [
    0.33244410157203674,
    0.6624168157577515,
    0.005139134358614683
  ],
  "16056514||1||537": [
    0.8904580473899841,
    0.1006949171423912,
    0.008847018703818321
  ],
  "16056514||2||537": [
    0.865693211555481,
    0.12805095314979553,
    0.006255777087062597
  ],
  "16056514||3||537": [
    0.7450201511383057,
    0.24721759557724,
    0.0077623026445508
  ],
  "16056514||4||537": [
    0.3701380491256714,
    0.3807506859302521,
    0.2491113245487213
  ],
  "16056514||5||537": [
    0.7700563669204712,
    0.22389061748981476,
    0.006053092889487743
  ],
  "16056514||6||537": [
    0.39887961745262146,
    0.5869424343109131,
    0.014178001321852207
  ],
  "16056514||0||930": [
    0.008144085295498371,
    0.9634244441986084,
    0.02843140810728073
  ],
  "16056514||1||930": [
    0.40678533911705017,
    0.5456134080886841,
    0.04760124906897545
  ],
  "16056514||2||930": [
    0.09072517603635788,
    0.8807377815246582,
    0.02853701077401638
  ],
  "16056514||3||930": [
    0.6788964867591858,
    0.31618255376815796,
    0.004921031650155783
  ],
  "16056514||4||930": [
    0.04573221132159233,
    0.9320915937423706,
    0.02217617817223072
  ],
  "16056514||5||930": [
    0.7720040082931519,
    0.20705291628837585,
    0.020943086594343185
  ],
  "16056514||6||930": [
    0.04100169241428375,
    0.9466879963874817,
    0.012310330756008625
  ],
  "16056514||0||536": [
    0.19591595232486725,
    0.7940289974212646,
    0.010055103339254856
  ],
  "16056514||1||536": [
    0.9507237076759338,
    0.04451847821474075,
    0.004757819697260857
  ],
  "16056514||2||536": [
    0.7188587188720703,
    0.13194240629673004,
    0.14919888973236084
  ],
  "16056514||3||536": [
    0.012695233337581158,
    0.9459829926490784,
    0.04132184386253357
  ],
  "16056514||4||536": [
    0.5452348589897156,
    0.25201573967933655,
    0.2027493566274643
  ],
  "16056514||5||536": [
    0.9361057877540588,
    0.056677378714084625,
    0.0072167618200182915
  ],
  "16056514||6||536": [
    0.5369090437889099,
    0.43754953145980835,
    0.025541434064507484
  ],
  "10648422||0||547": [
    0.133505716919899,
    0.8497553467750549,
    0.016738880425691605
  ],
  "10648422||1||547": [
    0.02171868458390236,
    0.9672013521194458,
    0.01107998937368393
  ],
  "10648422||2||547": [
    0.9246776103973389,
    0.06829702854156494,
    0.007025343831628561
  ],
  "10648422||3||547": [
    0.08068958669900894,
    0.8600682616233826,
    0.059242118149995804
  ],
  "10648422||4||547": [
    0.0035350590478628874,
    0.01471323985606432,
    0.9817517399787903
  ],
  "10648422||5||547": [
    0.1251220554113388,
    0.7039681077003479,
    0.1709098368883133
  ],
  "10648422||0||902": [
    0.018634462729096413,
    0.9496432542800903,
    0.031722329556941986
  ],
  "10648422||1||902": [
    0.0035072844475507736,
    0.818720281124115,
    0.17777247726917267
  ],
  "10648422||2||902": [
    0.929585337638855,
    0.06219508498907089,
    0.008219638839364052
  ],
  "10648422||3||902": [
    0.04002797231078148,
    0.2652568817138672,
    0.6947152018547058
  ],
  "10648422||4||902": [
    0.0016579673392698169,
    0.018677208572626114,
    0.9796648025512695
  ],
  "10648422||5||902": [
    0.008396707475185394,
    0.11476960778236389,
    0.8768336772918701
  ],
  "10648422||0||903": [
    0.493306964635849,
    0.4928523898124695,
    0.013840730302035809
  ],
  "10648422||1||903": [
    0.8750651478767395,
    0.11671840399503708,
    0.008216430433094501
  ],
  "10648422||2||903": [
    0.586244523525238,
    0.3436245322227478,
    0.07013092190027237
  ],
  "10648422||3||903": [
    0.8747370839118958,
    0.09915410727262497,
    0.026108795776963234
  ],
  "10648422||4||903": [
    0.9967058300971985,
    0.002108667977154255,
    0.0011855455813929439
  ],
  "10648422||5||903": [
    0.831425666809082,
    0.07400216162204742,
    0.09457219392061234
  ],
  "1049501||0||555": [
    0.13109299540519714,
    0.7883269786834717,
    0.08058002591133118
  ],
  "1049501||1||555": [
    0.03296981751918793,
    0.6974651217460632,
    0.2695651054382324
  ],
  "1049501||2||555": [
    0.0843193307518959,
    0.4629162549972534,
    0.45276445150375366
  ],
  "1049501||3||555": [
    0.8465594053268433,
    0.08553005754947662,
    0.06791055202484131
  ],
  "1049501||4||555": [
    0.14850592613220215,
    0.5591061115264893,
    0.2923879623413086
  ],
  "1049501||5||555": [
    0.07990971952676773,
    0.7600919008255005,
    0.15999843180179596
  ],
  "1049501||6||555": [
    0.7000345587730408,
    0.21390895545482635,
    0.08605649322271347
  ],
  "1049501||7||555": [
    0.665583074092865,
    0.223161980509758,
    0.1112549677491188
  ],
  "1049501||0||557": [
    0.1345682293176651,
    0.7299010753631592,
    0.13553068041801453
  ],
  "1049501||1||557": [
    0.15623795986175537,
    0.6701234579086304,
    0.17363861203193665
  ],
  "1049501||2||557": [
    0.11281795054674149,
    0.32657748460769653,
    0.5606045722961426
  ],
  "1049501||3||557": [
    0.9696820378303528,
    0.016239609569311142,
    0.014078373089432716
  ],
  "1049501||4||557": [
    0.1373686045408249,
    0.5761160254478455,
    0.28651535511016846
  ],
  "1049501||5||557": [
    0.06578446179628372,
    0.7975171804428101,
    0.136698380112648
  ],
  "1049501||6||557": [
    0.26934778690338135,
    0.6668110489845276,
    0.06384116411209106
  ],
  "1049501||7||557": [
    0.9028036594390869,
    0.05501357838511467,
    0.042182788252830505
  ],
  "1049501||0||554": [
    0.10133814066648483,
    0.8707417249679565,
    0.027920134365558624
  ],
  "1049501||1||554": [
    0.27547580003738403,
    0.6297380328178406,
    0.09478617459535599
  ],
  "1049501||2||554": [
    0.0702541247010231,
    0.6132115125656128,
    0.3165344297885895
  ],
  "1049501||3||554": [
    0.674702525138855,
    0.2965976595878601,
    0.028699787333607674
  ],
  "1049501||4||554": [
    0.18958984315395355,
    0.5886449813842773,
    0.2217651903629303
  ],
  "1049501||5||554": [
    0.06669928878545761,
    0.834337592124939,
    0.09896314889192581
  ],
  "1049501||6||554": [
    0.42158111929893494,
    0.47672393918037415,
    0.10169485956430435
  ],
  "1049501||7||554": [
    0.47863703966140747,
    0.41495195031166077,
    0.10641108453273773
  ],
  "3475317||0||559": [
    0.40014564990997314,
    0.27036136388778687,
    0.3294930160045624
  ],
  "3475317||1||559": [
    0.2589677572250366,
    0.4357910752296448,
    0.305241197347641
  ],
  "3475317||2||559": [
    0.31788843870162964,
    0.36122772097587585,
    0.3208838105201721
  ],
  "3475317||3||559": [
    0.2206876128911972,
    0.34846627712249756,
    0.43084609508514404
  ],
  "3475317||4||559": [
    0.19338923692703247,
    0.38990697264671326,
    0.4167037308216095
  ],
  "3475317||5||559": [
    0.02911483123898506,
    0.5029140114784241,
    0.46797114610671997
  ],
  "3475317||6||559": [
    0.22523152828216553,
    0.47237449884414673,
    0.30239394307136536
  ],
  "3475317||7||559": [
    0.007024808321148157,
    0.150239959359169,
    0.8427351713180542
  ],
  "3475317||8||559": [
    0.04251926392316818,
    0.3206807076931,
    0.6368000507354736
  ],
  "3475317||0||1276": [
    0.21655625104904175,
    0.7753278017044067,
    0.008115947246551514
  ],
  "3475317||1||1276": [
    0.03057888150215149,
    0.9197616577148438,
    0.049659471958875656
  ],
  "3475317||2||1276": [
    0.04328083619475365,
    0.953180193901062,
    0.0035390150733292103
  ],
  "3475317||3||1276": [
    0.019508715718984604,
    0.9787909984588623,
    0.0017002752283588052
  ],
  "3475317||4||1276": [
    0.9958239793777466,
    0.0034025972709059715,
    0.0007734156679362059
  ],
  "3475317||5||1276": [
    0.08339132368564606,
    0.37666741013526917,
    0.5399412512779236
  ],
  "3475317||6||1276": [
    0.06703127175569534,
    0.7872227430343628,
    0.14574597775936127
  ],
  "3475317||7||1276": [
    0.1066008135676384,
    0.8485543727874756,
    0.04484479874372482
  ],
  "3475317||8||1276": [
    0.5580451488494873,
    0.4321760833263397,
    0.009778786450624466
  ],
  "3475317||0||1328": [
    0.001315312460064888,
    0.9886012673377991,
    0.010083437897264957
  ],
  "3475317||1||1328": [
    0.012478229589760303,
    0.9536269307136536,
    0.033894844353199005
  ],
  "3475317||2||1328": [
    0.002920591039583087,
    0.969154417514801,
    0.027924995869398117
  ],
  "3475317||3||1328": [
    0.0012956928694620728,
    0.9948847889900208,
    0.003819497302174568
  ],
  "3475317||4||1328": [
    0.005230423528701067,
    0.904759407043457,
    0.0900101587176323
  ],
  "3475317||5||1328": [
    0.019886404275894165,
    0.7518422603607178,
    0.22827133536338806
  ],
  "3475317||6||1328": [
    0.017967665567994118,
    0.877874493598938,
    0.10415787249803543
  ],
  "3475317||7||1328": [
    0.0032441706862300634,
    0.6906563639640808,
    0.30609947443008423
  ],
  "3475317||8||1328": [
    0.005489898845553398,
    0.8361865878105164,
    0.1583235263824463
  ],
  "3475317||0||1202": [
    0.01801612414419651,
    0.9749955534934998,
    0.006988348439335823
  ],
  "3475317||1||1202": [
    0.05302683636546135,
    0.8994541764259338,
    0.04751906171441078
  ],
  "3475317||2||1202": [
    0.026260865852236748,
    0.9698058366775513,
    0.003933359868824482
  ],
  "3475317||3||1202": [
    0.013024767860770226,
    0.9848418235778809,
    0.002133368980139494
  ],
  "3475317||4||1202": [
    0.0019112760201096535,
    0.6817606091499329,
    0.31632810831069946
  ],
  "3475317||5||1202": [
    0.9963598847389221,
    0.002765991725027561,
    0.000874121964443475
  ],
  "3475317||6||1202": [
    0.09007252752780914,
    0.8221036791801453,
    0.08782382309436798
  ],
  "3475317||7||1202": [
    0.3234234154224396,
    0.632188618183136,
    0.04438793659210205
  ],
  "3475317||8||1202": [
    0.011103589087724686,
    0.7386590242385864,
    0.2502373456954956
  ],
  "10300888||0||573": [
    0.016040872782468796,
    0.97571861743927,
    0.008240471594035625
  ],
  "10300888||1||573": [
    0.008948590606451035,
    0.9835761189460754,
    0.007475290913134813
  ],
  "10300888||2||573": [
    0.024822544306516647,
    0.9636619687080383,
    0.011515447869896889
  ],
  "10300888||3||573": [
    0.10824321210384369,
    0.8525351881980896,
    0.03922160714864731
  ],
  "10300888||4||573": [
    0.11499468237161636,
    0.8254585862159729,
    0.059546731412410736
  ],
  "10300888||5||573": [
    0.07160861045122147,
    0.7018272876739502,
    0.22656410932540894
  ],
  "10300888||0||574": [
    0.13528227806091309,
    0.8604442477226257,
    0.0042734574526548386
  ],
  "10300888||1||574": [
    0.012421728111803532,
    0.9830924868583679,
    0.0044858320616185665
  ],
  "10300888||2||574": [
    0.03694970905780792,
    0.9527508020401001,
    0.010299411602318287
  ],
  "10300888||3||574": [
    0.0206757765263319,
    0.9572126865386963,
    0.022111574187874794
  ],
  "10300888||4||574": [
    0.0468570739030838,
    0.8595147728919983,
    0.09362813085317612
  ],
  "10300888||5||574": [
    0.01709301769733429,
    0.616287350654602,
    0.36661967635154724
  ],
  "10300888||0||575": [
    0.18746505677700043,
    0.8073567748069763,
    0.00517821591347456
  ],
  "10300888||1||575": [
    0.019155949354171753,
    0.9771389365196228,
    0.0037050708197057247
  ],
  "10300888||2||575": [
    0.04188474640250206,
    0.9522168040275574,
    0.005898421164602041
  ],
  "10300888||3||575": [
    0.05647876113653183,
    0.9163333773612976,
    0.027187803760170937
  ],
  "10300888||4||575": [
    0.11980564892292023,
    0.8198384046554565,
    0.06035596504807472
  ],
  "10300888||5||575": [
    0.09704604744911194,
    0.6752946972846985,
    0.2276592254638672
  ],
  "4824840||0||595": [
    0.9961898326873779,
    0.003342489944770932,
    0.0004676801327150315
  ],
  "4824840||1||595": [
    0.08301830291748047,
    0.915173351764679,
    0.0018083598697558045
  ],
  "4824840||2||595": [
    0.006556726060807705,
    0.9928434491157532,
    0.0005997392581775784
  ],
  "4824840||3||595": [
    0.0027365190908312798,
    0.9965671300888062,
    0.0006962820771150291
  ],
  "4824840||4||595": [
    0.008160908706486225,
    0.9912177920341492,
    0.0006213168380782008
  ],
  "4824840||5||595": [
    0.0793585479259491,
    0.9190853834152222,
    0.0015560914762318134
  ],
  "4824840||6||595": [
    0.01325659267604351,
    0.9860473871231079,
    0.0006960263708606362
  ],
  "4824840||7||595": [
    0.0593668669462204,
    0.9385022521018982,
    0.002130897482857108
  ],
  "4824840||8||595": [
    0.04501041769981384,
    0.9538741707801819,
    0.0011154129169881344
  ],
  "4824840||9||595": [
    0.9943239688873291,
    0.002300598891451955,
    0.0033754543401300907
  ],
  "4824840||10||595": [
    0.016046376898884773,
    0.9347861409187317,
    0.04916752502322197
  ],
  "4824840||11||595": [
    0.017137043178081512,
    0.8533908724784851,
    0.1294720470905304
  ],
  "4824840||12||595": [
    0.14443035423755646,
    0.8527666330337524,
    0.0028030043467879295
  ],
  "4824840||13||595": [
    0.9801843762397766,
    0.014900574460625648,
    0.004915091674774885
  ],
  "4824840||14||595": [
    0.03017396293580532,
    0.9689910411834717,
    0.0008349993731826544
  ],
  "4824840||0||1072": [
    0.20986567437648773,
    0.785111129283905,
    0.005023225210607052
  ],
  "4824840||1||1072": [
    0.6184632778167725,
    0.3758479356765747,
    0.005688797682523727
  ],
  "4824840||2||1072": [
    0.3310704827308655,
    0.6660552024841309,
    0.002874369965866208
  ],
  "4824840||3||1072": [
    0.10384944826364517,
    0.8927953839302063,
    0.003355199471116066
  ],
  "4824840||4||1072": [
    0.051474738866090775,
    0.9449645280838013,
    0.0035607663448899984
  ],
  "4824840||5||1072": [
    0.5778512358665466,
    0.4174383282661438,
    0.004710413049906492
  ],
  "4824840||6||1072": [
    0.1472596526145935,
    0.8472281694412231,
    0.0055121928453445435
  ],
  "4824840||7||1072": [
    0.07338451594114304,
    0.920121431350708,
    0.006494112778455019
  ],
  "4824840||8||1072": [
    0.05075324699282646,
    0.9441096782684326,
    0.005137123633176088
  ],
  "4824840||9||1072": [
    0.2686179578304291,
    0.20418545603752136,
    0.5271965861320496
  ],
  "4824840||10||1072": [
    0.16975627839565277,
    0.8144632577896118,
    0.015780463814735413
  ],
  "4824840||11||1072": [
    0.15736821293830872,
    0.8349001407623291,
    0.007731709163635969
  ],
  "4824840||12||1072": [
    0.2714332938194275,
    0.7161638736724854,
    0.012402845546603203
  ],
  "4824840||13||1072": [
    0.0018775841454043984,
    0.05643119290471077,
    0.9416912198066711
  ],
  "4824840||14||1072": [
    0.1917862594127655,
    0.8029850125312805,
    0.005228656809777021
  ],
  "4824840||0||1073": [
    0.8876402974128723,
    0.10725656151771545,
    0.0051031638868153095
  ],
  "4824840||1||1073": [
    0.05794108286499977,
    0.9269883036613464,
    0.01507058460265398
  ],
  "4824840||2||1073": [
    0.002136451890692115,
    0.9970484375953674,
    0.0008151425863616168
  ],
  "4824840||3||1073": [
    0.0037755523808300495,
    0.9953492283821106,
    0.000875186116900295
  ],
  "4824840||4||1073": [
    0.004095306154340506,
    0.9948458671569824,
    0.001058783964253962
  ],
  "4824840||5||1073": [
    0.010637020692229271,
    0.9874507188796997,
    0.0019122695084661245
  ],
  "4824840||6||1073": [
    0.017663905397057533,
    0.9801156520843506,
    0.0022204373963177204
  ],
  "4824840||7||1073": [
    0.003130038734525442,
    0.9941923022270203,
    0.0026776085142046213
  ],
  "4824840||8||1073": [
    0.0012598942266777158,
    0.9971686005592346,
    0.0015715491026639938
  ],
  "4824840||9||1073": [
    0.4524407386779785,
    0.19925019145011902,
    0.3483090102672577
  ],
  "4824840||10||1073": [
    0.8873419761657715,
    0.10931647568941116,
    0.0033416005317121744
  ],
  "4824840||11||1073": [
    0.9674087166786194,
    0.03039395622909069,
    0.0021973855327814817
  ],
  "4824840||12||1073": [
    0.025207938626408577,
    0.9695241451263428,
    0.005267856176942587
  ],
  "4824840||13||1073": [
    0.9873703718185425,
    0.009529593400657177,
    0.003099918132647872
  ],
  "4824840||14||1073": [
    0.05407151207327843,
    0.9438400864601135,
    0.0020883993711322546
  ],
  "12258338||0||600": [
    0.9759449362754822,
    0.02262995019555092,
    0.0014251194661483169
  ],
  "12258338||1||600": [
    0.8109404444694519,
    0.18034817278385162,
    0.00871132779866457
  ],
  "12258338||2||600": [
    0.8502973914146423,
    0.14671194553375244,
    0.002990588080137968
  ],
  "12258338||3||600": [
    0.6251732110977173,
    0.36535418033599854,
    0.009472631849348545
  ],
  "12258338||4||600": [
    0.6063722372055054,
    0.37756577134132385,
    0.016061991453170776
  ],
  "12258338||5||600": [
    0.2597618103027344,
    0.7333902716636658,
    0.006847914773970842
  ],
  "12258338||6||600": [
    0.5360448956489563,
    0.45751094818115234,
    0.006444175727665424
  ],
  "12258338||7||600": [
    0.25123414397239685,
    0.7456039190292358,
    0.0031619572546333075
  ],
  "12258338||8||600": [
    0.9378178119659424,
    0.06035061925649643,
    0.0018315608613193035
  ],
  "12258338||9||600": [
    0.4476958215236664,
    0.5494979619979858,
    0.00280620320700109
  ],
  "12258338||10||600": [
    0.38901519775390625,
    0.6070818305015564,
    0.0039029838517308235
  ],
  "12258338||11||600": [
    0.6887727975845337,
    0.3086726665496826,
    0.002554552163928747
  ],
  "12258338||12||600": [
    0.03731868043541908,
    0.9140959978103638,
    0.048585325479507446
  ],
  "12258338||13||600": [
    0.6277177333831787,
    0.3670502007007599,
    0.005232127849012613
  ],
  "12258338||14||600": [
    0.9982059001922607,
    0.0013047439279034734,
    0.000489309779368341
  ],
  "12258338||15||600": [
    0.617885947227478,
    0.37742066383361816,
    0.004693431314080954
  ],
  "12258338||0||601": [
    0.002483769552782178,
    0.711333155632019,
    0.28618305921554565
  ],
  "12258338||1||601": [
    0.12668214738368988,
    0.7368043661117554,
    0.13651351630687714
  ],
  "12258338||2||601": [
    0.008570684120059013,
    0.8512995839118958,
    0.14012973010540009
  ],
  "12258338||3||601": [
    0.02605782076716423,
    0.9250888824462891,
    0.04885333031415939
  ],
  "12258338||4||601": [
    0.04454212263226509,
    0.8477434515953064,
    0.1077144593000412
  ],
  "12258338||5||601": [
    0.023867638781666756,
    0.9612483978271484,
    0.014883972704410553
  ],
  "12258338||6||601": [
    0.016053618863224983,
    0.9549006223678589,
    0.029045753180980682
  ],
  "12258338||7||601": [
    0.0014102216809988022,
    0.9963364601135254,
    0.0022532937582582235
  ],
  "12258338||8||601": [
    0.0026975010987371206,
    0.8374436497688293,
    0.1598588526248932
  ],
  "12258338||9||601": [
    0.022414959967136383,
    0.9707794189453125,
    0.006805642042309046
  ],
  "12258338||10||601": [
    0.0014548765029758215,
    0.9956609606742859,
    0.0028841535095125437
  ],
  "12258338||11||601": [
    0.010239306837320328,
    0.9734441041946411,
    0.01631656102836132
  ],
  "12258338||12||601": [
    0.028013208881020546,
    0.9659945964813232,
    0.005992255639284849
  ],
  "12258338||13||601": [
    0.004460988100618124,
    0.990480363368988,
    0.005058626644313335
  ],
  "12258338||14||601": [
    0.0007945395773276687,
    0.01564328745007515,
    0.9835622906684875
  ],
  "12258338||15||601": [
    0.008912577293813229,
    0.9732446670532227,
    0.017842808738350868
  ],
  "12258338||0||940": [
    0.9932295083999634,
    0.0059462422505021095,
    0.0008242083713412285
  ],
  "12258338||1||940": [
    0.9667897820472717,
    0.030810222029685974,
    0.0023999291006475687
  ],
  "12258338||2||940": [
    0.24166378378868103,
    0.7413986921310425,
    0.016937509179115295
  ],
  "12258338||3||940": [
    0.08841369301080704,
    0.8812611699104309,
    0.03032516874372959
  ],
  "12258338||4||940": [
    0.10010933130979538,
    0.8628690838813782,
    0.03702153265476227
  ],
  "12258338||5||940": [
    0.08919951319694519,
    0.8473964333534241,
    0.06340403109788895
  ],
  "12258338||6||940": [
    0.1516355276107788,
    0.8074585199356079,
    0.04090595617890358
  ],
  "12258338||7||940": [
    0.08288513869047165,
    0.9120014905929565,
    0.005113366991281509
  ],
  "12258338||8||940": [
    0.9513676166534424,
    0.04510340467095375,
    0.0035289570223540068
  ],
  "12258338||9||940": [
    0.2803533673286438,
    0.7159348130226135,
    0.0037118776235729456
  ],
  "12258338||10||940": [
    0.4137042164802551,
    0.580521821975708,
    0.00577389495447278
  ],
  "12258338||11||940": [
    0.5505457520484924,
    0.44586169719696045,
    0.003592531196773052
  ],
  "12258338||12||940": [
    0.026298848912119865,
    0.9683272242546082,
    0.005373964551836252
  ],
  "12258338||13||940": [
    0.19051261246204376,
    0.8043277263641357,
    0.005159634165465832
  ],
  "12258338||14||940": [
    0.9990940093994141,
    0.0006762005505152047,
    0.00022973799786996096
  ],
  "12258338||15||940": [
    0.20777814090251923,
    0.772335410118103,
    0.019886469468474388
  ],
  "12258338||0||941": [
    0.008050422184169292,
    0.8578749299049377,
    0.13407471776008606
  ],
  "12258338||1||941": [
    0.41498610377311707,
    0.5700455904006958,
    0.014968281611800194
  ],
  "12258338||2||941": [
    0.017736544832587242,
    0.8664204478263855,
    0.11584300547838211
  ],
  "12258338||3||941": [
    0.03823815658688545,
    0.9057986736297607,
    0.05596310645341873
  ],
  "12258338||4||941": [
    0.0912633165717125,
    0.8493330478668213,
    0.05940360203385353
  ],
  "12258338||5||941": [
    0.04666510224342346,
    0.849031925201416,
    0.10430295765399933
  ],
  "12258338||6||941": [
    0.025817131623625755,
    0.9172641634941101,
    0.056918732821941376
  ],
  "12258338||7||941": [
    0.0016331402584910393,
    0.9949546456336975,
    0.0034121403004974127
  ],
  "12258338||8||941": [
    0.0013894819421693683,
    0.9700143933296204,
    0.028596075251698494
  ],
  "12258338||9||941": [
    0.06508568674325943,
    0.9250820279121399,
    0.009832300245761871
  ],
  "12258338||10||941": [
    0.003280864330008626,
    0.9853540658950806,
    0.011365055106580257
  ],
  "12258338||11||941": [
    0.01945919543504715,
    0.9686926603317261,
    0.011848135851323605
  ],
  "12258338||12||941": [
    0.02114548347890377,
    0.973178505897522,
    0.005675985012203455
  ],
  "12258338||13||941": [
    0.0057563818991184235,
    0.9900320768356323,
    0.004211610183119774
  ],
  "12258338||14||941": [
    0.001988078700378537,
    0.08523435145616531,
    0.9127775430679321
  ],
  "12258338||15||941": [
    0.004374129232019186,
    0.9856399297714233,
    0.009985900484025478
  ],
  "9638032||0||612": [
    0.011599082499742508,
    0.985491156578064,
    0.0029097655788064003
  ],
  "9638032||1||612": [
    0.11828038841485977,
    0.8785874247550964,
    0.0031322005670517683
  ],
  "9638032||2||612": [
    0.11107740551233292,
    0.8831542730331421,
    0.005768364295363426
  ],
  "9638032||3||612": [
    0.28454869985580444,
    0.6783076524734497,
    0.03714364022016525
  ],
  "9638032||4||612": [
    0.9980382323265076,
    0.0015175167936831713,
    0.00044431124115362763
  ],
  "9638032||5||612": [
    0.9094861149787903,
    0.08445732295513153,
    0.006056527607142925
  ],
  "9638032||6||612": [
    0.0504208467900753,
    0.9432600736618042,
    0.006319137290120125
  ],
  "9638032||0||614": [
    0.45970606803894043,
    0.5258370041847229,
    0.014457006007432938
  ],
  "9638032||1||614": [
    0.005343582481145859,
    0.9813045263290405,
    0.013351880013942719
  ],
  "9638032||2||614": [
    0.208879292011261,
    0.7873467206954956,
    0.0037739332765340805
  ],
  "9638032||3||614": [
    0.665617823600769,
    0.32941925525665283,
    0.0049628945998847485
  ],
  "9638032||4||614": [
    0.01167239248752594,
    0.5021107792854309,
    0.48621684312820435
  ],
  "9638032||5||614": [
    0.3415316045284271,
    0.5194555521011353,
    0.13901287317276
  ],
  "9638032||6||614": [
    0.08639669418334961,
    0.8989367485046387,
    0.014666509814560413
  ],
  "9638032||0||615": [
    0.011414877139031887,
    0.9823517203330994,
    0.006233425810933113
  ],
  "9638032||1||615": [
    0.051514577120542526,
    0.9450291395187378,
    0.003456233534961939
  ],
  "9638032||2||615": [
    0.021500129252672195,
    0.9752079248428345,
    0.003291891422122717
  ],
  "9638032||3||615": [
    0.10679125785827637,
    0.8329946994781494,
    0.0602140799164772
  ],
  "9638032||4||615": [
    0.9980838298797607,
    0.0013930563582107425,
    0.000523185939528048
  ],
  "9638032||5||615": [
    0.6782362461090088,
    0.31285783648490906,
    0.008905906230211258
  ],
  "9638032||6||615": [
    0.008271935395896435,
    0.988171398639679,
    0.0035566699225455523
  ],
  "9638032||0||613": [
    0.5406028032302856,
    0.44477954506874084,
    0.014617634937167168
  ],
  "9638032||1||613": [
    0.012877250090241432,
    0.9787802696228027,
    0.008342456072568893
  ],
  "9638032||2||613": [
    0.47239238023757935,
    0.5218241214752197,
    0.005783526226878166
  ],
  "9638032||3||613": [
    0.6542079448699951,
    0.30871346592903137,
    0.037078607827425
  ],
  "9638032||4||613": [
    0.014593491330742836,
    0.7508018612861633,
    0.23460467159748077
  ],
  "9638032||5||613": [
    0.39968982338905334,
    0.4676055610179901,
    0.1327047049999237
  ],
  "9638032||6||613": [
    0.11708929389715195,
    0.8541932106018066,
    0.02871742658317089
  ],
  "6836086||0||618": [
    0.004460889380425215,
    0.9935765862464905,
    0.001962554408237338
  ],
  "6836086||1||618": [
    0.05322055146098137,
    0.81800377368927,
    0.1287757009267807
  ],
  "6836086||2||618": [
    0.08572056144475937,
    0.8926840424537659,
    0.021595383062958717
  ],
  "6836086||3||618": [
    0.12739765644073486,
    0.6808550357818604,
    0.1917472779750824
  ],
  "6836086||4||618": [
    0.08481346070766449,
    0.8171592354774475,
    0.09802725911140442
  ],
  "6836086||5||618": [
    0.13673518598079681,
    0.8283768892288208,
    0.034887928515672684
  ],
  "6836086||0||1032": [
    0.03407323732972145,
    0.9632750153541565,
    0.002651816699653864
  ],
  "6836086||1||1032": [
    0.06248851120471954,
    0.8371726274490356,
    0.10033881664276123
  ],
  "6836086||2||1032": [
    0.05543100833892822,
    0.9341795444488525,
    0.010389496572315693
  ],
  "6836086||3||1032": [
    0.14037105441093445,
    0.7564854621887207,
    0.10314351320266724
  ],
  "6836086||4||1032": [
    0.1487366408109665,
    0.8012205958366394,
    0.0500427782535553
  ],
  "6836086||5||1032": [
    0.26639866828918457,
    0.6910660862922668,
    0.042535245418548584
  ],
  "6836086||0||1033": [
    0.03499376028776169,
    0.9623201489448547,
    0.0026861210353672504
  ],
  "6836086||1||1033": [
    0.0728948712348938,
    0.8093690276145935,
    0.11773613095283508
  ],
  "6836086||2||1033": [
    0.0586334653198719,
    0.9260084629058838,
    0.01535805594176054
  ],
  "6836086||3||1033": [
    0.16956323385238647,
    0.6923726201057434,
    0.13806414604187012
  ],
  "6836086||4||1033": [
    0.16868577897548676,
    0.7597665190696716,
    0.07154769450426102
  ],
  "6836086||5||1033": [
    0.24876420199871063,
    0.7186978459358215,
    0.03253798931837082
  ],
  "1642727||0||621": [
    0.0013679395196959376,
    0.9975814819335938,
    0.0010506031103432178
  ],
  "1642727||1||621": [
    0.0027707312256097794,
    0.9963477253913879,
    0.0008815973997116089
  ],
  "1642727||2||621": [
    0.0014979264233261347,
    0.9964858293533325,
    0.0020162214059382677
  ],
  "1642727||3||621": [
    0.03036557324230671,
    0.9595954418182373,
    0.010038899257779121
  ],
  "1642727||4||621": [
    0.12092304974794388,
    0.8763766288757324,
    0.0027003230061382055
  ],
  "1642727||5||621": [
    0.010569977574050426,
    0.9816243052482605,
    0.0078057292848825455
  ],
  "1642727||6||621": [
    0.005796854849904776,
    0.9321083426475525,
    0.06209475174546242
  ],
  "1642727||7||621": [
    0.0016603103140369058,
    0.9972604513168335,
    0.001079176552593708
  ],
  "1642727||8||621": [
    0.005406608805060387,
    0.9866264462471008,
    0.007966889068484306
  ],
  "1642727||9||621": [
    0.01839493215084076,
    0.9354796409606934,
    0.046125445514917374
  ],
  "1642727||10||621": [
    0.014254957437515259,
    0.9184728264808655,
    0.06727219372987747
  ],
  "1642727||11||621": [
    0.0075838700868189335,
    0.7146275043487549,
    0.27778857946395874
  ],
  "1642727||12||621": [
    0.06370221078395844,
    0.9311836361885071,
    0.0051141418516635895
  ],
  "1642727||13||621": [
    0.011919941753149033,
    0.7715612053871155,
    0.216518834233284
  ],
  "1642727||14||621": [
    0.007600776851177216,
    0.9752948880195618,
    0.017104286700487137
  ],
  "1642727||0||944": [
    0.9099311828613281,
    0.08727287501096725,
    0.0027959959115833044
  ],
  "1642727||1||944": [
    0.6970290541648865,
    0.29923880100250244,
    0.003732204670086503
  ],
  "1642727||2||944": [
    0.366055428981781,
    0.6300697922706604,
    0.003874747082591057
  ],
  "1642727||3||944": [
    0.27802467346191406,
    0.7060636878013611,
    0.015911631286144257
  ],
  "1642727||4||944": [
    0.38251838088035583,
    0.5998436808586121,
    0.01763795129954815
  ],
  "1642727||5||944": [
    0.24546954035758972,
    0.7368365526199341,
    0.017693908885121346
  ],
  "1642727||6||944": [
    0.39840254187583923,
    0.5641607642173767,
    0.03743666037917137
  ],
  "1642727||7||944": [
    0.4943622052669525,
    0.5015286207199097,
    0.00410920474678278
  ],
  "1642727||8||944": [
    0.40368416905403137,
    0.5841836333274841,
    0.01213217992335558
  ],
  "1642727||9||944": [
    0.842918872833252,
    0.1514149159193039,
    0.005666227545589209
  ],
  "1642727||10||944": [
    0.38243168592453003,
    0.5635936856269836,
    0.053974609822034836
  ],
  "1642727||11||944": [
    0.8372699618339539,
    0.15820524096488953,
    0.004524783231317997
  ],
  "1642727||12||944": [
    0.3259119689464569,
    0.6349303126335144,
    0.039157647639513016
  ],
  "1642727||13||944": [
    0.4323803782463074,
    0.563299834728241,
    0.004319784697145224
  ],
  "1642727||14||944": [
    0.32446008920669556,
    0.6349899172782898,
    0.04054995998740196
  ],
  "1642727||0||921": [
    0.0010908367112278938,
    0.9978310465812683,
    0.0010780623415485024
  ],
  "1642727||1||921": [
    0.0021665343083441257,
    0.9956939220428467,
    0.002139529911801219
  ],
  "1642727||2||921": [
    0.0011579155689105392,
    0.9966391324996948,
    0.0022029955871403217
  ],
  "1642727||3||921": [
    0.03436093404889107,
    0.9631964564323425,
    0.0024425892625004053
  ],
  "1642727||4||921": [
    0.017838982865214348,
    0.9801337718963623,
    0.0020273204427212477
  ],
  "1642727||5||921": [
    0.006943308748304844,
    0.9798063039779663,
    0.013250362128019333
  ],
  "1642727||6||921": [
    0.007517698686569929,
    0.9812884330749512,
    0.011193900369107723
  ],
  "1642727||7||921": [
    0.001010977546684444,
    0.9969561100006104,
    0.002032968681305647
  ],
  "1642727||8||921": [
    0.03178729861974716,
    0.9622792601585388,
    0.005933396052569151
  ],
  "1642727||9||921": [
    0.006684036459773779,
    0.9604689478874207,
    0.03284697234630585
  ],
  "1642727||10||921": [
    0.012514252215623856,
    0.9084296226501465,
    0.07905617356300354
  ],
  "1642727||11||921": [
    0.011124996468424797,
    0.8977794647216797,
    0.09109555184841156
  ],
  "1642727||12||921": [
    0.02908562310039997,
    0.9683288931846619,
    0.0025855230633169413
  ],
  "1642727||13||921": [
    0.0010217191884294152,
    0.022272668778896332,
    0.9767056107521057
  ],
  "1642727||14||921": [
    0.008851176127791405,
    0.9270728230476379,
    0.06407597661018372
  ],
  "16355392||0||626": [
    0.013432648032903671,
    0.9791883826255798,
    0.007378940004855394
  ],
  "16355392||1||626": [
    0.13242070376873016,
    0.7680683732032776,
    0.09951094537973404
  ],
  "16355392||2||626": [
    0.04403595253825188,
    0.04992801323533058,
    0.9060361385345459
  ],
  "16355392||3||626": [
    0.5413901209831238,
    0.43570035696029663,
    0.022909492254257202
  ],
  "16355392||4||626": [
    0.13259966671466827,
    0.5105817914009094,
    0.3568185567855835
  ],
  "16355392||5||626": [
    0.9951087832450867,
    0.0042666844092309475,
    0.0006246257689781487
  ],
  "16355392||6||626": [
    0.9681968092918396,
    0.027548370882868767,
    0.004254844039678574
  ],
  "16355392||7||626": [
    0.9153348207473755,
    0.08101288229227066,
    0.003652231302112341
  ],
  "16355392||0||696": [
    0.6778323650360107,
    0.30560576915740967,
    0.01656191796064377
  ],
  "16355392||1||696": [
    0.6880582571029663,
    0.27316564321517944,
    0.03877609223127365
  ],
  "16355392||2||696": [
    0.8732595443725586,
    0.11960116028785706,
    0.007139318622648716
  ],
  "16355392||3||696": [
    0.571204423904419,
    0.3969271779060364,
    0.03186832368373871
  ],
  "16355392||4||696": [
    0.7692217826843262,
    0.19528305530548096,
    0.035495202988386154
  ],
  "16355392||5||696": [
    0.4144085943698883,
    0.4325719475746155,
    0.1530194729566574
  ],
  "16355392||6||696": [
    0.3821668028831482,
    0.47048550844192505,
    0.14734770357608795
  ],
  "16355392||7||696": [
    0.3429566025733948,
    0.5581287145614624,
    0.09891471266746521
  ],
  "16355392||0||1215": [
    0.08230319619178772,
    0.87826007604599,
    0.03943672031164169
  ],
  "16355392||1||1215": [
    0.052576977759599686,
    0.8115348815917969,
    0.13588814437389374
  ],
  "16355392||2||1215": [
    0.04167928919196129,
    0.8115555047988892,
    0.14676514267921448
  ],
  "16355392||3||1215": [
    0.029451338574290276,
    0.9360348582267761,
    0.034513767808675766
  ],
  "16355392||4||1215": [
    0.0550679937005043,
    0.8153955936431885,
    0.12953639030456543
  ],
  "16355392||5||1215": [
    0.19335146248340607,
    0.7171704769134521,
    0.08947805315256119
  ],
  "16355392||6||1215": [
    0.22619664669036865,
    0.7270546555519104,
    0.04674875736236572
  ],
  "16355392||7||1215": [
    0.3162999749183655,
    0.6688084006309509,
    0.014891603961586952
  ],
  "25649714||0||638": [
    0.5568139553070068,
    0.43848752975463867,
    0.0046985093504190445
  ],
  "25649714||1||638": [
    0.39633116126060486,
    0.5687169432640076,
    0.03495190292596817
  ],
  "25649714||2||638": [
    0.33938080072402954,
    0.5908984541893005,
    0.06972075998783112
  ],
  "25649714||3||638": [
    0.6661627888679504,
    0.32410383224487305,
    0.009733348153531551
  ],
  "25649714||4||638": [
    0.9099161624908447,
    0.08584028482437134,
    0.004243565257638693
  ],
  "25649714||5||638": [
    0.02934800460934639,
    0.9201469421386719,
    0.05050504580140114
  ],
  "25649714||6||638": [
    0.024169860407710075,
    0.8627734184265137,
    0.11305670440196991
  ],
  "25649714||7||638": [
    0.533225953578949,
    0.4583706557750702,
    0.008403417654335499
  ],
  "25649714||8||638": [
    0.004372355528175831,
    0.8603585958480835,
    0.13526901602745056
  ],
  "25649714||9||638": [
    0.7553274631500244,
    0.23859523236751556,
    0.006077322643250227
  ],
  "25649714||0||1070": [
    0.04358647018671036,
    0.946354866027832,
    0.010058591142296791
  ],
  "25649714||1||1070": [
    0.19612501561641693,
    0.7143813967704773,
    0.08949361741542816
  ],
  "25649714||2||1070": [
    0.13315768539905548,
    0.7428308129310608,
    0.12401147931814194
  ],
  "25649714||3||1070": [
    0.034852635115385056,
    0.9524736404418945,
    0.012673737481236458
  ],
  "25649714||4||1070": [
    0.017393361777067184,
    0.9265735745429993,
    0.05603299289941788
  ],
  "25649714||5||1070": [
    0.3583311140537262,
    0.638009250164032,
    0.0036596853751689196
  ],
  "25649714||6||1070": [
    0.6018366813659668,
    0.3942108750343323,
    0.003952458966523409
  ],
  "25649714||7||1070": [
    0.17075152695178986,
    0.7865127325057983,
    0.04273577779531479
  ],
  "25649714||8||1070": [
    0.03677520900964737,
    0.9617592096328735,
    0.0014656244311481714
  ],
  "25649714||9||1070": [
    0.07944097369909286,
    0.9165545701980591,
    0.004004456102848053
  ],
  "25649714||0||637": [
    0.002924207132309675,
    0.9958674907684326,
    0.0012082761386409402
  ],
  "25649714||1||637": [
    0.09602880477905273,
    0.8656734824180603,
    0.03829771280288696
  ],
  "25649714||2||637": [
    0.054605476558208466,
    0.8493631482124329,
    0.09603141248226166
  ],
  "25649714||3||637": [
    0.032346952706575394,
    0.9387491345405579,
    0.028903856873512268
  ],
  "25649714||4||637": [
    0.0034414788242429495,
    0.896779477596283,
    0.09977903962135315
  ],
  "25649714||5||637": [
    0.19890905916690826,
    0.7958804965019226,
    0.005210434552282095
  ],
  "25649714||6||637": [
    0.7410389184951782,
    0.2519175708293915,
    0.007043474353849888
  ],
  "25649714||7||637": [
    0.05184578895568848,
    0.9387655258178711,
    0.009388652630150318
  ],
  "25649714||8||637": [
    0.671168863773346,
    0.3249458074569702,
    0.0038853087462484837
  ],
  "25649714||9||637": [
    0.020737629383802414,
    0.9598407745361328,
    0.019421566277742386
  ],
  "25649714||0||1196": [
    0.030776239931583405,
    0.9640984535217285,
    0.005125304684042931
  ],
  "25649714||1||1196": [
    0.05477926880121231,
    0.90998375415802,
    0.03523697704076767
  ],
  "25649714||2||1196": [
    0.04257446900010109,
    0.8947647213935852,
    0.062660813331604
  ],
  "25649714||3||1196": [
    0.03574725612998009,
    0.9423944354057312,
    0.021858351305127144
  ],
  "25649714||4||1196": [
    0.012190374545753002,
    0.9731374382972717,
    0.014672237448394299
  ],
  "25649714||5||1196": [
    0.4439682066440582,
    0.5532193183898926,
    0.0028124626260250807
  ],
  "25649714||6||1196": [
    0.4608007073402405,
    0.535899817943573,
    0.003299484495073557
  ],
  "25649714||7||1196": [
    0.28193944692611694,
    0.7088338136672974,
    0.009226745925843716
  ],
  "25649714||8||1196": [
    0.15588125586509705,
    0.842046856880188,
    0.0020719077438116074
  ],
  "25649714||9||1196": [
    0.06740300357341766,
    0.9277117252349854,
    0.0048852707259356976
  ],
  "25649714||0||1197": [
    0.5875416994094849,
    0.40723156929016113,
    0.0052267201244831085
  ],
  "25649714||1||1197": [
    0.6105265617370605,
    0.3763335645198822,
    0.013139864429831505
  ],
  "25649714||2||1197": [
    0.41769543290138245,
    0.533425509929657,
    0.04887903481721878
  ],
  "25649714||3||1197": [
    0.41331973671913147,
    0.576324999332428,
    0.010355236008763313
  ],
  "25649714||4||1197": [
    0.7634822130203247,
    0.23275500535964966,
    0.0037627725396305323
  ],
  "25649714||5||1197": [
    0.011196520179510117,
    0.9781719446182251,
    0.010631547309458256
  ],
  "25649714||6||1197": [
    0.02862526848912239,
    0.9363957047462463,
    0.034979041665792465
  ],
  "25649714||7||1197": [
    0.4780467450618744,
    0.5074833631515503,
    0.014469836838543415
  ],
  "25649714||8||1197": [
    0.03351876884698868,
    0.9584640860557556,
    0.008017142303287983
  ],
  "25649714||9||1197": [
    0.24689707159996033,
    0.7446708679199219,
    0.00843206699937582
  ],
  "13639330||0||679": [
    0.1668614149093628,
    0.7494426965713501,
    0.08369585126638412
  ],
  "13639330||1||679": [
    0.09754923731088638,
    0.8514896631240845,
    0.050961077213287354
  ],
  "13639330||2||679": [
    0.06098354235291481,
    0.9238676428794861,
    0.015148832462728024
  ],
  "13639330||3||679": [
    0.23437851667404175,
    0.681166410446167,
    0.08445503562688828
  ],
  "13639330||0||1002": [
    0.15733487904071808,
    0.8274840712547302,
    0.015181024558842182
  ],
  "13639330||1||1002": [
    0.9312465190887451,
    0.05858008190989494,
    0.010173410177230835
  ],
  "13639330||2||1002": [
    0.05614829808473587,
    0.9319303631782532,
    0.01192137598991394
  ],
  "13639330||3||1002": [
    0.5894098877906799,
    0.3982481360435486,
    0.012341939844191074
  ],
  "13639330||0||525": [
    0.007470549084246159,
    0.9637233018875122,
    0.028806155547499657
  ],
  "13639330||1||525": [
    0.5633271932601929,
    0.17128115892410278,
    0.26539164781570435
  ],
  "13639330||2||525": [
    0.006027433089911938,
    0.8894383311271667,
    0.10453420132398605
  ],
  "13639330||3||525": [
    0.12567365169525146,
    0.8095749616622925,
    0.06475131958723068
  ],
  "4452659||0||685": [
    0.7081976532936096,
    0.2761994004249573,
    0.015602909959852695
  ],
  "4452659||1||685": [
    0.24959500133991241,
    0.6826863288879395,
    0.06771864742040634
  ],
  "4452659||2||685": [
    0.03985876590013504,
    0.5211102366447449,
    0.4390310049057007
  ],
  "4452659||3||685": [
    0.005281931720674038,
    0.5576463341712952,
    0.43707171082496643
  ],
  "4452659||4||685": [
    0.05035888031125069,
    0.8521683216094971,
    0.09747276455163956
  ],
  "4452659||5||685": [
    0.042523179203271866,
    0.5531921982765198,
    0.40428462624549866
  ],
  "4452659||6||685": [
    0.04800165072083473,
    0.6887497305870056,
    0.26324865221977234
  ],
  "4452659||7||685": [
    0.1756000965833664,
    0.464887410402298,
    0.3595125079154968
  ],
  "4452659||0||686": [
    0.2574930191040039,
    0.7326741814613342,
    0.009832835756242275
  ],
  "4452659||1||686": [
    0.37507420778274536,
    0.5913977026939392,
    0.03352805972099304
  ],
  "4452659||2||686": [
    0.10998274385929108,
    0.8732645511627197,
    0.0167526975274086
  ],
  "4452659||3||686": [
    0.12334330379962921,
    0.8491604328155518,
    0.0274962168186903
  ],
  "4452659||4||686": [
    0.21727301180362701,
    0.775238037109375,
    0.007488979026675224
  ],
  "4452659||5||686": [
    0.3787989616394043,
    0.6028783917427063,
    0.01832268387079239
  ],
  "4452659||6||686": [
    0.20188921689987183,
    0.7914840579032898,
    0.00662671634927392
  ],
  "4452659||7||686": [
    0.3180426359176636,
    0.6227729916572571,
    0.059184376150369644
  ],
  "4452659||0||687": [
    0.28944164514541626,
    0.6998623609542847,
    0.010696036741137505
  ],
  "4452659||1||687": [
    0.2832660675048828,
    0.7080008387565613,
    0.008733117021620274
  ],
  "4452659||2||687": [
    0.067435123026371,
    0.9183244109153748,
    0.014240420423448086
  ],
  "4452659||3||687": [
    0.019547855481505394,
    0.951189398765564,
    0.02926272712647915
  ],
  "4452659||4||687": [
    0.25510168075561523,
    0.7382909059524536,
    0.006607451010495424
  ],
  "4452659||5||687": [
    0.344281405210495,
    0.6366219520568848,
    0.01909671537578106
  ],
  "4452659||6||687": [
    0.2331039309501648,
    0.7603703141212463,
    0.006525784265249968
  ],
  "4452659||7||687": [
    0.28844818472862244,
    0.6721182465553284,
    0.03943360969424248
  ],
  "4452659||0||688": [
    0.6177977919578552,
    0.3782378137111664,
    0.003964452538639307
  ],
  "4452659||1||688": [
    0.8238817453384399,
    0.1735980361700058,
    0.0025202950928360224
  ],
  "4452659||2||688": [
    0.9652811884880066,
    0.03323010727763176,
    0.00148873426951468
  ],
  "4452659||3||688": [
    0.9961207509040833,
    0.003503626910969615,
    0.0003755659272428602
  ],
  "4452659||4||688": [
    0.9280893802642822,
    0.06961779296398163,
    0.002292861230671406
  ],
  "4452659||5||688": [
    0.9842564463615417,
    0.014735852368175983,
    0.0010076668113470078
  ],
  "4452659||6||688": [
    0.9526668787002563,
    0.045523714274168015,
    0.0018094737315550447
  ],
  "4452659||7||688": [
    0.9286906123161316,
    0.06784725934267044,
    0.003462081542238593
  ],
  "4350400||0||703": [
    0.039506785571575165,
    0.9557508230209351,
    0.0047423518262803555
  ],
  "4350400||1||703": [
    0.021192817017436028,
    0.9764741063117981,
    0.0023331011179834604
  ],
  "4350400||2||703": [
    0.02569298818707466,
    0.9724004864692688,
    0.0019065572414547205
  ],
  "4350400||3||703": [
    0.07282499969005585,
    0.9182646870613098,
    0.008910248056054115
  ],
  "4350400||4||703": [
    0.09598492830991745,
    0.8980201482772827,
    0.005994918756186962
  ],
  "4350400||5||703": [
    0.09248191118240356,
    0.8778499960899353,
    0.02966812625527382
  ],
  "4350400||6||703": [
    0.049264393746852875,
    0.9457153677940369,
    0.005020261276513338
  ],
  "4350400||7||703": [
    0.04699033126235008,
    0.9262571334838867,
    0.026752503588795662
  ],
  "4350400||8||703": [
    0.020585881546139717,
    0.9728406071662903,
    0.006573502905666828
  ],
  "4350400||9||703": [
    0.06697531044483185,
    0.9000136852264404,
    0.033011022955179214
  ],
  "4350400||0||700": [
    0.5527161955833435,
    0.4414478540420532,
    0.005835908465087414
  ],
  "4350400||1||700": [
    0.1409980207681656,
    0.8529530167579651,
    0.006048953160643578
  ],
  "4350400||2||700": [
    0.4802449345588684,
    0.5152930617332458,
    0.004462051670998335
  ],
  "4350400||3||700": [
    0.5391749143600464,
    0.45391127467155457,
    0.006913815159350634
  ],
  "4350400||4||700": [
    0.5908529162406921,
    0.4021049737930298,
    0.007042165379971266
  ],
  "4350400||5||700": [
    0.8943957090377808,
    0.10095342248678207,
    0.004650850780308247
  ],
  "4350400||6||700": [
    0.521725594997406,
    0.4724261462688446,
    0.005848305765539408
  ],
  "4350400||7||700": [
    0.8247829675674438,
    0.16940638422966003,
    0.005810664966702461
  ],
  "4350400||8||700": [
    0.5468447804450989,
    0.4462432861328125,
    0.006911917589604855
  ],
  "4350400||9||700": [
    0.6322958469390869,
    0.3563633859157562,
    0.011340806260704994
  ],
  "4350400||0||702": [
    0.574276864528656,
    0.42060476541519165,
    0.005118372850120068
  ],
  "4350400||1||702": [
    0.125306636095047,
    0.8705083131790161,
    0.004185108933597803
  ],
  "4350400||2||702": [
    0.41157764196395874,
    0.584711492061615,
    0.0037108769174665213
  ],
  "4350400||3||702": [
    0.5039187669754028,
    0.4890649914741516,
    0.007016249932348728
  ],
  "4350400||4||702": [
    0.5479366183280945,
    0.4467795789241791,
    0.0052838013507425785
  ],
  "4350400||5||702": [
    0.8593443632125854,
    0.13622577488422394,
    0.00442976038902998
  ],
  "4350400||6||702": [
    0.46486717462539673,
    0.529607892036438,
    0.005524848587810993
  ],
  "4350400||7||702": [
    0.7958016991615295,
    0.19881470501422882,
    0.005383641459047794
  ],
  "4350400||8||702": [
    0.4607570469379425,
    0.5327636003494263,
    0.006479401607066393
  ],
  "4350400||9||702": [
    0.572404682636261,
    0.41461890935897827,
    0.012976434081792831
  ],
  "22442133||0||705": [
    0.4453015923500061,
    0.5509195327758789,
    0.0037788257468491793
  ],
  "22442133||1||705": [
    0.5915815830230713,
    0.3957371711730957,
    0.012681261636316776
  ],
  "22442133||2||705": [
    0.4610738158226013,
    0.4783405661582947,
    0.060585662722587585
  ],
  "22442133||3||705": [
    0.634963870048523,
    0.3438788652420044,
    0.021157264709472656
  ],
  "22442133||4||705": [
    0.5025309920310974,
    0.48567089438438416,
    0.011798077262938023
  ],
  "22442133||5||705": [
    0.3675682246685028,
    0.6263853907585144,
    0.00604641018435359
  ],
  "22442133||6||705": [
    0.33923158049583435,
    0.6372120380401611,
    0.023556360974907875
  ],
  "22442133||7||705": [
    0.7428231239318848,
    0.23895341157913208,
    0.01822342351078987
  ],
  "22442133||8||705": [
    0.14940014481544495,
    0.7556754350662231,
    0.09492440521717072
  ],
  "22442133||9||705": [
    0.30985620617866516,
    0.6864722371101379,
    0.003671597223728895
  ],
  "22442133||10||705": [
    0.4387401044368744,
    0.5246567130088806,
    0.036603186279535294
  ],
  "22442133||0||709": [
    0.025887349620461464,
    0.3639957308769226,
    0.6101168990135193
  ],
  "22442133||1||709": [
    0.03713315725326538,
    0.9126562476158142,
    0.050210561603307724
  ],
  "22442133||2||709": [
    0.03651733323931694,
    0.7729553580284119,
    0.19052733480930328
  ],
  "22442133||3||709": [
    0.07883645594120026,
    0.8536758422851562,
    0.06748772412538528
  ],
  "22442133||4||709": [
    0.012844073586165905,
    0.9623677134513855,
    0.024788212031126022
  ],
  "22442133||5||709": [
    0.13819965720176697,
    0.8572101593017578,
    0.004590142052620649
  ],
  "22442133||6||709": [
    0.01182460319250822,
    0.9603256583213806,
    0.027849743142724037
  ],
  "22442133||7||709": [
    0.057884227484464645,
    0.5406048893928528,
    0.40151092410087585
  ],
  "22442133||8||709": [
    0.04705594480037689,
    0.18948444724082947,
    0.7634596228599548
  ],
  "22442133||9||709": [
    0.10301433503627777,
    0.8934114575386047,
    0.0035742532927542925
  ],
  "22442133||10||709": [
    0.030528085306286812,
    0.8415078520774841,
    0.12796412408351898
  ],
  "22442133||0||710": [
    0.4136088192462921,
    0.5675437450408936,
    0.018847400322556496
  ],
  "22442133||1||710": [
    0.08644083142280579,
    0.7794910669326782,
    0.13406811654567719
  ],
  "22442133||2||710": [
    0.036578722298145294,
    0.7288752794265747,
    0.23454606533050537
  ],
  "22442133||3||710": [
    0.1065976694226265,
    0.7197967171669006,
    0.17360562086105347
  ],
  "22442133||4||710": [
    0.012223120778799057,
    0.9557802677154541,
    0.03199666365981102
  ],
  "22442133||5||710": [
    0.42823222279548645,
    0.558089554309845,
    0.013678311370313168
  ],
  "22442133||6||710": [
    0.147226944565773,
    0.8234286904335022,
    0.029344413429498672
  ],
  "22442133||7||710": [
    0.08221856504678726,
    0.6551252007484436,
    0.26265624165534973
  ],
  "22442133||8||710": [
    0.5164362192153931,
    0.4780709147453308,
    0.0054928697645664215
  ],
  "22442133||9||710": [
    0.1947142630815506,
    0.7999542355537415,
    0.005331534892320633
  ],
  "22442133||10||710": [
    0.03060300275683403,
    0.8324485421180725,
    0.13694851100444794
  ],
  "18421962||0||713": [
    0.6600415706634521,
    0.33632057905197144,
    0.0036378714721649885
  ],
  "18421962||1||713": [
    0.5044200420379639,
    0.4897645115852356,
    0.005815435666590929
  ],
  "18421962||2||713": [
    0.5615925788879395,
    0.4334547519683838,
    0.004952677059918642
  ],
  "18421962||3||713": [
    0.21767538785934448,
    0.7758346796035767,
    0.006489924155175686
  ],
  "18421962||4||713": [
    0.3947872817516327,
    0.5749622583389282,
    0.03025048039853573
  ],
  "18421962||5||713": [
    0.024530712515115738,
    0.9527832865715027,
    0.022685999050736427
  ],
  "18421962||0||714": [
    0.6944843530654907,
    0.3014080226421356,
    0.004107574932277203
  ],
  "18421962||1||714": [
    0.48691943287849426,
    0.5067746043205261,
    0.00630598422139883
  ],
  "18421962||2||714": [
    0.5617052316665649,
    0.43258756399154663,
    0.005707207601517439
  ],
  "18421962||3||714": [
    0.24399687349796295,
    0.7444514632225037,
    0.011551662348210812
  ],
  "18421962||4||714": [
    0.41704630851745605,
    0.5296196937561035,
    0.05333399400115013
  ],
  "18421962||5||714": [
    0.026427488774061203,
    0.9202457666397095,
    0.053326770663261414
  ],
  "18421962||0||715": [
    0.00633823499083519,
    0.9925865530967712,
    0.001075170817784965
  ],
  "18421962||1||715": [
    0.1249389573931694,
    0.8710081577301025,
    0.0040528434328734875
  ],
  "18421962||2||715": [
    0.17456194758415222,
    0.8052531480789185,
    0.020184893161058426
  ],
  "18421962||3||715": [
    0.11486613005399704,
    0.8799639940261841,
    0.005169888958334923
  ],
  "18421962||4||715": [
    0.416646808385849,
    0.572011411190033,
    0.011341826990246773
  ],
  "18421962||5||715": [
    0.48359882831573486,
    0.5128772854804993,
    0.0035239015705883503
  ],
  "18421962||0||716": [
    0.01214597187936306,
    0.9772342443466187,
    0.01061984058469534
  ],
  "18421962||1||716": [
    0.05799580737948418,
    0.9158108234405518,
    0.026193400844931602
  ],
  "18421962||2||716": [
    0.3120653033256531,
    0.6120787858963013,
    0.07585596293210983
  ],
  "18421962||3||716": [
    0.020272785797715187,
    0.8971968293190002,
    0.0825304239988327
  ],
  "18421962||4||716": [
    0.228036031126976,
    0.49939021468162537,
    0.2725737690925598
  ],
  "18421962||5||716": [
    0.20001865923404694,
    0.7784945964813232,
    0.021486755460500717
  ],
  "11291348||0||745": [
    0.029138298705220222,
    0.9562608599662781,
    0.01460085529834032
  ],
  "11291348||1||745": [
    0.07804571092128754,
    0.7685064673423767,
    0.15344777703285217
  ],
  "11291348||2||745": [
    0.030539346858859062,
    0.9521459937095642,
    0.017314622178673744
  ],
  "11291348||3||745": [
    0.6912166476249695,
    0.2716028392314911,
    0.03718055412173271
  ],
  "11291348||4||745": [
    0.12679041922092438,
    0.8110480904579163,
    0.06216152012348175
  ],
  "11291348||5||745": [
    0.9966523051261902,
    0.002154827583581209,
    0.001192882307805121
  ],
  "11291348||6||745": [
    0.9344818592071533,
    0.057844750583171844,
    0.007673421874642372
  ],
  "11291348||7||745": [
    0.48235222697257996,
    0.4764314591884613,
    0.04121633619070053
  ],
  "11291348||0||746": [
    0.016641195863485336,
    0.9771806001663208,
    0.0061781383119523525
  ],
  "11291348||1||746": [
    0.07994361221790314,
    0.7185518741607666,
    0.20150454342365265
  ],
  "11291348||2||746": [
    0.007973290979862213,
    0.9816927909851074,
    0.010333922691643238
  ],
  "11291348||3||746": [
    0.48588037490844727,
    0.4226363003253937,
    0.09148330986499786
  ],
  "11291348||4||746": [
    0.1277429312467575,
    0.8085882067680359,
    0.06366883218288422
  ],
  "11291348||5||746": [
    0.010026297532022,
    0.03503645956516266,
    0.954937219619751
  ],
  "11291348||6||746": [
    0.3502347767353058,
    0.4058164656162262,
    0.24394875764846802
  ],
  "11291348||7||746": [
    0.9766235947608948,
    0.02055363357067108,
    0.0028228263836354017
  ],
  "11291348||0||747": [
    0.07459773868322372,
    0.9075753092765808,
    0.01782696694135666
  ],
  "11291348||1||747": [
    0.2176886796951294,
    0.6582275032997131,
    0.12408383935689926
  ],
  "11291348||2||747": [
    0.08757268637418747,
    0.8897385597229004,
    0.02268875204026699
  ],
  "11291348||3||747": [
    0.38022691011428833,
    0.5964177846908569,
    0.023355327546596527
  ],
  "11291348||4||747": [
    0.1323288232088089,
    0.852989912033081,
    0.014681272208690643
  ],
  "11291348||5||747": [
    0.005508460570126772,
    0.9922788143157959,
    0.0022127481643110514
  ],
  "11291348||6||747": [
    0.9836156964302063,
    0.012802048586308956,
    0.0035822573117911816
  ],
  "11291348||7||747": [
    0.6262944936752319,
    0.26529839634895325,
    0.10840712487697601
  ],
  "11291348||0||748": [
    0.022776631638407707,
    0.9629529714584351,
    0.014270363375544548
  ],
  "11291348||1||748": [
    0.06044510751962662,
    0.7841013669967651,
    0.15545350313186646
  ],
  "11291348||2||748": [
    0.011059525422751904,
    0.9726232290267944,
    0.016317283734679222
  ],
  "11291348||3||748": [
    0.05174193158745766,
    0.8880829811096191,
    0.06017505005002022
  ],
  "11291348||4||748": [
    0.031489137560129166,
    0.9510406255722046,
    0.01747027412056923
  ],
  "11291348||5||748": [
    0.003596682334318757,
    0.9952799081802368,
    0.0011234809644520283
  ],
  "11291348||6||748": [
    0.024235539138317108,
    0.27011072635650635,
    0.7056537866592407
  ],
  "11291348||7||748": [
    0.9575730562210083,
    0.03595774993300438,
    0.006469145882874727
  ],
  "7552215||0||764": [
    0.16615216434001923,
    0.5472559928894043,
    0.2865918278694153
  ],
  "7552215||1||764": [
    0.3982059955596924,
    0.5887579321861267,
    0.013036093674600124
  ],
  "7552215||2||764": [
    0.32155612111091614,
    0.6697183847427368,
    0.008725469000637531
  ],
  "7552215||3||764": [
    0.4439513385295868,
    0.5433678030967712,
    0.012680823914706707
  ],
  "7552215||4||764": [
    0.12627579271793365,
    0.8678826093673706,
    0.0058415792882442474
  ],
  "7552215||5||764": [
    0.1898193359375,
    0.7974432110786438,
    0.012737514451146126
  ],
  "7552215||6||764": [
    0.43616729974746704,
    0.5527055859565735,
    0.011127173900604248
  ],
  "7552215||7||764": [
    0.4420434236526489,
    0.5518283247947693,
    0.00612822687253356
  ],
  "7552215||8||764": [
    0.12398842722177505,
    0.8257367014884949,
    0.05027492344379425
  ],
  "7552215||9||764": [
    0.0075564938597381115,
    0.862773060798645,
    0.12967047095298767
  ],
  "7552215||10||764": [
    0.7508948445320129,
    0.2367478907108307,
    0.012357288040220737
  ],
  "7552215||11||764": [
    0.37475794553756714,
    0.5712577104568481,
    0.05398440361022949
  ],
  "7552215||12||764": [
    0.7579744458198547,
    0.22448450326919556,
    0.017541036009788513
  ],
  "7552215||0||765": [
    0.955998420715332,
    0.041802503168582916,
    0.0021990404929965734
  ],
  "7552215||1||765": [
    0.9565660357475281,
    0.04002957046031952,
    0.0034044478088617325
  ],
  "7552215||2||765": [
    0.9528224468231201,
    0.04432743415236473,
    0.002850112970918417
  ],
  "7552215||3||765": [
    0.950838029384613,
    0.045195162296295166,
    0.003966722637414932
  ],
  "7552215||4||765": [
    0.9344658851623535,
    0.060760125517845154,
    0.004773924592882395
  ],
  "7552215||5||765": [
    0.9272083640098572,
    0.06966712325811386,
    0.0031245104037225246
  ],
  "7552215||6||765": [
    0.9724690914154053,
    0.024856189265847206,
    0.0026746466755867004
  ],
  "7552215||7||765": [
    0.957757294178009,
    0.04006586968898773,
    0.002176882466301322
  ],
  "7552215||8||765": [
    0.9932116270065308,
    0.005885773338377476,
    0.0009025562321767211
  ],
  "7552215||9||765": [
    0.8667160868644714,
    0.12984631955623627,
    0.0034375381655991077
  ],
  "7552215||10||765": [
    0.757958710193634,
    0.23969735205173492,
    0.002343891654163599
  ],
  "7552215||11||765": [
    0.9767772555351257,
    0.022208020091056824,
    0.001014703419059515
  ],
  "7552215||12||765": [
    0.9961142539978027,
    0.0033273145090788603,
    0.0005585128092207015
  ],
  "7552215||0||766": [
    0.01488721463829279,
    0.9245348572731018,
    0.06057792529463768
  ],
  "7552215||1||766": [
    0.010993102565407753,
    0.7857279181480408,
    0.2032790184020996
  ],
  "7552215||2||766": [
    0.007473888341337442,
    0.8002846837043762,
    0.19224147498607635
  ],
  "7552215||3||766": [
    0.012714090757071972,
    0.8058318495750427,
    0.1814541071653366
  ],
  "7552215||4||766": [
    0.002954541239887476,
    0.7901773452758789,
    0.20686814188957214
  ],
  "7552215||5||766": [
    0.0064774067141115665,
    0.772411048412323,
    0.2211115062236786
  ],
  "7552215||6||766": [
    0.006596610881388187,
    0.709252655506134,
    0.2841506898403168
  ],
  "7552215||7||766": [
    0.0043095313012599945,
    0.87064528465271,
    0.12504521012306213
  ],
  "7552215||8||766": [
    0.007999271154403687,
    0.6014856696128845,
    0.3905150294303894
  ],
  "7552215||9||766": [
    0.010142218321561813,
    0.9362833499908447,
    0.053574420511722565
  ],
  "7552215||10||766": [
    0.01723829284310341,
    0.3683967590332031,
    0.6143649816513062
  ],
  "7552215||11||766": [
    0.006453515030443668,
    0.3510936200618744,
    0.6424528360366821
  ],
  "7552215||12||766": [
    0.001495504635386169,
    0.12338411062955856,
    0.8751204609870911
  ],
  "32275758||0||774": [
    0.46982789039611816,
    0.4861812889575958,
    0.04399082809686661
  ],
  "32275758||1||774": [
    0.5307004451751709,
    0.424221396446228,
    0.04507813602685928
  ],
  "32275758||2||774": [
    0.6395828127861023,
    0.34091800451278687,
    0.019499223679304123
  ],
  "32275758||0||776": [
    0.42547905445098877,
    0.5392119884490967,
    0.035308968275785446
  ],
  "32275758||1||776": [
    0.5224399566650391,
    0.446035772562027,
    0.03152429684996605
  ],
  "32275758||2||776": [
    0.6288939714431763,
    0.3516384959220886,
    0.019467541947960854
  ],
  "32275758||0||777": [
    0.05668321251869202,
    0.9087871313095093,
    0.034529659897089005
  ],
  "32275758||1||777": [
    0.13228076696395874,
    0.8151939511299133,
    0.05252528935670853
  ],
  "32275758||2||777": [
    0.37460795044898987,
    0.5876431465148926,
    0.03774893283843994
  ],
  "32275758||0||775": [
    0.07744345813989639,
    0.8640374541282654,
    0.05851905047893524
  ],
  "32275758||1||775": [
    0.14087776839733124,
    0.7758054137229919,
    0.08331681787967682
  ],
  "32275758||2||775": [
    0.3380706310272217,
    0.6201034188270569,
    0.04182594269514084
  ],
  "8551160||0||795": [
    0.9214814901351929,
    0.07360627502202988,
    0.004912193398922682
  ],
  "8551160||1||795": [
    0.00264785997569561,
    0.20393548905849457,
    0.7934166789054871
  ],
  "8551160||2||795": [
    0.003922358155250549,
    0.9862313866615295,
    0.009846256114542484
  ],
  "8551160||3||795": [
    0.05420955270528793,
    0.9254775643348694,
    0.020312918350100517
  ],
  "8551160||4||795": [
    0.00861061830073595,
    0.9895420074462891,
    0.0018473759992048144
  ],
  "8551160||5||795": [
    0.07776898145675659,
    0.9064164757728577,
    0.015814514830708504
  ],
  "8551160||0||797": [
    0.0008712018607184291,
    0.023876691237092018,
    0.9752520322799683
  ],
  "8551160||1||797": [
    0.0034796998370438814,
    0.8509715795516968,
    0.14554868638515472
  ],
  "8551160||2||797": [
    0.0012197718024253845,
    0.9887142777442932,
    0.010065906681120396
  ],
  "8551160||3||797": [
    0.011385466903448105,
    0.9739370942115784,
    0.01467745378613472
  ],
  "8551160||4||797": [
    0.002203114330768585,
    0.9947769641876221,
    0.003019958036020398
  ],
  "8551160||5||797": [
    0.13013097643852234,
    0.8421586155891418,
    0.027710439637303352
  ],
  "8551160||0||798": [
    0.882434606552124,
    0.11524805426597595,
    0.0023173734080046415
  ],
  "8551160||1||798": [
    0.8348199129104614,
    0.15673650801181793,
    0.008443542756140232
  ],
  "8551160||2||798": [
    0.6641759276390076,
    0.33183372020721436,
    0.003990270663052797
  ],
  "8551160||3||798": [
    0.5435962677001953,
    0.4490273892879486,
    0.007376301568001509
  ],
  "8551160||4||798": [
    0.05947314575314522,
    0.9387791752815247,
    0.0017476248322054744
  ],
  "8551160||5||798": [
    0.8961154818534851,
    0.10117974132299423,
    0.0027047530747950077
  ],
  "8551160||0||793": [
    0.23641476035118103,
    0.7533722519874573,
    0.010212969966232777
  ],
  "8551160||1||793": [
    0.9992491602897644,
    0.0006119075696915388,
    0.0001388847449561581
  ],
  "8551160||2||793": [
    0.9809194207191467,
    0.017657676711678505,
    0.001422865898348391
  ],
  "8551160||3||793": [
    0.9441798329353333,
    0.05218082293868065,
    0.0036393716000020504
  ],
  "8551160||4||793": [
    0.700116753578186,
    0.2950589060783386,
    0.004824306350201368
  ],
  "8551160||5||793": [
    0.9527462720870972,
    0.04545705020427704,
    0.0017966243904083967
  ],
  "15319019||0||822": [
    0.17385493218898773,
    0.813854455947876,
    0.012290597893297672
  ],
  "15319019||1||822": [
    0.18139122426509857,
    0.7670961022377014,
    0.05151268467307091
  ],
  "15319019||2||822": [
    0.03703431785106659,
    0.9521456360816956,
    0.010820041410624981
  ],
  "15319019||3||822": [
    0.007315979804843664,
    0.9910914301872253,
    0.0015925613697618246
  ],
  "15319019||4||822": [
    0.005871345289051533,
    0.9896173477172852,
    0.0045113456435501575
  ],
  "15319019||5||822": [
    0.009602010250091553,
    0.9867558479309082,
    0.003642062423750758
  ],
  "15319019||6||822": [
    0.004782179836183786,
    0.9934778213500977,
    0.0017400204669684172
  ],
  "15319019||7||822": [
    0.0736125260591507,
    0.8926759362220764,
    0.033711496740579605
  ],
  "15319019||8||822": [
    0.02917003072798252,
    0.251246839761734,
    0.7195831537246704
  ],
  "15319019||9||822": [
    0.057575441896915436,
    0.9381788372993469,
    0.004245715215802193
  ],
  "15319019||10||822": [
    0.14931128919124603,
    0.8397125005722046,
    0.010976187884807587
  ],
  "15319019||11||822": [
    0.08069384098052979,
    0.8098372220993042,
    0.1094689667224884
  ],
  "15319019||12||822": [
    0.8978271484375,
    0.09590228646993637,
    0.006270658224821091
  ],
  "15319019||13||822": [
    0.021906200796365738,
    0.593747079372406,
    0.38434678316116333
  ],
  "15319019||14||822": [
    0.02864973619580269,
    0.3833997845649719,
    0.5879505276679993
  ],
  "15319019||15||822": [
    0.08110277354717255,
    0.893783450126648,
    0.025113755837082863
  ],
  "15319019||0||825": [
    0.2132227122783661,
    0.7590842247009277,
    0.027693074196577072
  ],
  "15319019||1||825": [
    0.13936027884483337,
    0.8058049082756042,
    0.05483478680253029
  ],
  "15319019||2||825": [
    0.13217748701572418,
    0.8514682054519653,
    0.01635430008172989
  ],
  "15319019||3||825": [
    0.005362591240555048,
    0.9935482144355774,
    0.0010891575366258621
  ],
  "15319019||4||825": [
    0.27062973380088806,
    0.7258837819099426,
    0.0034865017514675856
  ],
  "15319019||5||825": [
    0.13667018711566925,
    0.8600260615348816,
    0.0033037986140698195
  ],
  "15319019||6||825": [
    0.0202147476375103,
    0.9769585728645325,
    0.0028266196604818106
  ],
  "15319019||7||825": [
    0.08000557124614716,
    0.9072890877723694,
    0.012705349363386631
  ],
  "15319019||8||825": [
    0.3388166129589081,
    0.511191725730896,
    0.1499916911125183
  ],
  "15319019||9||825": [
    0.2756815254688263,
    0.7196152210235596,
    0.004703234415501356
  ],
  "15319019||10||825": [
    0.1718137413263321,
    0.8122049570083618,
    0.015981338918209076
  ],
  "15319019||11||825": [
    0.22023341059684753,
    0.7440124154090881,
    0.03575421869754791
  ],
  "15319019||12||825": [
    0.04456079378724098,
    0.5010475516319275,
    0.4543916881084442
  ],
  "15319019||13||825": [
    0.8995200991630554,
    0.05527546629309654,
    0.04520436003804207
  ],
  "15319019||14||825": [
    0.3324287235736847,
    0.48948898911476135,
    0.17808230221271515
  ],
  "15319019||15||825": [
    0.10153006762266159,
    0.8458684086799622,
    0.05260149762034416
  ],
  "15319019||0||823": [
    0.30439823865890503,
    0.6864521503448486,
    0.00914959516376257
  ],
  "15319019||1||823": [
    0.22927303612232208,
    0.7467314004898071,
    0.02399558387696743
  ],
  "15319019||2||823": [
    0.060085657984018326,
    0.9233541488647461,
    0.016560187563300133
  ],
  "15319019||3||823": [
    0.008324792608618736,
    0.9903163313865662,
    0.0013589519076049328
  ],
  "15319019||4||823": [
    0.011211761273443699,
    0.9717357754707336,
    0.017052480950951576
  ],
  "15319019||5||823": [
    0.015988433733582497,
    0.9793137907981873,
    0.004697747062891722
  ],
  "15319019||6||823": [
    0.01750117540359497,
    0.979800820350647,
    0.002698038937523961
  ],
  "15319019||7||823": [
    0.294554740190506,
    0.6412652134895325,
    0.06418004631996155
  ],
  "15319019||8||823": [
    0.09377231448888779,
    0.4482123851776123,
    0.4580152630805969
  ],
  "15319019||9||823": [
    0.12411358952522278,
    0.8708226084709167,
    0.00506378710269928
  ],
  "15319019||10||823": [
    0.1687363237142563,
    0.8212369084358215,
    0.010026838630437851
  ],
  "15319019||11||823": [
    0.30465880036354065,
    0.6604950428009033,
    0.03484613075852394
  ],
  "15319019||12||823": [
    0.5768917798995972,
    0.4034918248653412,
    0.019616402685642242
  ],
  "15319019||13||823": [
    0.08870319277048111,
    0.8365679979324341,
    0.07472878694534302
  ],
  "15319019||14||823": [
    0.04273483529686928,
    0.3515293002128601,
    0.6057358384132385
  ],
  "15319019||15||823": [
    0.10665526986122131,
    0.862951397895813,
    0.030393358319997787
  ],
  "15928989||0||835": [
    0.70372074842453,
    0.2917342185974121,
    0.004545043688267469
  ],
  "15928989||1||835": [
    0.22587265074253082,
    0.756323516368866,
    0.01780378818511963
  ],
  "15928989||2||835": [
    0.9946945309638977,
    0.0043172151781618595,
    0.0009882156737148762
  ],
  "15928989||3||835": [
    0.12489384412765503,
    0.8617531657218933,
    0.013353000394999981
  ],
  "15928989||4||835": [
    0.7319273352622986,
    0.2616358697414398,
    0.006436777766793966
  ],
  "15928989||5||835": [
    0.6375607848167419,
    0.33908259868621826,
    0.023356586694717407
  ],
  "15928989||6||835": [
    0.7845621109008789,
    0.19162830710411072,
    0.02380954660475254
  ],
  "15928989||7||835": [
    0.8966475129127502,
    0.09515678137540817,
    0.008195648901164532
  ],
  "15928989||8||835": [
    0.1999257355928421,
    0.7841933965682983,
    0.015880823135375977
  ],
  "15928989||9||835": [
    0.9891085624694824,
    0.010129565373063087,
    0.0007618279778398573
  ],
  "15928989||0||838": [
    0.039637088775634766,
    0.80484938621521,
    0.1555134803056717
  ],
  "15928989||1||838": [
    0.5856965184211731,
    0.3948063552379608,
    0.019497118890285492
  ],
  "15928989||2||838": [
    0.004807597957551479,
    0.9576876163482666,
    0.03750482574105263
  ],
  "15928989||3||838": [
    0.27227815985679626,
    0.7229143381118774,
    0.004807536490261555
  ],
  "15928989||4||838": [
    0.42124342918395996,
    0.5127378106117249,
    0.06601878255605698
  ],
  "15928989||5||838": [
    0.5258371829986572,
    0.42481327056884766,
    0.04934949055314064
  ],
  "15928989||6||838": [
    0.15186011791229248,
    0.6090677380561829,
    0.23907218873500824
  ],
  "15928989||7||838": [
    0.013738680630922318,
    0.975732684135437,
    0.010528694838285446
  ],
  "15928989||8||838": [
    0.44423797726631165,
    0.5345674753189087,
    0.021194549277424812
  ],
  "15928989||9||838": [
    0.11046423017978668,
    0.7176664471626282,
    0.17186926305294037
  ],
  "15928989||0||837": [
    0.0065605673007667065,
    0.9600040912628174,
    0.03343529254198074
  ],
  "15928989||1||837": [
    0.5169750452041626,
    0.47499585151672363,
    0.008029098622500896
  ],
  "15928989||2||837": [
    0.00264909490942955,
    0.7099319100379944,
    0.28741905093193054
  ],
  "15928989||3||837": [
    0.17053966224193573,
    0.8197208642959595,
    0.009739406406879425
  ],
  "15928989||4||837": [
    0.25244927406311035,
    0.6673952341079712,
    0.08015547692775726
  ],
  "15928989||5||837": [
    0.37849143147468567,
    0.4838477671146393,
    0.13766078650951385
  ],
  "15928989||6||837": [
    0.039480287581682205,
    0.8566081523895264,
    0.10391156375408173
  ],
  "15928989||7||837": [
    0.0038665246684104204,
    0.9435655474662781,
    0.052567947655916214
  ],
  "15928989||8||837": [
    0.45197269320487976,
    0.5322681069374084,
    0.015759184956550598
  ],
  "15928989||9||837": [
    0.014444761909544468,
    0.894115149974823,
    0.09144005924463272
  ],
  "15663829||0||840": [
    0.9310591220855713,
    0.04678719490766525,
    0.022153634577989578
  ],
  "15663829||1||840": [
    0.05951555445790291,
    0.6368698477745056,
    0.30361461639404297
  ],
  "15663829||2||840": [
    0.17364591360092163,
    0.7446406483650208,
    0.08171341568231583
  ],
  "15663829||3||840": [
    0.06784333288669586,
    0.8167008757591248,
    0.11545582860708237
  ],
  "15663829||4||840": [
    0.7175909280776978,
    0.26102176308631897,
    0.02138727530837059
  ],
  "15663829||5||840": [
    0.06614429503679276,
    0.7954013347625732,
    0.1384543776512146
  ],
  "15663829||6||840": [
    0.16989177465438843,
    0.810498058795929,
    0.019610203802585602
  ],
  "15663829||7||840": [
    0.04510629177093506,
    0.8766494989395142,
    0.07824425399303436
  ],
  "15663829||8||840": [
    0.08822987973690033,
    0.865990936756134,
    0.04577920585870743
  ],
  "15663829||9||840": [
    0.08701562881469727,
    0.8388611078262329,
    0.07412319630384445
  ],
  "15663829||0||841": [
    0.9020747542381287,
    0.08791124075651169,
    0.01001389417797327
  ],
  "15663829||1||841": [
    0.5415610074996948,
    0.4115937650203705,
    0.04684525728225708
  ],
  "15663829||2||841": [
    0.20431388914585114,
    0.6023154258728027,
    0.19337067008018494
  ],
  "15663829||3||841": [
    0.18438297510147095,
    0.6846819519996643,
    0.13093511760234833
  ],
  "15663829||4||841": [
    0.20705197751522064,
    0.5820964574813843,
    0.21085159480571747
  ],
  "15663829||5||841": [
    0.33249205350875854,
    0.5712283253669739,
    0.09627960622310638
  ],
  "15663829||6||841": [
    0.24398283660411835,
    0.5850312113761902,
    0.17098593711853027
  ],
  "15663829||7||841": [
    0.6950069665908813,
    0.27804747223854065,
    0.026945577934384346
  ],
  "15663829||8||841": [
    0.09618827700614929,
    0.7750532031059265,
    0.128758504986763
  ],
  "15663829||9||841": [
    0.08067059516906738,
    0.643559455871582,
    0.275769978761673
  ],
  "15663829||0||517": [
    0.6996396780014038,
    0.26748019456863403,
    0.03288009390234947
  ],
  "15663829||1||517": [
    0.34236016869544983,
    0.6358049511909485,
    0.021834861487150192
  ],
  "15663829||2||517": [
    0.11031951010227203,
    0.8072973489761353,
    0.08238319307565689
  ],
  "15663829||3||517": [
    0.08168233931064606,
    0.877889096736908,
    0.04042850807309151
  ],
  "15663829||4||517": [
    0.09772510081529617,
    0.5504705905914307,
    0.35180428624153137
  ],
  "15663829||5||517": [
    0.08714523166418076,
    0.865942656993866,
    0.04691218212246895
  ],
  "15663829||6||517": [
    0.1331762820482254,
    0.8444757461547852,
    0.022347964346408844
  ],
  "15663829||7||517": [
    0.16027946770191193,
    0.8228648900985718,
    0.01685563288629055
  ],
  "15663829||8||517": [
    0.061226967722177505,
    0.8938664793968201,
    0.04490659758448601
  ],
  "15663829||9||517": [
    0.07139170169830322,
    0.8246532082557678,
    0.10395514965057373
  ],
  "1982286||0||858": [
    0.123125359416008,
    0.8290947079658508,
    0.04777992516756058
  ],
  "1982286||1||858": [
    0.025621721521019936,
    0.9253614544868469,
    0.049016837030649185
  ],
  "1982286||2||858": [
    0.015249521471560001,
    0.9261943697929382,
    0.05855617672204971
  ],
  "1982286||3||858": [
    0.916114330291748,
    0.0666690394282341,
    0.01721658930182457
  ],
  "1982286||4||858": [
    0.23444540798664093,
    0.7610076665878296,
    0.004546962212771177
  ],
  "1982286||5||858": [
    0.8431035280227661,
    0.12959185242652893,
    0.02730461396276951
  ],
  "1982286||0||1009": [
    0.13981996476650238,
    0.83046954870224,
    0.029710453003644943
  ],
  "1982286||1||1009": [
    0.20742449164390564,
    0.7773957252502441,
    0.015179810114204884
  ],
  "1982286||2||1009": [
    0.04432278499007225,
    0.9323976039886475,
    0.023279573768377304
  ],
  "1982286||3||1009": [
    0.8968004584312439,
    0.0956517681479454,
    0.007547779940068722
  ],
  "1982286||4||1009": [
    0.0036011580377817154,
    0.09853313118219376,
    0.8978657722473145
  ],
  "1982286||5||1009": [
    0.7834845185279846,
    0.19330787658691406,
    0.023207644000649452
  ],
  "1982286||0||859": [
    0.01792953722178936,
    0.47588393092155457,
    0.5061865448951721
  ],
  "1982286||1||859": [
    0.1644071489572525,
    0.5530036687850952,
    0.28258922696113586
  ],
  "1982286||2||859": [
    0.0041408599354326725,
    0.3827509582042694,
    0.6131081581115723
  ],
  "1982286||3||859": [
    0.9961889386177063,
    0.003122210269793868,
    0.0006888746866025031
  ],
  "1982286||4||859": [
    0.5764603018760681,
    0.4173652231693268,
    0.006174408830702305
  ],
  "1982286||5||859": [
    0.9894288182258606,
    0.009309260174632072,
    0.0012619257904589176
  ],
  "195689316||0||871": [
    0.0032935799099504948,
    0.7375243902206421,
    0.25918203592300415
  ],
  "195689316||1||871": [
    0.02317637950181961,
    0.8899794220924377,
    0.08684419095516205
  ],
  "195689316||2||871": [
    0.003822985338047147,
    0.8101972341537476,
    0.18597978353500366
  ],
  "195689316||3||871": [
    0.009775570593774319,
    0.8748849630355835,
    0.11533944308757782
  ],
  "195689316||4||871": [
    0.004550552926957607,
    0.9512996673583984,
    0.0441497303545475
  ],
  "195689316||5||871": [
    0.02883218787610531,
    0.9441872239112854,
    0.02698056772351265
  ],
  "195689316||6||871": [
    0.003631506348028779,
    0.6538538932800293,
    0.3425145447254181
  ],
  "195689316||7||871": [
    0.11691104620695114,
    0.7915976643562317,
    0.09149132668972015
  ],
  "195689316||8||871": [
    0.00730590894818306,
    0.9704082608222961,
    0.02228585071861744
  ],
  "195689316||9||871": [
    0.0023810977581888437,
    0.4624217748641968,
    0.5351971387863159
  ],
  "195689316||10||871": [
    0.0030778672080487013,
    0.7846077084541321,
    0.2123144567012787
  ],
  "195689316||11||871": [
    0.002266911556944251,
    0.5639726519584656,
    0.43376049399375916
  ],
  "195689316||12||871": [
    0.0028421843890100718,
    0.5841073989868164,
    0.4130503833293915
  ],
  "195689316||0||876": [
    0.9583655595779419,
    0.03825462609529495,
    0.003379801055416465
  ],
  "195689316||1||876": [
    0.6279028058052063,
    0.3639160990715027,
    0.008181151933968067
  ],
  "195689316||2||876": [
    0.6861135363578796,
    0.30576565861701965,
    0.008120798505842686
  ],
  "195689316||3||876": [
    0.7182495594024658,
    0.2719355523586273,
    0.009814905002713203
  ],
  "195689316||4||876": [
    0.6654318571090698,
    0.32211044430732727,
    0.012457696720957756
  ],
  "195689316||5||876": [
    0.5206702351570129,
    0.4657999873161316,
    0.013529801741242409
  ],
  "195689316||6||876": [
    0.9434679746627808,
    0.04939776286482811,
    0.00713421031832695
  ],
  "195689316||7||876": [
    0.403787225484848,
    0.5253753662109375,
    0.07083733379840851
  ],
  "195689316||8||876": [
    0.4601123332977295,
    0.5344648957252502,
    0.005422757938504219
  ],
  "195689316||9||876": [
    0.995376706123352,
    0.0037115043960511684,
    0.000911820912733674
  ],
  "195689316||10||876": [
    0.8049969673156738,
    0.18303123116493225,
    0.011971780098974705
  ],
  "195689316||11||876": [
    0.9807683825492859,
    0.015819914638996124,
    0.003411761252209544
  ],
  "195689316||12||876": [
    0.8971379995346069,
    0.09430170804262161,
    0.008560292422771454
  ],
  "195689316||0||870": [
    0.0032935799099504948,
    0.7375243902206421,
    0.25918203592300415
  ],
  "195689316||1||870": [
    0.02317637950181961,
    0.8899794220924377,
    0.08684419095516205
  ],
  "195689316||2||870": [
    0.003822985338047147,
    0.8101972341537476,
    0.18597978353500366
  ],
  "195689316||3||870": [
    0.009775570593774319,
    0.8748849630355835,
    0.11533944308757782
  ],
  "195689316||4||870": [
    0.004550552926957607,
    0.9512996673583984,
    0.0441497303545475
  ],
  "195689316||5||870": [
    0.02883218787610531,
    0.9441872239112854,
    0.02698056772351265
  ],
  "195689316||6||870": [
    0.003631506348028779,
    0.6538538932800293,
    0.3425145447254181
  ],
  "195689316||7||870": [
    0.11691104620695114,
    0.7915976643562317,
    0.09149132668972015
  ],
  "195689316||8||870": [
    0.00730590894818306,
    0.9704082608222961,
    0.02228585071861744
  ],
  "195689316||9||870": [
    0.0023810977581888437,
    0.4624217748641968,
    0.5351971387863159
  ],
  "195689316||10||870": [
    0.0030778672080487013,
    0.7846077084541321,
    0.2123144567012787
  ],
  "195689316||11||870": [
    0.002266911556944251,
    0.5639726519584656,
    0.43376049399375916
  ],
  "195689316||12||870": [
    0.0028421843890100718,
    0.5841073989868164,
    0.4130503833293915
  ],
  "11254556||0||909": [
    0.22034181654453278,
    0.771500825881958,
    0.008157329633831978
  ],
  "11254556||1||909": [
    0.3536287248134613,
    0.5669913291931152,
    0.07937993854284286
  ],
  "11254556||2||909": [
    0.4704947769641876,
    0.4721742868423462,
    0.057330939918756485
  ],
  "11254556||3||909": [
    0.26359039545059204,
    0.7320655584335327,
    0.004344083368778229
  ],
  "11254556||4||909": [
    0.09828674793243408,
    0.7670075297355652,
    0.13470570743083954
  ],
  "11254556||5||909": [
    0.43001148104667664,
    0.4680279791355133,
    0.10196059942245483
  ],
  "11254556||6||909": [
    0.3380002975463867,
    0.652642548084259,
    0.00935710035264492
  ],
  "11254556||7||909": [
    0.3952651619911194,
    0.5805040597915649,
    0.024230727925896645
  ],
  "11254556||8||909": [
    0.1747862696647644,
    0.8132827877998352,
    0.011930950917303562
  ],
  "11254556||9||909": [
    0.3166678249835968,
    0.6788190603256226,
    0.004513062071055174
  ],
  "11254556||0||910": [
    0.21274253726005554,
    0.7718828916549683,
    0.01537457387894392
  ],
  "11254556||1||910": [
    0.3541075885295868,
    0.572155237197876,
    0.07373718917369843
  ],
  "11254556||2||910": [
    0.40799325704574585,
    0.544794499874115,
    0.04721224680542946
  ],
  "11254556||3||910": [
    0.1958470642566681,
    0.7976914644241333,
    0.0064614941366016865
  ],
  "11254556||4||910": [
    0.06510157138109207,
    0.7165281772613525,
    0.21837028861045837
  ],
  "11254556||5||910": [
    0.32100731134414673,
    0.5288457274436951,
    0.15014703571796417
  ],
  "11254556||6||910": [
    0.3203307092189789,
    0.6681867837905884,
    0.01148255355656147
  ],
  "11254556||7||910": [
    0.25134044885635376,
    0.723588228225708,
    0.025071337819099426
  ],
  "11254556||8||910": [
    0.19655710458755493,
    0.7890146374702454,
    0.014428273774683475
  ],
  "11254556||9||910": [
    0.3547664284706116,
    0.6407109498977661,
    0.004522617440670729
  ],
  "11254556||0||912": [
    0.18535511195659637,
    0.8057650327682495,
    0.008879810571670532
  ],
  "11254556||1||912": [
    0.3085986375808716,
    0.6616118550300598,
    0.029789485037326813
  ],
  "11254556||2||912": [
    0.6264684796333313,
    0.3512391149997711,
    0.02229241468012333
  ],
  "11254556||3||912": [
    0.8699018359184265,
    0.11186876893043518,
    0.018229350447654724
  ],
  "11254556||4||912": [
    0.2958385646343231,
    0.6900460720062256,
    0.01411533635109663
  ],
  "11254556||5||912": [
    0.6460790038108826,
    0.3184455931186676,
    0.03547539934515953
  ],
  "11254556||6||912": [
    0.8282663822174072,
    0.1654909998178482,
    0.0062426915392279625
  ],
  "11254556||7||912": [
    0.8592839241027832,
    0.1300661414861679,
    0.010649941861629486
  ],
  "11254556||8||912": [
    0.6059515476226807,
    0.3795948028564453,
    0.014453659765422344
  ],
  "11254556||9||912": [
    0.8824371099472046,
    0.10800119489431381,
    0.009561623446643353
  ],
  "11254556||0||911": [
    0.5262811779975891,
    0.4560440480709076,
    0.017674745991826057
  ],
  "11254556||1||911": [
    0.37025436758995056,
    0.6106331944465637,
    0.019112443551421165
  ],
  "11254556||2||911": [
    0.5620970129966736,
    0.40418416261672974,
    0.033718742430210114
  ],
  "11254556||3||911": [
    0.8795915842056274,
    0.11009331047534943,
    0.010315004736185074
  ],
  "11254556||4||911": [
    0.3009761571884155,
    0.6902251243591309,
    0.008798744529485703
  ],
  "11254556||5||911": [
    0.6318535208702087,
    0.34200984239578247,
    0.02613663859665394
  ],
  "11254556||6||911": [
    0.8141732811927795,
    0.1812993437051773,
    0.004527400713413954
  ],
  "11254556||7||911": [
    0.8239709734916687,
    0.1671953797340393,
    0.008833710104227066
  ],
  "11254556||8||911": [
    0.5704191327095032,
    0.41701358556747437,
    0.012567304074764252
  ],
  "11254556||9||911": [
    0.9001080989837646,
    0.09063165634870529,
    0.009260185062885284
  ],
  "5483793||0||935": [
    0.289696604013443,
    0.7041109800338745,
    0.006192436441779137
  ],
  "5483793||1||935": [
    0.4305112063884735,
    0.5388842225074768,
    0.03060455061495304
  ],
  "5483793||2||935": [
    0.37749260663986206,
    0.5541795492172241,
    0.0683279037475586
  ],
  "5483793||3||935": [
    0.04731651395559311,
    0.8641108870506287,
    0.08857261389493942
  ],
  "5483793||4||935": [
    0.6013862490653992,
    0.38888978958129883,
    0.009723974391818047
  ],
  "5483793||5||935": [
    0.062378235161304474,
    0.9337722063064575,
    0.003849518485367298
  ],
  "5483793||0||834": [
    0.3502223789691925,
    0.5567600131034851,
    0.09301761537790298
  ],
  "5483793||1||834": [
    0.2619566321372986,
    0.5082499980926514,
    0.22979336977005005
  ],
  "5483793||2||834": [
    0.3674582242965698,
    0.5109568238258362,
    0.12158500403165817
  ],
  "5483793||3||834": [
    0.26040810346603394,
    0.6449340581893921,
    0.09465781599283218
  ],
  "5483793||4||834": [
    0.10538119822740555,
    0.7627821564674377,
    0.13183671236038208
  ],
  "5483793||5||834": [
    0.09977538138628006,
    0.7782757878303528,
    0.12194887548685074
  ],
  "5483793||0||936": [
    0.17924189567565918,
    0.8126916289329529,
    0.008066454902291298
  ],
  "5483793||1||936": [
    0.19346283376216888,
    0.7999964952468872,
    0.006540645379573107
  ],
  "5483793||2||936": [
    0.08481103181838989,
    0.8765908479690552,
    0.038598086684942245
  ],
  "5483793||3||936": [
    0.026397673413157463,
    0.37745073437690735,
    0.59615159034729
  ],
  "5483793||4||936": [
    0.04496839642524719,
    0.9526529312133789,
    0.002378690056502819
  ],
  "5483793||5||936": [
    0.3530087471008301,
    0.6058683395385742,
    0.0411229245364666
  ],
  "14075252||0||978": [
    0.33269527554512024,
    0.6477603316307068,
    0.01954437606036663
  ],
  "14075252||1||978": [
    0.4569266140460968,
    0.5131018757820129,
    0.029971493408083916
  ],
  "14075252||2||978": [
    0.8653908967971802,
    0.11264457553625107,
    0.02196456305682659
  ],
  "14075252||3||978": [
    0.29483675956726074,
    0.6617488861083984,
    0.04341433569788933
  ],
  "14075252||0||1330": [
    0.29136306047439575,
    0.6816325783729553,
    0.027004322037100792
  ],
  "14075252||1||1330": [
    0.2625514566898346,
    0.3394734263420105,
    0.3979750871658325
  ],
  "14075252||2||1330": [
    0.8133163452148438,
    0.15522295236587524,
    0.03146063908934593
  ],
  "14075252||3||1330": [
    0.711098849773407,
    0.2731693387031555,
    0.0157318115234375
  ],
  "14075252||0||1331": [
    0.0178547203540802,
    0.8979091048240662,
    0.08423622697591782
  ],
  "14075252||1||1331": [
    0.1461358517408371,
    0.5444077253341675,
    0.30945637822151184
  ],
  "14075252||2||1331": [
    0.06743151694536209,
    0.31510746479034424,
    0.6174610257148743
  ],
  "14075252||3||1331": [
    0.07310599833726883,
    0.8218894600868225,
    0.10500457882881165
  ],
  "16472469||0||990": [
    0.07042048871517181,
    0.9264945983886719,
    0.003084939904510975
  ],
  "16472469||1||990": [
    0.1507510244846344,
    0.7851499319076538,
    0.06409908086061478
  ],
  "16472469||2||990": [
    0.32570138573646545,
    0.6322446465492249,
    0.04205397889018059
  ],
  "16472469||3||990": [
    0.37811172008514404,
    0.5507033467292786,
    0.0711849257349968
  ],
  "16472469||4||990": [
    0.997670590877533,
    0.0012466582702472806,
    0.001082763192243874
  ],
  "16472469||5||990": [
    0.4306216239929199,
    0.5545415282249451,
    0.014836860820651054
  ],
  "16472469||6||990": [
    0.7202441096305847,
    0.25472137331962585,
    0.025034457445144653
  ],
  "16472469||7||990": [
    0.06001218780875206,
    0.8624828457832336,
    0.07750497758388519
  ],
  "16472469||0||992": [
    0.27716943621635437,
    0.717202365398407,
    0.005628171842545271
  ],
  "16472469||1||992": [
    0.5757094025611877,
    0.390077143907547,
    0.034213464707136154
  ],
  "16472469||2||992": [
    0.7166685461997986,
    0.23534691333770752,
    0.04798456281423569
  ],
  "16472469||3||992": [
    0.2712475657463074,
    0.6982964873313904,
    0.030455948784947395
  ],
  "16472469||4||992": [
    0.6601743698120117,
    0.28928840160369873,
    0.05053724721074104
  ],
  "16472469||5||992": [
    0.14334449172019958,
    0.6484699845314026,
    0.20818550884723663
  ],
  "16472469||6||992": [
    0.564152717590332,
    0.3718232810497284,
    0.06402398645877838
  ],
  "16472469||7||992": [
    0.18294885754585266,
    0.7971185445785522,
    0.019932560622692108
  ],
  "16472469||0||994": [
    0.7772669196128845,
    0.21719950437545776,
    0.005533603951334953
  ],
  "16472469||1||994": [
    0.7573915719985962,
    0.23720626533031464,
    0.005402139388024807
  ],
  "16472469||2||994": [
    0.9378604292869568,
    0.05906737595796585,
    0.0030722394585609436
  ],
  "16472469||3||994": [
    0.567662239074707,
    0.4148663580417633,
    0.01747138611972332
  ],
  "16472469||4||994": [
    0.5793244242668152,
    0.34321558475494385,
    0.07745996117591858
  ],
  "16472469||5||994": [
    0.9570053219795227,
    0.04032383859157562,
    0.0026708210352808237
  ],
  "16472469||6||994": [
    0.5480616092681885,
    0.3800477981567383,
    0.07189059257507324
  ],
  "16472469||7||994": [
    0.9570281505584717,
    0.03920578956604004,
    0.003766121808439493
  ],
  "16472469||0||996": [
    0.2898918390274048,
    0.5670642256736755,
    0.14304392039775848
  ],
  "16472469||1||996": [
    0.4734326899051666,
    0.4210412800312042,
    0.10552596300840378
  ],
  "16472469||2||996": [
    0.6678870320320129,
    0.260334312915802,
    0.07177860289812088
  ],
  "16472469||3||996": [
    0.279556542634964,
    0.5463466048240662,
    0.17409682273864746
  ],
  "16472469||4||996": [
    0.6113349199295044,
    0.35001927614212036,
    0.03864573314785957
  ],
  "16472469||5||996": [
    0.4367712736129761,
    0.37055814266204834,
    0.19267062842845917
  ],
  "16472469||6||996": [
    0.799343466758728,
    0.1755882203578949,
    0.02506830543279648
  ],
  "16472469||7||996": [
    0.1773194521665573,
    0.7890517711639404,
    0.033628784120082855
  ],
  "16472469||0||997": [
    0.47114813327789307,
    0.49255871772766113,
    0.03629326447844505
  ],
  "16472469||1||997": [
    0.7791931629180908,
    0.21276342868804932,
    0.008043329231441021
  ],
  "16472469||2||997": [
    0.8010560870170593,
    0.18314726650714874,
    0.015796639025211334
  ],
  "16472469||3||997": [
    0.44347554445266724,
    0.49367648363113403,
    0.06284797936677933
  ],
  "16472469||4||997": [
    0.503451943397522,
    0.42059919238090515,
    0.07594887912273407
  ],
  "16472469||5||997": [
    0.4867822825908661,
    0.4163086414337158,
    0.09690910577774048
  ],
  "16472469||6||997": [
    0.3671756684780121,
    0.5104215145111084,
    0.12240279465913773
  ],
  "16472469||7||997": [
    0.5505791306495667,
    0.42892441153526306,
    0.020496437326073647
  ],
  "16472469||0||998": [
    0.39191991090774536,
    0.5648400783538818,
    0.04324006289243698
  ],
  "16472469||1||998": [
    0.5110106468200684,
    0.47105672955513,
    0.017932631075382233
  ],
  "16472469||2||998": [
    0.5885085463523865,
    0.3791923522949219,
    0.03229903429746628
  ],
  "16472469||3||998": [
    0.4005047380924225,
    0.5201988220214844,
    0.07929643988609314
  ],
  "16472469||4||998": [
    0.35505959391593933,
    0.5722532868385315,
    0.07268711924552917
  ],
  "16472469||5||998": [
    0.5565882921218872,
    0.3871900737285614,
    0.056221604347229004
  ],
  "16472469||6||998": [
    0.7361912727355957,
    0.23894904553890228,
    0.02485969103872776
  ],
  "16472469||7||998": [
    0.11809220165014267,
    0.8553038239479065,
    0.02660396136343479
  ],
  "16472469||0||999": [
    0.11273251473903656,
    0.8385821580886841,
    0.04868536442518234
  ],
  "16472469||1||999": [
    0.7057454586029053,
    0.2862965166568756,
    0.007957961410284042
  ],
  "16472469||2||999": [
    0.4617694616317749,
    0.5107996463775635,
    0.02743092179298401
  ],
  "16472469||3||999": [
    0.19010670483112335,
    0.6697068214416504,
    0.14018651843070984
  ],
  "16472469||4||999": [
    0.5485119223594666,
    0.4004323184490204,
    0.05105578526854515
  ],
  "16472469||5||999": [
    0.7822891473770142,
    0.19198985397815704,
    0.025720953941345215
  ],
  "16472469||6||999": [
    0.4061141610145569,
    0.5270615816116333,
    0.06682422012090683
  ],
  "16472469||7||999": [
    0.014743083156645298,
    0.9545104503631592,
    0.030746500939130783
  ],
  "16472469||0||1000": [
    0.05675734952092171,
    0.9400344491004944,
    0.003208209527656436
  ],
  "16472469||1||1000": [
    0.5717505812644958,
    0.40683311223983765,
    0.021416332572698593
  ],
  "16472469||2||1000": [
    0.5067619681358337,
    0.44516536593437195,
    0.04807266220450401
  ],
  "16472469||3||1000": [
    0.18355070054531097,
    0.8046161532402039,
    0.011833125725388527
  ],
  "16472469||4||1000": [
    0.028363971039652824,
    0.4206853210926056,
    0.5509507060050964
  ],
  "16472469||5||1000": [
    0.40265020728111267,
    0.565705418586731,
    0.03164441138505936
  ],
  "16472469||6||1000": [
    0.850630521774292,
    0.13717897236347198,
    0.012190471403300762
  ],
  "16472469||7||1000": [
    0.0030670014675706625,
    0.9955877065658569,
    0.0013452575076371431
  ],
  "16472469||0||993": [
    0.31877169013023376,
    0.6774206161499023,
    0.0038076876662671566
  ],
  "16472469||1||993": [
    0.8776910901069641,
    0.11680439114570618,
    0.005504483822733164
  ],
  "16472469||2||993": [
    0.9186525940895081,
    0.07689686864614487,
    0.004450598731637001
  ],
  "16472469||3||993": [
    0.36865586042404175,
    0.6241032481193542,
    0.007240848615765572
  ],
  "16472469||4||993": [
    0.9890121221542358,
    0.006922481581568718,
    0.0040654283948242664
  ],
  "16472469||5||993": [
    0.2405681014060974,
    0.7098442316055298,
    0.04958770424127579
  ],
  "16472469||6||993": [
    0.15295642614364624,
    0.6935698390007019,
    0.15347369015216827
  ],
  "16472469||7||993": [
    0.8096494078636169,
    0.1821560561656952,
    0.008194572292268276
  ],
  "6277638||0||1015": [
    0.6146175265312195,
    0.368602454662323,
    0.016779975965619087
  ],
  "6277638||1||1015": [
    0.027478333562612534,
    0.9674896001815796,
    0.005032065790146589
  ],
  "6277638||2||1015": [
    0.32540562748908997,
    0.2332748919725418,
    0.4413195550441742
  ],
  "6277638||3||1015": [
    0.011979201808571815,
    0.9416238069534302,
    0.04639703035354614
  ],
  "6277638||4||1015": [
    0.022616934031248093,
    0.9583781361579895,
    0.019004996865987778
  ],
  "6277638||5||1015": [
    0.008880719542503357,
    0.9860257506370544,
    0.00509356614202261
  ],
  "6277638||0||1016": [
    0.13270355761051178,
    0.8606130480766296,
    0.006683375686407089
  ],
  "6277638||1||1016": [
    0.2581785321235657,
    0.7383384108543396,
    0.003483109176158905
  ],
  "6277638||2||1016": [
    0.23866882920265198,
    0.6338897347450256,
    0.12744148075580597
  ],
  "6277638||3||1016": [
    0.13495604693889618,
    0.8184453248977661,
    0.04659861698746681
  ],
  "6277638||4||1016": [
    0.09103379398584366,
    0.869024932384491,
    0.03994126245379448
  ],
  "6277638||5||1016": [
    0.052676357328891754,
    0.9397841095924377,
    0.0075395493768155575
  ],
  "6277638||0||1014": [
    0.08443320542573929,
    0.9075210094451904,
    0.00804578885436058
  ],
  "6277638||1||1014": [
    0.007694001775234938,
    0.9893102645874023,
    0.002995788585394621
  ],
  "6277638||2||1014": [
    0.22954684495925903,
    0.6704508066177368,
    0.10000231862068176
  ],
  "6277638||3||1014": [
    0.10423734784126282,
    0.8458624482154846,
    0.049900226294994354
  ],
  "6277638||4||1014": [
    0.3066164553165436,
    0.6660304665565491,
    0.027353037148714066
  ],
  "6277638||5||1014": [
    0.12853696942329407,
    0.8631425499916077,
    0.008320415392518044
  ],
  "4547102||0||1034": [
    0.027489451691508293,
    0.9562078714370728,
    0.01630271039903164
  ],
  "4547102||1||1034": [
    0.052702222019433975,
    0.9423627853393555,
    0.004935021512210369
  ],
  "4547102||2||1034": [
    0.029240239411592484,
    0.9503881931304932,
    0.02037154696881771
  ],
  "4547102||3||1034": [
    0.4028771221637726,
    0.5912961959838867,
    0.005826715379953384
  ],
  "4547102||4||1034": [
    0.06126467138528824,
    0.9263734221458435,
    0.012361855246126652
  ],
  "4547102||5||1034": [
    0.19331015646457672,
    0.7963083982467651,
    0.010381479747593403
  ],
  "4547102||6||1034": [
    0.08127520233392715,
    0.9061058163642883,
    0.012619022279977798
  ],
  "4547102||0||1035": [
    0.05237070098519325,
    0.9455421566963196,
    0.002087182365357876
  ],
  "4547102||1||1035": [
    0.043333977460861206,
    0.9548974633216858,
    0.0017686157952994108
  ],
  "4547102||2||1035": [
    0.013862041756510735,
    0.97540682554245,
    0.010731089860200882
  ],
  "4547102||3||1035": [
    0.01975543424487114,
    0.9064260721206665,
    0.07381848245859146
  ],
  "4547102||4||1035": [
    0.025504620745778084,
    0.9726741313934326,
    0.0018212295835837722
  ],
  "4547102||5||1035": [
    0.010603329166769981,
    0.9699418544769287,
    0.019454818218946457
  ],
  "4547102||6||1035": [
    0.00693530822172761,
    0.9857922196388245,
    0.007272480987012386
  ],
  "4547102||0||1036": [
    0.036245107650756836,
    0.9620758891105652,
    0.0016789741348475218
  ],
  "4547102||1||1036": [
    0.0735546201467514,
    0.9238858222961426,
    0.002559604123234749
  ],
  "4547102||2||1036": [
    0.040316443890333176,
    0.9497917294502258,
    0.009891818277537823
  ],
  "4547102||3||1036": [
    0.0598134808242321,
    0.9215941429138184,
    0.01859242096543312
  ],
  "4547102||4||1036": [
    0.009514952078461647,
    0.9867644309997559,
    0.0037205980625003576
  ],
  "4547102||5||1036": [
    0.004663418512791395,
    0.9762998223304749,
    0.019036779180169106
  ],
  "4547102||6||1036": [
    0.030097389593720436,
    0.9619317054748535,
    0.00797095987945795
  ],
  "18816720||0||1052": [
    0.0015443179290741682,
    0.9974952936172485,
    0.0009604468941688538
  ],
  "18816720||1||1052": [
    0.006864206865429878,
    0.9914074540138245,
    0.0017283466877415776
  ],
  "18816720||2||1052": [
    0.01339652482420206,
    0.9792630076408386,
    0.007340473122894764
  ],
  "18816720||3||1052": [
    0.0015550056705251336,
    0.9964501857757568,
    0.001994810998439789
  ],
  "18816720||4||1052": [
    0.011230174452066422,
    0.9790240526199341,
    0.009745785035192966
  ],
  "18816720||5||1052": [
    0.0017409530701115727,
    0.9962291121482849,
    0.002029954455792904
  ],
  "18816720||6||1052": [
    0.002445672173053026,
    0.994358479976654,
    0.0031958993058651686
  ],
  "18816720||7||1052": [
    0.010459423065185547,
    0.9740724563598633,
    0.015468084253370762
  ],
  "18816720||8||1052": [
    0.022828685119748116,
    0.6290284395217896,
    0.3481428921222687
  ],
  "18816720||9||1052": [
    0.0016824482008814812,
    0.9968448877334595,
    0.0014726558001711965
  ],
  "18816720||10||1052": [
    0.031242696568369865,
    0.8535307049751282,
    0.11522659659385681
  ],
  "18816720||11||1052": [
    0.02200791984796524,
    0.7936710715293884,
    0.18432094156742096
  ],
  "18816720||12||1052": [
    0.004427996464073658,
    0.9935710430145264,
    0.002000942127779126
  ],
  "18816720||13||1052": [
    0.008357892744243145,
    0.9764116406440735,
    0.015230495482683182
  ],
  "18816720||14||1052": [
    0.0024296496994793415,
    0.9943417310714722,
    0.003228637855499983
  ],
  "18816720||15||1052": [
    0.07597772777080536,
    0.9204608798027039,
    0.0035614483058452606
  ],
  "18816720||16||1052": [
    0.011735920794308186,
    0.9852938055992126,
    0.002970305271446705
  ],
  "18816720||17||1052": [
    0.01677936129271984,
    0.9747979044914246,
    0.00842268206179142
  ],
  "18816720||0||1053": [
    0.05202610418200493,
    0.9468480348587036,
    0.0011258432641625404
  ],
  "18816720||1||1053": [
    0.23949281871318817,
    0.757571816444397,
    0.0029353590216487646
  ],
  "18816720||2||1053": [
    0.27353477478027344,
    0.7230209112167358,
    0.0034443442709743977
  ],
  "18816720||3||1053": [
    0.12859167158603668,
    0.8693503141403198,
    0.0020580096170306206
  ],
  "18816720||4||1053": [
    0.4323127567768097,
    0.5641903877258301,
    0.00349684851244092
  ],
  "18816720||5||1053": [
    0.32036805152893066,
    0.6766868829727173,
    0.0029450359288603067
  ],
  "18816720||6||1053": [
    0.31805822253227234,
    0.6786431074142456,
    0.0032986896112561226
  ],
  "18816720||7||1053": [
    0.4842377007007599,
    0.5115137696266174,
    0.004248527344316244
  ],
  "18816720||8||1053": [
    0.47536540031433105,
    0.44525715708732605,
    0.07937745749950409
  ],
  "18816720||9||1053": [
    0.2720012962818146,
    0.7250035405158997,
    0.002995141549035907
  ],
  "18816720||10||1053": [
    0.6169484853744507,
    0.37176069617271423,
    0.011290788650512695
  ],
  "18816720||11||1053": [
    0.40625932812690735,
    0.5565673112869263,
    0.037173300981521606
  ],
  "18816720||12||1053": [
    0.23087891936302185,
    0.7668256759643555,
    0.002295438200235367
  ],
  "18816720||13||1053": [
    0.3826013505458832,
    0.6118496656417847,
    0.005548956338316202
  ],
  "18816720||14||1053": [
    0.3234671950340271,
    0.6739845871925354,
    0.0025482000783085823
  ],
  "18816720||15||1053": [
    0.2805594801902771,
    0.7146144509315491,
    0.0048260996118187904
  ],
  "18816720||16||1053": [
    0.34002935886383057,
    0.656926155090332,
    0.0030445046722888947
  ],
  "18816720||17||1053": [
    0.4189460277557373,
    0.5759027600288391,
    0.00515122851356864
  ],
  "18816720||0||1353": [
    0.0017207203200086951,
    0.9961084723472595,
    0.0021708186250180006
  ],
  "18816720||1||1353": [
    0.0060316454619169235,
    0.9860821962356567,
    0.007886144332587719
  ],
  "18816720||2||1353": [
    0.04138021171092987,
    0.9243438243865967,
    0.03427590802311897
  ],
  "18816720||3||1353": [
    0.0034684438724070787,
    0.9353758692741394,
    0.06115570291876793
  ],
  "18816720||4||1353": [
    0.02654675953090191,
    0.9058231711387634,
    0.06763006001710892
  ],
  "18816720||5||1353": [
    0.011475474573671818,
    0.8987851142883301,
    0.08973940461874008
  ],
  "18816720||6||1353": [
    0.0027634394355118275,
    0.8481550812721252,
    0.14908146858215332
  ],
  "18816720||7||1353": [
    0.007913097739219666,
    0.9164074659347534,
    0.0756794661283493
  ],
  "18816720||8||1353": [
    0.0586523562669754,
    0.6150884032249451,
    0.32625919580459595
  ],
  "18816720||9||1353": [
    0.0026754974387586117,
    0.8198301792144775,
    0.1774943470954895
  ],
  "18816720||10||1353": [
    0.00555817736312747,
    0.9322144389152527,
    0.06222740188241005
  ],
  "18816720||11||1353": [
    0.03386107459664345,
    0.7773336172103882,
    0.18880526721477509
  ],
  "18816720||12||1353": [
    0.009521069005131721,
    0.9741911292076111,
    0.01628776639699936
  ],
  "18816720||13||1353": [
    0.007431706879287958,
    0.9116814732551575,
    0.08088681101799011
  ],
  "18816720||14||1353": [
    0.7569848895072937,
    0.22828051447868347,
    0.014734608121216297
  ],
  "18816720||15||1353": [
    0.9333959817886353,
    0.05743339657783508,
    0.009170557372272015
  ],
  "18816720||16||1353": [
    0.005723890848457813,
    0.9835303425788879,
    0.010745706968009472
  ],
  "18816720||17||1353": [
    0.006919198203831911,
    0.9832730293273926,
    0.009807746857404709
  ],
  "5691302||0||1081": [
    0.5533650517463684,
    0.44252705574035645,
    0.0041078850626945496
  ],
  "5691302||1||1081": [
    0.6625264286994934,
    0.33034664392471313,
    0.007126898970454931
  ],
  "5691302||2||1081": [
    0.6505862474441528,
    0.32968243956565857,
    0.019731387495994568
  ],
  "5691302||3||1081": [
    0.7747777104377747,
    0.21887899935245514,
    0.006343328393995762
  ],
  "5691302||4||1081": [
    0.7715891599655151,
    0.2254781574010849,
    0.0029326602816581726
  ],
  "5691302||5||1081": [
    0.6537114977836609,
    0.3419095575809479,
    0.00437889015302062
  ],
  "5691302||6||1081": [
    0.30772024393081665,
    0.6788532137870789,
    0.013426564633846283
  ],
  "5691302||7||1081": [
    0.38876011967658997,
    0.5963801741600037,
    0.014859769493341446
  ],
  "5691302||8||1081": [
    0.29329049587249756,
    0.7028692364692688,
    0.003840304911136627
  ],
  "5691302||9||1081": [
    0.8277634978294373,
    0.1679656058549881,
    0.004270894918590784
  ],
  "5691302||10||1081": [
    0.95103520154953,
    0.046609826385974884,
    0.0023549289908260107
  ],
  "5691302||11||1081": [
    0.005348446778953075,
    0.8582332730293274,
    0.13641828298568726
  ],
  "5691302||12||1081": [
    0.5790218114852905,
    0.41562098264694214,
    0.005357254296541214
  ],
  "5691302||13||1081": [
    0.9236459732055664,
    0.07429131120443344,
    0.0020627512130886316
  ],
  "5691302||14||1081": [
    0.3138120770454407,
    0.6816095113754272,
    0.004578359425067902
  ],
  "5691302||15||1081": [
    0.8735906481742859,
    0.1239466592669487,
    0.002462729113176465
  ],
  "5691302||16||1081": [
    0.43309035897254944,
    0.5633987784385681,
    0.0035108423326164484
  ],
  "5691302||17||1081": [
    0.40203920006752014,
    0.5938108563423157,
    0.004149988759309053
  ],
  "5691302||0||1084": [
    0.005021163262426853,
    0.9936657547950745,
    0.001313089276663959
  ],
  "5691302||1||1084": [
    0.062011998146772385,
    0.9297016859054565,
    0.008286370895802975
  ],
  "5691302||2||1084": [
    0.0556727796792984,
    0.9004417657852173,
    0.04388546571135521
  ],
  "5691302||3||1084": [
    0.058432113379240036,
    0.9354762434959412,
    0.006091614253818989
  ],
  "5691302||4||1084": [
    0.012415256351232529,
    0.860765814781189,
    0.12681888043880463
  ],
  "5691302||5||1084": [
    0.01439359039068222,
    0.9828729033470154,
    0.002733493922278285
  ],
  "5691302||6||1084": [
    0.012243672274053097,
    0.9855850338935852,
    0.0021712416782975197
  ],
  "5691302||7||1084": [
    0.024585189297795296,
    0.9717119932174683,
    0.003702849382534623
  ],
  "5691302||8||1084": [
    0.0022040936164557934,
    0.9969666600227356,
    0.0008292863494716585
  ],
  "5691302||9||1084": [
    0.22000718116760254,
    0.7391577363014221,
    0.040835071355104446
  ],
  "5691302||10||1084": [
    0.005597197916358709,
    0.43362337350845337,
    0.5607793927192688
  ],
  "5691302||11||1084": [
    0.09186412394046783,
    0.904464602470398,
    0.0036712652072310448
  ],
  "5691302||12||1084": [
    0.028950132429599762,
    0.9682217240333557,
    0.0028281512204557657
  ],
  "5691302||13||1084": [
    0.02814246155321598,
    0.9353020191192627,
    0.036555446684360504
  ],
  "5691302||14||1084": [
    0.0010372026590630412,
    0.9977317452430725,
    0.0012310409219935536
  ],
  "5691302||15||1084": [
    0.0009278571233153343,
    0.996489942073822,
    0.0025821663439273834
  ],
  "5691302||16||1084": [
    0.003485326189547777,
    0.9953141212463379,
    0.0012005456956103444
  ],
  "5691302||17||1084": [
    0.0028535467572510242,
    0.995898425579071,
    0.0012479664292186499
  ],
  "5691302||0||1085": [
    0.3717687129974365,
    0.6210119128227234,
    0.007219337392598391
  ],
  "5691302||1||1085": [
    0.22327075898647308,
    0.749341607093811,
    0.0273875892162323
  ],
  "5691302||2||1085": [
    0.135016530752182,
    0.7770702838897705,
    0.08791319280862808
  ],
  "5691302||3||1085": [
    0.06335432082414627,
    0.9245726466178894,
    0.012073065154254436
  ],
  "5691302||4||1085": [
    0.6178378462791443,
    0.36811527609825134,
    0.014046846888959408
  ],
  "5691302||5||1085": [
    0.28248247504234314,
    0.7048676013946533,
    0.01264990121126175
  ],
  "5691302||6||1085": [
    0.03648418188095093,
    0.9522844552993774,
    0.011231325566768646
  ],
  "5691302||7||1085": [
    0.0924057886004448,
    0.888713002204895,
    0.018881244584918022
  ],
  "5691302||8||1085": [
    0.026542896404862404,
    0.9721587300300598,
    0.0012983938213437796
  ],
  "5691302||9||1085": [
    0.46229544281959534,
    0.5304187536239624,
    0.00728577421978116
  ],
  "5691302||10||1085": [
    0.7432464957237244,
    0.25006216764450073,
    0.006691304035484791
  ],
  "5691302||11||1085": [
    0.037884604185819626,
    0.9553272128105164,
    0.006788168102502823
  ],
  "5691302||12||1085": [
    0.22889076173305511,
    0.7659053802490234,
    0.005203883163630962
  ],
  "5691302||13||1085": [
    0.3410506248474121,
    0.6519869565963745,
    0.006962410174310207
  ],
  "5691302||14||1085": [
    0.4744082987308502,
    0.5218302011489868,
    0.003761579282581806
  ],
  "5691302||15||1085": [
    0.8507726192474365,
    0.14455150067806244,
    0.004675835836678743
  ],
  "5691302||16||1085": [
    0.6550756692886353,
    0.3392704427242279,
    0.005653905216604471
  ],
  "5691302||17||1085": [
    0.19387200474739075,
    0.8016296029090881,
    0.004498352762311697
  ],
  "33370||0||1134": [
    0.23194369673728943,
    0.7433081269264221,
    0.02474820986390114
  ],
  "33370||1||1134": [
    0.7819701433181763,
    0.2122989147901535,
    0.005730994511395693
  ],
  "33370||2||1134": [
    0.998872697353363,
    0.0008756352472119033,
    0.0002515577943995595
  ],
  "33370||3||1134": [
    0.5435435771942139,
    0.4241986870765686,
    0.032257772982120514
  ],
  "33370||4||1134": [
    0.7662584185600281,
    0.21332532167434692,
    0.020416300743818283
  ],
  "33370||5||1134": [
    0.6941879391670227,
    0.28602540493011475,
    0.019786681979894638
  ],
  "33370||6||1134": [
    0.9885220527648926,
    0.008345833979547024,
    0.0031321393325924873
  ],
  "33370||7||1134": [
    0.5198715329170227,
    0.431059330701828,
    0.04906915873289108
  ],
  "33370||8||1134": [
    0.9207135438919067,
    0.0718032717704773,
    0.00748313358053565
  ],
  "33370||9||1134": [
    0.6656172871589661,
    0.292969286441803,
    0.041413385421037674
  ],
  "33370||10||1134": [
    0.9551320672035217,
    0.04031669721007347,
    0.004551287740468979
  ],
  "33370||0||1135": [
    0.19820572435855865,
    0.7924178242683411,
    0.009376456961035728
  ],
  "33370||1||1135": [
    0.10516765713691711,
    0.8911987543106079,
    0.003633519634604454
  ],
  "33370||2||1135": [
    0.8784448504447937,
    0.08692946285009384,
    0.03462570160627365
  ],
  "33370||3||1135": [
    0.3223460912704468,
    0.6225004196166992,
    0.05515352264046669
  ],
  "33370||4||1135": [
    0.6434016227722168,
    0.3191433548927307,
    0.0374549962580204
  ],
  "33370||5||1135": [
    0.6210706233978271,
    0.3393460512161255,
    0.03958331421017647
  ],
  "33370||6||1135": [
    0.3536888659000397,
    0.48037126660346985,
    0.16593985259532928
  ],
  "33370||7||1135": [
    0.5859923958778381,
    0.3729315400123596,
    0.04107607528567314
  ],
  "33370||8||1135": [
    0.761201798915863,
    0.1971929371356964,
    0.04160524904727936
  ],
  "33370||9||1135": [
    0.8652390241622925,
    0.12574318051338196,
    0.009017848409712315
  ],
  "33370||10||1135": [
    0.11374732851982117,
    0.8786978125572205,
    0.007554834708571434
  ],
  "33370||0||1136": [
    0.12916362285614014,
    0.844767153263092,
    0.026069214567542076
  ],
  "33370||1||1136": [
    0.868591845035553,
    0.12821395695209503,
    0.0031942157074809074
  ],
  "33370||2||1136": [
    0.9989489912986755,
    0.0008199335425160825,
    0.00023118301760405302
  ],
  "33370||3||1136": [
    0.6438440680503845,
    0.3319684565067291,
    0.02418743073940277
  ],
  "33370||4||1136": [
    0.7019920945167542,
    0.27476009726524353,
    0.0232478566467762
  ],
  "33370||5||1136": [
    0.5949686169624329,
    0.37983059883117676,
    0.02520068921148777
  ],
  "33370||6||1136": [
    0.982179582118988,
    0.013294825330376625,
    0.004525522235780954
  ],
  "33370||7||1136": [
    0.3155486583709717,
    0.6228674650192261,
    0.06158386915922165
  ],
  "33370||8||1136": [
    0.9263279438018799,
    0.06783729046583176,
    0.005834681447595358
  ],
  "33370||9||1136": [
    0.720134437084198,
    0.2520289719104767,
    0.02783658728003502
  ],
  "33370||10||1136": [
    0.9637124538421631,
    0.03374369814991951,
    0.0025439118035137653
  ],
  "33370||0||1137": [
    0.26891180872917175,
    0.7204329371452332,
    0.010655290447175503
  ],
  "33370||1||1137": [
    0.041272155940532684,
    0.9571351408958435,
    0.0015926894266158342
  ],
  "33370||2||1137": [
    0.7394153475761414,
    0.16631031036376953,
    0.09427438676357269
  ],
  "33370||3||1137": [
    0.3979441523551941,
    0.5391013026237488,
    0.06295452266931534
  ],
  "33370||4||1137": [
    0.703341543674469,
    0.2610444128513336,
    0.035614099353551865
  ],
  "33370||5||1137": [
    0.5779067873954773,
    0.3751307725906372,
    0.0469624400138855
  ],
  "33370||6||1137": [
    0.40375176072120667,
    0.47284021973609924,
    0.12340810149908066
  ],
  "33370||7||1137": [
    0.7239251732826233,
    0.24813306331634521,
    0.027941742911934853
  ],
  "33370||8||1137": [
    0.7031316161155701,
    0.2422845959663391,
    0.05458368360996246
  ],
  "33370||9||1137": [
    0.8976527452468872,
    0.09618101269006729,
    0.006166284903883934
  ],
  "33370||10||1137": [
    0.05974026024341583,
    0.935228705406189,
    0.005031034350395203
  ],
  "12009265||0||1139": [
    0.504588782787323,
    0.4916994273662567,
    0.003711804049089551
  ],
  "12009265||1||1139": [
    0.8578731417655945,
    0.1384076625108719,
    0.0037192178424447775
  ],
  "12009265||2||1139": [
    0.7741756439208984,
    0.22044163942337036,
    0.005382785573601723
  ],
  "12009265||3||1139": [
    0.787830650806427,
    0.20816347002983093,
    0.004005933180451393
  ],
  "12009265||4||1139": [
    0.620793879032135,
    0.36624500155448914,
    0.012961121276021004
  ],
  "12009265||5||1139": [
    0.672322154045105,
    0.31574493646621704,
    0.011932820081710815
  ],
  "12009265||6||1139": [
    0.6269011497497559,
    0.3660971522331238,
    0.007001648191362619
  ],
  "12009265||7||1139": [
    0.12272218614816666,
    0.8533875942230225,
    0.023890195414423943
  ],
  "12009265||8||1139": [
    0.08297375589609146,
    0.8803128004074097,
    0.03671341389417648
  ],
  "12009265||9||1139": [
    0.10833505541086197,
    0.5708798766136169,
    0.3207851052284241
  ],
  "12009265||10||1139": [
    0.30732667446136475,
    0.5858457684516907,
    0.10682752728462219
  ],
  "12009265||11||1139": [
    0.08176053315401077,
    0.7524426579475403,
    0.16579681634902954
  ],
  "12009265||12||1139": [
    0.4220186471939087,
    0.5210608243942261,
    0.0569206140935421
  ],
  "12009265||13||1139": [
    0.11897323280572891,
    0.749901294708252,
    0.13112550973892212
  ],
  "12009265||14||1139": [
    0.008350338786840439,
    0.9412413239479065,
    0.05040830746293068
  ],
  "12009265||15||1139": [
    0.0058956085704267025,
    0.9871771335601807,
    0.006927201524376869
  ],
  "12009265||16||1139": [
    0.5407696962356567,
    0.43023115396499634,
    0.02899906225502491
  ],
  "12009265||0||1141": [
    0.001658326480537653,
    0.9970135688781738,
    0.0013281151186674833
  ],
  "12009265||1||1141": [
    0.043573759496212006,
    0.9534991383552551,
    0.002927068155258894
  ],
  "12009265||2||1141": [
    0.01657308079302311,
    0.9785445928573608,
    0.004882263019680977
  ],
  "12009265||3||1141": [
    0.00407060282304883,
    0.9910205006599426,
    0.0049088383093476295
  ],
  "12009265||4||1141": [
    0.005751127377152443,
    0.9920998215675354,
    0.002149002393707633
  ],
  "12009265||5||1141": [
    0.02035510167479515,
    0.9611297845840454,
    0.018515102565288544
  ],
  "12009265||6||1141": [
    0.006338794715702534,
    0.9838380813598633,
    0.009823059663176537
  ],
  "12009265||7||1141": [
    0.08940206468105316,
    0.9073425531387329,
    0.003255316521972418
  ],
  "12009265||8||1141": [
    0.05786551907658577,
    0.9391438961029053,
    0.0029905943665653467
  ],
  "12009265||9||1141": [
    0.28396108746528625,
    0.7103449106216431,
    0.005694055929780006
  ],
  "12009265||10||1141": [
    0.17378976941108704,
    0.8197406530380249,
    0.006469566375017166
  ],
  "12009265||11||1141": [
    0.3194881081581116,
    0.6771621704101562,
    0.003349747508764267
  ],
  "12009265||12||1141": [
    0.021031271666288376,
    0.8561579585075378,
    0.12281075865030289
  ],
  "12009265||13||1141": [
    0.08835070580244064,
    0.9096989631652832,
    0.0019503545481711626
  ],
  "12009265||14||1141": [
    0.9085488319396973,
    0.08780968189239502,
    0.0036414111964404583
  ],
  "12009265||15||1141": [
    0.05516570061445236,
    0.9429126381874084,
    0.0019216608488932252
  ],
  "12009265||16||1141": [
    0.0172455832362175,
    0.8807874321937561,
    0.10196694731712341
  ],
  "12009265||0||1140": [
    0.004014273639768362,
    0.9946721196174622,
    0.0013136683264747262
  ],
  "12009265||1||1140": [
    0.030661074444651604,
    0.9455726146697998,
    0.02376623824238777
  ],
  "12009265||2||1140": [
    0.06152210384607315,
    0.9204381108283997,
    0.018039802089333534
  ],
  "12009265||3||1140": [
    0.03714006394147873,
    0.9548853039741516,
    0.007974605076014996
  ],
  "12009265||4||1140": [
    0.026762383058667183,
    0.9606659412384033,
    0.012571731582283974
  ],
  "12009265||5||1140": [
    0.031456951051950455,
    0.9546487927436829,
    0.013894262723624706
  ],
  "12009265||6||1140": [
    0.14861510694026947,
    0.8325558304786682,
    0.01882900297641754
  ],
  "12009265||7||1140": [
    0.17265620827674866,
    0.8238372206687927,
    0.0035065333358943462
  ],
  "12009265||8||1140": [
    0.07996193319559097,
    0.9170543551445007,
    0.002983700018376112
  ],
  "12009265||9||1140": [
    0.48808321356773376,
    0.48676228523254395,
    0.025154491886496544
  ],
  "12009265||10||1140": [
    0.3127466142177582,
    0.673581063747406,
    0.013672346249222755
  ],
  "12009265||11||1140": [
    0.2872932255268097,
    0.7092230916023254,
    0.0034836858976632357
  ],
  "12009265||12||1140": [
    0.04922493174672127,
    0.8495020270347595,
    0.1012730747461319
  ],
  "12009265||13||1140": [
    0.10085029900074005,
    0.8871926665306091,
    0.011957001872360706
  ],
  "12009265||14||1140": [
    0.6517764329910278,
    0.3440884053707123,
    0.004135154653340578
  ],
  "12009265||15||1140": [
    0.23977340757846832,
    0.7564593553543091,
    0.003767234506085515
  ],
  "12009265||16||1140": [
    0.028100095689296722,
    0.9098343253135681,
    0.06206560134887695
  ],
  "7370282||0||1153": [
    0.20684587955474854,
    0.7597672343254089,
    0.03338686749339104
  ],
  "7370282||1||1153": [
    0.7179535627365112,
    0.21824312210083008,
    0.06380333751440048
  ],
  "7370282||2||1153": [
    0.00881597213447094,
    0.9712805151939392,
    0.019903533160686493
  ],
  "7370282||3||1153": [
    0.11060033738613129,
    0.8543521761894226,
    0.03504754230380058
  ],
  "7370282||4||1153": [
    0.03804364055395126,
    0.7892398238182068,
    0.17271652817726135
  ],
  "7370282||5||1153": [
    0.03425794094800949,
    0.8608595728874207,
    0.10488252341747284
  ],
  "7370282||6||1153": [
    0.009029686450958252,
    0.5234229564666748,
    0.46754738688468933
  ],
  "7370282||0||1173": [
    0.0545826181769371,
    0.9419530630111694,
    0.003464367240667343
  ],
  "7370282||1||1173": [
    0.982555627822876,
    0.005980697460472584,
    0.011463725008070469
  ],
  "7370282||2||1173": [
    0.7887635827064514,
    0.2076440006494522,
    0.0035924501717090607
  ],
  "7370282||3||1173": [
    0.6243726015090942,
    0.3684472441673279,
    0.00718016317114234
  ],
  "7370282||4||1173": [
    0.5728958249092102,
    0.37697020173072815,
    0.05013388395309448
  ],
  "7370282||5||1173": [
    0.9771825671195984,
    0.020260700955986977,
    0.002556720282882452
  ],
  "7370282||6||1173": [
    0.9893333315849304,
    0.0053168004378676414,
    0.005349860526621342
  ],
  "7370282||0||904": [
    0.001461195875890553,
    0.9936488270759583,
    0.004889924079179764
  ],
  "7370282||1||904": [
    0.3792795240879059,
    0.3959308862686157,
    0.224789559841156
  ],
  "7370282||2||904": [
    0.4945423901081085,
    0.4595196843147278,
    0.04593794420361519
  ],
  "7370282||3||904": [
    0.6765519380569458,
    0.31230971217155457,
    0.011138349771499634
  ],
  "7370282||4||904": [
    0.009922105818986893,
    0.9795252084732056,
    0.01055267732590437
  ],
  "7370282||5||904": [
    0.6656568646430969,
    0.291683554649353,
    0.04265955835580826
  ],
  "7370282||6||904": [
    0.2574498951435089,
    0.28860893845558167,
    0.45394107699394226
  ],
  "12584053||0||1156": [
    0.0017321566119790077,
    0.9974283576011658,
    0.000839473505038768
  ],
  "12584053||1||1156": [
    0.002570324344560504,
    0.9967067837715149,
    0.0007228610338643193
  ],
  "12584053||2||1156": [
    0.028835183009505272,
    0.9677106142044067,
    0.0034541883505880833
  ],
  "12584053||3||1156": [
    0.001998127670958638,
    0.9972291588783264,
    0.0007726640906184912
  ],
  "12584053||4||1156": [
    0.002431322354823351,
    0.9968583583831787,
    0.0007103338721208274
  ],
  "12584053||5||1156": [
    0.1949319988489151,
    0.8028353452682495,
    0.002232627011835575
  ],
  "12584053||6||1156": [
    0.01685127429664135,
    0.9824174046516418,
    0.0007312791422009468
  ],
  "12584053||7||1156": [
    0.005174728110432625,
    0.9942228198051453,
    0.000602465181145817
  ],
  "12584053||8||1156": [
    0.02274503745138645,
    0.975498378276825,
    0.0017565726302564144
  ],
  "12584053||9||1156": [
    0.25674906373023987,
    0.7409130930900574,
    0.0023377693723887205
  ],
  "12584053||10||1156": [
    0.03589319810271263,
    0.9633640646934509,
    0.0007427743403241038
  ],
  "12584053||11||1156": [
    0.0028888399247080088,
    0.9963196516036987,
    0.0007915021269582212
  ],
  "12584053||12||1156": [
    0.11106518656015396,
    0.887506365776062,
    0.0014284186763688922
  ],
  "12584053||13||1156": [
    0.1844952553510666,
    0.8141982555389404,
    0.0013064667582511902
  ],
  "12584053||14||1156": [
    0.04200642928481102,
    0.9527141451835632,
    0.005279440898448229
  ],
  "12584053||0||1157": [
    0.6361716985702515,
    0.3609525263309479,
    0.0028758395928889513
  ],
  "12584053||1||1157": [
    0.09327572584152222,
    0.9044716358184814,
    0.0022526083048433065
  ],
  "12584053||2||1157": [
    0.5481610298156738,
    0.4325086176395416,
    0.019330333918333054
  ],
  "12584053||3||1157": [
    0.4332984983921051,
    0.5501317381858826,
    0.016569703817367554
  ],
  "12584053||4||1157": [
    0.7778019309043884,
    0.21620520949363708,
    0.005992869846522808
  ],
  "12584053||5||1157": [
    0.7561700940132141,
    0.23615849018096924,
    0.007671380415558815
  ],
  "12584053||6||1157": [
    0.7771835923194885,
    0.21886608004570007,
    0.003950338810682297
  ],
  "12584053||7||1157": [
    0.9256457090377808,
    0.07195909321308136,
    0.0023951788898557425
  ],
  "12584053||8||1157": [
    0.9327167272567749,
    0.06090173497796059,
    0.006381557788699865
  ],
  "12584053||9||1157": [
    0.011547685600817204,
    0.9367642998695374,
    0.05168803036212921
  ],
  "12584053||10||1157": [
    0.01198740303516388,
    0.7926186919212341,
    0.19539391994476318
  ],
  "12584053||11||1157": [
    0.8990604281425476,
    0.09789399802684784,
    0.003045522142201662
  ],
  "12584053||12||1157": [
    0.03125673532485962,
    0.8176971077919006,
    0.15104617178440094
  ],
  "12584053||13||1157": [
    0.0038525813724845648,
    0.9721174836158752,
    0.024029958993196487
  ],
  "12584053||14||1157": [
    0.3195951581001282,
    0.6725543737411499,
    0.007850413210690022
  ],
  "12584053||0||1158": [
    0.6855345964431763,
    0.3114105463027954,
    0.0030548530630767345
  ],
  "12584053||1||1158": [
    0.14995227754116058,
    0.8475213050842285,
    0.002526446245610714
  ],
  "12584053||2||1158": [
    0.6911658644676208,
    0.30003640055656433,
    0.008797730319201946
  ],
  "12584053||3||1158": [
    0.5062562227249146,
    0.4772491753101349,
    0.016494648531079292
  ],
  "12584053||4||1158": [
    0.5954567790031433,
    0.3922329545021057,
    0.012310337275266647
  ],
  "12584053||5||1158": [
    0.707038164138794,
    0.2874855697154999,
    0.005476313177496195
  ],
  "12584053||6||1158": [
    0.8082531690597534,
    0.18723386526107788,
    0.00451303506270051
  ],
  "12584053||7||1158": [
    0.9198902249336243,
    0.07762731611728668,
    0.002482509706169367
  ],
  "12584053||8||1158": [
    0.8700920343399048,
    0.1215299740433693,
    0.00837788451462984
  ],
  "12584053||9||1158": [
    0.01784505322575569,
    0.9383869767189026,
    0.04376796633005142
  ],
  "12584053||10||1158": [
    0.007484107743948698,
    0.8311811089515686,
    0.16133475303649902
  ],
  "12584053||11||1158": [
    0.9923604130744934,
    0.00686282804235816,
    0.000776774191763252
  ],
  "12584053||12||1158": [
    0.005315019283443689,
    0.8035154938697815,
    0.19116942584514618
  ],
  "12584053||13||1158": [
    0.0044121393002569675,
    0.9681177735328674,
    0.027470026165246964
  ],
  "12584053||14||1158": [
    0.3536332845687866,
    0.6369642615318298,
    0.009402460418641567
  ],
  "12584053||0||1159": [
    0.666226327419281,
    0.33046677708625793,
    0.0033068745397031307
  ],
  "12584053||1||1159": [
    0.13376197218894958,
    0.8636417984962463,
    0.002596203237771988
  ],
  "12584053||2||1159": [
    0.5561481714248657,
    0.42772987484931946,
    0.01612192578613758
  ],
  "12584053||3||1159": [
    0.4468822181224823,
    0.5396093130111694,
    0.013508389703929424
  ],
  "12584053||4||1159": [
    0.5008192658424377,
    0.49000781774520874,
    0.009172914549708366
  ],
  "12584053||5||1159": [
    0.782408595085144,
    0.21176950633525848,
    0.005821970757097006
  ],
  "12584053||6||1159": [
    0.6116161346435547,
    0.3815520405769348,
    0.006831740029156208
  ],
  "12584053||7||1159": [
    0.8269714117050171,
    0.17024455964565277,
    0.002783929230645299
  ],
  "12584053||8||1159": [
    0.8624120950698853,
    0.13069286942481995,
    0.006895145401358604
  ],
  "12584053||9||1159": [
    0.010323814116418362,
    0.9377073645591736,
    0.051968831568956375
  ],
  "12584053||10||1159": [
    0.023203521966934204,
    0.9111390113830566,
    0.06565751135349274
  ],
  "12584053||11||1159": [
    0.6162869930267334,
    0.37974485754966736,
    0.003968199249356985
  ],
  "12584053||12||1159": [
    0.14410792291164398,
    0.8048611879348755,
    0.05103091895580292
  ],
  "12584053||13||1159": [
    0.0035938306245952845,
    0.9856131672859192,
    0.010792999528348446
  ],
  "12584053||14||1159": [
    0.2698233425617218,
    0.7234475612640381,
    0.006729148328304291
  ],
  "31272411||0||1174": [
    0.15135718882083893,
    0.8432005643844604,
    0.005442190449684858
  ],
  "31272411||1||1174": [
    0.3417034447193146,
    0.650362491607666,
    0.007934105582535267
  ],
  "31272411||2||1174": [
    0.14247336983680725,
    0.8431603908538818,
    0.014366185292601585
  ],
  "31272411||3||1174": [
    0.12476377934217453,
    0.8571717143058777,
    0.018064504489302635
  ],
  "31272411||4||1174": [
    0.1674812287092209,
    0.7725455164909363,
    0.05997331067919731
  ],
  "31272411||5||1174": [
    0.14497290551662445,
    0.804860532283783,
    0.05016661807894707
  ],
  "31272411||0||1178": [
    0.18717463314533234,
    0.7790278792381287,
    0.03379744663834572
  ],
  "31272411||1||1178": [
    0.443139910697937,
    0.5448845028877258,
    0.011975565925240517
  ],
  "31272411||2||1178": [
    0.22939889132976532,
    0.7564965486526489,
    0.014104551635682583
  ],
  "31272411||3||1178": [
    0.3708973824977875,
    0.5623139142990112,
    0.06678874790668488
  ],
  "31272411||4||1178": [
    0.2899896502494812,
    0.5956776738166809,
    0.11433269828557968
  ],
  "31272411||5||1178": [
    0.2585243880748749,
    0.6549116969108582,
    0.08656391501426697
  ],
  "31272411||0||1175": [
    0.20135729014873505,
    0.7793056964874268,
    0.019337046891450882
  ],
  "31272411||1||1175": [
    0.47130313515663147,
    0.5078264474868774,
    0.020870473235845566
  ],
  "31272411||2||1175": [
    0.2599231004714966,
    0.6877738833427429,
    0.05230306461453438
  ],
  "31272411||3||1175": [
    0.2486688643693924,
    0.6316371560096741,
    0.11969403922557831
  ],
  "31272411||4||1175": [
    0.20232635736465454,
    0.557856023311615,
    0.23981766402721405
  ],
  "31272411||5||1175": [
    0.1930430680513382,
    0.6401817202568054,
    0.16677521169185638
  ],
  "31272411||0||1179": [
    0.11169497668743134,
    0.880337655544281,
    0.007967397570610046
  ],
  "31272411||1||1179": [
    0.28367727994918823,
    0.7100271582603455,
    0.006295595318078995
  ],
  "31272411||2||1179": [
    0.11581563949584961,
    0.8787376284599304,
    0.005446670111268759
  ],
  "31272411||3||1179": [
    0.32829731702804565,
    0.6352899074554443,
    0.03641273453831673
  ],
  "31272411||4||1179": [
    0.33238595724105835,
    0.5910300612449646,
    0.07658397406339645
  ],
  "31272411||5||1179": [
    0.1644066870212555,
    0.7956860065460205,
    0.039907317608594894
  ],
  "31272411||0||1180": [
    0.02021598629653454,
    0.016094056889414787,
    0.9636898636817932
  ],
  "31272411||1||1180": [
    0.5537254214286804,
    0.39928197860717773,
    0.046992551535367966
  ],
  "31272411||2||1180": [
    0.23469841480255127,
    0.760261595249176,
    0.005039918702095747
  ],
  "31272411||3||1180": [
    0.6965227127075195,
    0.2921437919139862,
    0.011333572678267956
  ],
  "31272411||4||1180": [
    0.7014000415802002,
    0.2786533534526825,
    0.019946526736021042
  ],
  "31272411||5||1180": [
    0.30047401785850525,
    0.6755595207214355,
    0.02396647445857525
  ],
  "13905670||0||1230": [
    0.3221689462661743,
    0.5859190821647644,
    0.09191197156906128
  ],
  "13905670||1||1230": [
    0.03452569246292114,
    0.9624870419502258,
    0.002987195271998644
  ],
  "13905670||2||1230": [
    0.06729517132043839,
    0.8638626933097839,
    0.06884206086397171
  ],
  "13905670||3||1230": [
    0.1674290895462036,
    0.8193625211715698,
    0.013208410702645779
  ],
  "13905670||4||1230": [
    0.007290865294635296,
    0.8956543207168579,
    0.09705480933189392
  ],
  "13905670||5||1230": [
    0.0031556442845612764,
    0.9798398613929749,
    0.01700454391539097
  ],
  "13905670||0||1231": [
    0.011313633993268013,
    0.9822831749916077,
    0.006403173319995403
  ],
  "13905670||1||1231": [
    0.0018591369735077024,
    0.997078537940979,
    0.00106240704189986
  ],
  "13905670||2||1231": [
    0.002204288262873888,
    0.9945675134658813,
    0.0032282653264701366
  ],
  "13905670||3||1231": [
    0.0013274032389745116,
    0.007399400230497122,
    0.9912732243537903
  ],
  "13905670||4||1231": [
    0.06271098554134369,
    0.932461678981781,
    0.0048273405991494656
  ],
  "13905670||5||1231": [
    0.001174170058220625,
    0.9974260926246643,
    0.0013996772468090057
  ],
  "13905670||0||1234": [
    0.27225029468536377,
    0.5035601854324341,
    0.22418951988220215
  ],
  "13905670||1||1234": [
    0.054350096732378006,
    0.9404249787330627,
    0.005224866326898336
  ],
  "13905670||2||1234": [
    0.07658126205205917,
    0.8181667327880859,
    0.1052519753575325
  ],
  "13905670||3||1234": [
    0.11021551489830017,
    0.8862079381942749,
    0.003576552029699087
  ],
  "13905670||4||1234": [
    0.024208776652812958,
    0.6349077224731445,
    0.3408834934234619
  ],
  "13905670||5||1234": [
    0.002158795716241002,
    0.995826780796051,
    0.0020144530571997166
  ],
  "13905670||0||1232": [
    0.005942482501268387,
    0.9905130863189697,
    0.003544385312125087
  ],
  "13905670||1||1232": [
    0.0016020725015550852,
    0.9972834587097168,
    0.0011144746094942093
  ],
  "13905670||2||1232": [
    0.019018929451704025,
    0.9774981737136841,
    0.0034828679636120796
  ],
  "13905670||3||1232": [
    0.9982925057411194,
    0.0010583262192085385,
    0.0006491416716016829
  ],
  "13905670||4||1232": [
    0.18933136761188507,
    0.8077461123466492,
    0.0029225493781268597
  ],
  "13905670||5||1232": [
    0.51012122631073,
    0.48698556423187256,
    0.0028931922279298306
  ],
  "16284655||0||1322": [
    0.027392340824007988,
    0.5578758120536804,
    0.41473186016082764
  ],
  "16284655||1||1322": [
    0.00432091997936368,
    0.7050532102584839,
    0.2906258702278137
  ],
  "16284655||2||1322": [
    0.0024407703895121813,
    0.0586867518723011,
    0.9388723969459534
  ],
  "16284655||3||1322": [
    0.012581990100443363,
    0.22481882572174072,
    0.7625992298126221
  ],
  "16284655||4||1322": [
    0.012882237322628498,
    0.2441353052854538,
    0.7429825067520142
  ],
  "16284655||5||1322": [
    0.5657780766487122,
    0.29231807589530945,
    0.1419038623571396
  ],
  "16284655||6||1322": [
    0.008761164732277393,
    0.38561302423477173,
    0.6056258082389832
  ],
  "16284655||0||1319": [
    0.01007133163511753,
    0.3592382073402405,
    0.6306905150413513
  ],
  "16284655||1||1319": [
    0.005901299882680178,
    0.4121840000152588,
    0.5819147229194641
  ],
  "16284655||2||1319": [
    0.003587515791878104,
    0.10660936683416367,
    0.8898031711578369
  ],
  "16284655||3||1319": [
    0.017394164577126503,
    0.24257323145866394,
    0.7400325536727905
  ],
  "16284655||4||1319": [
    0.026129238307476044,
    0.31321537494659424,
    0.6606554388999939
  ],
  "16284655||5||1319": [
    0.29764166474342346,
    0.4768243134021759,
    0.22553397715091705
  ],
  "16284655||6||1319": [
    0.0021493779495358467,
    0.14359569549560547,
    0.854254961013794
  ],
  "16284655||0||1320": [
    0.9863887429237366,
    0.012910820543766022,
    0.0007004138315096498
  ],
  "16284655||1||1320": [
    0.8949477076530457,
    0.10275895893573761,
    0.0022933422587811947
  ],
  "16284655||2||1320": [
    0.9334926009178162,
    0.06413339078426361,
    0.0023740679025650024
  ],
  "16284655||3||1320": [
    0.9966446161270142,
    0.0028840387240052223,
    0.00047128889127634466
  ],
  "16284655||4||1320": [
    0.9943581223487854,
    0.005030523054301739,
    0.0006112898699939251
  ],
  "16284655||5||1320": [
    0.4121917188167572,
    0.5364482402801514,
    0.05136002600193024
  ],
  "16284655||6||1320": [
    0.9981847405433655,
    0.0015901225851848722,
    0.0002251873374916613
  ],
  "15482274||0||1340": [
    0.023467492312192917,
    0.9694757461547852,
    0.007056704722344875
  ],
  "15482274||1||1340": [
    0.3209995627403259,
    0.6475094556808472,
    0.0314909927546978
  ],
  "15482274||2||1340": [
    0.07493731379508972,
    0.9155521988868713,
    0.009510435163974762
  ],
  "15482274||3||1340": [
    0.0064789000898599625,
    0.9924744963645935,
    0.001046591205522418
  ],
  "15482274||4||1340": [
    0.002040412975475192,
    0.9970356225967407,
    0.0009239270002581179
  ],
  "15482274||5||1340": [
    0.03357267379760742,
    0.9654409289360046,
    0.0009863858576864004
  ],
  "15482274||6||1340": [
    0.01997360959649086,
    0.9772979021072388,
    0.0027284654788672924
  ],
  "15482274||7||1340": [
    0.0014291922561824322,
    0.9968569278717041,
    0.0017138747498393059
  ],
  "15482274||8||1340": [
    0.06691964715719223,
    0.923322856426239,
    0.009757534600794315
  ],
  "15482274||9||1340": [
    0.003789405571296811,
    0.06529295444488525,
    0.9309176802635193
  ],
  "15482274||10||1340": [
    0.0026818932965397835,
    0.5139676332473755,
    0.4833504557609558
  ],
  "15482274||11||1340": [
    0.0012619212502613664,
    0.9977390766143799,
    0.0009989571990445256
  ],
  "15482274||0||1341": [
    0.025411177426576614,
    0.9701569676399231,
    0.004431800451129675
  ],
  "15482274||1||1341": [
    0.18431879580020905,
    0.777851939201355,
    0.037829313427209854
  ],
  "15482274||2||1341": [
    0.067286916077137,
    0.9184224605560303,
    0.014290586113929749
  ],
  "15482274||3||1341": [
    0.006940316408872604,
    0.9920652508735657,
    0.0009944047778844833
  ],
  "15482274||4||1341": [
    0.0025641454849392176,
    0.9965103268623352,
    0.0009255486656911671
  ],
  "15482274||5||1341": [
    0.0268398504704237,
    0.9722183346748352,
    0.0009417926776222885
  ],
  "15482274||6||1341": [
    0.0033563452307134867,
    0.9951549768447876,
    0.0014886336866766214
  ],
  "15482274||7||1341": [
    0.0010084917303174734,
    0.997654139995575,
    0.00133744056802243
  ],
  "15482274||8||1341": [
    0.1306993067264557,
    0.8572313785552979,
    0.01206936128437519
  ],
  "15482274||9||1341": [
    0.009868987835943699,
    0.11267010122537613,
    0.8774610161781311
  ],
  "15482274||10||1341": [
    0.006219995208084583,
    0.5772565603256226,
    0.41652345657348633
  ],
  "15482274||11||1341": [
    0.002011991338804364,
    0.9971686005592346,
    0.0008194532128982246
  ],
  "15482274||0||1339": [
    0.9979585409164429,
    0.0016648350283503532,
    0.0003766578738577664
  ],
  "15482274||1||1339": [
    0.4049893319606781,
    0.5796487331390381,
    0.01536194421350956
  ],
  "15482274||2||1339": [
    0.2770492732524872,
    0.7080007791519165,
    0.014949950389564037
  ],
  "15482274||3||1339": [
    0.3309481143951416,
    0.6661326289176941,
    0.002919229445978999
  ],
  "15482274||4||1339": [
    0.048570144921541214,
    0.9495164752006531,
    0.001913403975777328
  ],
  "15482274||5||1339": [
    0.161185622215271,
    0.8359915018081665,
    0.002822846407070756
  ],
  "15482274||6||1339": [
    0.06568833440542221,
    0.9313927888870239,
    0.0029187952168285847
  ],
  "15482274||7||1339": [
    0.9867429733276367,
    0.012189801782369614,
    0.0010672489879652858
  ],
  "15482274||8||1339": [
    0.9723009467124939,
    0.025691138580441475,
    0.0020079815294593573
  ],
  "15482274||9||1339": [
    0.9982105493545532,
    0.00113086705096066,
    0.0006586491945199668
  ],
  "15482274||10||1339": [
    0.9992550015449524,
    0.0005234979325905442,
    0.00022148812422528863
  ],
  "15482274||11||1339": [
    0.6336314678192139,
    0.3630675971508026,
    0.003300958313047886
  ],
  "2425364||0||1367": [
    0.021562421694397926,
    0.9174084067344666,
    0.061029188334941864
  ],
  "2425364||1||1367": [
    0.06251049786806107,
    0.6917847394943237,
    0.2457047551870346
  ],
  "2425364||2||1367": [
    0.044943053275346756,
    0.7329217195510864,
    0.2221352458000183
  ],
  "2425364||3||1367": [
    0.05176973342895508,
    0.9229048490524292,
    0.02532537281513214
  ],
  "2425364||4||1367": [
    0.07975262403488159,
    0.6816080212593079,
    0.23863938450813293
  ],
  "2425364||5||1367": [
    0.03387904912233353,
    0.6549221873283386,
    0.31119877099990845
  ],
  "2425364||6||1367": [
    0.061634376645088196,
    0.7138016223907471,
    0.22456404566764832
  ],
  "2425364||7||1367": [
    0.03236115351319313,
    0.6534364223480225,
    0.3142023980617523
  ],
  "2425364||8||1367": [
    0.03537926822900772,
    0.6297252774238586,
    0.33489546179771423
  ],
  "2425364||9||1367": [
    0.2323242425918579,
    0.5787385702133179,
    0.18893718719482422
  ],
  "2425364||10||1367": [
    0.045638710260391235,
    0.7831358313560486,
    0.17122547328472137
  ],
  "2425364||11||1367": [
    0.013098690658807755,
    0.17113454639911652,
    0.8157667517662048
  ],
  "2425364||12||1367": [
    0.025746790692210197,
    0.6174055933952332,
    0.3568475842475891
  ],
  "2425364||0||1368": [
    0.027276471257209778,
    0.8616043925285339,
    0.11111915111541748
  ],
  "2425364||1||1368": [
    0.0691305547952652,
    0.7335389256477356,
    0.197330504655838
  ],
  "2425364||2||1368": [
    0.041718315333127975,
    0.8332523703575134,
    0.12502937018871307
  ],
  "2425364||3||1368": [
    0.06095324084162712,
    0.821654200553894,
    0.11739252507686615
  ],
  "2425364||4||1368": [
    0.06888870149850845,
    0.6808856725692749,
    0.250225692987442
  ],
  "2425364||5||1368": [
    0.04495170712471008,
    0.6761763691902161,
    0.27887195348739624
  ],
  "2425364||6||1368": [
    0.08229078352451324,
    0.7615686058998108,
    0.15614062547683716
  ],
  "2425364||7||1368": [
    0.04576348885893822,
    0.7211486101150513,
    0.2330879420042038
  ],
  "2425364||8||1368": [
    0.04178295284509659,
    0.7043058276176453,
    0.25391116738319397
  ],
  "2425364||9||1368": [
    0.19125139713287354,
    0.605614960193634,
    0.20313362777233124
  ],
  "2425364||10||1368": [
    0.04646764695644379,
    0.833175539970398,
    0.12035684287548065
  ],
  "2425364||11||1368": [
    0.15944595634937286,
    0.6621367335319519,
    0.17841725051403046
  ],
  "2425364||12||1368": [
    0.04621847718954086,
    0.7140475511550903,
    0.23973394930362701
  ],
  "2425364||0||1370": [
    0.7660066485404968,
    0.22854307293891907,
    0.005450261756777763
  ],
  "2425364||1||1370": [
    0.72906494140625,
    0.2408481240272522,
    0.030086949467658997
  ],
  "2425364||2||1370": [
    0.7762354016304016,
    0.20706789195537567,
    0.01669677160680294
  ],
  "2425364||3||1370": [
    0.7821745872497559,
    0.21450771391391754,
    0.003317712340503931
  ],
  "2425364||4||1370": [
    0.787186861038208,
    0.19927284121513367,
    0.013540280051529408
  ],
  "2425364||5||1370": [
    0.7260379791259766,
    0.24314895272254944,
    0.030813096091151237
  ],
  "2425364||6||1370": [
    0.7206031084060669,
    0.2553996741771698,
    0.02399723045527935
  ],
  "2425364||7||1370": [
    0.6761202216148376,
    0.29097995162010193,
    0.03289983421564102
  ],
  "2425364||8||1370": [
    0.7174670696258545,
    0.2528519034385681,
    0.02968106046319008
  ],
  "2425364||9||1370": [
    0.6650621891021729,
    0.32850074768066406,
    0.00643713166937232
  ],
  "2425364||10||1370": [
    0.8340014219284058,
    0.1617041826248169,
    0.0042943404987454414
  ],
  "2425364||11||1370": [
    0.8566433191299438,
    0.137776717543602,
    0.0055798920802772045
  ],
  "2425364||12||1370": [
    0.8902960419654846,
    0.1059819757938385,
    0.0037219671066850424
  ],
  "17717391||0||1397": [
    0.07335785776376724,
    0.9045132398605347,
    0.022128906100988388
  ],
  "17717391||1||1397": [
    0.7098483443260193,
    0.2864511013031006,
    0.0037005410995334387
  ],
  "17717391||2||1397": [
    0.20511934161186218,
    0.7858698964118958,
    0.009010780602693558
  ],
  "17717391||3||1397": [
    0.20303712785243988,
    0.7915596961975098,
    0.005403205286711454
  ],
  "17717391||4||1397": [
    0.5880330801010132,
    0.40542182326316833,
    0.006545165553689003
  ],
  "17717391||5||1397": [
    0.9613999724388123,
    0.03660259023308754,
    0.001997428247705102
  ],
  "17717391||6||1397": [
    0.9723033308982849,
    0.02531057596206665,
    0.002386026317253709
  ],
  "17717391||0||1398": [
    0.3707226514816284,
    0.5202983617782593,
    0.10897904634475708
  ],
  "17717391||1||1398": [
    0.7288548350334167,
    0.2647736072540283,
    0.006371505092829466
  ],
  "17717391||2||1398": [
    0.5885571837425232,
    0.399303138256073,
    0.012139593251049519
  ],
  "17717391||3||1398": [
    0.2934446930885315,
    0.700620710849762,
    0.005934595130383968
  ],
  "17717391||4||1398": [
    0.7050347328186035,
    0.2870907187461853,
    0.007874608039855957
  ],
  "17717391||5||1398": [
    0.8566417694091797,
    0.13839852809906006,
    0.004959706217050552
  ],
  "17717391||6||1398": [
    0.7469721436500549,
    0.24966022372245789,
    0.003367640543729067
  ],
  "17717391||0||1395": [
    0.0802619606256485,
    0.9060556292533875,
    0.013682412914931774
  ],
  "17717391||1||1395": [
    0.1430419683456421,
    0.8517805337905884,
    0.005177525337785482
  ],
  "17717391||2||1395": [
    0.08463869988918304,
    0.9086641073226929,
    0.0066971867345273495
  ],
  "17717391||3||1395": [
    0.22541573643684387,
    0.7700150012969971,
    0.0045692953281104565
  ],
  "17717391||4||1395": [
    0.3311830163002014,
    0.6475834846496582,
    0.021233495324850082
  ],
  "17717391||5||1395": [
    0.039412934333086014,
    0.9496278762817383,
    0.0109592629596591
  ],
  "17717391||6||1395": [
    0.16631093621253967,
    0.8148365020751953,
    0.01885257102549076
  ],
  "21366394||0||216": [
    0.05384863168001175,
    0.933210551738739,
    0.012940876185894012
  ],
  "21366394||1||216": [
    0.3430452346801758,
    0.6351649165153503,
    0.02178989350795746
  ],
  "21366394||2||216": [
    0.06409860402345657,
    0.9219629168510437,
    0.013938406482338905
  ],
  "21366394||3||216": [
    0.16263769567012787,
    0.7660620212554932,
    0.07130030542612076
  ],
  "21366394||4||216": [
    0.9837473034858704,
    0.013661578297615051,
    0.0025911154225468636
  ],
  "21366394||5||216": [
    0.9529423117637634,
    0.042870741337537766,
    0.004186905920505524
  ],
  "21366394||6||216": [
    0.18025469779968262,
    0.8104064464569092,
    0.0093388631939888
  ],
  "21366394||0||217": [
    0.04640359804034233,
    0.9362152814865112,
    0.017381101846694946
  ],
  "21366394||1||217": [
    0.02372795343399048,
    0.942736804485321,
    0.03353526443243027
  ],
  "21366394||2||217": [
    0.3458293080329895,
    0.6446133255958557,
    0.009557378478348255
  ],
  "21366394||3||217": [
    0.16966471076011658,
    0.7362533807754517,
    0.09408193826675415
  ],
  "21366394||4||217": [
    0.034288838505744934,
    0.7100796103477478,
    0.25563156604766846
  ],
  "21366394||5||217": [
    0.20564115047454834,
    0.717536985874176,
    0.07682184875011444
  ],
  "21366394||6||217": [
    0.09911125153303146,
    0.8944945931434631,
    0.006394172552973032
  ],
  "21366394||0||218": [
    0.05149830877780914,
    0.9208207726478577,
    0.027680935338139534
  ],
  "21366394||1||218": [
    0.7879860401153564,
    0.17485998570919037,
    0.037153907120227814
  ],
  "21366394||2||218": [
    0.17749188840389252,
    0.7835877537727356,
    0.03892035409808159
  ],
  "21366394||3||218": [
    0.9848928451538086,
    0.011075769551098347,
    0.004031435586512089
  ],
  "21366394||4||218": [
    0.8457006812095642,
    0.08906994014978409,
    0.06522940844297409
  ],
  "21366394||5||218": [
    0.7989181876182556,
    0.14045795798301697,
    0.060623832046985626
  ],
  "21366394||6||218": [
    0.7904391884803772,
    0.20368383824825287,
    0.0058770254254341125
  ],
  "21366394||0||219": [
    0.3592853248119354,
    0.6267836689949036,
    0.013931021094322205
  ],
  "21366394||1||219": [
    0.2448968142271042,
    0.41280364990234375,
    0.3422994613647461
  ],
  "21366394||2||219": [
    0.31909990310668945,
    0.6228413581848145,
    0.05805877596139908
  ],
  "21366394||3||219": [
    0.10310705751180649,
    0.1886124312877655,
    0.7082805037498474
  ],
  "21366394||4||219": [
    0.48290926218032837,
    0.266094446182251,
    0.25099626183509827
  ],
  "21366394||5||219": [
    0.9419497847557068,
    0.04832029342651367,
    0.009729927405714989
  ],
  "21366394||6||219": [
    0.05356955900788307,
    0.9419586658477783,
    0.004471749532967806
  ],
  "27910499||0||1316": [
    0.15496599674224854,
    0.8359606862068176,
    0.009073292836546898
  ],
  "27910499||1||1316": [
    0.058973588049411774,
    0.8660044074058533,
    0.07502197474241257
  ],
  "27910499||2||1316": [
    0.023115579038858414,
    0.9412478804588318,
    0.03563658148050308
  ],
  "27910499||3||1316": [
    0.14433062076568604,
    0.5847142934799194,
    0.2709551453590393
  ],
  "27910499||4||1316": [
    0.07614587247371674,
    0.8682054281234741,
    0.05564866214990616
  ],
  "27910499||5||1316": [
    0.0645189881324768,
    0.919923722743988,
    0.015557288192212582
  ],
  "27910499||6||1316": [
    0.02002423256635666,
    0.9681107401847839,
    0.011864961124956608
  ],
  "27910499||0||1335": [
    0.9477429986000061,
    0.050024934113025665,
    0.002232031198218465
  ],
  "27910499||1||1335": [
    0.5783502459526062,
    0.4161253869533539,
    0.005524314008653164
  ],
  "27910499||2||1335": [
    0.2065596878528595,
    0.7627821564674377,
    0.030658163130283356
  ],
  "27910499||3||1335": [
    0.07101873308420181,
    0.9138582348823547,
    0.015123063698410988
  ],
  "27910499||4||1335": [
    0.8060915470123291,
    0.1768358200788498,
    0.017072532325983047
  ],
  "27910499||5||1335": [
    0.5898630619049072,
    0.4029446840286255,
    0.007192237768322229
  ],
  "27910499||6||1335": [
    0.4387527108192444,
    0.5366071462631226,
    0.024640150368213654
  ],
  "27910499||0||1336": [
    0.04304732009768486,
    0.8352150917053223,
    0.12173757702112198
  ],
  "27910499||1||1336": [
    0.1709396094083786,
    0.7837415933609009,
    0.04531878978013992
  ],
  "27910499||2||1336": [
    0.2856810986995697,
    0.7064026594161987,
    0.00791624654084444
  ],
  "27910499||3||1336": [
    0.07638690620660782,
    0.9146428108215332,
    0.00897026713937521
  ],
  "27910499||4||1336": [
    0.03054969012737274,
    0.26952481269836426,
    0.6999254822731018
  ],
  "27910499||5||1336": [
    0.06618968397378922,
    0.8924731016159058,
    0.04133719205856323
  ],
  "27910499||6||1336": [
    0.6064489483833313,
    0.3484521508216858,
    0.04509884864091873
  ],
  "OBJECTIVES To carry out a further survey of archived appendix samples to understand better the differences between existing estimates of the prevalence of subclinical infection with prions after the bovine spongiform encephalopathy epizootic and to see whether a broader birth cohort was affected, and to understand better the implications for the management of blood and blood products and for the handling of surgical instruments.   \n||1 in 5 million in UK have abnormal PrP positivity.": [
    0.10614556819200516,
    0.8783295750617981,
    0.01552482321858406
  ],
  "DESIGN Irreversibly unlinked and anonymised large scale survey of archived appendix samples.   \n||1 in 5 million in UK have abnormal PrP positivity.": [
    0.0965159460902214,
    0.8878967761993408,
    0.015587292611598969
  ],
  "SETTING Archived appendix samples from the pathology departments of 41 UK hospitals participating in the earlier survey, and additional hospitals in regions with lower levels of participation in that survey.   ||1 in 5 million in UK have abnormal PrP positivity.": [
    0.10319370031356812,
    0.8895328640937805,
    0.007273480761796236
  ],
  "SAMPLE 32,441 archived appendix samples fixed in formalin and embedded in paraffin and tested for the presence of abnormal prion protein (PrP).   \n||1 in 5 million in UK have abnormal PrP positivity.": [
    0.019893616437911987,
    0.977959394454956,
    0.002147048246115446
  ],
  "RESULTS Of the 32,441 appendix samples 16 were positive for abnormal PrP, indicating an overall prevalence of 493 per million population (95% confidence interval 282 to 801 per million).||1 in 5 million in UK have abnormal PrP positivity.": [
    0.0985116958618164,
    0.7765727639198303,
    0.12491554021835327
  ],
  "The prevalence in those born in 1941-60 (733 per million, 269 to 1596 per million) did not differ significantly from those born between 1961 and 1985 (412 per million, 198 to 758 per million) and was similar in both sexes and across the three broad geographical areas sampled.||1 in 5 million in UK have abnormal PrP positivity.": [
    0.08127173781394958,
    0.8874476552009583,
    0.031280532479286194
  ],
  "Genetic testing of the positive specimens for the genotype at PRNP codon 129 revealed a high proportion that were valine homozygous compared with the frequency in the normal population, and in stark contrast with confirmed clinical cases of vCJD, all of which were methionine homozygous at PRNP codon 129.   \n||1 in 5 million in UK have abnormal PrP positivity.": [
    0.023367255926132202,
    0.9737953543663025,
    0.002837361767888069
  ],
  "CONCLUSIONS This study corroborates previous studies and suggests a high prevalence of infection with abnormal PrP, indicating vCJD carrier status in the population compared with the 177 vCJD cases to date.||1 in 5 million in UK have abnormal PrP positivity.": [
    0.0071709733456373215,
    0.9913622736930847,
    0.0014668179210275412
  ],
  "These findings have important implications for the management of blood and blood products and for the handling of surgical instruments.||1 in 5 million in UK have abnormal PrP positivity.": [
    0.10574155300855637,
    0.8844977617263794,
    0.009760626591742039
  ],
  "OBJECTIVES To carry out a further survey of archived appendix samples to understand better the differences between existing estimates of the prevalence of subclinical infection with prions after the bovine spongiform encephalopathy epizootic and to see whether a broader birth cohort was affected, and to understand better the implications for the management of blood and blood products and for the handling of surgical instruments.   \n||1/2000 in UK have abnormal PrP positivity.": [
    0.11988881975412369,
    0.8552921414375305,
    0.02481902204453945
  ],
  "DESIGN Irreversibly unlinked and anonymised large scale survey of archived appendix samples.   \n||1/2000 in UK have abnormal PrP positivity.": [
    0.16811126470565796,
    0.8172469735145569,
    0.01464176457375288
  ],
  "SETTING Archived appendix samples from the pathology departments of 41 UK hospitals participating in the earlier survey, and additional hospitals in regions with lower levels of participation in that survey.   ||1/2000 in UK have abnormal PrP positivity.": [
    0.2403278350830078,
    0.743179440498352,
    0.01649278961122036
  ],
  "SAMPLE 32,441 archived appendix samples fixed in formalin and embedded in paraffin and tested for the presence of abnormal prion protein (PrP).   \n||1/2000 in UK have abnormal PrP positivity.": [
    0.06170934438705444,
    0.9343591332435608,
    0.003931532613933086
  ],
  "RESULTS Of the 32,441 appendix samples 16 were positive for abnormal PrP, indicating an overall prevalence of 493 per million population (95% confidence interval 282 to 801 per million).||1/2000 in UK have abnormal PrP positivity.": [
    0.3607800006866455,
    0.5902187824249268,
    0.04900122061371803
  ],
  "The prevalence in those born in 1941-60 (733 per million, 269 to 1596 per million) did not differ significantly from those born between 1961 and 1985 (412 per million, 198 to 758 per million) and was similar in both sexes and across the three broad geographical areas sampled.||1/2000 in UK have abnormal PrP positivity.": [
    0.50581955909729,
    0.471828430891037,
    0.0223519466817379
  ],
  "Genetic testing of the positive specimens for the genotype at PRNP codon 129 revealed a high proportion that were valine homozygous compared with the frequency in the normal population, and in stark contrast with confirmed clinical cases of vCJD, all of which were methionine homozygous at PRNP codon 129.   \n||1/2000 in UK have abnormal PrP positivity.": [
    0.029463447630405426,
    0.9664146900177002,
    0.004121917765587568
  ],
  "CONCLUSIONS This study corroborates previous studies and suggests a high prevalence of infection with abnormal PrP, indicating vCJD carrier status in the population compared with the 177 vCJD cases to date.||1/2000 in UK have abnormal PrP positivity.": [
    0.06413676589727402,
    0.9289939403533936,
    0.006869315169751644
  ],
  "These findings have important implications for the management of blood and blood products and for the handling of surgical instruments.||1/2000 in UK have abnormal PrP positivity.": [
    0.12478885799646378,
    0.8610967993736267,
    0.014114356599748135
  ],
  "OBJECTIVES To carry out a further survey of archived appendix samples to understand better the differences between existing estimates of the prevalence of subclinical infection with prions after the bovine spongiform encephalopathy epizootic and to see whether a broader birth cohort was affected, and to understand better the implications for the management of blood and blood products and for the handling of surgical instruments.   \n||A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.": [
    0.1512478142976761,
    0.8440978527069092,
    0.00465439585968852
  ],
  "DESIGN Irreversibly unlinked and anonymised large scale survey of archived appendix samples.   \n||A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.": [
    0.054035723209381104,
    0.9430188536643982,
    0.0029454415198415518
  ],
  "SETTING Archived appendix samples from the pathology departments of 41 UK hospitals participating in the earlier survey, and additional hospitals in regions with lower levels of participation in that survey.   ||A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.": [
    0.02929026447236538,
    0.968403697013855,
    0.002306064125150442
  ],
  "SAMPLE 32,441 archived appendix samples fixed in formalin and embedded in paraffin and tested for the presence of abnormal prion protein (PrP).   \n||A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.": [
    0.6407184600830078,
    0.3523672819137573,
    0.006914168130606413
  ],
  "RESULTS Of the 32,441 appendix samples 16 were positive for abnormal PrP, indicating an overall prevalence of 493 per million population (95% confidence interval 282 to 801 per million).||A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.": [
    0.6205917000770569,
    0.3659248948097229,
    0.01348343025892973
  ],
  "The prevalence in those born in 1941-60 (733 per million, 269 to 1596 per million) did not differ significantly from those born between 1961 and 1985 (412 per million, 198 to 758 per million) and was similar in both sexes and across the three broad geographical areas sampled.||A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.": [
    0.15749794244766235,
    0.8377252817153931,
    0.004776765592396259
  ],
  "Genetic testing of the positive specimens for the genotype at PRNP codon 129 revealed a high proportion that were valine homozygous compared with the frequency in the normal population, and in stark contrast with confirmed clinical cases of vCJD, all of which were methionine homozygous at PRNP codon 129.   \n||A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.": [
    0.04332491010427475,
    0.9550166130065918,
    0.0016584321856498718
  ],
  "CONCLUSIONS This study corroborates previous studies and suggests a high prevalence of infection with abnormal PrP, indicating vCJD carrier status in the population compared with the 177 vCJD cases to date.||A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.": [
    0.7265167832374573,
    0.26581236720085144,
    0.007670889142900705
  ],
  "These findings have important implications for the management of blood and blood products and for the handling of surgical instruments.||A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.": [
    0.06782738119363785,
    0.9281859993934631,
    0.003986602649092674
  ],
  "Previous studies investigating the role of smooth muscle cells (SMCs) and macrophages in the pathogenesis of atherosclerosis have provided controversial results owing to the use of unreliable methods for clearly identifying each of these cell types.||50% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.07435969263315201,
    0.9220542311668396,
    0.0035860815551131964
  ],
  "Here, using Myh11-CreERT2 ROSA floxed STOP eYFP Apoe\u2212/\u2212 mice to perform SMC lineage tracing, we find that traditional methods for detecting SMCs based on immunostaining for SMC markers fail to detect >80% of SMC-derived cells within advanced atherosclerotic lesions.||50% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.1888371706008911,
    0.7950667142868042,
    0.01609610579907894
  ],
  "These unidentified SMC-derived cells exhibit phenotypes of other cell lineages, including macrophages and mesenchymal stem cells (MSCs).||50% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.006853042170405388,
    0.9922598004341125,
    0.0008871371392160654
  ],
  "SMC-specific conditional knockout of Kr\u00fcppel-like factor 4 (Klf4) resulted in reduced numbers of SMC-derived MSC- and macrophage-like cells, a marked reduction in lesion size, and increases in multiple indices of plaque stability, including an increase in fibrous cap thickness as compared to wild-type controls.||50% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.09235794097185135,
    0.8999655842781067,
    0.007676508743315935
  ],
  "On the basis of in vivo KLF4 chromatin immunoprecipitation\u2013sequencing (ChIP-seq) analyses and studies of cholesterol-treated cultured SMCs, we identified >800 KLF4 target genes, including many that regulate pro-inflammatory responses of SMCs.||50% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.0832238644361496,
    0.9037949442863464,
    0.012981200590729713
  ],
  "Our findings indicate that the contribution of SMCs to atherosclerotic plaques has been greatly underestimated, and that KLF4-dependent transitions in SMC phenotype are critical in lesion pathogenesis.||50% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.09754785895347595,
    0.8880331516265869,
    0.014418991282582283
  ],
  "Previous studies investigating the role of smooth muscle cells (SMCs) and macrophages in the pathogenesis of atherosclerosis have provided controversial results owing to the use of unreliable methods for clearly identifying each of these cell types.||At least 85% of patients exposed to radiation have activated markers of myofibroblasts.": [
    0.09189871698617935,
    0.8977102041244507,
    0.010391059331595898
  ],
  "Here, using Myh11-CreERT2 ROSA floxed STOP eYFP Apoe\u2212/\u2212 mice to perform SMC lineage tracing, we find that traditional methods for detecting SMCs based on immunostaining for SMC markers fail to detect >80% of SMC-derived cells within advanced atherosclerotic lesions.||At least 85% of patients exposed to radiation have activated markers of myofibroblasts.": [
    0.28677117824554443,
    0.6351739764213562,
    0.07805490493774414
  ],
  "These unidentified SMC-derived cells exhibit phenotypes of other cell lineages, including macrophages and mesenchymal stem cells (MSCs).||At least 85% of patients exposed to radiation have activated markers of myofibroblasts.": [
    0.06485210359096527,
    0.9322882890701294,
    0.002859619678929448
  ],
  "SMC-specific conditional knockout of Kr\u00fcppel-like factor 4 (Klf4) resulted in reduced numbers of SMC-derived MSC- and macrophage-like cells, a marked reduction in lesion size, and increases in multiple indices of plaque stability, including an increase in fibrous cap thickness as compared to wild-type controls.||At least 85% of patients exposed to radiation have activated markers of myofibroblasts.": [
    0.10600727051496506,
    0.8784324526786804,
    0.015560304746031761
  ],
  "On the basis of in vivo KLF4 chromatin immunoprecipitation\u2013sequencing (ChIP-seq) analyses and studies of cholesterol-treated cultured SMCs, we identified >800 KLF4 target genes, including many that regulate pro-inflammatory responses of SMCs.||At least 85% of patients exposed to radiation have activated markers of myofibroblasts.": [
    0.09419173747301102,
    0.841599702835083,
    0.06420855969190598
  ],
  "Our findings indicate that the contribution of SMCs to atherosclerotic plaques has been greatly underestimated, and that KLF4-dependent transitions in SMC phenotype are critical in lesion pathogenesis.||At least 85% of patients exposed to radiation have activated markers of myofibroblasts.": [
    0.16829335689544678,
    0.76105135679245,
    0.07065525650978088
  ],
  "Previous studies investigating the role of smooth muscle cells (SMCs) and macrophages in the pathogenesis of atherosclerosis have provided controversial results owing to the use of unreliable methods for clearly identifying each of these cell types.||Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.": [
    0.01106348354369402,
    0.986874520778656,
    0.0020619614515453577
  ],
  "Here, using Myh11-CreERT2 ROSA floxed STOP eYFP Apoe\u2212/\u2212 mice to perform SMC lineage tracing, we find that traditional methods for detecting SMCs based on immunostaining for SMC markers fail to detect >80% of SMC-derived cells within advanced atherosclerotic lesions.||Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.": [
    0.034388668835163116,
    0.9264969229698181,
    0.039114441722631454
  ],
  "These unidentified SMC-derived cells exhibit phenotypes of other cell lineages, including macrophages and mesenchymal stem cells (MSCs).||Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.": [
    0.015692932531237602,
    0.9823216199874878,
    0.0019854502752423286
  ],
  "SMC-specific conditional knockout of Kr\u00fcppel-like factor 4 (Klf4) resulted in reduced numbers of SMC-derived MSC- and macrophage-like cells, a marked reduction in lesion size, and increases in multiple indices of plaque stability, including an increase in fibrous cap thickness as compared to wild-type controls.||Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.": [
    0.5484219789505005,
    0.44128116965293884,
    0.01029678713530302
  ],
  "On the basis of in vivo KLF4 chromatin immunoprecipitation\u2013sequencing (ChIP-seq) analyses and studies of cholesterol-treated cultured SMCs, we identified >800 KLF4 target genes, including many that regulate pro-inflammatory responses of SMCs.||Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.": [
    0.00744747556746006,
    0.723423421382904,
    0.26912909746170044
  ],
  "Our findings indicate that the contribution of SMCs to atherosclerotic plaques has been greatly underestimated, and that KLF4-dependent transitions in SMC phenotype are critical in lesion pathogenesis.||Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.": [
    0.015589003451168537,
    0.9765784740447998,
    0.00783253088593483
  ],
  "Previous studies investigating the role of smooth muscle cells (SMCs) and macrophages in the pathogenesis of atherosclerosis have provided controversial results owing to the use of unreliable methods for clearly identifying each of these cell types.||KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.": [
    0.04181044548749924,
    0.951251208782196,
    0.0069383280351758
  ],
  "Here, using Myh11-CreERT2 ROSA floxed STOP eYFP Apoe\u2212/\u2212 mice to perform SMC lineage tracing, we find that traditional methods for detecting SMCs based on immunostaining for SMC markers fail to detect >80% of SMC-derived cells within advanced atherosclerotic lesions.||KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.": [
    0.12554971873760223,
    0.8475070595741272,
    0.026943162083625793
  ],
  "These unidentified SMC-derived cells exhibit phenotypes of other cell lineages, including macrophages and mesenchymal stem cells (MSCs).||KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.": [
    0.036868054419755936,
    0.9556816220283508,
    0.007450375240296125
  ],
  "SMC-specific conditional knockout of Kr\u00fcppel-like factor 4 (Klf4) resulted in reduced numbers of SMC-derived MSC- and macrophage-like cells, a marked reduction in lesion size, and increases in multiple indices of plaque stability, including an increase in fibrous cap thickness as compared to wild-type controls.||KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.": [
    0.04864976182579994,
    0.9093115329742432,
    0.0420386828482151
  ],
  "On the basis of in vivo KLF4 chromatin immunoprecipitation\u2013sequencing (ChIP-seq) analyses and studies of cholesterol-treated cultured SMCs, we identified >800 KLF4 target genes, including many that regulate pro-inflammatory responses of SMCs.||KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.": [
    0.021231910213828087,
    0.9656179547309875,
    0.013150135055184364
  ],
  "Our findings indicate that the contribution of SMCs to atherosclerotic plaques has been greatly underestimated, and that KLF4-dependent transitions in SMC phenotype are critical in lesion pathogenesis.||KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.": [
    0.00805972982198,
    0.6691703200340271,
    0.3227699398994446
  ],
  "Previous studies investigating the role of smooth muscle cells (SMCs) and macrophages in the pathogenesis of atherosclerosis have provided controversial results owing to the use of unreliable methods for clearly identifying each of these cell types.||Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.02951924316585064,
    0.963166356086731,
    0.007314399350434542
  ],
  "Here, using Myh11-CreERT2 ROSA floxed STOP eYFP Apoe\u2212/\u2212 mice to perform SMC lineage tracing, we find that traditional methods for detecting SMCs based on immunostaining for SMC markers fail to detect >80% of SMC-derived cells within advanced atherosclerotic lesions.||Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.3241358697414398,
    0.6394527554512024,
    0.036411356180906296
  ],
  "These unidentified SMC-derived cells exhibit phenotypes of other cell lineages, including macrophages and mesenchymal stem cells (MSCs).||Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.003909007646143436,
    0.9951325058937073,
    0.000958403164986521
  ],
  "SMC-specific conditional knockout of Kr\u00fcppel-like factor 4 (Klf4) resulted in reduced numbers of SMC-derived MSC- and macrophage-like cells, a marked reduction in lesion size, and increases in multiple indices of plaque stability, including an increase in fibrous cap thickness as compared to wild-type controls.||Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.017457274720072746,
    0.9685020446777344,
    0.014040699228644371
  ],
  "On the basis of in vivo KLF4 chromatin immunoprecipitation\u2013sequencing (ChIP-seq) analyses and studies of cholesterol-treated cultured SMCs, we identified >800 KLF4 target genes, including many that regulate pro-inflammatory responses of SMCs.||Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.055282238870859146,
    0.9186771512031555,
    0.026040632277727127
  ],
  "Our findings indicate that the contribution of SMCs to atherosclerotic plaques has been greatly underestimated, and that KLF4-dependent transitions in SMC phenotype are critical in lesion pathogenesis.||Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.": [
    0.11166263371706009,
    0.8724470734596252,
    0.015890296548604965
  ],
  "In systemic lupus erythematosus (SLE), self-reactive antibodies can target the kidney (lupus nephritis), leading to functional failure and possible mortality.||A T helper 2 cell (Th2) environment impedes disease development in patients with systemic lupus erythematosus (SLE).": [
    0.7529624700546265,
    0.2153385877609253,
    0.03169896453619003
  ],
  "We report that activation of basophils by autoreactive IgE causes their homing to lymph nodes, promoting T helper type 2 (T(H)2) cell differentiation and enhancing the production of self-reactive antibodies that cause lupus-like nephritis in mice lacking the Src family protein tyrosine kinase Lyn (Lyn(-/-) mice).||A T helper 2 cell (Th2) environment impedes disease development in patients with systemic lupus erythematosus (SLE).": [
    0.8913698792457581,
    0.0645541399717331,
    0.04407588765025139
  ],
  "Individuals with SLE also have elevated serum IgE, self-reactive IgEs and activated basophils that express CD62 ligand (CD62L) and the major histocompatibility complex (MHC) class II molecule human leukocyte antigen-DR (HLA-DR), parameters that are associated with increased disease activity and active lupus nephritis.||A T helper 2 cell (Th2) environment impedes disease development in patients with systemic lupus erythematosus (SLE).": [
    0.932904064655304,
    0.05739433318376541,
    0.009701632894575596
  ],
  "Basophils were also present in the lymph nodes and spleen of subjects with SLE.||A T helper 2 cell (Th2) environment impedes disease development in patients with systemic lupus erythematosus (SLE).": [
    0.5314497351646423,
    0.40475353598594666,
    0.06379672139883041
  ],
  "Thus, in Lyn(-/-) mice, basophils and IgE autoantibodies amplify autoantibody production that leads to lupus nephritis, and in individuals with SLE IgE autoantibodies and activated basophils are factors associated with disease activity and nephritis.||A T helper 2 cell (Th2) environment impedes disease development in patients with systemic lupus erythematosus (SLE).": [
    0.8534254431724548,
    0.1378779262304306,
    0.008696602657437325
  ],
  "In systemic lupus erythematosus (SLE), self-reactive antibodies can target the kidney (lupus nephritis), leading to functional failure and possible mortality.||Basophils promote disease development in patients with systemic lupus erythematosus (SLE).": [
    0.2527483403682709,
    0.41895121335983276,
    0.3283005356788635
  ],
  "We report that activation of basophils by autoreactive IgE causes their homing to lymph nodes, promoting T helper type 2 (T(H)2) cell differentiation and enhancing the production of self-reactive antibodies that cause lupus-like nephritis in mice lacking the Src family protein tyrosine kinase Lyn (Lyn(-/-) mice).||Basophils promote disease development in patients with systemic lupus erythematosus (SLE).": [
    0.07068131864070892,
    0.4374156892299652,
    0.49190306663513184
  ],
  "Individuals with SLE also have elevated serum IgE, self-reactive IgEs and activated basophils that express CD62 ligand (CD62L) and the major histocompatibility complex (MHC) class II molecule human leukocyte antigen-DR (HLA-DR), parameters that are associated with increased disease activity and active lupus nephritis.||Basophils promote disease development in patients with systemic lupus erythematosus (SLE).": [
    0.002121011493727565,
    0.11528429388999939,
    0.8825947046279907
  ],
  "Basophils were also present in the lymph nodes and spleen of subjects with SLE.||Basophils promote disease development in patients with systemic lupus erythematosus (SLE).": [
    0.10654854774475098,
    0.881673276424408,
    0.011778191663324833
  ],
  "Thus, in Lyn(-/-) mice, basophils and IgE autoantibodies amplify autoantibody production that leads to lupus nephritis, and in individuals with SLE IgE autoantibodies and activated basophils are factors associated with disease activity and nephritis.||Basophils promote disease development in patients with systemic lupus erythematosus (SLE).": [
    0.003482552943751216,
    0.15646494925022125,
    0.8400524854660034
  ],
  "In systemic lupus erythematosus (SLE), self-reactive antibodies can target the kidney (lupus nephritis), leading to functional failure and possible mortality.||Basophils counteract disease development in patients with systemic lupus erythematosus (SLE).": [
    0.8756441473960876,
    0.11876759678125381,
    0.005588196218013763
  ],
  "We report that activation of basophils by autoreactive IgE causes their homing to lymph nodes, promoting T helper type 2 (T(H)2) cell differentiation and enhancing the production of self-reactive antibodies that cause lupus-like nephritis in mice lacking the Src family protein tyrosine kinase Lyn (Lyn(-/-) mice).||Basophils counteract disease development in patients with systemic lupus erythematosus (SLE).": [
    0.9744857549667358,
    0.022191502153873444,
    0.00332274055108428
  ],
  "Individuals with SLE also have elevated serum IgE, self-reactive IgEs and activated basophils that express CD62 ligand (CD62L) and the major histocompatibility complex (MHC) class II molecule human leukocyte antigen-DR (HLA-DR), parameters that are associated with increased disease activity and active lupus nephritis.||Basophils counteract disease development in patients with systemic lupus erythematosus (SLE).": [
    0.9965923428535461,
    0.0027518391143530607,
    0.000655828567687422
  ],
  "Basophils were also present in the lymph nodes and spleen of subjects with SLE.||Basophils counteract disease development in patients with systemic lupus erythematosus (SLE).": [
    0.009144369512796402,
    0.9593116641044617,
    0.03154397010803223
  ],
  "Thus, in Lyn(-/-) mice, basophils and IgE autoantibodies amplify autoantibody production that leads to lupus nephritis, and in individuals with SLE IgE autoantibodies and activated basophils are factors associated with disease activity and nephritis.||Basophils counteract disease development in patients with systemic lupus erythematosus (SLE).": [
    0.995055079460144,
    0.003943383693695068,
    0.0010014967992901802
  ],
  "CONTEXT The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen.||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.0023850256111472845,
    0.6046803593635559,
    0.3929345905780792
  ],
  "The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme.   \n||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.0023987903259694576,
    0.9807901382446289,
    0.016811100766062737
  ],
  "OBJECTIVE To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen.   \n||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.002581285545602441,
    0.7675941586494446,
    0.22982454299926758
  ],
  "DESIGN, SETTING, AND PATIENTS Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer.||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.003060384886339307,
    0.7062305808067322,
    0.2907090485095978
  ],
  "The 1325 patients had diagnoses between 1986 and 2005 of stage I through III breast cancer and were mainly postmenopausal (95.4%).||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.00989316962659359,
    0.899219274520874,
    0.09088751673698425
  ],
  "Last follow-up was in December 2008; inclusion criteria were hormone receptor positivity, no metastatic disease at diagnosis, adjuvant tamoxifen therapy, and no chemotherapy.||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.0031703521963208914,
    0.8005979657173157,
    0.1962316632270813
  ],
  "DNA from tumor tissue or blood was genotyped for CYP2D6 variants associated with reduced (*10, *41) or absent (*3, *4, *5) enzyme activity.||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.00666706170886755,
    0.834471583366394,
    0.15886132419109344
  ],
  "Women were classified as having an extensive (n=609), heterozygous extensive/intermediate (n=637), or poor (n=79) CYP2D6 metabolism.   \n||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.0033191523980349302,
    0.9867788553237915,
    0.009902006946504116
  ],
  "MAIN OUTCOME MEASURES Time to recurrence, event-free survival, disease-free survival, and overall survival.   \n||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.017249228432774544,
    0.9351239800453186,
    0.04762677475810051
  ],
  "RESULTS Median follow-up was 6.3 years.||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.013559971004724503,
    0.5455048084259033,
    0.4409352242946625
  ],
  "At 9 years of follow-up, the recurrence rates were 14.9% for extensive metabolizers, 20.9% for heterozygous extensive/intermediate metabolizers, and 29.0% for poor metabolizers, and all-cause mortality rates were 16.7%, 18.0%, and 22.8%, respectively.||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.002471225569024682,
    0.7912750840187073,
    0.20625364780426025
  ],
  "Compared with extensive metabolizers, there was a significantly increased risk of recurrence for heterozygous extensive/intermediate metabolizers (time to recurrence adjusted hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.04-1.90) and for poor metabolizers (time to recurrence HR, 1.90; 95% CI, 1.10-3.28).||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.0033687972463667393,
    0.8928558230400085,
    0.10377535969018936
  ],
  "Compared with extensive metabolizers, those with decreased CYP2D6 activity (heterozygous extensive/intermediate and poor metabolism) had worse event-free survival (HR, 1.33; 95% CI, 1.06-1.68) and disease-free survival (HR, 1.29; 95% CI, 1.03-1.61), but there was no significant difference in overall survival (HR, 1.15; 95% CI, 0.88-1.51).   \n||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.008005211129784584,
    0.7571102380752563,
    0.234884575009346
  ],
  "CONCLUSION Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP2D6 alleles was associated with better clinical outcomes and the presence of nonfunctional or reduced-function alleles with worse outcomes.||A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.": [
    0.009247378446161747,
    0.29521632194519043,
    0.6955363154411316
  ],
  "CONTEXT The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.07557978481054306,
    0.9194656610488892,
    0.004954518750309944
  ],
  "The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme.   \n||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.5048776865005493,
    0.48241719603538513,
    0.012705116532742977
  ],
  "OBJECTIVE To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen.   \n||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.8460109233856201,
    0.14833307266235352,
    0.005656010005623102
  ],
  "DESIGN, SETTING, AND PATIENTS Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.2607005536556244,
    0.729832649230957,
    0.009466765448451042
  ],
  "The 1325 patients had diagnoses between 1986 and 2005 of stage I through III breast cancer and were mainly postmenopausal (95.4%).||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.6306112408638,
    0.36226290464401245,
    0.007125868462026119
  ],
  "Last follow-up was in December 2008; inclusion criteria were hormone receptor positivity, no metastatic disease at diagnosis, adjuvant tamoxifen therapy, and no chemotherapy.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.5950911045074463,
    0.3998224139213562,
    0.005086482968181372
  ],
  "DNA from tumor tissue or blood was genotyped for CYP2D6 variants associated with reduced (*10, *41) or absent (*3, *4, *5) enzyme activity.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.8185688853263855,
    0.1766444742679596,
    0.0047865984961390495
  ],
  "Women were classified as having an extensive (n=609), heterozygous extensive/intermediate (n=637), or poor (n=79) CYP2D6 metabolism.   \n||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.7942348718643188,
    0.19935716688632965,
    0.0064079854637384415
  ],
  "MAIN OUTCOME MEASURES Time to recurrence, event-free survival, disease-free survival, and overall survival.   \n||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.2055862694978714,
    0.7849358916282654,
    0.009477821178734303
  ],
  "RESULTS Median follow-up was 6.3 years.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.32937386631965637,
    0.5912106037139893,
    0.07941558957099915
  ],
  "At 9 years of follow-up, the recurrence rates were 14.9% for extensive metabolizers, 20.9% for heterozygous extensive/intermediate metabolizers, and 29.0% for poor metabolizers, and all-cause mortality rates were 16.7%, 18.0%, and 22.8%, respectively.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.613004744052887,
    0.35154855251312256,
    0.03544670715928078
  ],
  "Compared with extensive metabolizers, there was a significantly increased risk of recurrence for heterozygous extensive/intermediate metabolizers (time to recurrence adjusted hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.04-1.90) and for poor metabolizers (time to recurrence HR, 1.90; 95% CI, 1.10-3.28).||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.7195560932159424,
    0.2662334740161896,
    0.01421038806438446
  ],
  "Compared with extensive metabolizers, those with decreased CYP2D6 activity (heterozygous extensive/intermediate and poor metabolism) had worse event-free survival (HR, 1.33; 95% CI, 1.06-1.68) and disease-free survival (HR, 1.29; 95% CI, 1.03-1.61), but there was no significant difference in overall survival (HR, 1.15; 95% CI, 0.88-1.51).   \n||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.6461625099182129,
    0.33114102482795715,
    0.02269643172621727
  ],
  "CONCLUSION Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP2D6 alleles was associated with better clinical outcomes and the presence of nonfunctional or reduced-function alleles with worse outcomes.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.": [
    0.9242965579032898,
    0.07191239297389984,
    0.0037909941747784615
  ],
  "CONTEXT The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.02221108041703701,
    0.9757512807846069,
    0.002037585712969303
  ],
  "The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme.   \n||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.04331294447183609,
    0.9471729397773743,
    0.00951413344591856
  ],
  "OBJECTIVE To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen.   \n||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.025433802977204323,
    0.8431874513626099,
    0.13137879967689514
  ],
  "DESIGN, SETTING, AND PATIENTS Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.027587926015257835,
    0.967384397983551,
    0.005027660168707371
  ],
  "The 1325 patients had diagnoses between 1986 and 2005 of stage I through III breast cancer and were mainly postmenopausal (95.4%).||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.052878379821777344,
    0.9222028255462646,
    0.024918822571635246
  ],
  "Last follow-up was in December 2008; inclusion criteria were hormone receptor positivity, no metastatic disease at diagnosis, adjuvant tamoxifen therapy, and no chemotherapy.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.048654649406671524,
    0.9455389380455017,
    0.005806343629956245
  ],
  "DNA from tumor tissue or blood was genotyped for CYP2D6 variants associated with reduced (*10, *41) or absent (*3, *4, *5) enzyme activity.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.007851755246520042,
    0.8921064138412476,
    0.10004183650016785
  ],
  "Women were classified as having an extensive (n=609), heterozygous extensive/intermediate (n=637), or poor (n=79) CYP2D6 metabolism.   \n||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.0043009365908801556,
    0.9072679877281189,
    0.08843106776475906
  ],
  "MAIN OUTCOME MEASURES Time to recurrence, event-free survival, disease-free survival, and overall survival.   \n||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.05756025016307831,
    0.938502848148346,
    0.003936834167689085
  ],
  "RESULTS Median follow-up was 6.3 years.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.12432514876127243,
    0.7566024661064148,
    0.11907241493463516
  ],
  "At 9 years of follow-up, the recurrence rates were 14.9% for extensive metabolizers, 20.9% for heterozygous extensive/intermediate metabolizers, and 29.0% for poor metabolizers, and all-cause mortality rates were 16.7%, 18.0%, and 22.8%, respectively.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.0061584338545799255,
    0.7877434492111206,
    0.20609815418720245
  ],
  "Compared with extensive metabolizers, there was a significantly increased risk of recurrence for heterozygous extensive/intermediate metabolizers (time to recurrence adjusted hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.04-1.90) and for poor metabolizers (time to recurrence HR, 1.90; 95% CI, 1.10-3.28).||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.009299234487116337,
    0.8924721479415894,
    0.09822863340377808
  ],
  "Compared with extensive metabolizers, those with decreased CYP2D6 activity (heterozygous extensive/intermediate and poor metabolism) had worse event-free survival (HR, 1.33; 95% CI, 1.06-1.68) and disease-free survival (HR, 1.29; 95% CI, 1.03-1.61), but there was no significant difference in overall survival (HR, 1.15; 95% CI, 0.88-1.51).   \n||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.041523125022649765,
    0.8677009344100952,
    0.09077594429254532
  ],
  "CONCLUSION Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP2D6 alleles was associated with better clinical outcomes and the presence of nonfunctional or reduced-function alleles with worse outcomes.||The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.": [
    0.013388431631028652,
    0.8441945910453796,
    0.14241693913936615
  ],
  "Importance Despite lack of evidence of their utility, biomarkers of ovarian reserve are being promoted as potential markers of reproductive potential.||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.005325058940798044,
    0.6011177897453308,
    0.3935571312904358
  ],
  "Objective To determine the associations between biomarkers of ovarian reserve and reproductive potential among women of late reproductive age.||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.007158335298299789,
    0.6251220107078552,
    0.3677196204662323
  ],
  "Design, Setting, and Participants Prospective time-to-pregnancy cohort study (2008 to date of last follow-up in March 2016) of women (N = 981) aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, recruited from the community in the Raleigh-Durham, North Carolina, area.||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.00829195324331522,
    0.6836776733398438,
    0.308030366897583
  ],
  "Exposures Early-follicular-phase serum level of antim\u00fcllerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B and urinary level of FSH.||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.01906384527683258,
    0.7062553763389587,
    0.2746807932853699
  ],
  "Main Outcomes and Measures The primary outcomes were the cumulative probability of conception by 6 and 12 cycles of attempt and relative fecundability (probability of conception in a given menstrual cycle).||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.04653584584593773,
    0.8619390726089478,
    0.09152509272098541
  ],
  "Conception was defined as a positive pregnancy test result.||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.06621566414833069,
    0.6893949508666992,
    0.2443893998861313
  ],
  "Results A total of 750 women (mean age, 33.3 [SD, 3.2] years; 77% white; 36% overweight or obese) provided a blood and urine sample and were included in the analysis.||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.009433669969439507,
    0.7595406770706177,
    0.23102566599845886
  ],
  "After adjusting for age, body mass index, race, current smoking status, and recent hormonal contraceptive use, women with low AMH values (<0.7 ng/mL [n = 84]) did not have a significantly different predicted probability of conceiving by 6 cycles of attempt (65%; 95% CI, 50%-75%) compared with women (n = 579) with normal values (62%; 95% CI, 57%-66%) or by 12 cycles of attempt (84% [95% CI, 70%-91%] vs 75% [95% CI, 70%-79%], respectively).||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.003744036890566349,
    0.3538290560245514,
    0.6424269676208496
  ],
  "Women with high serum FSH values (>10 mIU/mL [n = 83]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (63%; 95% CI, 50%-73%) compared with women (n = 654) with normal values (62%; 95% CI, 57%-66%) or after 12 cycles of attempt (82% [95% CI, 70%-89%] vs 75% [95% CI, 70%-78%], respectively).||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.0033072668593376875,
    0.41070622205734253,
    0.5859864950180054
  ],
  "Women with high urinary FSH values (>11.5 mIU/mg creatinine [n = 69]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (61%; 95% CI, 46%-74%) compared with women (n = 660) with normal values (62%; 95% CI, 58%-66%) or after 12 cycles of attempt (70% [95% CI, 54%-80%] vs 76% [95% CI, 72%-80%], respectively).||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.0030147021170705557,
    0.3355887234210968,
    0.6613965630531311
  ],
  "Inhibin B levels (n = 737) were not associated with the probability of conceiving in a given cycle (hazard ratio per 1-pg/mL increase, 0.999; 95% CI, 0.997-1.001).||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.0025725734885782003,
    0.35339486598968506,
    0.6440325975418091
  ],
  "Conclusions and Relevance Among women aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, biomarkers indicating diminished ovarian reserve compared with normal ovarian reserve were not associated with reduced fertility.||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.0009087169892154634,
    0.09215201437473297,
    0.9069392681121826
  ],
  "These findings do not support the use of urinary or blood follicle-stimulating hormone tests or antim\u00fcllerian hormone levels to assess natural fertility for women with these characteristics.||A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.": [
    0.008735695853829384,
    0.394205778837204,
    0.5970584750175476
  ],
  "Importance Despite lack of evidence of their utility, biomarkers of ovarian reserve are being promoted as potential markers of reproductive potential.||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.8141170740127563,
    0.18216624855995178,
    0.0037166806869208813
  ],
  "Objective To determine the associations between biomarkers of ovarian reserve and reproductive potential among women of late reproductive age.||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.20132684707641602,
    0.7954235076904297,
    0.003249655244871974
  ],
  "Design, Setting, and Participants Prospective time-to-pregnancy cohort study (2008 to date of last follow-up in March 2016) of women (N = 981) aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, recruited from the community in the Raleigh-Durham, North Carolina, area.||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.49558955430984497,
    0.49839821457862854,
    0.006012262310832739
  ],
  "Exposures Early-follicular-phase serum level of antim\u00fcllerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B and urinary level of FSH.||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.058920975774526596,
    0.9275417923927307,
    0.013537311926484108
  ],
  "Main Outcomes and Measures The primary outcomes were the cumulative probability of conception by 6 and 12 cycles of attempt and relative fecundability (probability of conception in a given menstrual cycle).||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.11056894809007645,
    0.8836390972137451,
    0.005791904870420694
  ],
  "Conception was defined as a positive pregnancy test result.||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.48830410838127136,
    0.4995584785938263,
    0.01213732548058033
  ],
  "Results A total of 750 women (mean age, 33.3 [SD, 3.2] years; 77% white; 36% overweight or obese) provided a blood and urine sample and were included in the analysis.||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.07547660917043686,
    0.9173904061317444,
    0.00713295629248023
  ],
  "After adjusting for age, body mass index, race, current smoking status, and recent hormonal contraceptive use, women with low AMH values (<0.7 ng/mL [n = 84]) did not have a significantly different predicted probability of conceiving by 6 cycles of attempt (65%; 95% CI, 50%-75%) compared with women (n = 579) with normal values (62%; 95% CI, 57%-66%) or by 12 cycles of attempt (84% [95% CI, 70%-91%] vs 75% [95% CI, 70%-79%], respectively).||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.6504549384117126,
    0.3365054428577423,
    0.013039602898061275
  ],
  "Women with high serum FSH values (>10 mIU/mL [n = 83]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (63%; 95% CI, 50%-73%) compared with women (n = 654) with normal values (62%; 95% CI, 57%-66%) or after 12 cycles of attempt (82% [95% CI, 70%-89%] vs 75% [95% CI, 70%-78%], respectively).||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.558041512966156,
    0.42528417706489563,
    0.016674388200044632
  ],
  "Women with high urinary FSH values (>11.5 mIU/mg creatinine [n = 69]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (61%; 95% CI, 46%-74%) compared with women (n = 660) with normal values (62%; 95% CI, 58%-66%) or after 12 cycles of attempt (70% [95% CI, 54%-80%] vs 76% [95% CI, 72%-80%], respectively).||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.5912491083145142,
    0.39203616976737976,
    0.01671472005546093
  ],
  "Inhibin B levels (n = 737) were not associated with the probability of conceiving in a given cycle (hazard ratio per 1-pg/mL increase, 0.999; 95% CI, 0.997-1.001).||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.8932623267173767,
    0.10325546562671661,
    0.0034821685403585434
  ],
  "Conclusions and Relevance Among women aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, biomarkers indicating diminished ovarian reserve compared with normal ovarian reserve were not associated with reduced fertility.||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.9784947633743286,
    0.01922224834561348,
    0.0022830197121948004
  ],
  "These findings do not support the use of urinary or blood follicle-stimulating hormone tests or antim\u00fcllerian hormone levels to assess natural fertility for women with these characteristics.||A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.": [
    0.2017844319343567,
    0.7770309448242188,
    0.021184632554650307
  ],
  "Importance Despite lack of evidence of their utility, biomarkers of ovarian reserve are being promoted as potential markers of reproductive potential.||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.8198646903038025,
    0.17503944039344788,
    0.0050958301872015
  ],
  "Objective To determine the associations between biomarkers of ovarian reserve and reproductive potential among women of late reproductive age.||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.4029698967933655,
    0.590094268321991,
    0.006935812532901764
  ],
  "Design, Setting, and Participants Prospective time-to-pregnancy cohort study (2008 to date of last follow-up in March 2016) of women (N = 981) aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, recruited from the community in the Raleigh-Durham, North Carolina, area.||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.3600514829158783,
    0.6145467758178711,
    0.025401698425412178
  ],
  "Exposures Early-follicular-phase serum level of antim\u00fcllerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B and urinary level of FSH.||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.28169479966163635,
    0.6947132349014282,
    0.023591944947838783
  ],
  "Main Outcomes and Measures The primary outcomes were the cumulative probability of conception by 6 and 12 cycles of attempt and relative fecundability (probability of conception in a given menstrual cycle).||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.2781403958797455,
    0.7068201899528503,
    0.015039396472275257
  ],
  "Conception was defined as a positive pregnancy test result.||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.5982438325881958,
    0.37953981757164,
    0.022216377779841423
  ],
  "Results A total of 750 women (mean age, 33.3 [SD, 3.2] years; 77% white; 36% overweight or obese) provided a blood and urine sample and were included in the analysis.||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.16733619570732117,
    0.8140188455581665,
    0.01864500902593136
  ],
  "After adjusting for age, body mass index, race, current smoking status, and recent hormonal contraceptive use, women with low AMH values (<0.7 ng/mL [n = 84]) did not have a significantly different predicted probability of conceiving by 6 cycles of attempt (65%; 95% CI, 50%-75%) compared with women (n = 579) with normal values (62%; 95% CI, 57%-66%) or by 12 cycles of attempt (84% [95% CI, 70%-91%] vs 75% [95% CI, 70%-79%], respectively).||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.41126105189323425,
    0.4841562807559967,
    0.1045827567577362
  ],
  "Women with high serum FSH values (>10 mIU/mL [n = 83]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (63%; 95% CI, 50%-73%) compared with women (n = 654) with normal values (62%; 95% CI, 57%-66%) or after 12 cycles of attempt (82% [95% CI, 70%-89%] vs 75% [95% CI, 70%-78%], respectively).||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.4100019037723541,
    0.4933747947216034,
    0.09662329405546188
  ],
  "Women with high urinary FSH values (>11.5 mIU/mg creatinine [n = 69]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (61%; 95% CI, 46%-74%) compared with women (n = 660) with normal values (62%; 95% CI, 58%-66%) or after 12 cycles of attempt (70% [95% CI, 54%-80%] vs 76% [95% CI, 72%-80%], respectively).||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.4468887746334076,
    0.45671626925468445,
    0.09639496356248856
  ],
  "Inhibin B levels (n = 737) were not associated with the probability of conceiving in a given cycle (hazard ratio per 1-pg/mL increase, 0.999; 95% CI, 0.997-1.001).||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.7304588556289673,
    0.26058050990104675,
    0.008960648439824581
  ],
  "Conclusions and Relevance Among women aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, biomarkers indicating diminished ovarian reserve compared with normal ovarian reserve were not associated with reduced fertility.||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.9541696310043335,
    0.036083582788705826,
    0.00974674429744482
  ],
  "These findings do not support the use of urinary or blood follicle-stimulating hormone tests or antim\u00fcllerian hormone levels to assess natural fertility for women with these characteristics.||Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.": [
    0.8016300797462463,
    0.183721125125885,
    0.014648889191448689
  ],
  "BACKGROUND The heritable haemoglobinopathy alpha(+)-thalassaemia is caused by the reduced synthesis of alpha-globin chains that form part of normal adult haemoglobin (Hb).||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.39357107877731323,
    0.6024510264396667,
    0.003977816551923752
  ],
  "Individuals homozygous for alpha(+)-thalassaemia have microcytosis and an increased erythrocyte count.||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.006781376898288727,
    0.9213513135910034,
    0.07186730951070786
  ],
  "Alpha(+)-thalassaemia homozygosity confers considerable protection against severe malaria, including severe malarial anaemia (SMA) (Hb concentration < 50 g/l), but does not influence parasite count.||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.08106101304292679,
    0.7951154708862305,
    0.12382357567548752
  ],
  "We tested the hypothesis that the erythrocyte indices associated with alpha(+)-thalassaemia homozygosity provide a haematological benefit during acute malaria.   \n||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.007350706961005926,
    0.7688636183738708,
    0.2237856686115265
  ],
  "METHODS AND FINDINGS Data from children living on the north coast of Papua New Guinea who had participated in a case-control study of the protection afforded by alpha(+)-thalassaemia against severe malaria were reanalysed to assess the genotype-specific reduction in erythrocyte count and Hb levels associated with acute malarial disease.||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.2606941759586334,
    0.3787490129470825,
    0.36055684089660645
  ],
  "We observed a reduction in median erythrocyte count of approximately 1.5 x 10(12)/l in all children with acute falciparum malaria relative to values in community children (p < 0.001).||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.23949086666107178,
    0.7529643177986145,
    0.007544815540313721
  ],
  "We developed a simple mathematical model of the linear relationship between Hb concentration and erythrocyte count.||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.011267262510955334,
    0.9813298583030701,
    0.007402895949780941
  ],
  "This model predicted that children homozygous for alpha(+)-thalassaemia lose less Hb than children of normal genotype for a reduction in erythrocyte count of >1.1 x 10(12)/l as a result of the reduced mean cell Hb in homozygous alpha(+)-thalassaemia.||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.5596184134483337,
    0.424520343542099,
    0.015861334279179573
  ],
  "In addition, children homozygous for alpha(+)-thalassaemia require a 10% greater reduction in erythrocyte count than children of normal genotype (p = 0.02) for Hb concentration to fall to 50 g/l, the cutoff for SMA.||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.9735401272773743,
    0.02015385404229164,
    0.006306015886366367
  ],
  "We estimated that the haematological profile in children homozygous for alpha(+)-thalassaemia reduces the risk of SMA during acute malaria compared to children of normal genotype (relative risk 0.52; 95% confidence interval [CI] 0.24-1.12, p = 0.09).   \n||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.02105141617357731,
    0.8770467042922974,
    0.10190192610025406
  ],
  "CONCLUSIONS The increased erythrocyte count and microcytosis in children homozygous for alpha(+)-thalassaemia may contribute substantially to their protection against SMA.||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.004683888982981443,
    0.07662414014339447,
    0.9186919331550598
  ],
  "A lower concentration of Hb per erythrocyte and a larger population of erythrocytes may be a biologically advantageous strategy against the significant reduction in erythrocyte count that occurs during acute infection with the malaria parasite Plasmodium falciparum.||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.025982443243265152,
    0.8735726475715637,
    0.10044493526220322
  ],
  "This haematological profile may reduce the risk of anaemia by other Plasmodium species, as well as other causes of anaemia.||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.011296396143734455,
    0.8060600161552429,
    0.1826435923576355
  ],
  "Other host polymorphisms that induce an increased erythrocyte count and microcytosis may confer a similar advantage.||A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.008158503100275993,
    0.970562756061554,
    0.02127869985997677
  ],
  "BACKGROUND The heritable haemoglobinopathy alpha(+)-thalassaemia is caused by the reduced synthesis of alpha-globin chains that form part of normal adult haemoglobin (Hb).||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.023676373064517975,
    0.9474326968193054,
    0.028890879824757576
  ],
  "Individuals homozygous for alpha(+)-thalassaemia have microcytosis and an increased erythrocyte count.||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.00913184229284525,
    0.9798464179039001,
    0.011021736077964306
  ],
  "Alpha(+)-thalassaemia homozygosity confers considerable protection against severe malaria, including severe malarial anaemia (SMA) (Hb concentration < 50 g/l), but does not influence parasite count.||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.21468758583068848,
    0.7761536836624146,
    0.00915869977325201
  ],
  "We tested the hypothesis that the erythrocyte indices associated with alpha(+)-thalassaemia homozygosity provide a haematological benefit during acute malaria.   \n||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.9633422493934631,
    0.03259705752134323,
    0.004060728941112757
  ],
  "METHODS AND FINDINGS Data from children living on the north coast of Papua New Guinea who had participated in a case-control study of the protection afforded by alpha(+)-thalassaemia against severe malaria were reanalysed to assess the genotype-specific reduction in erythrocyte count and Hb levels associated with acute malarial disease.||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.28158479928970337,
    0.6728612184524536,
    0.04555391147732735
  ],
  "We observed a reduction in median erythrocyte count of approximately 1.5 x 10(12)/l in all children with acute falciparum malaria relative to values in community children (p < 0.001).||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.1356411725282669,
    0.8378913402557373,
    0.0264674611389637
  ],
  "We developed a simple mathematical model of the linear relationship between Hb concentration and erythrocyte count.||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.09052960574626923,
    0.8977845311164856,
    0.011685816571116447
  ],
  "This model predicted that children homozygous for alpha(+)-thalassaemia lose less Hb than children of normal genotype for a reduction in erythrocyte count of >1.1 x 10(12)/l as a result of the reduced mean cell Hb in homozygous alpha(+)-thalassaemia.||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.18218521773815155,
    0.8070893883705139,
    0.01072536688297987
  ],
  "In addition, children homozygous for alpha(+)-thalassaemia require a 10% greater reduction in erythrocyte count than children of normal genotype (p = 0.02) for Hb concentration to fall to 50 g/l, the cutoff for SMA.||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.03026796504855156,
    0.9291144013404846,
    0.04061764478683472
  ],
  "We estimated that the haematological profile in children homozygous for alpha(+)-thalassaemia reduces the risk of SMA during acute malaria compared to children of normal genotype (relative risk 0.52; 95% confidence interval [CI] 0.24-1.12, p = 0.09).   \n||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.9444752335548401,
    0.04632769152522087,
    0.009197065606713295
  ],
  "CONCLUSIONS The increased erythrocyte count and microcytosis in children homozygous for alpha(+)-thalassaemia may contribute substantially to their protection against SMA.||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.9912661910057068,
    0.007237723097205162,
    0.0014961590059101582
  ],
  "A lower concentration of Hb per erythrocyte and a larger population of erythrocytes may be a biologically advantageous strategy against the significant reduction in erythrocyte count that occurs during acute infection with the malaria parasite Plasmodium falciparum.||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.8252870440483093,
    0.15975239872932434,
    0.014960513450205326
  ],
  "This haematological profile may reduce the risk of anaemia by other Plasmodium species, as well as other causes of anaemia.||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.8304532766342163,
    0.16377714276313782,
    0.005769569426774979
  ],
  "Other host polymorphisms that induce an increased erythrocyte count and microcytosis may confer a similar advantage.||Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.9219657778739929,
    0.0739685595035553,
    0.004065636079758406
  ],
  "BACKGROUND The heritable haemoglobinopathy alpha(+)-thalassaemia is caused by the reduced synthesis of alpha-globin chains that form part of normal adult haemoglobin (Hb).||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.42292577028274536,
    0.5626567006111145,
    0.014417575672268867
  ],
  "Individuals homozygous for alpha(+)-thalassaemia have microcytosis and an increased erythrocyte count.||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.06237876042723656,
    0.9324733018875122,
    0.005147990304976702
  ],
  "Alpha(+)-thalassaemia homozygosity confers considerable protection against severe malaria, including severe malarial anaemia (SMA) (Hb concentration < 50 g/l), but does not influence parasite count.||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.17357474565505981,
    0.7940818667411804,
    0.0323433056473732
  ],
  "We tested the hypothesis that the erythrocyte indices associated with alpha(+)-thalassaemia homozygosity provide a haematological benefit during acute malaria.   \n||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.008783258497714996,
    0.9515372514724731,
    0.03967941924929619
  ],
  "METHODS AND FINDINGS Data from children living on the north coast of Papua New Guinea who had participated in a case-control study of the protection afforded by alpha(+)-thalassaemia against severe malaria were reanalysed to assess the genotype-specific reduction in erythrocyte count and Hb levels associated with acute malarial disease.||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.08264733105897903,
    0.8223204612731934,
    0.09503214806318283
  ],
  "We observed a reduction in median erythrocyte count of approximately 1.5 x 10(12)/l in all children with acute falciparum malaria relative to values in community children (p < 0.001).||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.4119775593280792,
    0.5773739814758301,
    0.010648444294929504
  ],
  "We developed a simple mathematical model of the linear relationship between Hb concentration and erythrocyte count.||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.024886952713131905,
    0.9298897385597229,
    0.04522324725985527
  ],
  "This model predicted that children homozygous for alpha(+)-thalassaemia lose less Hb than children of normal genotype for a reduction in erythrocyte count of >1.1 x 10(12)/l as a result of the reduced mean cell Hb in homozygous alpha(+)-thalassaemia.||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.09282010048627853,
    0.8958864808082581,
    0.01129343081265688
  ],
  "In addition, children homozygous for alpha(+)-thalassaemia require a 10% greater reduction in erythrocyte count than children of normal genotype (p = 0.02) for Hb concentration to fall to 50 g/l, the cutoff for SMA.||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.6560582518577576,
    0.3368357717990875,
    0.007105985656380653
  ],
  "We estimated that the haematological profile in children homozygous for alpha(+)-thalassaemia reduces the risk of SMA during acute malaria compared to children of normal genotype (relative risk 0.52; 95% confidence interval [CI] 0.24-1.12, p = 0.09).   \n||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.010547010228037834,
    0.7106304168701172,
    0.2788226008415222
  ],
  "CONCLUSIONS The increased erythrocyte count and microcytosis in children homozygous for alpha(+)-thalassaemia may contribute substantially to their protection against SMA.||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.026320423930883408,
    0.9212127923965454,
    0.05246677249670029
  ],
  "A lower concentration of Hb per erythrocyte and a larger population of erythrocytes may be a biologically advantageous strategy against the significant reduction in erythrocyte count that occurs during acute infection with the malaria parasite Plasmodium falciparum.||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.18611861765384674,
    0.7612252831459045,
    0.052656129002571106
  ],
  "This haematological profile may reduce the risk of anaemia by other Plasmodium species, as well as other causes of anaemia.||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.005883064586669207,
    0.9649247527122498,
    0.029192201793193817
  ],
  "Other host polymorphisms that induce an increased erythrocyte count and microcytosis may confer a similar advantage.||Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.": [
    0.0020233800169080496,
    0.9940491914749146,
    0.0039274911396205425
  ],
  "BACKGROUND The heritable haemoglobinopathy alpha(+)-thalassaemia is caused by the reduced synthesis of alpha-globin chains that form part of normal adult haemoglobin (Hb).||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.01920103281736374,
    0.9077023267745972,
    0.07309668511152267
  ],
  "Individuals homozygous for alpha(+)-thalassaemia have microcytosis and an increased erythrocyte count.||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.01551612839102745,
    0.975666880607605,
    0.008816977962851524
  ],
  "Alpha(+)-thalassaemia homozygosity confers considerable protection against severe malaria, including severe malarial anaemia (SMA) (Hb concentration < 50 g/l), but does not influence parasite count.||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.8105534315109253,
    0.17863982915878296,
    0.010806681588292122
  ],
  "We tested the hypothesis that the erythrocyte indices associated with alpha(+)-thalassaemia homozygosity provide a haematological benefit during acute malaria.   \n||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.9644043445587158,
    0.033602550625801086,
    0.001993076177313924
  ],
  "METHODS AND FINDINGS Data from children living on the north coast of Papua New Guinea who had participated in a case-control study of the protection afforded by alpha(+)-thalassaemia against severe malaria were reanalysed to assess the genotype-specific reduction in erythrocyte count and Hb levels associated with acute malarial disease.||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.43882644176483154,
    0.5391873717308044,
    0.021986182779073715
  ],
  "We observed a reduction in median erythrocyte count of approximately 1.5 x 10(12)/l in all children with acute falciparum malaria relative to values in community children (p < 0.001).||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.0641261488199234,
    0.9299324154853821,
    0.005941423587501049
  ],
  "We developed a simple mathematical model of the linear relationship between Hb concentration and erythrocyte count.||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.04781916365027428,
    0.9454447627067566,
    0.006736099720001221
  ],
  "This model predicted that children homozygous for alpha(+)-thalassaemia lose less Hb than children of normal genotype for a reduction in erythrocyte count of >1.1 x 10(12)/l as a result of the reduced mean cell Hb in homozygous alpha(+)-thalassaemia.||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.08079999685287476,
    0.9023721218109131,
    0.016827916726469994
  ],
  "In addition, children homozygous for alpha(+)-thalassaemia require a 10% greater reduction in erythrocyte count than children of normal genotype (p = 0.02) for Hb concentration to fall to 50 g/l, the cutoff for SMA.||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.003577780444175005,
    0.7831236124038696,
    0.21329858899116516
  ],
  "We estimated that the haematological profile in children homozygous for alpha(+)-thalassaemia reduces the risk of SMA during acute malaria compared to children of normal genotype (relative risk 0.52; 95% confidence interval [CI] 0.24-1.12, p = 0.09).   \n||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.9455535411834717,
    0.05039846897125244,
    0.0040479786694049835
  ],
  "CONCLUSIONS The increased erythrocyte count and microcytosis in children homozygous for alpha(+)-thalassaemia may contribute substantially to their protection against SMA.||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.9950280785560608,
    0.004034958779811859,
    0.0009369614417664707
  ],
  "A lower concentration of Hb per erythrocyte and a larger population of erythrocytes may be a biologically advantageous strategy against the significant reduction in erythrocyte count that occurs during acute infection with the malaria parasite Plasmodium falciparum.||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.6384355425834656,
    0.35314151644706726,
    0.008422872982919216
  ],
  "This haematological profile may reduce the risk of anaemia by other Plasmodium species, as well as other causes of anaemia.||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.9752633571624756,
    0.021613243967294693,
    0.0031233387999236584
  ],
  "Other host polymorphisms that induce an increased erythrocyte count and microcytosis may confer a similar advantage.||A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.": [
    0.9456223249435425,
    0.051672615110874176,
    0.002705070422962308
  ],
  "Background  Macrosomia is associated with considerable neonatal and maternal morbidity.||A mutation in HNF4A leads to an increased risk of developing diabetes by the age of 14 years.": [
    0.06866316497325897,
    0.9066324830055237,
    0.024704299867153168
  ],
  "Factors that predict macrosomia are poorly understood.||A mutation in HNF4A leads to an increased risk of developing diabetes by the age of 14 years.": [
    0.07904697954654694,
    0.9173873066902161,
    0.0035657163243740797
  ],
  "The increased rate of macrosomia in the offspring of pregnant women with diabetes and in congenital hyperinsulinaemia is mediated by increased foetal insulin secretion.||A mutation in HNF4A leads to an increased risk of developing diabetes by the age of 14 years.": [
    0.019367700442671776,
    0.9729874134063721,
    0.007644880097359419
  ],
  "We assessed the in utero and neonatal role of two key regulators of pancreatic insulin secretion by studying birthweight and the incidence of neonatal hypoglycaemia in patients with heterozygous mutations in the maturity-onset diabetes of the young (MODY) genes HNF4A (encoding HNF-4\u03b1) and HNF1A/TCF1 (encoding HNF-1\u03b1), and the effect of pancreatic deletion of Hnf4a on foetal and neonatal insulin secretion in mice.||A mutation in HNF4A leads to an increased risk of developing diabetes by the age of 14 years.": [
    0.006800794508308172,
    0.9869586825370789,
    0.006240468006581068
  ],
  "Background  Macrosomia is associated with considerable neonatal and maternal morbidity.||A mutation in HNF4A leads to an increased risk of diabetes by the age of 14 years.": [
    0.038813166320323944,
    0.9475274085998535,
    0.013659416697919369
  ],
  "Factors that predict macrosomia are poorly understood.||A mutation in HNF4A leads to an increased risk of diabetes by the age of 14 years.": [
    0.0880337581038475,
    0.9085226058959961,
    0.003443657886236906
  ],
  "The increased rate of macrosomia in the offspring of pregnant women with diabetes and in congenital hyperinsulinaemia is mediated by increased foetal insulin secretion.||A mutation in HNF4A leads to an increased risk of diabetes by the age of 14 years.": [
    0.024915611371397972,
    0.9674944281578064,
    0.007590000052005053
  ],
  "We assessed the in utero and neonatal role of two key regulators of pancreatic insulin secretion by studying birthweight and the incidence of neonatal hypoglycaemia in patients with heterozygous mutations in the maturity-onset diabetes of the young (MODY) genes HNF4A (encoding HNF-4\u03b1) and HNF1A/TCF1 (encoding HNF-1\u03b1), and the effect of pancreatic deletion of Hnf4a on foetal and neonatal insulin secretion in mice.||A mutation in HNF4A leads to an increased risk of diabetes by the age of 14 years.": [
    0.007604926824569702,
    0.9870213866233826,
    0.005373639054596424
  ],
  "Background  Macrosomia is associated with considerable neonatal and maternal morbidity.||Carriers of HNF4A mutations are at reduced risk for diabetes.": [
    0.15773391723632812,
    0.8380821347236633,
    0.004183976911008358
  ],
  "Factors that predict macrosomia are poorly understood.||Carriers of HNF4A mutations are at reduced risk for diabetes.": [
    0.20595136284828186,
    0.7789987921714783,
    0.015049814246594906
  ],
  "The increased rate of macrosomia in the offspring of pregnant women with diabetes and in congenital hyperinsulinaemia is mediated by increased foetal insulin secretion.||Carriers of HNF4A mutations are at reduced risk for diabetes.": [
    0.4006859064102173,
    0.5934979319572449,
    0.005816157441586256
  ],
  "We assessed the in utero and neonatal role of two key regulators of pancreatic insulin secretion by studying birthweight and the incidence of neonatal hypoglycaemia in patients with heterozygous mutations in the maturity-onset diabetes of the young (MODY) genes HNF4A (encoding HNF-4\u03b1) and HNF1A/TCF1 (encoding HNF-1\u03b1), and the effect of pancreatic deletion of Hnf4a on foetal and neonatal insulin secretion in mice.||Carriers of HNF4A mutations are at reduced risk for diabetes.": [
    0.3320995569229126,
    0.6517407894134521,
    0.01615959219634533
  ],
  "Background  Macrosomia is associated with considerable neonatal and maternal morbidity.||HNF4A mutations are associated with macrosomia in infancy.": [
    0.0031189254950731993,
    0.993595540523529,
    0.003285506973043084
  ],
  "Factors that predict macrosomia are poorly understood.||HNF4A mutations are associated with macrosomia in infancy.": [
    0.01567666232585907,
    0.9825838208198547,
    0.0017395231407135725
  ],
  "The increased rate of macrosomia in the offspring of pregnant women with diabetes and in congenital hyperinsulinaemia is mediated by increased foetal insulin secretion.||HNF4A mutations are associated with macrosomia in infancy.": [
    0.07853427529335022,
    0.7811093330383301,
    0.14035643637180328
  ],
  "We assessed the in utero and neonatal role of two key regulators of pancreatic insulin secretion by studying birthweight and the incidence of neonatal hypoglycaemia in patients with heterozygous mutations in the maturity-onset diabetes of the young (MODY) genes HNF4A (encoding HNF-4\u03b1) and HNF1A/TCF1 (encoding HNF-1\u03b1), and the effect of pancreatic deletion of Hnf4a on foetal and neonatal insulin secretion in mice.||HNF4A mutations are associated with macrosomia in infancy.": [
    0.20735585689544678,
    0.30395832657814026,
    0.4886857867240906
  ],
  "Background  Macrosomia is associated with considerable neonatal and maternal morbidity.||There is no association between HNF4A mutations and diabetes risks.": [
    0.8454163074493408,
    0.15208761394023895,
    0.00249604694545269
  ],
  "Factors that predict macrosomia are poorly understood.||There is no association between HNF4A mutations and diabetes risks.": [
    0.9576598405838013,
    0.04074829816818237,
    0.001591893145814538
  ],
  "The increased rate of macrosomia in the offspring of pregnant women with diabetes and in congenital hyperinsulinaemia is mediated by increased foetal insulin secretion.||There is no association between HNF4A mutations and diabetes risks.": [
    0.989651620388031,
    0.009717782959342003,
    0.0006306305876933038
  ],
  "We assessed the in utero and neonatal role of two key regulators of pancreatic insulin secretion by studying birthweight and the incidence of neonatal hypoglycaemia in patients with heterozygous mutations in the maturity-onset diabetes of the young (MODY) genes HNF4A (encoding HNF-4\u03b1) and HNF1A/TCF1 (encoding HNF-1\u03b1), and the effect of pancreatic deletion of Hnf4a on foetal and neonatal insulin secretion in mice.||There is no association between HNF4A mutations and diabetes risks.": [
    0.9980983138084412,
    0.0016649379394948483,
    0.00023679759760852903
  ],
  "Background  Macrosomia is associated with considerable neonatal and maternal morbidity.||HNF4A mutations can cause diabetes in mutant carriers by the age of 14 years": [
    0.020855901762843132,
    0.9635021090507507,
    0.01564192585647106
  ],
  "Factors that predict macrosomia are poorly understood.||HNF4A mutations can cause diabetes in mutant carriers by the age of 14 years": [
    0.05473649874329567,
    0.9402527809143066,
    0.005010752938687801
  ],
  "The increased rate of macrosomia in the offspring of pregnant women with diabetes and in congenital hyperinsulinaemia is mediated by increased foetal insulin secretion.||HNF4A mutations can cause diabetes in mutant carriers by the age of 14 years": [
    0.007978334091603756,
    0.9812650084495544,
    0.010756663046777248
  ],
  "We assessed the in utero and neonatal role of two key regulators of pancreatic insulin secretion by studying birthweight and the incidence of neonatal hypoglycaemia in patients with heterozygous mutations in the maturity-onset diabetes of the young (MODY) genes HNF4A (encoding HNF-4\u03b1) and HNF1A/TCF1 (encoding HNF-1\u03b1), and the effect of pancreatic deletion of Hnf4a on foetal and neonatal insulin secretion in mice.||HNF4A mutations can cause diabetes in mutant carriers by the age of 14 years": [
    0.005097391549497843,
    0.9904040098190308,
    0.004498610273003578
  ],
  "Application of stem cell biology to breast cancer research has been limited by the lack of simple methods for identification and isolation of normal and malignant stem cells.||ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.": [
    0.05088100582361221,
    0.836068332195282,
    0.11305062472820282
  ],
  "Utilizing in vitro and in vivo experimental systems, we show that normal and cancer human mammary epithelial cells with increased aldehyde dehydrogenase activity (ALDH) have stem/progenitor properties.||ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.": [
    0.7478479743003845,
    0.23989742994308472,
    0.012254503555595875
  ],
  "These cells contain the subpopulation of normal breast epithelium with the broadest lineage differentiation potential and greatest growth capacity in a xenotransplant model.||ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.": [
    0.12161477655172348,
    0.8138625025749207,
    0.06452266871929169
  ],
  "In breast carcinomas, high ALDH activity identifies the tumorigenic cell fraction, capable of self-renewal and of generating tumors that recapitulate the heterogeneity of the parental tumor.||ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.": [
    0.11047093570232391,
    0.6264142990112305,
    0.2631148099899292
  ],
  "In a series of 577 breast carcinomas, expression of ALDH1 detected by immunostaining correlated with poor prognosis.||ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.": [
    0.0029447004199028015,
    0.07149909436702728,
    0.9255561828613281
  ],
  "These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts.||ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.": [
    0.12581820785999298,
    0.8194344639778137,
    0.05474725738167763
  ],
  "Application of stem cell biology to breast cancer research has been limited by the lack of simple methods for identification and isolation of normal and malignant stem cells.||ALDH1 expression is associated with better breast cancer outcomes.": [
    0.14759832620620728,
    0.7982249855995178,
    0.054176658391952515
  ],
  "Utilizing in vitro and in vivo experimental systems, we show that normal and cancer human mammary epithelial cells with increased aldehyde dehydrogenase activity (ALDH) have stem/progenitor properties.||ALDH1 expression is associated with better breast cancer outcomes.": [
    0.015041562728583813,
    0.919635534286499,
    0.06532292813062668
  ],
  "These cells contain the subpopulation of normal breast epithelium with the broadest lineage differentiation potential and greatest growth capacity in a xenotransplant model.||ALDH1 expression is associated with better breast cancer outcomes.": [
    0.09253520518541336,
    0.8611413836479187,
    0.04632342979311943
  ],
  "In breast carcinomas, high ALDH activity identifies the tumorigenic cell fraction, capable of self-renewal and of generating tumors that recapitulate the heterogeneity of the parental tumor.||ALDH1 expression is associated with better breast cancer outcomes.": [
    0.05916934832930565,
    0.8178313374519348,
    0.12299935519695282
  ],
  "In a series of 577 breast carcinomas, expression of ALDH1 detected by immunostaining correlated with poor prognosis.||ALDH1 expression is associated with better breast cancer outcomes.": [
    0.9989823698997498,
    0.0006241198279894888,
    0.00039342796662822366
  ],
  "These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts.||ALDH1 expression is associated with better breast cancer outcomes.": [
    0.05072370171546936,
    0.9177966117858887,
    0.03147963806986809
  ],
  "Application of stem cell biology to breast cancer research has been limited by the lack of simple methods for identification and isolation of normal and malignant stem cells.||ALDH1 expression is associated with poorer prognosis in breast cancer.": [
    0.0663454607129097,
    0.8221033215522766,
    0.11155123263597488
  ],
  "Utilizing in vitro and in vivo experimental systems, we show that normal and cancer human mammary epithelial cells with increased aldehyde dehydrogenase activity (ALDH) have stem/progenitor properties.||ALDH1 expression is associated with poorer prognosis in breast cancer.": [
    0.8058649301528931,
    0.18573500216007233,
    0.008400014601647854
  ],
  "These cells contain the subpopulation of normal breast epithelium with the broadest lineage differentiation potential and greatest growth capacity in a xenotransplant model.||ALDH1 expression is associated with poorer prognosis in breast cancer.": [
    0.11671076714992523,
    0.8322191834449768,
    0.05107008293271065
  ],
  "In breast carcinomas, high ALDH activity identifies the tumorigenic cell fraction, capable of self-renewal and of generating tumors that recapitulate the heterogeneity of the parental tumor.||ALDH1 expression is associated with poorer prognosis in breast cancer.": [
    0.16846394538879395,
    0.6496540904045105,
    0.18188196420669556
  ],
  "In a series of 577 breast carcinomas, expression of ALDH1 detected by immunostaining correlated with poor prognosis.||ALDH1 expression is associated with poorer prognosis in breast cancer.": [
    0.0009094160050153732,
    0.007243035826832056,
    0.9918476343154907
  ],
  "These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts.||ALDH1 expression is associated with poorer prognosis in breast cancer.": [
    0.12216634303331375,
    0.8251755237579346,
    0.05265810713171959
  ],
  "Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems.||APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.": [
    0.19100748002529144,
    0.765595018863678,
    0.0433974489569664
  ],
  "Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-\u03b2 (A\u03b2) peptides, and that they displayed GABAergic neuron degeneration.||APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.": [
    0.9979932308197021,
    0.0015280772931873798,
    0.00047876217286102474
  ],
  "ApoE4 increased A\u03b2 production in human, but not in mouse, neurons.||APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.": [
    0.056086860597133636,
    0.9170274138450623,
    0.02688571996986866
  ],
  "Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4.||APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.": [
    0.40991324186325073,
    0.5836890935897827,
    0.006397682707756758
  ],
  "Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4.||APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.": [
    0.022473439574241638,
    0.9714880585670471,
    0.006038508843630552
  ],
  "Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.||APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.": [
    0.06218225881457329,
    0.9304156303405762,
    0.0074021173641085625
  ],
  "Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems.||Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.4323149025440216,
    0.5639671683311462,
    0.0037179822102189064
  ],
  "Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-\u03b2 (A\u03b2) peptides, and that they displayed GABAergic neuron degeneration.||Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.10559432208538055,
    0.8920202851295471,
    0.002385350177064538
  ],
  "ApoE4 increased A\u03b2 production in human, but not in mouse, neurons.||Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.04773259907960892,
    0.9500244855880737,
    0.0022428680676966906
  ],
  "Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4.||Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.007406473159790039,
    0.9498273134231567,
    0.042766179889440536
  ],
  "Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4.||Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.6508965492248535,
    0.34609395265579224,
    0.0030094177927821875
  ],
  "Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.||Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.005237226840108633,
    0.9603795409202576,
    0.034383244812488556
  ],
  "Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems.||Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.17461368441581726,
    0.8211778998374939,
    0.004208413418382406
  ],
  "Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-\u03b2 (A\u03b2) peptides, and that they displayed GABAergic neuron degeneration.||Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.047344934195280075,
    0.9472648501396179,
    0.00539026316255331
  ],
  "ApoE4 increased A\u03b2 production in human, but not in mouse, neurons.||Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.12414523214101791,
    0.8732013702392578,
    0.002653418807312846
  ],
  "Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4.||Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.976593017578125,
    0.021094705909490585,
    0.002312327269464731
  ],
  "Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4.||Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.014276674948632717,
    0.7755579948425293,
    0.2101653516292572
  ],
  "Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.||Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.": [
    0.9960232973098755,
    0.0034105400554835796,
    0.0005660854512825608
  ],
  "Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.": [
    0.27347898483276367,
    0.6740105152130127,
    0.052510544657707214
  ],
  "Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-\u03b2 (A\u03b2) peptides, and that they displayed GABAergic neuron degeneration.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.": [
    0.002986838109791279,
    0.407987117767334,
    0.5890260934829712
  ],
  "ApoE4 increased A\u03b2 production in human, but not in mouse, neurons.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.": [
    0.024935396388173103,
    0.9639204144477844,
    0.011144197545945644
  ],
  "Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.": [
    0.33904749155044556,
    0.6525681018829346,
    0.00838430318981409
  ],
  "Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.": [
    0.0030136480927467346,
    0.9906508922576904,
    0.006335464771836996
  ],
  "Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.": [
    0.013151168823242188,
    0.9794197678565979,
    0.007429064251482487
  ],
  "Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.": [
    0.4532760977745056,
    0.5164749026298523,
    0.03024899773299694
  ],
  "Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-\u03b2 (A\u03b2) peptides, and that they displayed GABAergic neuron degeneration.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.": [
    0.9913023710250854,
    0.007111730054020882,
    0.0015858603874221444
  ],
  "ApoE4 increased A\u03b2 production in human, but not in mouse, neurons.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.": [
    0.006993943825364113,
    0.9831489324569702,
    0.009857112541794777
  ],
  "Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.": [
    0.6741819977760315,
    0.31690698862075806,
    0.00891098938882351
  ],
  "Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.": [
    0.5917453169822693,
    0.4045965373516083,
    0.0036581638269126415
  ],
  "Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.||APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.": [
    0.029213473200798035,
    0.9649098515510559,
    0.005876690614968538
  ],
  "Developmental abnormalities, cancer, and premature aging each have been linked to defects in the DNA damage response (DDR).||ATM and Rad3 related protein are critical for sensing DNA damage.": [
    0.08645103126764297,
    0.9003058671951294,
    0.013243068009614944
  ],
  "Mutations in the ATR checkpoint regulator cause developmental defects in mice (pregastrulation lethality) and humans (Seckel syndrome).||ATM and Rad3 related protein are critical for sensing DNA damage.": [
    0.10691921412944794,
    0.8790613412857056,
    0.014019413851201534
  ],
  "Here we show that eliminating ATR in adult mice leads to defects in tissue homeostasis and the rapid appearance of age-related phenotypes, such as hair graying, alopecia, kyphosis, osteoporosis, thymic involution, fibrosis, and other abnormalities.||ATM and Rad3 related protein are critical for sensing DNA damage.": [
    0.18560783565044403,
    0.8087109923362732,
    0.0056811426766216755
  ],
  "Histological and genetic analyses indicate that ATR deletion causes acute cellular loss in tissues in which continuous cell proliferation is required for maintenance.||ATM and Rad3 related protein are critical for sensing DNA damage.": [
    0.26350870728492737,
    0.7242383360862732,
    0.012252907268702984
  ],
  "Importantly, thymic involution, alopecia, and hair graying in ATR knockout mice were associated with dramatic reductions in tissue-specific stem and progenitor cells and exhaustion of tissue renewal and homeostatic capacity.||ATM and Rad3 related protein are critical for sensing DNA damage.": [
    0.32102999091148376,
    0.6411246061325073,
    0.037845440208911896
  ],
  "In aggregate, these studies suggest that reduced regenerative capacity in adults via deletion of a developmentally essential DDR gene is sufficient to cause the premature appearance of age-related phenotypes.||ATM and Rad3 related protein are critical for sensing DNA damage.": [
    0.1934044510126114,
    0.7295879125595093,
    0.07700759917497635
  ],
  "Developmental abnormalities, cancer, and premature aging each have been linked to defects in the DNA damage response (DDR).||ATM and Rad3 related protein have no role in sensing DNA damage.": [
    0.9092519879341125,
    0.08739204704761505,
    0.0033558751456439495
  ],
  "Mutations in the ATR checkpoint regulator cause developmental defects in mice (pregastrulation lethality) and humans (Seckel syndrome).||ATM and Rad3 related protein have no role in sensing DNA damage.": [
    0.9432374835014343,
    0.05499789118766785,
    0.0017646957421675324
  ],
  "Here we show that eliminating ATR in adult mice leads to defects in tissue homeostasis and the rapid appearance of age-related phenotypes, such as hair graying, alopecia, kyphosis, osteoporosis, thymic involution, fibrosis, and other abnormalities.||ATM and Rad3 related protein have no role in sensing DNA damage.": [
    0.6598214507102966,
    0.33510956168174744,
    0.005068930797278881
  ],
  "Histological and genetic analyses indicate that ATR deletion causes acute cellular loss in tissues in which continuous cell proliferation is required for maintenance.||ATM and Rad3 related protein have no role in sensing DNA damage.": [
    0.6557834148406982,
    0.33793067932128906,
    0.006285944487899542
  ],
  "Importantly, thymic involution, alopecia, and hair graying in ATR knockout mice were associated with dramatic reductions in tissue-specific stem and progenitor cells and exhaustion of tissue renewal and homeostatic capacity.||ATM and Rad3 related protein have no role in sensing DNA damage.": [
    0.8468897938728333,
    0.14846199750900269,
    0.0046482086181640625
  ],
  "In aggregate, these studies suggest that reduced regenerative capacity in adults via deletion of a developmentally essential DDR gene is sufficient to cause the premature appearance of age-related phenotypes.||ATM and Rad3 related protein have no role in sensing DNA damage.": [
    0.9274513125419617,
    0.06950506567955017,
    0.0030436604283750057
  ],
  "Developmental abnormalities, cancer, and premature aging each have been linked to defects in the DNA damage response (DDR).||Deletion of ATM and Rad3 related protein is not predictive of acute tissue loss.": [
    0.9373577833175659,
    0.059937406331300735,
    0.002704785205423832
  ],
  "Mutations in the ATR checkpoint regulator cause developmental defects in mice (pregastrulation lethality) and humans (Seckel syndrome).||Deletion of ATM and Rad3 related protein is not predictive of acute tissue loss.": [
    0.8925337791442871,
    0.10381020605564117,
    0.0036560825537890196
  ],
  "Here we show that eliminating ATR in adult mice leads to defects in tissue homeostasis and the rapid appearance of age-related phenotypes, such as hair graying, alopecia, kyphosis, osteoporosis, thymic involution, fibrosis, and other abnormalities.||Deletion of ATM and Rad3 related protein is not predictive of acute tissue loss.": [
    0.9372602701187134,
    0.06024252623319626,
    0.0024971147067844868
  ],
  "Histological and genetic analyses indicate that ATR deletion causes acute cellular loss in tissues in which continuous cell proliferation is required for maintenance.||Deletion of ATM and Rad3 related protein is not predictive of acute tissue loss.": [
    0.9071127772331238,
    0.08954774588346481,
    0.00333948596380651
  ],
  "Importantly, thymic involution, alopecia, and hair graying in ATR knockout mice were associated with dramatic reductions in tissue-specific stem and progenitor cells and exhaustion of tissue renewal and homeostatic capacity.||Deletion of ATM and Rad3 related protein is not predictive of acute tissue loss.": [
    0.9520266056060791,
    0.044416286051273346,
    0.0035571677144616842
  ],
  "In aggregate, these studies suggest that reduced regenerative capacity in adults via deletion of a developmentally essential DDR gene is sufficient to cause the premature appearance of age-related phenotypes.||Deletion of ATM and Rad3 related protein is not predictive of acute tissue loss.": [
    0.6253835558891296,
    0.3698001801967621,
    0.004816283006221056
  ],
  "Developmental abnormalities, cancer, and premature aging each have been linked to defects in the DNA damage response (DDR).||Deletion of ATM and Rad3 related protein leads to acute tissue loss.": [
    0.06917402893304825,
    0.8922402262687683,
    0.03858578950166702
  ],
  "Mutations in the ATR checkpoint regulator cause developmental defects in mice (pregastrulation lethality) and humans (Seckel syndrome).||Deletion of ATM and Rad3 related protein leads to acute tissue loss.": [
    0.08994898945093155,
    0.8510467410087585,
    0.05900424346327782
  ],
  "Here we show that eliminating ATR in adult mice leads to defects in tissue homeostasis and the rapid appearance of age-related phenotypes, such as hair graying, alopecia, kyphosis, osteoporosis, thymic involution, fibrosis, and other abnormalities.||Deletion of ATM and Rad3 related protein leads to acute tissue loss.": [
    0.004769016522914171,
    0.9734696745872498,
    0.021761322394013405
  ],
  "Histological and genetic analyses indicate that ATR deletion causes acute cellular loss in tissues in which continuous cell proliferation is required for maintenance.||Deletion of ATM and Rad3 related protein leads to acute tissue loss.": [
    0.0015545935602858663,
    0.9839940071105957,
    0.014451378025114536
  ],
  "Importantly, thymic involution, alopecia, and hair graying in ATR knockout mice were associated with dramatic reductions in tissue-specific stem and progenitor cells and exhaustion of tissue renewal and homeostatic capacity.||Deletion of ATM and Rad3 related protein leads to acute tissue loss.": [
    0.008736759424209595,
    0.7158426642417908,
    0.27542057633399963
  ],
  "In aggregate, these studies suggest that reduced regenerative capacity in adults via deletion of a developmentally essential DDR gene is sufficient to cause the premature appearance of age-related phenotypes.||Deletion of ATM and Rad3 related protein leads to acute tissue loss.": [
    0.0972597599029541,
    0.8926252126693726,
    0.010115057229995728
  ],
  "Half the world's population is chronically infected with Helicobacter pylori, causing gastritis, gastric ulcers and an increased incidence of gastric adenocarcinoma.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.08096679300069809,
    0.9065700769424438,
    0.012463114224374294
  ],
  "Its proton-gated inner-membrane urea channel, HpUreI, is essential for survival in the acidic environment of the stomach.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.06536351144313812,
    0.900850772857666,
    0.03378571942448616
  ],
  "The channel is closed at neutral pH and opens at acidic pH to allow the rapid access of urea to cytoplasmic urease.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.109944649040699,
    0.8749963045120239,
    0.01505906879901886
  ],
  "Urease produces NH(3) and CO(2), neutralizing entering protons and thus buffering the periplasm to a pH of roughly 6.1 even in gastric juice at a pH below 2.0.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.043761394917964935,
    0.9476882815361023,
    0.008550352416932583
  ],
  "Here we report the structure of HpUreI, revealing six protomers assembled in a hexameric ring surrounding a central bilayer plug of ordered lipids.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.38552311062812805,
    0.22738167643547058,
    0.387095183134079
  ],
  "Each protomer encloses a channel formed by a twisted bundle of six transmembrane helices.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.41354188323020935,
    0.35931408405303955,
    0.22714407742023468
  ],
  "The bundle defines a previously unobserved fold comprising a two-helix hairpin motif repeated three times around the central axis of the channel, without the inverted repeat of mammalian-type urea transporters.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.3283222019672394,
    0.61745685338974,
    0.05422103404998779
  ],
  "Both the channel and the protomer interface contain residues conserved in the AmiS/UreI superfamily, suggesting the preservation of channel architecture and oligomeric state in this superfamily.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.25759947299957275,
    0.7204766869544983,
    0.021923774853348732
  ],
  "Predominantly aromatic or aliphatic side chains line the entire channel and define two consecutive constriction sites in the middle of the channel.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.1975894272327423,
    0.7394022941589355,
    0.06300821155309677
  ],
  "Mutation of Trp 153 in the cytoplasmic constriction site to Ala or Phe decreases the selectivity for urea in comparison with thiourea, suggesting that solute interaction with Trp 153 contributes specificity.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.11755265295505524,
    0.847733199596405,
    0.03471412882208824
  ],
  "The previously unobserved hexameric channel structure described here provides a new model for the permeation of urea and other small amide solutes in prokaryotes and archaea.||Active H. pylori urease has a polymeric structure consisting of five distinct subunits.": [
    0.3583885431289673,
    0.4313164949417114,
    0.2102949172258377
  ],
  "Half the world's population is chronically infected with Helicobacter pylori, causing gastritis, gastric ulcers and an increased incidence of gastric adenocarcinoma.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.07599829137325287,
    0.9127753376960754,
    0.01122631411999464
  ],
  "Its proton-gated inner-membrane urea channel, HpUreI, is essential for survival in the acidic environment of the stomach.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.45671531558036804,
    0.5093109607696533,
    0.033973727375268936
  ],
  "The channel is closed at neutral pH and opens at acidic pH to allow the rapid access of urea to cytoplasmic urease.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.22766001522541046,
    0.7451421022415161,
    0.027197908610105515
  ],
  "Urease produces NH(3) and CO(2), neutralizing entering protons and thus buffering the periplasm to a pH of roughly 6.1 even in gastric juice at a pH below 2.0.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.17095141112804413,
    0.815972626209259,
    0.01307593286037445
  ],
  "Here we report the structure of HpUreI, revealing six protomers assembled in a hexameric ring surrounding a central bilayer plug of ordered lipids.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.6220107674598694,
    0.3216753304004669,
    0.05631382018327713
  ],
  "Each protomer encloses a channel formed by a twisted bundle of six transmembrane helices.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.6436147093772888,
    0.29087233543395996,
    0.0655129998922348
  ],
  "The bundle defines a previously unobserved fold comprising a two-helix hairpin motif repeated three times around the central axis of the channel, without the inverted repeat of mammalian-type urea transporters.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.42217040061950684,
    0.5223885774612427,
    0.055440984666347504
  ],
  "Both the channel and the protomer interface contain residues conserved in the AmiS/UreI superfamily, suggesting the preservation of channel architecture and oligomeric state in this superfamily.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.5757032632827759,
    0.4000759422779083,
    0.024220764636993408
  ],
  "Predominantly aromatic or aliphatic side chains line the entire channel and define two consecutive constriction sites in the middle of the channel.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.504916787147522,
    0.42016446590423584,
    0.07491875439882278
  ],
  "Mutation of Trp 153 in the cytoplasmic constriction site to Ala or Phe decreases the selectivity for urea in comparison with thiourea, suggesting that solute interaction with Trp 153 contributes specificity.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.3723049759864807,
    0.5770419836044312,
    0.050653062760829926
  ],
  "The previously unobserved hexameric channel structure described here provides a new model for the permeation of urea and other small amide solutes in prokaryotes and archaea.||Active H. pylori urease has a polymeric structure that compromises two subunits, UreA and UreB.": [
    0.6188122630119324,
    0.3164772093296051,
    0.06471055746078491
  ],
  "Half the world's population is chronically infected with Helicobacter pylori, causing gastritis, gastric ulcers and an increased incidence of gastric adenocarcinoma.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.27792420983314514,
    0.3819262683391571,
    0.34014949202537537
  ],
  "Its proton-gated inner-membrane urea channel, HpUreI, is essential for survival in the acidic environment of the stomach.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.6355969905853271,
    0.33254387974739075,
    0.031859055161476135
  ],
  "The channel is closed at neutral pH and opens at acidic pH to allow the rapid access of urea to cytoplasmic urease.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.17878998816013336,
    0.7456032633781433,
    0.07560671120882034
  ],
  "Urease produces NH(3) and CO(2), neutralizing entering protons and thus buffering the periplasm to a pH of roughly 6.1 even in gastric juice at a pH below 2.0.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.08564583957195282,
    0.8735676407814026,
    0.04078654199838638
  ],
  "Here we report the structure of HpUreI, revealing six protomers assembled in a hexameric ring surrounding a central bilayer plug of ordered lipids.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.49652600288391113,
    0.4654594361782074,
    0.038014572113752365
  ],
  "Each protomer encloses a channel formed by a twisted bundle of six transmembrane helices.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.2771430015563965,
    0.6121827363967896,
    0.11067425459623337
  ],
  "The bundle defines a previously unobserved fold comprising a two-helix hairpin motif repeated three times around the central axis of the channel, without the inverted repeat of mammalian-type urea transporters.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.3208729922771454,
    0.6240741014480591,
    0.05505296587944031
  ],
  "Both the channel and the protomer interface contain residues conserved in the AmiS/UreI superfamily, suggesting the preservation of channel architecture and oligomeric state in this superfamily.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.33755749464035034,
    0.6231480240821838,
    0.03929450735449791
  ],
  "Predominantly aromatic or aliphatic side chains line the entire channel and define two consecutive constriction sites in the middle of the channel.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.18534357845783234,
    0.7118031978607178,
    0.1028531938791275
  ],
  "Mutation of Trp 153 in the cytoplasmic constriction site to Ala or Phe decreases the selectivity for urea in comparison with thiourea, suggesting that solute interaction with Trp 153 contributes specificity.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.1896333396434784,
    0.6846472024917603,
    0.12571950256824493
  ],
  "The previously unobserved hexameric channel structure described here provides a new model for the permeation of urea and other small amide solutes in prokaryotes and archaea.||The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.": [
    0.3847196102142334,
    0.5654109716415405,
    0.04986945539712906
  ],
  "Half the world's population is chronically infected with Helicobacter pylori, causing gastritis, gastric ulcers and an increased incidence of gastric adenocarcinoma.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.655489981174469,
    0.33049893379211426,
    0.014011034741997719
  ],
  "Its proton-gated inner-membrane urea channel, HpUreI, is essential for survival in the acidic environment of the stomach.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.7625580430030823,
    0.22627882659435272,
    0.01116317417472601
  ],
  "The channel is closed at neutral pH and opens at acidic pH to allow the rapid access of urea to cytoplasmic urease.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.32394877076148987,
    0.6406302452087402,
    0.03542095795273781
  ],
  "Urease produces NH(3) and CO(2), neutralizing entering protons and thus buffering the periplasm to a pH of roughly 6.1 even in gastric juice at a pH below 2.0.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.766139805316925,
    0.225271537899971,
    0.008588695898652077
  ],
  "Here we report the structure of HpUreI, revealing six protomers assembled in a hexameric ring surrounding a central bilayer plug of ordered lipids.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.7036131024360657,
    0.28886744379997253,
    0.0075194016098976135
  ],
  "Each protomer encloses a channel formed by a twisted bundle of six transmembrane helices.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.3210964798927307,
    0.6316014528274536,
    0.04730210453271866
  ],
  "The bundle defines a previously unobserved fold comprising a two-helix hairpin motif repeated three times around the central axis of the channel, without the inverted repeat of mammalian-type urea transporters.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.41678762435913086,
    0.5668401122093201,
    0.016372237354516983
  ],
  "Both the channel and the protomer interface contain residues conserved in the AmiS/UreI superfamily, suggesting the preservation of channel architecture and oligomeric state in this superfamily.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.49862003326416016,
    0.4926428496837616,
    0.008737151511013508
  ],
  "Predominantly aromatic or aliphatic side chains line the entire channel and define two consecutive constriction sites in the middle of the channel.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.36399519443511963,
    0.6107528805732727,
    0.025251923128962517
  ],
  "Mutation of Trp 153 in the cytoplasmic constriction site to Ala or Phe decreases the selectivity for urea in comparison with thiourea, suggesting that solute interaction with Trp 153 contributes specificity.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.8853626251220703,
    0.10854192078113556,
    0.0060954331420362
  ],
  "The previously unobserved hexameric channel structure described here provides a new model for the permeation of urea and other small amide solutes in prokaryotes and archaea.||The ureABIEFGH gene cluster is induced by nickel (II) ion.": [
    0.36964738368988037,
    0.6199839115142822,
    0.010368669405579567
  ],
  "Neutrophils rapidly undergo polarization and directional movement to infiltrate the sites of infection and inflammation.||Active Ly49Q induces neutrophil polarization.": [
    0.007586142513900995,
    0.9658073782920837,
    0.026606466621160507
  ],
  "Here, we show that an inhibitory MHC I receptor, Ly49Q, was crucial for the swift polarization of and tissue infiltration by neutrophils.||Active Ly49Q induces neutrophil polarization.": [
    0.9636586308479309,
    0.02148730680346489,
    0.014854023233056068
  ],
  "During the steady state, Ly49Q inhibited neutrophil adhesion by preventing focal-complex formation, likely by inhibiting Src and PI3 kinases.||Active Ly49Q induces neutrophil polarization.": [
    0.9259548187255859,
    0.06687652319669724,
    0.007168630138039589
  ],
  "However, in the presence of inflammatory stimuli, Ly49Q mediated rapid neutrophil polarization and tissue infiltration in an ITIM-domain-dependent manner.||Active Ly49Q induces neutrophil polarization.": [
    0.0037594903260469437,
    0.08039865642786026,
    0.915841817855835
  ],
  "These opposite functions appeared to be mediated by distinct use of effector phosphatase SHP-1 and SHP-2.||Active Ly49Q induces neutrophil polarization.": [
    0.2954884469509125,
    0.6517030000686646,
    0.052808478474617004
  ],
  "Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions.||Active Ly49Q induces neutrophil polarization.": [
    0.17080596089363098,
    0.7641679644584656,
    0.06502603739500046
  ],
  "We propose that Ly49Q is pivotal in switching neutrophils to their polarized morphology and rapid migration upon inflammation, through its spatiotemporal regulation of membrane rafts and raft-associated signaling molecules.||Active Ly49Q induces neutrophil polarization.": [
    0.004368460737168789,
    0.13890421390533447,
    0.8567273616790771
  ],
  "Neutrophils rapidly undergo polarization and directional movement to infiltrate the sites of infection and inflammation.||Active Ly49Q prevents neutrophil polarization.": [
    0.96694415807724,
    0.031039947643876076,
    0.002015927340835333
  ],
  "Here, we show that an inhibitory MHC I receptor, Ly49Q, was crucial for the swift polarization of and tissue infiltration by neutrophils.||Active Ly49Q prevents neutrophil polarization.": [
    0.9714854955673218,
    0.016936227679252625,
    0.01157836988568306
  ],
  "During the steady state, Ly49Q inhibited neutrophil adhesion by preventing focal-complex formation, likely by inhibiting Src and PI3 kinases.||Active Ly49Q prevents neutrophil polarization.": [
    0.24578751623630524,
    0.2984171509742737,
    0.4557953476905823
  ],
  "However, in the presence of inflammatory stimuli, Ly49Q mediated rapid neutrophil polarization and tissue infiltration in an ITIM-domain-dependent manner.||Active Ly49Q prevents neutrophil polarization.": [
    0.9971404075622559,
    0.0021630392875522375,
    0.00069651153171435
  ],
  "These opposite functions appeared to be mediated by distinct use of effector phosphatase SHP-1 and SHP-2.||Active Ly49Q prevents neutrophil polarization.": [
    0.3895927369594574,
    0.5577626824378967,
    0.05264455825090408
  ],
  "Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions.||Active Ly49Q prevents neutrophil polarization.": [
    0.4554316997528076,
    0.5152484774589539,
    0.02931986004114151
  ],
  "We propose that Ly49Q is pivotal in switching neutrophils to their polarized morphology and rapid migration upon inflammation, through its spatiotemporal regulation of membrane rafts and raft-associated signaling molecules.||Active Ly49Q prevents neutrophil polarization.": [
    0.9968000650405884,
    0.0023827021941542625,
    0.0008172343368642032
  ],
  "Neutrophils rapidly undergo polarization and directional movement to infiltrate the sites of infection and inflammation.||Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.": [
    0.022948717698454857,
    0.9696988463401794,
    0.007352398242801428
  ],
  "Here, we show that an inhibitory MHC I receptor, Ly49Q, was crucial for the swift polarization of and tissue infiltration by neutrophils.||Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.": [
    0.006638570223003626,
    0.9635024666786194,
    0.029858943074941635
  ],
  "During the steady state, Ly49Q inhibited neutrophil adhesion by preventing focal-complex formation, likely by inhibiting Src and PI3 kinases.||Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.": [
    0.35626113414764404,
    0.40818092226982117,
    0.23555797338485718
  ],
  "However, in the presence of inflammatory stimuli, Ly49Q mediated rapid neutrophil polarization and tissue infiltration in an ITIM-domain-dependent manner.||Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.": [
    0.022035755217075348,
    0.9420943856239319,
    0.03586988151073456
  ],
  "These opposite functions appeared to be mediated by distinct use of effector phosphatase SHP-1 and SHP-2.||Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.": [
    0.24428929388523102,
    0.6523683071136475,
    0.10334241390228271
  ],
  "Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions.||Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.": [
    0.004379757214337587,
    0.7728064060211182,
    0.22281379997730255
  ],
  "We propose that Ly49Q is pivotal in switching neutrophils to their polarized morphology and rapid migration upon inflammation, through its spatiotemporal regulation of membrane rafts and raft-associated signaling molecules.||Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.": [
    0.001113784615881741,
    0.02287791483104229,
    0.9760082960128784
  ],
  "Neutrophils rapidly undergo polarization and directional movement to infiltrate the sites of infection and inflammation.||Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.": [
    0.01346982829272747,
    0.9815976619720459,
    0.0049325586296617985
  ],
  "Here, we show that an inhibitory MHC I receptor, Ly49Q, was crucial for the swift polarization of and tissue infiltration by neutrophils.||Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.": [
    0.005793184507638216,
    0.9686338901519775,
    0.0255728829652071
  ],
  "During the steady state, Ly49Q inhibited neutrophil adhesion by preventing focal-complex formation, likely by inhibiting Src and PI3 kinases.||Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.": [
    0.9752379655838013,
    0.018171807751059532,
    0.006590129341930151
  ],
  "However, in the presence of inflammatory stimuli, Ly49Q mediated rapid neutrophil polarization and tissue infiltration in an ITIM-domain-dependent manner.||Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.": [
    0.010395375080406666,
    0.9080022573471069,
    0.08160240203142166
  ],
  "These opposite functions appeared to be mediated by distinct use of effector phosphatase SHP-1 and SHP-2.||Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.": [
    0.16372309625148773,
    0.7621100544929504,
    0.07416687160730362
  ],
  "Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions.||Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.": [
    0.004419759847223759,
    0.9877617359161377,
    0.007818473502993584
  ],
  "We propose that Ly49Q is pivotal in switching neutrophils to their polarized morphology and rapid migration upon inflammation, through its spatiotemporal regulation of membrane rafts and raft-associated signaling molecules.||Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.": [
    0.0009164008661173284,
    0.03134700655937195,
    0.9677366018295288
  ],
  "Chaperone-mediated autophagy (CMA), a selective mechanism for degradation of cytosolic proteins in lysosomes, contributes to the removal of altered proteins as part of the cellular quality-control systems.||Aged patients are less susceptible to ischaemia/reperfusion injury.": [
    0.057930801063776016,
    0.9228287935256958,
    0.019240371882915497
  ],
  "We have previously found that CMA activity declines in aged organisms and have proposed that this failure in cellular clearance could contribute to the accumulation of altered proteins, the abnormal cellular homeostasis and, eventually, the functional loss characteristic of aged organisms.||Aged patients are less susceptible to ischaemia/reperfusion injury.": [
    0.3563048839569092,
    0.6280674338340759,
    0.015627674758434296
  ],
  "To determine whether these negative features of aging can be prevented by maintaining efficient autophagic activity until late in life, in this work we have corrected the CMA defect in aged rodents.||Aged patients are less susceptible to ischaemia/reperfusion injury.": [
    0.03613464534282684,
    0.9349228143692017,
    0.02894255705177784
  ],
  "We have generated a double transgenic mouse model in which the amount of the lysosomal receptor for CMA, previously shown to decrease in abundance with age, can be modulated.||Aged patients are less susceptible to ischaemia/reperfusion injury.": [
    0.34175044298171997,
    0.6502798199653625,
    0.007969741709530354
  ],
  "We have analyzed in this model the consequences of preventing the age-dependent decrease in receptor abundance in aged rodents at the cellular and organ levels.||Aged patients are less susceptible to ischaemia/reperfusion injury.": [
    0.18038398027420044,
    0.7846195697784424,
    0.03499643877148628
  ],
  "We show here that CMA activity is maintained until advanced ages if the decrease in the receptor abundance is prevented and that preservation of autophagic activity is associated with lower intracellular accumulation of damaged proteins, better ability to handle protein damage and improved organ function.||Aged patients are less susceptible to ischaemia/reperfusion injury.": [
    0.0031217087525874376,
    0.957941472530365,
    0.03893684595823288
  ],
  "Chaperone-mediated autophagy (CMA), a selective mechanism for degradation of cytosolic proteins in lysosomes, contributes to the removal of altered proteins as part of the cellular quality-control systems.||Aged patients are more susceptible to ischaemia/reperfusion injury.": [
    0.027259059250354767,
    0.9556317329406738,
    0.017109224572777748
  ],
  "We have previously found that CMA activity declines in aged organisms and have proposed that this failure in cellular clearance could contribute to the accumulation of altered proteins, the abnormal cellular homeostasis and, eventually, the functional loss characteristic of aged organisms.||Aged patients are more susceptible to ischaemia/reperfusion injury.": [
    0.00818636640906334,
    0.9567863345146179,
    0.03502731770277023
  ],
  "To determine whether these negative features of aging can be prevented by maintaining efficient autophagic activity until late in life, in this work we have corrected the CMA defect in aged rodents.||Aged patients are more susceptible to ischaemia/reperfusion injury.": [
    0.004447268322110176,
    0.9827969074249268,
    0.012755784206092358
  ],
  "We have generated a double transgenic mouse model in which the amount of the lysosomal receptor for CMA, previously shown to decrease in abundance with age, can be modulated.||Aged patients are more susceptible to ischaemia/reperfusion injury.": [
    0.00917714275419712,
    0.9827837944030762,
    0.008039036765694618
  ],
  "We have analyzed in this model the consequences of preventing the age-dependent decrease in receptor abundance in aged rodents at the cellular and organ levels.||Aged patients are more susceptible to ischaemia/reperfusion injury.": [
    0.030664075165987015,
    0.9374686479568481,
    0.03186725452542305
  ],
  "We show here that CMA activity is maintained until advanced ages if the decrease in the receptor abundance is prevented and that preservation of autophagic activity is associated with lower intracellular accumulation of damaged proteins, better ability to handle protein damage and improved organ function.||Aged patients are more susceptible to ischaemia/reperfusion injury.": [
    0.4303383529186249,
    0.5647946000099182,
    0.004867082927376032
  ],
  "Chaperone-mediated autophagy (CMA), a selective mechanism for degradation of cytosolic proteins in lysosomes, contributes to the removal of altered proteins as part of the cellular quality-control systems.||Autophagy declines in aged organisms.": [
    0.04138714447617531,
    0.9562782049179077,
    0.0023346322122961283
  ],
  "We have previously found that CMA activity declines in aged organisms and have proposed that this failure in cellular clearance could contribute to the accumulation of altered proteins, the abnormal cellular homeostasis and, eventually, the functional loss characteristic of aged organisms.||Autophagy declines in aged organisms.": [
    0.4992147982120514,
    0.2683783769607544,
    0.2324068248271942
  ],
  "To determine whether these negative features of aging can be prevented by maintaining efficient autophagic activity until late in life, in this work we have corrected the CMA defect in aged rodents.||Autophagy declines in aged organisms.": [
    0.8275994062423706,
    0.12883366644382477,
    0.04356699436903
  ],
  "We have generated a double transgenic mouse model in which the amount of the lysosomal receptor for CMA, previously shown to decrease in abundance with age, can be modulated.||Autophagy declines in aged organisms.": [
    0.038238655775785446,
    0.5320237874984741,
    0.42973756790161133
  ],
  "We have analyzed in this model the consequences of preventing the age-dependent decrease in receptor abundance in aged rodents at the cellular and organ levels.||Autophagy declines in aged organisms.": [
    0.14353449642658234,
    0.4330577850341797,
    0.4234076738357544
  ],
  "We show here that CMA activity is maintained until advanced ages if the decrease in the receptor abundance is prevented and that preservation of autophagic activity is associated with lower intracellular accumulation of damaged proteins, better ability to handle protein damage and improved organ function.||Autophagy declines in aged organisms.": [
    0.9926432967185974,
    0.006181633565574884,
    0.001175045152194798
  ],
  "BACKGROUND Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB).||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.31741878390312195,
    0.6059813499450684,
    0.07659994065761566
  ],
  "Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowering by PCSK9 inhibitors, there have been no human studies characterizing the effects of PCSK9 inhibitors on lipoprotein metabolism.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.16428986191749573,
    0.794737696647644,
    0.040972426533699036
  ],
  "In particular, it is not known whether inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lipoprotein (IDL) metabolism.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.1594478040933609,
    0.8149437308311462,
    0.02560841105878353
  ],
  "Inhibition of PCSK9 also results in reductions of plasma lipoprotein (a) levels.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.0197082981467247,
    0.8916500210762024,
    0.0886417031288147
  ],
  "The regulation of plasma Lp(a) levels, including the role of LDL receptors in the clearance of Lp(a), is poorly defined, and no mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to date.   \n||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.21830326318740845,
    0.3714301884174347,
    0.41026654839515686
  ],
  "METHODS Eighteen (10 F, 8 mol/L) participants completed a placebo-controlled, 2-period study.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.015929047018289566,
    0.9788361191749573,
    0.005234844051301479
  ],
  "They received 2 doses of placebo, 2 weeks apart, followed by 5 doses of 150 mg of alirocumab, 2 weeks apart.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.0019214098574593663,
    0.9856062531471252,
    0.012472382746636868
  ],
  "At the end of each period, fractional clearance rates (FCRs) and production rates (PRs) of apoB and apo(a) were determined.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.012063916772603989,
    0.9864892959594727,
    0.001446732203476131
  ],
  "In 10 participants, postprandial triglycerides and apoB48 levels were measured.   \n||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.03482627123594284,
    0.9612641334533691,
    0.003909566439688206
  ],
  "RESULTS Alirocumab reduced ultracentrifugally isolated LDL-C by 55.1%, LDL-apoB by 56.3%, and plasma Lp(a) by 18.7%.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.1809016764163971,
    0.32629185914993286,
    0.49280640482902527
  ],
  "The fall in LDL-apoB was caused by an 80.4% increase in LDL-apoB FCR and a 23.9% reduction in LDL-apoB PR.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.022930053994059563,
    0.9619469046592712,
    0.015123071148991585
  ],
  "The latter was due to a 46.1% increase in IDL-apoB FCR coupled with a 27.2% decrease in conversion of IDL to LDL.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.13827583193778992,
    0.8554319739341736,
    0.006292205769568682
  ],
  "The FCR of apo(a) tended to increase (24.6%) without any change in apo(a) PR.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.4316854476928711,
    0.5627526640892029,
    0.005561877973377705
  ],
  "Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandial plasma triglycerides or apoB48 concentrations.   \n||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.5704575777053833,
    0.402911901473999,
    0.026630554348230362
  ],
  "CONCLUSIONS Alirocumab decreased LDL-C and LDL-apoB by increasing IDL- and LDL-apoB FCRs and decreasing LDL-apoB PR.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.2722961902618408,
    0.25383079051971436,
    0.4738730192184448
  ],
  "These results are consistent with increases in LDL receptors available to clear IDL and LDL from blood during PCSK9 inhibition.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.5448288917541504,
    0.4412016272544861,
    0.013969454914331436
  ],
  "The increase in apo(a) FCR during alirocumab treatment suggests that increased LDL receptors may also play a role in the reduction of plasma Lp(a).   ||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.9850244522094727,
    0.008294331841170788,
    0.006681229919195175
  ],
  "CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.02898872271180153,
    0.9340583682060242,
    0.036952901631593704
  ],
  "Unique identifier: NCT01959971.||Alirocumab treatment reduces apo(a) fractional clearance rate.": [
    0.04760201275348663,
    0.9066237807273865,
    0.04577425867319107
  ],
  "BACKGROUND Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB).||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.29255521297454834,
    0.6951028108596802,
    0.012341911904513836
  ],
  "Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowering by PCSK9 inhibitors, there have been no human studies characterizing the effects of PCSK9 inhibitors on lipoprotein metabolism.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.026743251830339432,
    0.4335002601146698,
    0.5397565364837646
  ],
  "In particular, it is not known whether inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lipoprotein (IDL) metabolism.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.0996641218662262,
    0.8875854015350342,
    0.012750498950481415
  ],
  "Inhibition of PCSK9 also results in reductions of plasma lipoprotein (a) levels.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.09391576051712036,
    0.8998590111732483,
    0.006225232966244221
  ],
  "The regulation of plasma Lp(a) levels, including the role of LDL receptors in the clearance of Lp(a), is poorly defined, and no mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to date.   \n||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.014348088763654232,
    0.6837472915649414,
    0.3019045889377594
  ],
  "METHODS Eighteen (10 F, 8 mol/L) participants completed a placebo-controlled, 2-period study.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.03343619778752327,
    0.9124508500099182,
    0.05411297455430031
  ],
  "They received 2 doses of placebo, 2 weeks apart, followed by 5 doses of 150 mg of alirocumab, 2 weeks apart.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.08316875249147415,
    0.8658605813980103,
    0.050970617681741714
  ],
  "At the end of each period, fractional clearance rates (FCRs) and production rates (PRs) of apoB and apo(a) were determined.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.07664026319980621,
    0.9097257256507874,
    0.013634000904858112
  ],
  "In 10 participants, postprandial triglycerides and apoB48 levels were measured.   \n||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.03646409884095192,
    0.9596529006958008,
    0.00388296484015882
  ],
  "RESULTS Alirocumab reduced ultracentrifugally isolated LDL-C by 55.1%, LDL-apoB by 56.3%, and plasma Lp(a) by 18.7%.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.03797891363501549,
    0.958763599395752,
    0.0032575002405792475
  ],
  "The fall in LDL-apoB was caused by an 80.4% increase in LDL-apoB FCR and a 23.9% reduction in LDL-apoB PR.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.04244866222143173,
    0.5605009198188782,
    0.3970504105091095
  ],
  "The latter was due to a 46.1% increase in IDL-apoB FCR coupled with a 27.2% decrease in conversion of IDL to LDL.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.6181633472442627,
    0.3589423894882202,
    0.022894253954291344
  ],
  "The FCR of apo(a) tended to increase (24.6%) without any change in apo(a) PR.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.15931732952594757,
    0.831850528717041,
    0.008832145482301712
  ],
  "Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandial plasma triglycerides or apoB48 concentrations.   \n||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.08613797277212143,
    0.8890728950500488,
    0.024789106100797653
  ],
  "CONCLUSIONS Alirocumab decreased LDL-C and LDL-apoB by increasing IDL- and LDL-apoB FCRs and decreasing LDL-apoB PR.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.03628271818161011,
    0.8362032771110535,
    0.12751401960849762
  ],
  "These results are consistent with increases in LDL receptors available to clear IDL and LDL from blood during PCSK9 inhibition.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.004385072272270918,
    0.8506776690483093,
    0.14493727684020996
  ],
  "The increase in apo(a) FCR during alirocumab treatment suggests that increased LDL receptors may also play a role in the reduction of plasma Lp(a).   ||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.0010976848425343633,
    0.026003165170550346,
    0.9728990197181702
  ],
  "CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.03291292116045952,
    0.9011932611465454,
    0.06589382141828537
  ],
  "Unique identifier: NCT01959971.||Increased LDL receptors plays a role in the reduction of plasma Lp(a).": [
    0.0433395653963089,
    0.9029604196548462,
    0.053699977695941925
  ],
  "BACKGROUND Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB).||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.08974511921405792,
    0.22469061613082886,
    0.6855642199516296
  ],
  "Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowering by PCSK9 inhibitors, there have been no human studies characterizing the effects of PCSK9 inhibitors on lipoprotein metabolism.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.0883139818906784,
    0.45305919647216797,
    0.4586268663406372
  ],
  "In particular, it is not known whether inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lipoprotein (IDL) metabolism.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.1755199432373047,
    0.8156071901321411,
    0.008872860111296177
  ],
  "Inhibition of PCSK9 also results in reductions of plasma lipoprotein (a) levels.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.002259736182168126,
    0.010980198159813881,
    0.986760139465332
  ],
  "The regulation of plasma Lp(a) levels, including the role of LDL receptors in the clearance of Lp(a), is poorly defined, and no mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to date.   \n||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.24091127514839172,
    0.5984947681427002,
    0.16059400141239166
  ],
  "METHODS Eighteen (10 F, 8 mol/L) participants completed a placebo-controlled, 2-period study.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.029507549479603767,
    0.9287319779396057,
    0.04176044464111328
  ],
  "They received 2 doses of placebo, 2 weeks apart, followed by 5 doses of 150 mg of alirocumab, 2 weeks apart.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.020388610661029816,
    0.8169546723365784,
    0.1626567840576172
  ],
  "At the end of each period, fractional clearance rates (FCRs) and production rates (PRs) of apoB and apo(a) were determined.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.24445562064647675,
    0.7266301512718201,
    0.028914229944348335
  ],
  "In 10 participants, postprandial triglycerides and apoB48 levels were measured.   \n||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.07933804392814636,
    0.9119928479194641,
    0.008669042959809303
  ],
  "RESULTS Alirocumab reduced ultracentrifugally isolated LDL-C by 55.1%, LDL-apoB by 56.3%, and plasma Lp(a) by 18.7%.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.21002034842967987,
    0.5573904514312744,
    0.23258920013904572
  ],
  "The fall in LDL-apoB was caused by an 80.4% increase in LDL-apoB FCR and a 23.9% reduction in LDL-apoB PR.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.2188647985458374,
    0.7402512431144714,
    0.040883924812078476
  ],
  "The latter was due to a 46.1% increase in IDL-apoB FCR coupled with a 27.2% decrease in conversion of IDL to LDL.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.0934801697731018,
    0.8711165189743042,
    0.035403378307819366
  ],
  "The FCR of apo(a) tended to increase (24.6%) without any change in apo(a) PR.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.21691997349262238,
    0.7690467238426208,
    0.01403328962624073
  ],
  "Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandial plasma triglycerides or apoB48 concentrations.   \n||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.19890591502189636,
    0.7631974816322327,
    0.03789662942290306
  ],
  "CONCLUSIONS Alirocumab decreased LDL-C and LDL-apoB by increasing IDL- and LDL-apoB FCRs and decreasing LDL-apoB PR.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.6008381843566895,
    0.3612719774246216,
    0.03788990154862404
  ],
  "These results are consistent with increases in LDL receptors available to clear IDL and LDL from blood during PCSK9 inhibition.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.11465403437614441,
    0.5203884243965149,
    0.3649575412273407
  ],
  "The increase in apo(a) FCR during alirocumab treatment suggests that increased LDL receptors may also play a role in the reduction of plasma Lp(a).   ||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.020105209201574326,
    0.6772001385688782,
    0.3026946187019348
  ],
  "CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.03690659999847412,
    0.8804463744163513,
    0.08264707773923874
  ],
  "Unique identifier: NCT01959971.||PCSK9 inhibitors decrease plasma Lp(a) levels.": [
    0.07080663740634918,
    0.819566011428833,
    0.1096273735165596
  ],
  "Many fundamental aspects of DNA replication, such as the exact locations where DNA synthesis is initiated and terminated, how frequently origins are used, and how fork progression is influenced by transcription, are poorly understood.||Alteration of origin firing causes changes in termination zones of Okazaki fragments.": [
    0.021451180800795555,
    0.9620712399482727,
    0.016477622091770172
  ],
  "Via the deep sequencing of Okazaki fragments, we comprehensively document replication fork directionality throughout the S. cerevisiae genome, which permits the systematic analysis of initiation, origin efficiency, fork progression, and termination.||Alteration of origin firing causes changes in termination zones of Okazaki fragments.": [
    0.01407566200941801,
    0.947253406047821,
    0.03867097198963165
  ],
  "We show that leading-strand initiation preferentially occurs within a nucleosome-free region at replication origins.||Alteration of origin firing causes changes in termination zones of Okazaki fragments.": [
    0.09927792102098465,
    0.783193051815033,
    0.11752899736166
  ],
  "Using a strain in which late origins can be induced to fire early, we show that replication termination is a largely passive phenomenon that does not rely on cis-acting sequences or replication fork pausing.||Alteration of origin firing causes changes in termination zones of Okazaki fragments.": [
    0.02391256019473076,
    0.952381432056427,
    0.023705990985035896
  ],
  "The replication profile is predominantly determined by the kinetics of origin firing, allowing us to reconstruct chromosome-wide timing profiles from an asynchronous culture.||Alteration of origin firing causes changes in termination zones of Okazaki fragments.": [
    0.0828746110200882,
    0.8729869723320007,
    0.044138435274362564
  ],
  "Many fundamental aspects of DNA replication, such as the exact locations where DNA synthesis is initiated and terminated, how frequently origins are used, and how fork progression is influenced by transcription, are poorly understood.||Most termination events in Okazaki fragments are dictated by initiation patterns.": [
    0.033370133489370346,
    0.9646437764167786,
    0.001986078917980194
  ],
  "Via the deep sequencing of Okazaki fragments, we comprehensively document replication fork directionality throughout the S. cerevisiae genome, which permits the systematic analysis of initiation, origin efficiency, fork progression, and termination.||Most termination events in Okazaki fragments are dictated by initiation patterns.": [
    0.003050826722756028,
    0.9960976839065552,
    0.0008514818036928773
  ],
  "We show that leading-strand initiation preferentially occurs within a nucleosome-free region at replication origins.||Most termination events in Okazaki fragments are dictated by initiation patterns.": [
    0.019357997924089432,
    0.9761438369750977,
    0.004498196300119162
  ],
  "Using a strain in which late origins can be induced to fire early, we show that replication termination is a largely passive phenomenon that does not rely on cis-acting sequences or replication fork pausing.||Most termination events in Okazaki fragments are dictated by initiation patterns.": [
    0.844989538192749,
    0.1483433097600937,
    0.00666711525991559
  ],
  "The replication profile is predominantly determined by the kinetics of origin firing, allowing us to reconstruct chromosome-wide timing profiles from an asynchronous culture.||Most termination events in Okazaki fragments are dictated by initiation patterns.": [
    0.6590798497200012,
    0.33368346095085144,
    0.007236704230308533
  ],
  "Many fundamental aspects of DNA replication, such as the exact locations where DNA synthesis is initiated and terminated, how frequently origins are used, and how fork progression is influenced by transcription, are poorly understood.||Most termination events in Okazaki fragments are sequence specific.": [
    0.05293536186218262,
    0.9450851678848267,
    0.0019794723484665155
  ],
  "Via the deep sequencing of Okazaki fragments, we comprehensively document replication fork directionality throughout the S. cerevisiae genome, which permits the systematic analysis of initiation, origin efficiency, fork progression, and termination.||Most termination events in Okazaki fragments are sequence specific.": [
    0.003573835361748934,
    0.9953287839889526,
    0.0010973524767905474
  ],
  "We show that leading-strand initiation preferentially occurs within a nucleosome-free region at replication origins.||Most termination events in Okazaki fragments are sequence specific.": [
    0.280989408493042,
    0.7141395807266235,
    0.004870988428592682
  ],
  "Using a strain in which late origins can be induced to fire early, we show that replication termination is a largely passive phenomenon that does not rely on cis-acting sequences or replication fork pausing.||Most termination events in Okazaki fragments are sequence specific.": [
    0.951102077960968,
    0.045200515538454056,
    0.003697457490488887
  ],
  "The replication profile is predominantly determined by the kinetics of origin firing, allowing us to reconstruct chromosome-wide timing profiles from an asynchronous culture.||Most termination events in Okazaki fragments are sequence specific.": [
    0.52315753698349,
    0.46721264719963074,
    0.009629838168621063
  ],
  "CONTEXT Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging.||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.32848209142684937,
    0.6683415174484253,
    0.0031763887964189053
  ],
  "Reportedly, mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease.   \n||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.003311815205961466,
    0.956060528755188,
    0.04062765836715698
  ],
  "OBJECTIVE To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor.   \n||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.0031796745024621487,
    0.9921604990959167,
    0.0046598175540566444
  ],
  "DESIGN, SETTING, AND PATIENTS One hundred fifty-nine patients were enrolled in this single-site, prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed.   \n||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.1061142310500145,
    0.7132493257522583,
    0.180636465549469
  ],
  "INTERVENTION Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney reperfusion and two weeks later.||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.0017431034939363599,
    0.9964442849159241,
    0.00181266525760293
  ],
  "Fifty-three patients received standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose CNIs.   \n||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.02573738992214203,
    0.9609122276306152,
    0.01335038710385561
  ],
  "MAIN OUTCOME MEASURES The primary measure was 1-year incidence of acute rejection and renal function (estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence of adverse events.   \n||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.04464785382151604,
    0.949337899684906,
    0.00601422693580389
  ],
  "RESULTS Patient and graft survival at 13 to 30 months was similar in all groups.||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.09378214180469513,
    0.8991740942001343,
    0.007043750956654549
  ],
  "After 6 months, 4 of 53 patients (7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P = .04) and 4 of 52 patients (7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P = .046) compared with 11 of 51 controls (21.6%; 95% CI, 10.5%-32.6%) had biopsy-confirmed acute rejection.||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.028496846556663513,
    0.9535664319992065,
    0.01793668419122696
  ],
  "None of the patients in either autologous MSC group had glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control group did (95% CI, 0.6%-15.1%; overall P = .02).||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.013102056458592415,
    0.9519268870353699,
    0.03497103601694107
  ],
  "Renal function recovered faster among both MSC groups showing increased eGFR levels during the first month after surgery than the control group.||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.021251024678349495,
    0.7846797704696655,
    0.19406923651695251
  ],
  "Patients receiving standard-dose CNI had a mean difference of 6.2 mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95% CI, 3.8-16.2; P=.002).||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.06889089196920395,
    0.7875460386276245,
    0.14356310665607452
  ],
  "Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-0.85, P=.02)   CONCLUSION Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year.   \n||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.008895914070308208,
    0.37639984488487244,
    0.6147042512893677
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00658073.||Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.044649478048086166,
    0.9029140472412109,
    0.0524364672601223
  ],
  "CONTEXT Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging.||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.07279662042856216,
    0.9184772372245789,
    0.00872612651437521
  ],
  "Reportedly, mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease.   \n||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.9299394488334656,
    0.06812376528978348,
    0.0019368118373677135
  ],
  "OBJECTIVE To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor.   \n||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.40208545327186584,
    0.594391942024231,
    0.0035225702449679375
  ],
  "DESIGN, SETTING, AND PATIENTS One hundred fifty-nine patients were enrolled in this single-site, prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed.   \n||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.32929614186286926,
    0.5414294600486755,
    0.1292743980884552
  ],
  "INTERVENTION Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney reperfusion and two weeks later.||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.13361814618110657,
    0.8629103899002075,
    0.0034715058282017708
  ],
  "Fifty-three patients received standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose CNIs.   \n||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.14351603388786316,
    0.8449365496635437,
    0.011547358706593513
  ],
  "MAIN OUTCOME MEASURES The primary measure was 1-year incidence of acute rejection and renal function (estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence of adverse events.   \n||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.044982414692640305,
    0.9343118667602539,
    0.020705731585621834
  ],
  "RESULTS Patient and graft survival at 13 to 30 months was similar in all groups.||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.5442938208580017,
    0.44044357538223267,
    0.01526262704282999
  ],
  "After 6 months, 4 of 53 patients (7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P = .04) and 4 of 52 patients (7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P = .046) compared with 11 of 51 controls (21.6%; 95% CI, 10.5%-32.6%) had biopsy-confirmed acute rejection.||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.1140376627445221,
    0.8157190680503845,
    0.07024326175451279
  ],
  "None of the patients in either autologous MSC group had glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control group did (95% CI, 0.6%-15.1%; overall P = .02).||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.7436478734016418,
    0.24739129841327667,
    0.008960830979049206
  ],
  "Renal function recovered faster among both MSC groups showing increased eGFR levels during the first month after surgery than the control group.||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.5998134613037109,
    0.38800472021102905,
    0.01218182872980833
  ],
  "Patients receiving standard-dose CNI had a mean difference of 6.2 mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95% CI, 3.8-16.2; P=.002).||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.236285001039505,
    0.6525135040283203,
    0.11120152473449707
  ],
  "Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-0.85, P=.02)   CONCLUSION Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year.   \n||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.9971681237220764,
    0.0019664710853248835,
    0.000865363166667521
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00658073.||Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.21538184583187103,
    0.7446519732475281,
    0.03996617719531059
  ],
  "CONTEXT Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging.||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.21805930137634277,
    0.7691770792007446,
    0.012763665057718754
  ],
  "Reportedly, mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease.   \n||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.09608123451471329,
    0.8918400406837463,
    0.012078797444701195
  ],
  "OBJECTIVE To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor.   \n||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.01899091526865959,
    0.9746814966201782,
    0.006327534094452858
  ],
  "DESIGN, SETTING, AND PATIENTS One hundred fifty-nine patients were enrolled in this single-site, prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed.   \n||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.1676718145608902,
    0.6506499648094177,
    0.18167825043201447
  ],
  "INTERVENTION Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney reperfusion and two weeks later.||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.005004311446100473,
    0.9918943047523499,
    0.0031013530679047108
  ],
  "Fifty-three patients received standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose CNIs.   \n||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.051995899528265,
    0.9238272309303284,
    0.02417687326669693
  ],
  "MAIN OUTCOME MEASURES The primary measure was 1-year incidence of acute rejection and renal function (estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence of adverse events.   \n||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.11580874025821686,
    0.8517029285430908,
    0.032488346099853516
  ],
  "RESULTS Patient and graft survival at 13 to 30 months was similar in all groups.||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.07367356866598129,
    0.8850153088569641,
    0.04131108149886131
  ],
  "After 6 months, 4 of 53 patients (7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P = .04) and 4 of 52 patients (7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P = .046) compared with 11 of 51 controls (21.6%; 95% CI, 10.5%-32.6%) had biopsy-confirmed acute rejection.||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.12175697088241577,
    0.8387396931648254,
    0.03950338065624237
  ],
  "None of the patients in either autologous MSC group had glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control group did (95% CI, 0.6%-15.1%; overall P = .02).||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.029336940497159958,
    0.8417288064956665,
    0.12893423438072205
  ],
  "Renal function recovered faster among both MSC groups showing increased eGFR levels during the first month after surgery than the control group.||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.1121087372303009,
    0.7905915379524231,
    0.09729970246553421
  ],
  "Patients receiving standard-dose CNI had a mean difference of 6.2 mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95% CI, 3.8-16.2; P=.002).||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.1740601807832718,
    0.6872951984405518,
    0.13864460587501526
  ],
  "Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-0.85, P=.02)   CONCLUSION Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year.   \n||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.004591206554323435,
    0.17958761751651764,
    0.8158211708068848
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00658073.||Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.107683464884758,
    0.8217608332633972,
    0.07055564224720001
  ],
  "CONTEXT Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging.||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.7116931080818176,
    0.26322636008262634,
    0.025080569088459015
  ],
  "Reportedly, mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease.   \n||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.007262817118316889,
    0.9803935289382935,
    0.0123435752466321
  ],
  "OBJECTIVE To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor.   \n||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.004627198446542025,
    0.9933284521102905,
    0.002044385066255927
  ],
  "DESIGN, SETTING, AND PATIENTS One hundred fifty-nine patients were enrolled in this single-site, prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed.   \n||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.10275392979383469,
    0.6282693147659302,
    0.26897674798965454
  ],
  "INTERVENTION Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney reperfusion and two weeks later.||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.0019449886167421937,
    0.996309220790863,
    0.0017457434441894293
  ],
  "Fifty-three patients received standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose CNIs.   \n||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.021648384630680084,
    0.9426183104515076,
    0.035733286291360855
  ],
  "MAIN OUTCOME MEASURES The primary measure was 1-year incidence of acute rejection and renal function (estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence of adverse events.   \n||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.08635301887989044,
    0.9101321697235107,
    0.0035148330498486757
  ],
  "RESULTS Patient and graft survival at 13 to 30 months was similar in all groups.||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.015551814809441566,
    0.9325685501098633,
    0.05187966674566269
  ],
  "After 6 months, 4 of 53 patients (7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P = .04) and 4 of 52 patients (7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P = .046) compared with 11 of 51 controls (21.6%; 95% CI, 10.5%-32.6%) had biopsy-confirmed acute rejection.||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.08910880237817764,
    0.8382460474967957,
    0.07264521718025208
  ],
  "None of the patients in either autologous MSC group had glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control group did (95% CI, 0.6%-15.1%; overall P = .02).||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.018084589391946793,
    0.8073472380638123,
    0.17456823587417603
  ],
  "Renal function recovered faster among both MSC groups showing increased eGFR levels during the first month after surgery than the control group.||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.03733508661389351,
    0.7865317463874817,
    0.1761332005262375
  ],
  "Patients receiving standard-dose CNI had a mean difference of 6.2 mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95% CI, 3.8-16.2; P=.002).||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.06459922343492508,
    0.688544750213623,
    0.2468559890985489
  ],
  "Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-0.85, P=.02)   CONCLUSION Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year.   \n||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.0038134546484798193,
    0.23052100837230682,
    0.7656655311584473
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00658073.||Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.": [
    0.06243858113884926,
    0.8541393876075745,
    0.08342201262712479
  ],
  "Resistance to apoptosis, often achieved by the overexpression of antiapoptotic proteins, is common and perhaps required in the genesis of cancer.||BCL-2 activation antagonizes the apoptotic effects of c-Myc.": [
    0.0774187371134758,
    0.9148426651954651,
    0.007738560438156128
  ],
  "However, it remains uncertain whether apoptotic defects are essential for tumor maintenance.||BCL-2 activation antagonizes the apoptotic effects of c-Myc.": [
    0.25885456800460815,
    0.7327901124954224,
    0.008355299010872841
  ],
  "To test this, we generated mice expressing a conditional BCL-2 gene and constitutive c-myc that develop lymphoblastic leukemia.||BCL-2 activation antagonizes the apoptotic effects of c-Myc.": [
    0.2155923843383789,
    0.7765647768974304,
    0.007842856459319592
  ],
  "Eliminating BCL-2 yielded rapid loss of leukemic cells and significantly prolonged survival, formally validating BCL-2 as a rational target for cancer therapy.||BCL-2 activation antagonizes the apoptotic effects of c-Myc.": [
    0.09168535470962524,
    0.8909140825271606,
    0.017400572076439857
  ],
  "Loss of this single molecule resulted in cell death, despite or perhaps attributable to the presence of other oncogenic events.||BCL-2 activation antagonizes the apoptotic effects of c-Myc.": [
    0.5006875991821289,
    0.46312427520751953,
    0.036188092082738876
  ],
  "This suggests a generalizable model in which aberrations inherent to cancer generate tonic death signals that would otherwise kill the cell if not opposed by a requisite apoptotic defect(s).||BCL-2 activation antagonizes the apoptotic effects of c-Myc.": [
    0.07000076770782471,
    0.9242650270462036,
    0.005734240636229515
  ],
  "Resistance to apoptosis, often achieved by the overexpression of antiapoptotic proteins, is common and perhaps required in the genesis of cancer.||BCL-2 promotes the apoptotic effects of c-Myc.": [
    0.8068562150001526,
    0.1881222128868103,
    0.005021617282181978
  ],
  "However, it remains uncertain whether apoptotic defects are essential for tumor maintenance.||BCL-2 promotes the apoptotic effects of c-Myc.": [
    0.2624974846839905,
    0.7298368215560913,
    0.007665670942515135
  ],
  "To test this, we generated mice expressing a conditional BCL-2 gene and constitutive c-myc that develop lymphoblastic leukemia.||BCL-2 promotes the apoptotic effects of c-Myc.": [
    0.6391513347625732,
    0.3564646244049072,
    0.004384052008390427
  ],
  "Eliminating BCL-2 yielded rapid loss of leukemic cells and significantly prolonged survival, formally validating BCL-2 as a rational target for cancer therapy.||BCL-2 promotes the apoptotic effects of c-Myc.": [
    0.0919370949268341,
    0.8974831700325012,
    0.010579760186374187
  ],
  "Loss of this single molecule resulted in cell death, despite or perhaps attributable to the presence of other oncogenic events.||BCL-2 promotes the apoptotic effects of c-Myc.": [
    0.04184675216674805,
    0.9221059679985046,
    0.03604733571410179
  ],
  "This suggests a generalizable model in which aberrations inherent to cancer generate tonic death signals that would otherwise kill the cell if not opposed by a requisite apoptotic defect(s).||BCL-2 promotes the apoptotic effects of c-Myc.": [
    0.015541693195700645,
    0.9812204837799072,
    0.0032377985771745443
  ],
  "Resistance to apoptosis, often achieved by the overexpression of antiapoptotic proteins, is common and perhaps required in the genesis of cancer.||Silencing of Bcl2 is important for the maintenance and progression of tumors.": [
    0.5879170298576355,
    0.3920970559120178,
    0.019985999912023544
  ],
  "However, it remains uncertain whether apoptotic defects are essential for tumor maintenance.||Silencing of Bcl2 is important for the maintenance and progression of tumors.": [
    0.44486910104751587,
    0.47284752130508423,
    0.08228334784507751
  ],
  "To test this, we generated mice expressing a conditional BCL-2 gene and constitutive c-myc that develop lymphoblastic leukemia.||Silencing of Bcl2 is important for the maintenance and progression of tumors.": [
    0.2871181070804596,
    0.7011772990226746,
    0.011704573407769203
  ],
  "Eliminating BCL-2 yielded rapid loss of leukemic cells and significantly prolonged survival, formally validating BCL-2 as a rational target for cancer therapy.||Silencing of Bcl2 is important for the maintenance and progression of tumors.": [
    0.9701324105262756,
    0.022920748218894005,
    0.006946757435798645
  ],
  "Loss of this single molecule resulted in cell death, despite or perhaps attributable to the presence of other oncogenic events.||Silencing of Bcl2 is important for the maintenance and progression of tumors.": [
    0.6122093796730042,
    0.3291071057319641,
    0.05868355557322502
  ],
  "This suggests a generalizable model in which aberrations inherent to cancer generate tonic death signals that would otherwise kill the cell if not opposed by a requisite apoptotic defect(s).||Silencing of Bcl2 is important for the maintenance and progression of tumors.": [
    0.8586385846138,
    0.1347009241580963,
    0.00666050473228097
  ],
  "BACKGROUND Bariatric surgery is becoming a more widespread treatment for obesity.||Bariatric surgery increases rates of colorectal cancer.": [
    0.6934464573860168,
    0.3029509484767914,
    0.003602549433708191
  ],
  "Comprehensive evidence of the long-term effects of contemporary surgery on a broad range of clinical outcomes in large populations treated in routine clinical practice is lacking.||Bariatric surgery increases rates of colorectal cancer.": [
    0.21578697860240936,
    0.7795736789703369,
    0.004639339633285999
  ],
  "The objective of this study was to measure the association between bariatric surgery, weight, body mass index, and obesity-related co-morbidities.   \n||Bariatric surgery increases rates of colorectal cancer.": [
    0.08447320759296417,
    0.9112427234649658,
    0.004284121096134186
  ],
  "METHODS AND FINDINGS This was an observational retrospective cohort study using data from the United Kingdom Clinical Practice Research Datalink.||Bariatric surgery increases rates of colorectal cancer.": [
    0.09382878243923187,
    0.8930516242980957,
    0.013119615614414215
  ],
  "All 3,882 patients registered in the database and with bariatric surgery on or before 31 December 2014 were included and matched by propensity score to 3,882 obese patients without surgery.||Bariatric surgery increases rates of colorectal cancer.": [
    0.05228138715028763,
    0.94411700963974,
    0.003601625096052885
  ],
  "The main outcome measures were change in weight and body mass index over 4 y; incident diagnoses of type 2 diabetes mellitus (T2DM), hypertension, angina, myocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and resolution of hypertension and T2DM.||Bariatric surgery increases rates of colorectal cancer.": [
    0.06723245233297348,
    0.9238331317901611,
    0.008934477344155312
  ],
  "Weight measures were available for 3,847 patients between 1 and 4 mo, 2,884 patients between 5 and 12 mo, and 2,258 patients between 13 and 48 mo post-procedure.||Bariatric surgery increases rates of colorectal cancer.": [
    0.12599331140518188,
    0.8650737404823303,
    0.008932962082326412
  ],
  "Bariatric surgery patients exhibited rapid weight loss for the first four postoperative months, at a rate of 4.98 kg/mo (95% CI 4.88-5.08).||Bariatric surgery increases rates of colorectal cancer.": [
    0.3387461304664612,
    0.6557571887969971,
    0.005496687721461058
  ],
  "Slower weight loss was sustained to the end of 4 y. Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater initial weight reduction than gastric banding (2.77 kg/mo).||Bariatric surgery increases rates of colorectal cancer.": [
    0.3132735788822174,
    0.6818345785140991,
    0.0048918831162154675
  ],
  "Protective hazard ratios (HRs) were detected for bariatric surgery for incident T2DM, 0.68 (95% CI 0.55-0.83); hypertension, 0.35 (95% CI 0.27-0.45); angina, 0.59 (95% CI 0.40-0.87);MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).||Bariatric surgery increases rates of colorectal cancer.": [
    0.47378987073898315,
    0.5139908194541931,
    0.01221928745508194
  ],
  "Strong associations were found between bariatric surgery and the resolution of T2DM, with a HR of 9.29 (95% CI 6.84-12.62), and between bariatric surgery and the resolution of hypertension, with a HR of 5.64 (95% CI 2.65-11.99).||Bariatric surgery increases rates of colorectal cancer.": [
    0.8688867688179016,
    0.12859416007995605,
    0.00251906574703753
  ],
  "No association was detected between bariatric surgery and fractures, cancer, or stroke.||Bariatric surgery increases rates of colorectal cancer.": [
    0.8936337828636169,
    0.10322587192058563,
    0.003140424145385623
  ],
  "Effect estimates for mortality found no protective association with bariatric surgery overall, with a HR of 0.97 (95% CI 0.66-1.43).||Bariatric surgery increases rates of colorectal cancer.": [
    0.5359624624252319,
    0.45997169613838196,
    0.0040658521465957165
  ],
  "The data used were recorded for the management of patients in primary care and may be subject to inaccuracy, which would tend to lead to underestimates of true relative effect sizes.   \n||Bariatric surgery increases rates of colorectal cancer.": [
    0.1891808658838272,
    0.7895945310592651,
    0.021224642172455788
  ],
  "CONCLUSIONS Bariatric surgery as delivered in the UK healthcare system is associated with dramatic weight loss, sustained at least 4 y after surgery.||Bariatric surgery increases rates of colorectal cancer.": [
    0.7779703140258789,
    0.21911513805389404,
    0.0029146072920411825
  ],
  "This weight loss is accompanied by substantial improvements in pre-existing T2DM and hypertension, as well as a reduced risk of incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea.||Bariatric surgery increases rates of colorectal cancer.": [
    0.9936740398406982,
    0.005390943493694067,
    0.0009350409382022917
  ],
  "Widening the availability of bariatric surgery could lead to substantial health benefits for many people who are morbidly obese.||Bariatric surgery increases rates of colorectal cancer.": [
    0.9940295219421387,
    0.005498741753399372,
    0.00047179704415611923
  ],
  "BACKGROUND Bariatric surgery is becoming a more widespread treatment for obesity.||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.6279927492141724,
    0.36763858795166016,
    0.00436862837523222
  ],
  "Comprehensive evidence of the long-term effects of contemporary surgery on a broad range of clinical outcomes in large populations treated in routine clinical practice is lacking.||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.1910291314125061,
    0.8049514293670654,
    0.004019472748041153
  ],
  "The objective of this study was to measure the association between bariatric surgery, weight, body mass index, and obesity-related co-morbidities.   \n||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.13325858116149902,
    0.8620510697364807,
    0.004690301604568958
  ],
  "METHODS AND FINDINGS This was an observational retrospective cohort study using data from the United Kingdom Clinical Practice Research Datalink.||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.075701043009758,
    0.9121752381324768,
    0.012123743072152138
  ],
  "All 3,882 patients registered in the database and with bariatric surgery on or before 31 December 2014 were included and matched by propensity score to 3,882 obese patients without surgery.||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.0637158676981926,
    0.9318466186523438,
    0.004437523894011974
  ],
  "The main outcome measures were change in weight and body mass index over 4 y; incident diagnoses of type 2 diabetes mellitus (T2DM), hypertension, angina, myocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and resolution of hypertension and T2DM.||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.057841453701257706,
    0.929801344871521,
    0.012357257306575775
  ],
  "Weight measures were available for 3,847 patients between 1 and 4 mo, 2,884 patients between 5 and 12 mo, and 2,258 patients between 13 and 48 mo post-procedure.||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.08055052161216736,
    0.9096992611885071,
    0.009750223718583584
  ],
  "Bariatric surgery patients exhibited rapid weight loss for the first four postoperative months, at a rate of 4.98 kg/mo (95% CI 4.88-5.08).||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.48243632912635803,
    0.5129006505012512,
    0.004663065541535616
  ],
  "Slower weight loss was sustained to the end of 4 y. Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater initial weight reduction than gastric banding (2.77 kg/mo).||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.256336510181427,
    0.7387941479682922,
    0.004869300406426191
  ],
  "Protective hazard ratios (HRs) were detected for bariatric surgery for incident T2DM, 0.68 (95% CI 0.55-0.83); hypertension, 0.35 (95% CI 0.27-0.45); angina, 0.59 (95% CI 0.40-0.87);MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.4193129539489746,
    0.5663771629333496,
    0.014309876598417759
  ],
  "Strong associations were found between bariatric surgery and the resolution of T2DM, with a HR of 9.29 (95% CI 6.84-12.62), and between bariatric surgery and the resolution of hypertension, with a HR of 5.64 (95% CI 2.65-11.99).||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.8362392783164978,
    0.16084371507167816,
    0.0029170082416385412
  ],
  "No association was detected between bariatric surgery and fractures, cancer, or stroke.||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.9149397611618042,
    0.081563800573349,
    0.0034964794758707285
  ],
  "Effect estimates for mortality found no protective association with bariatric surgery overall, with a HR of 0.97 (95% CI 0.66-1.43).||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.6862930059432983,
    0.30946052074432373,
    0.004246443510055542
  ],
  "The data used were recorded for the management of patients in primary care and may be subject to inaccuracy, which would tend to lead to underestimates of true relative effect sizes.   \n||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.1765747368335724,
    0.7969272136688232,
    0.026498030871152878
  ],
  "CONCLUSIONS Bariatric surgery as delivered in the UK healthcare system is associated with dramatic weight loss, sustained at least 4 y after surgery.||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.733756959438324,
    0.26301562786102295,
    0.003227428300306201
  ],
  "This weight loss is accompanied by substantial improvements in pre-existing T2DM and hypertension, as well as a reduced risk of incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea.||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.9897769689559937,
    0.008934799581766129,
    0.001288262428715825
  ],
  "Widening the availability of bariatric surgery could lead to substantial health benefits for many people who are morbidly obese.||Bariatric surgery increases rates of postmenopausal breast cancer.": [
    0.9868432879447937,
    0.012409971095621586,
    0.0007468070834875107
  ],
  "BACKGROUND Bariatric surgery is becoming a more widespread treatment for obesity.||Bariatric surgery reduces colorectal cancer.": [
    0.49564024806022644,
    0.4948952794075012,
    0.009464455768465996
  ],
  "Comprehensive evidence of the long-term effects of contemporary surgery on a broad range of clinical outcomes in large populations treated in routine clinical practice is lacking.||Bariatric surgery reduces colorectal cancer.": [
    0.10701365023851395,
    0.888674259185791,
    0.004312093369662762
  ],
  "The objective of this study was to measure the association between bariatric surgery, weight, body mass index, and obesity-related co-morbidities.   \n||Bariatric surgery reduces colorectal cancer.": [
    0.1182563528418541,
    0.87688809633255,
    0.0048555354587733746
  ],
  "METHODS AND FINDINGS This was an observational retrospective cohort study using data from the United Kingdom Clinical Practice Research Datalink.||Bariatric surgery reduces colorectal cancer.": [
    0.08866140991449356,
    0.8804909586906433,
    0.030847618356347084
  ],
  "All 3,882 patients registered in the database and with bariatric surgery on or before 31 December 2014 were included and matched by propensity score to 3,882 obese patients without surgery.||Bariatric surgery reduces colorectal cancer.": [
    0.016143791377544403,
    0.9814746379852295,
    0.0023815555032342672
  ],
  "The main outcome measures were change in weight and body mass index over 4 y; incident diagnoses of type 2 diabetes mellitus (T2DM), hypertension, angina, myocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and resolution of hypertension and T2DM.||Bariatric surgery reduces colorectal cancer.": [
    0.11338509619235992,
    0.8731579184532166,
    0.013456941582262516
  ],
  "Weight measures were available for 3,847 patients between 1 and 4 mo, 2,884 patients between 5 and 12 mo, and 2,258 patients between 13 and 48 mo post-procedure.||Bariatric surgery reduces colorectal cancer.": [
    0.03066997602581978,
    0.9547813534736633,
    0.014548640698194504
  ],
  "Bariatric surgery patients exhibited rapid weight loss for the first four postoperative months, at a rate of 4.98 kg/mo (95% CI 4.88-5.08).||Bariatric surgery reduces colorectal cancer.": [
    0.013375798240303993,
    0.9757875204086304,
    0.010836716741323471
  ],
  "Slower weight loss was sustained to the end of 4 y. Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater initial weight reduction than gastric banding (2.77 kg/mo).||Bariatric surgery reduces colorectal cancer.": [
    0.12320160865783691,
    0.8696039915084839,
    0.007194385398179293
  ],
  "Protective hazard ratios (HRs) were detected for bariatric surgery for incident T2DM, 0.68 (95% CI 0.55-0.83); hypertension, 0.35 (95% CI 0.27-0.45); angina, 0.59 (95% CI 0.40-0.87);MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).||Bariatric surgery reduces colorectal cancer.": [
    0.041360270231962204,
    0.9216371774673462,
    0.0370025709271431
  ],
  "Strong associations were found between bariatric surgery and the resolution of T2DM, with a HR of 9.29 (95% CI 6.84-12.62), and between bariatric surgery and the resolution of hypertension, with a HR of 5.64 (95% CI 2.65-11.99).||Bariatric surgery reduces colorectal cancer.": [
    0.2750743627548218,
    0.7119836211204529,
    0.012942006811499596
  ],
  "No association was detected between bariatric surgery and fractures, cancer, or stroke.||Bariatric surgery reduces colorectal cancer.": [
    0.03951596841216087,
    0.9546598792076111,
    0.005824148189276457
  ],
  "Effect estimates for mortality found no protective association with bariatric surgery overall, with a HR of 0.97 (95% CI 0.66-1.43).||Bariatric surgery reduces colorectal cancer.": [
    0.11329495161771774,
    0.8828501105308533,
    0.0038548633456230164
  ],
  "The data used were recorded for the management of patients in primary care and may be subject to inaccuracy, which would tend to lead to underestimates of true relative effect sizes.   \n||Bariatric surgery reduces colorectal cancer.": [
    0.09905785322189331,
    0.8623360991477966,
    0.03860604017972946
  ],
  "CONCLUSIONS Bariatric surgery as delivered in the UK healthcare system is associated with dramatic weight loss, sustained at least 4 y after surgery.||Bariatric surgery reduces colorectal cancer.": [
    0.05576780438423157,
    0.938788890838623,
    0.005443343427032232
  ],
  "This weight loss is accompanied by substantial improvements in pre-existing T2DM and hypertension, as well as a reduced risk of incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea.||Bariatric surgery reduces colorectal cancer.": [
    0.10491307079792023,
    0.7886514067649841,
    0.10643556714057922
  ],
  "Widening the availability of bariatric surgery could lead to substantial health benefits for many people who are morbidly obese.||Bariatric surgery reduces colorectal cancer.": [
    0.0053862230852246284,
    0.9912059903144836,
    0.003407801501452923
  ],
  "BACKGROUND Bariatric surgery is becoming a more widespread treatment for obesity.||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.30007338523864746,
    0.6856128573417664,
    0.014313760213553905
  ],
  "Comprehensive evidence of the long-term effects of contemporary surgery on a broad range of clinical outcomes in large populations treated in routine clinical practice is lacking.||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.13425999879837036,
    0.8618742823600769,
    0.0038657125551253557
  ],
  "The objective of this study was to measure the association between bariatric surgery, weight, body mass index, and obesity-related co-morbidities.   \n||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.13078317046165466,
    0.8640051484107971,
    0.005211677867919207
  ],
  "METHODS AND FINDINGS This was an observational retrospective cohort study using data from the United Kingdom Clinical Practice Research Datalink.||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.05882113426923752,
    0.9104321599006653,
    0.03074677102267742
  ],
  "All 3,882 patients registered in the database and with bariatric surgery on or before 31 December 2014 were included and matched by propensity score to 3,882 obese patients without surgery.||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.015756547451019287,
    0.9806734323501587,
    0.0035699992440640926
  ],
  "The main outcome measures were change in weight and body mass index over 4 y; incident diagnoses of type 2 diabetes mellitus (T2DM), hypertension, angina, myocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and resolution of hypertension and T2DM.||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.11492973566055298,
    0.8640568852424622,
    0.021013397723436356
  ],
  "Weight measures were available for 3,847 patients between 1 and 4 mo, 2,884 patients between 5 and 12 mo, and 2,258 patients between 13 and 48 mo post-procedure.||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.024509131908416748,
    0.961606502532959,
    0.013884395360946655
  ],
  "Bariatric surgery patients exhibited rapid weight loss for the first four postoperative months, at a rate of 4.98 kg/mo (95% CI 4.88-5.08).||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.009989416226744652,
    0.9675753116607666,
    0.022435305640101433
  ],
  "Slower weight loss was sustained to the end of 4 y. Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater initial weight reduction than gastric banding (2.77 kg/mo).||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.12758761644363403,
    0.8662587404251099,
    0.006153605412691832
  ],
  "Protective hazard ratios (HRs) were detected for bariatric surgery for incident T2DM, 0.68 (95% CI 0.55-0.83); hypertension, 0.35 (95% CI 0.27-0.45); angina, 0.59 (95% CI 0.40-0.87);MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.02596270479261875,
    0.923146665096283,
    0.050890643149614334
  ],
  "Strong associations were found between bariatric surgery and the resolution of T2DM, with a HR of 9.29 (95% CI 6.84-12.62), and between bariatric surgery and the resolution of hypertension, with a HR of 5.64 (95% CI 2.65-11.99).||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.10308035463094711,
    0.8807926177978516,
    0.01612699404358864
  ],
  "No association was detected between bariatric surgery and fractures, cancer, or stroke.||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.03191068395972252,
    0.9579242467880249,
    0.010165028274059296
  ],
  "Effect estimates for mortality found no protective association with bariatric surgery overall, with a HR of 0.97 (95% CI 0.66-1.43).||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.22318220138549805,
    0.7711613178253174,
    0.005656514782458544
  ],
  "The data used were recorded for the management of patients in primary care and may be subject to inaccuracy, which would tend to lead to underestimates of true relative effect sizes.   \n||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.08220754563808441,
    0.8607445359230042,
    0.05704789236187935
  ],
  "CONCLUSIONS Bariatric surgery as delivered in the UK healthcare system is associated with dramatic weight loss, sustained at least 4 y after surgery.||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.02207711711525917,
    0.9708973169326782,
    0.007025603670626879
  ],
  "This weight loss is accompanied by substantial improvements in pre-existing T2DM and hypertension, as well as a reduced risk of incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea.||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.05244371294975281,
    0.8041508197784424,
    0.14340543746948242
  ],
  "Widening the availability of bariatric surgery could lead to substantial health benefits for many people who are morbidly obese.||Bariatric surgery reduces postmenopausal breast cancer.": [
    0.010361645370721817,
    0.9845770001411438,
    0.005061364267021418
  ],
  "IMPORTANCE Bariatric surgery is associated with sustained weight loss and improved physical health status for severely obese individuals.||Bariatric surgery leads to negative outcomes in mental health.": [
    0.8988130688667297,
    0.09954024851322174,
    0.0016466093948110938
  ],
  "Mental health conditions may be common among patients seeking bariatric surgery; however, the prevalence of these conditions and whether they are associated with postoperative outcomes remains unknown.   \n||Bariatric surgery leads to negative outcomes in mental health.": [
    0.05106138437986374,
    0.896034836769104,
    0.05290384963154793
  ],
  "OBJECTIVE To determine the prevalence of mental health conditions among bariatric surgery candidates and recipients, to evaluate the association between preoperative mental health conditions and health outcomes following bariatric surgery, and to evaluate the association between surgery and the clinical course of mental health conditions.   \n||Bariatric surgery leads to negative outcomes in mental health.": [
    0.050916969776153564,
    0.9330452084541321,
    0.016037805005908012
  ],
  "DATA SOURCES We searched PubMed, MEDLINE on OVID, and PsycINFO for studies published between January 1988 and November 2015.||Bariatric surgery leads to negative outcomes in mental health.": [
    0.07815660536289215,
    0.8923174142837524,
    0.02952602319419384
  ],
  "Study quality was assessed using an adapted tool for risk of bias; quality of evidence was rated based on GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria.   \n||Bariatric surgery leads to negative outcomes in mental health.": [
    0.10674665123224258,
    0.8606070280075073,
    0.0326463058590889
  ],
  "FINDINGS We identified 68 publications meeting inclusion criteria: 59 reporting the prevalence of preoperative mental health conditions (65,363 patients) and 27 reporting associations between preoperative mental health conditions and postoperative outcomes (50,182 patients).||Bariatric surgery leads to negative outcomes in mental health.": [
    0.022786207497119904,
    0.9631924629211426,
    0.014021304436028004
  ],
  "Among patients seeking and undergoing bariatric surgery, the most common mental health conditions, based on random-effects estimates of prevalence, were depression (19% [95% CI, 14%-25%]) and binge eating disorder (17% [95% CI, 13%-21%]).||Bariatric surgery leads to negative outcomes in mental health.": [
    0.006013222970068455,
    0.5762766599655151,
    0.4177100658416748
  ],
  "There was conflicting evidence regarding the association between preoperative mental health conditions and postoperative weight loss.||Bariatric surgery leads to negative outcomes in mental health.": [
    0.06712298840284348,
    0.9071967601776123,
    0.02568024769425392
  ],
  "Neither depression nor binge eating disorder was consistently associated with differences in weight outcomes.||Bariatric surgery leads to negative outcomes in mental health.": [
    0.09554622322320938,
    0.891152560710907,
    0.013301249593496323
  ],
  "Bariatric surgery was, however, consistently associated with postoperative decreases in the prevalence of depression (7 studies; 8%-74% decrease) and the severity of depressive symptoms (6 studies; 40%-70% decrease).   \n||Bariatric surgery leads to negative outcomes in mental health.": [
    0.9604833722114563,
    0.028129246085882187,
    0.011387396603822708
  ],
  "CONCLUSIONS AND RELEVANCE Mental health conditions are common among bariatric surgery patients-in particular, depression and binge eating disorder.||Bariatric surgery leads to negative outcomes in mental health.": [
    0.0025353392120450735,
    0.20331044495105743,
    0.7941542267799377
  ],
  "There is inconsistent evidence regarding the association between preoperative mental health conditions and postoperative weight loss.||Bariatric surgery leads to negative outcomes in mental health.": [
    0.09336280077695847,
    0.8823036551475525,
    0.02433355525135994
  ],
  "Moderate-quality evidence supports an association between bariatric surgery and lower rates of depression postoperatively.||Bariatric surgery leads to negative outcomes in mental health.": [
    0.9976335763931274,
    0.001852908288128674,
    0.0005135678220540285
  ],
  "IMPORTANCE Bariatric surgery is associated with sustained weight loss and improved physical health status for severely obese individuals.||Bariatric surgery leads to positive outcomes in mental health.": [
    0.7733045220375061,
    0.20323407649993896,
    0.02346138469874859
  ],
  "Mental health conditions may be common among patients seeking bariatric surgery; however, the prevalence of these conditions and whether they are associated with postoperative outcomes remains unknown.   \n||Bariatric surgery leads to positive outcomes in mental health.": [
    0.6186894774436951,
    0.37737590074539185,
    0.003934602253139019
  ],
  "OBJECTIVE To determine the prevalence of mental health conditions among bariatric surgery candidates and recipients, to evaluate the association between preoperative mental health conditions and health outcomes following bariatric surgery, and to evaluate the association between surgery and the clinical course of mental health conditions.   \n||Bariatric surgery leads to positive outcomes in mental health.": [
    0.1122731938958168,
    0.8837746977806091,
    0.00395211111754179
  ],
  "DATA SOURCES We searched PubMed, MEDLINE on OVID, and PsycINFO for studies published between January 1988 and November 2015.||Bariatric surgery leads to positive outcomes in mental health.": [
    0.12097650021314621,
    0.8514145612716675,
    0.02760889381170273
  ],
  "Study quality was assessed using an adapted tool for risk of bias; quality of evidence was rated based on GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria.   \n||Bariatric surgery leads to positive outcomes in mental health.": [
    0.15574118494987488,
    0.8196000456809998,
    0.02465881034731865
  ],
  "FINDINGS We identified 68 publications meeting inclusion criteria: 59 reporting the prevalence of preoperative mental health conditions (65,363 patients) and 27 reporting associations between preoperative mental health conditions and postoperative outcomes (50,182 patients).||Bariatric surgery leads to positive outcomes in mental health.": [
    0.1408051997423172,
    0.8529350757598877,
    0.006259671878069639
  ],
  "Among patients seeking and undergoing bariatric surgery, the most common mental health conditions, based on random-effects estimates of prevalence, were depression (19% [95% CI, 14%-25%]) and binge eating disorder (17% [95% CI, 13%-21%]).||Bariatric surgery leads to positive outcomes in mental health.": [
    0.5158987045288086,
    0.47944411635398865,
    0.004657209850847721
  ],
  "There was conflicting evidence regarding the association between preoperative mental health conditions and postoperative weight loss.||Bariatric surgery leads to positive outcomes in mental health.": [
    0.34760260581970215,
    0.6468340158462524,
    0.005563346203416586
  ],
  "Neither depression nor binge eating disorder was consistently associated with differences in weight outcomes.||Bariatric surgery leads to positive outcomes in mental health.": [
    0.2992870807647705,
    0.6975610256195068,
    0.003151920158416033
  ],
  "Bariatric surgery was, however, consistently associated with postoperative decreases in the prevalence of depression (7 studies; 8%-74% decrease) and the severity of depressive symptoms (6 studies; 40%-70% decrease).   \n||Bariatric surgery leads to positive outcomes in mental health.": [
    0.002218206413090229,
    0.1653824746608734,
    0.8323993682861328
  ],
  "CONCLUSIONS AND RELEVANCE Mental health conditions are common among bariatric surgery patients-in particular, depression and binge eating disorder.||Bariatric surgery leads to positive outcomes in mental health.": [
    0.8958379030227661,
    0.10132179409265518,
    0.002840364119037986
  ],
  "There is inconsistent evidence regarding the association between preoperative mental health conditions and postoperative weight loss.||Bariatric surgery leads to positive outcomes in mental health.": [
    0.39551401138305664,
    0.5996168851852417,
    0.004869051277637482
  ],
  "Moderate-quality evidence supports an association between bariatric surgery and lower rates of depression postoperatively.||Bariatric surgery leads to positive outcomes in mental health.": [
    0.0029242669697850943,
    0.2784160375595093,
    0.7186596393585205
  ],
  "IMPORTANCE Bariatric surgery is associated with sustained weight loss and improved physical health status for severely obese individuals.||Bariatric surgery has a positive impact on mental health.": [
    0.6636607646942139,
    0.30761781334877014,
    0.028721453621983528
  ],
  "Mental health conditions may be common among patients seeking bariatric surgery; however, the prevalence of these conditions and whether they are associated with postoperative outcomes remains unknown.   \n||Bariatric surgery has a positive impact on mental health.": [
    0.9578135013580322,
    0.03985060378909111,
    0.0023359088227152824
  ],
  "OBJECTIVE To determine the prevalence of mental health conditions among bariatric surgery candidates and recipients, to evaluate the association between preoperative mental health conditions and health outcomes following bariatric surgery, and to evaluate the association between surgery and the clinical course of mental health conditions.   \n||Bariatric surgery has a positive impact on mental health.": [
    0.3867805004119873,
    0.6092873215675354,
    0.003932164050638676
  ],
  "DATA SOURCES We searched PubMed, MEDLINE on OVID, and PsycINFO for studies published between January 1988 and November 2015.||Bariatric surgery has a positive impact on mental health.": [
    0.12346743792295456,
    0.8422043323516846,
    0.03432822227478027
  ],
  "Study quality was assessed using an adapted tool for risk of bias; quality of evidence was rated based on GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria.   \n||Bariatric surgery has a positive impact on mental health.": [
    0.11068526655435562,
    0.8267892599105835,
    0.06252548098564148
  ],
  "FINDINGS We identified 68 publications meeting inclusion criteria: 59 reporting the prevalence of preoperative mental health conditions (65,363 patients) and 27 reporting associations between preoperative mental health conditions and postoperative outcomes (50,182 patients).||Bariatric surgery has a positive impact on mental health.": [
    0.4778960645198822,
    0.5179295539855957,
    0.004174372181296349
  ],
  "Among patients seeking and undergoing bariatric surgery, the most common mental health conditions, based on random-effects estimates of prevalence, were depression (19% [95% CI, 14%-25%]) and binge eating disorder (17% [95% CI, 13%-21%]).||Bariatric surgery has a positive impact on mental health.": [
    0.6450498700141907,
    0.34967470169067383,
    0.005275423172861338
  ],
  "There was conflicting evidence regarding the association between preoperative mental health conditions and postoperative weight loss.||Bariatric surgery has a positive impact on mental health.": [
    0.357771635055542,
    0.6348965764045715,
    0.007331731729209423
  ],
  "Neither depression nor binge eating disorder was consistently associated with differences in weight outcomes.||Bariatric surgery has a positive impact on mental health.": [
    0.25389721989631653,
    0.7423409223556519,
    0.003761881496757269
  ],
  "Bariatric surgery was, however, consistently associated with postoperative decreases in the prevalence of depression (7 studies; 8%-74% decrease) and the severity of depressive symptoms (6 studies; 40%-70% decrease).   \n||Bariatric surgery has a positive impact on mental health.": [
    0.004051358439028263,
    0.3434108793735504,
    0.6525377631187439
  ],
  "CONCLUSIONS AND RELEVANCE Mental health conditions are common among bariatric surgery patients-in particular, depression and binge eating disorder.||Bariatric surgery has a positive impact on mental health.": [
    0.937315046787262,
    0.05907875671982765,
    0.0036061350256204605
  ],
  "There is inconsistent evidence regarding the association between preoperative mental health conditions and postoperative weight loss.||Bariatric surgery has a positive impact on mental health.": [
    0.41656145453453064,
    0.5763707756996155,
    0.00706779770553112
  ],
  "Moderate-quality evidence supports an association between bariatric surgery and lower rates of depression postoperatively.||Bariatric surgery has a positive impact on mental health.": [
    0.004577220883220434,
    0.3115711212158203,
    0.6838517189025879
  ],
  "Chemokines orchestrate immune cell trafficking by eliciting either directed or random migration and by activating integrins in order to induce cell adhesion.||CCL19 is a ligand for CCR7.": [
    0.2157905250787735,
    0.6977629065513611,
    0.08644656836986542
  ],
  "Analyzing dendritic cell (DC) migration, we showed that these distinct cellular responses depended on the mode of chemokine presentation within tissues.||CCL19 is a ligand for CCR7.": [
    0.2643687129020691,
    0.5642939209938049,
    0.17133739590644836
  ],
  "The surface-immobilized form of the chemokine CCL21, the heparan sulfate-anchoring ligand of the CC-chemokine receptor 7 (CCR7), caused random movement of DCs that was confined to the chemokine-presenting surface because it triggered integrin-mediated adhesion.||CCL19 is a ligand for CCR7.": [
    0.9755182266235352,
    0.01858074590563774,
    0.00590108847245574
  ],
  "Upon direct contact with CCL21, DCs truncated the anchoring residues of CCL21, thereby releasing it from the solid phase.||CCL19 is a ligand for CCR7.": [
    0.4321798086166382,
    0.5617007613182068,
    0.0061194151639938354
  ],
  "Soluble CCL21 functionally resembles the second CCR7 ligand, CCL19, which lacks anchoring residues and forms soluble gradients.||CCL19 is a ligand for CCR7.": [
    0.008688627742230892,
    0.013522234745323658,
    0.9777892231941223
  ],
  "Both soluble CCR7 ligands triggered chemotactic movement, but not surface adhesion.||CCL19 is a ligand for CCR7.": [
    0.30806076526641846,
    0.6175487637519836,
    0.07439049333333969
  ],
  "Adhesive random migration and directional steering cooperate to produce dynamic but spatially restricted locomotion patterns closely resembling the cellular dynamics observed in secondary lymphoid organs.||CCL19 is a ligand for CCR7.": [
    0.3312077522277832,
    0.47673365473747253,
    0.19205860793590546
  ],
  "Chemokines orchestrate immune cell trafficking by eliciting either directed or random migration and by activating integrins in order to induce cell adhesion.||CCL19 is predominantly present within dLNs.": [
    0.01691870391368866,
    0.9784753322601318,
    0.004605934955179691
  ],
  "Analyzing dendritic cell (DC) migration, we showed that these distinct cellular responses depended on the mode of chemokine presentation within tissues.||CCL19 is predominantly present within dLNs.": [
    0.09580916166305542,
    0.8963881134986877,
    0.007802770007401705
  ],
  "The surface-immobilized form of the chemokine CCL21, the heparan sulfate-anchoring ligand of the CC-chemokine receptor 7 (CCR7), caused random movement of DCs that was confined to the chemokine-presenting surface because it triggered integrin-mediated adhesion.||CCL19 is predominantly present within dLNs.": [
    0.5525321960449219,
    0.44143691658973694,
    0.006030908785760403
  ],
  "Upon direct contact with CCL21, DCs truncated the anchoring residues of CCL21, thereby releasing it from the solid phase.||CCL19 is predominantly present within dLNs.": [
    0.20128792524337769,
    0.7941916584968567,
    0.004520461428910494
  ],
  "Soluble CCL21 functionally resembles the second CCR7 ligand, CCL19, which lacks anchoring residues and forms soluble gradients.||CCL19 is predominantly present within dLNs.": [
    0.03207682445645332,
    0.9648348689079285,
    0.0030883322469890118
  ],
  "Both soluble CCR7 ligands triggered chemotactic movement, but not surface adhesion.||CCL19 is predominantly present within dLNs.": [
    0.49645352363586426,
    0.4926842749118805,
    0.0108622582629323
  ],
  "Adhesive random migration and directional steering cooperate to produce dynamic but spatially restricted locomotion patterns closely resembling the cellular dynamics observed in secondary lymphoid organs.||CCL19 is predominantly present within dLNs.": [
    0.10780718922615051,
    0.7974200248718262,
    0.0947728380560875
  ],
  "Chemokines orchestrate immune cell trafficking by eliciting either directed or random migration and by activating integrins in order to induce cell adhesion.||CCL19 is absent within dLNs.": [
    0.6632140874862671,
    0.3245624601840973,
    0.012223540805280209
  ],
  "Analyzing dendritic cell (DC) migration, we showed that these distinct cellular responses depended on the mode of chemokine presentation within tissues.||CCL19 is absent within dLNs.": [
    0.7659893035888672,
    0.22363118827342987,
    0.010379471816122532
  ],
  "The surface-immobilized form of the chemokine CCL21, the heparan sulfate-anchoring ligand of the CC-chemokine receptor 7 (CCR7), caused random movement of DCs that was confined to the chemokine-presenting surface because it triggered integrin-mediated adhesion.||CCL19 is absent within dLNs.": [
    0.40509265661239624,
    0.5845654010772705,
    0.010341919027268887
  ],
  "Upon direct contact with CCL21, DCs truncated the anchoring residues of CCL21, thereby releasing it from the solid phase.||CCL19 is absent within dLNs.": [
    0.20186343789100647,
    0.7803428173065186,
    0.01779373735189438
  ],
  "Soluble CCL21 functionally resembles the second CCR7 ligand, CCL19, which lacks anchoring residues and forms soluble gradients.||CCL19 is absent within dLNs.": [
    0.8205623626708984,
    0.1690148562192917,
    0.010422776453197002
  ],
  "Both soluble CCR7 ligands triggered chemotactic movement, but not surface adhesion.||CCL19 is absent within dLNs.": [
    0.3634183704853058,
    0.6120542883872986,
    0.02452731691300869
  ],
  "Adhesive random migration and directional steering cooperate to produce dynamic but spatially restricted locomotion patterns closely resembling the cellular dynamics observed in secondary lymphoid organs.||CCL19 is absent within dLNs.": [
    0.8839274048805237,
    0.10897015035152435,
    0.00710243359208107
  ],
  "Chimeric antigen receptors (CARs) targeting CD19 have mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarely occurred using CARs targeting other antigens.||CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.": [
    0.3501744568347931,
    0.6464626789093018,
    0.0033628931269049644
  ],
  "It remains unknown whether the impressive effects of CD19 CARs relate to greater susceptibility of hematologic malignancies to CAR therapies, or superior functionality of the CD19 CAR itself.||CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.": [
    0.7733901739120483,
    0.22314895689487457,
    0.0034609290305525064
  ],
  "We show that tonic CAR CD3-\u03b6 phosphorylation, triggered by antigen-independent clustering of CAR single-chain variable fragments, can induce early exhaustion of CAR T cells that limits antitumor efficacy.||CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.": [
    0.8972625136375427,
    0.085691437125206,
    0.017046034336090088
  ],
  "Such activation is present to varying degrees in all CARs studied, except the highly effective CD19 CAR.||CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.": [
    0.22550973296165466,
    0.7658693194389343,
    0.00862092338502407
  ],
  "We further determine that CD28 costimulation augments, whereas 4-1BB costimulation reduces, exhaustion induced by persistent CAR signaling.||CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.": [
    0.12220117449760437,
    0.7526971101760864,
    0.1251017451286316
  ],
  "Our results provide biological explanations for the antitumor effects of CD19 CARs and for the observations that CD19 CAR T cells incorporating the 4-1BB costimulatory domain are more persistent than those incorporating CD28 in clinical trials.||CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.": [
    0.10033770650625229,
    0.8970744013786316,
    0.0025879014283418655
  ],
  "Chimeric antigen receptors (CARs) targeting CD19 have mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarely occurred using CARs targeting other antigens.||Tonic signaling from the scFv induces constitutive stimulation.": [
    0.47810569405555725,
    0.4933657944202423,
    0.02852841652929783
  ],
  "It remains unknown whether the impressive effects of CD19 CARs relate to greater susceptibility of hematologic malignancies to CAR therapies, or superior functionality of the CD19 CAR itself.||Tonic signaling from the scFv induces constitutive stimulation.": [
    0.28659486770629883,
    0.5983725190162659,
    0.11503268033266068
  ],
  "We show that tonic CAR CD3-\u03b6 phosphorylation, triggered by antigen-independent clustering of CAR single-chain variable fragments, can induce early exhaustion of CAR T cells that limits antitumor efficacy.||Tonic signaling from the scFv induces constitutive stimulation.": [
    0.8675398230552673,
    0.10847792774438858,
    0.023982252925634384
  ],
  "Such activation is present to varying degrees in all CARs studied, except the highly effective CD19 CAR.||Tonic signaling from the scFv induces constitutive stimulation.": [
    0.010890579782426357,
    0.9855000376701355,
    0.0036093720700591803
  ],
  "We further determine that CD28 costimulation augments, whereas 4-1BB costimulation reduces, exhaustion induced by persistent CAR signaling.||Tonic signaling from the scFv induces constitutive stimulation.": [
    0.8625668883323669,
    0.11480320990085602,
    0.02262989617884159
  ],
  "Our results provide biological explanations for the antitumor effects of CD19 CARs and for the observations that CD19 CAR T cells incorporating the 4-1BB costimulatory domain are more persistent than those incorporating CD28 in clinical trials.||Tonic signaling from the scFv induces constitutive stimulation.": [
    0.3049471080303192,
    0.6664890050888062,
    0.028563831001520157
  ],
  "Chimeric antigen receptors (CARs) targeting CD19 have mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarely occurred using CARs targeting other antigens.||Tonic signaling from the scFv is amplified by MyD88/CD40.": [
    0.24509772658348083,
    0.734134316444397,
    0.020767901092767715
  ],
  "It remains unknown whether the impressive effects of CD19 CARs relate to greater susceptibility of hematologic malignancies to CAR therapies, or superior functionality of the CD19 CAR itself.||Tonic signaling from the scFv is amplified by MyD88/CD40.": [
    0.09761936962604523,
    0.8546127080917358,
    0.04776795208454132
  ],
  "We show that tonic CAR CD3-\u03b6 phosphorylation, triggered by antigen-independent clustering of CAR single-chain variable fragments, can induce early exhaustion of CAR T cells that limits antitumor efficacy.||Tonic signaling from the scFv is amplified by MyD88/CD40.": [
    0.1628778874874115,
    0.8049559593200684,
    0.03216616064310074
  ],
  "Such activation is present to varying degrees in all CARs studied, except the highly effective CD19 CAR.||Tonic signaling from the scFv is amplified by MyD88/CD40.": [
    0.06570177525281906,
    0.9051331877708435,
    0.029165012761950493
  ],
  "We further determine that CD28 costimulation augments, whereas 4-1BB costimulation reduces, exhaustion induced by persistent CAR signaling.||Tonic signaling from the scFv is amplified by MyD88/CD40.": [
    0.5466035008430481,
    0.39975932240486145,
    0.05363721400499344
  ],
  "Our results provide biological explanations for the antitumor effects of CD19 CARs and for the observations that CD19 CAR T cells incorporating the 4-1BB costimulatory domain are more persistent than those incorporating CD28 in clinical trials.||Tonic signaling from the scFv is amplified by MyD88/CD40.": [
    0.16913779079914093,
    0.7949633002281189,
    0.035898882895708084
  ],
  "Chimeric antigen receptors (CARs) targeting CD19 have mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarely occurred using CARs targeting other antigens.||Tonic signaling from the scFv prevents constitutive stimulation.": [
    0.6769618391990662,
    0.31743863224983215,
    0.005599486641585827
  ],
  "It remains unknown whether the impressive effects of CD19 CARs relate to greater susceptibility of hematologic malignancies to CAR therapies, or superior functionality of the CD19 CAR itself.||Tonic signaling from the scFv prevents constitutive stimulation.": [
    0.7305328845977783,
    0.2567291855812073,
    0.012737911194562912
  ],
  "We show that tonic CAR CD3-\u03b6 phosphorylation, triggered by antigen-independent clustering of CAR single-chain variable fragments, can induce early exhaustion of CAR T cells that limits antitumor efficacy.||Tonic signaling from the scFv prevents constitutive stimulation.": [
    0.7849587798118591,
    0.17892077565193176,
    0.0361204519867897
  ],
  "Such activation is present to varying degrees in all CARs studied, except the highly effective CD19 CAR.||Tonic signaling from the scFv prevents constitutive stimulation.": [
    0.6002731919288635,
    0.3936096429824829,
    0.006117112468928099
  ],
  "We further determine that CD28 costimulation augments, whereas 4-1BB costimulation reduces, exhaustion induced by persistent CAR signaling.||Tonic signaling from the scFv prevents constitutive stimulation.": [
    0.7092636823654175,
    0.253198504447937,
    0.03753777965903282
  ],
  "Our results provide biological explanations for the antitumor effects of CD19 CARs and for the observations that CD19 CAR T cells incorporating the 4-1BB costimulatory domain are more persistent than those incorporating CD28 in clinical trials.||Tonic signaling from the scFv prevents constitutive stimulation.": [
    0.6331496834754944,
    0.35815417766571045,
    0.008696099743247032
  ],
  "Uncoupling protein 1 (UCP1) plays a central role in nonshivering thermogenesis in brown fat; however, its role in beige fat remains unclear.||Ca2+ cycling controls whole-body energy homeostasis in beige fat.": [
    0.3863527774810791,
    0.5923293232917786,
    0.02131793089210987
  ],
  "Here we report a robust UCP1-independent thermogenic mechanism in beige fat that involves enhanced ATP-dependent Ca2+ cycling by sarco/endoplasmic reticulum Ca2+-ATPase 2b (SERCA2b) and ryanodine receptor 2 (RyR2).||Ca2+ cycling controls whole-body energy homeostasis in beige fat.": [
    0.015270069241523743,
    0.690468966960907,
    0.29426097869873047
  ],
  "Inhibition of SERCA2b impairs UCP1-independent beige fat thermogenesis in humans and mice as well as in pigs, a species that lacks a functional UCP1 protein.||Ca2+ cycling controls whole-body energy homeostasis in beige fat.": [
    0.31084492802619934,
    0.3569765090942383,
    0.33217859268188477
  ],
  "Conversely, enhanced Ca2+ cycling by activation of \u03b11- and/or \u03b23-adrenergic receptors or the SERCA2b-RyR2 pathway stimulates UCP1-independent thermogenesis in beige adipocytes.||Ca2+ cycling controls whole-body energy homeostasis in beige fat.": [
    0.08967679738998413,
    0.4494541883468628,
    0.4608689844608307
  ],
  "In the absence of UCP1, beige fat dynamically expends glucose through enhanced glycolysis, tricarboxylic acid metabolism and pyruvate dehydrogenase activity for ATP-dependent thermogenesis through the SERCA2b pathway; beige fat thereby functions as a 'glucose sink' and improves glucose tolerance independently of body weight loss.||Ca2+ cycling controls whole-body energy homeostasis in beige fat.": [
    0.6580770611763,
    0.21131601929664612,
    0.13060694932937622
  ],
  "Our study uncovers a noncanonical thermogenic mechanism through which beige fat controls whole-body energy homeostasis via Ca2+ cycling.||Ca2+ cycling controls whole-body energy homeostasis in beige fat.": [
    0.002204301068559289,
    0.0057167066261172295,
    0.992078959941864
  ],
  "Uncoupling protein 1 (UCP1) plays a central role in nonshivering thermogenesis in brown fat; however, its role in beige fat remains unclear.||Ca2+ cycling is a UCP1-dependent thermogenic mechanism.": [
    0.28242337703704834,
    0.6758256554603577,
    0.0417509600520134
  ],
  "Here we report a robust UCP1-independent thermogenic mechanism in beige fat that involves enhanced ATP-dependent Ca2+ cycling by sarco/endoplasmic reticulum Ca2+-ATPase 2b (SERCA2b) and ryanodine receptor 2 (RyR2).||Ca2+ cycling is a UCP1-dependent thermogenic mechanism.": [
    0.935204029083252,
    0.0144112603738904,
    0.05038478970527649
  ],
  "Inhibition of SERCA2b impairs UCP1-independent beige fat thermogenesis in humans and mice as well as in pigs, a species that lacks a functional UCP1 protein.||Ca2+ cycling is a UCP1-dependent thermogenic mechanism.": [
    0.8363841772079468,
    0.11416374891996384,
    0.04945207014679909
  ],
  "Conversely, enhanced Ca2+ cycling by activation of \u03b11- and/or \u03b23-adrenergic receptors or the SERCA2b-RyR2 pathway stimulates UCP1-independent thermogenesis in beige adipocytes.||Ca2+ cycling is a UCP1-dependent thermogenic mechanism.": [
    0.9909424185752869,
    0.003847365966066718,
    0.005210171919316053
  ],
  "In the absence of UCP1, beige fat dynamically expends glucose through enhanced glycolysis, tricarboxylic acid metabolism and pyruvate dehydrogenase activity for ATP-dependent thermogenesis through the SERCA2b pathway; beige fat thereby functions as a 'glucose sink' and improves glucose tolerance independently of body weight loss.||Ca2+ cycling is a UCP1-dependent thermogenic mechanism.": [
    0.7207050323486328,
    0.12826767563819885,
    0.15102723240852356
  ],
  "Our study uncovers a noncanonical thermogenic mechanism through which beige fat controls whole-body energy homeostasis via Ca2+ cycling.||Ca2+ cycling is a UCP1-dependent thermogenic mechanism.": [
    0.16342894732952118,
    0.814971387386322,
    0.021599626168608665
  ],
  "Uncoupling protein 1 (UCP1) plays a central role in nonshivering thermogenesis in brown fat; however, its role in beige fat remains unclear.||Ca2+ cycling is a UCP1-independent thermogenic mechanism.": [
    0.6569637060165405,
    0.33657047152519226,
    0.006465747952461243
  ],
  "Here we report a robust UCP1-independent thermogenic mechanism in beige fat that involves enhanced ATP-dependent Ca2+ cycling by sarco/endoplasmic reticulum Ca2+-ATPase 2b (SERCA2b) and ryanodine receptor 2 (RyR2).||Ca2+ cycling is a UCP1-independent thermogenic mechanism.": [
    0.0040677268989384174,
    0.01677083969116211,
    0.9791614413261414
  ],
  "Inhibition of SERCA2b impairs UCP1-independent beige fat thermogenesis in humans and mice as well as in pigs, a species that lacks a functional UCP1 protein.||Ca2+ cycling is a UCP1-independent thermogenic mechanism.": [
    0.6553632616996765,
    0.24061544239521027,
    0.1040213406085968
  ],
  "Conversely, enhanced Ca2+ cycling by activation of \u03b11- and/or \u03b23-adrenergic receptors or the SERCA2b-RyR2 pathway stimulates UCP1-independent thermogenesis in beige adipocytes.||Ca2+ cycling is a UCP1-independent thermogenic mechanism.": [
    0.013868915848433971,
    0.03155110403895378,
    0.9545799493789673
  ],
  "In the absence of UCP1, beige fat dynamically expends glucose through enhanced glycolysis, tricarboxylic acid metabolism and pyruvate dehydrogenase activity for ATP-dependent thermogenesis through the SERCA2b pathway; beige fat thereby functions as a 'glucose sink' and improves glucose tolerance independently of body weight loss.||Ca2+ cycling is a UCP1-independent thermogenic mechanism.": [
    0.346269428730011,
    0.16303607821464539,
    0.49069443345069885
  ],
  "Our study uncovers a noncanonical thermogenic mechanism through which beige fat controls whole-body energy homeostasis via Ca2+ cycling.||Ca2+ cycling is a UCP1-independent thermogenic mechanism.": [
    0.10450899600982666,
    0.741084098815918,
    0.15440692007541656
  ],
  "Myeloid-derived suppressor cells (MDSCs) play critical roles in primary and metastatic cancer progression.||Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.": [
    0.12210805714130402,
    0.8665019273757935,
    0.011389940045773983
  ],
  "MDSC regulation is widely variable even among patients harbouring the same type of malignancy, and the mechanisms governing such heterogeneity are largely unknown.||Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.": [
    0.16612732410430908,
    0.7107933163642883,
    0.12307930737733841
  ],
  "Here, integrating human tumour genomics and syngeneic mammary tumour models, we demonstrate that mTOR signalling in cancer cells dictates a mammary tumour's ability to stimulate MDSC accumulation through regulating G-CSF.||Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.": [
    0.10225439816713333,
    0.2676313817501068,
    0.6301142573356628
  ],
  "Inhibiting this pathway or its activators (for example, FGFR) impairs tumour progression, which is partially rescued by restoring MDSCs or G-CSF.||Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.": [
    0.6353702545166016,
    0.29023364186286926,
    0.07439611852169037
  ],
  "Tumour-initiating cells (TICs) exhibit elevated G-CSF.||Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.": [
    0.018267592415213585,
    0.6990897059440613,
    0.282642662525177
  ],
  "MDSCs reciprocally increase TIC frequency through activating Notch in tumour cells, forming a feedforward loop.||Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.": [
    0.21806207299232483,
    0.4940733313560486,
    0.2878645360469818
  ],
  "Analyses of primary breast cancers and patient-derived xenografts corroborate these mechanisms in patients.||Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.": [
    0.05905722454190254,
    0.8643919229507446,
    0.07655085623264313
  ],
  "These findings establish a non-canonical oncogenic role of mTOR signalling in recruiting pro-tumorigenic MDSCs and show how defined cancer subsets may evolve to promote and depend on a distinct immune microenvironment.||Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.": [
    0.3516708016395569,
    0.5362273454666138,
    0.11210181564092636
  ],
  "Myeloid-derived suppressor cells (MDSCs) play critical roles in primary and metastatic cancer progression.||Deleting Raptor increases G-CSF levels.": [
    0.2401035577058792,
    0.7564054131507874,
    0.003491019131615758
  ],
  "MDSC regulation is widely variable even among patients harbouring the same type of malignancy, and the mechanisms governing such heterogeneity are largely unknown.||Deleting Raptor increases G-CSF levels.": [
    0.3809565007686615,
    0.5946363210678101,
    0.024407191202044487
  ],
  "Here, integrating human tumour genomics and syngeneic mammary tumour models, we demonstrate that mTOR signalling in cancer cells dictates a mammary tumour's ability to stimulate MDSC accumulation through regulating G-CSF.||Deleting Raptor increases G-CSF levels.": [
    0.4366883635520935,
    0.5588594079017639,
    0.0044521763920784
  ],
  "Inhibiting this pathway or its activators (for example, FGFR) impairs tumour progression, which is partially rescued by restoring MDSCs or G-CSF.||Deleting Raptor increases G-CSF levels.": [
    0.24395354092121124,
    0.7484208941459656,
    0.0076255956664681435
  ],
  "Tumour-initiating cells (TICs) exhibit elevated G-CSF.||Deleting Raptor increases G-CSF levels.": [
    0.2526938021183014,
    0.6800077557563782,
    0.06729841977357864
  ],
  "MDSCs reciprocally increase TIC frequency through activating Notch in tumour cells, forming a feedforward loop.||Deleting Raptor increases G-CSF levels.": [
    0.4783948063850403,
    0.48910343647003174,
    0.03250173106789589
  ],
  "Analyses of primary breast cancers and patient-derived xenografts corroborate these mechanisms in patients.||Deleting Raptor increases G-CSF levels.": [
    0.2762058675289154,
    0.6665523052215576,
    0.057241834700107574
  ],
  "These findings establish a non-canonical oncogenic role of mTOR signalling in recruiting pro-tumorigenic MDSCs and show how defined cancer subsets may evolve to promote and depend on a distinct immune microenvironment.||Deleting Raptor increases G-CSF levels.": [
    0.27351143956184387,
    0.6919713616371155,
    0.034517209976911545
  ],
  "Myeloid-derived suppressor cells (MDSCs) play critical roles in primary and metastatic cancer progression.||G-CSF increases the expansion and infiltration of MDSCs into tumors.": [
    0.05424505099654198,
    0.942359983921051,
    0.0033949294593185186
  ],
  "MDSC regulation is widely variable even among patients harbouring the same type of malignancy, and the mechanisms governing such heterogeneity are largely unknown.||G-CSF increases the expansion and infiltration of MDSCs into tumors.": [
    0.19595834612846375,
    0.8005902767181396,
    0.0034514288417994976
  ],
  "Here, integrating human tumour genomics and syngeneic mammary tumour models, we demonstrate that mTOR signalling in cancer cells dictates a mammary tumour's ability to stimulate MDSC accumulation through regulating G-CSF.||G-CSF increases the expansion and infiltration of MDSCs into tumors.": [
    0.005669105798006058,
    0.4473075568675995,
    0.5470232963562012
  ],
  "Inhibiting this pathway or its activators (for example, FGFR) impairs tumour progression, which is partially rescued by restoring MDSCs or G-CSF.||G-CSF increases the expansion and infiltration of MDSCs into tumors.": [
    0.0018883568700402975,
    0.9706326127052307,
    0.027478989213705063
  ],
  "Tumour-initiating cells (TICs) exhibit elevated G-CSF.||G-CSF increases the expansion and infiltration of MDSCs into tumors.": [
    0.061832789331674576,
    0.9127388000488281,
    0.02542848140001297
  ],
  "MDSCs reciprocally increase TIC frequency through activating Notch in tumour cells, forming a feedforward loop.||G-CSF increases the expansion and infiltration of MDSCs into tumors.": [
    0.06113721430301666,
    0.9240109920501709,
    0.014851842075586319
  ],
  "Analyses of primary breast cancers and patient-derived xenografts corroborate these mechanisms in patients.||G-CSF increases the expansion and infiltration of MDSCs into tumors.": [
    0.08089053630828857,
    0.9086623191833496,
    0.01044717337936163
  ],
  "These findings establish a non-canonical oncogenic role of mTOR signalling in recruiting pro-tumorigenic MDSCs and show how defined cancer subsets may evolve to promote and depend on a distinct immune microenvironment.||G-CSF increases the expansion and infiltration of MDSCs into tumors.": [
    0.03257085010409355,
    0.9414336681365967,
    0.025995442643761635
  ],
  "Myeloid-derived suppressor cells (MDSCs) play critical roles in primary and metastatic cancer progression.||Deleting Raptor reduces G-CSF levels.": [
    0.24245420098304749,
    0.7527137398719788,
    0.004831998609006405
  ],
  "MDSC regulation is widely variable even among patients harbouring the same type of malignancy, and the mechanisms governing such heterogeneity are largely unknown.||Deleting Raptor reduces G-CSF levels.": [
    0.31159651279449463,
    0.6480031609535217,
    0.04040038585662842
  ],
  "Here, integrating human tumour genomics and syngeneic mammary tumour models, we demonstrate that mTOR signalling in cancer cells dictates a mammary tumour's ability to stimulate MDSC accumulation through regulating G-CSF.||Deleting Raptor reduces G-CSF levels.": [
    0.1685255467891693,
    0.828330397605896,
    0.0031440858729183674
  ],
  "Inhibiting this pathway or its activators (for example, FGFR) impairs tumour progression, which is partially rescued by restoring MDSCs or G-CSF.||Deleting Raptor reduces G-CSF levels.": [
    0.19225752353668213,
    0.7953292727470398,
    0.012413266114890575
  ],
  "Tumour-initiating cells (TICs) exhibit elevated G-CSF.||Deleting Raptor reduces G-CSF levels.": [
    0.13835303485393524,
    0.8588707447052002,
    0.002776139182969928
  ],
  "MDSCs reciprocally increase TIC frequency through activating Notch in tumour cells, forming a feedforward loop.||Deleting Raptor reduces G-CSF levels.": [
    0.36762404441833496,
    0.5671674013137817,
    0.06520852446556091
  ],
  "Analyses of primary breast cancers and patient-derived xenografts corroborate these mechanisms in patients.||Deleting Raptor reduces G-CSF levels.": [
    0.2770150303840637,
    0.63259357213974,
    0.0903913602232933
  ],
  "These findings establish a non-canonical oncogenic role of mTOR signalling in recruiting pro-tumorigenic MDSCs and show how defined cancer subsets may evolve to promote and depend on a distinct immune microenvironment.||Deleting Raptor reduces G-CSF levels.": [
    0.24214716255664825,
    0.7006099224090576,
    0.057242944836616516
  ],
  "Cancers develop in complex tissue environments, which they depend on for sustained growth, invasion and metastasis.||Cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments": [
    0.007082990370690823,
    0.6746492981910706,
    0.31826773285865784
  ],
  "Unlike tumor cells, stromal cell types within the tumor microenvironment (TME) are genetically stable and thus represent an attractive therapeutic target with reduced risk of resistance and tumor recurrence.||Cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments": [
    0.5282456278800964,
    0.3333086669445038,
    0.13844574987888336
  ],
  "However, specifically disrupting the pro-tumorigenic TME is a challenging undertaking, as the TME has diverse capacities to induce both beneficial and adverse consequences for tumorigenesis.||Cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments": [
    0.08615680038928986,
    0.5813694596290588,
    0.3324737846851349
  ],
  "Furthermore, many studies have shown that the microenvironment is capable of normalizing tumor cells, suggesting that re-education of stromal cells, rather than targeted ablation per se, may be an effective strategy for treating cancer.||Cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments": [
    0.7447453141212463,
    0.22624969482421875,
    0.029005005955696106
  ],
  "Here we discuss the paradoxical roles of the TME during specific stages of cancer progression and metastasis, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects.||Cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments": [
    0.1878720223903656,
    0.5646971464157104,
    0.24743083119392395
  ],
  "Cancers develop in complex tissue environments, which they depend on for sustained growth, invasion and metastasis.||Cancer-associated fibroblasts (CAFs) have no known interaction with cancer cells in the formation and activation of CAFs.": [
    0.9602460861206055,
    0.037557315081357956,
    0.0021965736523270607
  ],
  "Unlike tumor cells, stromal cell types within the tumor microenvironment (TME) are genetically stable and thus represent an attractive therapeutic target with reduced risk of resistance and tumor recurrence.||Cancer-associated fibroblasts (CAFs) have no known interaction with cancer cells in the formation and activation of CAFs.": [
    0.6324669718742371,
    0.3500050902366638,
    0.017527934163808823
  ],
  "However, specifically disrupting the pro-tumorigenic TME is a challenging undertaking, as the TME has diverse capacities to induce both beneficial and adverse consequences for tumorigenesis.||Cancer-associated fibroblasts (CAFs) have no known interaction with cancer cells in the formation and activation of CAFs.": [
    0.9588742852210999,
    0.037875205278396606,
    0.0032505381386727095
  ],
  "Furthermore, many studies have shown that the microenvironment is capable of normalizing tumor cells, suggesting that re-education of stromal cells, rather than targeted ablation per se, may be an effective strategy for treating cancer.||Cancer-associated fibroblasts (CAFs) have no known interaction with cancer cells in the formation and activation of CAFs.": [
    0.9777650237083435,
    0.020631486549973488,
    0.0016035394510254264
  ],
  "Here we discuss the paradoxical roles of the TME during specific stages of cancer progression and metastasis, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects.||Cancer-associated fibroblasts (CAFs) have no known interaction with cancer cells in the formation and activation of CAFs.": [
    0.9493727087974548,
    0.04778406023979187,
    0.0028432284016162157
  ],
  "Cancers develop in complex tissue environments, which they depend on for sustained growth, invasion and metastasis.||Cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs.": [
    0.04841294139623642,
    0.936316967010498,
    0.01527009904384613
  ],
  "Unlike tumor cells, stromal cell types within the tumor microenvironment (TME) are genetically stable and thus represent an attractive therapeutic target with reduced risk of resistance and tumor recurrence.||Cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs.": [
    0.6538968682289124,
    0.3263247311115265,
    0.01977841556072235
  ],
  "However, specifically disrupting the pro-tumorigenic TME is a challenging undertaking, as the TME has diverse capacities to induce both beneficial and adverse consequences for tumorigenesis.||Cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs.": [
    0.2954237461090088,
    0.40523767471313477,
    0.29933854937553406
  ],
  "Furthermore, many studies have shown that the microenvironment is capable of normalizing tumor cells, suggesting that re-education of stromal cells, rather than targeted ablation per se, may be an effective strategy for treating cancer.||Cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs.": [
    0.09827648848295212,
    0.8885053396224976,
    0.013218213804066181
  ],
  "Here we discuss the paradoxical roles of the TME during specific stages of cancer progression and metastasis, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects.||Cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs.": [
    0.40475335717201233,
    0.4540221691131592,
    0.1412244588136673
  ],
  "In the mammalian model of sex determination, embryos are considered to be sexually indifferent until the transient action of a sex-determining gene initiates gonadal differentiation.||Cell autonomous sex determination in somatic cells occurs in Galliformes.": [
    0.19278666377067566,
    0.7297748923301697,
    0.07743840664625168
  ],
  "Although this model is thought to apply to all vertebrates, this has yet to be established.||Cell autonomous sex determination in somatic cells occurs in Galliformes.": [
    0.25130850076675415,
    0.6673681139945984,
    0.08132339268922806
  ],
  "Here we have examined three lateral gynandromorph chickens (a rare, naturally occurring phenomenon in which one side of the animal appears male and the other female) to investigate the sex-determining mechanism in birds.||Cell autonomous sex determination in somatic cells occurs in Galliformes.": [
    0.16059494018554688,
    0.8048588037490845,
    0.03454623371362686
  ],
  "These studies demonstrated that gynandromorph birds are genuine male:female chimaeras, and indicated that male and female avian somatic cells may have an inherent sex identity.||Cell autonomous sex determination in somatic cells occurs in Galliformes.": [
    0.0730806514620781,
    0.9026015400886536,
    0.024317873641848564
  ],
  "To test this hypothesis, we transplanted presumptive mesoderm between embryos of reciprocal sexes to generate embryos containing male:female chimaeric gonads.||Cell autonomous sex determination in somatic cells occurs in Galliformes.": [
    0.44505661725997925,
    0.46487149596214294,
    0.09007196128368378
  ],
  "In contrast to the outcome for mammalian mixed-sex chimaeras, in chicken mixed-sex chimaeras the donor cells were excluded from the functional structures of the host gonad.||Cell autonomous sex determination in somatic cells occurs in Galliformes.": [
    0.3697867691516876,
    0.43627461791038513,
    0.19393858313560486
  ],
  "In an example where female tissue was transplanted into a male host, donor cells contributing to the developing testis retained a female identity and expressed a marker of female function.||Cell autonomous sex determination in somatic cells occurs in Galliformes.": [
    0.11686767637729645,
    0.8241084218025208,
    0.05902385339140892
  ],
  "Our study demonstrates that avian somatic cells possess an inherent sex identity and that, in birds, sexual differentiation is substantively cell autonomous.||Cell autonomous sex determination in somatic cells occurs in Galliformes.": [
    0.032744478434324265,
    0.9463989734649658,
    0.020856522023677826
  ],
  "In the mammalian model of sex determination, embryos are considered to be sexually indifferent until the transient action of a sex-determining gene initiates gonadal differentiation.||Cell autonomous sex determination in somatic cells does not occur in Galliformes.": [
    0.5162359476089478,
    0.4496993124485016,
    0.03406473621726036
  ],
  "Although this model is thought to apply to all vertebrates, this has yet to be established.||Cell autonomous sex determination in somatic cells does not occur in Galliformes.": [
    0.5652143359184265,
    0.413519948720932,
    0.02126569300889969
  ],
  "Here we have examined three lateral gynandromorph chickens (a rare, naturally occurring phenomenon in which one side of the animal appears male and the other female) to investigate the sex-determining mechanism in birds.||Cell autonomous sex determination in somatic cells does not occur in Galliformes.": [
    0.701396107673645,
    0.28166747093200684,
    0.016936367377638817
  ],
  "These studies demonstrated that gynandromorph birds are genuine male:female chimaeras, and indicated that male and female avian somatic cells may have an inherent sex identity.||Cell autonomous sex determination in somatic cells does not occur in Galliformes.": [
    0.36801737546920776,
    0.623153567314148,
    0.008829033933579922
  ],
  "To test this hypothesis, we transplanted presumptive mesoderm between embryos of reciprocal sexes to generate embryos containing male:female chimaeric gonads.||Cell autonomous sex determination in somatic cells does not occur in Galliformes.": [
    0.700859546661377,
    0.27301591634750366,
    0.026124607771635056
  ],
  "In contrast to the outcome for mammalian mixed-sex chimaeras, in chicken mixed-sex chimaeras the donor cells were excluded from the functional structures of the host gonad.||Cell autonomous sex determination in somatic cells does not occur in Galliformes.": [
    0.22054198384284973,
    0.3809688091278076,
    0.39848920702934265
  ],
  "In an example where female tissue was transplanted into a male host, donor cells contributing to the developing testis retained a female identity and expressed a marker of female function.||Cell autonomous sex determination in somatic cells does not occur in Galliformes.": [
    0.7853294610977173,
    0.20301075279712677,
    0.011659777723252773
  ],
  "Our study demonstrates that avian somatic cells possess an inherent sex identity and that, in birds, sexual differentiation is substantively cell autonomous.||Cell autonomous sex determination in somatic cells does not occur in Galliformes.": [
    0.13352231681346893,
    0.8600602746009827,
    0.006417378783226013
  ],
  "In the mammalian model of sex determination, embryos are considered to be sexually indifferent until the transient action of a sex-determining gene initiates gonadal differentiation.||Cell autonomous sex determination in somatic cells occurs in Passeriformes.": [
    0.08133961260318756,
    0.8742475509643555,
    0.044412799179553986
  ],
  "Although this model is thought to apply to all vertebrates, this has yet to be established.||Cell autonomous sex determination in somatic cells occurs in Passeriformes.": [
    0.26517757773399353,
    0.6839090585708618,
    0.05091334879398346
  ],
  "Here we have examined three lateral gynandromorph chickens (a rare, naturally occurring phenomenon in which one side of the animal appears male and the other female) to investigate the sex-determining mechanism in birds.||Cell autonomous sex determination in somatic cells occurs in Passeriformes.": [
    0.08715525269508362,
    0.9012686014175415,
    0.011576169170439243
  ],
  "These studies demonstrated that gynandromorph birds are genuine male:female chimaeras, and indicated that male and female avian somatic cells may have an inherent sex identity.||Cell autonomous sex determination in somatic cells occurs in Passeriformes.": [
    0.07852563261985779,
    0.9103460907936096,
    0.011128291487693787
  ],
  "To test this hypothesis, we transplanted presumptive mesoderm between embryos of reciprocal sexes to generate embryos containing male:female chimaeric gonads.||Cell autonomous sex determination in somatic cells occurs in Passeriformes.": [
    0.46718502044677734,
    0.47081178426742554,
    0.06200314685702324
  ],
  "In contrast to the outcome for mammalian mixed-sex chimaeras, in chicken mixed-sex chimaeras the donor cells were excluded from the functional structures of the host gonad.||Cell autonomous sex determination in somatic cells occurs in Passeriformes.": [
    0.3846781551837921,
    0.4928585886955261,
    0.12246321141719818
  ],
  "In an example where female tissue was transplanted into a male host, donor cells contributing to the developing testis retained a female identity and expressed a marker of female function.||Cell autonomous sex determination in somatic cells occurs in Passeriformes.": [
    0.1795482188463211,
    0.7717136740684509,
    0.04873806983232498
  ],
  "Our study demonstrates that avian somatic cells possess an inherent sex identity and that, in birds, sexual differentiation is substantively cell autonomous.||Cell autonomous sex determination in somatic cells occurs in Passeriformes.": [
    0.013744105584919453,
    0.975028932094574,
    0.011226890608668327
  ],
  "In the mammalian model of sex determination, embryos are considered to be sexually indifferent until the transient action of a sex-determining gene initiates gonadal differentiation.||DMRT1 is a sex-determining gene that is epigenetically regulated by the MHM region.": [
    0.004301890265196562,
    0.9928580522537231,
    0.0028400965966284275
  ],
  "Although this model is thought to apply to all vertebrates, this has yet to be established.||DMRT1 is a sex-determining gene that is epigenetically regulated by the MHM region.": [
    0.13904248178005219,
    0.8345857262611389,
    0.0263717882335186
  ],
  "Here we have examined three lateral gynandromorph chickens (a rare, naturally occurring phenomenon in which one side of the animal appears male and the other female) to investigate the sex-determining mechanism in birds.||DMRT1 is a sex-determining gene that is epigenetically regulated by the MHM region.": [
    0.021578095853328705,
    0.9723854660987854,
    0.0060364860109984875
  ],
  "These studies demonstrated that gynandromorph birds are genuine male:female chimaeras, and indicated that male and female avian somatic cells may have an inherent sex identity.||DMRT1 is a sex-determining gene that is epigenetically regulated by the MHM region.": [
    0.016998538747429848,
    0.9729413390159607,
    0.010060121305286884
  ],
  "To test this hypothesis, we transplanted presumptive mesoderm between embryos of reciprocal sexes to generate embryos containing male:female chimaeric gonads.||DMRT1 is a sex-determining gene that is epigenetically regulated by the MHM region.": [
    0.08599773049354553,
    0.8924997448921204,
    0.021502507850527763
  ],
  "In contrast to the outcome for mammalian mixed-sex chimaeras, in chicken mixed-sex chimaeras the donor cells were excluded from the functional structures of the host gonad.||DMRT1 is a sex-determining gene that is epigenetically regulated by the MHM region.": [
    0.20653095841407776,
    0.7738855481147766,
    0.019583484157919884
  ],
  "In an example where female tissue was transplanted into a male host, donor cells contributing to the developing testis retained a female identity and expressed a marker of female function.||DMRT1 is a sex-determining gene that is epigenetically regulated by the MHM region.": [
    0.006947780027985573,
    0.9828760027885437,
    0.010176184587180614
  ],
  "Our study demonstrates that avian somatic cells possess an inherent sex identity and that, in birds, sexual differentiation is substantively cell autonomous.||DMRT1 is a sex-determining gene that is epigenetically regulated by the MHM region.": [
    0.011559193953871727,
    0.9797908663749695,
    0.008649867959320545
  ],
  "The interest in brown adipose tissue (BAT) as a target to combat metabolic disease has recently been renewed with the discovery of functional BAT in humans.||Chenodeoxycholic acid treatment decreases brown adipose tissue activity.": [
    0.6901428699493408,
    0.30521824955940247,
    0.004638855345547199
  ],
  "In rodents, BAT can be activated by bile acids, which activate type 2 iodothyronine deiodinase (D2) in BAT via the G-coupled protein receptor TGR5, resulting in increased oxygen consumption and energy expenditure.||Chenodeoxycholic acid treatment decreases brown adipose tissue activity.": [
    0.5145654678344727,
    0.47251829504966736,
    0.01291617751121521
  ],
  "Here we examined the effects of oral supplementation of the bile acid chenodeoxycholic acid (CDCA) on human BAT activity.||Chenodeoxycholic acid treatment decreases brown adipose tissue activity.": [
    0.4042833149433136,
    0.5707007646560669,
    0.025015980005264282
  ],
  "Treatment of 12 healthy female subjects with CDCA for 2 days resulted in increased BAT activity.||Chenodeoxycholic acid treatment decreases brown adipose tissue activity.": [
    0.8992511034011841,
    0.09128858894109726,
    0.00946034025400877
  ],
  "Whole-body energy expenditure was also increased upon CDCA treatment.||Chenodeoxycholic acid treatment decreases brown adipose tissue activity.": [
    0.6253623366355896,
    0.33776089549064636,
    0.03687681630253792
  ],
  "In vitro treatment of primary human brown adipocytes derived with CDCA or specific TGR5 agonists increased mitochondrial uncoupling and D2 expression, an effect that was absent in human primary white adipocytes.||Chenodeoxycholic acid treatment decreases brown adipose tissue activity.": [
    0.9940018057823181,
    0.004634839482605457,
    0.0013633916387334466
  ],
  "These findings identify bile acids as a target to activate BAT in humans.||Chenodeoxycholic acid treatment decreases brown adipose tissue activity.": [
    0.6151811480522156,
    0.3754630982875824,
    0.009355760179460049
  ],
  "The interest in brown adipose tissue (BAT) as a target to combat metabolic disease has recently been renewed with the discovery of functional BAT in humans.||Chenodeoxycholic acid treatment increases brown adipose tissue activity.": [
    0.005224829073995352,
    0.9889784455299377,
    0.005796762648969889
  ],
  "In rodents, BAT can be activated by bile acids, which activate type 2 iodothyronine deiodinase (D2) in BAT via the G-coupled protein receptor TGR5, resulting in increased oxygen consumption and energy expenditure.||Chenodeoxycholic acid treatment increases brown adipose tissue activity.": [
    0.44489797949790955,
    0.538263738155365,
    0.016838232055306435
  ],
  "Here we examined the effects of oral supplementation of the bile acid chenodeoxycholic acid (CDCA) on human BAT activity.||Chenodeoxycholic acid treatment increases brown adipose tissue activity.": [
    0.3796091377735138,
    0.6081094145774841,
    0.012281399220228195
  ],
  "Treatment of 12 healthy female subjects with CDCA for 2 days resulted in increased BAT activity.||Chenodeoxycholic acid treatment increases brown adipose tissue activity.": [
    0.31374362111091614,
    0.27476638555526733,
    0.41148999333381653
  ],
  "Whole-body energy expenditure was also increased upon CDCA treatment.||Chenodeoxycholic acid treatment increases brown adipose tissue activity.": [
    0.056349679827690125,
    0.8793988823890686,
    0.06425147503614426
  ],
  "In vitro treatment of primary human brown adipocytes derived with CDCA or specific TGR5 agonists increased mitochondrial uncoupling and D2 expression, an effect that was absent in human primary white adipocytes.||Chenodeoxycholic acid treatment increases brown adipose tissue activity.": [
    0.011982440017163754,
    0.25871846079826355,
    0.7292991280555725
  ],
  "These findings identify bile acids as a target to activate BAT in humans.||Chenodeoxycholic acid treatment increases brown adipose tissue activity.": [
    0.22436249256134033,
    0.7371985912322998,
    0.038438841700553894
  ],
  "The interest in brown adipose tissue (BAT) as a target to combat metabolic disease has recently been renewed with the discovery of functional BAT in humans.||Chenodeosycholic acid treatment increases whole-body energy expenditure.": [
    0.01814926043152809,
    0.9755310416221619,
    0.006319679785519838
  ],
  "In rodents, BAT can be activated by bile acids, which activate type 2 iodothyronine deiodinase (D2) in BAT via the G-coupled protein receptor TGR5, resulting in increased oxygen consumption and energy expenditure.||Chenodeosycholic acid treatment increases whole-body energy expenditure.": [
    0.16219061613082886,
    0.5282540917396545,
    0.309555321931839
  ],
  "Here we examined the effects of oral supplementation of the bile acid chenodeoxycholic acid (CDCA) on human BAT activity.||Chenodeosycholic acid treatment increases whole-body energy expenditure.": [
    0.03914748132228851,
    0.9466812610626221,
    0.014171205461025238
  ],
  "Treatment of 12 healthy female subjects with CDCA for 2 days resulted in increased BAT activity.||Chenodeosycholic acid treatment increases whole-body energy expenditure.": [
    0.006167109124362469,
    0.2714309096336365,
    0.7224019765853882
  ],
  "Whole-body energy expenditure was also increased upon CDCA treatment.||Chenodeosycholic acid treatment increases whole-body energy expenditure.": [
    0.01197442039847374,
    0.3398459851741791,
    0.6481795907020569
  ],
  "In vitro treatment of primary human brown adipocytes derived with CDCA or specific TGR5 agonists increased mitochondrial uncoupling and D2 expression, an effect that was absent in human primary white adipocytes.||Chenodeosycholic acid treatment increases whole-body energy expenditure.": [
    0.06464335322380066,
    0.8458579182624817,
    0.08949870616197586
  ],
  "These findings identify bile acids as a target to activate BAT in humans.||Chenodeosycholic acid treatment increases whole-body energy expenditure.": [
    0.048049427568912506,
    0.8945822715759277,
    0.05736831575632095
  ],
  "The interest in brown adipose tissue (BAT) as a target to combat metabolic disease has recently been renewed with the discovery of functional BAT in humans.||Chenodeosycholic acid treatment reduces whole-body energy expenditure.": [
    0.015413261950016022,
    0.9764066338539124,
    0.008180072531104088
  ],
  "In rodents, BAT can be activated by bile acids, which activate type 2 iodothyronine deiodinase (D2) in BAT via the G-coupled protein receptor TGR5, resulting in increased oxygen consumption and energy expenditure.||Chenodeosycholic acid treatment reduces whole-body energy expenditure.": [
    0.507854163646698,
    0.48884353041648865,
    0.0033023396972566843
  ],
  "Here we examined the effects of oral supplementation of the bile acid chenodeoxycholic acid (CDCA) on human BAT activity.||Chenodeosycholic acid treatment reduces whole-body energy expenditure.": [
    0.019157763570547104,
    0.9520623683929443,
    0.028779862448573112
  ],
  "Treatment of 12 healthy female subjects with CDCA for 2 days resulted in increased BAT activity.||Chenodeosycholic acid treatment reduces whole-body energy expenditure.": [
    0.621708869934082,
    0.25434499979019165,
    0.12394620478153229
  ],
  "Whole-body energy expenditure was also increased upon CDCA treatment.||Chenodeosycholic acid treatment reduces whole-body energy expenditure.": [
    0.9966933727264404,
    0.002292138524353504,
    0.0010144845582544804
  ],
  "In vitro treatment of primary human brown adipocytes derived with CDCA or specific TGR5 agonists increased mitochondrial uncoupling and D2 expression, an effect that was absent in human primary white adipocytes.||Chenodeosycholic acid treatment reduces whole-body energy expenditure.": [
    0.05252879485487938,
    0.9073017239570618,
    0.04016948118805885
  ],
  "These findings identify bile acids as a target to activate BAT in humans.||Chenodeosycholic acid treatment reduces whole-body energy expenditure.": [
    0.05643640458583832,
    0.9174585342407227,
    0.02610500529408455
  ],
  "IMPORTANCE Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence.   \n||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.001406730618327856,
    0.9965069890022278,
    0.0020862596575170755
  ],
  "OBJECTIVE To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers.   \n||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.002245415234938264,
    0.9969403743743896,
    0.0008142862352542579
  ],
  "DESIGN, SETTING, AND PARTICIPANTS Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites.||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.007582413963973522,
    0.9797108769416809,
    0.012706748209893703
  ],
  "Five hundred six adult (\u226518 years) cigarette smokers were randomly assigned and 315 (62%) completed the study.   \n||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.011256812140345573,
    0.9707886576652527,
    0.017954587936401367
  ],
  "INTERVENTIONS Twelve weeks of varenicline and bupropion SR or varenicline and placebo.   \n||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.0039031547494232655,
    0.9524187445640564,
    0.043678104877471924
  ],
  "MAIN OUTCOMES AND MEASURES Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date) abstinence and 7-day point-prevalence (no smoking past 7 days) abstinence.||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.006969342473894358,
    0.9785822629928589,
    0.014448320493102074
  ],
  "Secondary outcomes were prolonged and point-prevalence smoking abstinence rates at weeks 26 and 52.||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.016368336975574493,
    0.9237345457077026,
    0.059897106140851974
  ],
  "Outcomes were biochemically confirmed.   \n||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.01564391702413559,
    0.8534143567085266,
    0.13094179332256317
  ],
  "RESULTS At 12 weeks, 53.0% of the combination therapy group achieved prolonged smoking abstinence and 56.2% achieved 7-day point-prevalence smoking abstinence compared with 43.2% and 48.6% in varenicline monotherapy (odds ratio [OR], 1.49; 95% CI, 1.05-2.12; P = .03 and OR, 1.36; 95% CI, 0.95-1.93; P = .09, respectively).||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.00522830942645669,
    0.45094048976898193,
    0.5438311696052551
  ],
  "At 26 weeks, 36.6% of the combination therapy group achieved prolonged and 38.2% achieved 7-day point-prevalence smoking abstinence compared with 27.6% and 31.9% in varenicline monotherapy (OR, 1.52; 95% CI, 1.04-2.22; P = .03 and OR, 1.32; 95% CI, 0.91-1.91; P = .14, respectively).||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.0660269558429718,
    0.7325534224510193,
    0.20141960680484772
  ],
  "At 52 weeks, 30.9% of the combination therapy group achieved prolonged and 36.6% achieved 7-day point-prevalence smoking abstinence compared with 24.5% and 29.2% in varenicline monotherapy (OR, 1.39; 95% CI, 0.93-2.07; P = .11 and OR, 1.40; 95% CI, 0.96-2.05; P = .08, respectively).||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.07562445849180222,
    0.8049737215042114,
    0.11940178275108337
  ],
  "Participants receiving combination therapy reported more anxiety (7.2% vs 3.1%; P = .04) and depressive symptoms (3.6% vs 0.8%; P = .03).   \n||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.2157125473022461,
    0.7796854972839355,
    0.004602030850946903
  ],
  "CONCLUSIONS AND RELEVANCE Among cigarette smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased prolonged abstinence but not 7-day point prevalence at 12 and 26 weeks.||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.003610791638493538,
    0.18429946899414062,
    0.8120898008346558
  ],
  "Neither outcome was significantly different at 52 weeks.||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.3443215787410736,
    0.635097086429596,
    0.020581362769007683
  ],
  "Further research is required to determine the role of combination therapy in smoking cessation.   \n||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.04554750397801399,
    0.9522579908370972,
    0.0021945007611066103
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: http://clinicaltrials.gov/show/NCT00935818.||Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.": [
    0.010030796751379967,
    0.8823971152305603,
    0.10757210850715637
  ],
  "IMPORTANCE Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence.   \n||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.0632663145661354,
    0.9343146085739136,
    0.0024191036354750395
  ],
  "OBJECTIVE To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers.   \n||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.007823951542377472,
    0.9913358688354492,
    0.0008401390514336526
  ],
  "DESIGN, SETTING, AND PARTICIPANTS Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites.||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.016428807750344276,
    0.979158341884613,
    0.004412864800542593
  ],
  "Five hundred six adult (\u226518 years) cigarette smokers were randomly assigned and 315 (62%) completed the study.   \n||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.016959168016910553,
    0.97504061460495,
    0.008000212721526623
  ],
  "INTERVENTIONS Twelve weeks of varenicline and bupropion SR or varenicline and placebo.   \n||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.07135380059480667,
    0.9222782850265503,
    0.006367966067045927
  ],
  "MAIN OUTCOMES AND MEASURES Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date) abstinence and 7-day point-prevalence (no smoking past 7 days) abstinence.||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.022800017148256302,
    0.9715626835823059,
    0.005637351889163256
  ],
  "Secondary outcomes were prolonged and point-prevalence smoking abstinence rates at weeks 26 and 52.||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.017799589782953262,
    0.9758437871932983,
    0.006356618832796812
  ],
  "Outcomes were biochemically confirmed.   \n||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.010160821489989758,
    0.9779174327850342,
    0.011921700090169907
  ],
  "RESULTS At 12 weeks, 53.0% of the combination therapy group achieved prolonged smoking abstinence and 56.2% achieved 7-day point-prevalence smoking abstinence compared with 43.2% and 48.6% in varenicline monotherapy (odds ratio [OR], 1.49; 95% CI, 1.05-2.12; P = .03 and OR, 1.36; 95% CI, 0.95-1.93; P = .09, respectively).||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.3115532398223877,
    0.6772109270095825,
    0.011235849931836128
  ],
  "At 26 weeks, 36.6% of the combination therapy group achieved prolonged and 38.2% achieved 7-day point-prevalence smoking abstinence compared with 27.6% and 31.9% in varenicline monotherapy (OR, 1.52; 95% CI, 1.04-2.22; P = .03 and OR, 1.32; 95% CI, 0.91-1.91; P = .14, respectively).||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.17090503871440887,
    0.36016878485679626,
    0.46892616152763367
  ],
  "At 52 weeks, 30.9% of the combination therapy group achieved prolonged and 36.6% achieved 7-day point-prevalence smoking abstinence compared with 24.5% and 29.2% in varenicline monotherapy (OR, 1.39; 95% CI, 0.93-2.07; P = .11 and OR, 1.40; 95% CI, 0.96-2.05; P = .08, respectively).||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.4199487864971161,
    0.48921382427215576,
    0.09083735197782516
  ],
  "Participants receiving combination therapy reported more anxiety (7.2% vs 3.1%; P = .04) and depressive symptoms (3.6% vs 0.8%; P = .03).   \n||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.015041975304484367,
    0.9812657237052917,
    0.0036923198495060205
  ],
  "CONCLUSIONS AND RELEVANCE Among cigarette smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased prolonged abstinence but not 7-day point prevalence at 12 and 26 weeks.||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.718254029750824,
    0.19876429438591003,
    0.0829816609621048
  ],
  "Neither outcome was significantly different at 52 weeks.||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.5117382407188416,
    0.48174166679382324,
    0.006520089227706194
  ],
  "Further research is required to determine the role of combination therapy in smoking cessation.   \n||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.09034615010023117,
    0.907170832157135,
    0.002483024960383773
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: http://clinicaltrials.gov/show/NCT00935818.||Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.01847180165350437,
    0.9532611966133118,
    0.028267009183764458
  ],
  "IMPORTANCE Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence.   \n||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.0017033226322382689,
    0.9973115921020508,
    0.000985112157650292
  ],
  "OBJECTIVE To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers.   \n||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.006630266550928354,
    0.9926648736000061,
    0.0007048273109830916
  ],
  "DESIGN, SETTING, AND PARTICIPANTS Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites.||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.010321115143597126,
    0.9873908162117004,
    0.002288037445396185
  ],
  "Five hundred six adult (\u226518 years) cigarette smokers were randomly assigned and 315 (62%) completed the study.   \n||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.02454550936818123,
    0.9724574089050293,
    0.002997106406837702
  ],
  "INTERVENTIONS Twelve weeks of varenicline and bupropion SR or varenicline and placebo.   \n||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.006639779079705477,
    0.990724503993988,
    0.002635674085468054
  ],
  "MAIN OUTCOMES AND MEASURES Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date) abstinence and 7-day point-prevalence (no smoking past 7 days) abstinence.||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.021905746310949326,
    0.9744611382484436,
    0.0036331014707684517
  ],
  "Secondary outcomes were prolonged and point-prevalence smoking abstinence rates at weeks 26 and 52.||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.005178516265004873,
    0.9891156554222107,
    0.005705852527171373
  ],
  "Outcomes were biochemically confirmed.   \n||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.025150246918201447,
    0.9360316395759583,
    0.03881809487938881
  ],
  "RESULTS At 12 weeks, 53.0% of the combination therapy group achieved prolonged smoking abstinence and 56.2% achieved 7-day point-prevalence smoking abstinence compared with 43.2% and 48.6% in varenicline monotherapy (odds ratio [OR], 1.49; 95% CI, 1.05-2.12; P = .03 and OR, 1.36; 95% CI, 0.95-1.93; P = .09, respectively).||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.41772258281707764,
    0.4673914909362793,
    0.11488599330186844
  ],
  "At 26 weeks, 36.6% of the combination therapy group achieved prolonged and 38.2% achieved 7-day point-prevalence smoking abstinence compared with 27.6% and 31.9% in varenicline monotherapy (OR, 1.52; 95% CI, 1.04-2.22; P = .03 and OR, 1.32; 95% CI, 0.91-1.91; P = .14, respectively).||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.6549887657165527,
    0.2892298400402069,
    0.05578140169382095
  ],
  "At 52 weeks, 30.9% of the combination therapy group achieved prolonged and 36.6% achieved 7-day point-prevalence smoking abstinence compared with 24.5% and 29.2% in varenicline monotherapy (OR, 1.39; 95% CI, 0.93-2.07; P = .11 and OR, 1.40; 95% CI, 0.96-2.05; P = .08, respectively).||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.38483214378356934,
    0.36331069469451904,
    0.25185713171958923
  ],
  "Participants receiving combination therapy reported more anxiety (7.2% vs 3.1%; P = .04) and depressive symptoms (3.6% vs 0.8%; P = .03).   \n||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.5673703551292419,
    0.4284106194972992,
    0.004219024907797575
  ],
  "CONCLUSIONS AND RELEVANCE Among cigarette smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased prolonged abstinence but not 7-day point prevalence at 12 and 26 weeks.||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.28085198998451233,
    0.6409184336662292,
    0.07822953909635544
  ],
  "Neither outcome was significantly different at 52 weeks.||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.7039623260498047,
    0.2916540503501892,
    0.004383549559861422
  ],
  "Further research is required to determine the role of combination therapy in smoking cessation.   \n||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.12575165927410126,
    0.8722862601280212,
    0.0019620852544903755
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: http://clinicaltrials.gov/show/NCT00935818.||Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.": [
    0.030269762501120567,
    0.9188888669013977,
    0.05084139108657837
  ],
  "IMPORTANCE Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence.   \n||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.06784624606370926,
    0.9293641448020935,
    0.0027896305546164513
  ],
  "OBJECTIVE To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers.   \n||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.006467039696872234,
    0.9926503300666809,
    0.0008826207485981286
  ],
  "DESIGN, SETTING, AND PARTICIPANTS Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites.||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.011516083963215351,
    0.9854298830032349,
    0.003054035361856222
  ],
  "Five hundred six adult (\u226518 years) cigarette smokers were randomly assigned and 315 (62%) completed the study.   \n||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.01921195536851883,
    0.9700114727020264,
    0.010776587761938572
  ],
  "INTERVENTIONS Twelve weeks of varenicline and bupropion SR or varenicline and placebo.   \n||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.06175940856337547,
    0.9310117959976196,
    0.007228838745504618
  ],
  "MAIN OUTCOMES AND MEASURES Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date) abstinence and 7-day point-prevalence (no smoking past 7 days) abstinence.||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.007403988856822252,
    0.9900426864624023,
    0.0025533142033964396
  ],
  "Secondary outcomes were prolonged and point-prevalence smoking abstinence rates at weeks 26 and 52.||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.03289724513888359,
    0.9260050058364868,
    0.04109780117869377
  ],
  "Outcomes were biochemically confirmed.   \n||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.009912543930113316,
    0.9801762104034424,
    0.009911201894283295
  ],
  "RESULTS At 12 weeks, 53.0% of the combination therapy group achieved prolonged smoking abstinence and 56.2% achieved 7-day point-prevalence smoking abstinence compared with 43.2% and 48.6% in varenicline monotherapy (odds ratio [OR], 1.49; 95% CI, 1.05-2.12; P = .03 and OR, 1.36; 95% CI, 0.95-1.93; P = .09, respectively).||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.28672224283218384,
    0.42141881585121155,
    0.2918589115142822
  ],
  "At 26 weeks, 36.6% of the combination therapy group achieved prolonged and 38.2% achieved 7-day point-prevalence smoking abstinence compared with 27.6% and 31.9% in varenicline monotherapy (OR, 1.52; 95% CI, 1.04-2.22; P = .03 and OR, 1.32; 95% CI, 0.91-1.91; P = .14, respectively).||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.1622827798128128,
    0.7342960238456726,
    0.10342114418745041
  ],
  "At 52 weeks, 30.9% of the combination therapy group achieved prolonged and 36.6% achieved 7-day point-prevalence smoking abstinence compared with 24.5% and 29.2% in varenicline monotherapy (OR, 1.39; 95% CI, 0.93-2.07; P = .11 and OR, 1.40; 95% CI, 0.96-2.05; P = .08, respectively).||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.15459249913692474,
    0.7713485360145569,
    0.07405900955200195
  ],
  "Participants receiving combination therapy reported more anxiety (7.2% vs 3.1%; P = .04) and depressive symptoms (3.6% vs 0.8%; P = .03).   \n||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.01502419076859951,
    0.9788954257965088,
    0.006080443970859051
  ],
  "CONCLUSIONS AND RELEVANCE Among cigarette smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased prolonged abstinence but not 7-day point prevalence at 12 and 26 weeks.||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.5575750470161438,
    0.28944164514541626,
    0.15298330783843994
  ],
  "Neither outcome was significantly different at 52 weeks.||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.42432376742362976,
    0.5691502690315247,
    0.006525983102619648
  ],
  "Further research is required to determine the role of combination therapy in smoking cessation.   \n||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.07681789249181747,
    0.9206458330154419,
    0.0025362924207001925
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: http://clinicaltrials.gov/show/NCT00935818.||Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.": [
    0.017808610573410988,
    0.9475914239883423,
    0.03459995239973068
  ],
  "The non-enveloped bacilliform viruses are the second group of plant viruses known to possess a genome consisting of circular double-stranded DNA.||Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.": [
    0.07777880877256393,
    0.9094414710998535,
    0.012779741548001766
  ],
  "We have characterized the viral transcript and determined the complete sequence of the genome of Commelina mellow mottle virus (CoYMV), a member of this group.||Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.": [
    0.9228498339653015,
    0.06909886002540588,
    0.008051319047808647
  ],
  "Analysis of the viral transcript indicates that the virus encodes a single terminally-redundant genome-length plus 120 nucleotide transcript.||Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.": [
    0.8360224962234497,
    0.15753750503063202,
    0.006440005265176296
  ],
  "A fraction of the transcripts is polyadenylated, although the majority of the transcript is not polyadenylated.||Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.": [
    0.13594360649585724,
    0.7176907062530518,
    0.1463656723499298
  ],
  "Analysis of the genome sequence indicates that the genome is 7489 bp in size and that the transcribed strand contains three open reading frames capable of encoding proteins of 23, 15 and 216 kd.||Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.": [
    0.018574312329292297,
    0.7049081921577454,
    0.27651742100715637
  ],
  "The function of the 25 and 15 kd proteins is unknown.||Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.": [
    0.12599432468414307,
    0.7908716797828674,
    0.0831340104341507
  ],
  "Similarities between the 216 kd polypeptide and the cauliflower mosaic virus coat protein and protease/reverse transcriptase polyprotein suggest that the 216 kd polypeptide is a polyprotein that is proteolytically processed to yield the virion coat protein, a protease, and replicase (reverse transcriptase and ribonuclease H).||Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.": [
    0.3018423914909363,
    0.5808348059654236,
    0.11732282489538193
  ],
  "Each strand of the CoYMV genome is interrupted by site-specific discontinuities.||Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.": [
    0.13849130272865295,
    0.7538406252861023,
    0.10766805708408356
  ],
  "The locations of the 5'-ends of these discontinuities, and the presence and location of a region on the CoYMV transcript capable of annealing with the 3'-end of cytosolic initiator methionine tRNA are consistent with replication by reverse transcription.||Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.": [
    0.1418008655309677,
    0.7869688868522644,
    0.07123029977083206
  ],
  "We have demonstrated that a construct containing 1.3 CoYMV genomes is infective when introduced into Commelina diffusa, the host for CoYMV, using Agrobacterium-mediated infection.||Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.": [
    0.12463008612394333,
    0.8428748846054077,
    0.03249495103955269
  ],
  "The non-enveloped bacilliform viruses are the second group of plant viruses known to possess a genome consisting of circular double-stranded DNA.||Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.": [
    0.06463520228862762,
    0.9245879650115967,
    0.01077684573829174
  ],
  "We have characterized the viral transcript and determined the complete sequence of the genome of Commelina mellow mottle virus (CoYMV), a member of this group.||Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.": [
    0.8635664582252502,
    0.1262730062007904,
    0.010160515084862709
  ],
  "Analysis of the viral transcript indicates that the virus encodes a single terminally-redundant genome-length plus 120 nucleotide transcript.||Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.": [
    0.6416438817977905,
    0.30374664068222046,
    0.054609525948762894
  ],
  "A fraction of the transcripts is polyadenylated, although the majority of the transcript is not polyadenylated.||Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.": [
    0.10540755838155746,
    0.8593291640281677,
    0.035263314843177795
  ],
  "Analysis of the genome sequence indicates that the genome is 7489 bp in size and that the transcribed strand contains three open reading frames capable of encoding proteins of 23, 15 and 216 kd.||Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.": [
    0.7560489177703857,
    0.1902741938829422,
    0.05367681384086609
  ],
  "The function of the 25 and 15 kd proteins is unknown.||Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.": [
    0.3235373795032501,
    0.5226250886917114,
    0.15383756160736084
  ],
  "Similarities between the 216 kd polypeptide and the cauliflower mosaic virus coat protein and protease/reverse transcriptase polyprotein suggest that the 216 kd polypeptide is a polyprotein that is proteolytically processed to yield the virion coat protein, a protease, and replicase (reverse transcriptase and ribonuclease H).||Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.": [
    0.37412044405937195,
    0.580636203289032,
    0.04524337127804756
  ],
  "Each strand of the CoYMV genome is interrupted by site-specific discontinuities.||Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.": [
    0.023761894553899765,
    0.9532161355018616,
    0.02302190661430359
  ],
  "The locations of the 5'-ends of these discontinuities, and the presence and location of a region on the CoYMV transcript capable of annealing with the 3'-end of cytosolic initiator methionine tRNA are consistent with replication by reverse transcription.||Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.": [
    0.08358294516801834,
    0.903788149356842,
    0.012628943659365177
  ],
  "We have demonstrated that a construct containing 1.3 CoYMV genomes is infective when introduced into Commelina diffusa, the host for CoYMV, using Agrobacterium-mediated infection.||Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.": [
    0.6691526770591736,
    0.3192574977874756,
    0.01158978883177042
  ],
  "The non-enveloped bacilliform viruses are the second group of plant viruses known to possess a genome consisting of circular double-stranded DNA.||Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.": [
    0.05158519372344017,
    0.9407300353050232,
    0.007684832904487848
  ],
  "We have characterized the viral transcript and determined the complete sequence of the genome of Commelina mellow mottle virus (CoYMV), a member of this group.||Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.": [
    0.8664243817329407,
    0.12262497842311859,
    0.01095066498965025
  ],
  "Analysis of the viral transcript indicates that the virus encodes a single terminally-redundant genome-length plus 120 nucleotide transcript.||Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.": [
    0.46135082840919495,
    0.49003854393959045,
    0.0486106276512146
  ],
  "A fraction of the transcripts is polyadenylated, although the majority of the transcript is not polyadenylated.||Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.": [
    0.11089494079351425,
    0.8517700433731079,
    0.03733498975634575
  ],
  "Analysis of the genome sequence indicates that the genome is 7489 bp in size and that the transcribed strand contains three open reading frames capable of encoding proteins of 23, 15 and 216 kd.||Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.": [
    0.019776923581957817,
    0.8173472285270691,
    0.16287581622600555
  ],
  "The function of the 25 and 15 kd proteins is unknown.||Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.": [
    0.34967806935310364,
    0.481142520904541,
    0.16917948424816132
  ],
  "Similarities between the 216 kd polypeptide and the cauliflower mosaic virus coat protein and protease/reverse transcriptase polyprotein suggest that the 216 kd polypeptide is a polyprotein that is proteolytically processed to yield the virion coat protein, a protease, and replicase (reverse transcriptase and ribonuclease H).||Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.": [
    0.34394338726997375,
    0.6135510802268982,
    0.04250553622841835
  ],
  "Each strand of the CoYMV genome is interrupted by site-specific discontinuities.||Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.": [
    0.028453709557652473,
    0.945642352104187,
    0.025903914123773575
  ],
  "The locations of the 5'-ends of these discontinuities, and the presence and location of a region on the CoYMV transcript capable of annealing with the 3'-end of cytosolic initiator methionine tRNA are consistent with replication by reverse transcription.||Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.": [
    0.07165142148733139,
    0.9107500314712524,
    0.01759849116206169
  ],
  "We have demonstrated that a construct containing 1.3 CoYMV genomes is infective when introduced into Commelina diffusa, the host for CoYMV, using Agrobacterium-mediated infection.||Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.": [
    0.6717893481254578,
    0.3158618211746216,
    0.012348920106887817
  ],
  "Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in \u223c30% of patients with breast cancer.||DUSP4 decreases apoptosis.": [
    0.3113689720630646,
    0.5796504020690918,
    0.10898064821958542
  ],
  "However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR.||DUSP4 decreases apoptosis.": [
    0.12374523282051086,
    0.8544647693634033,
    0.021790022030472755
  ],
  "We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance.||DUSP4 decreases apoptosis.": [
    0.14852726459503174,
    0.7475606799125671,
    0.10391207039356232
  ],
  "Digital transcript counting was used to profile surgically resected breast cancers after NAC.||DUSP4 decreases apoptosis.": [
    0.19551724195480347,
    0.757321834564209,
    0.04716087132692337
  ],
  "Low concentrations of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status.||DUSP4 decreases apoptosis.": [
    0.7054805159568787,
    0.26153767108917236,
    0.03298178315162659
  ],
  "BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes.||DUSP4 decreases apoptosis.": [
    0.08384069800376892,
    0.8810954093933105,
    0.03506391495466232
  ],
  "DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy.||DUSP4 decreases apoptosis.": [
    0.8718480467796326,
    0.034312181174755096,
    0.09383981674909592
  ],
  "Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival.||DUSP4 decreases apoptosis.": [
    0.0737435594201088,
    0.8782188892364502,
    0.0480375662446022
  ],
  "Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts.||DUSP4 decreases apoptosis.": [
    0.17453086376190186,
    0.7235605120658875,
    0.10190864652395248
  ],
  "Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.||DUSP4 decreases apoptosis.": [
    0.5241327285766602,
    0.415986567735672,
    0.05988067761063576
  ],
  "Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in \u223c30% of patients with breast cancer.||DUSP4 downregulation deactivates the Ras-ERK pathway": [
    0.25010961294174194,
    0.7194305658340454,
    0.03045983798801899
  ],
  "However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR.||DUSP4 downregulation deactivates the Ras-ERK pathway": [
    0.3551177680492401,
    0.6253237724304199,
    0.019558535888791084
  ],
  "We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance.||DUSP4 downregulation deactivates the Ras-ERK pathway": [
    0.3438605070114136,
    0.6394157409667969,
    0.01672377437353134
  ],
  "Digital transcript counting was used to profile surgically resected breast cancers after NAC.||DUSP4 downregulation deactivates the Ras-ERK pathway": [
    0.39803439378738403,
    0.5832607746124268,
    0.01870482787489891
  ],
  "Low concentrations of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status.||DUSP4 downregulation deactivates the Ras-ERK pathway": [
    0.08563362061977386,
    0.9083429574966431,
    0.006023421883583069
  ],
  "BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes.||DUSP4 downregulation deactivates the Ras-ERK pathway": [
    0.9385928511619568,
    0.05795929208397865,
    0.0034479110036045313
  ],
  "DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy.||DUSP4 downregulation deactivates the Ras-ERK pathway": [
    0.10879164189100266,
    0.884489119052887,
    0.006719275843352079
  ],
  "Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival.||DUSP4 downregulation deactivates the Ras-ERK pathway": [
    0.040653325617313385,
    0.9563905000686646,
    0.0029562111012637615
  ],
  "Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts.||DUSP4 downregulation deactivates the Ras-ERK pathway": [
    0.5184932947158813,
    0.4686351418495178,
    0.012871503829956055
  ],
  "Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.||DUSP4 downregulation deactivates the Ras-ERK pathway": [
    0.9989466071128845,
    0.0006488504004664719,
    0.00040454414556734264
  ],
  "Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in \u223c30% of patients with breast cancer.||DUSP4 increases apoptosis.": [
    0.17350277304649353,
    0.7413715124130249,
    0.08512574434280396
  ],
  "However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR.||DUSP4 increases apoptosis.": [
    0.3043053448200226,
    0.6881749629974365,
    0.007519679144024849
  ],
  "We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance.||DUSP4 increases apoptosis.": [
    0.19154243171215057,
    0.7762619256973267,
    0.03219561651349068
  ],
  "Digital transcript counting was used to profile surgically resected breast cancers after NAC.||DUSP4 increases apoptosis.": [
    0.13701944053173065,
    0.824698269367218,
    0.03828233852982521
  ],
  "Low concentrations of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status.||DUSP4 increases apoptosis.": [
    0.9840223789215088,
    0.013523831032216549,
    0.0024538016878068447
  ],
  "BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes.||DUSP4 increases apoptosis.": [
    0.3051633834838867,
    0.676730215549469,
    0.01810639351606369
  ],
  "DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy.||DUSP4 increases apoptosis.": [
    0.012277323752641678,
    0.014963868074119091,
    0.9727588295936584
  ],
  "Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival.||DUSP4 increases apoptosis.": [
    0.3650687634944916,
    0.6185340881347656,
    0.01639711670577526
  ],
  "Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts.||DUSP4 increases apoptosis.": [
    0.32976865768432617,
    0.642553985118866,
    0.027677297592163086
  ],
  "Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.||DUSP4 increases apoptosis.": [
    0.8487431406974792,
    0.1388935148715973,
    0.01236339658498764
  ],
  "IMPORTANCE Identification of the bacterium responsible for an outbreak can aid in disease management.||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.10565673559904099,
    0.6922992467880249,
    0.2020440250635147
  ],
  "However, traditional culture-based diagnosis can be difficult, particularly if no specific diagnostic test is available for an outbreak strain.   \n||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.07270584255456924,
    0.8177130818367004,
    0.10958103090524673
  ],
  "OBJECTIVE To explore the potential of metagenomics, which is the direct sequencing of DNA extracted from microbiologically complex samples, as an open-ended clinical discovery platform capable of identifying and characterizing bacterial strains from an outbreak without laboratory culture.   \n||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.19999372959136963,
    0.677541196346283,
    0.1224651113152504
  ],
  "DESIGN, SETTING, AND PATIENTS In a retrospective investigation, 45 samples were selected from fecal specimens obtained from patients with diarrhea during the 2011 outbreak of Shiga-toxigenic Escherichia coli (STEC) O104:H4 in Germany.||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.0870482325553894,
    0.8340567946434021,
    0.07889493554830551
  ],
  "Samples were subjected to high-throughput sequencing (August-September 2012), followed by a 3-phase analysis (November 2012-February 2013).||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.04483705013990402,
    0.9237053394317627,
    0.03145758435130119
  ],
  "In phase 1, a de novo assembly approach was developed to obtain a draft genome of the outbreak strain.||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.037410955876111984,
    0.9494178295135498,
    0.0131711820140481
  ],
  "In phase 2, the depth of coverage of the outbreak strain genome was determined in each sample.||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.16907662153244019,
    0.7432981133460999,
    0.08762535452842712
  ],
  "In phase 3, sequences from each sample were compared with sequences from known bacteria to identify pathogens other than the outbreak strain.   \n||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.03291327878832817,
    0.9508645534515381,
    0.016222113743424416
  ],
  "MAIN OUTCOMES AND MEASURES The recovery of genome sequence data for the purposes of identification and characterization of the outbreak strain and other pathogens from fecal samples.   \n||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.07035328447818756,
    0.9165191054344177,
    0.013127545826137066
  ],
  "RESULTS During phase 1, a draft genome of the STEC outbreak strain was obtained.||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.05139673873782158,
    0.8821218013763428,
    0.06648147106170654
  ],
  "During phase 2, the outbreak strain genome was recovered from 10 samples at greater than 10-fold coverage and from 26 samples at greater than 1-fold coverage.||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.11767639964818954,
    0.7808263301849365,
    0.10149728506803513
  ],
  "Sequences from the Shiga-toxin genes were detected in 27 of 40 STEC-positive samples (67%).||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.061875347048044205,
    0.8597506880760193,
    0.07837401330471039
  ],
  "In phase 3, sequences from Clostridium difficile, Campylobacter jejuni, Campylobacter concisus, and Salmonella enterica were recovered.   \n||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.09802417457103729,
    0.8623406291007996,
    0.039635226130485535
  ],
  "CONCLUSIONS AND RELEVANCE These results suggest the potential of metagenomics as a culture-independent approach for the identification of bacterial pathogens during an outbreak of diarrheal disease.||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.15484607219696045,
    0.7000821232795715,
    0.1450718343257904
  ],
  "Challenges include improving diagnostic sensitivity, speeding up and simplifying workflows, and reducing costs.||De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.": [
    0.08566058427095413,
    0.6753460168838501,
    0.23899343609809875
  ],
  "IMPORTANCE Identification of the bacterium responsible for an outbreak can aid in disease management.||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.09780480712652206,
    0.5974991917610168,
    0.3046959936618805
  ],
  "However, traditional culture-based diagnosis can be difficult, particularly if no specific diagnostic test is available for an outbreak strain.   \n||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.10542692244052887,
    0.6197872161865234,
    0.2747858166694641
  ],
  "OBJECTIVE To explore the potential of metagenomics, which is the direct sequencing of DNA extracted from microbiologically complex samples, as an open-ended clinical discovery platform capable of identifying and characterizing bacterial strains from an outbreak without laboratory culture.   \n||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.08432228863239288,
    0.8127475380897522,
    0.10293020308017731
  ],
  "DESIGN, SETTING, AND PATIENTS In a retrospective investigation, 45 samples were selected from fecal specimens obtained from patients with diarrhea during the 2011 outbreak of Shiga-toxigenic Escherichia coli (STEC) O104:H4 in Germany.||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.06580298393964767,
    0.8341764807701111,
    0.10002052783966064
  ],
  "Samples were subjected to high-throughput sequencing (August-September 2012), followed by a 3-phase analysis (November 2012-February 2013).||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.025322064757347107,
    0.9496917128562927,
    0.024986201897263527
  ],
  "In phase 1, a de novo assembly approach was developed to obtain a draft genome of the outbreak strain.||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.013450580649077892,
    0.979861855506897,
    0.00668759411200881
  ],
  "In phase 2, the depth of coverage of the outbreak strain genome was determined in each sample.||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.1365130990743637,
    0.7848288416862488,
    0.07865806668996811
  ],
  "In phase 3, sequences from each sample were compared with sequences from known bacteria to identify pathogens other than the outbreak strain.   \n||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.016320908442139626,
    0.9723278880119324,
    0.011351260356605053
  ],
  "MAIN OUTCOMES AND MEASURES The recovery of genome sequence data for the purposes of identification and characterization of the outbreak strain and other pathogens from fecal samples.   \n||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.02117791213095188,
    0.9607691168785095,
    0.01805289275944233
  ],
  "RESULTS During phase 1, a draft genome of the STEC outbreak strain was obtained.||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.02881019562482834,
    0.9248766303062439,
    0.04631313681602478
  ],
  "During phase 2, the outbreak strain genome was recovered from 10 samples at greater than 10-fold coverage and from 26 samples at greater than 1-fold coverage.||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.062400754541158676,
    0.8817927241325378,
    0.05580649897456169
  ],
  "Sequences from the Shiga-toxin genes were detected in 27 of 40 STEC-positive samples (67%).||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.037738945335149765,
    0.8897461891174316,
    0.07251490652561188
  ],
  "In phase 3, sequences from Clostridium difficile, Campylobacter jejuni, Campylobacter concisus, and Salmonella enterica were recovered.   \n||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.018784448504447937,
    0.9481345415115356,
    0.03308102488517761
  ],
  "CONCLUSIONS AND RELEVANCE These results suggest the potential of metagenomics as a culture-independent approach for the identification of bacterial pathogens during an outbreak of diarrheal disease.||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.0896969735622406,
    0.7012917995452881,
    0.20901119709014893
  ],
  "Challenges include improving diagnostic sensitivity, speeding up and simplifying workflows, and reducing costs.||De novo assembly of sequence data has shorter contigs than unassembled sequence data.": [
    0.11850991100072861,
    0.6755940914154053,
    0.20589599013328552
  ],
  "IMPORTANCE Identification of the bacterium responsible for an outbreak can aid in disease management.||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.043759945780038834,
    0.6225213408470154,
    0.33371874690055847
  ],
  "However, traditional culture-based diagnosis can be difficult, particularly if no specific diagnostic test is available for an outbreak strain.   \n||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.11714078485965729,
    0.8210312128067017,
    0.061827994883060455
  ],
  "OBJECTIVE To explore the potential of metagenomics, which is the direct sequencing of DNA extracted from microbiologically complex samples, as an open-ended clinical discovery platform capable of identifying and characterizing bacterial strains from an outbreak without laboratory culture.   \n||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.03430100157856941,
    0.6927615404129028,
    0.2729374170303345
  ],
  "DESIGN, SETTING, AND PATIENTS In a retrospective investigation, 45 samples were selected from fecal specimens obtained from patients with diarrhea during the 2011 outbreak of Shiga-toxigenic Escherichia coli (STEC) O104:H4 in Germany.||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.019366567954421043,
    0.8583306670188904,
    0.12230277061462402
  ],
  "Samples were subjected to high-throughput sequencing (August-September 2012), followed by a 3-phase analysis (November 2012-February 2013).||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.008716531097888947,
    0.9650309681892395,
    0.02625253051519394
  ],
  "In phase 1, a de novo assembly approach was developed to obtain a draft genome of the outbreak strain.||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.003929583355784416,
    0.9649831056594849,
    0.031087318435311317
  ],
  "In phase 2, the depth of coverage of the outbreak strain genome was determined in each sample.||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.029671339318156242,
    0.817011833190918,
    0.15331678092479706
  ],
  "In phase 3, sequences from each sample were compared with sequences from known bacteria to identify pathogens other than the outbreak strain.   \n||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.01092089805752039,
    0.9677176475524902,
    0.021361419931054115
  ],
  "MAIN OUTCOMES AND MEASURES The recovery of genome sequence data for the purposes of identification and characterization of the outbreak strain and other pathogens from fecal samples.   \n||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.005399348679929972,
    0.9580068588256836,
    0.0365937314927578
  ],
  "RESULTS During phase 1, a draft genome of the STEC outbreak strain was obtained.||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.011073215864598751,
    0.8909730911254883,
    0.09795363247394562
  ],
  "During phase 2, the outbreak strain genome was recovered from 10 samples at greater than 10-fold coverage and from 26 samples at greater than 1-fold coverage.||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.015721824020147324,
    0.7916656732559204,
    0.19261251389980316
  ],
  "Sequences from the Shiga-toxin genes were detected in 27 of 40 STEC-positive samples (67%).||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.01830253377556801,
    0.8895580768585205,
    0.09213938564062119
  ],
  "In phase 3, sequences from Clostridium difficile, Campylobacter jejuni, Campylobacter concisus, and Salmonella enterica were recovered.   \n||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.00714511051774025,
    0.9112949967384338,
    0.08155985921621323
  ],
  "CONCLUSIONS AND RELEVANCE These results suggest the potential of metagenomics as a culture-independent approach for the identification of bacterial pathogens during an outbreak of diarrheal disease.||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.038264527916908264,
    0.7407222390174866,
    0.22101324796676636
  ],
  "Challenges include improving diagnostic sensitivity, speeding up and simplifying workflows, and reducing costs.||De novo assembly of sequence data has more specific contigs than unassembled sequence data.": [
    0.06678440421819687,
    0.6880748271942139,
    0.24514071643352509
  ],
  "BACKGROUND Aedes aegypti, the major vector of dengue viruses, often breeds in water storage containers used by households without tap water supply, and occurs in high numbers even in dense urban areas.||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.13822253048419952,
    0.8162698149681091,
    0.045507702976465225
  ],
  "We analysed the interaction between human population density and lack of tap water as a cause of dengue fever outbreaks with the aim of identifying geographic areas at highest risk.   \n||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.19567403197288513,
    0.6886795163154602,
    0.11564649641513824
  ],
  "METHODS AND FINDINGS We conducted an individual-level cohort study in a population of 75,000 geo-referenced households in Vietnam over the course of two epidemics, on the basis of dengue hospital admissions (n = 3,013).||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.10376717150211334,
    0.7889742851257324,
    0.10725857317447662
  ],
  "We applied space-time scan statistics and mathematical models to confirm the findings.||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.05971183255314827,
    0.700191855430603,
    0.240096315741539
  ],
  "We identified a surprisingly narrow range of critical human population densities between around 3,000 to 7,000 people/km\u00b2 prone to dengue outbreaks.||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.03955580294132233,
    0.899124264717102,
    0.061319999396800995
  ],
  "In the study area, this population density was typical of villages and some peri-urban areas.||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.10974770784378052,
    0.5953116416931152,
    0.29494068026542664
  ],
  "Scan statistics showed that areas with a high population density or adequate water supply did not experience severe outbreaks.||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.08040545880794525,
    0.8144014477729797,
    0.10519307106733322
  ],
  "The risk of dengue was higher in rural than in urban areas, largely explained by lack of piped water supply, and in human population densities more often falling within the critical range.||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.06484412401914597,
    0.7885240912437439,
    0.14663174748420715
  ],
  "Mathematical modeling suggests that simple assumptions regarding area-level vector/host ratios may explain the occurrence of outbreaks.   \n||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.06755603849887848,
    0.8467081785202026,
    0.08573579788208008
  ],
  "CONCLUSIONS Rural areas may contribute at least as much to the dissemination of dengue fever as cities.||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.08021341264247894,
    0.8134949803352356,
    0.10629159957170486
  ],
  "Improving water supply and vector control in areas with a human population density critical for dengue transmission could increase the efficiency of control efforts.||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.09162245690822601,
    0.8070049285888672,
    0.1013726219534874
  ],
  "Please see later in the article for the Editors' Summary.||Destination container port throughput(CPT) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.049584224820137024,
    0.7946702241897583,
    0.15574553608894348
  ],
  "BACKGROUND Aedes aegypti, the major vector of dengue viruses, often breeds in water storage containers used by households without tap water supply, and occurs in high numbers even in dense urban areas.||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.4802362322807312,
    0.44209060072898865,
    0.07767320424318314
  ],
  "We analysed the interaction between human population density and lack of tap water as a cause of dengue fever outbreaks with the aim of identifying geographic areas at highest risk.   \n||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.2887663245201111,
    0.5690796375274658,
    0.1421540081501007
  ],
  "METHODS AND FINDINGS We conducted an individual-level cohort study in a population of 75,000 geo-referenced households in Vietnam over the course of two epidemics, on the basis of dengue hospital admissions (n = 3,013).||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.13933494687080383,
    0.6986725926399231,
    0.16199254989624023
  ],
  "We applied space-time scan statistics and mathematical models to confirm the findings.||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.11539744585752487,
    0.7173336148262024,
    0.16726893186569214
  ],
  "We identified a surprisingly narrow range of critical human population densities between around 3,000 to 7,000 people/km\u00b2 prone to dengue outbreaks.||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.12867821753025055,
    0.8090781569480896,
    0.06224365532398224
  ],
  "In the study area, this population density was typical of villages and some peri-urban areas.||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.20330746471881866,
    0.5705738663673401,
    0.22611872851848602
  ],
  "Scan statistics showed that areas with a high population density or adequate water supply did not experience severe outbreaks.||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.26108282804489136,
    0.6322131752967834,
    0.10670392215251923
  ],
  "The risk of dengue was higher in rural than in urban areas, largely explained by lack of piped water supply, and in human population densities more often falling within the critical range.||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.14033599197864532,
    0.6894392967224121,
    0.17022469639778137
  ],
  "Mathematical modeling suggests that simple assumptions regarding area-level vector/host ratios may explain the occurrence of outbreaks.   \n||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.16059628129005432,
    0.759550929069519,
    0.07985282689332962
  ],
  "CONCLUSIONS Rural areas may contribute at least as much to the dissemination of dengue fever as cities.||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.2664693295955658,
    0.6308412551879883,
    0.10268943011760712
  ],
  "Improving water supply and vector control in areas with a human population density critical for dengue transmission could increase the efficiency of control efforts.||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.19298666715621948,
    0.6882451176643372,
    0.11876829713582993
  ],
  "Please see later in the article for the Editors' Summary.||Destination container port throughput(CPT) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.16433869302272797,
    0.723734438419342,
    0.11192689090967178
  ],
  "BACKGROUND Aedes aegypti, the major vector of dengue viruses, often breeds in water storage containers used by households without tap water supply, and occurs in high numbers even in dense urban areas.||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.16048955917358398,
    0.7707661986351013,
    0.06874416768550873
  ],
  "We analysed the interaction between human population density and lack of tap water as a cause of dengue fever outbreaks with the aim of identifying geographic areas at highest risk.   \n||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.25507286190986633,
    0.6733867526054382,
    0.07154034078121185
  ],
  "METHODS AND FINDINGS We conducted an individual-level cohort study in a population of 75,000 geo-referenced households in Vietnam over the course of two epidemics, on the basis of dengue hospital admissions (n = 3,013).||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.12045195698738098,
    0.8377617597579956,
    0.0417863167822361
  ],
  "We applied space-time scan statistics and mathematical models to confirm the findings.||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.07091309130191803,
    0.7811822295188904,
    0.14790470898151398
  ],
  "We identified a surprisingly narrow range of critical human population densities between around 3,000 to 7,000 people/km\u00b2 prone to dengue outbreaks.||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.12056265771389008,
    0.8549347519874573,
    0.024502558633685112
  ],
  "In the study area, this population density was typical of villages and some peri-urban areas.||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.11809652298688889,
    0.8162335157394409,
    0.0656699687242508
  ],
  "Scan statistics showed that areas with a high population density or adequate water supply did not experience severe outbreaks.||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.1697382628917694,
    0.8010920286178589,
    0.029169686138629913
  ],
  "The risk of dengue was higher in rural than in urban areas, largely explained by lack of piped water supply, and in human population densities more often falling within the critical range.||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.08998438715934753,
    0.8452978134155273,
    0.06471780687570572
  ],
  "Mathematical modeling suggests that simple assumptions regarding area-level vector/host ratios may explain the occurrence of outbreaks.   \n||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.08122485131025314,
    0.8906437158584595,
    0.02813139744102955
  ],
  "CONCLUSIONS Rural areas may contribute at least as much to the dissemination of dengue fever as cities.||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.07711739093065262,
    0.8702085018157959,
    0.052674081176519394
  ],
  "Improving water supply and vector control in areas with a human population density critical for dengue transmission could increase the efficiency of control efforts.||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.15300285816192627,
    0.8116240501403809,
    0.035373102873563766
  ],
  "Please see later in the article for the Editors' Summary.||Origin gross domestic product(GDP) is negatively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.04764251783490181,
    0.8719573616981506,
    0.08040019869804382
  ],
  "BACKGROUND Aedes aegypti, the major vector of dengue viruses, often breeds in water storage containers used by households without tap water supply, and occurs in high numbers even in dense urban areas.||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.4403001368045807,
    0.5000198483467102,
    0.059679992496967316
  ],
  "We analysed the interaction between human population density and lack of tap water as a cause of dengue fever outbreaks with the aim of identifying geographic areas at highest risk.   \n||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.4967648684978485,
    0.4431987404823303,
    0.06003636121749878
  ],
  "METHODS AND FINDINGS We conducted an individual-level cohort study in a population of 75,000 geo-referenced households in Vietnam over the course of two epidemics, on the basis of dengue hospital admissions (n = 3,013).||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.18712346255779266,
    0.7588720321655273,
    0.05400453135371208
  ],
  "We applied space-time scan statistics and mathematical models to confirm the findings.||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.15760333836078644,
    0.7416980862617493,
    0.10069862753152847
  ],
  "We identified a surprisingly narrow range of critical human population densities between around 3,000 to 7,000 people/km\u00b2 prone to dengue outbreaks.||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.42998161911964417,
    0.5496900081634521,
    0.02032836712896824
  ],
  "In the study area, this population density was typical of villages and some peri-urban areas.||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.293671578168869,
    0.6519659161567688,
    0.05436251312494278
  ],
  "Scan statistics showed that areas with a high population density or adequate water supply did not experience severe outbreaks.||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.452789306640625,
    0.5106679201126099,
    0.03654278442263603
  ],
  "The risk of dengue was higher in rural than in urban areas, largely explained by lack of piped water supply, and in human population densities more often falling within the critical range.||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.34665167331695557,
    0.6083966493606567,
    0.04495171830058098
  ],
  "Mathematical modeling suggests that simple assumptions regarding area-level vector/host ratios may explain the occurrence of outbreaks.   \n||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.2678631842136383,
    0.705862820148468,
    0.026273945346474648
  ],
  "CONCLUSIONS Rural areas may contribute at least as much to the dissemination of dengue fever as cities.||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.3962298631668091,
    0.5607209801673889,
    0.04304913803935051
  ],
  "Improving water supply and vector control in areas with a human population density critical for dengue transmission could increase the efficiency of control efforts.||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.4976779818534851,
    0.47230425477027893,
    0.0300177913159132
  ],
  "Please see later in the article for the Editors' Summary.||Origin gross domestic product(GDP) is positively related to dengue virus (DENV-1) diffusion in air traffic shipments.": [
    0.17179881036281586,
    0.749461829662323,
    0.07873935997486115
  ],
  "The mammalian radiation has corresponded with rapid changes in noncoding regions of the genome, but we lack a comprehensive understanding of regulatory evolution in mammals.||Distant CREs are important for transcriptional regulation.": [
    0.020547091960906982,
    0.9445256590843201,
    0.03492732346057892
  ],
  "Here, we track the evolution of promoters and enhancers active in liver across 20 mammalian species from six diverse orders by profiling genomic enrichment of H3K27 acetylation and H3K4 trimethylation.||Distant CREs are important for transcriptional regulation.": [
    0.024643078446388245,
    0.779297411441803,
    0.19605958461761475
  ],
  "We report that rapid evolution of enhancers is a universal feature of mammalian genomes.||Distant CREs are important for transcriptional regulation.": [
    0.0186159685254097,
    0.937212347984314,
    0.044171664863824844
  ],
  "Most of the recently evolved enhancers arise from ancestral DNA exaptation, rather than lineage-specific expansions of repeat elements.||Distant CREs are important for transcriptional regulation.": [
    0.0613388828933239,
    0.878496527671814,
    0.060164615511894226
  ],
  "In contrast, almost all liver promoters are partially or fully conserved across these species.||Distant CREs are important for transcriptional regulation.": [
    0.010014756582677364,
    0.903803288936615,
    0.08618191629648209
  ],
  "Our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.||Distant CREs are important for transcriptional regulation.": [
    0.02090730331838131,
    0.8015652298927307,
    0.17752742767333984
  ],
  "These results provide important insight into the functional genetics underpinning mammalian regulatory evolution.||Distant CREs are important for transcriptional regulation.": [
    0.01566152088344097,
    0.9003035426139832,
    0.08403497189283371
  ],
  "The mammalian radiation has corresponded with rapid changes in noncoding regions of the genome, but we lack a comprehensive understanding of regulatory evolution in mammals.||Distant CREs are less conserved among species.": [
    0.0176737941801548,
    0.6482402682304382,
    0.33408594131469727
  ],
  "Here, we track the evolution of promoters and enhancers active in liver across 20 mammalian species from six diverse orders by profiling genomic enrichment of H3K27 acetylation and H3K4 trimethylation.||Distant CREs are less conserved among species.": [
    0.07743344455957413,
    0.8935933709144592,
    0.028973136097192764
  ],
  "We report that rapid evolution of enhancers is a universal feature of mammalian genomes.||Distant CREs are less conserved among species.": [
    0.19511082768440247,
    0.7990040183067322,
    0.005885133985430002
  ],
  "Most of the recently evolved enhancers arise from ancestral DNA exaptation, rather than lineage-specific expansions of repeat elements.||Distant CREs are less conserved among species.": [
    0.07045061141252518,
    0.5187526941299438,
    0.4107966125011444
  ],
  "In contrast, almost all liver promoters are partially or fully conserved across these species.||Distant CREs are less conserved among species.": [
    0.08757508546113968,
    0.9005852937698364,
    0.011839593760669231
  ],
  "Our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.||Distant CREs are less conserved among species.": [
    0.042800772935152054,
    0.7214598059654236,
    0.23573942482471466
  ],
  "These results provide important insight into the functional genetics underpinning mammalian regulatory evolution.||Distant CREs are less conserved among species.": [
    0.24045011401176453,
    0.7074273228645325,
    0.052122604101896286
  ],
  "The mammalian radiation has corresponded with rapid changes in noncoding regions of the genome, but we lack a comprehensive understanding of regulatory evolution in mammals.||Long - range chromatin interactions regulate transcription.": [
    0.04023582860827446,
    0.9137411713600159,
    0.046023011207580566
  ],
  "Here, we track the evolution of promoters and enhancers active in liver across 20 mammalian species from six diverse orders by profiling genomic enrichment of H3K27 acetylation and H3K4 trimethylation.||Long - range chromatin interactions regulate transcription.": [
    0.08966825157403946,
    0.5127311944961548,
    0.39760056138038635
  ],
  "We report that rapid evolution of enhancers is a universal feature of mammalian genomes.||Long - range chromatin interactions regulate transcription.": [
    0.15205858647823334,
    0.5714815258979797,
    0.2764599323272705
  ],
  "Most of the recently evolved enhancers arise from ancestral DNA exaptation, rather than lineage-specific expansions of repeat elements.||Long - range chromatin interactions regulate transcription.": [
    0.09996119886636734,
    0.471627801656723,
    0.42841094732284546
  ],
  "In contrast, almost all liver promoters are partially or fully conserved across these species.||Long - range chromatin interactions regulate transcription.": [
    0.01990836299955845,
    0.6250209212303162,
    0.35507068037986755
  ],
  "Our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.||Long - range chromatin interactions regulate transcription.": [
    0.02944638766348362,
    0.6275878548622131,
    0.3429657816886902
  ],
  "These results provide important insight into the functional genetics underpinning mammalian regulatory evolution.||Long - range chromatin interactions regulate transcription.": [
    0.013558387756347656,
    0.8878158330917358,
    0.09862570464611053
  ],
  "The mammalian radiation has corresponded with rapid changes in noncoding regions of the genome, but we lack a comprehensive understanding of regulatory evolution in mammals.||Sequence conservation in gene regulatory regions between species is a high-accuracy predictor of conserved functionality.": [
    0.9554476737976074,
    0.04225091636180878,
    0.0023014473263174295
  ],
  "Here, we track the evolution of promoters and enhancers active in liver across 20 mammalian species from six diverse orders by profiling genomic enrichment of H3K27 acetylation and H3K4 trimethylation.||Sequence conservation in gene regulatory regions between species is a high-accuracy predictor of conserved functionality.": [
    0.08434883505105972,
    0.8690129518508911,
    0.04663825407624245
  ],
  "We report that rapid evolution of enhancers is a universal feature of mammalian genomes.||Sequence conservation in gene regulatory regions between species is a high-accuracy predictor of conserved functionality.": [
    0.3879193961620331,
    0.5494232177734375,
    0.06265738606452942
  ],
  "Most of the recently evolved enhancers arise from ancestral DNA exaptation, rather than lineage-specific expansions of repeat elements.||Sequence conservation in gene regulatory regions between species is a high-accuracy predictor of conserved functionality.": [
    0.244980588555336,
    0.691188395023346,
    0.06383104622364044
  ],
  "In contrast, almost all liver promoters are partially or fully conserved across these species.||Sequence conservation in gene regulatory regions between species is a high-accuracy predictor of conserved functionality.": [
    0.014600898139178753,
    0.8815767168998718,
    0.10382242500782013
  ],
  "Our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.||Sequence conservation in gene regulatory regions between species is a high-accuracy predictor of conserved functionality.": [
    0.0069652944803237915,
    0.9203541874885559,
    0.0726805329322815
  ],
  "These results provide important insight into the functional genetics underpinning mammalian regulatory evolution.||Sequence conservation in gene regulatory regions between species is a high-accuracy predictor of conserved functionality.": [
    0.03302780166268349,
    0.9471820592880249,
    0.019790159538388252
  ],
  "The mammalian radiation has corresponded with rapid changes in noncoding regions of the genome, but we lack a comprehensive understanding of regulatory evolution in mammals.||Sequence conservation in gene regulatory regions between species is a poor predictor of conserved functionality.": [
    0.02596127614378929,
    0.8408369421958923,
    0.13320185244083405
  ],
  "Here, we track the evolution of promoters and enhancers active in liver across 20 mammalian species from six diverse orders by profiling genomic enrichment of H3K27 acetylation and H3K4 trimethylation.||Sequence conservation in gene regulatory regions between species is a poor predictor of conserved functionality.": [
    0.4952574372291565,
    0.49671638011932373,
    0.00802622176706791
  ],
  "We report that rapid evolution of enhancers is a universal feature of mammalian genomes.||Sequence conservation in gene regulatory regions between species is a poor predictor of conserved functionality.": [
    0.017777973785996437,
    0.797023594379425,
    0.18519845604896545
  ],
  "Most of the recently evolved enhancers arise from ancestral DNA exaptation, rather than lineage-specific expansions of repeat elements.||Sequence conservation in gene regulatory regions between species is a poor predictor of conserved functionality.": [
    0.18613332509994507,
    0.7100347876548767,
    0.10383187979459763
  ],
  "In contrast, almost all liver promoters are partially or fully conserved across these species.||Sequence conservation in gene regulatory regions between species is a poor predictor of conserved functionality.": [
    0.37030503153800964,
    0.6020107865333557,
    0.027684159576892853
  ],
  "Our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.||Sequence conservation in gene regulatory regions between species is a poor predictor of conserved functionality.": [
    0.805907666683197,
    0.18946132063865662,
    0.004631063435226679
  ],
  "These results provide important insight into the functional genetics underpinning mammalian regulatory evolution.||Sequence conservation in gene regulatory regions between species is a poor predictor of conserved functionality.": [
    0.796227753162384,
    0.19792935252189636,
    0.005842935293912888
  ],
  "Lymphocytes provide optimal responses against pathogens with minimal inflammatory pathology.||EGR2 is important to myelination of the peripheral nervous system.": [
    0.0499751903116703,
    0.7107986211776733,
    0.23922613263130188
  ],
  "However, the intrinsic mechanisms regulating these responses are unknown.||EGR2 is important to myelination of the peripheral nervous system.": [
    0.05150223150849342,
    0.8479424118995667,
    0.10055530071258545
  ],
  "Here, we report that deletion of both transcription factors Egr2 and Egr3 in lymphocytes resulted in a lethal autoimmune syndrome with excessive serum proinflammatory cytokines but also impaired antigen receptor-induced proliferation of B and T cells.||EGR2 is important to myelination of the peripheral nervous system.": [
    0.02294088341295719,
    0.9240161776542664,
    0.05304292216897011
  ],
  "Egr2- and Egr3-defective B and T cells had hyperactive signal transducer and activator of transcription-1 (STAT1) and STAT3 while antigen receptor-induced activation of transcription factor AP-1 was severely impaired.||EGR2 is important to myelination of the peripheral nervous system.": [
    0.09748633205890656,
    0.8573181629180908,
    0.045195482671260834
  ],
  "We discovered that Egr2 and/or Egr3 directly induced expression of suppressor of cytokine signaling-1 (SOCS1) and SOCS3, inhibitors of STAT1 and STAT3, and also blocked the function of Batf, an AP-1 inhibitor, in B and T cells.||EGR2 is important to myelination of the peripheral nervous system.": [
    0.020935311913490295,
    0.9670546054840088,
    0.012010094709694386
  ],
  "Thus, Egr2 and Egr3 regulate B and T cell function in adaptive immune responses and homeostasis by promoting antigen receptor signaling and controlling inflammation.||EGR2 is important to myelination of the peripheral nervous system.": [
    0.03701380640268326,
    0.7160518169403076,
    0.24693438410758972
  ],
  "Lymphocytes provide optimal responses against pathogens with minimal inflammatory pathology.||Egr2 regulates the homeostasis of B and T cells.": [
    0.06589090079069138,
    0.8649970293045044,
    0.06911203265190125
  ],
  "However, the intrinsic mechanisms regulating these responses are unknown.||Egr2 regulates the homeostasis of B and T cells.": [
    0.349631130695343,
    0.6403011083602905,
    0.010067769326269627
  ],
  "Here, we report that deletion of both transcription factors Egr2 and Egr3 in lymphocytes resulted in a lethal autoimmune syndrome with excessive serum proinflammatory cytokines but also impaired antigen receptor-induced proliferation of B and T cells.||Egr2 regulates the homeostasis of B and T cells.": [
    0.8925262689590454,
    0.07956713438034058,
    0.02790657989680767
  ],
  "Egr2- and Egr3-defective B and T cells had hyperactive signal transducer and activator of transcription-1 (STAT1) and STAT3 while antigen receptor-induced activation of transcription factor AP-1 was severely impaired.||Egr2 regulates the homeostasis of B and T cells.": [
    0.9167453050613403,
    0.06560898572206497,
    0.017645716667175293
  ],
  "We discovered that Egr2 and/or Egr3 directly induced expression of suppressor of cytokine signaling-1 (SOCS1) and SOCS3, inhibitors of STAT1 and STAT3, and also blocked the function of Batf, an AP-1 inhibitor, in B and T cells.||Egr2 regulates the homeostasis of B and T cells.": [
    0.0827299952507019,
    0.8553329110145569,
    0.061937082558870316
  ],
  "Thus, Egr2 and Egr3 regulate B and T cell function in adaptive immune responses and homeostasis by promoting antigen receptor signaling and controlling inflammation.||Egr2 regulates the homeostasis of B and T cells.": [
    0.010752877220511436,
    0.008217161521315575,
    0.9810299873352051
  ],
  "Lymphocytes provide optimal responses against pathogens with minimal inflammatory pathology.||Egr3 regulates the homeostasis of B and T cells.": [
    0.06353770941495895,
    0.8624601364135742,
    0.07400213181972504
  ],
  "However, the intrinsic mechanisms regulating these responses are unknown.||Egr3 regulates the homeostasis of B and T cells.": [
    0.3407483398914337,
    0.6489987969398499,
    0.010252920910716057
  ],
  "Here, we report that deletion of both transcription factors Egr2 and Egr3 in lymphocytes resulted in a lethal autoimmune syndrome with excessive serum proinflammatory cytokines but also impaired antigen receptor-induced proliferation of B and T cells.||Egr3 regulates the homeostasis of B and T cells.": [
    0.8368817567825317,
    0.1272977888584137,
    0.035820506513118744
  ],
  "Egr2- and Egr3-defective B and T cells had hyperactive signal transducer and activator of transcription-1 (STAT1) and STAT3 while antigen receptor-induced activation of transcription factor AP-1 was severely impaired.||Egr3 regulates the homeostasis of B and T cells.": [
    0.8399271965026855,
    0.12732480466365814,
    0.03274799883365631
  ],
  "We discovered that Egr2 and/or Egr3 directly induced expression of suppressor of cytokine signaling-1 (SOCS1) and SOCS3, inhibitors of STAT1 and STAT3, and also blocked the function of Batf, an AP-1 inhibitor, in B and T cells.||Egr3 regulates the homeostasis of B and T cells.": [
    0.03087637946009636,
    0.9100992679595947,
    0.05902436003088951
  ],
  "Thus, Egr2 and Egr3 regulate B and T cell function in adaptive immune responses and homeostasis by promoting antigen receptor signaling and controlling inflammation.||Egr3 regulates the homeostasis of B and T cells.": [
    0.0032741944305598736,
    0.009402763098478317,
    0.987322986125946
  ],
  "Traditionally, vaccine development involves tradeoffs between immunogenicity and safety.||Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.": [
    0.6749598383903503,
    0.31260475516319275,
    0.012435424141585827
  ],
  "Live-attenuated vaccines typically offer rapid and durable immunity but have reduced safety when compared to inactivated vaccines.||Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.": [
    0.06033898890018463,
    0.9103116989135742,
    0.029349347576498985
  ],
  "In contrast, the inability of inactivated vaccines to replicate enhances safety at the expense of immunogenicity, often necessitating multiple doses and boosters.||Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.": [
    0.78194659948349,
    0.20478391647338867,
    0.01326946821063757
  ],
  "To overcome these tradeoffs, we developed the insect-specific alphavirus, Eilat virus (EILV), as a vaccine platform.||Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.": [
    0.002693095011636615,
    0.993553638458252,
    0.00375322881154716
  ],
  "To address the chikungunya fever (CHIKF) pandemic, we used an EILV cDNA clone to design a chimeric virus containing the chikungunya virus (CHIKV) structural proteins.||Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.": [
    0.2569113075733185,
    0.7104774117469788,
    0.03261129558086395
  ],
  "The recombinant EILV/CHIKV was structurally identical at 10 \u00c5 to wild-type CHIKV, as determined by single-particle cryo-electron microscopy, and it mimicked the early stages of CHIKV replication in vertebrate cells from attachment and entry to viral RNA delivery.||Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.": [
    0.2854861915111542,
    0.698101282119751,
    0.016412479802966118
  ],
  "Yet the recombinant virus remained completely defective for productive replication, providing a high degree of safety.||Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.": [
    0.31220898032188416,
    0.6705669164657593,
    0.017224077135324478
  ],
  "A single dose of EILV/CHIKV produced in mosquito cells elicited rapid (within 4 d) and long-lasting (>290 d) neutralizing antibodies that provided complete protection in two different mouse models.||Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.": [
    0.04931052029132843,
    0.18688639998435974,
    0.7638030648231506
  ],
  "In nonhuman primates, EILV/CHIKV elicited rapid and robust immunity that protected against viremia and telemetrically monitored fever.||Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.": [
    0.20963728427886963,
    0.6748367547988892,
    0.11552596092224121
  ],
  "Our EILV platform represents the first structurally native application of an insect-specific virus in preclinical vaccine development and highlights the potential application of such viruses in vaccinology.||Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.": [
    0.012236550450325012,
    0.9725689888000488,
    0.015194418840110302
  ],
  "Traditionally, vaccine development involves tradeoffs between immunogenicity and safety.||Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.": [
    0.6974223852157593,
    0.29807737469673157,
    0.004500205162912607
  ],
  "Live-attenuated vaccines typically offer rapid and durable immunity but have reduced safety when compared to inactivated vaccines.||Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.": [
    0.915583074092865,
    0.0817478597164154,
    0.0026690850500017405
  ],
  "In contrast, the inability of inactivated vaccines to replicate enhances safety at the expense of immunogenicity, often necessitating multiple doses and boosters.||Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.": [
    0.46309444308280945,
    0.5211300253868103,
    0.01577547751367092
  ],
  "To overcome these tradeoffs, we developed the insect-specific alphavirus, Eilat virus (EILV), as a vaccine platform.||Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.": [
    0.6892387866973877,
    0.30599161982536316,
    0.004769633989781141
  ],
  "To address the chikungunya fever (CHIKF) pandemic, we used an EILV cDNA clone to design a chimeric virus containing the chikungunya virus (CHIKV) structural proteins.||Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.": [
    0.7414823174476624,
    0.25034448504447937,
    0.008173185400664806
  ],
  "The recombinant EILV/CHIKV was structurally identical at 10 \u00c5 to wild-type CHIKV, as determined by single-particle cryo-electron microscopy, and it mimicked the early stages of CHIKV replication in vertebrate cells from attachment and entry to viral RNA delivery.||Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.": [
    0.919625461101532,
    0.07593756914138794,
    0.004436981864273548
  ],
  "Yet the recombinant virus remained completely defective for productive replication, providing a high degree of safety.||Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.": [
    0.7756022810935974,
    0.2122562676668167,
    0.012141435407102108
  ],
  "A single dose of EILV/CHIKV produced in mosquito cells elicited rapid (within 4 d) and long-lasting (>290 d) neutralizing antibodies that provided complete protection in two different mouse models.||Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.": [
    0.9900642037391663,
    0.008815557695925236,
    0.0011202782625332475
  ],
  "In nonhuman primates, EILV/CHIKV elicited rapid and robust immunity that protected against viremia and telemetrically monitored fever.||Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.": [
    0.8949034810066223,
    0.10178877413272858,
    0.003307715291157365
  ],
  "Our EILV platform represents the first structurally native application of an insect-specific virus in preclinical vaccine development and highlights the potential application of such viruses in vaccinology.||Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.": [
    0.7079172134399414,
    0.28671061992645264,
    0.005372184328734875
  ],
  "Traditionally, vaccine development involves tradeoffs between immunogenicity and safety.||Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.": [
    0.7883725762367249,
    0.20556087791919708,
    0.006066545844078064
  ],
  "Live-attenuated vaccines typically offer rapid and durable immunity but have reduced safety when compared to inactivated vaccines.||Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.": [
    0.9192404747009277,
    0.07662313431501389,
    0.004136391915380955
  ],
  "In contrast, the inability of inactivated vaccines to replicate enhances safety at the expense of immunogenicity, often necessitating multiple doses and boosters.||Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.": [
    0.789579451084137,
    0.18984456360340118,
    0.020575927570462227
  ],
  "To overcome these tradeoffs, we developed the insect-specific alphavirus, Eilat virus (EILV), as a vaccine platform.||Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.": [
    0.8388599753379822,
    0.15465138852596283,
    0.006488558370620012
  ],
  "To address the chikungunya fever (CHIKF) pandemic, we used an EILV cDNA clone to design a chimeric virus containing the chikungunya virus (CHIKV) structural proteins.||Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.": [
    0.8203561305999756,
    0.16966494917869568,
    0.009978871792554855
  ],
  "The recombinant EILV/CHIKV was structurally identical at 10 \u00c5 to wild-type CHIKV, as determined by single-particle cryo-electron microscopy, and it mimicked the early stages of CHIKV replication in vertebrate cells from attachment and entry to viral RNA delivery.||Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.": [
    0.9344642758369446,
    0.06142337620258331,
    0.004112280905246735
  ],
  "Yet the recombinant virus remained completely defective for productive replication, providing a high degree of safety.||Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.": [
    0.7879994511604309,
    0.19518707692623138,
    0.016813477501273155
  ],
  "A single dose of EILV/CHIKV produced in mosquito cells elicited rapid (within 4 d) and long-lasting (>290 d) neutralizing antibodies that provided complete protection in two different mouse models.||Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.": [
    0.9750729203224182,
    0.02318246103823185,
    0.0017445867415517569
  ],
  "In nonhuman primates, EILV/CHIKV elicited rapid and robust immunity that protected against viremia and telemetrically monitored fever.||Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.": [
    0.993610680103302,
    0.005721892695873976,
    0.0006674931501038373
  ],
  "Our EILV platform represents the first structurally native application of an insect-specific virus in preclinical vaccine development and highlights the potential application of such viruses in vaccinology.||Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.": [
    0.6884708404541016,
    0.29512447118759155,
    0.016404729336500168
  ],
  "Inflammation induced by recognition of pathogen-associated molecular patterns markedly affects subsequent adaptive responses.||Enhanced early production of inflammatory chemokines damages viral control in the lung.": [
    0.0009715771884657443,
    0.995928943157196,
    0.0030994550324976444
  ],
  "We asked whether the adaptive immune system can also affect the character and magnitude of innate inflammatory responses.||Enhanced early production of inflammatory chemokines damages viral control in the lung.": [
    0.005795456934720278,
    0.9892673492431641,
    0.0049371980130672455
  ],
  "We found that the response of memory, but not naive, CD4+ T cells enhances production of multiple innate inflammatory cytokines and chemokines (IICs) in the lung and that, during influenza infection, this leads to early control of virus.||Enhanced early production of inflammatory chemokines damages viral control in the lung.": [
    0.9975276589393616,
    0.0019732273649424314,
    0.0004991010646335781
  ],
  "Memory CD4+ T cell\u2013induced IICs and viral control require cognate antigen recognition and are optimal when memory cells are either T helper type 1 (TH1) or TH17 polarized but are independent of interferon-\u03b3 (IFN-\u03b3) and tumor necrosis factor-\u03b1 (TNF-\u03b1) production and do not require activation of conserved pathogen recognition pathways.||Enhanced early production of inflammatory chemokines damages viral control in the lung.": [
    0.5792132616043091,
    0.4142952561378479,
    0.006491462234407663
  ],
  "This represents a previously undescribed mechanism by which memory CD4+ T cells induce an early innate response that enhances immune protection against pathogens.||Enhanced early production of inflammatory chemokines damages viral control in the lung.": [
    0.8428415656089783,
    0.1491403877735138,
    0.008018065243959427
  ],
  "Inflammation induced by recognition of pathogen-associated molecular patterns markedly affects subsequent adaptive responses.||Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.": [
    0.8454945683479309,
    0.1517113745212555,
    0.0027941125445067883
  ],
  "We asked whether the adaptive immune system can also affect the character and magnitude of innate inflammatory responses.||Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.": [
    0.04516737163066864,
    0.9536827802658081,
    0.0011498283129185438
  ],
  "We found that the response of memory, but not naive, CD4+ T cells enhances production of multiple innate inflammatory cytokines and chemokines (IICs) in the lung and that, during influenza infection, this leads to early control of virus.||Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.": [
    0.999180018901825,
    0.0005886125145480037,
    0.0002312700089532882
  ],
  "Memory CD4+ T cell\u2013induced IICs and viral control require cognate antigen recognition and are optimal when memory cells are either T helper type 1 (TH1) or TH17 polarized but are independent of interferon-\u03b3 (IFN-\u03b3) and tumor necrosis factor-\u03b1 (TNF-\u03b1) production and do not require activation of conserved pathogen recognition pathways.||Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.": [
    0.03026849776506424,
    0.9665151238441467,
    0.0032163304276764393
  ],
  "This represents a previously undescribed mechanism by which memory CD4+ T cells induce an early innate response that enhances immune protection against pathogens.||Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.": [
    0.010691349394619465,
    0.9873437881469727,
    0.0019648324232548475
  ],
  "Inflammation induced by recognition of pathogen-associated molecular patterns markedly affects subsequent adaptive responses.||Upon viral challenge, influenza-specific memory CD4+ T cells greatly enhance the early production of inflammatory chemokines in the lung.": [
    0.20450851321220398,
    0.7853118181228638,
    0.010179716162383556
  ],
  "We asked whether the adaptive immune system can also affect the character and magnitude of innate inflammatory responses.||Upon viral challenge, influenza-specific memory CD4+ T cells greatly enhance the early production of inflammatory chemokines in the lung.": [
    0.045174192637205124,
    0.9524531364440918,
    0.0023726343642920256
  ],
  "We found that the response of memory, but not naive, CD4+ T cells enhances production of multiple innate inflammatory cytokines and chemokines (IICs) in the lung and that, during influenza infection, this leads to early control of virus.||Upon viral challenge, influenza-specific memory CD4+ T cells greatly enhance the early production of inflammatory chemokines in the lung.": [
    0.0016661400441080332,
    0.02487432211637497,
    0.9734594821929932
  ],
  "Memory CD4+ T cell\u2013induced IICs and viral control require cognate antigen recognition and are optimal when memory cells are either T helper type 1 (TH1) or TH17 polarized but are independent of interferon-\u03b3 (IFN-\u03b3) and tumor necrosis factor-\u03b1 (TNF-\u03b1) production and do not require activation of conserved pathogen recognition pathways.||Upon viral challenge, influenza-specific memory CD4+ T cells greatly enhance the early production of inflammatory chemokines in the lung.": [
    0.05929432436823845,
    0.9357936978340149,
    0.004911966156214476
  ],
  "This represents a previously undescribed mechanism by which memory CD4+ T cells induce an early innate response that enhances immune protection against pathogens.||Upon viral challenge, influenza-specific memory CD4+ T cells greatly enhance the early production of inflammatory chemokines in the lung.": [
    0.0014638188295066357,
    0.9963794350624084,
    0.0021567516960203648
  ],
  "Inflammation induced by recognition of pathogen-associated molecular patterns markedly affects subsequent adaptive responses.||Enhanced early production of inflammatory chemokines improves viral control in the lung.": [
    0.41888704895973206,
    0.5784497857093811,
    0.0026631634682416916
  ],
  "We asked whether the adaptive immune system can also affect the character and magnitude of innate inflammatory responses.||Enhanced early production of inflammatory chemokines improves viral control in the lung.": [
    0.027853524312376976,
    0.9694501161575317,
    0.0026964202988892794
  ],
  "We found that the response of memory, but not naive, CD4+ T cells enhances production of multiple innate inflammatory cytokines and chemokines (IICs) in the lung and that, during influenza infection, this leads to early control of virus.||Enhanced early production of inflammatory chemokines improves viral control in the lung.": [
    0.0005854463670402765,
    0.03145935386419296,
    0.9679551124572754
  ],
  "Memory CD4+ T cell\u2013induced IICs and viral control require cognate antigen recognition and are optimal when memory cells are either T helper type 1 (TH1) or TH17 polarized but are independent of interferon-\u03b3 (IFN-\u03b3) and tumor necrosis factor-\u03b1 (TNF-\u03b1) production and do not require activation of conserved pathogen recognition pathways.||Enhanced early production of inflammatory chemokines improves viral control in the lung.": [
    0.0038067020941525698,
    0.9811404943466187,
    0.015052848495543003
  ],
  "This represents a previously undescribed mechanism by which memory CD4+ T cells induce an early innate response that enhances immune protection against pathogens.||Enhanced early production of inflammatory chemokines improves viral control in the lung.": [
    0.0008685308275744319,
    0.9907160997390747,
    0.008415368385612965
  ],
  "Understanding the genetic basis of adaptation is a central problem in biology.||Ethanol stress increases the expression of IBP in bacteria.": [
    0.08621422201395035,
    0.8396679162979126,
    0.07411787658929825
  ],
  "However, revealing the underlying molecular mechanisms has been challenging as changes in fitness may result from perturbations to many pathways, any of which may contribute relatively little.||Ethanol stress increases the expression of IBP in bacteria.": [
    0.12759961187839508,
    0.8281868696212769,
    0.04421348124742508
  ],
  "We have developed a combined experimental/computational framework to address this problem and used it to understand the genetic basis of ethanol tolerance in Escherichia coli.||Ethanol stress increases the expression of IBP in bacteria.": [
    0.5101257562637329,
    0.4777153432369232,
    0.012158860452473164
  ],
  "We used fitness profiling to measure the consequences of single-locus perturbations in the context of ethanol exposure.||Ethanol stress increases the expression of IBP in bacteria.": [
    0.037280939519405365,
    0.943494975566864,
    0.019224151968955994
  ],
  "A module-level computational analysis was then used to reveal the organization of the contributing loci into cellular processes and regulatory pathways (e.g. osmoregulation and cell-wall biogenesis) whose modifications significantly affect ethanol tolerance.||Ethanol stress increases the expression of IBP in bacteria.": [
    0.14288583397865295,
    0.8259769678115845,
    0.03113720938563347
  ],
  "Strikingly, we discovered that a dominant component of adaptation involves metabolic rewiring that boosts intracellular ethanol degradation and assimilation.||Ethanol stress increases the expression of IBP in bacteria.": [
    0.09090617299079895,
    0.8074055910110474,
    0.10168829560279846
  ],
  "Through phenotypic and metabolomic analysis of laboratory-evolved ethanol-tolerant strains, we investigated naturally accessible pathways of ethanol tolerance.||Ethanol stress increases the expression of IBP in bacteria.": [
    0.07649261504411697,
    0.8674700260162354,
    0.05603737384080887
  ],
  "Remarkably, these laboratory-evolved strains, by and large, follow the same adaptive paths as inferred from our coarse-grained search of the fitness landscape.||Ethanol stress increases the expression of IBP in bacteria.": [
    0.08466754853725433,
    0.8335733413696289,
    0.08175911754369736
  ],
  "Understanding the genetic basis of adaptation is a central problem in biology.||Ethanol stress increases the expression of PSP in bacteria.": [
    0.07495054602622986,
    0.8759507536888123,
    0.049098752439022064
  ],
  "However, revealing the underlying molecular mechanisms has been challenging as changes in fitness may result from perturbations to many pathways, any of which may contribute relatively little.||Ethanol stress increases the expression of PSP in bacteria.": [
    0.1173776164650917,
    0.8425441384315491,
    0.04007824510335922
  ],
  "We have developed a combined experimental/computational framework to address this problem and used it to understand the genetic basis of ethanol tolerance in Escherichia coli.||Ethanol stress increases the expression of PSP in bacteria.": [
    0.5732815861701965,
    0.4160366356372833,
    0.01068184245377779
  ],
  "We used fitness profiling to measure the consequences of single-locus perturbations in the context of ethanol exposure.||Ethanol stress increases the expression of PSP in bacteria.": [
    0.03204454109072685,
    0.9519690871238708,
    0.015986403450369835
  ],
  "A module-level computational analysis was then used to reveal the organization of the contributing loci into cellular processes and regulatory pathways (e.g. osmoregulation and cell-wall biogenesis) whose modifications significantly affect ethanol tolerance.||Ethanol stress increases the expression of PSP in bacteria.": [
    0.10895995795726776,
    0.8724609017372131,
    0.018579142168164253
  ],
  "Strikingly, we discovered that a dominant component of adaptation involves metabolic rewiring that boosts intracellular ethanol degradation and assimilation.||Ethanol stress increases the expression of PSP in bacteria.": [
    0.10747025907039642,
    0.8498390913009644,
    0.04269067198038101
  ],
  "Through phenotypic and metabolomic analysis of laboratory-evolved ethanol-tolerant strains, we investigated naturally accessible pathways of ethanol tolerance.||Ethanol stress increases the expression of PSP in bacteria.": [
    0.0716177225112915,
    0.8968905210494995,
    0.031491801142692566
  ],
  "Remarkably, these laboratory-evolved strains, by and large, follow the same adaptive paths as inferred from our coarse-grained search of the fitness landscape.||Ethanol stress increases the expression of PSP in bacteria.": [
    0.07500968873500824,
    0.8512359261512756,
    0.07375437766313553
  ],
  "Understanding the genetic basis of adaptation is a central problem in biology.||Ethanol stress increases the expression of SRL in bacteria.": [
    0.0758306160569191,
    0.8855704665184021,
    0.0385989174246788
  ],
  "However, revealing the underlying molecular mechanisms has been challenging as changes in fitness may result from perturbations to many pathways, any of which may contribute relatively little.||Ethanol stress increases the expression of SRL in bacteria.": [
    0.12992604076862335,
    0.834688127040863,
    0.0353858508169651
  ],
  "We have developed a combined experimental/computational framework to address this problem and used it to understand the genetic basis of ethanol tolerance in Escherichia coli.||Ethanol stress increases the expression of SRL in bacteria.": [
    0.758583128452301,
    0.23211990296840668,
    0.009296986274421215
  ],
  "We used fitness profiling to measure the consequences of single-locus perturbations in the context of ethanol exposure.||Ethanol stress increases the expression of SRL in bacteria.": [
    0.06462708860635757,
    0.9047533273696899,
    0.03061959706246853
  ],
  "A module-level computational analysis was then used to reveal the organization of the contributing loci into cellular processes and regulatory pathways (e.g. osmoregulation and cell-wall biogenesis) whose modifications significantly affect ethanol tolerance.||Ethanol stress increases the expression of SRL in bacteria.": [
    0.12613463401794434,
    0.8544390797615051,
    0.019426263868808746
  ],
  "Strikingly, we discovered that a dominant component of adaptation involves metabolic rewiring that boosts intracellular ethanol degradation and assimilation.||Ethanol stress increases the expression of SRL in bacteria.": [
    0.04467396065592766,
    0.8924174308776855,
    0.06290855258703232
  ],
  "Through phenotypic and metabolomic analysis of laboratory-evolved ethanol-tolerant strains, we investigated naturally accessible pathways of ethanol tolerance.||Ethanol stress increases the expression of SRL in bacteria.": [
    0.08468865603208542,
    0.873100221157074,
    0.042211104184389114
  ],
  "Remarkably, these laboratory-evolved strains, by and large, follow the same adaptive paths as inferred from our coarse-grained search of the fitness landscape.||Ethanol stress increases the expression of SRL in bacteria.": [
    0.07679902017116547,
    0.8663558959960938,
    0.056845128536224365
  ],
  "Understanding the genetic basis of adaptation is a central problem in biology.||Ethanol stress lowers the expression of PSP in bacteria.": [
    0.04236561432480812,
    0.8778792023658752,
    0.07975523918867111
  ],
  "However, revealing the underlying molecular mechanisms has been challenging as changes in fitness may result from perturbations to many pathways, any of which may contribute relatively little.||Ethanol stress lowers the expression of PSP in bacteria.": [
    0.04883540794253349,
    0.8948283791542053,
    0.05633620172739029
  ],
  "We have developed a combined experimental/computational framework to address this problem and used it to understand the genetic basis of ethanol tolerance in Escherichia coli.||Ethanol stress lowers the expression of PSP in bacteria.": [
    0.3135360777378082,
    0.6394583582878113,
    0.04700556397438049
  ],
  "We used fitness profiling to measure the consequences of single-locus perturbations in the context of ethanol exposure.||Ethanol stress lowers the expression of PSP in bacteria.": [
    0.011417068541049957,
    0.9518744945526123,
    0.03670840710401535
  ],
  "A module-level computational analysis was then used to reveal the organization of the contributing loci into cellular processes and regulatory pathways (e.g. osmoregulation and cell-wall biogenesis) whose modifications significantly affect ethanol tolerance.||Ethanol stress lowers the expression of PSP in bacteria.": [
    0.04084230214357376,
    0.9027837514877319,
    0.05637393146753311
  ],
  "Strikingly, we discovered that a dominant component of adaptation involves metabolic rewiring that boosts intracellular ethanol degradation and assimilation.||Ethanol stress lowers the expression of PSP in bacteria.": [
    0.10726041346788406,
    0.798681378364563,
    0.09405816346406937
  ],
  "Through phenotypic and metabolomic analysis of laboratory-evolved ethanol-tolerant strains, we investigated naturally accessible pathways of ethanol tolerance.||Ethanol stress lowers the expression of PSP in bacteria.": [
    0.11007517576217651,
    0.8342139720916748,
    0.05571087449789047
  ],
  "Remarkably, these laboratory-evolved strains, by and large, follow the same adaptive paths as inferred from our coarse-grained search of the fitness landscape.||Ethanol stress lowers the expression of PSP in bacteria.": [
    0.08958055824041367,
    0.8207752108573914,
    0.08964423090219498
  ],
  "Understanding the genetic basis of adaptation is a central problem in biology.||Ethanol stress reduces the expression of SRL in bacteria.": [
    0.04003756865859032,
    0.8913295269012451,
    0.06863287836313248
  ],
  "However, revealing the underlying molecular mechanisms has been challenging as changes in fitness may result from perturbations to many pathways, any of which may contribute relatively little.||Ethanol stress reduces the expression of SRL in bacteria.": [
    0.049562979489564896,
    0.9053816199302673,
    0.04505538195371628
  ],
  "We have developed a combined experimental/computational framework to address this problem and used it to understand the genetic basis of ethanol tolerance in Escherichia coli.||Ethanol stress reduces the expression of SRL in bacteria.": [
    0.40468740463256836,
    0.549304187297821,
    0.04600836709141731
  ],
  "We used fitness profiling to measure the consequences of single-locus perturbations in the context of ethanol exposure.||Ethanol stress reduces the expression of SRL in bacteria.": [
    0.007809668779373169,
    0.8850296139717102,
    0.10716072469949722
  ],
  "A module-level computational analysis was then used to reveal the organization of the contributing loci into cellular processes and regulatory pathways (e.g. osmoregulation and cell-wall biogenesis) whose modifications significantly affect ethanol tolerance.||Ethanol stress reduces the expression of SRL in bacteria.": [
    0.031016886234283447,
    0.90884929895401,
    0.060133885592222214
  ],
  "Strikingly, we discovered that a dominant component of adaptation involves metabolic rewiring that boosts intracellular ethanol degradation and assimilation.||Ethanol stress reduces the expression of SRL in bacteria.": [
    0.1799827516078949,
    0.7551383376121521,
    0.0648789256811142
  ],
  "Through phenotypic and metabolomic analysis of laboratory-evolved ethanol-tolerant strains, we investigated naturally accessible pathways of ethanol tolerance.||Ethanol stress reduces the expression of SRL in bacteria.": [
    0.11690567433834076,
    0.8190310001373291,
    0.06406329572200775
  ],
  "Remarkably, these laboratory-evolved strains, by and large, follow the same adaptive paths as inferred from our coarse-grained search of the fitness landscape.||Ethanol stress reduces the expression of SRL in bacteria.": [
    0.11460116505622864,
    0.8297165036201477,
    0.055682338774204254
  ],
  "Understanding the genetic basis of adaptation is a central problem in biology.||Ethanol stress decreases the expression of IBP in bacteria.": [
    0.05497670918703079,
    0.8298956751823425,
    0.11512763798236847
  ],
  "However, revealing the underlying molecular mechanisms has been challenging as changes in fitness may result from perturbations to many pathways, any of which may contribute relatively little.||Ethanol stress decreases the expression of IBP in bacteria.": [
    0.05592924728989601,
    0.893634021282196,
    0.050436753779649734
  ],
  "We have developed a combined experimental/computational framework to address this problem and used it to understand the genetic basis of ethanol tolerance in Escherichia coli.||Ethanol stress decreases the expression of IBP in bacteria.": [
    0.26333728432655334,
    0.6965029835700989,
    0.040159717202186584
  ],
  "We used fitness profiling to measure the consequences of single-locus perturbations in the context of ethanol exposure.||Ethanol stress decreases the expression of IBP in bacteria.": [
    0.012132593430578709,
    0.9578123688697815,
    0.03005501627922058
  ],
  "A module-level computational analysis was then used to reveal the organization of the contributing loci into cellular processes and regulatory pathways (e.g. osmoregulation and cell-wall biogenesis) whose modifications significantly affect ethanol tolerance.||Ethanol stress decreases the expression of IBP in bacteria.": [
    0.041819408535957336,
    0.878376305103302,
    0.07980430871248245
  ],
  "Strikingly, we discovered that a dominant component of adaptation involves metabolic rewiring that boosts intracellular ethanol degradation and assimilation.||Ethanol stress decreases the expression of IBP in bacteria.": [
    0.2071855366230011,
    0.6881498098373413,
    0.1046646386384964
  ],
  "Through phenotypic and metabolomic analysis of laboratory-evolved ethanol-tolerant strains, we investigated naturally accessible pathways of ethanol tolerance.||Ethanol stress decreases the expression of IBP in bacteria.": [
    0.13303488492965698,
    0.7831990718841553,
    0.08376603573560715
  ],
  "Remarkably, these laboratory-evolved strains, by and large, follow the same adaptive paths as inferred from our coarse-grained search of the fitness landscape.||Ethanol stress decreases the expression of IBP in bacteria.": [
    0.1272512525320053,
    0.7926729917526245,
    0.08007575571537018
  ],
  "CONTEXT Exogenous estrogen use may lower risk of dementia in postmenopausal women.||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.10634270310401917,
    0.48821160197257996,
    0.40544575452804565
  ],
  "A relationship between long-term exposure to endogenous estrogens and incident dementia has been hypothesized but not studied.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.2014138549566269,
    0.7869284152984619,
    0.011657774448394775
  ],
  "OBJECTIVE To determine whether a longer reproductive period, as an indicator of longer exposure to endogenous estrogens, is associated with lower risk of dementia and Alzheimer disease (AD) in women who have natural menopause.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.05035535246133804,
    0.8279072642326355,
    0.12173742800951004
  ],
  "DESIGN AND SETTING The Rotterdam Study, a population-based prospective cohort study conducted in the Netherlands.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.04189164564013481,
    0.8764297366142273,
    0.08167863637208939
  ],
  "PARTICIPANTS A total of 3601 women aged 55 years or older who did not have dementia at baseline (1990-1993) and had information on age at menarche, age at menopause, and type of menopause.||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.02735404670238495,
    0.963033139705658,
    0.009612827561795712
  ],
  "Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for development of dementia.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.046094901859760284,
    0.9500144124031067,
    0.00389067898504436
  ],
  "MAIN OUTCOME MEASURES Incidence of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, compared by quartiles of reproductive period among women with natural menopause.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.09645083546638489,
    0.8843434453010559,
    0.019205721095204353
  ],
  "RESULTS During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD.||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.1800527125597,
    0.8168889880180359,
    0.003058263100683689
  ],
  "After adjusting for age, dementia was not clearly associated with length of reproductive period.||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.07255808264017105,
    0.9180428385734558,
    0.009399102069437504
  ],
  "However, after adjusting for multiple covariates, women with natural menopause and more reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women with >39 reproductive years [highest quartile] compared with <34 reproductive years [lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84).||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.1866765022277832,
    0.8070990443229675,
    0.006224462296813726
  ],
  "The adjusted RR per year of increase was 1.04 (95% CI, 1.01-1.08).||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.11582157015800476,
    0.7196882963180542,
    0.164490208029747
  ],
  "For risk of AD, the adjusted RRs were 1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively.||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.0878182053565979,
    0.9067047238349915,
    0.005477112717926502
  ],
  "Risk of dementia associated with a longer reproductive period was most pronounced in APOE epsilon4 carriers (adjusted RR for >39 reproductive years compared with <34 reproductive years, 4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas in noncarriers, no clear association with dementia or AD was observed.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.5498411655426025,
    0.4335949718952179,
    0.016563856974244118
  ],
  "CONCLUSION Our findings do not support the hypothesis that a longer reproductive period reduces risk of dementia in women who have natural menopause.||Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.": [
    0.5309368968009949,
    0.453642874956131,
    0.015420233830809593
  ],
  "CONTEXT Exogenous estrogen use may lower risk of dementia in postmenopausal women.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.7529298067092896,
    0.23194631934165955,
    0.015123826451599598
  ],
  "A relationship between long-term exposure to endogenous estrogens and incident dementia has been hypothesized but not studied.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.05401463806629181,
    0.8155214190483093,
    0.13046400249004364
  ],
  "OBJECTIVE To determine whether a longer reproductive period, as an indicator of longer exposure to endogenous estrogens, is associated with lower risk of dementia and Alzheimer disease (AD) in women who have natural menopause.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.6516335606575012,
    0.339232474565506,
    0.009133975021541119
  ],
  "DESIGN AND SETTING The Rotterdam Study, a population-based prospective cohort study conducted in the Netherlands.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.03967277333140373,
    0.8734968900680542,
    0.08683035522699356
  ],
  "PARTICIPANTS A total of 3601 women aged 55 years or older who did not have dementia at baseline (1990-1993) and had information on age at menarche, age at menopause, and type of menopause.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.06927550584077835,
    0.9148311018943787,
    0.015893368050456047
  ],
  "Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for development of dementia.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.015010684728622437,
    0.9622078537940979,
    0.02278149500489235
  ],
  "MAIN OUTCOME MEASURES Incidence of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, compared by quartiles of reproductive period among women with natural menopause.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.014940096996724606,
    0.9504677653312683,
    0.03459208831191063
  ],
  "RESULTS During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.003315103007480502,
    0.983141303062439,
    0.0135435676202178
  ],
  "After adjusting for age, dementia was not clearly associated with length of reproductive period.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.27083417773246765,
    0.7171596884727478,
    0.012006206437945366
  ],
  "However, after adjusting for multiple covariates, women with natural menopause and more reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women with >39 reproductive years [highest quartile] compared with <34 reproductive years [lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84).||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.012294313870370388,
    0.8464308381080627,
    0.1412748098373413
  ],
  "The adjusted RR per year of increase was 1.04 (95% CI, 1.01-1.08).||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.048590440303087234,
    0.8150632381439209,
    0.13634635508060455
  ],
  "For risk of AD, the adjusted RRs were 1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.015170098282396793,
    0.958886444568634,
    0.025943422690033913
  ],
  "Risk of dementia associated with a longer reproductive period was most pronounced in APOE epsilon4 carriers (adjusted RR for >39 reproductive years compared with <34 reproductive years, 4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas in noncarriers, no clear association with dementia or AD was observed.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.026740141212940216,
    0.46669891476631165,
    0.5065609216690063
  ],
  "CONCLUSION Our findings do not support the hypothesis that a longer reproductive period reduces risk of dementia in women who have natural menopause.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.": [
    0.1028636023402214,
    0.8765690326690674,
    0.02056736871600151
  ],
  "CONTEXT Exogenous estrogen use may lower risk of dementia in postmenopausal women.||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.005113999824970961,
    0.9919688105583191,
    0.0029172308277338743
  ],
  "A relationship between long-term exposure to endogenous estrogens and incident dementia has been hypothesized but not studied.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.0026895664632320404,
    0.9961073994636536,
    0.001203019986860454
  ],
  "OBJECTIVE To determine whether a longer reproductive period, as an indicator of longer exposure to endogenous estrogens, is associated with lower risk of dementia and Alzheimer disease (AD) in women who have natural menopause.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.006501682568341494,
    0.9313920140266418,
    0.06210629269480705
  ],
  "DESIGN AND SETTING The Rotterdam Study, a population-based prospective cohort study conducted in the Netherlands.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.04155498743057251,
    0.7713620066642761,
    0.18708296120166779
  ],
  "PARTICIPANTS A total of 3601 women aged 55 years or older who did not have dementia at baseline (1990-1993) and had information on age at menarche, age at menopause, and type of menopause.||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.02092263661324978,
    0.9641722440719604,
    0.01490516122430563
  ],
  "Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for development of dementia.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.10618538409471512,
    0.6267299652099609,
    0.26708468794822693
  ],
  "MAIN OUTCOME MEASURES Incidence of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, compared by quartiles of reproductive period among women with natural menopause.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.017936835065484047,
    0.9528459310531616,
    0.029217183589935303
  ],
  "RESULTS During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD.||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.012811924330890179,
    0.9859824776649475,
    0.0012055597035214305
  ],
  "After adjusting for age, dementia was not clearly associated with length of reproductive period.||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.211608424782753,
    0.7770406007766724,
    0.011350978165864944
  ],
  "However, after adjusting for multiple covariates, women with natural menopause and more reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women with >39 reproductive years [highest quartile] compared with <34 reproductive years [lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84).||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.012540196068584919,
    0.9260832071304321,
    0.06137661263346672
  ],
  "The adjusted RR per year of increase was 1.04 (95% CI, 1.01-1.08).||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.026773879304528236,
    0.862589418888092,
    0.11063674837350845
  ],
  "For risk of AD, the adjusted RRs were 1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively.||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.08293119817972183,
    0.6846641898155212,
    0.2324046790599823
  ],
  "Risk of dementia associated with a longer reproductive period was most pronounced in APOE epsilon4 carriers (adjusted RR for >39 reproductive years compared with <34 reproductive years, 4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas in noncarriers, no clear association with dementia or AD was observed.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.007600649259984493,
    0.6856486201286316,
    0.3067507743835449
  ],
  "CONCLUSION Our findings do not support the hypothesis that a longer reproductive period reduces risk of dementia in women who have natural menopause.||Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.": [
    0.019733333960175514,
    0.9713025689125061,
    0.008964105509221554
  ],
  "CONTEXT Exogenous estrogen use may lower risk of dementia in postmenopausal women.||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.003980537876486778,
    0.9912790656089783,
    0.004740341566503048
  ],
  "A relationship between long-term exposure to endogenous estrogens and incident dementia has been hypothesized but not studied.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.011045929044485092,
    0.9879412055015564,
    0.001012827386148274
  ],
  "OBJECTIVE To determine whether a longer reproductive period, as an indicator of longer exposure to endogenous estrogens, is associated with lower risk of dementia and Alzheimer disease (AD) in women who have natural menopause.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.9838733077049255,
    0.013491183519363403,
    0.0026355721056461334
  ],
  "DESIGN AND SETTING The Rotterdam Study, a population-based prospective cohort study conducted in the Netherlands.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.055845972150564194,
    0.7523552775382996,
    0.19179876148700714
  ],
  "PARTICIPANTS A total of 3601 women aged 55 years or older who did not have dementia at baseline (1990-1993) and had information on age at menarche, age at menopause, and type of menopause.||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.035597413778305054,
    0.9528806805610657,
    0.011521875858306885
  ],
  "Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for development of dementia.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.12006641179323196,
    0.5926960110664368,
    0.28723764419555664
  ],
  "MAIN OUTCOME MEASURES Incidence of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, compared by quartiles of reproductive period among women with natural menopause.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.0337371863424778,
    0.9304363131523132,
    0.035826534032821655
  ],
  "RESULTS During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD.||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.03716248273849487,
    0.960915207862854,
    0.0019222891423851252
  ],
  "After adjusting for age, dementia was not clearly associated with length of reproductive period.||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.2095714658498764,
    0.7726464867591858,
    0.017782088369131088
  ],
  "However, after adjusting for multiple covariates, women with natural menopause and more reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women with >39 reproductive years [highest quartile] compared with <34 reproductive years [lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84).||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.28363972902297974,
    0.6825170516967773,
    0.03384324908256531
  ],
  "The adjusted RR per year of increase was 1.04 (95% CI, 1.01-1.08).||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.0871562510728836,
    0.7668116092681885,
    0.1460321545600891
  ],
  "For risk of AD, the adjusted RRs were 1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively.||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.13140009343624115,
    0.6846873760223389,
    0.18391253054141998
  ],
  "Risk of dementia associated with a longer reproductive period was most pronounced in APOE epsilon4 carriers (adjusted RR for >39 reproductive years compared with <34 reproductive years, 4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas in noncarriers, no clear association with dementia or AD was observed.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.8616936206817627,
    0.10544081032276154,
    0.03286556527018547
  ],
  "CONCLUSION Our findings do not support the hypothesis that a longer reproductive period reduces risk of dementia in women who have natural menopause.||Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.": [
    0.7468599081039429,
    0.2483561486005783,
    0.004783887881785631
  ],
  "CONTEXT Exogenous estrogen use may lower risk of dementia in postmenopausal women.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.753829300403595,
    0.23511959612369537,
    0.01105115469545126
  ],
  "A relationship between long-term exposure to endogenous estrogens and incident dementia has been hypothesized but not studied.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.053146593272686005,
    0.8636369109153748,
    0.08321652561426163
  ],
  "OBJECTIVE To determine whether a longer reproductive period, as an indicator of longer exposure to endogenous estrogens, is associated with lower risk of dementia and Alzheimer disease (AD) in women who have natural menopause.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.699604868888855,
    0.29250234365463257,
    0.007892734371125698
  ],
  "DESIGN AND SETTING The Rotterdam Study, a population-based prospective cohort study conducted in the Netherlands.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.04477866739034653,
    0.8774732947349548,
    0.07774800807237625
  ],
  "PARTICIPANTS A total of 3601 women aged 55 years or older who did not have dementia at baseline (1990-1993) and had information on age at menarche, age at menopause, and type of menopause.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.07651002705097198,
    0.913988471031189,
    0.00950152799487114
  ],
  "Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for development of dementia.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.010283851996064186,
    0.984091579914093,
    0.005624552257359028
  ],
  "MAIN OUTCOME MEASURES Incidence of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, compared by quartiles of reproductive period among women with natural menopause.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.02220400609076023,
    0.9386166930198669,
    0.03917933627963066
  ],
  "RESULTS During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.0027018063701689243,
    0.9925984144210815,
    0.004699737764894962
  ],
  "After adjusting for age, dementia was not clearly associated with length of reproductive period.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.24693407118320465,
    0.7464368343353271,
    0.006629088893532753
  ],
  "However, after adjusting for multiple covariates, women with natural menopause and more reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women with >39 reproductive years [highest quartile] compared with <34 reproductive years [lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84).||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.006037448532879353,
    0.9477230906486511,
    0.0462394580245018
  ],
  "The adjusted RR per year of increase was 1.04 (95% CI, 1.01-1.08).||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.06693626940250397,
    0.8180508017539978,
    0.11501290649175644
  ],
  "For risk of AD, the adjusted RRs were 1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.01821652054786682,
    0.9579145312309265,
    0.023868942633271217
  ],
  "Risk of dementia associated with a longer reproductive period was most pronounced in APOE epsilon4 carriers (adjusted RR for >39 reproductive years compared with <34 reproductive years, 4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas in noncarriers, no clear association with dementia or AD was observed.   \n||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.012835376895964146,
    0.38018882274627686,
    0.606975793838501
  ],
  "CONCLUSION Our findings do not support the hypothesis that a longer reproductive period reduces risk of dementia in women who have natural menopause.||Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.": [
    0.1269557923078537,
    0.8595084547996521,
    0.013535775244235992
  ],
  "BACKGROUND Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity.||Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.": [
    0.027935495600104332,
    0.9640224575996399,
    0.00804207380861044
  ],
  "It acts as a key downstream target of both peroxisome proliferator-activated receptor \u03b1 and \u03b3, the agonists of which have been used for lipid lowering and insulin sensitization, respectively.||Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.": [
    0.1149921864271164,
    0.8163166046142578,
    0.0686912089586258
  ],
  "However, the role of FGF21 in the cardiovascular system remains elusive.   \n||Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.": [
    0.4362019896507263,
    0.558976411819458,
    0.0048216464929282665
  ],
  "METHODS AND RESULTS The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E(-/-) mice.||Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.": [
    0.8287630081176758,
    0.1665056049823761,
    0.004731453023850918
  ],
  "FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E(-/-) mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia.||Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.": [
    0.7427161931991577,
    0.24458244442939758,
    0.012701420113444328
  ],
  "Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E(-/-)mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia.||Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.": [
    0.003108468372374773,
    0.23454803228378296,
    0.7623434662818909
  ],
  "Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E(-/-) mice.||Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.": [
    0.2094639390707016,
    0.7650877237319946,
    0.025448322296142578
  ],
  "By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.   \n||Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.": [
    0.93317711353302,
    0.06129085272550583,
    0.005532037001103163
  ],
  "CONCLUSIONS FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.||Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.": [
    0.1035195142030716,
    0.8579705357551575,
    0.03850989788770676
  ],
  "BACKGROUND Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity.||Lack of FGF21 in mice increases life expectancy.": [
    0.38221651315689087,
    0.6143408417701721,
    0.003442647634074092
  ],
  "It acts as a key downstream target of both peroxisome proliferator-activated receptor \u03b1 and \u03b3, the agonists of which have been used for lipid lowering and insulin sensitization, respectively.||Lack of FGF21 in mice increases life expectancy.": [
    0.38996490836143494,
    0.5994817614555359,
    0.010553387925028801
  ],
  "However, the role of FGF21 in the cardiovascular system remains elusive.   \n||Lack of FGF21 in mice increases life expectancy.": [
    0.4075401723384857,
    0.5877621173858643,
    0.004697753116488457
  ],
  "METHODS AND RESULTS The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E(-/-) mice.||Lack of FGF21 in mice increases life expectancy.": [
    0.7749125361442566,
    0.22113986313343048,
    0.003947653342038393
  ],
  "FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E(-/-) mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia.||Lack of FGF21 in mice increases life expectancy.": [
    0.9911483526229858,
    0.0074696592055261135,
    0.001381980604492128
  ],
  "Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E(-/-)mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia.||Lack of FGF21 in mice increases life expectancy.": [
    0.8900945782661438,
    0.10477301478385925,
    0.0051324148662388325
  ],
  "Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E(-/-) mice.||Lack of FGF21 in mice increases life expectancy.": [
    0.8579959869384766,
    0.13773806393146515,
    0.004265910945832729
  ],
  "By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.   \n||Lack of FGF21 in mice increases life expectancy.": [
    0.29138803482055664,
    0.7043926119804382,
    0.004219362046569586
  ],
  "CONCLUSIONS FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.||Lack of FGF21 in mice increases life expectancy.": [
    0.8136736154556274,
    0.1831657886505127,
    0.0031605830881744623
  ],
  "BACKGROUND Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity.||Lack of FGF21 in mice leads to atherosclerotic plaque formation.": [
    0.03828045725822449,
    0.9595523476600647,
    0.0021671613212674856
  ],
  "It acts as a key downstream target of both peroxisome proliferator-activated receptor \u03b1 and \u03b3, the agonists of which have been used for lipid lowering and insulin sensitization, respectively.||Lack of FGF21 in mice leads to atherosclerotic plaque formation.": [
    0.22050875425338745,
    0.7728367447853088,
    0.0066545396111905575
  ],
  "However, the role of FGF21 in the cardiovascular system remains elusive.   \n||Lack of FGF21 in mice leads to atherosclerotic plaque formation.": [
    0.056625477969646454,
    0.9401233792304993,
    0.0032511611934751272
  ],
  "METHODS AND RESULTS The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E(-/-) mice.||Lack of FGF21 in mice leads to atherosclerotic plaque formation.": [
    0.011326050385832787,
    0.7262498140335083,
    0.2624240815639496
  ],
  "FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E(-/-) mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia.||Lack of FGF21 in mice leads to atherosclerotic plaque formation.": [
    0.0011923892889171839,
    0.0056886933743953705,
    0.9931188821792603
  ],
  "Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E(-/-)mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia.||Lack of FGF21 in mice leads to atherosclerotic plaque formation.": [
    0.09089608490467072,
    0.8045574426651001,
    0.10454646497964859
  ],
  "Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E(-/-) mice.||Lack of FGF21 in mice leads to atherosclerotic plaque formation.": [
    0.10056321322917938,
    0.3561526834964752,
    0.5432840585708618
  ],
  "By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.   \n||Lack of FGF21 in mice leads to atherosclerotic plaque formation.": [
    0.10638552159070969,
    0.8853894472122192,
    0.00822504609823227
  ],
  "CONCLUSIONS FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.||Lack of FGF21 in mice leads to atherosclerotic plaque formation.": [
    0.22885575890541077,
    0.76217120885849,
    0.00897304993122816
  ],
  "BACKGROUND Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity.||Lack of FGF21 in mice leads to reduced lifespan.": [
    0.0025712833739817142,
    0.9961624145507812,
    0.001266289153136313
  ],
  "It acts as a key downstream target of both peroxisome proliferator-activated receptor \u03b1 and \u03b3, the agonists of which have been used for lipid lowering and insulin sensitization, respectively.||Lack of FGF21 in mice leads to reduced lifespan.": [
    0.06869358569383621,
    0.9173731803894043,
    0.013933274894952774
  ],
  "However, the role of FGF21 in the cardiovascular system remains elusive.   \n||Lack of FGF21 in mice leads to reduced lifespan.": [
    0.04665721580386162,
    0.9503855109214783,
    0.0029572502244263887
  ],
  "METHODS AND RESULTS The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E(-/-) mice.||Lack of FGF21 in mice leads to reduced lifespan.": [
    0.006544829811900854,
    0.9807153940200806,
    0.012739776633679867
  ],
  "FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E(-/-) mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia.||Lack of FGF21 in mice leads to reduced lifespan.": [
    0.00800906028598547,
    0.22664859890937805,
    0.7653422951698303
  ],
  "Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E(-/-)mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia.||Lack of FGF21 in mice leads to reduced lifespan.": [
    0.031051283702254295,
    0.9483993053436279,
    0.020549455657601357
  ],
  "Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E(-/-) mice.||Lack of FGF21 in mice leads to reduced lifespan.": [
    0.00875544361770153,
    0.9775974154472351,
    0.013647114858031273
  ],
  "By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.   \n||Lack of FGF21 in mice leads to reduced lifespan.": [
    0.056409627199172974,
    0.9383503198623657,
    0.00524006737396121
  ],
  "CONCLUSIONS FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.||Lack of FGF21 in mice leads to reduced lifespan.": [
    0.03416948765516281,
    0.962152361869812,
    0.003678139066323638
  ],
  "BACKGROUND Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity.||Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.": [
    0.25494515895843506,
    0.7380051612854004,
    0.007049723528325558
  ],
  "It acts as a key downstream target of both peroxisome proliferator-activated receptor \u03b1 and \u03b3, the agonists of which have been used for lipid lowering and insulin sensitization, respectively.||Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.": [
    0.15838393568992615,
    0.7932287454605103,
    0.04838729277253151
  ],
  "However, the role of FGF21 in the cardiovascular system remains elusive.   \n||Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.": [
    0.43777593970298767,
    0.5578833222389221,
    0.004340703133493662
  ],
  "METHODS AND RESULTS The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E(-/-) mice.||Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.": [
    0.27144306898117065,
    0.7201440334320068,
    0.008412890136241913
  ],
  "FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E(-/-) mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia.||Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.": [
    0.9979825019836426,
    0.0011722464114427567,
    0.0008452470065094531
  ],
  "Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E(-/-)mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia.||Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.": [
    0.9000334739685059,
    0.08141699433326721,
    0.018549570813775063
  ],
  "Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E(-/-) mice.||Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.": [
    0.3443000614643097,
    0.31333619356155396,
    0.34236377477645874
  ],
  "By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.   \n||Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.": [
    0.4958678185939789,
    0.4926374852657318,
    0.011494621634483337
  ],
  "CONCLUSIONS FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.||Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.": [
    0.83956378698349,
    0.15210935473442078,
    0.008326822891831398
  ],
  "Maintaining hematopoietic stem cell (HSC) quiescence is a critical property for the life-long generation of blood cells.||GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.": [
    0.022635772824287415,
    0.9377343654632568,
    0.039629895240068436
  ],
  "Approximately 75% of cells in a highly enriched long-term repopulating HSC (LT-HSC) pool (Lin(-)Sca1(+)c-Kit(hi)CD150(+)CD48(-)) are quiescent, with only a small percentage of the LT-HSCs in cycle.||GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.": [
    0.05065957456827164,
    0.9108359813690186,
    0.03850444406270981
  ],
  "Transcription factor GATA-3 is known to be vital for the development of T cells at multiple stages in the thymus and for Th2 differentiation in the peripheral organs.||GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.": [
    0.1341385543346405,
    0.7491419315338135,
    0.11671949177980423
  ],
  "Although it is well documented that GATA-3 is expressed in HSCs, a role for GATA-3 in any prethymic progenitor cell has not been established.||GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.": [
    0.0850299745798111,
    0.8758208155632019,
    0.03914918005466461
  ],
  "In the present study, we show that Gata3-null mutant mice generate fewer LT-HSCs and that fewer Gata3-null LT-HSCs are in cycle.||GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.": [
    0.006692271679639816,
    0.9501147866249084,
    0.043192990124225616
  ],
  "Furthermore, Gata3 mutant hematopoietic progenitor cells fail to be recruited into an increased cycling state after 5-fluorouracil-induced myelosuppression.||GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.": [
    0.5786404013633728,
    0.3487650156021118,
    0.07259450852870941
  ],
  "Therefore, GATA-3 is required for the maintenance of a normal number of LT-HSCs and for their entry into the cell cycle.||GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.": [
    0.014661584049463272,
    0.5986603498458862,
    0.3866780400276184
  ],
  "Maintaining hematopoietic stem cell (HSC) quiescence is a critical property for the life-long generation of blood cells.||GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.": [
    0.01286059059202671,
    0.9678459167480469,
    0.01929353177547455
  ],
  "Approximately 75% of cells in a highly enriched long-term repopulating HSC (LT-HSC) pool (Lin(-)Sca1(+)c-Kit(hi)CD150(+)CD48(-)) are quiescent, with only a small percentage of the LT-HSCs in cycle.||GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.": [
    0.05704190582036972,
    0.8716229200363159,
    0.07133518159389496
  ],
  "Transcription factor GATA-3 is known to be vital for the development of T cells at multiple stages in the thymus and for Th2 differentiation in the peripheral organs.||GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.": [
    0.3693830072879791,
    0.5562312602996826,
    0.07438570261001587
  ],
  "Although it is well documented that GATA-3 is expressed in HSCs, a role for GATA-3 in any prethymic progenitor cell has not been established.||GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.": [
    0.04009311646223068,
    0.9439879059791565,
    0.015918929129838943
  ],
  "In the present study, we show that Gata3-null mutant mice generate fewer LT-HSCs and that fewer Gata3-null LT-HSCs are in cycle.||GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.": [
    0.011335308663547039,
    0.9392212629318237,
    0.04944336414337158
  ],
  "Furthermore, Gata3 mutant hematopoietic progenitor cells fail to be recruited into an increased cycling state after 5-fluorouracil-induced myelosuppression.||GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.": [
    0.2900860607624054,
    0.529241144657135,
    0.1806727796792984
  ],
  "Therefore, GATA-3 is required for the maintenance of a normal number of LT-HSCs and for their entry into the cell cycle.||GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.": [
    0.04271407797932625,
    0.6619299650192261,
    0.29535597562789917
  ],
  "Maintaining hematopoietic stem cell (HSC) quiescence is a critical property for the life-long generation of blood cells.||GATA-3 is important for hematopoietic stem cell (HSC) function.": [
    0.007305195089429617,
    0.9400085210800171,
    0.05268622562289238
  ],
  "Approximately 75% of cells in a highly enriched long-term repopulating HSC (LT-HSC) pool (Lin(-)Sca1(+)c-Kit(hi)CD150(+)CD48(-)) are quiescent, with only a small percentage of the LT-HSCs in cycle.||GATA-3 is important for hematopoietic stem cell (HSC) function.": [
    0.03359818458557129,
    0.815163254737854,
    0.1512385606765747
  ],
  "Transcription factor GATA-3 is known to be vital for the development of T cells at multiple stages in the thymus and for Th2 differentiation in the peripheral organs.||GATA-3 is important for hematopoietic stem cell (HSC) function.": [
    0.1046971008181572,
    0.5923286080360413,
    0.30297431349754333
  ],
  "Although it is well documented that GATA-3 is expressed in HSCs, a role for GATA-3 in any prethymic progenitor cell has not been established.||GATA-3 is important for hematopoietic stem cell (HSC) function.": [
    0.01084569375962019,
    0.6419657468795776,
    0.3471885919570923
  ],
  "In the present study, we show that Gata3-null mutant mice generate fewer LT-HSCs and that fewer Gata3-null LT-HSCs are in cycle.||GATA-3 is important for hematopoietic stem cell (HSC) function.": [
    0.010411919094622135,
    0.9086610674858093,
    0.08092699199914932
  ],
  "Furthermore, Gata3 mutant hematopoietic progenitor cells fail to be recruited into an increased cycling state after 5-fluorouracil-induced myelosuppression.||GATA-3 is important for hematopoietic stem cell (HSC) function.": [
    0.2938639521598816,
    0.5011663436889648,
    0.20496973395347595
  ],
  "Therefore, GATA-3 is required for the maintenance of a normal number of LT-HSCs and for their entry into the cell cycle.||GATA-3 is important for hematopoietic stem cell (HSC) function.": [
    0.004709628876298666,
    0.2695941627025604,
    0.7256962656974792
  ],
  "OBJECTIVE To evaluate if a specific exercise strategy, targeting the rotator cuff and scapula stabilisers, improves shoulder function and pain more than unspecific exercises in patients with subacromial impingement syndrome, thereby decreasing the need for arthroscopic subacromial decompression.   \n||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.9409703612327576,
    0.034075021743774414,
    0.024954544380307198
  ],
  "DESIGN Randomised, participant and single assessor blinded, controlled study.   \n||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.28555670380592346,
    0.6935497522354126,
    0.02089347317814827
  ],
  "SETTING Department of orthopaedics in a Swedish university hospital.   \n||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.25594818592071533,
    0.7378397583961487,
    0.006211999803781509
  ],
  "PARTICIPANTS 102 patients with long standing (over six months) persistent subacromial impingement syndrome in whom earlier conservative treatment had failed, recruited through orthopaedic specialists.   \n||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.37258487939834595,
    0.62177973985672,
    0.00563545199111104
  ],
  "INTERVENTIONS The specific exercise strategy consisted of strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers in combination with manual mobilisation.||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.31851544976234436,
    0.6787434816360474,
    0.002741110511124134
  ],
  "The control exercise programme consisted of unspecific movement exercises for the neck and shoulder.||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.015452586114406586,
    0.9772588014602661,
    0.0072886454872787
  ],
  "Patients in both groups received five to six individual guided treatment sessions during 12 weeks.||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.042652565985918045,
    0.9554811716079712,
    0.001866281614638865
  ],
  "In between these supervised sessions the participants performed home exercises once or twice a day for 12 weeks.   \n||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.0024119685404002666,
    0.9964794516563416,
    0.0011085980804637074
  ],
  "MAIN OUTCOME MEASURES The primary outcome was the Constant-Murley shoulder assessment score evaluating shoulder function and pain.||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.009268755093216896,
    0.9898848533630371,
    0.0008464272250421345
  ],
  "Secondary outcomes were patients' global impression of change because of treatment and decision regarding surgery.   \n||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.13210445642471313,
    0.8617295622825623,
    0.006165968719869852
  ],
  "RESULTS Most (97, 95%) participants completed the 12 week study.||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.23726296424865723,
    0.7343383431434631,
    0.028398752212524414
  ],
  "There was a significantly greater improvement in the Constant-Murley score in the specific exercise group than in the control exercise group (24 points (95% confidence interval 19 to 28.0) v 9 points (5 to 13); mean difference between group: 15 points (8.5 to 20.6)).||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.13408879935741425,
    0.8072658777236938,
    0.05864529311656952
  ],
  "Significantly more patients in the specific exercise group reported successful outcome (defined as large improvement or recovered) in the patients' global assessment of change because of treatment: 69% (35/51) v 24% (11/46); odds ratio 7.6, 3.1 to 18.9; P<0.001.||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.22097857296466827,
    0.7532234787940979,
    0.025797918438911438
  ],
  "A significantly lower proportion of patients in the specific exercise group subsequently chose to undergo surgery: 20% (10/51) v 63% (29/46); odds ratio 7.7, 3.1 to 19.4; P<0.001).   \n||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.005718738306313753,
    0.8736017346382141,
    0.12067951261997223
  ],
  "CONCLUSION A specific exercise strategy, focusing on strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers, is effective in reducing pain and improving shoulder function in patients with persistent subacromial impingement syndrome.||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.9656786322593689,
    0.03283414617180824,
    0.0014871786115691066
  ],
  "By extension, this exercise strategy reduces the need for arthroscopic subacromial decompression within the three month timeframe used in the study.   \n||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.026551447808742523,
    0.8376784920692444,
    0.13577011227607727
  ],
  "TRIAL REGISTRATION Clinical trials NCT01037673.||General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.": [
    0.31354665756225586,
    0.6745178699493408,
    0.011935465037822723
  ],
  "OBJECTIVE To evaluate if a specific exercise strategy, targeting the rotator cuff and scapula stabilisers, improves shoulder function and pain more than unspecific exercises in patients with subacromial impingement syndrome, thereby decreasing the need for arthroscopic subacromial decompression.   \n||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.9698336124420166,
    0.01849503442645073,
    0.011671390384435654
  ],
  "DESIGN Randomised, participant and single assessor blinded, controlled study.   \n||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.1893167793750763,
    0.7689699530601501,
    0.041713278740644455
  ],
  "SETTING Department of orthopaedics in a Swedish university hospital.   \n||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.2021789848804474,
    0.7909294962882996,
    0.006891454569995403
  ],
  "PARTICIPANTS 102 patients with long standing (over six months) persistent subacromial impingement syndrome in whom earlier conservative treatment had failed, recruited through orthopaedic specialists.   \n||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.34901314973831177,
    0.6467002034187317,
    0.004286620300263166
  ],
  "INTERVENTIONS The specific exercise strategy consisted of strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers in combination with manual mobilisation.||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.22627823054790497,
    0.7714139819145203,
    0.0023077840451151133
  ],
  "The control exercise programme consisted of unspecific movement exercises for the neck and shoulder.||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.016780270263552666,
    0.9769200086593628,
    0.006299707572907209
  ],
  "Patients in both groups received five to six individual guided treatment sessions during 12 weeks.||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.010642239823937416,
    0.9883390665054321,
    0.0010186745785176754
  ],
  "In between these supervised sessions the participants performed home exercises once or twice a day for 12 weeks.   \n||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.001271913992241025,
    0.9976840019226074,
    0.0010440521873533726
  ],
  "MAIN OUTCOME MEASURES The primary outcome was the Constant-Murley shoulder assessment score evaluating shoulder function and pain.||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.006280805915594101,
    0.9929693341255188,
    0.0007498560007661581
  ],
  "Secondary outcomes were patients' global impression of change because of treatment and decision regarding surgery.   \n||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.1259540170431137,
    0.8698325157165527,
    0.004213448613882065
  ],
  "RESULTS Most (97, 95%) participants completed the 12 week study.||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.16779786348342896,
    0.7895863652229309,
    0.04261581599712372
  ],
  "There was a significantly greater improvement in the Constant-Murley score in the specific exercise group than in the control exercise group (24 points (95% confidence interval 19 to 28.0) v 9 points (5 to 13); mean difference between group: 15 points (8.5 to 20.6)).||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.02300834283232689,
    0.876969039440155,
    0.10002263635396957
  ],
  "Significantly more patients in the specific exercise group reported successful outcome (defined as large improvement or recovered) in the patients' global assessment of change because of treatment: 69% (35/51) v 24% (11/46); odds ratio 7.6, 3.1 to 18.9; P<0.001.||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.05570424720644951,
    0.9042007923126221,
    0.04009493440389633
  ],
  "A significantly lower proportion of patients in the specific exercise group subsequently chose to undergo surgery: 20% (10/51) v 63% (29/46); odds ratio 7.7, 3.1 to 19.4; P<0.001).   \n||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.00494670495390892,
    0.8717966675758362,
    0.12325660139322281
  ],
  "CONCLUSION A specific exercise strategy, focusing on strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers, is effective in reducing pain and improving shoulder function in patients with persistent subacromial impingement syndrome.||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.9574306607246399,
    0.040553607046604156,
    0.0020157229155302048
  ],
  "By extension, this exercise strategy reduces the need for arthroscopic subacromial decompression within the three month timeframe used in the study.   \n||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.01572992652654648,
    0.7641392350196838,
    0.22013084590435028
  ],
  "TRIAL REGISTRATION Clinical trials NCT01037673.||General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.": [
    0.20061299204826355,
    0.7742248177528381,
    0.02516225539147854
  ],
  "OBJECTIVE To evaluate if a specific exercise strategy, targeting the rotator cuff and scapula stabilisers, improves shoulder function and pain more than unspecific exercises in patients with subacromial impingement syndrome, thereby decreasing the need for arthroscopic subacromial decompression.   \n||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.019408676773309708,
    0.7069382071495056,
    0.2736530900001526
  ],
  "DESIGN Randomised, participant and single assessor blinded, controlled study.   \n||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.06209582835435867,
    0.8882594108581543,
    0.04964478686451912
  ],
  "SETTING Department of orthopaedics in a Swedish university hospital.   \n||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.02293788082897663,
    0.9697203040122986,
    0.007341868244111538
  ],
  "PARTICIPANTS 102 patients with long standing (over six months) persistent subacromial impingement syndrome in whom earlier conservative treatment had failed, recruited through orthopaedic specialists.   \n||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.3467095196247101,
    0.6496407389640808,
    0.003649720223620534
  ],
  "INTERVENTIONS The specific exercise strategy consisted of strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers in combination with manual mobilisation.||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.001394985942170024,
    0.997648298740387,
    0.0009567438974045217
  ],
  "The control exercise programme consisted of unspecific movement exercises for the neck and shoulder.||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.020582154393196106,
    0.978228747844696,
    0.0011890437453985214
  ],
  "Patients in both groups received five to six individual guided treatment sessions during 12 weeks.||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.0019639749079942703,
    0.997072696685791,
    0.0009633178706280887
  ],
  "In between these supervised sessions the participants performed home exercises once or twice a day for 12 weeks.   \n||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.0014156409306451678,
    0.9976669549942017,
    0.0009173803846351802
  ],
  "MAIN OUTCOME MEASURES The primary outcome was the Constant-Murley shoulder assessment score evaluating shoulder function and pain.||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.006244190968573093,
    0.9930042624473572,
    0.0007515569450333714
  ],
  "Secondary outcomes were patients' global impression of change because of treatment and decision regarding surgery.   \n||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.06645680218935013,
    0.9225699305534363,
    0.010973259806632996
  ],
  "RESULTS Most (97, 95%) participants completed the 12 week study.||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.12908917665481567,
    0.7746800184249878,
    0.09623081982135773
  ],
  "There was a significantly greater improvement in the Constant-Murley score in the specific exercise group than in the control exercise group (24 points (95% confidence interval 19 to 28.0) v 9 points (5 to 13); mean difference between group: 15 points (8.5 to 20.6)).||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.005406991112977266,
    0.9394353628158569,
    0.055157676339149475
  ],
  "Significantly more patients in the specific exercise group reported successful outcome (defined as large improvement or recovered) in the patients' global assessment of change because of treatment: 69% (35/51) v 24% (11/46); odds ratio 7.6, 3.1 to 18.9; P<0.001.||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.002657580655068159,
    0.974748969078064,
    0.02259342558681965
  ],
  "A significantly lower proportion of patients in the specific exercise group subsequently chose to undergo surgery: 20% (10/51) v 63% (29/46); odds ratio 7.7, 3.1 to 19.4; P<0.001).   \n||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.00552339619025588,
    0.9171870946884155,
    0.07728952914476395
  ],
  "CONCLUSION A specific exercise strategy, focusing on strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers, is effective in reducing pain and improving shoulder function in patients with persistent subacromial impingement syndrome.||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.0012963460758328438,
    0.99275803565979,
    0.005945650860667229
  ],
  "By extension, this exercise strategy reduces the need for arthroscopic subacromial decompression within the three month timeframe used in the study.   \n||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.006999645847827196,
    0.9713525176048279,
    0.021647820249199867
  ],
  "TRIAL REGISTRATION Clinical trials NCT01037673.||Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.06248984858393669,
    0.9024237394332886,
    0.03508642688393593
  ],
  "OBJECTIVE To evaluate if a specific exercise strategy, targeting the rotator cuff and scapula stabilisers, improves shoulder function and pain more than unspecific exercises in patients with subacromial impingement syndrome, thereby decreasing the need for arthroscopic subacromial decompression.   \n||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.03212105482816696,
    0.6122869253158569,
    0.35559195280075073
  ],
  "DESIGN Randomised, participant and single assessor blinded, controlled study.   \n||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.07853685319423676,
    0.8476077914237976,
    0.07385535538196564
  ],
  "SETTING Department of orthopaedics in a Swedish university hospital.   \n||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.03356937691569328,
    0.9523060917854309,
    0.014124606736004353
  ],
  "PARTICIPANTS 102 patients with long standing (over six months) persistent subacromial impingement syndrome in whom earlier conservative treatment had failed, recruited through orthopaedic specialists.   \n||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.4305383563041687,
    0.5658947825431824,
    0.003566868370398879
  ],
  "INTERVENTIONS The specific exercise strategy consisted of strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers in combination with manual mobilisation.||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.0015004788292571902,
    0.9975624084472656,
    0.0009370804764330387
  ],
  "The control exercise programme consisted of unspecific movement exercises for the neck and shoulder.||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.033826153725385666,
    0.9646068811416626,
    0.0015669554704800248
  ],
  "Patients in both groups received five to six individual guided treatment sessions during 12 weeks.||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.0017856501508504152,
    0.9973616003990173,
    0.0008527842001058161
  ],
  "In between these supervised sessions the participants performed home exercises once or twice a day for 12 weeks.   \n||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.0014285671059042215,
    0.9976626634597778,
    0.0009087506914511323
  ],
  "MAIN OUTCOME MEASURES The primary outcome was the Constant-Murley shoulder assessment score evaluating shoulder function and pain.||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.007268632762134075,
    0.9918770790100098,
    0.0008542880532331765
  ],
  "Secondary outcomes were patients' global impression of change because of treatment and decision regarding surgery.   \n||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.06057450547814369,
    0.9300053119659424,
    0.009420187212526798
  ],
  "RESULTS Most (97, 95%) participants completed the 12 week study.||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.15171431005001068,
    0.7385891675949097,
    0.10969649255275726
  ],
  "There was a significantly greater improvement in the Constant-Murley score in the specific exercise group than in the control exercise group (24 points (95% confidence interval 19 to 28.0) v 9 points (5 to 13); mean difference between group: 15 points (8.5 to 20.6)).||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.007932513020932674,
    0.9135364890098572,
    0.07853105664253235
  ],
  "Significantly more patients in the specific exercise group reported successful outcome (defined as large improvement or recovered) in the patients' global assessment of change because of treatment: 69% (35/51) v 24% (11/46); odds ratio 7.6, 3.1 to 18.9; P<0.001.||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.003677320433780551,
    0.9687336683273315,
    0.0275889802724123
  ],
  "A significantly lower proportion of patients in the specific exercise group subsequently chose to undergo surgery: 20% (10/51) v 63% (29/46); odds ratio 7.7, 3.1 to 19.4; P<0.001).   \n||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.005175692494958639,
    0.8810341358184814,
    0.1137901321053505
  ],
  "CONCLUSION A specific exercise strategy, focusing on strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers, is effective in reducing pain and improving shoulder function in patients with persistent subacromial impingement syndrome.||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.002589727519080043,
    0.9913434982299805,
    0.006066728848963976
  ],
  "By extension, this exercise strategy reduces the need for arthroscopic subacromial decompression within the three month timeframe used in the study.   \n||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.010471389628946781,
    0.9072705507278442,
    0.08225808292627335
  ],
  "TRIAL REGISTRATION Clinical trials NCT01037673.||Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.": [
    0.09476001560688019,
    0.862998902797699,
    0.04224105551838875
  ],
  "Mice lacking junctional adhesion molecule A (JAM-A, encoded by F11r) exhibit enhanced intestinal epithelial permeability, bacterial translocation, and elevated colonic lymphocyte numbers, yet do not develop colitis.||Genetic deletion of JAM-A increases gut permeability.": [
    0.0028480777982622385,
    0.19749952852725983,
    0.7996523976325989
  ],
  "To investigate the contribution of adaptive immune compensation in response to increased intestinal epithelial permeability, we examined the susceptibility of F11r(-/-)Rag1(-/-) mice to acute colitis.||Genetic deletion of JAM-A increases gut permeability.": [
    0.07809107005596161,
    0.8929647207260132,
    0.02894425019621849
  ],
  "Although negligible contributions of adaptive immunity in F11r(+/+)Rag1(-/-) mice were observed, F11r(-/-)Rag1(-/-) mice exhibited increased microflora-dependent colitis.||Genetic deletion of JAM-A increases gut permeability.": [
    0.4499884247779846,
    0.5429829359054565,
    0.007028657477349043
  ],
  "Elimination of T cell subsets and cytokine analyses revealed a protective role for TGF-\u03b2-producing CD4(+) T cells in F11r(-/-) mice.||Genetic deletion of JAM-A increases gut permeability.": [
    0.4156131148338318,
    0.5610493421554565,
    0.02333751507103443
  ],
  "Additionally, loss of JAM-A resulted in elevated mucosal and serum IgA that was dependent upon CD4(+) T cells and TGF-\u03b2.||Genetic deletion of JAM-A increases gut permeability.": [
    0.8178067207336426,
    0.16593682765960693,
    0.016256513074040413
  ],
  "Absence of IgA in F11r(+/+)Igha(-/-) mice did not affect disease, whereas F11r(-/-)Igha(-/-) mice displayed markedly increased susceptibility to acute injury-induced colitis.||Genetic deletion of JAM-A increases gut permeability.": [
    0.5734871625900269,
    0.3892337679862976,
    0.037279050797224045
  ],
  "These data establish a role for adaptive immune-mediated protection from acute colitis under conditions of intestinal epithelial barrier compromise.||Genetic deletion of JAM-A increases gut permeability.": [
    0.517391562461853,
    0.4719832241535187,
    0.010625191032886505
  ],
  "Mice lacking junctional adhesion molecule A (JAM-A, encoded by F11r) exhibit enhanced intestinal epithelial permeability, bacterial translocation, and elevated colonic lymphocyte numbers, yet do not develop colitis.||Increased flux of microbial products provokes immune responses.": [
    0.008413161151111126,
    0.49624529480934143,
    0.4953414797782898
  ],
  "To investigate the contribution of adaptive immune compensation in response to increased intestinal epithelial permeability, we examined the susceptibility of F11r(-/-)Rag1(-/-) mice to acute colitis.||Increased flux of microbial products provokes immune responses.": [
    0.013861652463674545,
    0.39371851086616516,
    0.5924198627471924
  ],
  "Although negligible contributions of adaptive immunity in F11r(+/+)Rag1(-/-) mice were observed, F11r(-/-)Rag1(-/-) mice exhibited increased microflora-dependent colitis.||Increased flux of microbial products provokes immune responses.": [
    0.27382463216781616,
    0.4107801020145416,
    0.3153952956199646
  ],
  "Elimination of T cell subsets and cytokine analyses revealed a protective role for TGF-\u03b2-producing CD4(+) T cells in F11r(-/-) mice.||Increased flux of microbial products provokes immune responses.": [
    0.10145621001720428,
    0.7948894500732422,
    0.10365430265665054
  ],
  "Additionally, loss of JAM-A resulted in elevated mucosal and serum IgA that was dependent upon CD4(+) T cells and TGF-\u03b2.||Increased flux of microbial products provokes immune responses.": [
    0.007004485931247473,
    0.3352753520011902,
    0.657720148563385
  ],
  "Absence of IgA in F11r(+/+)Igha(-/-) mice did not affect disease, whereas F11r(-/-)Igha(-/-) mice displayed markedly increased susceptibility to acute injury-induced colitis.||Increased flux of microbial products provokes immune responses.": [
    0.06568195670843124,
    0.769120991230011,
    0.16519702970981598
  ],
  "These data establish a role for adaptive immune-mediated protection from acute colitis under conditions of intestinal epithelial barrier compromise.||Increased flux of microbial products provokes immune responses.": [
    0.01552830170840025,
    0.889436662197113,
    0.09503500908613205
  ],
  "Mice lacking junctional adhesion molecule A (JAM-A, encoded by F11r) exhibit enhanced intestinal epithelial permeability, bacterial translocation, and elevated colonic lymphocyte numbers, yet do not develop colitis.||Increased flux of microbial products suppresses immune responses.": [
    0.21683093905448914,
    0.6754336953163147,
    0.10773542523384094
  ],
  "To investigate the contribution of adaptive immune compensation in response to increased intestinal epithelial permeability, we examined the susceptibility of F11r(-/-)Rag1(-/-) mice to acute colitis.||Increased flux of microbial products suppresses immune responses.": [
    0.7860273718833923,
    0.18497419357299805,
    0.02899840846657753
  ],
  "Although negligible contributions of adaptive immunity in F11r(+/+)Rag1(-/-) mice were observed, F11r(-/-)Rag1(-/-) mice exhibited increased microflora-dependent colitis.||Increased flux of microbial products suppresses immune responses.": [
    0.004722642246633768,
    0.6696953773498535,
    0.32558202743530273
  ],
  "Elimination of T cell subsets and cytokine analyses revealed a protective role for TGF-\u03b2-producing CD4(+) T cells in F11r(-/-) mice.||Increased flux of microbial products suppresses immune responses.": [
    0.7152733206748962,
    0.27451467514038086,
    0.0102120041847229
  ],
  "Additionally, loss of JAM-A resulted in elevated mucosal and serum IgA that was dependent upon CD4(+) T cells and TGF-\u03b2.||Increased flux of microbial products suppresses immune responses.": [
    0.47965067625045776,
    0.4461873173713684,
    0.07416192442178726
  ],
  "Absence of IgA in F11r(+/+)Igha(-/-) mice did not affect disease, whereas F11r(-/-)Igha(-/-) mice displayed markedly increased susceptibility to acute injury-induced colitis.||Increased flux of microbial products suppresses immune responses.": [
    0.021299324929714203,
    0.8813291192054749,
    0.09737151861190796
  ],
  "These data establish a role for adaptive immune-mediated protection from acute colitis under conditions of intestinal epithelial barrier compromise.||Increased flux of microbial products suppresses immune responses.": [
    0.7557672262191772,
    0.23783659934997559,
    0.006396165117621422
  ],
  "Mice lacking junctional adhesion molecule A (JAM-A, encoded by F11r) exhibit enhanced intestinal epithelial permeability, bacterial translocation, and elevated colonic lymphocyte numbers, yet do not develop colitis.||Immune responses result in the development of inflammatory Th17 cells and anti-inflammatory iTregs.": [
    0.09878847002983093,
    0.8961830735206604,
    0.005028437357395887
  ],
  "To investigate the contribution of adaptive immune compensation in response to increased intestinal epithelial permeability, we examined the susceptibility of F11r(-/-)Rag1(-/-) mice to acute colitis.||Immune responses result in the development of inflammatory Th17 cells and anti-inflammatory iTregs.": [
    0.0036192908883094788,
    0.9949005246162415,
    0.0014802230289205909
  ],
  "Although negligible contributions of adaptive immunity in F11r(+/+)Rag1(-/-) mice were observed, F11r(-/-)Rag1(-/-) mice exhibited increased microflora-dependent colitis.||Immune responses result in the development of inflammatory Th17 cells and anti-inflammatory iTregs.": [
    0.17203320562839508,
    0.82309490442276,
    0.0048718685284256935
  ],
  "Elimination of T cell subsets and cytokine analyses revealed a protective role for TGF-\u03b2-producing CD4(+) T cells in F11r(-/-) mice.||Immune responses result in the development of inflammatory Th17 cells and anti-inflammatory iTregs.": [
    0.9216371774673462,
    0.07373209297657013,
    0.004630679730325937
  ],
  "Additionally, loss of JAM-A resulted in elevated mucosal and serum IgA that was dependent upon CD4(+) T cells and TGF-\u03b2.||Immune responses result in the development of inflammatory Th17 cells and anti-inflammatory iTregs.": [
    0.16179053485393524,
    0.7186837792396545,
    0.11952567845582962
  ],
  "Absence of IgA in F11r(+/+)Igha(-/-) mice did not affect disease, whereas F11r(-/-)Igha(-/-) mice displayed markedly increased susceptibility to acute injury-induced colitis.||Immune responses result in the development of inflammatory Th17 cells and anti-inflammatory iTregs.": [
    0.07336270809173584,
    0.9127954840660095,
    0.013841837644577026
  ],
  "These data establish a role for adaptive immune-mediated protection from acute colitis under conditions of intestinal epithelial barrier compromise.||Immune responses result in the development of inflammatory Th17 cells and anti-inflammatory iTregs.": [
    0.02129462920129299,
    0.9759829044342041,
    0.0027224437799304724
  ],
  "The multifunctional signaling protein p75 neurotrophin receptor (p75(NTR)) is a central regulator and major contributor to the highly invasive nature of malignant gliomas.||Guanine nucleotide dissociation inhibitor (Rho-GDI) interacts with the p75 NTR death domain": [
    0.29345130920410156,
    0.6970241665840149,
    0.009524472989141941
  ],
  "Here, we show that neurotrophin-dependent regulated intramembrane proteolysis (RIP) of p75(NTR) is required for p75(NTR)-mediated glioma invasion, and identify a previously unnamed process for targeted glioma therapy.||Guanine nucleotide dissociation inhibitor (Rho-GDI) interacts with the p75 NTR death domain": [
    0.3016824722290039,
    0.6208727955818176,
    0.07744476944208145
  ],
  "Expression of cleavage-resistant chimeras of p75(NTR) or treatment of animals bearing p75(NTR)-positive intracranial tumors with clinically applicable gamma-secretase inhibitors resulted in dramatically decreased glioma invasion and prolonged survival.||Guanine nucleotide dissociation inhibitor (Rho-GDI) interacts with the p75 NTR death domain": [
    0.21589556336402893,
    0.695825457572937,
    0.08827898651361465
  ],
  "Importantly, proteolytic processing of p75(NTR) was observed in p75(NTR)-positive patient tumor specimens and brain tumor initiating cells.||Guanine nucleotide dissociation inhibitor (Rho-GDI) interacts with the p75 NTR death domain": [
    0.08451825380325317,
    0.8846771717071533,
    0.030804522335529327
  ],
  "This work highlights the importance of p75(NTR) as a therapeutic target, suggesting that gamma-secretase inhibitors may have direct clinical application for the treatment of malignant glioma.||Guanine nucleotide dissociation inhibitor (Rho-GDI) interacts with the p75 NTR death domain": [
    0.15380319952964783,
    0.7935090065002441,
    0.052687790244817734
  ],
  "The multifunctional signaling protein p75 neurotrophin receptor (p75(NTR)) is a central regulator and major contributor to the highly invasive nature of malignant gliomas.||Ribosome-inactivating protein-2 (RIP-2) interacts with the p75 NTR death domain": [
    0.2542850971221924,
    0.7392241358757019,
    0.006490806117653847
  ],
  "Here, we show that neurotrophin-dependent regulated intramembrane proteolysis (RIP) of p75(NTR) is required for p75(NTR)-mediated glioma invasion, and identify a previously unnamed process for targeted glioma therapy.||Ribosome-inactivating protein-2 (RIP-2) interacts with the p75 NTR death domain": [
    0.13507626950740814,
    0.7785992622375488,
    0.08632444590330124
  ],
  "Expression of cleavage-resistant chimeras of p75(NTR) or treatment of animals bearing p75(NTR)-positive intracranial tumors with clinically applicable gamma-secretase inhibitors resulted in dramatically decreased glioma invasion and prolonged survival.||Ribosome-inactivating protein-2 (RIP-2) interacts with the p75 NTR death domain": [
    0.07552909106016159,
    0.8880613446235657,
    0.03640959784388542
  ],
  "Importantly, proteolytic processing of p75(NTR) was observed in p75(NTR)-positive patient tumor specimens and brain tumor initiating cells.||Ribosome-inactivating protein-2 (RIP-2) interacts with the p75 NTR death domain": [
    0.02553636208176613,
    0.9514947533607483,
    0.022968867793679237
  ],
  "This work highlights the importance of p75(NTR) as a therapeutic target, suggesting that gamma-secretase inhibitors may have direct clinical application for the treatment of malignant glioma.||Ribosome-inactivating protein-2 (RIP-2) interacts with the p75 NTR death domain": [
    0.03205827623605728,
    0.9512330889701843,
    0.016708627343177795
  ],
  "The multifunctional signaling protein p75 neurotrophin receptor (p75(NTR)) is a central regulator and major contributor to the highly invasive nature of malignant gliomas.||p75 NTR - associated cell death executor (NADE) interacts with the p75 NTR death domain": [
    0.41852253675460815,
    0.5585147738456726,
    0.02296276018023491
  ],
  "Here, we show that neurotrophin-dependent regulated intramembrane proteolysis (RIP) of p75(NTR) is required for p75(NTR)-mediated glioma invasion, and identify a previously unnamed process for targeted glioma therapy.||p75 NTR - associated cell death executor (NADE) interacts with the p75 NTR death domain": [
    0.3346799910068512,
    0.5065672993659973,
    0.1587526500225067
  ],
  "Expression of cleavage-resistant chimeras of p75(NTR) or treatment of animals bearing p75(NTR)-positive intracranial tumors with clinically applicable gamma-secretase inhibitors resulted in dramatically decreased glioma invasion and prolonged survival.||p75 NTR - associated cell death executor (NADE) interacts with the p75 NTR death domain": [
    0.3216717839241028,
    0.561818540096283,
    0.11650969088077545
  ],
  "Importantly, proteolytic processing of p75(NTR) was observed in p75(NTR)-positive patient tumor specimens and brain tumor initiating cells.||p75 NTR - associated cell death executor (NADE) interacts with the p75 NTR death domain": [
    0.306880384683609,
    0.555378258228302,
    0.13774137198925018
  ],
  "This work highlights the importance of p75(NTR) as a therapeutic target, suggesting that gamma-secretase inhibitors may have direct clinical application for the treatment of malignant glioma.||p75 NTR - associated cell death executor (NADE) interacts with the p75 NTR death domain": [
    0.370457261800766,
    0.5629764199256897,
    0.06656632572412491
  ],
  "Histone levels are tightly regulated to prevent harmful effects such as genomic instability and hypersensitivity to DNA-damaging agents due to the accumulation of these highly basic proteins when DNA replication slows down or stops.||H4 G94P proteins induce chromatin assembly, which increases free histones.": [
    0.09175097197294235,
    0.8836496472358704,
    0.02459939755499363
  ],
  "Although chromosomal histones are stable, excess (non-chromatin bound) histones are rapidly degraded in a Rad53 (radiation sensitive 53) kinase-dependent manner in Saccharomyces cerevisiae.||H4 G94P proteins induce chromatin assembly, which increases free histones.": [
    0.7195772528648376,
    0.27293720841407776,
    0.007485513109713793
  ],
  "Here we demonstrate that excess histones associate with Rad53 in vivo and seem to undergo modifications such as tyrosine phosphorylation and polyubiquitylation, before their proteolysis by the proteasome.||H4 G94P proteins induce chromatin assembly, which increases free histones.": [
    0.7148046493530273,
    0.27647197246551514,
    0.008723357692360878
  ],
  "We have identified the Tyr 99 residue of histone H3 as being critical for the efficient ubiquitylation and degradation of this histone.||H4 G94P proteins induce chromatin assembly, which increases free histones.": [
    0.4952736496925354,
    0.4967646300792694,
    0.007961656898260117
  ],
  "We have also identified the ubiquitin conjugating enzymes (E2) Ubc4 and Ubc5, as well as the ubiquitin ligase (E3) Tom1 (temperature dependent organization in mitotic nucleus 1), as enzymes involved in the ubiquitylation of excess histones.||H4 G94P proteins induce chromatin assembly, which increases free histones.": [
    0.6946582198143005,
    0.26642853021621704,
    0.03891323134303093
  ],
  "Regulated histone proteolysis has major implications for the maintenance of epigenetic marks on chromatin, genomic stability and the packaging of sperm DNA.||H4 G94P proteins induce chromatin assembly, which increases free histones.": [
    0.20963166654109955,
    0.7745948433876038,
    0.015773534774780273
  ],
  "Histone levels are tightly regulated to prevent harmful effects such as genomic instability and hypersensitivity to DNA-damaging agents due to the accumulation of these highly basic proteins when DNA replication slows down or stops.||H4 G94P proteins induce degradation of free histones via Rad53-dependent mechanisms.": [
    0.8341654539108276,
    0.1598772257566452,
    0.005957361776381731
  ],
  "Although chromosomal histones are stable, excess (non-chromatin bound) histones are rapidly degraded in a Rad53 (radiation sensitive 53) kinase-dependent manner in Saccharomyces cerevisiae.||H4 G94P proteins induce degradation of free histones via Rad53-dependent mechanisms.": [
    0.03753228858113289,
    0.9034180641174316,
    0.05904962867498398
  ],
  "Here we demonstrate that excess histones associate with Rad53 in vivo and seem to undergo modifications such as tyrosine phosphorylation and polyubiquitylation, before their proteolysis by the proteasome.||H4 G94P proteins induce degradation of free histones via Rad53-dependent mechanisms.": [
    0.5378381013870239,
    0.3792705833911896,
    0.0828913077712059
  ],
  "We have identified the Tyr 99 residue of histone H3 as being critical for the efficient ubiquitylation and degradation of this histone.||H4 G94P proteins induce degradation of free histones via Rad53-dependent mechanisms.": [
    0.4477260112762451,
    0.5360639095306396,
    0.016210105270147324
  ],
  "We have also identified the ubiquitin conjugating enzymes (E2) Ubc4 and Ubc5, as well as the ubiquitin ligase (E3) Tom1 (temperature dependent organization in mitotic nucleus 1), as enzymes involved in the ubiquitylation of excess histones.||H4 G94P proteins induce degradation of free histones via Rad53-dependent mechanisms.": [
    0.7752218842506409,
    0.21358861029148102,
    0.01118940208107233
  ],
  "Regulated histone proteolysis has major implications for the maintenance of epigenetic marks on chromatin, genomic stability and the packaging of sperm DNA.||H4 G94P proteins induce degradation of free histones via Rad53-dependent mechanisms.": [
    0.05306049808859825,
    0.9388952255249023,
    0.008044270798563957
  ],
  "Histone levels are tightly regulated to prevent harmful effects such as genomic instability and hypersensitivity to DNA-damaging agents due to the accumulation of these highly basic proteins when DNA replication slows down or stops.||H4 G94P proteins inhibit chromatin assembly, which decreases free histones.": [
    0.40967339277267456,
    0.5643597841262817,
    0.02596678026020527
  ],
  "Although chromosomal histones are stable, excess (non-chromatin bound) histones are rapidly degraded in a Rad53 (radiation sensitive 53) kinase-dependent manner in Saccharomyces cerevisiae.||H4 G94P proteins inhibit chromatin assembly, which decreases free histones.": [
    0.2006528079509735,
    0.7742615342140198,
    0.025085633620619774
  ],
  "Here we demonstrate that excess histones associate with Rad53 in vivo and seem to undergo modifications such as tyrosine phosphorylation and polyubiquitylation, before their proteolysis by the proteasome.||H4 G94P proteins inhibit chromatin assembly, which decreases free histones.": [
    0.5856545567512512,
    0.4055668115615845,
    0.008778628893196583
  ],
  "We have identified the Tyr 99 residue of histone H3 as being critical for the efficient ubiquitylation and degradation of this histone.||H4 G94P proteins inhibit chromatin assembly, which decreases free histones.": [
    0.5355831980705261,
    0.45583537220954895,
    0.008581404574215412
  ],
  "We have also identified the ubiquitin conjugating enzymes (E2) Ubc4 and Ubc5, as well as the ubiquitin ligase (E3) Tom1 (temperature dependent organization in mitotic nucleus 1), as enzymes involved in the ubiquitylation of excess histones.||H4 G94P proteins inhibit chromatin assembly, which decreases free histones.": [
    0.8908711671829224,
    0.09785345196723938,
    0.011275378055870533
  ],
  "Regulated histone proteolysis has major implications for the maintenance of epigenetic marks on chromatin, genomic stability and the packaging of sperm DNA.||H4 G94P proteins inhibit chromatin assembly, which decreases free histones.": [
    0.15314333140850067,
    0.8304597735404968,
    0.016396930441260338
  ],
  "Histone levels are tightly regulated to prevent harmful effects such as genomic instability and hypersensitivity to DNA-damaging agents due to the accumulation of these highly basic proteins when DNA replication slows down or stops.||H4 G94P proteins suppress degradation of free histones via Rad53-dependent mechanisms.": [
    0.022651689127087593,
    0.9677978157997131,
    0.00955049879848957
  ],
  "Although chromosomal histones are stable, excess (non-chromatin bound) histones are rapidly degraded in a Rad53 (radiation sensitive 53) kinase-dependent manner in Saccharomyces cerevisiae.||H4 G94P proteins suppress degradation of free histones via Rad53-dependent mechanisms.": [
    0.8517501354217529,
    0.11654892563819885,
    0.03170089051127434
  ],
  "Here we demonstrate that excess histones associate with Rad53 in vivo and seem to undergo modifications such as tyrosine phosphorylation and polyubiquitylation, before their proteolysis by the proteasome.||H4 G94P proteins suppress degradation of free histones via Rad53-dependent mechanisms.": [
    0.5966752767562866,
    0.32205528020858765,
    0.08126941323280334
  ],
  "We have identified the Tyr 99 residue of histone H3 as being critical for the efficient ubiquitylation and degradation of this histone.||H4 G94P proteins suppress degradation of free histones via Rad53-dependent mechanisms.": [
    0.6761707663536072,
    0.31934285163879395,
    0.004486399237066507
  ],
  "We have also identified the ubiquitin conjugating enzymes (E2) Ubc4 and Ubc5, as well as the ubiquitin ligase (E3) Tom1 (temperature dependent organization in mitotic nucleus 1), as enzymes involved in the ubiquitylation of excess histones.||H4 G94P proteins suppress degradation of free histones via Rad53-dependent mechanisms.": [
    0.702564537525177,
    0.28597864508628845,
    0.011456772685050964
  ],
  "Regulated histone proteolysis has major implications for the maintenance of epigenetic marks on chromatin, genomic stability and the packaging of sperm DNA.||H4 G94P proteins suppress degradation of free histones via Rad53-dependent mechanisms.": [
    0.01810077577829361,
    0.9766801595687866,
    0.005219061393290758
  ],
  "Histone levels are tightly regulated to prevent harmful effects such as genomic instability and hypersensitivity to DNA-damaging agents due to the accumulation of these highly basic proteins when DNA replication slows down or stops.||Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.": [
    0.7715756893157959,
    0.21550728380680084,
    0.01291697472333908
  ],
  "Although chromosomal histones are stable, excess (non-chromatin bound) histones are rapidly degraded in a Rad53 (radiation sensitive 53) kinase-dependent manner in Saccharomyces cerevisiae.||Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.": [
    0.013805168680846691,
    0.9600057601928711,
    0.026189038529992104
  ],
  "Here we demonstrate that excess histones associate with Rad53 in vivo and seem to undergo modifications such as tyrosine phosphorylation and polyubiquitylation, before their proteolysis by the proteasome.||Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.": [
    0.16092367470264435,
    0.826820969581604,
    0.012255413457751274
  ],
  "We have identified the Tyr 99 residue of histone H3 as being critical for the efficient ubiquitylation and degradation of this histone.||Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.": [
    0.06457521766424179,
    0.9294060468673706,
    0.006018708925694227
  ],
  "We have also identified the ubiquitin conjugating enzymes (E2) Ubc4 and Ubc5, as well as the ubiquitin ligase (E3) Tom1 (temperature dependent organization in mitotic nucleus 1), as enzymes involved in the ubiquitylation of excess histones.||Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.": [
    0.3594222664833069,
    0.6362958550453186,
    0.004281874746084213
  ],
  "Regulated histone proteolysis has major implications for the maintenance of epigenetic marks on chromatin, genomic stability and the packaging of sperm DNA.||Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.": [
    0.08173029869794846,
    0.9132378101348877,
    0.005031936336308718
  ],
  "OBJECTIVES To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART).   \n||Having a main partner improves HIV outcomes.": [
    0.006967621389776468,
    0.686992347240448,
    0.306039959192276
  ],
  "DESIGN Prospective cohort study of adults with HIV (Swiss HIV cohort study).   \n||Having a main partner improves HIV outcomes.": [
    0.07912582904100418,
    0.9068475961685181,
    0.01402656827121973
  ],
  "SETTING Seven outpatient clinics throughout Switzerland.   \n||Having a main partner improves HIV outcomes.": [
    0.07068658620119095,
    0.852428674697876,
    0.07688481360673904
  ],
  "PARTICIPANTS The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years).   \n||Having a main partner improves HIV outcomes.": [
    0.004464860539883375,
    0.9659609794616699,
    0.029574168846011162
  ],
  "MAIN OUTCOME MEASURES Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound.   \n||Having a main partner improves HIV outcomes.": [
    0.016466684639453888,
    0.9692995548248291,
    0.014233742840588093
  ],
  "RESULTS During follow up 2985 (80%) participants reported a stable partnership on at least one occasion.||Having a main partner improves HIV outcomes.": [
    0.002544619608670473,
    0.9959778189659119,
    0.001477542333304882
  ],
  "When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership.||Having a main partner improves HIV outcomes.": [
    0.006867954041808844,
    0.973901629447937,
    0.01923045516014099
  ],
  "In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without.||Having a main partner improves HIV outcomes.": [
    0.009540317580103874,
    0.8201476335525513,
    0.1703120768070221
  ],
  "Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression.   \n||Having a main partner improves HIV outcomes.": [
    0.050352804362773895,
    0.8464689254760742,
    0.1031782403588295
  ],
  "CONCLUSIONS A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.||Having a main partner improves HIV outcomes.": [
    0.0019323771120980382,
    0.06734097748994827,
    0.9307267069816589
  ],
  "OBJECTIVES To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART).   \n||Having a main partner worsens HIV outcomes.": [
    0.9583927989006042,
    0.04016700014472008,
    0.0014401762746274471
  ],
  "DESIGN Prospective cohort study of adults with HIV (Swiss HIV cohort study).   \n||Having a main partner worsens HIV outcomes.": [
    0.017036108300089836,
    0.9748890995979309,
    0.00807478278875351
  ],
  "SETTING Seven outpatient clinics throughout Switzerland.   \n||Having a main partner worsens HIV outcomes.": [
    0.1633610725402832,
    0.7974070310592651,
    0.03923185542225838
  ],
  "PARTICIPANTS The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years).   \n||Having a main partner worsens HIV outcomes.": [
    0.034872930496931076,
    0.9535266757011414,
    0.011600377038121223
  ],
  "MAIN OUTCOME MEASURES Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound.   \n||Having a main partner worsens HIV outcomes.": [
    0.13439448177814484,
    0.8604445457458496,
    0.005161010194569826
  ],
  "RESULTS During follow up 2985 (80%) participants reported a stable partnership on at least one occasion.||Having a main partner worsens HIV outcomes.": [
    0.050799623131752014,
    0.9444363117218018,
    0.004764064680784941
  ],
  "When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership.||Having a main partner worsens HIV outcomes.": [
    0.15201395750045776,
    0.8394904732704163,
    0.00849558599293232
  ],
  "In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without.||Having a main partner worsens HIV outcomes.": [
    0.04958963021636009,
    0.791386604309082,
    0.15902379155158997
  ],
  "Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression.   \n||Having a main partner worsens HIV outcomes.": [
    0.03277340531349182,
    0.9099913835525513,
    0.057235222309827805
  ],
  "CONCLUSIONS A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.||Having a main partner worsens HIV outcomes.": [
    0.9985364675521851,
    0.0012054265243932605,
    0.0002580449800007045
  ],
  "OBJECTIVES To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART).   \n||Patients in stable partnerships have a slower progression from HIV to AIDS.": [
    0.010126682929694653,
    0.9867532253265381,
    0.0031201750971376896
  ],
  "DESIGN Prospective cohort study of adults with HIV (Swiss HIV cohort study).   \n||Patients in stable partnerships have a slower progression from HIV to AIDS.": [
    0.007009139284491539,
    0.9920334219932556,
    0.0009574191644787788
  ],
  "SETTING Seven outpatient clinics throughout Switzerland.   \n||Patients in stable partnerships have a slower progression from HIV to AIDS.": [
    0.036924634128808975,
    0.943952202796936,
    0.019123172387480736
  ],
  "PARTICIPANTS The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years).   \n||Patients in stable partnerships have a slower progression from HIV to AIDS.": [
    0.004924665205180645,
    0.9848796725273132,
    0.010195684619247913
  ],
  "MAIN OUTCOME MEASURES Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound.   \n||Patients in stable partnerships have a slower progression from HIV to AIDS.": [
    0.01090383529663086,
    0.9878811836242676,
    0.0012149389367550611
  ],
  "RESULTS During follow up 2985 (80%) participants reported a stable partnership on at least one occasion.||Patients in stable partnerships have a slower progression from HIV to AIDS.": [
    0.002585537265986204,
    0.9965046644210815,
    0.0009098747395910323
  ],
  "When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership.||Patients in stable partnerships have a slower progression from HIV to AIDS.": [
    0.011913321912288666,
    0.9859914183616638,
    0.0020952573977410793
  ],
  "In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without.||Patients in stable partnerships have a slower progression from HIV to AIDS.": [
    0.0035637759137898684,
    0.27495959401130676,
    0.7214766144752502
  ],
  "Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression.   \n||Patients in stable partnerships have a slower progression from HIV to AIDS.": [
    0.049216631799936295,
    0.9403018951416016,
    0.010481423698365688
  ],
  "CONCLUSIONS A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.||Patients in stable partnerships have a slower progression from HIV to AIDS.": [
    0.0020174668170511723,
    0.005843102466315031,
    0.9921393990516663
  ],
  "OBJECTIVES To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART).   \n||Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.": [
    0.5773019194602966,
    0.42034050822257996,
    0.002357569057494402
  ],
  "DESIGN Prospective cohort study of adults with HIV (Swiss HIV cohort study).   \n||Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.": [
    0.2565303146839142,
    0.736596941947937,
    0.006872734986245632
  ],
  "SETTING Seven outpatient clinics throughout Switzerland.   \n||Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.": [
    0.5743934512138367,
    0.4120667576789856,
    0.013539810664951801
  ],
  "PARTICIPANTS The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years).   \n||Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.": [
    0.2355422079563141,
    0.7606863975524902,
    0.003771362826228142
  ],
  "MAIN OUTCOME MEASURES Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound.   \n||Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.": [
    0.21266183257102966,
    0.7829284071922302,
    0.00440980913117528
  ],
  "RESULTS During follow up 2985 (80%) participants reported a stable partnership on at least one occasion.||Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.": [
    0.03702109679579735,
    0.9612273573875427,
    0.0017515551298856735
  ],
  "When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership.||Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.": [
    0.12455668300390244,
    0.8723958730697632,
    0.0030474935192614794
  ],
  "In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without.||Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.": [
    0.8659133911132812,
    0.1215885728597641,
    0.012498069554567337
  ],
  "Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression.   \n||Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.": [
    0.29661861062049866,
    0.6914218068122864,
    0.011959564872086048
  ],
  "CONCLUSIONS A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.||Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.": [
    0.9534059166908264,
    0.04395369067788124,
    0.0026402934454381466
  ],
  "OBJECTIVES To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART).   \n||Patients in stable partnerships have a faster progression from HIV to AIDS.": [
    0.3860093653202057,
    0.610030472278595,
    0.003960154484957457
  ],
  "DESIGN Prospective cohort study of adults with HIV (Swiss HIV cohort study).   \n||Patients in stable partnerships have a faster progression from HIV to AIDS.": [
    0.007523005828261375,
    0.9911631345748901,
    0.0013138403883203864
  ],
  "SETTING Seven outpatient clinics throughout Switzerland.   \n||Patients in stable partnerships have a faster progression from HIV to AIDS.": [
    0.13592658936977386,
    0.8397358059883118,
    0.0243376474827528
  ],
  "PARTICIPANTS The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years).   \n||Patients in stable partnerships have a faster progression from HIV to AIDS.": [
    0.06940039247274399,
    0.9251955151557922,
    0.00540410028770566
  ],
  "MAIN OUTCOME MEASURES Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound.   \n||Patients in stable partnerships have a faster progression from HIV to AIDS.": [
    0.09881120175123215,
    0.8984880447387695,
    0.002700742334127426
  ],
  "RESULTS During follow up 2985 (80%) participants reported a stable partnership on at least one occasion.||Patients in stable partnerships have a faster progression from HIV to AIDS.": [
    0.034088294953107834,
    0.9640258550643921,
    0.0018858361290767789
  ],
  "When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership.||Patients in stable partnerships have a faster progression from HIV to AIDS.": [
    0.1136140525341034,
    0.8838216066360474,
    0.002564339665696025
  ],
  "In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without.||Patients in stable partnerships have a faster progression from HIV to AIDS.": [
    0.6476392149925232,
    0.32920601963996887,
    0.023154770955443382
  ],
  "Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression.   \n||Patients in stable partnerships have a faster progression from HIV to AIDS.": [
    0.21731938421726227,
    0.7736053466796875,
    0.009075339883565903
  ],
  "CONCLUSIONS A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.||Patients in stable partnerships have a faster progression from HIV to AIDS.": [
    0.9983443021774292,
    0.0009012705413624644,
    0.000754444336052984
  ],
  "Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.": [
    0.00885599385946989,
    0.9887945652008057,
    0.002349437214434147
  ],
  "We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.": [
    0.21462254226207733,
    0.7536748647689819,
    0.03170255199074745
  ],
  "Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.": [
    0.14525796473026276,
    0.8414705991744995,
    0.013271408155560493
  ],
  "The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.": [
    0.05814617872238159,
    0.9343066811561584,
    0.007547155022621155
  ],
  "Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.": [
    0.5441023707389832,
    0.3401110768318176,
    0.1157865896821022
  ],
  "Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.": [
    0.40534430742263794,
    0.5070644021034241,
    0.08759123086929321
  ],
  "In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.": [
    0.06069638952612877,
    0.9351068735122681,
    0.004196702502667904
  ],
  "Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.": [
    0.02029513753950596,
    0.7126374840736389,
    0.2670673727989197
  ],
  "Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.": [
    0.011851910501718521,
    0.9857670068740845,
    0.002381148748099804
  ],
  "We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.": [
    0.242485910654068,
    0.7334116101264954,
    0.02410251647233963
  ],
  "Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.": [
    0.16776734590530396,
    0.8173813819885254,
    0.014851225540041924
  ],
  "The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.": [
    0.08887249231338501,
    0.9029861092567444,
    0.008141390979290009
  ],
  "Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.": [
    0.7337532639503479,
    0.1515018790960312,
    0.11474484205245972
  ],
  "Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.": [
    0.6057882308959961,
    0.3577865958213806,
    0.03642519563436508
  ],
  "In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.": [
    0.16584262251853943,
    0.8300005197525024,
    0.004156856797635555
  ],
  "Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.||Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.": [
    0.03406757488846779,
    0.7681905627250671,
    0.19774186611175537
  ],
  "Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.03177618607878685,
    0.9666918516159058,
    0.00153198535554111
  ],
  "We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.29528316855430603,
    0.7006745934486389,
    0.004042300395667553
  ],
  "Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.9856365919113159,
    0.008025609888136387,
    0.006337776780128479
  ],
  "The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.11881843954324722,
    0.8130512237548828,
    0.06813036650419235
  ],
  "Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.16710828244686127,
    0.8195741176605225,
    0.013317660428583622
  ],
  "Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.44409453868865967,
    0.5276855826377869,
    0.028219887986779213
  ],
  "In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.1004178449511528,
    0.8133252859115601,
    0.08625680953264236
  ],
  "Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.15914186835289001,
    0.7826094031333923,
    0.05824870243668556
  ],
  "Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.00801520049571991,
    0.9910916686058044,
    0.0008930986514315009
  ],
  "We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.1237405389547348,
    0.8709390759468079,
    0.005320461001247168
  ],
  "Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.14769934117794037,
    0.1256125420331955,
    0.7266881465911865
  ],
  "The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.06392603367567062,
    0.90474933385849,
    0.031324587762355804
  ],
  "Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.11197642236948013,
    0.8774950504302979,
    0.010528543032705784
  ],
  "Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.18539036810398102,
    0.7899209260940552,
    0.024688757956027985
  ],
  "In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.08782587945461273,
    0.8910147547721863,
    0.021159421652555466
  ],
  "Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.": [
    0.09727143496274948,
    0.8525128364562988,
    0.05021575465798378
  ],
  "Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.005473392549902201,
    0.9937204122543335,
    0.0008061667322181165
  ],
  "We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.11935152113437653,
    0.875812828540802,
    0.004835622385144234
  ],
  "Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.14300939440727234,
    0.11178626120090485,
    0.7452043294906616
  ],
  "The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.06532062590122223,
    0.909318208694458,
    0.025361089035868645
  ],
  "Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.1085154116153717,
    0.8781695365905762,
    0.013315060175955296
  ],
  "Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.17208918929100037,
    0.803191065788269,
    0.024719757959246635
  ],
  "In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.07467778772115707,
    0.9087615609169006,
    0.016560636460781097
  ],
  "Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.||Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.09033127129077911,
    0.8746858239173889,
    0.034982867538928986
  ],
  "Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.016787927597761154,
    0.9820318222045898,
    0.0011802730150520802
  ],
  "We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.22663956880569458,
    0.7693709135055542,
    0.003989506047219038
  ],
  "Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.9841341376304626,
    0.008816876448690891,
    0.007048981264233589
  ],
  "The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.10423842817544937,
    0.8351383209228516,
    0.060623202472925186
  ],
  "Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.1649487167596817,
    0.8137256503105164,
    0.021325668320059776
  ],
  "Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.3302108943462372,
    0.6341031193733215,
    0.035685956478118896
  ],
  "In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.0846673771739006,
    0.8537825345993042,
    0.06155003607273102
  ],
  "Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.||Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.": [
    0.1291271150112152,
    0.8150413632392883,
    0.05583149939775467
  ],
  "Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks.||Hypocretin neurones suppress panicprone state in rats.": [
    0.33244410157203674,
    0.6624168157577515,
    0.005139134358614683
  ],
  "In individuals with panic disorder there is evidence of decreased central gamma-aminobutyric acid (GABA) activity as well as marked increases in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate.||Hypocretin neurones suppress panicprone state in rats.": [
    0.8904580473899841,
    0.1006949171423912,
    0.008847018703818321
  ],
  "In a rat model of panic disorder, chronic inhibition of GABA synthesis in the dorsomedial-perifornical hypothalamus of rats produces anxiety-like states and a similar vulnerability to sodium lactate-induced cardioexcitatory responses.||Hypocretin neurones suppress panicprone state in rats.": [
    0.865693211555481,
    0.12805095314979553,
    0.006255777087062597
  ],
  "The dorsomedial-perifornical hypothalamus is enriched in neurons containing orexin (ORX, also known as hypocretin), which have a crucial role in arousal, vigilance and central autonomic mobilization, all of which are key components of panic.||Hypocretin neurones suppress panicprone state in rats.": [
    0.7450201511383057,
    0.24721759557724,
    0.0077623026445508
  ],
  "Here we show that activation of ORX-synthesizing neurons is necessary for developing a panic-prone state in the rat panic model, and either silencing of the hypothalamic gene encoding ORX (Hcrt) with RNAi or systemic ORX-1 receptor antagonists blocks the panic responses.||Hypocretin neurones suppress panicprone state in rats.": [
    0.3701380491256714,
    0.3807506859302521,
    0.2491113245487213
  ],
  "Moreover, we show that human subjects with panic anxiety have elevated levels of ORX in the cerebrospinal fluid compared to subjects without panic anxiety.||Hypocretin neurones suppress panicprone state in rats.": [
    0.7700563669204712,
    0.22389061748981476,
    0.006053092889487743
  ],
  "Taken together, our results suggest that the ORX system may be involved in the pathophysiology of panic anxiety and that ORX antagonists constitute a potential new treatment strategy for panic disorder.||Hypocretin neurones suppress panicprone state in rats.": [
    0.39887961745262146,
    0.5869424343109131,
    0.014178001321852207
  ],
  "Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks.||Patients with panic anxiety show decreased CSF levels of hypocretin.": [
    0.008144085295498371,
    0.9634244441986084,
    0.02843140810728073
  ],
  "In individuals with panic disorder there is evidence of decreased central gamma-aminobutyric acid (GABA) activity as well as marked increases in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate.||Patients with panic anxiety show decreased CSF levels of hypocretin.": [
    0.40678533911705017,
    0.5456134080886841,
    0.04760124906897545
  ],
  "In a rat model of panic disorder, chronic inhibition of GABA synthesis in the dorsomedial-perifornical hypothalamus of rats produces anxiety-like states and a similar vulnerability to sodium lactate-induced cardioexcitatory responses.||Patients with panic anxiety show decreased CSF levels of hypocretin.": [
    0.09072517603635788,
    0.8807377815246582,
    0.02853701077401638
  ],
  "The dorsomedial-perifornical hypothalamus is enriched in neurons containing orexin (ORX, also known as hypocretin), which have a crucial role in arousal, vigilance and central autonomic mobilization, all of which are key components of panic.||Patients with panic anxiety show decreased CSF levels of hypocretin.": [
    0.6788964867591858,
    0.31618255376815796,
    0.004921031650155783
  ],
  "Here we show that activation of ORX-synthesizing neurons is necessary for developing a panic-prone state in the rat panic model, and either silencing of the hypothalamic gene encoding ORX (Hcrt) with RNAi or systemic ORX-1 receptor antagonists blocks the panic responses.||Patients with panic anxiety show decreased CSF levels of hypocretin.": [
    0.04573221132159233,
    0.9320915937423706,
    0.02217617817223072
  ],
  "Moreover, we show that human subjects with panic anxiety have elevated levels of ORX in the cerebrospinal fluid compared to subjects without panic anxiety.||Patients with panic anxiety show decreased CSF levels of hypocretin.": [
    0.7720040082931519,
    0.20705291628837585,
    0.020943086594343185
  ],
  "Taken together, our results suggest that the ORX system may be involved in the pathophysiology of panic anxiety and that ORX antagonists constitute a potential new treatment strategy for panic disorder.||Patients with panic anxiety show decreased CSF levels of hypocretin.": [
    0.04100169241428375,
    0.9466879963874817,
    0.012310330756008625
  ],
  "Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks.||Hypocretin neurones induce panicprone state in rats.": [
    0.19591595232486725,
    0.7940289974212646,
    0.010055103339254856
  ],
  "In individuals with panic disorder there is evidence of decreased central gamma-aminobutyric acid (GABA) activity as well as marked increases in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate.||Hypocretin neurones induce panicprone state in rats.": [
    0.9507237076759338,
    0.04451847821474075,
    0.004757819697260857
  ],
  "In a rat model of panic disorder, chronic inhibition of GABA synthesis in the dorsomedial-perifornical hypothalamus of rats produces anxiety-like states and a similar vulnerability to sodium lactate-induced cardioexcitatory responses.||Hypocretin neurones induce panicprone state in rats.": [
    0.7188587188720703,
    0.13194240629673004,
    0.14919888973236084
  ],
  "The dorsomedial-perifornical hypothalamus is enriched in neurons containing orexin (ORX, also known as hypocretin), which have a crucial role in arousal, vigilance and central autonomic mobilization, all of which are key components of panic.||Hypocretin neurones induce panicprone state in rats.": [
    0.012695233337581158,
    0.9459829926490784,
    0.04132184386253357
  ],
  "Here we show that activation of ORX-synthesizing neurons is necessary for developing a panic-prone state in the rat panic model, and either silencing of the hypothalamic gene encoding ORX (Hcrt) with RNAi or systemic ORX-1 receptor antagonists blocks the panic responses.||Hypocretin neurones induce panicprone state in rats.": [
    0.5452348589897156,
    0.25201573967933655,
    0.2027493566274643
  ],
  "Moreover, we show that human subjects with panic anxiety have elevated levels of ORX in the cerebrospinal fluid compared to subjects without panic anxiety.||Hypocretin neurones induce panicprone state in rats.": [
    0.9361057877540588,
    0.056677378714084625,
    0.0072167618200182915
  ],
  "Taken together, our results suggest that the ORX system may be involved in the pathophysiology of panic anxiety and that ORX antagonists constitute a potential new treatment strategy for panic disorder.||Hypocretin neurones induce panicprone state in rats.": [
    0.5369090437889099,
    0.43754953145980835,
    0.025541434064507484
  ],
  "Viral replication and microbial translocation from the gut to the blood during HIV infection lead to hyperimmune activation, which contributes to the decline in CD4+ T cell numbers during HIV infection.||IL-10 production by monocytes inhibits CD4 + T cell response.": [
    0.133505716919899,
    0.8497553467750549,
    0.016738880425691605
  ],
  "Programmed death-1 (PD-1) and interleukin-10 (IL-10) are both upregulated during HIV infection.||IL-10 production by monocytes inhibits CD4 + T cell response.": [
    0.02171868458390236,
    0.9672013521194458,
    0.01107998937368393
  ],
  "Blocking interactions between PD-1 and programmed death ligand-1 (PD-L1) and between IL-10 and IL-10 receptor (IL-10R) results in viral clearance and improves T cell function in animal models of chronic viral infections.||IL-10 production by monocytes inhibits CD4 + T cell response.": [
    0.9246776103973389,
    0.06829702854156494,
    0.007025343831628561
  ],
  "Here we show that high amounts of microbial products and inflammatory cytokines in the plasma of HIV-infected subjects lead to upregulation of PD-1 expression on monocytes that correlates with high plasma concentrations of IL-10.||IL-10 production by monocytes inhibits CD4 + T cell response.": [
    0.08068958669900894,
    0.8600682616233826,
    0.059242118149995804
  ],
  "Triggering of PD-1 expressed on monocytes by PD-L1 expressed on various cell types induced IL-10 production and led to reversible CD4+ T cell dysfunction.||IL-10 production by monocytes inhibits CD4 + T cell response.": [
    0.0035350590478628874,
    0.01471323985606432,
    0.9817517399787903
  ],
  "We describe a new function for PD-1 whereby microbial products inhibit T cell expansion and function by upregulating PD-1 levels and IL-10 production by monocytes after binding of PD-1 by PD-L1.||IL-10 production by monocytes inhibits CD4 + T cell response.": [
    0.1251220554113388,
    0.7039681077003479,
    0.1709098368883133
  ],
  "Viral replication and microbial translocation from the gut to the blood during HIV infection lead to hyperimmune activation, which contributes to the decline in CD4+ T cell numbers during HIV infection.||PD-1 triggering on monocytes enhances IL-10 production by monocytes.": [
    0.018634462729096413,
    0.9496432542800903,
    0.031722329556941986
  ],
  "Programmed death-1 (PD-1) and interleukin-10 (IL-10) are both upregulated during HIV infection.||PD-1 triggering on monocytes enhances IL-10 production by monocytes.": [
    0.0035072844475507736,
    0.818720281124115,
    0.17777247726917267
  ],
  "Blocking interactions between PD-1 and programmed death ligand-1 (PD-L1) and between IL-10 and IL-10 receptor (IL-10R) results in viral clearance and improves T cell function in animal models of chronic viral infections.||PD-1 triggering on monocytes enhances IL-10 production by monocytes.": [
    0.929585337638855,
    0.06219508498907089,
    0.008219638839364052
  ],
  "Here we show that high amounts of microbial products and inflammatory cytokines in the plasma of HIV-infected subjects lead to upregulation of PD-1 expression on monocytes that correlates with high plasma concentrations of IL-10.||PD-1 triggering on monocytes enhances IL-10 production by monocytes.": [
    0.04002797231078148,
    0.2652568817138672,
    0.6947152018547058
  ],
  "Triggering of PD-1 expressed on monocytes by PD-L1 expressed on various cell types induced IL-10 production and led to reversible CD4+ T cell dysfunction.||PD-1 triggering on monocytes enhances IL-10 production by monocytes.": [
    0.0016579673392698169,
    0.018677208572626114,
    0.9796648025512695
  ],
  "We describe a new function for PD-1 whereby microbial products inhibit T cell expansion and function by upregulating PD-1 levels and IL-10 production by monocytes after binding of PD-1 by PD-L1.||PD-1 triggering on monocytes enhances IL-10 production by monocytes.": [
    0.008396707475185394,
    0.11476960778236389,
    0.8768336772918701
  ],
  "Viral replication and microbial translocation from the gut to the blood during HIV infection lead to hyperimmune activation, which contributes to the decline in CD4+ T cell numbers during HIV infection.||PD-1 triggering on monocytes reduces IL-10 production by monocytes.": [
    0.493306964635849,
    0.4928523898124695,
    0.013840730302035809
  ],
  "Programmed death-1 (PD-1) and interleukin-10 (IL-10) are both upregulated during HIV infection.||PD-1 triggering on monocytes reduces IL-10 production by monocytes.": [
    0.8750651478767395,
    0.11671840399503708,
    0.008216430433094501
  ],
  "Blocking interactions between PD-1 and programmed death ligand-1 (PD-L1) and between IL-10 and IL-10 receptor (IL-10R) results in viral clearance and improves T cell function in animal models of chronic viral infections.||PD-1 triggering on monocytes reduces IL-10 production by monocytes.": [
    0.586244523525238,
    0.3436245322227478,
    0.07013092190027237
  ],
  "Here we show that high amounts of microbial products and inflammatory cytokines in the plasma of HIV-infected subjects lead to upregulation of PD-1 expression on monocytes that correlates with high plasma concentrations of IL-10.||PD-1 triggering on monocytes reduces IL-10 production by monocytes.": [
    0.8747370839118958,
    0.09915410727262497,
    0.026108795776963234
  ],
  "Triggering of PD-1 expressed on monocytes by PD-L1 expressed on various cell types induced IL-10 production and led to reversible CD4+ T cell dysfunction.||PD-1 triggering on monocytes reduces IL-10 production by monocytes.": [
    0.9967058300971985,
    0.002108667977154255,
    0.0011855455813929439
  ],
  "We describe a new function for PD-1 whereby microbial products inhibit T cell expansion and function by upregulating PD-1 levels and IL-10 production by monocytes after binding of PD-1 by PD-L1.||PD-1 triggering on monocytes reduces IL-10 production by monocytes.": [
    0.831425666809082,
    0.07400216162204742,
    0.09457219392061234
  ],
  "Neutrophil extracellular traps (NETs) are implicated in autoimmunity, but how they are generated and their roles in sterile inflammation remain unclear.||Immune complex triggered cell death leads to extracellular release of nuclear DNA.": [
    0.13109299540519714,
    0.7883269786834717,
    0.08058002591133118
  ],
  "Ribonucleoprotein immune complexes (RNP ICs), inducers of NETosis, require mitochondrial reactive oxygen species (ROS) for maximal NET stimulation.||Immune complex triggered cell death leads to extracellular release of nuclear DNA.": [
    0.03296981751918793,
    0.6974651217460632,
    0.2695651054382324
  ],
  "After RNP IC stimulation of neutrophils, mitochondria become hypopolarized and translocate to the cell surface.||Immune complex triggered cell death leads to extracellular release of nuclear DNA.": [
    0.0843193307518959,
    0.4629162549972534,
    0.45276445150375366
  ],
  "Extracellular release of oxidized mitochondrial DNA is proinflammatory in vitro, and when this DNA is injected into mice, it stimulates type I interferon (IFN) signaling through a pathway dependent on the DNA sensor STING.||Immune complex triggered cell death leads to extracellular release of nuclear DNA.": [
    0.8465594053268433,
    0.08553005754947662,
    0.06791055202484131
  ],
  "Mitochondrial ROS are also necessary for spontaneous NETosis of low-density granulocytes from individuals with systemic lupus erythematosus.||Immune complex triggered cell death leads to extracellular release of nuclear DNA.": [
    0.14850592613220215,
    0.5591061115264893,
    0.2923879623413086
  ],
  "This was also observed in individuals with chronic granulomatous disease, who lack NADPH oxidase activity but still develop autoimmunity and type I IFN signatures.||Immune complex triggered cell death leads to extracellular release of nuclear DNA.": [
    0.07990971952676773,
    0.7600919008255005,
    0.15999843180179596
  ],
  "Mitochondrial ROS inhibition in vivo reduces disease severity and type I IFN responses in a mouse model of lupus.||Immune complex triggered cell death leads to extracellular release of nuclear DNA.": [
    0.7000345587730408,
    0.21390895545482635,
    0.08605649322271347
  ],
  "Together, these findings highlight a role for mitochondria in the generation not only of NETs but also of pro-inflammatory oxidized mitochondrial DNA in autoimmune diseases.||Immune complex triggered cell death leads to extracellular release of nuclear DNA.": [
    0.665583074092865,
    0.223161980509758,
    0.1112549677491188
  ],
  "Neutrophil extracellular traps (NETs) are implicated in autoimmunity, but how they are generated and their roles in sterile inflammation remain unclear.||Immune complex triggered cell death leads to sequestration of oxidized mitochondrial DNA.": [
    0.1345682293176651,
    0.7299010753631592,
    0.13553068041801453
  ],
  "Ribonucleoprotein immune complexes (RNP ICs), inducers of NETosis, require mitochondrial reactive oxygen species (ROS) for maximal NET stimulation.||Immune complex triggered cell death leads to sequestration of oxidized mitochondrial DNA.": [
    0.15623795986175537,
    0.6701234579086304,
    0.17363861203193665
  ],
  "After RNP IC stimulation of neutrophils, mitochondria become hypopolarized and translocate to the cell surface.||Immune complex triggered cell death leads to sequestration of oxidized mitochondrial DNA.": [
    0.11281795054674149,
    0.32657748460769653,
    0.5606045722961426
  ],
  "Extracellular release of oxidized mitochondrial DNA is proinflammatory in vitro, and when this DNA is injected into mice, it stimulates type I interferon (IFN) signaling through a pathway dependent on the DNA sensor STING.||Immune complex triggered cell death leads to sequestration of oxidized mitochondrial DNA.": [
    0.9696820378303528,
    0.016239609569311142,
    0.014078373089432716
  ],
  "Mitochondrial ROS are also necessary for spontaneous NETosis of low-density granulocytes from individuals with systemic lupus erythematosus.||Immune complex triggered cell death leads to sequestration of oxidized mitochondrial DNA.": [
    0.1373686045408249,
    0.5761160254478455,
    0.28651535511016846
  ],
  "This was also observed in individuals with chronic granulomatous disease, who lack NADPH oxidase activity but still develop autoimmunity and type I IFN signatures.||Immune complex triggered cell death leads to sequestration of oxidized mitochondrial DNA.": [
    0.06578446179628372,
    0.7975171804428101,
    0.136698380112648
  ],
  "Mitochondrial ROS inhibition in vivo reduces disease severity and type I IFN responses in a mouse model of lupus.||Immune complex triggered cell death leads to sequestration of oxidized mitochondrial DNA.": [
    0.26934778690338135,
    0.6668110489845276,
    0.06384116411209106
  ],
  "Together, these findings highlight a role for mitochondria in the generation not only of NETs but also of pro-inflammatory oxidized mitochondrial DNA in autoimmune diseases.||Immune complex triggered cell death leads to sequestration of oxidized mitochondrial DNA.": [
    0.9028036594390869,
    0.05501357838511467,
    0.042182788252830505
  ],
  "Neutrophil extracellular traps (NETs) are implicated in autoimmunity, but how they are generated and their roles in sterile inflammation remain unclear.||Immune complex triggered cell death leads to extracellular release of neutrophil protein HMGB1.": [
    0.10133814066648483,
    0.8707417249679565,
    0.027920134365558624
  ],
  "Ribonucleoprotein immune complexes (RNP ICs), inducers of NETosis, require mitochondrial reactive oxygen species (ROS) for maximal NET stimulation.||Immune complex triggered cell death leads to extracellular release of neutrophil protein HMGB1.": [
    0.27547580003738403,
    0.6297380328178406,
    0.09478617459535599
  ],
  "After RNP IC stimulation of neutrophils, mitochondria become hypopolarized and translocate to the cell surface.||Immune complex triggered cell death leads to extracellular release of neutrophil protein HMGB1.": [
    0.0702541247010231,
    0.6132115125656128,
    0.3165344297885895
  ],
  "Extracellular release of oxidized mitochondrial DNA is proinflammatory in vitro, and when this DNA is injected into mice, it stimulates type I interferon (IFN) signaling through a pathway dependent on the DNA sensor STING.||Immune complex triggered cell death leads to extracellular release of neutrophil protein HMGB1.": [
    0.674702525138855,
    0.2965976595878601,
    0.028699787333607674
  ],
  "Mitochondrial ROS are also necessary for spontaneous NETosis of low-density granulocytes from individuals with systemic lupus erythematosus.||Immune complex triggered cell death leads to extracellular release of neutrophil protein HMGB1.": [
    0.18958984315395355,
    0.5886449813842773,
    0.2217651903629303
  ],
  "This was also observed in individuals with chronic granulomatous disease, who lack NADPH oxidase activity but still develop autoimmunity and type I IFN signatures.||Immune complex triggered cell death leads to extracellular release of neutrophil protein HMGB1.": [
    0.06669928878545761,
    0.834337592124939,
    0.09896314889192581
  ],
  "Mitochondrial ROS inhibition in vivo reduces disease severity and type I IFN responses in a mouse model of lupus.||Immune complex triggered cell death leads to extracellular release of neutrophil protein HMGB1.": [
    0.42158111929893494,
    0.47672393918037415,
    0.10169485956430435
  ],
  "Together, these findings highlight a role for mitochondria in the generation not only of NETs but also of pro-inflammatory oxidized mitochondrial DNA in autoimmune diseases.||Immune complex triggered cell death leads to extracellular release of neutrophil protein HMGB1.": [
    0.47863703966140747,
    0.41495195031166077,
    0.10641108453273773
  ],
  "Granulomas are the pathological hallmark of tuberculosis (TB).||Immune responses in immune cells are geographically segregated.": [
    0.40014564990997314,
    0.27036136388778687,
    0.3294930160045624
  ],
  "However, their function and mechanisms of formation remain poorly understood.||Immune responses in immune cells are geographically segregated.": [
    0.2589677572250366,
    0.4357910752296448,
    0.305241197347641
  ],
  "To understand the role of granulomas in TB, we analyzed the proteomes of granulomas from subjects with tuberculosis in an unbiased manner.||Immune responses in immune cells are geographically segregated.": [
    0.31788843870162964,
    0.36122772097587585,
    0.3208838105201721
  ],
  "Using laser-capture microdissection, mass spectrometry and confocal microscopy, we generated detailed molecular maps of human granulomas.||Immune responses in immune cells are geographically segregated.": [
    0.2206876128911972,
    0.34846627712249756,
    0.43084609508514404
  ],
  "We found that the centers of granulomas have a pro-inflammatory environment that is characterized by the presence of antimicrobial peptides, reactive oxygen species and pro-inflammatory eicosanoids.||Immune responses in immune cells are geographically segregated.": [
    0.19338923692703247,
    0.38990697264671326,
    0.4167037308216095
  ],
  "Conversely, the tissue surrounding the caseum has a comparatively anti-inflammatory signature.||Immune responses in immune cells are geographically segregated.": [
    0.02911483123898506,
    0.5029140114784241,
    0.46797114610671997
  ],
  "These findings are consistent across a set of six human subjects and in rabbits.||Immune responses in immune cells are geographically segregated.": [
    0.22523152828216553,
    0.47237449884414673,
    0.30239394307136536
  ],
  "Although the balance between systemic pro- and anti-inflammatory signals is crucial to TB disease outcome, here we find that these signals are physically segregated within each granuloma.||Immune responses in immune cells are geographically segregated.": [
    0.007024808321148157,
    0.150239959359169,
    0.8427351713180542
  ],
  "From the protein and lipid snapshots of human and rabbit lesions analyzed here, we hypothesize that the pathologic response to TB is shaped by the precise anatomical localization of these inflammatory pathways during the development of the granuloma.||Immune responses in immune cells are geographically segregated.": [
    0.04251926392316818,
    0.3206807076931,
    0.6368000507354736
  ],
  "Granulomas are the pathological hallmark of tuberculosis (TB).||The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.": [
    0.21655625104904175,
    0.7753278017044067,
    0.008115947246551514
  ],
  "However, their function and mechanisms of formation remain poorly understood.||The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.": [
    0.03057888150215149,
    0.9197616577148438,
    0.049659471958875656
  ],
  "To understand the role of granulomas in TB, we analyzed the proteomes of granulomas from subjects with tuberculosis in an unbiased manner.||The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.": [
    0.04328083619475365,
    0.953180193901062,
    0.0035390150733292103
  ],
  "Using laser-capture microdissection, mass spectrometry and confocal microscopy, we generated detailed molecular maps of human granulomas.||The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.": [
    0.019508715718984604,
    0.9787909984588623,
    0.0017002752283588052
  ],
  "We found that the centers of granulomas have a pro-inflammatory environment that is characterized by the presence of antimicrobial peptides, reactive oxygen species and pro-inflammatory eicosanoids.||The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.": [
    0.9958239793777466,
    0.0034025972709059715,
    0.0007734156679362059
  ],
  "Conversely, the tissue surrounding the caseum has a comparatively anti-inflammatory signature.||The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.": [
    0.08339132368564606,
    0.37666741013526917,
    0.5399412512779236
  ],
  "These findings are consistent across a set of six human subjects and in rabbits.||The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.": [
    0.06703127175569534,
    0.7872227430343628,
    0.14574597775936127
  ],
  "Although the balance between systemic pro- and anti-inflammatory signals is crucial to TB disease outcome, here we find that these signals are physically segregated within each granuloma.||The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.": [
    0.1066008135676384,
    0.8485543727874756,
    0.04484479874372482
  ],
  "From the protein and lipid snapshots of human and rabbit lesions analyzed here, we hypothesize that the pathologic response to TB is shaped by the precise anatomical localization of these inflammatory pathways during the development of the granuloma.||The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.": [
    0.5580451488494873,
    0.4321760833263397,
    0.009778786450624466
  ],
  "Granulomas are the pathological hallmark of tuberculosis (TB).||Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.": [
    0.001315312460064888,
    0.9886012673377991,
    0.010083437897264957
  ],
  "However, their function and mechanisms of formation remain poorly understood.||Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.": [
    0.012478229589760303,
    0.9536269307136536,
    0.033894844353199005
  ],
  "To understand the role of granulomas in TB, we analyzed the proteomes of granulomas from subjects with tuberculosis in an unbiased manner.||Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.": [
    0.002920591039583087,
    0.969154417514801,
    0.027924995869398117
  ],
  "Using laser-capture microdissection, mass spectrometry and confocal microscopy, we generated detailed molecular maps of human granulomas.||Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.": [
    0.0012956928694620728,
    0.9948847889900208,
    0.003819497302174568
  ],
  "We found that the centers of granulomas have a pro-inflammatory environment that is characterized by the presence of antimicrobial peptides, reactive oxygen species and pro-inflammatory eicosanoids.||Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.": [
    0.005230423528701067,
    0.904759407043457,
    0.0900101587176323
  ],
  "Conversely, the tissue surrounding the caseum has a comparatively anti-inflammatory signature.||Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.": [
    0.019886404275894165,
    0.7518422603607178,
    0.22827133536338806
  ],
  "These findings are consistent across a set of six human subjects and in rabbits.||Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.": [
    0.017967665567994118,
    0.877874493598938,
    0.10415787249803543
  ],
  "Although the balance between systemic pro- and anti-inflammatory signals is crucial to TB disease outcome, here we find that these signals are physically segregated within each granuloma.||Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.": [
    0.0032441706862300634,
    0.6906563639640808,
    0.30609947443008423
  ],
  "From the protein and lipid snapshots of human and rabbit lesions analyzed here, we hypothesize that the pathologic response to TB is shaped by the precise anatomical localization of these inflammatory pathways during the development of the granuloma.||Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.": [
    0.005489898845553398,
    0.8361865878105164,
    0.1583235263824463
  ],
  "Granulomas are the pathological hallmark of tuberculosis (TB).||The center of the granuloma in an immune cell induces a pro-inflammatory immune response.": [
    0.01801612414419651,
    0.9749955534934998,
    0.006988348439335823
  ],
  "However, their function and mechanisms of formation remain poorly understood.||The center of the granuloma in an immune cell induces a pro-inflammatory immune response.": [
    0.05302683636546135,
    0.8994541764259338,
    0.04751906171441078
  ],
  "To understand the role of granulomas in TB, we analyzed the proteomes of granulomas from subjects with tuberculosis in an unbiased manner.||The center of the granuloma in an immune cell induces a pro-inflammatory immune response.": [
    0.026260865852236748,
    0.9698058366775513,
    0.003933359868824482
  ],
  "Using laser-capture microdissection, mass spectrometry and confocal microscopy, we generated detailed molecular maps of human granulomas.||The center of the granuloma in an immune cell induces a pro-inflammatory immune response.": [
    0.013024767860770226,
    0.9848418235778809,
    0.002133368980139494
  ],
  "We found that the centers of granulomas have a pro-inflammatory environment that is characterized by the presence of antimicrobial peptides, reactive oxygen species and pro-inflammatory eicosanoids.||The center of the granuloma in an immune cell induces a pro-inflammatory immune response.": [
    0.0019112760201096535,
    0.6817606091499329,
    0.31632810831069946
  ],
  "Conversely, the tissue surrounding the caseum has a comparatively anti-inflammatory signature.||The center of the granuloma in an immune cell induces a pro-inflammatory immune response.": [
    0.9963598847389221,
    0.002765991725027561,
    0.000874121964443475
  ],
  "These findings are consistent across a set of six human subjects and in rabbits.||The center of the granuloma in an immune cell induces a pro-inflammatory immune response.": [
    0.09007252752780914,
    0.8221036791801453,
    0.08782382309436798
  ],
  "Although the balance between systemic pro- and anti-inflammatory signals is crucial to TB disease outcome, here we find that these signals are physically segregated within each granuloma.||The center of the granuloma in an immune cell induces a pro-inflammatory immune response.": [
    0.3234234154224396,
    0.632188618183136,
    0.04438793659210205
  ],
  "From the protein and lipid snapshots of human and rabbit lesions analyzed here, we hypothesize that the pathologic response to TB is shaped by the precise anatomical localization of these inflammatory pathways during the development of the granuloma.||The center of the granuloma in an immune cell induces a pro-inflammatory immune response.": [
    0.011103589087724686,
    0.7386590242385864,
    0.2502373456954956
  ],
  "Whereas domestication of livestock, pets, and crops is well documented, it is still unclear to what extent microbes associated with the production of food have also undergone human selection and where the plethora of industrial strains originates from.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy is very common.": [
    0.016040872782468796,
    0.97571861743927,
    0.008240471594035625
  ],
  "Here, we present the genomes and phenomes of 157 industrial Saccharomyces cerevisiae yeasts.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy is very common.": [
    0.008948590606451035,
    0.9835761189460754,
    0.007475290913134813
  ],
  "Our analyses reveal that today's industrial yeasts can be divided into five sublineages that are genetically and phenotypically separated from wild strains and originate from only a few ancestors through complex patterns of domestication and local divergence.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy is very common.": [
    0.024822544306516647,
    0.9636619687080383,
    0.011515447869896889
  ],
  "Large-scale phenotyping and genome analysis further show strong industry-specific selection for stress tolerance, sugar utilization, and flavor production, while the sexual cycle and other phenotypes related to survival in nature show decay, particularly in beer yeasts.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy is very common.": [
    0.10824321210384369,
    0.8525351881980896,
    0.03922160714864731
  ],
  "Together, these results shed light on the origins, evolutionary history, and phenotypic diversity of industrial yeasts and provide a resource for further selection of superior strains.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy is very common.": [
    0.11499468237161636,
    0.8254585862159729,
    0.059546731412410736
  ],
  "PAPERCLIP.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy is very common.": [
    0.07160861045122147,
    0.7018272876739502,
    0.22656410932540894
  ],
  "Whereas domestication of livestock, pets, and crops is well documented, it is still unclear to what extent microbes associated with the production of food have also undergone human selection and where the plethora of industrial strains originates from.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.": [
    0.13528227806091309,
    0.8604442477226257,
    0.0042734574526548386
  ],
  "Here, we present the genomes and phenomes of 157 industrial Saccharomyces cerevisiae yeasts.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.": [
    0.012421728111803532,
    0.9830924868583679,
    0.0044858320616185665
  ],
  "Our analyses reveal that today's industrial yeasts can be divided into five sublineages that are genetically and phenotypically separated from wild strains and originate from only a few ancestors through complex patterns of domestication and local divergence.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.": [
    0.03694970905780792,
    0.9527508020401001,
    0.010299411602318287
  ],
  "Large-scale phenotyping and genome analysis further show strong industry-specific selection for stress tolerance, sugar utilization, and flavor production, while the sexual cycle and other phenotypes related to survival in nature show decay, particularly in beer yeasts.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.": [
    0.0206757765263319,
    0.9572126865386963,
    0.022111574187874794
  ],
  "Together, these results shed light on the origins, evolutionary history, and phenotypic diversity of industrial yeasts and provide a resource for further selection of superior strains.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.": [
    0.0468570739030838,
    0.8595147728919983,
    0.09362813085317612
  ],
  "PAPERCLIP.||In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.": [
    0.01709301769733429,
    0.616287350654602,
    0.36661967635154724
  ],
  "Whereas domestication of livestock, pets, and crops is well documented, it is still unclear to what extent microbes associated with the production of food have also undergone human selection and where the plethora of industrial strains originates from.||In domesticated populations of Saccharomyces cerevisiae, whole chromosome aneuploidy is very uncommon.": [
    0.18746505677700043,
    0.8073567748069763,
    0.00517821591347456
  ],
  "Here, we present the genomes and phenomes of 157 industrial Saccharomyces cerevisiae yeasts.||In domesticated populations of Saccharomyces cerevisiae, whole chromosome aneuploidy is very uncommon.": [
    0.019155949354171753,
    0.9771389365196228,
    0.0037050708197057247
  ],
  "Our analyses reveal that today's industrial yeasts can be divided into five sublineages that are genetically and phenotypically separated from wild strains and originate from only a few ancestors through complex patterns of domestication and local divergence.||In domesticated populations of Saccharomyces cerevisiae, whole chromosome aneuploidy is very uncommon.": [
    0.04188474640250206,
    0.9522168040275574,
    0.005898421164602041
  ],
  "Large-scale phenotyping and genome analysis further show strong industry-specific selection for stress tolerance, sugar utilization, and flavor production, while the sexual cycle and other phenotypes related to survival in nature show decay, particularly in beer yeasts.||In domesticated populations of Saccharomyces cerevisiae, whole chromosome aneuploidy is very uncommon.": [
    0.05647876113653183,
    0.9163333773612976,
    0.027187803760170937
  ],
  "Together, these results shed light on the origins, evolutionary history, and phenotypic diversity of industrial yeasts and provide a resource for further selection of superior strains.||In domesticated populations of Saccharomyces cerevisiae, whole chromosome aneuploidy is very uncommon.": [
    0.11980564892292023,
    0.8198384046554565,
    0.06035596504807472
  ],
  "PAPERCLIP.||In domesticated populations of Saccharomyces cerevisiae, whole chromosome aneuploidy is very uncommon.": [
    0.09704604744911194,
    0.6752946972846985,
    0.2276592254638672
  ],
  "Importance Estimates from claims-based analyses suggest that the incidence of sepsis is increasing and mortality rates from sepsis are decreasing.||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.9961898326873779,
    0.003342489944770932,
    0.0004676801327150315
  ],
  "However, estimates from claims data may lack clinical fidelity and can be affected by changing diagnosis and coding practices over time.||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.08301830291748047,
    0.915173351764679,
    0.0018083598697558045
  ],
  "Objective To estimate the US national incidence of sepsis and trends using detailed clinical data from the electronic health record (EHR) systems of diverse hospitals.||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.006556726060807705,
    0.9928434491157532,
    0.0005997392581775784
  ],
  "Design, Setting, and Population Retrospective cohort study of adult patients admitted to 409 academic, community, and federal hospitals from 2009-2014.||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.0027365190908312798,
    0.9965671300888062,
    0.0006962820771150291
  ],
  "Exposures Sepsis was identified using clinical indicators of presumed infection and concurrent acute organ dysfunction, adapting Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria for objective and consistent EHR-based surveillance.||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.008160908706486225,
    0.9912177920341492,
    0.0006213168380782008
  ],
  "Main Outcomes and Measures Sepsis incidence, outcomes, and trends from 2009-2014 were calculated using regression models and compared with claims-based estimates using International Classification of Diseases, Ninth Revision, Clinical Modification codes for severe sepsis or septic shock.||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.0793585479259491,
    0.9190853834152222,
    0.0015560914762318134
  ],
  "Case-finding criteria were validated against Sepsis-3 criteria using medical record reviews.||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.01325659267604351,
    0.9860473871231079,
    0.0006960263708606362
  ],
  "Results A total of 173 690 sepsis cases (mean age, 66.5 [SD, 15.5] y; 77 660 [42.4%] women) were identified using clinical criteria among 2 901 019 adults admitted to study hospitals in 2014 (6.0% incidence).||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.0593668669462204,
    0.9385022521018982,
    0.002130897482857108
  ],
  "Of these, 26 061 (15.0%) died in the hospital and 10 731 (6.2%) were discharged to hospice.||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.04501041769981384,
    0.9538741707801819,
    0.0011154129169881344
  ],
  "From 2009-2014, sepsis incidence using clinical criteria was stable (+0.6% relative change/y [95% CI, \u22122.3% to 3.5%], P = .67) whereas incidence per claims increased (+10.3%/y [95% CI, 7.2% to 13.3%], P < .001).||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.9943239688873291,
    0.002300598891451955,
    0.0033754543401300907
  ],
  "In-hospital mortality using clinical criteria declined (\u22123.3%/y [95% CI, \u22125.6% to \u22121.0%], P = .004), but there was no significant change in the combined outcome of death or discharge to hospice (\u22121.3%/y [95% CI, \u22123.2% to 0.6%], P = .19).||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.016046376898884773,
    0.9347861409187317,
    0.04916752502322197
  ],
  "In contrast, mortality using claims declined significantly (\u22127.0%/y [95% CI, \u22128.8% to \u22125.2%], P < .001), as did death or discharge to hospice (\u22124.5%/y [95% CI, \u22126.1% to \u22122.8%], P < .001).||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.017137043178081512,
    0.8533908724784851,
    0.1294720470905304
  ],
  "Clinical criteria were more sensitive in identifying sepsis than claims (69.7% [95% CI, 52.9% to 92.0%] vs 32.3% [95% CI, 24.4% to 43.0%], P < .001), with comparable positive predictive value (70.4% [95% CI, 64.0% to 76.8%] vs 75.2% [95% CI, 69.8% to 80.6%], P = .23).||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.14443035423755646,
    0.8527666330337524,
    0.0028030043467879295
  ],
  "Conclusions and Relevance In clinical data from 409 hospitals, sepsis was present in 6% of adult hospitalizations, and in contrast to claims-based analyses, neither the incidence of sepsis nor the combined outcome of death or discharge to hospice changed significantly between 2009-2014.||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.9801843762397766,
    0.014900574460625648,
    0.004915091674774885
  ],
  "The findings also suggest that EHR-based clinical data provide more objective estimates than claims-based data for sepsis surveillance.||Incidence of sepsis has fallen substantially from 2009 to 2014.": [
    0.03017396293580532,
    0.9689910411834717,
    0.0008349993731826544
  ],
  "Importance Estimates from claims-based analyses suggest that the incidence of sepsis is increasing and mortality rates from sepsis are decreasing.||Sepsis related mortality has remained stable between 2009-2014.": [
    0.20986567437648773,
    0.785111129283905,
    0.005023225210607052
  ],
  "However, estimates from claims data may lack clinical fidelity and can be affected by changing diagnosis and coding practices over time.||Sepsis related mortality has remained stable between 2009-2014.": [
    0.6184632778167725,
    0.3758479356765747,
    0.005688797682523727
  ],
  "Objective To estimate the US national incidence of sepsis and trends using detailed clinical data from the electronic health record (EHR) systems of diverse hospitals.||Sepsis related mortality has remained stable between 2009-2014.": [
    0.3310704827308655,
    0.6660552024841309,
    0.002874369965866208
  ],
  "Design, Setting, and Population Retrospective cohort study of adult patients admitted to 409 academic, community, and federal hospitals from 2009-2014.||Sepsis related mortality has remained stable between 2009-2014.": [
    0.10384944826364517,
    0.8927953839302063,
    0.003355199471116066
  ],
  "Exposures Sepsis was identified using clinical indicators of presumed infection and concurrent acute organ dysfunction, adapting Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria for objective and consistent EHR-based surveillance.||Sepsis related mortality has remained stable between 2009-2014.": [
    0.051474738866090775,
    0.9449645280838013,
    0.0035607663448899984
  ],
  "Main Outcomes and Measures Sepsis incidence, outcomes, and trends from 2009-2014 were calculated using regression models and compared with claims-based estimates using International Classification of Diseases, Ninth Revision, Clinical Modification codes for severe sepsis or septic shock.||Sepsis related mortality has remained stable between 2009-2014.": [
    0.5778512358665466,
    0.4174383282661438,
    0.004710413049906492
  ],
  "Case-finding criteria were validated against Sepsis-3 criteria using medical record reviews.||Sepsis related mortality has remained stable between 2009-2014.": [
    0.1472596526145935,
    0.8472281694412231,
    0.0055121928453445435
  ],
  "Results A total of 173 690 sepsis cases (mean age, 66.5 [SD, 15.5] y; 77 660 [42.4%] women) were identified using clinical criteria among 2 901 019 adults admitted to study hospitals in 2014 (6.0% incidence).||Sepsis related mortality has remained stable between 2009-2014.": [
    0.07338451594114304,
    0.920121431350708,
    0.006494112778455019
  ],
  "Of these, 26 061 (15.0%) died in the hospital and 10 731 (6.2%) were discharged to hospice.||Sepsis related mortality has remained stable between 2009-2014.": [
    0.05075324699282646,
    0.9441096782684326,
    0.005137123633176088
  ],
  "From 2009-2014, sepsis incidence using clinical criteria was stable (+0.6% relative change/y [95% CI, \u22122.3% to 3.5%], P = .67) whereas incidence per claims increased (+10.3%/y [95% CI, 7.2% to 13.3%], P < .001).||Sepsis related mortality has remained stable between 2009-2014.": [
    0.2686179578304291,
    0.20418545603752136,
    0.5271965861320496
  ],
  "In-hospital mortality using clinical criteria declined (\u22123.3%/y [95% CI, \u22125.6% to \u22121.0%], P = .004), but there was no significant change in the combined outcome of death or discharge to hospice (\u22121.3%/y [95% CI, \u22123.2% to 0.6%], P = .19).||Sepsis related mortality has remained stable between 2009-2014.": [
    0.16975627839565277,
    0.8144632577896118,
    0.015780463814735413
  ],
  "In contrast, mortality using claims declined significantly (\u22127.0%/y [95% CI, \u22128.8% to \u22125.2%], P < .001), as did death or discharge to hospice (\u22124.5%/y [95% CI, \u22126.1% to \u22122.8%], P < .001).||Sepsis related mortality has remained stable between 2009-2014.": [
    0.15736821293830872,
    0.8349001407623291,
    0.007731709163635969
  ],
  "Clinical criteria were more sensitive in identifying sepsis than claims (69.7% [95% CI, 52.9% to 92.0%] vs 32.3% [95% CI, 24.4% to 43.0%], P < .001), with comparable positive predictive value (70.4% [95% CI, 64.0% to 76.8%] vs 75.2% [95% CI, 69.8% to 80.6%], P = .23).||Sepsis related mortality has remained stable between 2009-2014.": [
    0.2714332938194275,
    0.7161638736724854,
    0.012402845546603203
  ],
  "Conclusions and Relevance In clinical data from 409 hospitals, sepsis was present in 6% of adult hospitalizations, and in contrast to claims-based analyses, neither the incidence of sepsis nor the combined outcome of death or discharge to hospice changed significantly between 2009-2014.||Sepsis related mortality has remained stable between 2009-2014.": [
    0.0018775841454043984,
    0.05643119290471077,
    0.9416912198066711
  ],
  "The findings also suggest that EHR-based clinical data provide more objective estimates than claims-based data for sepsis surveillance.||Sepsis related mortality has remained stable between 2009-2014.": [
    0.1917862594127655,
    0.8029850125312805,
    0.005228656809777021
  ],
  "Importance Estimates from claims-based analyses suggest that the incidence of sepsis is increasing and mortality rates from sepsis are decreasing.||Sepsis related mortality has risen from 2009 to 2014.": [
    0.8876402974128723,
    0.10725656151771545,
    0.0051031638868153095
  ],
  "However, estimates from claims data may lack clinical fidelity and can be affected by changing diagnosis and coding practices over time.||Sepsis related mortality has risen from 2009 to 2014.": [
    0.05794108286499977,
    0.9269883036613464,
    0.01507058460265398
  ],
  "Objective To estimate the US national incidence of sepsis and trends using detailed clinical data from the electronic health record (EHR) systems of diverse hospitals.||Sepsis related mortality has risen from 2009 to 2014.": [
    0.002136451890692115,
    0.9970484375953674,
    0.0008151425863616168
  ],
  "Design, Setting, and Population Retrospective cohort study of adult patients admitted to 409 academic, community, and federal hospitals from 2009-2014.||Sepsis related mortality has risen from 2009 to 2014.": [
    0.0037755523808300495,
    0.9953492283821106,
    0.000875186116900295
  ],
  "Exposures Sepsis was identified using clinical indicators of presumed infection and concurrent acute organ dysfunction, adapting Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria for objective and consistent EHR-based surveillance.||Sepsis related mortality has risen from 2009 to 2014.": [
    0.004095306154340506,
    0.9948458671569824,
    0.001058783964253962
  ],
  "Main Outcomes and Measures Sepsis incidence, outcomes, and trends from 2009-2014 were calculated using regression models and compared with claims-based estimates using International Classification of Diseases, Ninth Revision, Clinical Modification codes for severe sepsis or septic shock.||Sepsis related mortality has risen from 2009 to 2014.": [
    0.010637020692229271,
    0.9874507188796997,
    0.0019122695084661245
  ],
  "Case-finding criteria were validated against Sepsis-3 criteria using medical record reviews.||Sepsis related mortality has risen from 2009 to 2014.": [
    0.017663905397057533,
    0.9801156520843506,
    0.0022204373963177204
  ],
  "Results A total of 173 690 sepsis cases (mean age, 66.5 [SD, 15.5] y; 77 660 [42.4%] women) were identified using clinical criteria among 2 901 019 adults admitted to study hospitals in 2014 (6.0% incidence).||Sepsis related mortality has risen from 2009 to 2014.": [
    0.003130038734525442,
    0.9941923022270203,
    0.0026776085142046213
  ],
  "Of these, 26 061 (15.0%) died in the hospital and 10 731 (6.2%) were discharged to hospice.||Sepsis related mortality has risen from 2009 to 2014.": [
    0.0012598942266777158,
    0.9971686005592346,
    0.0015715491026639938
  ],
  "From 2009-2014, sepsis incidence using clinical criteria was stable (+0.6% relative change/y [95% CI, \u22122.3% to 3.5%], P = .67) whereas incidence per claims increased (+10.3%/y [95% CI, 7.2% to 13.3%], P < .001).||Sepsis related mortality has risen from 2009 to 2014.": [
    0.4524407386779785,
    0.19925019145011902,
    0.3483090102672577
  ],
  "In-hospital mortality using clinical criteria declined (\u22123.3%/y [95% CI, \u22125.6% to \u22121.0%], P = .004), but there was no significant change in the combined outcome of death or discharge to hospice (\u22121.3%/y [95% CI, \u22123.2% to 0.6%], P = .19).||Sepsis related mortality has risen from 2009 to 2014.": [
    0.8873419761657715,
    0.10931647568941116,
    0.0033416005317121744
  ],
  "In contrast, mortality using claims declined significantly (\u22127.0%/y [95% CI, \u22128.8% to \u22125.2%], P < .001), as did death or discharge to hospice (\u22124.5%/y [95% CI, \u22126.1% to \u22122.8%], P < .001).||Sepsis related mortality has risen from 2009 to 2014.": [
    0.9674087166786194,
    0.03039395622909069,
    0.0021973855327814817
  ],
  "Clinical criteria were more sensitive in identifying sepsis than claims (69.7% [95% CI, 52.9% to 92.0%] vs 32.3% [95% CI, 24.4% to 43.0%], P < .001), with comparable positive predictive value (70.4% [95% CI, 64.0% to 76.8%] vs 75.2% [95% CI, 69.8% to 80.6%], P = .23).||Sepsis related mortality has risen from 2009 to 2014.": [
    0.025207938626408577,
    0.9695241451263428,
    0.005267856176942587
  ],
  "Conclusions and Relevance In clinical data from 409 hospitals, sepsis was present in 6% of adult hospitalizations, and in contrast to claims-based analyses, neither the incidence of sepsis nor the combined outcome of death or discharge to hospice changed significantly between 2009-2014.||Sepsis related mortality has risen from 2009 to 2014.": [
    0.9873703718185425,
    0.009529593400657177,
    0.003099918132647872
  ],
  "The findings also suggest that EHR-based clinical data provide more objective estimates than claims-based data for sepsis surveillance.||Sepsis related mortality has risen from 2009 to 2014.": [
    0.05407151207327843,
    0.9438400864601135,
    0.0020883993711322546
  ],
  "CONTEXT Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs.||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.9759449362754822,
    0.02262995019555092,
    0.0014251194661483169
  ],
  "However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied.   \n||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.8109404444694519,
    0.18034817278385162,
    0.00871132779866457
  ],
  "OBJECTIVE To measure the effect of pharmacist participation on medical rounds in the ICU on the rate of preventable adverse drug events (ADEs) caused by ordering errors.   \n||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.8502973914146423,
    0.14671194553375244,
    0.002990588080137968
  ],
  "DESIGN Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention.   \n||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.6251732110977173,
    0.36535418033599854,
    0.009472631849348545
  ],
  "SETTING A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital.   \n||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.6063722372055054,
    0.37756577134132385,
    0.016061991453170776
  ],
  "PATIENTS Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions to the study unit (postintervention) and control unit from October 1, 1994, through July 7, 1995.||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.2597618103027344,
    0.7333902716636658,
    0.006847914773970842
  ],
  "In addition, 50 patients were selected at random from the control unit during the baseline period.   \n||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.5360448956489563,
    0.45751094818115234,
    0.006444175727665424
  ],
  "INTERVENTION A senior pharmacist made rounds with the ICU team and remained in the ICU for consultation in the morning, and was available on call throughout the day.   \n||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.25123414397239685,
    0.7456039190292358,
    0.0031619572546333075
  ],
  "MAIN OUTCOME MEASURES Preventable ADEs due to ordering (prescribing) errors and the number, type, and acceptance of interventions made by the pharmacist.||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.9378178119659424,
    0.06035061925649643,
    0.0018315608613193035
  ],
  "Preventable ADEs were identified by review of medical records of the randomly selected patients during both preintervention and postintervention phases.||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.4476958215236664,
    0.5494979619979858,
    0.00280620320700109
  ],
  "Pharmacists recorded all recommendations, which were then analyzed by type and acceptance.   \n||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.38901519775390625,
    0.6070818305015564,
    0.0039029838517308235
  ],
  "RESULTS The rate of preventable ordering ADEs decreased by 66% from 10.4 per 1000 patient-days (95% confidence interval [CI], 7-14) before the intervention to 3.5 (95% CI, 1-5; P<.001) after the intervention.||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.6887727975845337,
    0.3086726665496826,
    0.002554552163928747
  ],
  "In the control unit, the rate was essentially unchanged during the same time periods: 10.9 (95% CI, 6-16) and 12.4 (95% CI, 8-17) per 1000 patient-days.||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.03731868043541908,
    0.9140959978103638,
    0.048585325479507446
  ],
  "The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) were accepted by physicians.   \n||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.6277177333831787,
    0.3670502007007599,
    0.005232127849012613
  ],
  "CONCLUSIONS The presence of a pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a substantially lower rate of ADEs caused by prescribing errors.||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.9982059001922607,
    0.0013047439279034734,
    0.000489309779368341
  ],
  "Nearly all the changes were readily accepted by physicians.||Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).": [
    0.617885947227478,
    0.37742066383361816,
    0.004693431314080954
  ],
  "CONTEXT Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs.||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.002483769552782178,
    0.711333155632019,
    0.28618305921554565
  ],
  "However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied.   \n||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.12668214738368988,
    0.7368043661117554,
    0.13651351630687714
  ],
  "OBJECTIVE To measure the effect of pharmacist participation on medical rounds in the ICU on the rate of preventable adverse drug events (ADEs) caused by ordering errors.   \n||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.008570684120059013,
    0.8512995839118958,
    0.14012973010540009
  ],
  "DESIGN Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention.   \n||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.02605782076716423,
    0.9250888824462891,
    0.04885333031415939
  ],
  "SETTING A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital.   \n||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.04454212263226509,
    0.8477434515953064,
    0.1077144593000412
  ],
  "PATIENTS Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions to the study unit (postintervention) and control unit from October 1, 1994, through July 7, 1995.||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.023867638781666756,
    0.9612483978271484,
    0.014883972704410553
  ],
  "In addition, 50 patients were selected at random from the control unit during the baseline period.   \n||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.016053618863224983,
    0.9549006223678589,
    0.029045753180980682
  ],
  "INTERVENTION A senior pharmacist made rounds with the ICU team and remained in the ICU for consultation in the morning, and was available on call throughout the day.   \n||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.0014102216809988022,
    0.9963364601135254,
    0.0022532937582582235
  ],
  "MAIN OUTCOME MEASURES Preventable ADEs due to ordering (prescribing) errors and the number, type, and acceptance of interventions made by the pharmacist.||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.0026975010987371206,
    0.8374436497688293,
    0.1598588526248932
  ],
  "Preventable ADEs were identified by review of medical records of the randomly selected patients during both preintervention and postintervention phases.||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.022414959967136383,
    0.9707794189453125,
    0.006805642042309046
  ],
  "Pharmacists recorded all recommendations, which were then analyzed by type and acceptance.   \n||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.0014548765029758215,
    0.9956609606742859,
    0.0028841535095125437
  ],
  "RESULTS The rate of preventable ordering ADEs decreased by 66% from 10.4 per 1000 patient-days (95% confidence interval [CI], 7-14) before the intervention to 3.5 (95% CI, 1-5; P<.001) after the intervention.||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.010239306837320328,
    0.9734441041946411,
    0.01631656102836132
  ],
  "In the control unit, the rate was essentially unchanged during the same time periods: 10.9 (95% CI, 6-16) and 12.4 (95% CI, 8-17) per 1000 patient-days.||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.028013208881020546,
    0.9659945964813232,
    0.005992255639284849
  ],
  "The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) were accepted by physicians.   \n||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.004460988100618124,
    0.990480363368988,
    0.005058626644313335
  ],
  "CONCLUSIONS The presence of a pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a substantially lower rate of ADEs caused by prescribing errors.||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.0007945395773276687,
    0.01564328745007515,
    0.9835622906684875
  ],
  "Nearly all the changes were readily accepted by physicians.||Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).": [
    0.008912577293813229,
    0.9732446670532227,
    0.017842808738350868
  ],
  "CONTEXT Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs.||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.9932295083999634,
    0.0059462422505021095,
    0.0008242083713412285
  ],
  "However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied.   \n||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.9667897820472717,
    0.030810222029685974,
    0.0023999291006475687
  ],
  "OBJECTIVE To measure the effect of pharmacist participation on medical rounds in the ICU on the rate of preventable adverse drug events (ADEs) caused by ordering errors.   \n||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.24166378378868103,
    0.7413986921310425,
    0.016937509179115295
  ],
  "DESIGN Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention.   \n||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.08841369301080704,
    0.8812611699104309,
    0.03032516874372959
  ],
  "SETTING A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital.   \n||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.10010933130979538,
    0.8628690838813782,
    0.03702153265476227
  ],
  "PATIENTS Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions to the study unit (postintervention) and control unit from October 1, 1994, through July 7, 1995.||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.08919951319694519,
    0.8473964333534241,
    0.06340403109788895
  ],
  "In addition, 50 patients were selected at random from the control unit during the baseline period.   \n||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.1516355276107788,
    0.8074585199356079,
    0.04090595617890358
  ],
  "INTERVENTION A senior pharmacist made rounds with the ICU team and remained in the ICU for consultation in the morning, and was available on call throughout the day.   \n||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.08288513869047165,
    0.9120014905929565,
    0.005113366991281509
  ],
  "MAIN OUTCOME MEASURES Preventable ADEs due to ordering (prescribing) errors and the number, type, and acceptance of interventions made by the pharmacist.||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.9513676166534424,
    0.04510340467095375,
    0.0035289570223540068
  ],
  "Preventable ADEs were identified by review of medical records of the randomly selected patients during both preintervention and postintervention phases.||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.2803533673286438,
    0.7159348130226135,
    0.0037118776235729456
  ],
  "Pharmacists recorded all recommendations, which were then analyzed by type and acceptance.   \n||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.4137042164802551,
    0.580521821975708,
    0.00577389495447278
  ],
  "RESULTS The rate of preventable ordering ADEs decreased by 66% from 10.4 per 1000 patient-days (95% confidence interval [CI], 7-14) before the intervention to 3.5 (95% CI, 1-5; P<.001) after the intervention.||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.5505457520484924,
    0.44586169719696045,
    0.003592531196773052
  ],
  "In the control unit, the rate was essentially unchanged during the same time periods: 10.9 (95% CI, 6-16) and 12.4 (95% CI, 8-17) per 1000 patient-days.||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.026298848912119865,
    0.9683272242546082,
    0.005373964551836252
  ],
  "The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) were accepted by physicians.   \n||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.19051261246204376,
    0.8043277263641357,
    0.005159634165465832
  ],
  "CONCLUSIONS The presence of a pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a substantially lower rate of ADEs caused by prescribing errors.||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.9990940093994141,
    0.0006762005505152047,
    0.00022973799786996096
  ],
  "Nearly all the changes were readily accepted by physicians.||Pharmacist attendance at ward rounds increases adverse events in wards.": [
    0.20777814090251923,
    0.772335410118103,
    0.019886469468474388
  ],
  "CONTEXT Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs.||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.008050422184169292,
    0.8578749299049377,
    0.13407471776008606
  ],
  "However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied.   \n||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.41498610377311707,
    0.5700455904006958,
    0.014968281611800194
  ],
  "OBJECTIVE To measure the effect of pharmacist participation on medical rounds in the ICU on the rate of preventable adverse drug events (ADEs) caused by ordering errors.   \n||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.017736544832587242,
    0.8664204478263855,
    0.11584300547838211
  ],
  "DESIGN Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention.   \n||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.03823815658688545,
    0.9057986736297607,
    0.05596310645341873
  ],
  "SETTING A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital.   \n||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.0912633165717125,
    0.8493330478668213,
    0.05940360203385353
  ],
  "PATIENTS Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions to the study unit (postintervention) and control unit from October 1, 1994, through July 7, 1995.||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.04666510224342346,
    0.849031925201416,
    0.10430295765399933
  ],
  "In addition, 50 patients were selected at random from the control unit during the baseline period.   \n||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.025817131623625755,
    0.9172641634941101,
    0.056918732821941376
  ],
  "INTERVENTION A senior pharmacist made rounds with the ICU team and remained in the ICU for consultation in the morning, and was available on call throughout the day.   \n||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.0016331402584910393,
    0.9949546456336975,
    0.0034121403004974127
  ],
  "MAIN OUTCOME MEASURES Preventable ADEs due to ordering (prescribing) errors and the number, type, and acceptance of interventions made by the pharmacist.||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.0013894819421693683,
    0.9700143933296204,
    0.028596075251698494
  ],
  "Preventable ADEs were identified by review of medical records of the randomly selected patients during both preintervention and postintervention phases.||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.06508568674325943,
    0.9250820279121399,
    0.009832300245761871
  ],
  "Pharmacists recorded all recommendations, which were then analyzed by type and acceptance.   \n||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.003280864330008626,
    0.9853540658950806,
    0.011365055106580257
  ],
  "RESULTS The rate of preventable ordering ADEs decreased by 66% from 10.4 per 1000 patient-days (95% confidence interval [CI], 7-14) before the intervention to 3.5 (95% CI, 1-5; P<.001) after the intervention.||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.01945919543504715,
    0.9686926603317261,
    0.011848135851323605
  ],
  "In the control unit, the rate was essentially unchanged during the same time periods: 10.9 (95% CI, 6-16) and 12.4 (95% CI, 8-17) per 1000 patient-days.||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.02114548347890377,
    0.973178505897522,
    0.005675985012203455
  ],
  "The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) were accepted by physicians.   \n||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.0057563818991184235,
    0.9900320768356323,
    0.004211610183119774
  ],
  "CONCLUSIONS The presence of a pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a substantially lower rate of ADEs caused by prescribing errors.||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.001988078700378537,
    0.08523435145616531,
    0.9127775430679321
  ],
  "Nearly all the changes were readily accepted by physicians.||Pharmacist attendance at ward rounds reduces adverse events in wards.": [
    0.004374129232019186,
    0.9856399297714233,
    0.009985900484025478
  ],
  "Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease.||Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.011599082499742508,
    0.985491156578064,
    0.0029097655788064003
  ],
  "LRRK2 is a multifunctional protein affecting many cellular processes and has been described to bind microtubules.||Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.11828038841485977,
    0.8785874247550964,
    0.0031322005670517683
  ],
  "Defective microtubule-based axonal transport is hypothesized to contribute to Parkinson's disease, but whether LRRK2 mutations affect this process to mediate pathogenesis is not known.||Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.11107740551233292,
    0.8831542730331421,
    0.005768364295363426
  ],
  "Here we find that LRRK2 containing pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila, causing locomotor deficits in vivo.||Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.28454869985580444,
    0.6783076524734497,
    0.03714364022016525
  ],
  "In vitro, increasing microtubule acetylation using deacetylase inhibitors or the tubulin acetylase \u03b1TAT1 prevents association of mutant LRRK2 with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal transport.||Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.9980382323265076,
    0.0015175167936831713,
    0.00044431124115362763
  ],
  "In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA rescues both axonal transport and locomotor behavior.||Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.9094861149787903,
    0.08445732295513153,
    0.006056527607142925
  ],
  "Thus, this study reveals a pathogenic mechanism and a potential intervention for Parkinson's disease.||Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.0504208467900753,
    0.9432600736618042,
    0.006319137290120125
  ],
  "Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease.||Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.45970606803894043,
    0.5258370041847229,
    0.014457006007432938
  ],
  "LRRK2 is a multifunctional protein affecting many cellular processes and has been described to bind microtubules.||Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.005343582481145859,
    0.9813045263290405,
    0.013351880013942719
  ],
  "Defective microtubule-based axonal transport is hypothesized to contribute to Parkinson's disease, but whether LRRK2 mutations affect this process to mediate pathogenesis is not known.||Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.208879292011261,
    0.7873467206954956,
    0.0037739332765340805
  ],
  "Here we find that LRRK2 containing pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila, causing locomotor deficits in vivo.||Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.665617823600769,
    0.32941925525665283,
    0.0049628945998847485
  ],
  "In vitro, increasing microtubule acetylation using deacetylase inhibitors or the tubulin acetylase \u03b1TAT1 prevents association of mutant LRRK2 with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal transport.||Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.01167239248752594,
    0.5021107792854309,
    0.48621684312820435
  ],
  "In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA rescues both axonal transport and locomotor behavior.||Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.3415316045284271,
    0.5194555521011353,
    0.13901287317276
  ],
  "Thus, this study reveals a pathogenic mechanism and a potential intervention for Parkinson's disease.||Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.08639669418334961,
    0.8989367485046387,
    0.014666509814560413
  ],
  "Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease.||Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.011414877139031887,
    0.9823517203330994,
    0.006233425810933113
  ],
  "LRRK2 is a multifunctional protein affecting many cellular processes and has been described to bind microtubules.||Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.051514577120542526,
    0.9450291395187378,
    0.003456233534961939
  ],
  "Defective microtubule-based axonal transport is hypothesized to contribute to Parkinson's disease, but whether LRRK2 mutations affect this process to mediate pathogenesis is not known.||Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.021500129252672195,
    0.9752079248428345,
    0.003291891422122717
  ],
  "Here we find that LRRK2 containing pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila, causing locomotor deficits in vivo.||Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.10679125785827637,
    0.8329946994781494,
    0.0602140799164772
  ],
  "In vitro, increasing microtubule acetylation using deacetylase inhibitors or the tubulin acetylase \u03b1TAT1 prevents association of mutant LRRK2 with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal transport.||Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.9980838298797607,
    0.0013930563582107425,
    0.000523185939528048
  ],
  "In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA rescues both axonal transport and locomotor behavior.||Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.6782362461090088,
    0.31285783648490906,
    0.008905906230211258
  ],
  "Thus, this study reveals a pathogenic mechanism and a potential intervention for Parkinson's disease.||Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.": [
    0.008271935395896435,
    0.988171398639679,
    0.0035566699225455523
  ],
  "Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease.||Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.5406028032302856,
    0.44477954506874084,
    0.014617634937167168
  ],
  "LRRK2 is a multifunctional protein affecting many cellular processes and has been described to bind microtubules.||Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.012877250090241432,
    0.9787802696228027,
    0.008342456072568893
  ],
  "Defective microtubule-based axonal transport is hypothesized to contribute to Parkinson's disease, but whether LRRK2 mutations affect this process to mediate pathogenesis is not known.||Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.47239238023757935,
    0.5218241214752197,
    0.005783526226878166
  ],
  "Here we find that LRRK2 containing pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila, causing locomotor deficits in vivo.||Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.6542079448699951,
    0.30871346592903137,
    0.037078607827425
  ],
  "In vitro, increasing microtubule acetylation using deacetylase inhibitors or the tubulin acetylase \u03b1TAT1 prevents association of mutant LRRK2 with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal transport.||Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.014593491330742836,
    0.7508018612861633,
    0.23460467159748077
  ],
  "In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA rescues both axonal transport and locomotor behavior.||Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.39968982338905334,
    0.4676055610179901,
    0.1327047049999237
  ],
  "Thus, this study reveals a pathogenic mechanism and a potential intervention for Parkinson's disease.||Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.": [
    0.11708929389715195,
    0.8541932106018066,
    0.02871742658317089
  ],
  "Gram-negative bacteria have an outer membrane (OM) that functions as a barrier to protect the cell from toxic compounds such as antibiotics and detergents.||Increased purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.004460889380425215,
    0.9935765862464905,
    0.001962554408237338
  ],
  "The OM is a highly asymmetric bilayer composed of phospholipids, glycolipids, and proteins.||Increased purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.05322055146098137,
    0.81800377368927,
    0.1287757009267807
  ],
  "Assembly of this essential organelle occurs outside the cytoplasm in an environment that lacks obvious energy sources such as ATP, and the mechanisms involved are poorly understood.||Increased purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.08572056144475937,
    0.8926840424537659,
    0.021595383062958717
  ],
  "We describe the identification of a multiprotein complex required for the assembly of proteins in the OM of Escherichia coli.||Increased purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.12739765644073486,
    0.6808550357818604,
    0.1917472779750824
  ],
  "We also demonstrate genetic interactions between genes encoding components of this protein assembly complex and imp, which encodes a protein involved in the assembly of lipopolysaccharides (LPS) in the OM.||Increased purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.08481346070766449,
    0.8171592354774475,
    0.09802725911140442
  ],
  "These genetic interactions suggest a role for YfgL, one of the lipoprotein components of the protein assembly complex, in a homeostatic control mechanism that coordinates the overall OM assembly process.||Increased purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.13673518598079681,
    0.8283768892288208,
    0.034887928515672684
  ],
  "Gram-negative bacteria have an outer membrane (OM) that functions as a barrier to protect the cell from toxic compounds such as antibiotics and detergents.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpA in 2D BN-PAGE gels.": [
    0.03407323732972145,
    0.9632750153541565,
    0.002651816699653864
  ],
  "The OM is a highly asymmetric bilayer composed of phospholipids, glycolipids, and proteins.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpA in 2D BN-PAGE gels.": [
    0.06248851120471954,
    0.8371726274490356,
    0.10033881664276123
  ],
  "Assembly of this essential organelle occurs outside the cytoplasm in an environment that lacks obvious energy sources such as ATP, and the mechanisms involved are poorly understood.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpA in 2D BN-PAGE gels.": [
    0.05543100833892822,
    0.9341795444488525,
    0.010389496572315693
  ],
  "We describe the identification of a multiprotein complex required for the assembly of proteins in the OM of Escherichia coli.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpA in 2D BN-PAGE gels.": [
    0.14037105441093445,
    0.7564854621887207,
    0.10314351320266724
  ],
  "We also demonstrate genetic interactions between genes encoding components of this protein assembly complex and imp, which encodes a protein involved in the assembly of lipopolysaccharides (LPS) in the OM.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpA in 2D BN-PAGE gels.": [
    0.1487366408109665,
    0.8012205958366394,
    0.0500427782535553
  ],
  "These genetic interactions suggest a role for YfgL, one of the lipoprotein components of the protein assembly complex, in a homeostatic control mechanism that coordinates the overall OM assembly process.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpA in 2D BN-PAGE gels.": [
    0.26639866828918457,
    0.6910660862922668,
    0.042535245418548584
  ],
  "Gram-negative bacteria have an outer membrane (OM) that functions as a barrier to protect the cell from toxic compounds such as antibiotics and detergents.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.03499376028776169,
    0.9623201489448547,
    0.0026861210353672504
  ],
  "The OM is a highly asymmetric bilayer composed of phospholipids, glycolipids, and proteins.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.0728948712348938,
    0.8093690276145935,
    0.11773613095283508
  ],
  "Assembly of this essential organelle occurs outside the cytoplasm in an environment that lacks obvious energy sources such as ATP, and the mechanisms involved are poorly understood.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.0586334653198719,
    0.9260084629058838,
    0.01535805594176054
  ],
  "We describe the identification of a multiprotein complex required for the assembly of proteins in the OM of Escherichia coli.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.16956323385238647,
    0.6923726201057434,
    0.13806414604187012
  ],
  "We also demonstrate genetic interactions between genes encoding components of this protein assembly complex and imp, which encodes a protein involved in the assembly of lipopolysaccharides (LPS) in the OM.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.16868577897548676,
    0.7597665190696716,
    0.07154769450426102
  ],
  "These genetic interactions suggest a role for YfgL, one of the lipoprotein components of the protein assembly complex, in a homeostatic control mechanism that coordinates the overall OM assembly process.||Reduction of purity of cytoplasmic membranes isolated from overexpressors is indicated by stronger spots for OmpF in 2D BN-PAGE gels.": [
    0.24876420199871063,
    0.7186978459358215,
    0.03253798931837082
  ],
  "CONTEXT Many observational studies have shown that physical activity reduces the risk of cognitive decline; however, evidence from randomized trials is lacking.   \n||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.0013679395196959376,
    0.9975814819335938,
    0.0010506031103432178
  ],
  "OBJECTIVE To determine whether physical activity reduces the rate of cognitive decline among older adults at risk.   \n||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.0027707312256097794,
    0.9963477253913879,
    0.0008815973997116089
  ],
  "DESIGN AND SETTING Randomized controlled trial of a 24-week physical activity intervention conducted between 2004 and 2007 in metropolitan Perth, Western Australia.||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.0014979264233261347,
    0.9964858293533325,
    0.0020162214059382677
  ],
  "Assessors of cognitive function were blinded to group membership.   \n||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.03036557324230671,
    0.9595954418182373,
    0.010038899257779121
  ],
  "PARTICIPANTS We recruited volunteers who reported memory problems but did not meet criteria for dementia.||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.12092304974794388,
    0.8763766288757324,
    0.0027003230061382055
  ],
  "Three hundred eleven individuals aged 50 years or older were screened for eligibility, 89 were not eligible, and 52 refused to participate.||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.010569977574050426,
    0.9816243052482605,
    0.0078057292848825455
  ],
  "A total of 170 participants were randomized and 138 participants completed the 18-month assessment.   \n||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.005796854849904776,
    0.9321083426475525,
    0.06209475174546242
  ],
  "INTERVENTION Participants were randomly allocated to an education and usual care group or to a 24-week home-based program of physical activity.   \n||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.0016603103140369058,
    0.9972604513168335,
    0.001079176552593708
  ],
  "MAIN OUTCOME MEASURE Change in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores (possible range, 0-70) over 18 months.   \n||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.005406608805060387,
    0.9866264462471008,
    0.007966889068484306
  ],
  "RESULTS In an intent-to-treat analysis, participants in the intervention group improved 0.26 points (95% confidence interval, -0.89 to 0.54) and those in the usual care group deteriorated 1.04 points (95% confidence interval, 0.32 to 1.82) on the ADAS-Cog at the end of the intervention.||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.01839493215084076,
    0.9354796409606934,
    0.046125445514917374
  ],
  "The absolute difference of the outcome measure between the intervention and control groups was -1.3 points (95% confidence interval,-2.38 to -0.22) at the end of the intervention.||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.014254957437515259,
    0.9184728264808655,
    0.06727219372987747
  ],
  "At 18 months, participants in the intervention group improved 0.73 points (95% confidence interval, -1.27 to 0.03) on the ADAS-Cog, and those in the usual care group improved 0.04 points (95% confidence interval, -0.46 to 0.88).||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.0075838700868189335,
    0.7146275043487549,
    0.27778857946395874
  ],
  "Word list delayed recall and Clinical Dementia Rating sum of boxes improved modestly as well, whereas word list total immediate recall, digit symbol coding, verbal fluency, Beck depression score, and Medical Outcomes 36-Item Short-Form physical and mental component summaries did not change significantly.   \n||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.06370221078395844,
    0.9311836361885071,
    0.0051141418516635895
  ],
  "CONCLUSIONS In this study of adults with subjective memory impairment, a 6-month program of physical activity provided a modest improvement in cognition over an 18-month follow-up period.   \n||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.011919941753149033,
    0.7715612053871155,
    0.216518834233284
  ],
  "TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12605000136606.||Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.": [
    0.007600776851177216,
    0.9752948880195618,
    0.017104286700487137
  ],
  "CONTEXT Many observational studies have shown that physical activity reduces the risk of cognitive decline; however, evidence from randomized trials is lacking.   \n||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.9099311828613281,
    0.08727287501096725,
    0.0027959959115833044
  ],
  "OBJECTIVE To determine whether physical activity reduces the rate of cognitive decline among older adults at risk.   \n||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.6970290541648865,
    0.29923880100250244,
    0.003732204670086503
  ],
  "DESIGN AND SETTING Randomized controlled trial of a 24-week physical activity intervention conducted between 2004 and 2007 in metropolitan Perth, Western Australia.||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.366055428981781,
    0.6300697922706604,
    0.003874747082591057
  ],
  "Assessors of cognitive function were blinded to group membership.   \n||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.27802467346191406,
    0.7060636878013611,
    0.015911631286144257
  ],
  "PARTICIPANTS We recruited volunteers who reported memory problems but did not meet criteria for dementia.||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.38251838088035583,
    0.5998436808586121,
    0.01763795129954815
  ],
  "Three hundred eleven individuals aged 50 years or older were screened for eligibility, 89 were not eligible, and 52 refused to participate.||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.24546954035758972,
    0.7368365526199341,
    0.017693908885121346
  ],
  "A total of 170 participants were randomized and 138 participants completed the 18-month assessment.   \n||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.39840254187583923,
    0.5641607642173767,
    0.03743666037917137
  ],
  "INTERVENTION Participants were randomly allocated to an education and usual care group or to a 24-week home-based program of physical activity.   \n||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.4943622052669525,
    0.5015286207199097,
    0.00410920474678278
  ],
  "MAIN OUTCOME MEASURE Change in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores (possible range, 0-70) over 18 months.   \n||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.40368416905403137,
    0.5841836333274841,
    0.01213217992335558
  ],
  "RESULTS In an intent-to-treat analysis, participants in the intervention group improved 0.26 points (95% confidence interval, -0.89 to 0.54) and those in the usual care group deteriorated 1.04 points (95% confidence interval, 0.32 to 1.82) on the ADAS-Cog at the end of the intervention.||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.842918872833252,
    0.1514149159193039,
    0.005666227545589209
  ],
  "The absolute difference of the outcome measure between the intervention and control groups was -1.3 points (95% confidence interval,-2.38 to -0.22) at the end of the intervention.||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.38243168592453003,
    0.5635936856269836,
    0.053974609822034836
  ],
  "At 18 months, participants in the intervention group improved 0.73 points (95% confidence interval, -1.27 to 0.03) on the ADAS-Cog, and those in the usual care group improved 0.04 points (95% confidence interval, -0.46 to 0.88).||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.8372699618339539,
    0.15820524096488953,
    0.004524783231317997
  ],
  "Word list delayed recall and Clinical Dementia Rating sum of boxes improved modestly as well, whereas word list total immediate recall, digit symbol coding, verbal fluency, Beck depression score, and Medical Outcomes 36-Item Short-Form physical and mental component summaries did not change significantly.   \n||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.3259119689464569,
    0.6349303126335144,
    0.039157647639513016
  ],
  "CONCLUSIONS In this study of adults with subjective memory impairment, a 6-month program of physical activity provided a modest improvement in cognition over an 18-month follow-up period.   \n||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.4323803782463074,
    0.563299834728241,
    0.004319784697145224
  ],
  "TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12605000136606.||Physical activity does not improve cognitive function in individuals with Alzheimers.": [
    0.32446008920669556,
    0.6349899172782898,
    0.04054995998740196
  ],
  "CONTEXT Many observational studies have shown that physical activity reduces the risk of cognitive decline; however, evidence from randomized trials is lacking.   \n||Participating in six months of physical activity improves cognitive functioning.": [
    0.0010908367112278938,
    0.9978310465812683,
    0.0010780623415485024
  ],
  "OBJECTIVE To determine whether physical activity reduces the rate of cognitive decline among older adults at risk.   \n||Participating in six months of physical activity improves cognitive functioning.": [
    0.0021665343083441257,
    0.9956939220428467,
    0.002139529911801219
  ],
  "DESIGN AND SETTING Randomized controlled trial of a 24-week physical activity intervention conducted between 2004 and 2007 in metropolitan Perth, Western Australia.||Participating in six months of physical activity improves cognitive functioning.": [
    0.0011579155689105392,
    0.9966391324996948,
    0.0022029955871403217
  ],
  "Assessors of cognitive function were blinded to group membership.   \n||Participating in six months of physical activity improves cognitive functioning.": [
    0.03436093404889107,
    0.9631964564323425,
    0.0024425892625004053
  ],
  "PARTICIPANTS We recruited volunteers who reported memory problems but did not meet criteria for dementia.||Participating in six months of physical activity improves cognitive functioning.": [
    0.017838982865214348,
    0.9801337718963623,
    0.0020273204427212477
  ],
  "Three hundred eleven individuals aged 50 years or older were screened for eligibility, 89 were not eligible, and 52 refused to participate.||Participating in six months of physical activity improves cognitive functioning.": [
    0.006943308748304844,
    0.9798063039779663,
    0.013250362128019333
  ],
  "A total of 170 participants were randomized and 138 participants completed the 18-month assessment.   \n||Participating in six months of physical activity improves cognitive functioning.": [
    0.007517698686569929,
    0.9812884330749512,
    0.011193900369107723
  ],
  "INTERVENTION Participants were randomly allocated to an education and usual care group or to a 24-week home-based program of physical activity.   \n||Participating in six months of physical activity improves cognitive functioning.": [
    0.001010977546684444,
    0.9969561100006104,
    0.002032968681305647
  ],
  "MAIN OUTCOME MEASURE Change in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores (possible range, 0-70) over 18 months.   \n||Participating in six months of physical activity improves cognitive functioning.": [
    0.03178729861974716,
    0.9622792601585388,
    0.005933396052569151
  ],
  "RESULTS In an intent-to-treat analysis, participants in the intervention group improved 0.26 points (95% confidence interval, -0.89 to 0.54) and those in the usual care group deteriorated 1.04 points (95% confidence interval, 0.32 to 1.82) on the ADAS-Cog at the end of the intervention.||Participating in six months of physical activity improves cognitive functioning.": [
    0.006684036459773779,
    0.9604689478874207,
    0.03284697234630585
  ],
  "The absolute difference of the outcome measure between the intervention and control groups was -1.3 points (95% confidence interval,-2.38 to -0.22) at the end of the intervention.||Participating in six months of physical activity improves cognitive functioning.": [
    0.012514252215623856,
    0.9084296226501465,
    0.07905617356300354
  ],
  "At 18 months, participants in the intervention group improved 0.73 points (95% confidence interval, -1.27 to 0.03) on the ADAS-Cog, and those in the usual care group improved 0.04 points (95% confidence interval, -0.46 to 0.88).||Participating in six months of physical activity improves cognitive functioning.": [
    0.011124996468424797,
    0.8977794647216797,
    0.09109555184841156
  ],
  "Word list delayed recall and Clinical Dementia Rating sum of boxes improved modestly as well, whereas word list total immediate recall, digit symbol coding, verbal fluency, Beck depression score, and Medical Outcomes 36-Item Short-Form physical and mental component summaries did not change significantly.   \n||Participating in six months of physical activity improves cognitive functioning.": [
    0.02908562310039997,
    0.9683288931846619,
    0.0025855230633169413
  ],
  "CONCLUSIONS In this study of adults with subjective memory impairment, a 6-month program of physical activity provided a modest improvement in cognition over an 18-month follow-up period.   \n||Participating in six months of physical activity improves cognitive functioning.": [
    0.0010217191884294152,
    0.022272668778896332,
    0.9767056107521057
  ],
  "TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12605000136606.||Participating in six months of physical activity improves cognitive functioning.": [
    0.008851176127791405,
    0.9270728230476379,
    0.06407597661018372
  ],
  "Podocyte dysfunction, represented by foot process effacement and proteinuria, is often the starting point for progressive kidney disease.||Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.": [
    0.013432648032903671,
    0.9791883826255798,
    0.007378940004855394
  ],
  "Therapies aimed at the cellular level of the disease are currently not available.||Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.": [
    0.13242070376873016,
    0.7680683732032776,
    0.09951094537973404
  ],
  "Here we show that induction of urokinase receptor (uPAR) signaling in podocytes leads to foot process effacement and urinary protein loss via a mechanism that includes lipid-dependent activation of \u03b1v\u03b23 integrin.||Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.": [
    0.04403595253825188,
    0.04992801323533058,
    0.9060361385345459
  ],
  "Mice lacking uPAR (Plaur\u2212/\u2212) are protected from lipopolysaccharide (LPS)-mediated proteinuria but develop disease after expression of a constitutively active \u03b23 integrin.||Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.": [
    0.5413901209831238,
    0.43570035696029663,
    0.022909492254257202
  ],
  "Gene transfer studies reveal a prerequisite for uPAR expression in podocytes, but not in endothelial cells, for the development of LPS-mediated proteinuria.||Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.": [
    0.13259966671466827,
    0.5105817914009094,
    0.3568185567855835
  ],
  "Mechanistically, uPAR is required to activate \u03b1v\u03b23 integrin in podocytes, promoting cell motility and activation of the small GTPases Cdc42 and Rac1.||Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.": [
    0.9951087832450867,
    0.0042666844092309475,
    0.0006246257689781487
  ],
  "Blockade of \u03b1v\u03b23 integrin reduces podocyte motility in vitro and lowers proteinuria in mice.||Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.": [
    0.9681968092918396,
    0.027548370882868767,
    0.004254844039678574
  ],
  "Our findings show a physiological role for uPAR signaling in the regulation of kidney permeability.||Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.": [
    0.9153348207473755,
    0.08101288229227066,
    0.003652231302112341
  ],
  "Podocyte dysfunction, represented by foot process effacement and proteinuria, is often the starting point for progressive kidney disease.||Lipopolysaccharides have an inflammation independent effect on kidney barrier function.": [
    0.6778323650360107,
    0.30560576915740967,
    0.01656191796064377
  ],
  "Therapies aimed at the cellular level of the disease are currently not available.||Lipopolysaccharides have an inflammation independent effect on kidney barrier function.": [
    0.6880582571029663,
    0.27316564321517944,
    0.03877609223127365
  ],
  "Here we show that induction of urokinase receptor (uPAR) signaling in podocytes leads to foot process effacement and urinary protein loss via a mechanism that includes lipid-dependent activation of \u03b1v\u03b23 integrin.||Lipopolysaccharides have an inflammation independent effect on kidney barrier function.": [
    0.8732595443725586,
    0.11960116028785706,
    0.007139318622648716
  ],
  "Mice lacking uPAR (Plaur\u2212/\u2212) are protected from lipopolysaccharide (LPS)-mediated proteinuria but develop disease after expression of a constitutively active \u03b23 integrin.||Lipopolysaccharides have an inflammation independent effect on kidney barrier function.": [
    0.571204423904419,
    0.3969271779060364,
    0.03186832368373871
  ],
  "Gene transfer studies reveal a prerequisite for uPAR expression in podocytes, but not in endothelial cells, for the development of LPS-mediated proteinuria.||Lipopolysaccharides have an inflammation independent effect on kidney barrier function.": [
    0.7692217826843262,
    0.19528305530548096,
    0.035495202988386154
  ],
  "Mechanistically, uPAR is required to activate \u03b1v\u03b23 integrin in podocytes, promoting cell motility and activation of the small GTPases Cdc42 and Rac1.||Lipopolysaccharides have an inflammation independent effect on kidney barrier function.": [
    0.4144085943698883,
    0.4325719475746155,
    0.1530194729566574
  ],
  "Blockade of \u03b1v\u03b23 integrin reduces podocyte motility in vitro and lowers proteinuria in mice.||Lipopolysaccharides have an inflammation independent effect on kidney barrier function.": [
    0.3821668028831482,
    0.47048550844192505,
    0.14734770357608795
  ],
  "Our findings show a physiological role for uPAR signaling in the regulation of kidney permeability.||Lipopolysaccharides have an inflammation independent effect on kidney barrier function.": [
    0.3429566025733948,
    0.5581287145614624,
    0.09891471266746521
  ],
  "Podocyte dysfunction, represented by foot process effacement and proteinuria, is often the starting point for progressive kidney disease.||The effect of Lipopolysaccharides on kidney barrier function is dependent on inflammation levels.": [
    0.08230319619178772,
    0.87826007604599,
    0.03943672031164169
  ],
  "Therapies aimed at the cellular level of the disease are currently not available.||The effect of Lipopolysaccharides on kidney barrier function is dependent on inflammation levels.": [
    0.052576977759599686,
    0.8115348815917969,
    0.13588814437389374
  ],
  "Here we show that induction of urokinase receptor (uPAR) signaling in podocytes leads to foot process effacement and urinary protein loss via a mechanism that includes lipid-dependent activation of \u03b1v\u03b23 integrin.||The effect of Lipopolysaccharides on kidney barrier function is dependent on inflammation levels.": [
    0.04167928919196129,
    0.8115555047988892,
    0.14676514267921448
  ],
  "Mice lacking uPAR (Plaur\u2212/\u2212) are protected from lipopolysaccharide (LPS)-mediated proteinuria but develop disease after expression of a constitutively active \u03b23 integrin.||The effect of Lipopolysaccharides on kidney barrier function is dependent on inflammation levels.": [
    0.029451338574290276,
    0.9360348582267761,
    0.034513767808675766
  ],
  "Gene transfer studies reveal a prerequisite for uPAR expression in podocytes, but not in endothelial cells, for the development of LPS-mediated proteinuria.||The effect of Lipopolysaccharides on kidney barrier function is dependent on inflammation levels.": [
    0.0550679937005043,
    0.8153955936431885,
    0.12953639030456543
  ],
  "Mechanistically, uPAR is required to activate \u03b1v\u03b23 integrin in podocytes, promoting cell motility and activation of the small GTPases Cdc42 and Rac1.||The effect of Lipopolysaccharides on kidney barrier function is dependent on inflammation levels.": [
    0.19335146248340607,
    0.7171704769134521,
    0.08947805315256119
  ],
  "Blockade of \u03b1v\u03b23 integrin reduces podocyte motility in vitro and lowers proteinuria in mice.||The effect of Lipopolysaccharides on kidney barrier function is dependent on inflammation levels.": [
    0.22619664669036865,
    0.7270546555519104,
    0.04674875736236572
  ],
  "Our findings show a physiological role for uPAR signaling in the regulation of kidney permeability.||The effect of Lipopolysaccharides on kidney barrier function is dependent on inflammation levels.": [
    0.3162999749183655,
    0.6688084006309509,
    0.014891603961586952
  ],
  "OBJECTIVE To establish the mental health needs of homeless children and families before and after rehousing.   \n||Input from  mental and physical health care professionals is not effective at decreasing homelessness.": [
    0.5568139553070068,
    0.43848752975463867,
    0.0046985093504190445
  ],
  "DESIGN Cross sectional, longitudinal study.   \n||Input from  mental and physical health care professionals is not effective at decreasing homelessness.": [
    0.39633116126060486,
    0.5687169432640076,
    0.03495190292596817
  ],
  "SETTING City of Birmingham.   ||Input from  mental and physical health care professionals is not effective at decreasing homelessness.": [
    0.33938080072402954,
    0.5908984541893005,
    0.06972075998783112
  ],
  "SUBJECTS 58 rehoused families with 103 children aged 2-16 years and 21 comparison families of low socioeconomic status in stable housing, with 54 children.   \n||Input from  mental and physical health care professionals is not effective at decreasing homelessness.": [
    0.6661627888679504,
    0.32410383224487305,
    0.009733348153531551
  ],
  "MAIN OUTCOME MEASURES Children's mental health problems and level of communication; mothers' mental health problems and social support one year after rehousing.   \n||Input from  mental and physical health care professionals is not effective at decreasing homelessness.": [
    0.9099161624908447,
    0.08584028482437134,
    0.004243565257638693
  ],
  "RESULTS Mental health problems remained significantly higher in rehoused mothers and their children than in the comparison group (mothers 26% v 5%, P = 0.04; children 39% v 11%, P = 0.0003).||Input from  mental and physical health care professionals is not effective at decreasing homelessness.": [
    0.02934800460934639,
    0.9201469421386719,
    0.05050504580140114
  ],
  "Homeless mothers continued to have significantly less social support at follow up.||Input from  mental and physical health care professionals is not effective at decreasing homelessness.": [
    0.024169860407710075,
    0.8627734184265137,
    0.11305670440196991
  ],
  "Mothers with a history of abuse and poor social integration were more likely to have children with persistent mental health problems.   \n||Input from  mental and physical health care professionals is not effective at decreasing homelessness.": [
    0.533225953578949,
    0.4583706557750702,
    0.008403417654335499
  ],
  "CONCLUSIONS Homeless families have a high level of complex needs that cannot be met by conventional health services and arrangements.||Input from  mental and physical health care professionals is not effective at decreasing homelessness.": [
    0.004372355528175831,
    0.8603585958480835,
    0.13526901602745056
  ],
  "Local strategies for rapid rehousing into permanent accommodation, effective social support and health care for parents and children, and protection from violence and intimidation should be developed and implemented.||Input from  mental and physical health care professionals is not effective at decreasing homelessness.": [
    0.7553274631500244,
    0.23859523236751556,
    0.006077322643250227
  ],
  "OBJECTIVE To establish the mental health needs of homeless children and families before and after rehousing.   \n||Self-advocacy training is effective at decreasing homelessness.": [
    0.04358647018671036,
    0.946354866027832,
    0.010058591142296791
  ],
  "DESIGN Cross sectional, longitudinal study.   \n||Self-advocacy training is effective at decreasing homelessness.": [
    0.19612501561641693,
    0.7143813967704773,
    0.08949361741542816
  ],
  "SETTING City of Birmingham.   ||Self-advocacy training is effective at decreasing homelessness.": [
    0.13315768539905548,
    0.7428308129310608,
    0.12401147931814194
  ],
  "SUBJECTS 58 rehoused families with 103 children aged 2-16 years and 21 comparison families of low socioeconomic status in stable housing, with 54 children.   \n||Self-advocacy training is effective at decreasing homelessness.": [
    0.034852635115385056,
    0.9524736404418945,
    0.012673737481236458
  ],
  "MAIN OUTCOME MEASURES Children's mental health problems and level of communication; mothers' mental health problems and social support one year after rehousing.   \n||Self-advocacy training is effective at decreasing homelessness.": [
    0.017393361777067184,
    0.9265735745429993,
    0.05603299289941788
  ],
  "RESULTS Mental health problems remained significantly higher in rehoused mothers and their children than in the comparison group (mothers 26% v 5%, P = 0.04; children 39% v 11%, P = 0.0003).||Self-advocacy training is effective at decreasing homelessness.": [
    0.3583311140537262,
    0.638009250164032,
    0.0036596853751689196
  ],
  "Homeless mothers continued to have significantly less social support at follow up.||Self-advocacy training is effective at decreasing homelessness.": [
    0.6018366813659668,
    0.3942108750343323,
    0.003952458966523409
  ],
  "Mothers with a history of abuse and poor social integration were more likely to have children with persistent mental health problems.   \n||Self-advocacy training is effective at decreasing homelessness.": [
    0.17075152695178986,
    0.7865127325057983,
    0.04273577779531479
  ],
  "CONCLUSIONS Homeless families have a high level of complex needs that cannot be met by conventional health services and arrangements.||Self-advocacy training is effective at decreasing homelessness.": [
    0.03677520900964737,
    0.9617592096328735,
    0.0014656244311481714
  ],
  "Local strategies for rapid rehousing into permanent accommodation, effective social support and health care for parents and children, and protection from violence and intimidation should be developed and implemented.||Self-advocacy training is effective at decreasing homelessness.": [
    0.07944097369909286,
    0.9165545701980591,
    0.004004456102848053
  ],
  "OBJECTIVE To establish the mental health needs of homeless children and families before and after rehousing.   \n||Input from  mental and physical health care professionals is effective at decreasing homelessness.": [
    0.002924207132309675,
    0.9958674907684326,
    0.0012082761386409402
  ],
  "DESIGN Cross sectional, longitudinal study.   \n||Input from  mental and physical health care professionals is effective at decreasing homelessness.": [
    0.09602880477905273,
    0.8656734824180603,
    0.03829771280288696
  ],
  "SETTING City of Birmingham.   ||Input from  mental and physical health care professionals is effective at decreasing homelessness.": [
    0.054605476558208466,
    0.8493631482124329,
    0.09603141248226166
  ],
  "SUBJECTS 58 rehoused families with 103 children aged 2-16 years and 21 comparison families of low socioeconomic status in stable housing, with 54 children.   \n||Input from  mental and physical health care professionals is effective at decreasing homelessness.": [
    0.032346952706575394,
    0.9387491345405579,
    0.028903856873512268
  ],
  "MAIN OUTCOME MEASURES Children's mental health problems and level of communication; mothers' mental health problems and social support one year after rehousing.   \n||Input from  mental and physical health care professionals is effective at decreasing homelessness.": [
    0.0034414788242429495,
    0.896779477596283,
    0.09977903962135315
  ],
  "RESULTS Mental health problems remained significantly higher in rehoused mothers and their children than in the comparison group (mothers 26% v 5%, P = 0.04; children 39% v 11%, P = 0.0003).||Input from  mental and physical health care professionals is effective at decreasing homelessness.": [
    0.19890905916690826,
    0.7958804965019226,
    0.005210434552282095
  ],
  "Homeless mothers continued to have significantly less social support at follow up.||Input from  mental and physical health care professionals is effective at decreasing homelessness.": [
    0.7410389184951782,
    0.2519175708293915,
    0.007043474353849888
  ],
  "Mothers with a history of abuse and poor social integration were more likely to have children with persistent mental health problems.   \n||Input from  mental and physical health care professionals is effective at decreasing homelessness.": [
    0.05184578895568848,
    0.9387655258178711,
    0.009388652630150318
  ],
  "CONCLUSIONS Homeless families have a high level of complex needs that cannot be met by conventional health services and arrangements.||Input from  mental and physical health care professionals is effective at decreasing homelessness.": [
    0.671168863773346,
    0.3249458074569702,
    0.0038853087462484837
  ],
  "Local strategies for rapid rehousing into permanent accommodation, effective social support and health care for parents and children, and protection from violence and intimidation should be developed and implemented.||Input from  mental and physical health care professionals is effective at decreasing homelessness.": [
    0.020737629383802414,
    0.9598407745361328,
    0.019421566277742386
  ],
  "OBJECTIVE To establish the mental health needs of homeless children and families before and after rehousing.   \n||The availability of safe places to study is effective at decreasing homelessness.": [
    0.030776239931583405,
    0.9640984535217285,
    0.005125304684042931
  ],
  "DESIGN Cross sectional, longitudinal study.   \n||The availability of safe places to study is effective at decreasing homelessness.": [
    0.05477926880121231,
    0.90998375415802,
    0.03523697704076767
  ],
  "SETTING City of Birmingham.   ||The availability of safe places to study is effective at decreasing homelessness.": [
    0.04257446900010109,
    0.8947647213935852,
    0.062660813331604
  ],
  "SUBJECTS 58 rehoused families with 103 children aged 2-16 years and 21 comparison families of low socioeconomic status in stable housing, with 54 children.   \n||The availability of safe places to study is effective at decreasing homelessness.": [
    0.03574725612998009,
    0.9423944354057312,
    0.021858351305127144
  ],
  "MAIN OUTCOME MEASURES Children's mental health problems and level of communication; mothers' mental health problems and social support one year after rehousing.   \n||The availability of safe places to study is effective at decreasing homelessness.": [
    0.012190374545753002,
    0.9731374382972717,
    0.014672237448394299
  ],
  "RESULTS Mental health problems remained significantly higher in rehoused mothers and their children than in the comparison group (mothers 26% v 5%, P = 0.04; children 39% v 11%, P = 0.0003).||The availability of safe places to study is effective at decreasing homelessness.": [
    0.4439682066440582,
    0.5532193183898926,
    0.0028124626260250807
  ],
  "Homeless mothers continued to have significantly less social support at follow up.||The availability of safe places to study is effective at decreasing homelessness.": [
    0.4608007073402405,
    0.535899817943573,
    0.003299484495073557
  ],
  "Mothers with a history of abuse and poor social integration were more likely to have children with persistent mental health problems.   \n||The availability of safe places to study is effective at decreasing homelessness.": [
    0.28193944692611694,
    0.7088338136672974,
    0.009226745925843716
  ],
  "CONCLUSIONS Homeless families have a high level of complex needs that cannot be met by conventional health services and arrangements.||The availability of safe places to study is effective at decreasing homelessness.": [
    0.15588125586509705,
    0.842046856880188,
    0.0020719077438116074
  ],
  "Local strategies for rapid rehousing into permanent accommodation, effective social support and health care for parents and children, and protection from violence and intimidation should be developed and implemented.||The availability of safe places to study is effective at decreasing homelessness.": [
    0.06740300357341766,
    0.9277117252349854,
    0.0048852707259356976
  ],
  "OBJECTIVE To establish the mental health needs of homeless children and families before and after rehousing.   \n||The availability of safe places to study is not effective at decreasing homelessness.": [
    0.5875416994094849,
    0.40723156929016113,
    0.0052267201244831085
  ],
  "DESIGN Cross sectional, longitudinal study.   \n||The availability of safe places to study is not effective at decreasing homelessness.": [
    0.6105265617370605,
    0.3763335645198822,
    0.013139864429831505
  ],
  "SETTING City of Birmingham.   ||The availability of safe places to study is not effective at decreasing homelessness.": [
    0.41769543290138245,
    0.533425509929657,
    0.04887903481721878
  ],
  "SUBJECTS 58 rehoused families with 103 children aged 2-16 years and 21 comparison families of low socioeconomic status in stable housing, with 54 children.   \n||The availability of safe places to study is not effective at decreasing homelessness.": [
    0.41331973671913147,
    0.576324999332428,
    0.010355236008763313
  ],
  "MAIN OUTCOME MEASURES Children's mental health problems and level of communication; mothers' mental health problems and social support one year after rehousing.   \n||The availability of safe places to study is not effective at decreasing homelessness.": [
    0.7634822130203247,
    0.23275500535964966,
    0.0037627725396305323
  ],
  "RESULTS Mental health problems remained significantly higher in rehoused mothers and their children than in the comparison group (mothers 26% v 5%, P = 0.04; children 39% v 11%, P = 0.0003).||The availability of safe places to study is not effective at decreasing homelessness.": [
    0.011196520179510117,
    0.9781719446182251,
    0.010631547309458256
  ],
  "Homeless mothers continued to have significantly less social support at follow up.||The availability of safe places to study is not effective at decreasing homelessness.": [
    0.02862526848912239,
    0.9363957047462463,
    0.034979041665792465
  ],
  "Mothers with a history of abuse and poor social integration were more likely to have children with persistent mental health problems.   \n||The availability of safe places to study is not effective at decreasing homelessness.": [
    0.4780467450618744,
    0.5074833631515503,
    0.014469836838543415
  ],
  "CONCLUSIONS Homeless families have a high level of complex needs that cannot be met by conventional health services and arrangements.||The availability of safe places to study is not effective at decreasing homelessness.": [
    0.03351876884698868,
    0.9584640860557556,
    0.008017142303287983
  ],
  "Local strategies for rapid rehousing into permanent accommodation, effective social support and health care for parents and children, and protection from violence and intimidation should be developed and implemented.||The availability of safe places to study is not effective at decreasing homelessness.": [
    0.24689707159996033,
    0.7446708679199219,
    0.00843206699937582
  ],
  "Nuclear receptors undergo ligand-dependent conformational changes that are required for corepressor-coactivator exchange, but whether there is an actual requirement for specific epigenetic landmarks to impose ligand dependency for gene activation remains unknown.||LSD1-positive promoters are associated with RNA polymerase II": [
    0.1668614149093628,
    0.7494426965713501,
    0.08369585126638412
  ],
  "Here we report an unexpected and general strategy that is based on the requirement for specific cohorts of inhibitory histone methyltransferases (HMTs) to impose gene-specific gatekeeper functions that prevent unliganded nuclear receptors and other classes of regulated transcription factors from binding to their target gene promoters and causing constitutive gene activation in the absence of stimulating signals.||LSD1-positive promoters are associated with RNA polymerase II": [
    0.09754923731088638,
    0.8514896631240845,
    0.050961077213287354
  ],
  "This strategy, based at least in part on an HMT-dependent inhibitory histone code, imposes a requirement for specific histone demethylases, including LSD1, to permit ligand- and signal-dependent activation of regulated gene expression.||LSD1-positive promoters are associated with RNA polymerase II": [
    0.06098354235291481,
    0.9238676428794861,
    0.015148832462728024
  ],
  "These events link an inhibitory methylation component of the histone code to a broadly used strategy that circumvents pathological constitutive gene induction by physiologically regulated transcription factors.||LSD1-positive promoters are associated with RNA polymerase II": [
    0.23437851667404175,
    0.681166410446167,
    0.08445503562688828
  ],
  "Nuclear receptors undergo ligand-dependent conformational changes that are required for corepressor-coactivator exchange, but whether there is an actual requirement for specific epigenetic landmarks to impose ligand dependency for gene activation remains unknown.||RA activation of DIF2 and NB4 cells induces hallmarks of transcriptionally active promoters.": [
    0.15733487904071808,
    0.8274840712547302,
    0.015181024558842182
  ],
  "Here we report an unexpected and general strategy that is based on the requirement for specific cohorts of inhibitory histone methyltransferases (HMTs) to impose gene-specific gatekeeper functions that prevent unliganded nuclear receptors and other classes of regulated transcription factors from binding to their target gene promoters and causing constitutive gene activation in the absence of stimulating signals.||RA activation of DIF2 and NB4 cells induces hallmarks of transcriptionally active promoters.": [
    0.9312465190887451,
    0.05858008190989494,
    0.010173410177230835
  ],
  "This strategy, based at least in part on an HMT-dependent inhibitory histone code, imposes a requirement for specific histone demethylases, including LSD1, to permit ligand- and signal-dependent activation of regulated gene expression.||RA activation of DIF2 and NB4 cells induces hallmarks of transcriptionally active promoters.": [
    0.05614829808473587,
    0.9319303631782532,
    0.01192137598991394
  ],
  "These events link an inhibitory methylation component of the histone code to a broadly used strategy that circumvents pathological constitutive gene induction by physiologically regulated transcription factors.||RA activation of DIF2 and NB4 cells induces hallmarks of transcriptionally active promoters.": [
    0.5894098877906799,
    0.3982481360435486,
    0.012341939844191074
  ],
  "Nuclear receptors undergo ligand-dependent conformational changes that are required for corepressor-coactivator exchange, but whether there is an actual requirement for specific epigenetic landmarks to impose ligand dependency for gene activation remains unknown.||Histone demethylase recruitment and a transient decrease in histone methylation is necessary for ligand-dependent induction of transcription by nuclear receptors.": [
    0.007470549084246159,
    0.9637233018875122,
    0.028806155547499657
  ],
  "Here we report an unexpected and general strategy that is based on the requirement for specific cohorts of inhibitory histone methyltransferases (HMTs) to impose gene-specific gatekeeper functions that prevent unliganded nuclear receptors and other classes of regulated transcription factors from binding to their target gene promoters and causing constitutive gene activation in the absence of stimulating signals.||Histone demethylase recruitment and a transient decrease in histone methylation is necessary for ligand-dependent induction of transcription by nuclear receptors.": [
    0.5633271932601929,
    0.17128115892410278,
    0.26539164781570435
  ],
  "This strategy, based at least in part on an HMT-dependent inhibitory histone code, imposes a requirement for specific histone demethylases, including LSD1, to permit ligand- and signal-dependent activation of regulated gene expression.||Histone demethylase recruitment and a transient decrease in histone methylation is necessary for ligand-dependent induction of transcription by nuclear receptors.": [
    0.006027433089911938,
    0.8894383311271667,
    0.10453420132398605
  ],
  "These events link an inhibitory methylation component of the histone code to a broadly used strategy that circumvents pathological constitutive gene induction by physiologically regulated transcription factors.||Histone demethylase recruitment and a transient decrease in histone methylation is necessary for ligand-dependent induction of transcription by nuclear receptors.": [
    0.12567365169525146,
    0.8095749616622925,
    0.06475131958723068
  ],
  "Macroautophagy (hereafter referred to as autophagy) is a catabolic membrane trafficking process that degrades a variety of cellular constituents and is associated with human diseases.||Lamins are associated with nuclear membrane structure maintenance.": [
    0.7081976532936096,
    0.2761994004249573,
    0.015602909959852695
  ],
  "Although extensive studies have focused on autophagic turnover of cytoplasmic materials, little is known about the role of autophagy in degrading nuclear components.||Lamins are associated with nuclear membrane structure maintenance.": [
    0.24959500133991241,
    0.6826863288879395,
    0.06771864742040634
  ],
  "Here we report that the autophagy machinery mediates degradation of nuclear lamina components in mammals.||Lamins are associated with nuclear membrane structure maintenance.": [
    0.03985876590013504,
    0.5211102366447449,
    0.4390310049057007
  ],
  "The autophagy protein LC3/Atg8, which is involved in autophagy membrane trafficking and substrate delivery, is present in the nucleus and directly interacts with the nuclear lamina protein lamin B1, and binds to lamin-associated domains on chromatin.||Lamins are associated with nuclear membrane structure maintenance.": [
    0.005281931720674038,
    0.5576463341712952,
    0.43707171082496643
  ],
  "This LC3-lamin B1 interaction does not downregulate lamin B1 during starvation, but mediates its degradation upon oncogenic insults, such as by activated RAS.||Lamins are associated with nuclear membrane structure maintenance.": [
    0.05035888031125069,
    0.8521683216094971,
    0.09747276455163956
  ],
  "Lamin B1 degradation is achieved by nucleus-to-cytoplasm transport that delivers lamin B1 to the lysosome.||Lamins are associated with nuclear membrane structure maintenance.": [
    0.042523179203271866,
    0.5531921982765198,
    0.40428462624549866
  ],
  "Inhibiting autophagy or the LC3-lamin B1 interaction prevents activated RAS-induced lamin B1 loss and attenuates oncogene-induced senescence in primary human cells.||Lamins are associated with nuclear membrane structure maintenance.": [
    0.04800165072083473,
    0.6887497305870056,
    0.26324865221977234
  ],
  "Our study suggests that this new function of autophagy acts as a guarding mechanism protecting cells from tumorigenesis.||Lamins are associated with nuclear membrane structure maintenance.": [
    0.1756000965833664,
    0.464887410402298,
    0.3595125079154968
  ],
  "Macroautophagy (hereafter referred to as autophagy) is a catabolic membrane trafficking process that degrades a variety of cellular constituents and is associated with human diseases.||Lamins are found within the inner layer of the mitochondrial membrane of all cells.": [
    0.2574930191040039,
    0.7326741814613342,
    0.009832835756242275
  ],
  "Although extensive studies have focused on autophagic turnover of cytoplasmic materials, little is known about the role of autophagy in degrading nuclear components.||Lamins are found within the inner layer of the mitochondrial membrane of all cells.": [
    0.37507420778274536,
    0.5913977026939392,
    0.03352805972099304
  ],
  "Here we report that the autophagy machinery mediates degradation of nuclear lamina components in mammals.||Lamins are found within the inner layer of the mitochondrial membrane of all cells.": [
    0.10998274385929108,
    0.8732645511627197,
    0.0167526975274086
  ],
  "The autophagy protein LC3/Atg8, which is involved in autophagy membrane trafficking and substrate delivery, is present in the nucleus and directly interacts with the nuclear lamina protein lamin B1, and binds to lamin-associated domains on chromatin.||Lamins are found within the inner layer of the mitochondrial membrane of all cells.": [
    0.12334330379962921,
    0.8491604328155518,
    0.0274962168186903
  ],
  "This LC3-lamin B1 interaction does not downregulate lamin B1 during starvation, but mediates its degradation upon oncogenic insults, such as by activated RAS.||Lamins are found within the inner layer of the mitochondrial membrane of all cells.": [
    0.21727301180362701,
    0.775238037109375,
    0.007488979026675224
  ],
  "Lamin B1 degradation is achieved by nucleus-to-cytoplasm transport that delivers lamin B1 to the lysosome.||Lamins are found within the inner layer of the mitochondrial membrane of all cells.": [
    0.3787989616394043,
    0.6028783917427063,
    0.01832268387079239
  ],
  "Inhibiting autophagy or the LC3-lamin B1 interaction prevents activated RAS-induced lamin B1 loss and attenuates oncogene-induced senescence in primary human cells.||Lamins are found within the inner layer of the mitochondrial membrane of all cells.": [
    0.20188921689987183,
    0.7914840579032898,
    0.00662671634927392
  ],
  "Our study suggests that this new function of autophagy acts as a guarding mechanism protecting cells from tumorigenesis.||Lamins are found within the inner layer of the mitochondrial membrane of all cells.": [
    0.3180426359176636,
    0.6227729916572571,
    0.059184376150369644
  ],
  "Macroautophagy (hereafter referred to as autophagy) is a catabolic membrane trafficking process that degrades a variety of cellular constituents and is associated with human diseases.||Lamins are found within the inner layer of the nuclear membrane of all cells.": [
    0.28944164514541626,
    0.6998623609542847,
    0.010696036741137505
  ],
  "Although extensive studies have focused on autophagic turnover of cytoplasmic materials, little is known about the role of autophagy in degrading nuclear components.||Lamins are found within the inner layer of the nuclear membrane of all cells.": [
    0.2832660675048828,
    0.7080008387565613,
    0.008733117021620274
  ],
  "Here we report that the autophagy machinery mediates degradation of nuclear lamina components in mammals.||Lamins are found within the inner layer of the nuclear membrane of all cells.": [
    0.067435123026371,
    0.9183244109153748,
    0.014240420423448086
  ],
  "The autophagy protein LC3/Atg8, which is involved in autophagy membrane trafficking and substrate delivery, is present in the nucleus and directly interacts with the nuclear lamina protein lamin B1, and binds to lamin-associated domains on chromatin.||Lamins are found within the inner layer of the nuclear membrane of all cells.": [
    0.019547855481505394,
    0.951189398765564,
    0.02926272712647915
  ],
  "This LC3-lamin B1 interaction does not downregulate lamin B1 during starvation, but mediates its degradation upon oncogenic insults, such as by activated RAS.||Lamins are found within the inner layer of the nuclear membrane of all cells.": [
    0.25510168075561523,
    0.7382909059524536,
    0.006607451010495424
  ],
  "Lamin B1 degradation is achieved by nucleus-to-cytoplasm transport that delivers lamin B1 to the lysosome.||Lamins are found within the inner layer of the nuclear membrane of all cells.": [
    0.344281405210495,
    0.6366219520568848,
    0.01909671537578106
  ],
  "Inhibiting autophagy or the LC3-lamin B1 interaction prevents activated RAS-induced lamin B1 loss and attenuates oncogene-induced senescence in primary human cells.||Lamins are found within the inner layer of the nuclear membrane of all cells.": [
    0.2331039309501648,
    0.7603703141212463,
    0.006525784265249968
  ],
  "Our study suggests that this new function of autophagy acts as a guarding mechanism protecting cells from tumorigenesis.||Lamins are found within the inner layer of the nuclear membrane of all cells.": [
    0.28844818472862244,
    0.6721182465553284,
    0.03943360969424248
  ],
  "Macroautophagy (hereafter referred to as autophagy) is a catabolic membrane trafficking process that degrades a variety of cellular constituents and is associated with human diseases.||Lamins have no effect on nuclear membrane structure maintenance.": [
    0.6177977919578552,
    0.3782378137111664,
    0.003964452538639307
  ],
  "Although extensive studies have focused on autophagic turnover of cytoplasmic materials, little is known about the role of autophagy in degrading nuclear components.||Lamins have no effect on nuclear membrane structure maintenance.": [
    0.8238817453384399,
    0.1735980361700058,
    0.0025202950928360224
  ],
  "Here we report that the autophagy machinery mediates degradation of nuclear lamina components in mammals.||Lamins have no effect on nuclear membrane structure maintenance.": [
    0.9652811884880066,
    0.03323010727763176,
    0.00148873426951468
  ],
  "The autophagy protein LC3/Atg8, which is involved in autophagy membrane trafficking and substrate delivery, is present in the nucleus and directly interacts with the nuclear lamina protein lamin B1, and binds to lamin-associated domains on chromatin.||Lamins have no effect on nuclear membrane structure maintenance.": [
    0.9961207509040833,
    0.003503626910969615,
    0.0003755659272428602
  ],
  "This LC3-lamin B1 interaction does not downregulate lamin B1 during starvation, but mediates its degradation upon oncogenic insults, such as by activated RAS.||Lamins have no effect on nuclear membrane structure maintenance.": [
    0.9280893802642822,
    0.06961779296398163,
    0.002292861230671406
  ],
  "Lamin B1 degradation is achieved by nucleus-to-cytoplasm transport that delivers lamin B1 to the lysosome.||Lamins have no effect on nuclear membrane structure maintenance.": [
    0.9842564463615417,
    0.014735852368175983,
    0.0010076668113470078
  ],
  "Inhibiting autophagy or the LC3-lamin B1 interaction prevents activated RAS-induced lamin B1 loss and attenuates oncogene-induced senescence in primary human cells.||Lamins have no effect on nuclear membrane structure maintenance.": [
    0.9526668787002563,
    0.045523714274168015,
    0.0018094737315550447
  ],
  "Our study suggests that this new function of autophagy acts as a guarding mechanism protecting cells from tumorigenesis.||Lamins have no effect on nuclear membrane structure maintenance.": [
    0.9286906123161316,
    0.06784725934267044,
    0.003462081542238593
  ],
  "Dynamically polarized membrane proteins define different cell boundaries and have an important role in intercellular communication\u2014a vital feature of multicellular development.||Localization of PIN1 in the roots of Arabidopsis requires VPS9a": [
    0.039506785571575165,
    0.9557508230209351,
    0.0047423518262803555
  ],
  "Efflux carriers for the signalling molecule auxin from the PIN family are landmarks of cell polarity in plants and have a crucial involvement in auxin distribution-dependent development including embryo patterning, organogenesis and tropisms.||Localization of PIN1 in the roots of Arabidopsis requires VPS9a": [
    0.021192817017436028,
    0.9764741063117981,
    0.0023331011179834604
  ],
  "Polar PIN localization determines the direction of intercellular auxin flow, yet the mechanisms generating PIN polarity remain unclear.||Localization of PIN1 in the roots of Arabidopsis requires VPS9a": [
    0.02569298818707466,
    0.9724004864692688,
    0.0019065572414547205
  ],
  "Here we identify an endocytosis-dependent mechanism of PIN polarity generation and analyse its developmental implications.||Localization of PIN1 in the roots of Arabidopsis requires VPS9a": [
    0.07282499969005585,
    0.9182646870613098,
    0.008910248056054115
  ],
  "Real-time PIN tracking showed that after synthesis, PINs are initially delivered to the plasma membrane in a non-polar manner and their polarity is established by subsequent endocytic recycling.||Localization of PIN1 in the roots of Arabidopsis requires VPS9a": [
    0.09598492830991745,
    0.8980201482772827,
    0.005994918756186962
  ],
  "Interference with PIN endocytosis either by auxin or by manipulation of the Arabidopsis Rab5 GTPase pathway prevents PIN polarization.||Localization of PIN1 in the roots of Arabidopsis requires VPS9a": [
    0.09248191118240356,
    0.8778499960899353,
    0.02966812625527382
  ],
  "Failure of PIN polarization transiently alters asymmetric auxin distribution during embryogenesis and increases the local auxin response in apical embryo regions.||Localization of PIN1 in the roots of Arabidopsis requires VPS9a": [
    0.049264393746852875,
    0.9457153677940369,
    0.005020261276513338
  ],
  "This results in ectopic expression of auxin pathway-associated root-forming master regulators in embryonic leaves and promotes homeotic transformation of leaves to roots.||Localization of PIN1 in the roots of Arabidopsis requires VPS9a": [
    0.04699033126235008,
    0.9262571334838867,
    0.026752503588795662
  ],
  "Our results indicate a two-step mechanism for the generation of PIN polar localization and the essential role of endocytosis in this process.||Localization of PIN1 in the roots of Arabidopsis requires VPS9a": [
    0.020585881546139717,
    0.9728406071662903,
    0.006573502905666828
  ],
  "It also highlights the link between endocytosis-dependent polarity of individual cells and auxin distribution-dependent cell fate establishment for multicellular patterning.||Localization of PIN1 in the roots of Arabidopsis requires VPS9a": [
    0.06697531044483185,
    0.9000136852264404,
    0.033011022955179214
  ],
  "Dynamically polarized membrane proteins define different cell boundaries and have an important role in intercellular communication\u2014a vital feature of multicellular development.||Localization of PIN1 in the Arabidopsis embryo does not require VPS9a": [
    0.5527161955833435,
    0.4414478540420532,
    0.005835908465087414
  ],
  "Efflux carriers for the signalling molecule auxin from the PIN family are landmarks of cell polarity in plants and have a crucial involvement in auxin distribution-dependent development including embryo patterning, organogenesis and tropisms.||Localization of PIN1 in the Arabidopsis embryo does not require VPS9a": [
    0.1409980207681656,
    0.8529530167579651,
    0.006048953160643578
  ],
  "Polar PIN localization determines the direction of intercellular auxin flow, yet the mechanisms generating PIN polarity remain unclear.||Localization of PIN1 in the Arabidopsis embryo does not require VPS9a": [
    0.4802449345588684,
    0.5152930617332458,
    0.004462051670998335
  ],
  "Here we identify an endocytosis-dependent mechanism of PIN polarity generation and analyse its developmental implications.||Localization of PIN1 in the Arabidopsis embryo does not require VPS9a": [
    0.5391749143600464,
    0.45391127467155457,
    0.006913815159350634
  ],
  "Real-time PIN tracking showed that after synthesis, PINs are initially delivered to the plasma membrane in a non-polar manner and their polarity is established by subsequent endocytic recycling.||Localization of PIN1 in the Arabidopsis embryo does not require VPS9a": [
    0.5908529162406921,
    0.4021049737930298,
    0.007042165379971266
  ],
  "Interference with PIN endocytosis either by auxin or by manipulation of the Arabidopsis Rab5 GTPase pathway prevents PIN polarization.||Localization of PIN1 in the Arabidopsis embryo does not require VPS9a": [
    0.8943957090377808,
    0.10095342248678207,
    0.004650850780308247
  ],
  "Failure of PIN polarization transiently alters asymmetric auxin distribution during embryogenesis and increases the local auxin response in apical embryo regions.||Localization of PIN1 in the Arabidopsis embryo does not require VPS9a": [
    0.521725594997406,
    0.4724261462688446,
    0.005848305765539408
  ],
  "This results in ectopic expression of auxin pathway-associated root-forming master regulators in embryonic leaves and promotes homeotic transformation of leaves to roots.||Localization of PIN1 in the Arabidopsis embryo does not require VPS9a": [
    0.8247829675674438,
    0.16940638422966003,
    0.005810664966702461
  ],
  "Our results indicate a two-step mechanism for the generation of PIN polar localization and the essential role of endocytosis in this process.||Localization of PIN1 in the Arabidopsis embryo does not require VPS9a": [
    0.5468447804450989,
    0.4462432861328125,
    0.006911917589604855
  ],
  "It also highlights the link between endocytosis-dependent polarity of individual cells and auxin distribution-dependent cell fate establishment for multicellular patterning.||Localization of PIN1 in the Arabidopsis embryo does not require VPS9a": [
    0.6322958469390869,
    0.3563633859157562,
    0.011340806260704994
  ],
  "Dynamically polarized membrane proteins define different cell boundaries and have an important role in intercellular communication\u2014a vital feature of multicellular development.||Localization of PIN1 in the roots of Arabidopsis does not require VPS9a": [
    0.574276864528656,
    0.42060476541519165,
    0.005118372850120068
  ],
  "Efflux carriers for the signalling molecule auxin from the PIN family are landmarks of cell polarity in plants and have a crucial involvement in auxin distribution-dependent development including embryo patterning, organogenesis and tropisms.||Localization of PIN1 in the roots of Arabidopsis does not require VPS9a": [
    0.125306636095047,
    0.8705083131790161,
    0.004185108933597803
  ],
  "Polar PIN localization determines the direction of intercellular auxin flow, yet the mechanisms generating PIN polarity remain unclear.||Localization of PIN1 in the roots of Arabidopsis does not require VPS9a": [
    0.41157764196395874,
    0.584711492061615,
    0.0037108769174665213
  ],
  "Here we identify an endocytosis-dependent mechanism of PIN polarity generation and analyse its developmental implications.||Localization of PIN1 in the roots of Arabidopsis does not require VPS9a": [
    0.5039187669754028,
    0.4890649914741516,
    0.007016249932348728
  ],
  "Real-time PIN tracking showed that after synthesis, PINs are initially delivered to the plasma membrane in a non-polar manner and their polarity is established by subsequent endocytic recycling.||Localization of PIN1 in the roots of Arabidopsis does not require VPS9a": [
    0.5479366183280945,
    0.4467795789241791,
    0.0052838013507425785
  ],
  "Interference with PIN endocytosis either by auxin or by manipulation of the Arabidopsis Rab5 GTPase pathway prevents PIN polarization.||Localization of PIN1 in the roots of Arabidopsis does not require VPS9a": [
    0.8593443632125854,
    0.13622577488422394,
    0.00442976038902998
  ],
  "Failure of PIN polarization transiently alters asymmetric auxin distribution during embryogenesis and increases the local auxin response in apical embryo regions.||Localization of PIN1 in the roots of Arabidopsis does not require VPS9a": [
    0.46486717462539673,
    0.529607892036438,
    0.005524848587810993
  ],
  "This results in ectopic expression of auxin pathway-associated root-forming master regulators in embryonic leaves and promotes homeotic transformation of leaves to roots.||Localization of PIN1 in the roots of Arabidopsis does not require VPS9a": [
    0.7958016991615295,
    0.19881470501422882,
    0.005383641459047794
  ],
  "Our results indicate a two-step mechanism for the generation of PIN polar localization and the essential role of endocytosis in this process.||Localization of PIN1 in the roots of Arabidopsis does not require VPS9a": [
    0.4607570469379425,
    0.5327636003494263,
    0.006479401607066393
  ],
  "It also highlights the link between endocytosis-dependent polarity of individual cells and auxin distribution-dependent cell fate establishment for multicellular patterning.||Localization of PIN1 in the roots of Arabidopsis does not require VPS9a": [
    0.572404682636261,
    0.41461890935897827,
    0.012976434081792831
  ],
  "OBJECTIVE To determine whether dietary n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation of pregnant women with a fetus at high risk of allergic disease reduces immunoglobulin E associated eczema or food allergy at 1 year of age.   \n||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.4453015923500061,
    0.5509195327758789,
    0.0037788257468491793
  ],
  "DESIGN Follow-up of infants at high hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO) randomised controlled trial.   \n||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.5915815830230713,
    0.3957371711730957,
    0.012681261636316776
  ],
  "SETTING Adelaide, South Australia.   \n||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.4610738158226013,
    0.4783405661582947,
    0.060585662722587585
  ],
  "PARTICIPANTS 706 infants at high hereditary risk of developing allergic disease whose mothers were participating in the DOMInO trial.   \n||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.634963870048523,
    0.3438788652420044,
    0.021157264709472656
  ],
  "INTERVENTIONS The intervention group (n=368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n=338) received matched vegetable oil capsules without n-3 LCPUFA.   \n||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.5025309920310974,
    0.48567089438438416,
    0.011798077262938023
  ],
  "MAIN OUTCOME MEASURE Immunoglobulin E associated allergic disease (eczema or food allergy with sensitisation) at 1 year of age.   \n||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.3675682246685028,
    0.6263853907585144,
    0.00604641018435359
  ],
  "RESULTS No differences were seen in the overall percentage of infants with immunoglobulin E associated allergic disease between the n-3 LCPUFA and control groups (32/368 (9%) v 43/338 (13%); unadjusted relative risk 0.68, 95% confidence interval 0.43 to 1.05, P=0.08; adjusted relative risk 0.70, 0.45 to 1.09, P=0.12), although the percentage of infants diagnosed as having atopic eczema (that is, eczema with associated sensitisation) was lower in the n-3 LCPUFA group (26/368 (7%) v 39/338 (12%); unadjusted relative risk 0.61, 0.38 to 0.98, P=0.04; adjusted relative risk 0.64, 0.40 to 1.02, P=0.06).||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.33923158049583435,
    0.6372120380401611,
    0.023556360974907875
  ],
  "Fewer infants were sensitised to egg in the n-3 LCPUFA group (34/368 (9%) v 52/338 (15%); unadjusted relative risk 0.61, 0.40 to 0.91, P=0.02; adjusted relative risk 0.62, 0.41 to 0.93, P=0.02), but no difference between groups in immunoglobulin E associated food allergy was seen.   \n||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.7428231239318848,
    0.23895341157913208,
    0.01822342351078987
  ],
  "CONCLUSION n-3 LCPUFA supplementation in pregnancy did not reduce the overall incidence of immunoglobulin E associated allergies in the first year of life, although atopic eczema and egg sensitisation were lower.||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.14940014481544495,
    0.7556754350662231,
    0.09492440521717072
  ],
  "Longer term follow-up is needed to determine if supplementation has an effect on respiratory allergic diseases and aeroallergen sensitisation in childhood.   \n||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.30985620617866516,
    0.6864722371101379,
    0.003671597223728895
  ],
  "TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000735055 (DOMInO trial: ACTRN12605000569606).||Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.": [
    0.4387401044368744,
    0.5246567130088806,
    0.036603186279535294
  ],
  "OBJECTIVE To determine whether dietary n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation of pregnant women with a fetus at high risk of allergic disease reduces immunoglobulin E associated eczema or food allergy at 1 year of age.   \n||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.025887349620461464,
    0.3639957308769226,
    0.6101168990135193
  ],
  "DESIGN Follow-up of infants at high hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO) randomised controlled trial.   \n||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.03713315725326538,
    0.9126562476158142,
    0.050210561603307724
  ],
  "SETTING Adelaide, South Australia.   \n||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.03651733323931694,
    0.7729553580284119,
    0.19052733480930328
  ],
  "PARTICIPANTS 706 infants at high hereditary risk of developing allergic disease whose mothers were participating in the DOMInO trial.   \n||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.07883645594120026,
    0.8536758422851562,
    0.06748772412538528
  ],
  "INTERVENTIONS The intervention group (n=368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n=338) received matched vegetable oil capsules without n-3 LCPUFA.   \n||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.012844073586165905,
    0.9623677134513855,
    0.024788212031126022
  ],
  "MAIN OUTCOME MEASURE Immunoglobulin E associated allergic disease (eczema or food allergy with sensitisation) at 1 year of age.   \n||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.13819965720176697,
    0.8572101593017578,
    0.004590142052620649
  ],
  "RESULTS No differences were seen in the overall percentage of infants with immunoglobulin E associated allergic disease between the n-3 LCPUFA and control groups (32/368 (9%) v 43/338 (13%); unadjusted relative risk 0.68, 95% confidence interval 0.43 to 1.05, P=0.08; adjusted relative risk 0.70, 0.45 to 1.09, P=0.12), although the percentage of infants diagnosed as having atopic eczema (that is, eczema with associated sensitisation) was lower in the n-3 LCPUFA group (26/368 (7%) v 39/338 (12%); unadjusted relative risk 0.61, 0.38 to 0.98, P=0.04; adjusted relative risk 0.64, 0.40 to 1.02, P=0.06).||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.01182460319250822,
    0.9603256583213806,
    0.027849743142724037
  ],
  "Fewer infants were sensitised to egg in the n-3 LCPUFA group (34/368 (9%) v 52/338 (15%); unadjusted relative risk 0.61, 0.40 to 0.91, P=0.02; adjusted relative risk 0.62, 0.41 to 0.93, P=0.02), but no difference between groups in immunoglobulin E associated food allergy was seen.   \n||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.057884227484464645,
    0.5406048893928528,
    0.40151092410087585
  ],
  "CONCLUSION n-3 LCPUFA supplementation in pregnancy did not reduce the overall incidence of immunoglobulin E associated allergies in the first year of life, although atopic eczema and egg sensitisation were lower.||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.04705594480037689,
    0.18948444724082947,
    0.7634596228599548
  ],
  "Longer term follow-up is needed to determine if supplementation has an effect on respiratory allergic diseases and aeroallergen sensitisation in childhood.   \n||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.10301433503627777,
    0.8934114575386047,
    0.0035742532927542925
  ],
  "TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000735055 (DOMInO trial: ACTRN12605000569606).||Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.": [
    0.030528085306286812,
    0.8415078520774841,
    0.12796412408351898
  ],
  "OBJECTIVE To determine whether dietary n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation of pregnant women with a fetus at high risk of allergic disease reduces immunoglobulin E associated eczema or food allergy at 1 year of age.   \n||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.4136088192462921,
    0.5675437450408936,
    0.018847400322556496
  ],
  "DESIGN Follow-up of infants at high hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO) randomised controlled trial.   \n||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.08644083142280579,
    0.7794910669326782,
    0.13406811654567719
  ],
  "SETTING Adelaide, South Australia.   \n||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.036578722298145294,
    0.7288752794265747,
    0.23454606533050537
  ],
  "PARTICIPANTS 706 infants at high hereditary risk of developing allergic disease whose mothers were participating in the DOMInO trial.   \n||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.1065976694226265,
    0.7197967171669006,
    0.17360562086105347
  ],
  "INTERVENTIONS The intervention group (n=368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n=338) received matched vegetable oil capsules without n-3 LCPUFA.   \n||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.012223120778799057,
    0.9557802677154541,
    0.03199666365981102
  ],
  "MAIN OUTCOME MEASURE Immunoglobulin E associated allergic disease (eczema or food allergy with sensitisation) at 1 year of age.   \n||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.42823222279548645,
    0.558089554309845,
    0.013678311370313168
  ],
  "RESULTS No differences were seen in the overall percentage of infants with immunoglobulin E associated allergic disease between the n-3 LCPUFA and control groups (32/368 (9%) v 43/338 (13%); unadjusted relative risk 0.68, 95% confidence interval 0.43 to 1.05, P=0.08; adjusted relative risk 0.70, 0.45 to 1.09, P=0.12), although the percentage of infants diagnosed as having atopic eczema (that is, eczema with associated sensitisation) was lower in the n-3 LCPUFA group (26/368 (7%) v 39/338 (12%); unadjusted relative risk 0.61, 0.38 to 0.98, P=0.04; adjusted relative risk 0.64, 0.40 to 1.02, P=0.06).||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.147226944565773,
    0.8234286904335022,
    0.029344413429498672
  ],
  "Fewer infants were sensitised to egg in the n-3 LCPUFA group (34/368 (9%) v 52/338 (15%); unadjusted relative risk 0.61, 0.40 to 0.91, P=0.02; adjusted relative risk 0.62, 0.41 to 0.93, P=0.02), but no difference between groups in immunoglobulin E associated food allergy was seen.   \n||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.08221856504678726,
    0.6551252007484436,
    0.26265624165534973
  ],
  "CONCLUSION n-3 LCPUFA supplementation in pregnancy did not reduce the overall incidence of immunoglobulin E associated allergies in the first year of life, although atopic eczema and egg sensitisation were lower.||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.5164362192153931,
    0.4780709147453308,
    0.0054928697645664215
  ],
  "Longer term follow-up is needed to determine if supplementation has an effect on respiratory allergic diseases and aeroallergen sensitisation in childhood.   \n||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.1947142630815506,
    0.7999542355537415,
    0.005331534892320633
  ],
  "TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000735055 (DOMInO trial: ACTRN12605000569606).||Long chain polyunsaturated fatty acids supplementation reduces wheezing and asthma.": [
    0.03060300275683403,
    0.8324485421180725,
    0.13694851100444794
  ],
  "Recent studies have reported that competitive endogenous RNAs (ceRNAs) can act as sponges for a microRNA (miRNA) through their binding sites and that changes in ceRNA abundances from individual genes can modulate the activity of miRNAs.||Low expression of miR7a does not repress target genes or exert a biological function in ovaries.": [
    0.6600415706634521,
    0.33632057905197144,
    0.0036378714721649885
  ],
  "Consideration of this hypothesis would benefit from knowing the quantitative relationship between a miRNA and its endogenous target sites.||Low expression of miR7a does not repress target genes or exert a biological function in ovaries.": [
    0.5044200420379639,
    0.4897645115852356,
    0.005815435666590929
  ],
  "Here, we altered intracellular target site abundance through expression of an miR-122 target in hepatocytes and livers and analyzed the effects on miR-122 target genes.||Low expression of miR7a does not repress target genes or exert a biological function in ovaries.": [
    0.5615925788879395,
    0.4334547519683838,
    0.004952677059918642
  ],
  "Target repression was released in a threshold-like manner at high target site abundance (\u22651.5 \u00d7 10(5) added target sites per cell), and this threshold was insensitive to the effective levels of the miRNA.||Low expression of miR7a does not repress target genes or exert a biological function in ovaries.": [
    0.21767538785934448,
    0.7758346796035767,
    0.006489924155175686
  ],
  "Furthermore, in response to extreme metabolic liver disease models, global target site abundance of hepatocytes did not change sufficiently to affect miRNA-mediated repression.||Low expression of miR7a does not repress target genes or exert a biological function in ovaries.": [
    0.3947872817516327,
    0.5749622583389282,
    0.03025048039853573
  ],
  "Thus, modulation of miRNA target abundance is unlikely to cause significant effects on gene expression and metabolism through a ceRNA effect.||Low expression of miR7a does not repress target genes or exert a biological function in ovaries.": [
    0.024530712515115738,
    0.9527832865715027,
    0.022685999050736427
  ],
  "Recent studies have reported that competitive endogenous RNAs (ceRNAs) can act as sponges for a microRNA (miRNA) through their binding sites and that changes in ceRNA abundances from individual genes can modulate the activity of miRNAs.||Low expression of miR7a does not repress target genes or exert a biological function in testis.": [
    0.6944843530654907,
    0.3014080226421356,
    0.004107574932277203
  ],
  "Consideration of this hypothesis would benefit from knowing the quantitative relationship between a miRNA and its endogenous target sites.||Low expression of miR7a does not repress target genes or exert a biological function in testis.": [
    0.48691943287849426,
    0.5067746043205261,
    0.00630598422139883
  ],
  "Here, we altered intracellular target site abundance through expression of an miR-122 target in hepatocytes and livers and analyzed the effects on miR-122 target genes.||Low expression of miR7a does not repress target genes or exert a biological function in testis.": [
    0.5617052316665649,
    0.43258756399154663,
    0.005707207601517439
  ],
  "Target repression was released in a threshold-like manner at high target site abundance (\u22651.5 \u00d7 10(5) added target sites per cell), and this threshold was insensitive to the effective levels of the miRNA.||Low expression of miR7a does not repress target genes or exert a biological function in testis.": [
    0.24399687349796295,
    0.7444514632225037,
    0.011551662348210812
  ],
  "Furthermore, in response to extreme metabolic liver disease models, global target site abundance of hepatocytes did not change sufficiently to affect miRNA-mediated repression.||Low expression of miR7a does not repress target genes or exert a biological function in testis.": [
    0.41704630851745605,
    0.5296196937561035,
    0.05333399400115013
  ],
  "Thus, modulation of miRNA target abundance is unlikely to cause significant effects on gene expression and metabolism through a ceRNA effect.||Low expression of miR7a does not repress target genes or exert a biological function in testis.": [
    0.026427488774061203,
    0.9202457666397095,
    0.053326770663261414
  ],
  "Recent studies have reported that competitive endogenous RNAs (ceRNAs) can act as sponges for a microRNA (miRNA) through their binding sites and that changes in ceRNA abundances from individual genes can modulate the activity of miRNAs.||Low expression of miR7a does represses target genes and exerts a biological function in ovaries.": [
    0.00633823499083519,
    0.9925865530967712,
    0.001075170817784965
  ],
  "Consideration of this hypothesis would benefit from knowing the quantitative relationship between a miRNA and its endogenous target sites.||Low expression of miR7a does represses target genes and exerts a biological function in ovaries.": [
    0.1249389573931694,
    0.8710081577301025,
    0.0040528434328734875
  ],
  "Here, we altered intracellular target site abundance through expression of an miR-122 target in hepatocytes and livers and analyzed the effects on miR-122 target genes.||Low expression of miR7a does represses target genes and exerts a biological function in ovaries.": [
    0.17456194758415222,
    0.8052531480789185,
    0.020184893161058426
  ],
  "Target repression was released in a threshold-like manner at high target site abundance (\u22651.5 \u00d7 10(5) added target sites per cell), and this threshold was insensitive to the effective levels of the miRNA.||Low expression of miR7a does represses target genes and exerts a biological function in ovaries.": [
    0.11486613005399704,
    0.8799639940261841,
    0.005169888958334923
  ],
  "Furthermore, in response to extreme metabolic liver disease models, global target site abundance of hepatocytes did not change sufficiently to affect miRNA-mediated repression.||Low expression of miR7a does represses target genes and exerts a biological function in ovaries.": [
    0.416646808385849,
    0.572011411190033,
    0.011341826990246773
  ],
  "Thus, modulation of miRNA target abundance is unlikely to cause significant effects on gene expression and metabolism through a ceRNA effect.||Low expression of miR7a does represses target genes and exerts a biological function in ovaries.": [
    0.48359882831573486,
    0.5128772854804993,
    0.0035239015705883503
  ],
  "Recent studies have reported that competitive endogenous RNAs (ceRNAs) can act as sponges for a microRNA (miRNA) through their binding sites and that changes in ceRNA abundances from individual genes can modulate the activity of miRNAs.||Low expression of miR7a exerts a biological function in testis.": [
    0.01214597187936306,
    0.9772342443466187,
    0.01061984058469534
  ],
  "Consideration of this hypothesis would benefit from knowing the quantitative relationship between a miRNA and its endogenous target sites.||Low expression of miR7a exerts a biological function in testis.": [
    0.05799580737948418,
    0.9158108234405518,
    0.026193400844931602
  ],
  "Here, we altered intracellular target site abundance through expression of an miR-122 target in hepatocytes and livers and analyzed the effects on miR-122 target genes.||Low expression of miR7a exerts a biological function in testis.": [
    0.3120653033256531,
    0.6120787858963013,
    0.07585596293210983
  ],
  "Target repression was released in a threshold-like manner at high target site abundance (\u22651.5 \u00d7 10(5) added target sites per cell), and this threshold was insensitive to the effective levels of the miRNA.||Low expression of miR7a exerts a biological function in testis.": [
    0.020272785797715187,
    0.8971968293190002,
    0.0825304239988327
  ],
  "Furthermore, in response to extreme metabolic liver disease models, global target site abundance of hepatocytes did not change sufficiently to affect miRNA-mediated repression.||Low expression of miR7a exerts a biological function in testis.": [
    0.228036031126976,
    0.49939021468162537,
    0.2725737690925598
  ],
  "Thus, modulation of miRNA target abundance is unlikely to cause significant effects on gene expression and metabolism through a ceRNA effect.||Low expression of miR7a exerts a biological function in testis.": [
    0.20001865923404694,
    0.7784945964813232,
    0.021486755460500717
  ],
  "The Maf oncoproteins are b-Zip transcription factors of the AP-1 superfamily.||MafA phosphorylation decreases its ubiquitination.": [
    0.029138298705220222,
    0.9562608599662781,
    0.01460085529834032
  ],
  "They are involved in developmental, metabolic, and tumorigenic processes.||MafA phosphorylation decreases its ubiquitination.": [
    0.07804571092128754,
    0.7685064673423767,
    0.15344777703285217
  ],
  "Maf proteins are overexpressed in about 50% of human multiple myelomas.||MafA phosphorylation decreases its ubiquitination.": [
    0.030539346858859062,
    0.9521459937095642,
    0.017314622178673744
  ],
  "Here, we show that Maf-transforming activity is controlled by GSK-3-dependent phosphorylation and that phosphorylation by GSK-3 can increase the oncogenic activity of a protein.||MafA phosphorylation decreases its ubiquitination.": [
    0.6912166476249695,
    0.2716028392314911,
    0.03718055412173271
  ],
  "Using microarray analysis, we identify a gene-expression subprogram regulated by GSK-3-mediated Maf phosphorylation involved in extracellular matrix remodeling and relevant to cancer progression.||MafA phosphorylation decreases its ubiquitination.": [
    0.12679041922092438,
    0.8110480904579163,
    0.06216152012348175
  ],
  "We also demonstrate that GSK-3 triggers MafA sequential phosphorylation on residues S61, T57, T53, and S49, inducing its ubiquitination and degradation.||MafA phosphorylation decreases its ubiquitination.": [
    0.9966523051261902,
    0.002154827583581209,
    0.001192882307805121
  ],
  "Paradoxically, this phosphorylation increases MafA-transcriptional activity through the recruitment of the coactivator P/CAF.||MafA phosphorylation decreases its ubiquitination.": [
    0.9344818592071533,
    0.057844750583171844,
    0.007673421874642372
  ],
  "We further demonstrate that P/CAF protects MafA from ubiquitination and degradation, suggesting that, upon the release of the coactivator complex, MafA becomes polyubiquitinated and degraded to allow the response to terminate.||MafA phosphorylation decreases its ubiquitination.": [
    0.48235222697257996,
    0.4764314591884613,
    0.04121633619070053
  ],
  "The Maf oncoproteins are b-Zip transcription factors of the AP-1 superfamily.||MafA phosphorylation enhances its ubiquitination.": [
    0.016641195863485336,
    0.9771806001663208,
    0.0061781383119523525
  ],
  "They are involved in developmental, metabolic, and tumorigenic processes.||MafA phosphorylation enhances its ubiquitination.": [
    0.07994361221790314,
    0.7185518741607666,
    0.20150454342365265
  ],
  "Maf proteins are overexpressed in about 50% of human multiple myelomas.||MafA phosphorylation enhances its ubiquitination.": [
    0.007973290979862213,
    0.9816927909851074,
    0.010333922691643238
  ],
  "Here, we show that Maf-transforming activity is controlled by GSK-3-dependent phosphorylation and that phosphorylation by GSK-3 can increase the oncogenic activity of a protein.||MafA phosphorylation enhances its ubiquitination.": [
    0.48588037490844727,
    0.4226363003253937,
    0.09148330986499786
  ],
  "Using microarray analysis, we identify a gene-expression subprogram regulated by GSK-3-mediated Maf phosphorylation involved in extracellular matrix remodeling and relevant to cancer progression.||MafA phosphorylation enhances its ubiquitination.": [
    0.1277429312467575,
    0.8085882067680359,
    0.06366883218288422
  ],
  "We also demonstrate that GSK-3 triggers MafA sequential phosphorylation on residues S61, T57, T53, and S49, inducing its ubiquitination and degradation.||MafA phosphorylation enhances its ubiquitination.": [
    0.010026297532022,
    0.03503645956516266,
    0.954937219619751
  ],
  "Paradoxically, this phosphorylation increases MafA-transcriptional activity through the recruitment of the coactivator P/CAF.||MafA phosphorylation enhances its ubiquitination.": [
    0.3502347767353058,
    0.4058164656162262,
    0.24394875764846802
  ],
  "We further demonstrate that P/CAF protects MafA from ubiquitination and degradation, suggesting that, upon the release of the coactivator complex, MafA becomes polyubiquitinated and degraded to allow the response to terminate.||MafA phosphorylation enhances its ubiquitination.": [
    0.9766235947608948,
    0.02055363357067108,
    0.0028228263836354017
  ],
  "The Maf oncoproteins are b-Zip transcription factors of the AP-1 superfamily.||MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.": [
    0.07459773868322372,
    0.9075753092765808,
    0.01782696694135666
  ],
  "They are involved in developmental, metabolic, and tumorigenic processes.||MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.": [
    0.2176886796951294,
    0.6582275032997131,
    0.12408383935689926
  ],
  "Maf proteins are overexpressed in about 50% of human multiple myelomas.||MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.": [
    0.08757268637418747,
    0.8897385597229004,
    0.02268875204026699
  ],
  "Here, we show that Maf-transforming activity is controlled by GSK-3-dependent phosphorylation and that phosphorylation by GSK-3 can increase the oncogenic activity of a protein.||MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.": [
    0.38022691011428833,
    0.5964177846908569,
    0.023355327546596527
  ],
  "Using microarray analysis, we identify a gene-expression subprogram regulated by GSK-3-mediated Maf phosphorylation involved in extracellular matrix remodeling and relevant to cancer progression.||MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.": [
    0.1323288232088089,
    0.852989912033081,
    0.014681272208690643
  ],
  "We also demonstrate that GSK-3 triggers MafA sequential phosphorylation on residues S61, T57, T53, and S49, inducing its ubiquitination and degradation.||MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.": [
    0.005508460570126772,
    0.9922788143157959,
    0.0022127481643110514
  ],
  "Paradoxically, this phosphorylation increases MafA-transcriptional activity through the recruitment of the coactivator P/CAF.||MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.": [
    0.9836156964302063,
    0.012802048586308956,
    0.0035822573117911816
  ],
  "We further demonstrate that P/CAF protects MafA from ubiquitination and degradation, suggesting that, upon the release of the coactivator complex, MafA becomes polyubiquitinated and degraded to allow the response to terminate.||MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.": [
    0.6262944936752319,
    0.26529839634895325,
    0.10840712487697601
  ],
  "The Maf oncoproteins are b-Zip transcription factors of the AP-1 superfamily.||MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.": [
    0.022776631638407707,
    0.9629529714584351,
    0.014270363375544548
  ],
  "They are involved in developmental, metabolic, and tumorigenic processes.||MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.": [
    0.06044510751962662,
    0.7841013669967651,
    0.15545350313186646
  ],
  "Maf proteins are overexpressed in about 50% of human multiple myelomas.||MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.": [
    0.011059525422751904,
    0.9726232290267944,
    0.016317283734679222
  ],
  "Here, we show that Maf-transforming activity is controlled by GSK-3-dependent phosphorylation and that phosphorylation by GSK-3 can increase the oncogenic activity of a protein.||MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.": [
    0.05174193158745766,
    0.8880829811096191,
    0.06017505005002022
  ],
  "Using microarray analysis, we identify a gene-expression subprogram regulated by GSK-3-mediated Maf phosphorylation involved in extracellular matrix remodeling and relevant to cancer progression.||MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.": [
    0.031489137560129166,
    0.9510406255722046,
    0.01747027412056923
  ],
  "We also demonstrate that GSK-3 triggers MafA sequential phosphorylation on residues S61, T57, T53, and S49, inducing its ubiquitination and degradation.||MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.": [
    0.003596682334318757,
    0.9952799081802368,
    0.0011234809644520283
  ],
  "Paradoxically, this phosphorylation increases MafA-transcriptional activity through the recruitment of the coactivator P/CAF.||MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.": [
    0.024235539138317108,
    0.27011072635650635,
    0.7056537866592407
  ],
  "We further demonstrate that P/CAF protects MafA from ubiquitination and degradation, suggesting that, upon the release of the coactivator complex, MafA becomes polyubiquitinated and degraded to allow the response to terminate.||MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.": [
    0.9575730562210083,
    0.03595774993300438,
    0.006469145882874727
  ],
  "OBJECTIVE To summarise the long term efficacy of anti-obesity drugs in reducing weight and improving health status.   \n||Medications to treat obesity are highly effective.": [
    0.16615216434001923,
    0.5472559928894043,
    0.2865918278694153
  ],
  "DESIGN Updated meta-analysis of randomised trials.   \n||Medications to treat obesity are highly effective.": [
    0.3982059955596924,
    0.5887579321861267,
    0.013036093674600124
  ],
  "DATA SOURCES Medline, Embase, the Cochrane controlled trials register, the Current Science meta-register of controlled trials, and reference lists of identified articles.||Medications to treat obesity are highly effective.": [
    0.32155612111091614,
    0.6697183847427368,
    0.008725469000637531
  ],
  "All data sources were searched from December 2002 (end date of last search) to December 2006.   ||Medications to treat obesity are highly effective.": [
    0.4439513385295868,
    0.5433678030967712,
    0.012680823914706707
  ],
  "STUDIES REVIEWED Double blind randomised placebo controlled trials of approved anti-obesity drugs used in adults (age over 18) for one year or longer.   \n||Medications to treat obesity are highly effective.": [
    0.12627579271793365,
    0.8678826093673706,
    0.0058415792882442474
  ],
  "RESULTS 30 trials of one to four years' duration met the inclusion criteria: 16 orlistat (n=10 631 participants), 10 sibutramine (n=2623), and four rimonabant (n=6365).||Medications to treat obesity are highly effective.": [
    0.1898193359375,
    0.7974432110786438,
    0.012737514451146126
  ],
  "Of these, 14 trials were new and 16 had previously been identified.||Medications to treat obesity are highly effective.": [
    0.43616729974746704,
    0.5527055859565735,
    0.011127173900604248
  ],
  "Attrition rates averaged 30-40%.||Medications to treat obesity are highly effective.": [
    0.4420434236526489,
    0.5518283247947693,
    0.00612822687253356
  ],
  "Compared with placebo, orlistat reduced weight by 2.9 kg (95% confidence interval 2.5 kg to 3.2 kg), sibutramine by 4.2 kg (3.6 kg to 4.7 kg), and rimonabant by 4.7 kg (4.1 kg to 5.3 kg).||Medications to treat obesity are highly effective.": [
    0.12398842722177505,
    0.8257367014884949,
    0.05027492344379425
  ],
  "Patients receiving active drug treatment were significantly more likely to achieve 5% and 10% weight loss thresholds.||Medications to treat obesity are highly effective.": [
    0.0075564938597381115,
    0.862773060798645,
    0.12967047095298767
  ],
  "Orlistat reduced the incidence of diabetes and improved concentrations of total cholesterol and low density lipoprotein cholesterol, blood pressure, and glycaemic control in patients with diabetes but increased rates of gastrointestinal side effects and slightly lowered concentrations of high density lipoprotein.||Medications to treat obesity are highly effective.": [
    0.7508948445320129,
    0.2367478907108307,
    0.012357288040220737
  ],
  "Sibutramine improved [corrected] concentrations of high density lipoprotein cholesterol and triglycerides [corrected] Rimonabant improved concentrations of high density lipoprotein cholesterol and triglycerides, blood pressure, and glycaemic control in patients with diabetes but increased the risk of mood disorders.   \n||Medications to treat obesity are highly effective.": [
    0.37475794553756714,
    0.5712577104568481,
    0.05398440361022949
  ],
  "CONCLUSIONS Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.||Medications to treat obesity are highly effective.": [
    0.7579744458198547,
    0.22448450326919556,
    0.017541036009788513
  ],
  "OBJECTIVE To summarise the long term efficacy of anti-obesity drugs in reducing weight and improving health status.   \n||Medications to treat obesity do not have side effects.": [
    0.955998420715332,
    0.041802503168582916,
    0.0021990404929965734
  ],
  "DESIGN Updated meta-analysis of randomised trials.   \n||Medications to treat obesity do not have side effects.": [
    0.9565660357475281,
    0.04002957046031952,
    0.0034044478088617325
  ],
  "DATA SOURCES Medline, Embase, the Cochrane controlled trials register, the Current Science meta-register of controlled trials, and reference lists of identified articles.||Medications to treat obesity do not have side effects.": [
    0.9528224468231201,
    0.04432743415236473,
    0.002850112970918417
  ],
  "All data sources were searched from December 2002 (end date of last search) to December 2006.   ||Medications to treat obesity do not have side effects.": [
    0.950838029384613,
    0.045195162296295166,
    0.003966722637414932
  ],
  "STUDIES REVIEWED Double blind randomised placebo controlled trials of approved anti-obesity drugs used in adults (age over 18) for one year or longer.   \n||Medications to treat obesity do not have side effects.": [
    0.9344658851623535,
    0.060760125517845154,
    0.004773924592882395
  ],
  "RESULTS 30 trials of one to four years' duration met the inclusion criteria: 16 orlistat (n=10 631 participants), 10 sibutramine (n=2623), and four rimonabant (n=6365).||Medications to treat obesity do not have side effects.": [
    0.9272083640098572,
    0.06966712325811386,
    0.0031245104037225246
  ],
  "Of these, 14 trials were new and 16 had previously been identified.||Medications to treat obesity do not have side effects.": [
    0.9724690914154053,
    0.024856189265847206,
    0.0026746466755867004
  ],
  "Attrition rates averaged 30-40%.||Medications to treat obesity do not have side effects.": [
    0.957757294178009,
    0.04006586968898773,
    0.002176882466301322
  ],
  "Compared with placebo, orlistat reduced weight by 2.9 kg (95% confidence interval 2.5 kg to 3.2 kg), sibutramine by 4.2 kg (3.6 kg to 4.7 kg), and rimonabant by 4.7 kg (4.1 kg to 5.3 kg).||Medications to treat obesity do not have side effects.": [
    0.9932116270065308,
    0.005885773338377476,
    0.0009025562321767211
  ],
  "Patients receiving active drug treatment were significantly more likely to achieve 5% and 10% weight loss thresholds.||Medications to treat obesity do not have side effects.": [
    0.8667160868644714,
    0.12984631955623627,
    0.0034375381655991077
  ],
  "Orlistat reduced the incidence of diabetes and improved concentrations of total cholesterol and low density lipoprotein cholesterol, blood pressure, and glycaemic control in patients with diabetes but increased rates of gastrointestinal side effects and slightly lowered concentrations of high density lipoprotein.||Medications to treat obesity do not have side effects.": [
    0.757958710193634,
    0.23969735205173492,
    0.002343891654163599
  ],
  "Sibutramine improved [corrected] concentrations of high density lipoprotein cholesterol and triglycerides [corrected] Rimonabant improved concentrations of high density lipoprotein cholesterol and triglycerides, blood pressure, and glycaemic control in patients with diabetes but increased the risk of mood disorders.   \n||Medications to treat obesity do not have side effects.": [
    0.9767772555351257,
    0.022208020091056824,
    0.001014703419059515
  ],
  "CONCLUSIONS Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.||Medications to treat obesity do not have side effects.": [
    0.9961142539978027,
    0.0033273145090788603,
    0.0005585128092207015
  ],
  "OBJECTIVE To summarise the long term efficacy of anti-obesity drugs in reducing weight and improving health status.   \n||Medications to treat obesity have unwanted side effects.": [
    0.01488721463829279,
    0.9245348572731018,
    0.06057792529463768
  ],
  "DESIGN Updated meta-analysis of randomised trials.   \n||Medications to treat obesity have unwanted side effects.": [
    0.010993102565407753,
    0.7857279181480408,
    0.2032790184020996
  ],
  "DATA SOURCES Medline, Embase, the Cochrane controlled trials register, the Current Science meta-register of controlled trials, and reference lists of identified articles.||Medications to treat obesity have unwanted side effects.": [
    0.007473888341337442,
    0.8002846837043762,
    0.19224147498607635
  ],
  "All data sources were searched from December 2002 (end date of last search) to December 2006.   ||Medications to treat obesity have unwanted side effects.": [
    0.012714090757071972,
    0.8058318495750427,
    0.1814541071653366
  ],
  "STUDIES REVIEWED Double blind randomised placebo controlled trials of approved anti-obesity drugs used in adults (age over 18) for one year or longer.   \n||Medications to treat obesity have unwanted side effects.": [
    0.002954541239887476,
    0.7901773452758789,
    0.20686814188957214
  ],
  "RESULTS 30 trials of one to four years' duration met the inclusion criteria: 16 orlistat (n=10 631 participants), 10 sibutramine (n=2623), and four rimonabant (n=6365).||Medications to treat obesity have unwanted side effects.": [
    0.0064774067141115665,
    0.772411048412323,
    0.2211115062236786
  ],
  "Of these, 14 trials were new and 16 had previously been identified.||Medications to treat obesity have unwanted side effects.": [
    0.006596610881388187,
    0.709252655506134,
    0.2841506898403168
  ],
  "Attrition rates averaged 30-40%.||Medications to treat obesity have unwanted side effects.": [
    0.0043095313012599945,
    0.87064528465271,
    0.12504521012306213
  ],
  "Compared with placebo, orlistat reduced weight by 2.9 kg (95% confidence interval 2.5 kg to 3.2 kg), sibutramine by 4.2 kg (3.6 kg to 4.7 kg), and rimonabant by 4.7 kg (4.1 kg to 5.3 kg).||Medications to treat obesity have unwanted side effects.": [
    0.007999271154403687,
    0.6014856696128845,
    0.3905150294303894
  ],
  "Patients receiving active drug treatment were significantly more likely to achieve 5% and 10% weight loss thresholds.||Medications to treat obesity have unwanted side effects.": [
    0.010142218321561813,
    0.9362833499908447,
    0.053574420511722565
  ],
  "Orlistat reduced the incidence of diabetes and improved concentrations of total cholesterol and low density lipoprotein cholesterol, blood pressure, and glycaemic control in patients with diabetes but increased rates of gastrointestinal side effects and slightly lowered concentrations of high density lipoprotein.||Medications to treat obesity have unwanted side effects.": [
    0.01723829284310341,
    0.3683967590332031,
    0.6143649816513062
  ],
  "Sibutramine improved [corrected] concentrations of high density lipoprotein cholesterol and triglycerides [corrected] Rimonabant improved concentrations of high density lipoprotein cholesterol and triglycerides, blood pressure, and glycaemic control in patients with diabetes but increased the risk of mood disorders.   \n||Medications to treat obesity have unwanted side effects.": [
    0.006453515030443668,
    0.3510936200618744,
    0.6424528360366821
  ],
  "CONCLUSIONS Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.||Medications to treat obesity have unwanted side effects.": [
    0.001495504635386169,
    0.12338411062955856,
    0.8751204609870911
  ],
  "DNA polymerases mu (pol mu), lambda (pol lambda), and terminal deoxynucleotidyltransferase (TdT) are enzymes of the pol X family that share homology in sequence and functional domain organization.||Mice defective for deoxyribonucleic acid (DNA) polymerase I (polI) fail to reveal increased sensitivity to ionizing radiation (IR).": [
    0.46982789039611816,
    0.4861812889575958,
    0.04399082809686661
  ],
  "We showed previously that pol mu participates in light chain but surprisingly not heavy chain gene rearrangement.||Mice defective for deoxyribonucleic acid (DNA) polymerase I (polI) fail to reveal increased sensitivity to ionizing radiation (IR).": [
    0.5307004451751709,
    0.424221396446228,
    0.04507813602685928
  ],
  "We show here that immunoglobulin heavy chain junctions from pol lambda-deficient animals have shorter length with normal N-additions, thus indicating that pol lambda is recruited during heavy chain rearrangement at a step that precedes the action of TdT. In contrast to previous in vitro studies, analysis of animals with combined inactivation of these enzymes revealed no overlapping or compensatory activities for V(D)J recombination between pol mu, pol lambda, and TdT. This complex usage of polymerases with distinct catalytic specificities may correspond to the specific function that the third hypervariable region assumes for each immunoglobulin chain, with pol lambda maintaining a large heavy chain junctional heterogeneity and pol mu ensuring a restricted light chain junctional variability.||Mice defective for deoxyribonucleic acid (DNA) polymerase I (polI) fail to reveal increased sensitivity to ionizing radiation (IR).": [
    0.6395828127861023,
    0.34091800451278687,
    0.019499223679304123
  ],
  "DNA polymerases mu (pol mu), lambda (pol lambda), and terminal deoxynucleotidyltransferase (TdT) are enzymes of the pol X family that share homology in sequence and functional domain organization.||Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) fail to reveal increased sensitivity to ionizing radiation (IR).": [
    0.42547905445098877,
    0.5392119884490967,
    0.035308968275785446
  ],
  "We showed previously that pol mu participates in light chain but surprisingly not heavy chain gene rearrangement.||Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) fail to reveal increased sensitivity to ionizing radiation (IR).": [
    0.5224399566650391,
    0.446035772562027,
    0.03152429684996605
  ],
  "We show here that immunoglobulin heavy chain junctions from pol lambda-deficient animals have shorter length with normal N-additions, thus indicating that pol lambda is recruited during heavy chain rearrangement at a step that precedes the action of TdT. In contrast to previous in vitro studies, analysis of animals with combined inactivation of these enzymes revealed no overlapping or compensatory activities for V(D)J recombination between pol mu, pol lambda, and TdT. This complex usage of polymerases with distinct catalytic specificities may correspond to the specific function that the third hypervariable region assumes for each immunoglobulin chain, with pol lambda maintaining a large heavy chain junctional heterogeneity and pol mu ensuring a restricted light chain junctional variability.||Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) fail to reveal increased sensitivity to ionizing radiation (IR).": [
    0.6288939714431763,
    0.3516384959220886,
    0.019467541947960854
  ],
  "DNA polymerases mu (pol mu), lambda (pol lambda), and terminal deoxynucleotidyltransferase (TdT) are enzymes of the pol X family that share homology in sequence and functional domain organization.||Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) reveal increased sensitivity to ionizing radiation (IR).": [
    0.05668321251869202,
    0.9087871313095093,
    0.034529659897089005
  ],
  "We showed previously that pol mu participates in light chain but surprisingly not heavy chain gene rearrangement.||Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) reveal increased sensitivity to ionizing radiation (IR).": [
    0.13228076696395874,
    0.8151939511299133,
    0.05252528935670853
  ],
  "We show here that immunoglobulin heavy chain junctions from pol lambda-deficient animals have shorter length with normal N-additions, thus indicating that pol lambda is recruited during heavy chain rearrangement at a step that precedes the action of TdT. In contrast to previous in vitro studies, analysis of animals with combined inactivation of these enzymes revealed no overlapping or compensatory activities for V(D)J recombination between pol mu, pol lambda, and TdT. This complex usage of polymerases with distinct catalytic specificities may correspond to the specific function that the third hypervariable region assumes for each immunoglobulin chain, with pol lambda maintaining a large heavy chain junctional heterogeneity and pol mu ensuring a restricted light chain junctional variability.||Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) reveal increased sensitivity to ionizing radiation (IR).": [
    0.37460795044898987,
    0.5876431465148926,
    0.03774893283843994
  ],
  "DNA polymerases mu (pol mu), lambda (pol lambda), and terminal deoxynucleotidyltransferase (TdT) are enzymes of the pol X family that share homology in sequence and functional domain organization.||Mice defective for deoxyribonucleic acid (DNA) polymerase I (polI) reveal increased sensitivity to ionizing radiation (IR).": [
    0.07744345813989639,
    0.8640374541282654,
    0.05851905047893524
  ],
  "We showed previously that pol mu participates in light chain but surprisingly not heavy chain gene rearrangement.||Mice defective for deoxyribonucleic acid (DNA) polymerase I (polI) reveal increased sensitivity to ionizing radiation (IR).": [
    0.14087776839733124,
    0.7758054137229919,
    0.08331681787967682
  ],
  "We show here that immunoglobulin heavy chain junctions from pol lambda-deficient animals have shorter length with normal N-additions, thus indicating that pol lambda is recruited during heavy chain rearrangement at a step that precedes the action of TdT. In contrast to previous in vitro studies, analysis of animals with combined inactivation of these enzymes revealed no overlapping or compensatory activities for V(D)J recombination between pol mu, pol lambda, and TdT. This complex usage of polymerases with distinct catalytic specificities may correspond to the specific function that the third hypervariable region assumes for each immunoglobulin chain, with pol lambda maintaining a large heavy chain junctional heterogeneity and pol mu ensuring a restricted light chain junctional variability.||Mice defective for deoxyribonucleic acid (DNA) polymerase I (polI) reveal increased sensitivity to ionizing radiation (IR).": [
    0.3380706310272217,
    0.6201034188270569,
    0.04182594269514084
  ],
  "Mitochondria are the primary energy-generating system in most eukaryotic cells.||Mitochondria play a major role in apoptosis.": [
    0.9214814901351929,
    0.07360627502202988,
    0.004912193398922682
  ],
  "Additionally, they participate in intermediary metabolism, calcium signaling, and apoptosis.||Mitochondria play a major role in apoptosis.": [
    0.00264785997569561,
    0.20393548905849457,
    0.7934166789054871
  ],
  "Given these well-established functions, it might be expected that mitochondrial dysfunction would give rise to a simple and predictable set of defects in all tissues.||Mitochondria play a major role in apoptosis.": [
    0.003922358155250549,
    0.9862313866615295,
    0.009846256114542484
  ],
  "However, mitochondrial dysfunction has pleiotropic effects in multicellular organisms.||Mitochondria play a major role in apoptosis.": [
    0.05420955270528793,
    0.9254775643348694,
    0.020312918350100517
  ],
  "Clearly, much about the basic biology of mitochondria remains to be understood.||Mitochondria play a major role in apoptosis.": [
    0.00861061830073595,
    0.9895420074462891,
    0.0018473759992048144
  ],
  "Here we discuss recent work that suggests that the dynamics (fusion and fission) of these organelles is important in development and disease.||Mitochondria play a major role in apoptosis.": [
    0.07776898145675659,
    0.9064164757728577,
    0.015814514830708504
  ],
  "Mitochondria are the primary energy-generating system in most eukaryotic cells.||Mitochondria play a major role in energy production.": [
    0.0008712018607184291,
    0.023876691237092018,
    0.9752520322799683
  ],
  "Additionally, they participate in intermediary metabolism, calcium signaling, and apoptosis.||Mitochondria play a major role in energy production.": [
    0.0034796998370438814,
    0.8509715795516968,
    0.14554868638515472
  ],
  "Given these well-established functions, it might be expected that mitochondrial dysfunction would give rise to a simple and predictable set of defects in all tissues.||Mitochondria play a major role in energy production.": [
    0.0012197718024253845,
    0.9887142777442932,
    0.010065906681120396
  ],
  "However, mitochondrial dysfunction has pleiotropic effects in multicellular organisms.||Mitochondria play a major role in energy production.": [
    0.011385466903448105,
    0.9739370942115784,
    0.01467745378613472
  ],
  "Clearly, much about the basic biology of mitochondria remains to be understood.||Mitochondria play a major role in energy production.": [
    0.002203114330768585,
    0.9947769641876221,
    0.003019958036020398
  ],
  "Here we discuss recent work that suggests that the dynamics (fusion and fission) of these organelles is important in development and disease.||Mitochondria play a major role in energy production.": [
    0.13013097643852234,
    0.8421586155891418,
    0.027710439637303352
  ],
  "Mitochondria are the primary energy-generating system in most eukaryotic cells.||Mitochondria play a trivial role in calcium homeostasis.": [
    0.882434606552124,
    0.11524805426597595,
    0.0023173734080046415
  ],
  "Additionally, they participate in intermediary metabolism, calcium signaling, and apoptosis.||Mitochondria play a trivial role in calcium homeostasis.": [
    0.8348199129104614,
    0.15673650801181793,
    0.008443542756140232
  ],
  "Given these well-established functions, it might be expected that mitochondrial dysfunction would give rise to a simple and predictable set of defects in all tissues.||Mitochondria play a trivial role in calcium homeostasis.": [
    0.6641759276390076,
    0.33183372020721436,
    0.003990270663052797
  ],
  "However, mitochondrial dysfunction has pleiotropic effects in multicellular organisms.||Mitochondria play a trivial role in calcium homeostasis.": [
    0.5435962677001953,
    0.4490273892879486,
    0.007376301568001509
  ],
  "Clearly, much about the basic biology of mitochondria remains to be understood.||Mitochondria play a trivial role in calcium homeostasis.": [
    0.05947314575314522,
    0.9387791752815247,
    0.0017476248322054744
  ],
  "Here we discuss recent work that suggests that the dynamics (fusion and fission) of these organelles is important in development and disease.||Mitochondria play a trivial role in calcium homeostasis.": [
    0.8961154818534851,
    0.10117974132299423,
    0.0027047530747950077
  ],
  "Mitochondria are the primary energy-generating system in most eukaryotic cells.||Mitochondria are uninvolved in apoptosis.": [
    0.23641476035118103,
    0.7533722519874573,
    0.010212969966232777
  ],
  "Additionally, they participate in intermediary metabolism, calcium signaling, and apoptosis.||Mitochondria are uninvolved in apoptosis.": [
    0.9992491602897644,
    0.0006119075696915388,
    0.0001388847449561581
  ],
  "Given these well-established functions, it might be expected that mitochondrial dysfunction would give rise to a simple and predictable set of defects in all tissues.||Mitochondria are uninvolved in apoptosis.": [
    0.9809194207191467,
    0.017657676711678505,
    0.001422865898348391
  ],
  "However, mitochondrial dysfunction has pleiotropic effects in multicellular organisms.||Mitochondria are uninvolved in apoptosis.": [
    0.9441798329353333,
    0.05218082293868065,
    0.0036393716000020504
  ],
  "Clearly, much about the basic biology of mitochondria remains to be understood.||Mitochondria are uninvolved in apoptosis.": [
    0.700116753578186,
    0.2950589060783386,
    0.004824306350201368
  ],
  "Here we discuss recent work that suggests that the dynamics (fusion and fission) of these organelles is important in development and disease.||Mitochondria are uninvolved in apoptosis.": [
    0.9527462720870972,
    0.04545705020427704,
    0.0017966243904083967
  ],
  "Background The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) consists of DNA polymerase, connection, and ribonuclease H (RNase H) domains.||N348I mutations cause resistance to nevirapine.": [
    0.17385493218898773,
    0.813854455947876,
    0.012290597893297672
  ],
  "Almost all known RT inhibitor resistance mutations identified to date map to the polymerase domain of the enzyme.||N348I mutations cause resistance to nevirapine.": [
    0.18139122426509857,
    0.7670961022377014,
    0.05151268467307091
  ],
  "However, the connection and RNase H domains are not routinely analysed in clinical samples and none of the genotyping assays available for patient management sequence the entire RT coding region.||N348I mutations cause resistance to nevirapine.": [
    0.03703431785106659,
    0.9521456360816956,
    0.010820041410624981
  ],
  "The British Columbia Centre for Excellence in HIV/AIDS (the Centre) genotypes clinical isolates up to codon 400 in RT, and our retrospective statistical analyses of the Centre\u2019s database have identified an N348I mutation in the RT connection domain in treatment-experienced individuals.||N348I mutations cause resistance to nevirapine.": [
    0.007315979804843664,
    0.9910914301872253,
    0.0015925613697618246
  ],
  "The objective of this multidisciplinary study was to establish the in vivo relevance of this mutation and its role in drug resistance.||N348I mutations cause resistance to nevirapine.": [
    0.005871345289051533,
    0.9896173477172852,
    0.0045113456435501575
  ],
  "Methods and Findings The prevalence of N348I in clinical isolates, the time taken for it to emerge under selective drug pressure, and its association with changes in viral load, specific drug treatment, and known drug resistance mutations was analysed from genotypes, viral loads, and treatment histories from the Centre\u2019s database.||N348I mutations cause resistance to nevirapine.": [
    0.009602010250091553,
    0.9867558479309082,
    0.003642062423750758
  ],
  "N348I increased in prevalence from below 1% in 368 treatmentnao \u00a8ve individuals to 12.1% in 1,009 treatment-experienced patients (p \u00bc 7.7 3 10 \ufffd 12 ).||N348I mutations cause resistance to nevirapine.": [
    0.004782179836183786,
    0.9934778213500977,
    0.0017400204669684172
  ],
  "N348I appeared early in therapy and was highly associated with thymidine analogue mutations (TAMs) M41L and T215Y/F (p , 0.001), the lamivudine resistance mutations M184V/I (p , 0.001), and non-nucleoside RTI (NNRTI) resistance mutations K103N and Y181C/I (p , 0.001).||N348I mutations cause resistance to nevirapine.": [
    0.0736125260591507,
    0.8926759362220764,
    0.033711496740579605
  ],
  "The association with TAMs and NNRTI resistance mutations was consistent with the selection of N348I in patients treated with regimens that included both zidovudine and nevirapine (odds ratio 2.62, 95% confidence interval 1.43\u20134.81).||N348I mutations cause resistance to nevirapine.": [
    0.02917003072798252,
    0.251246839761734,
    0.7195831537246704
  ],
  "The appearance of N348I was associated with a significant increase in viral load (p , 0.001), which was as large as the viral load increases observed for any of the TAMs.||N348I mutations cause resistance to nevirapine.": [
    0.057575441896915436,
    0.9381788372993469,
    0.004245715215802193
  ],
  "However, this analysis did not account for the simultaneous selection of other RT or protease inhibitor resistance mutations on viral load.||N348I mutations cause resistance to nevirapine.": [
    0.14931128919124603,
    0.8397125005722046,
    0.010976187884807587
  ],
  "To delineate the role of this mutation in RT inhibitor resistance, N348I was introduced into HIV-1 molecular clones containing different genetic backbones.||N348I mutations cause resistance to nevirapine.": [
    0.08069384098052979,
    0.8098372220993042,
    0.1094689667224884
  ],
  "N348I decreased zidovudine susceptibility 2- to 4-fold in the context of wildtype HIV-1 or when combined with TAMs.||N348I mutations cause resistance to nevirapine.": [
    0.8978271484375,
    0.09590228646993637,
    0.006270658224821091
  ],
  "N348I also decreased susceptibility to nevirapine (7.4fold) and efavirenz (2.5-fold) and significantly potentiated resistance to these drugs when combined with K103N.||N348I mutations cause resistance to nevirapine.": [
    0.021906200796365738,
    0.593747079372406,
    0.38434678316116333
  ],
  "Biochemical analyses of recombinant RT containing N348I provide supporting evidence for the role of this mutation in zidovudine and NNRTI resistance and give some insight into the molecular mechanism of resistance.||N348I mutations cause resistance to nevirapine.": [
    0.02864973619580269,
    0.3833997845649719,
    0.5879505276679993
  ],
  "Conclusions||N348I mutations cause resistance to nevirapine.": [
    0.08110277354717255,
    0.893783450126648,
    0.025113755837082863
  ],
  "Background The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) consists of DNA polymerase, connection, and ribonuclease H (RNase H) domains.||N348I mutations reduce resistance to nevirapine.": [
    0.2132227122783661,
    0.7590842247009277,
    0.027693074196577072
  ],
  "Almost all known RT inhibitor resistance mutations identified to date map to the polymerase domain of the enzyme.||N348I mutations reduce resistance to nevirapine.": [
    0.13936027884483337,
    0.8058049082756042,
    0.05483478680253029
  ],
  "However, the connection and RNase H domains are not routinely analysed in clinical samples and none of the genotyping assays available for patient management sequence the entire RT coding region.||N348I mutations reduce resistance to nevirapine.": [
    0.13217748701572418,
    0.8514682054519653,
    0.01635430008172989
  ],
  "The British Columbia Centre for Excellence in HIV/AIDS (the Centre) genotypes clinical isolates up to codon 400 in RT, and our retrospective statistical analyses of the Centre\u2019s database have identified an N348I mutation in the RT connection domain in treatment-experienced individuals.||N348I mutations reduce resistance to nevirapine.": [
    0.005362591240555048,
    0.9935482144355774,
    0.0010891575366258621
  ],
  "The objective of this multidisciplinary study was to establish the in vivo relevance of this mutation and its role in drug resistance.||N348I mutations reduce resistance to nevirapine.": [
    0.27062973380088806,
    0.7258837819099426,
    0.0034865017514675856
  ],
  "Methods and Findings The prevalence of N348I in clinical isolates, the time taken for it to emerge under selective drug pressure, and its association with changes in viral load, specific drug treatment, and known drug resistance mutations was analysed from genotypes, viral loads, and treatment histories from the Centre\u2019s database.||N348I mutations reduce resistance to nevirapine.": [
    0.13667018711566925,
    0.8600260615348816,
    0.0033037986140698195
  ],
  "N348I increased in prevalence from below 1% in 368 treatmentnao \u00a8ve individuals to 12.1% in 1,009 treatment-experienced patients (p \u00bc 7.7 3 10 \ufffd 12 ).||N348I mutations reduce resistance to nevirapine.": [
    0.0202147476375103,
    0.9769585728645325,
    0.0028266196604818106
  ],
  "N348I appeared early in therapy and was highly associated with thymidine analogue mutations (TAMs) M41L and T215Y/F (p , 0.001), the lamivudine resistance mutations M184V/I (p , 0.001), and non-nucleoside RTI (NNRTI) resistance mutations K103N and Y181C/I (p , 0.001).||N348I mutations reduce resistance to nevirapine.": [
    0.08000557124614716,
    0.9072890877723694,
    0.012705349363386631
  ],
  "The association with TAMs and NNRTI resistance mutations was consistent with the selection of N348I in patients treated with regimens that included both zidovudine and nevirapine (odds ratio 2.62, 95% confidence interval 1.43\u20134.81).||N348I mutations reduce resistance to nevirapine.": [
    0.3388166129589081,
    0.511191725730896,
    0.1499916911125183
  ],
  "The appearance of N348I was associated with a significant increase in viral load (p , 0.001), which was as large as the viral load increases observed for any of the TAMs.||N348I mutations reduce resistance to nevirapine.": [
    0.2756815254688263,
    0.7196152210235596,
    0.004703234415501356
  ],
  "However, this analysis did not account for the simultaneous selection of other RT or protease inhibitor resistance mutations on viral load.||N348I mutations reduce resistance to nevirapine.": [
    0.1718137413263321,
    0.8122049570083618,
    0.015981338918209076
  ],
  "To delineate the role of this mutation in RT inhibitor resistance, N348I was introduced into HIV-1 molecular clones containing different genetic backbones.||N348I mutations reduce resistance to nevirapine.": [
    0.22023341059684753,
    0.7440124154090881,
    0.03575421869754791
  ],
  "N348I decreased zidovudine susceptibility 2- to 4-fold in the context of wildtype HIV-1 or when combined with TAMs.||N348I mutations reduce resistance to nevirapine.": [
    0.04456079378724098,
    0.5010475516319275,
    0.4543916881084442
  ],
  "N348I also decreased susceptibility to nevirapine (7.4fold) and efavirenz (2.5-fold) and significantly potentiated resistance to these drugs when combined with K103N.||N348I mutations reduce resistance to nevirapine.": [
    0.8995200991630554,
    0.05527546629309654,
    0.04520436003804207
  ],
  "Biochemical analyses of recombinant RT containing N348I provide supporting evidence for the role of this mutation in zidovudine and NNRTI resistance and give some insight into the molecular mechanism of resistance.||N348I mutations reduce resistance to nevirapine.": [
    0.3324287235736847,
    0.48948898911476135,
    0.17808230221271515
  ],
  "Conclusions||N348I mutations reduce resistance to nevirapine.": [
    0.10153006762266159,
    0.8458684086799622,
    0.05260149762034416
  ],
  "Background The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) consists of DNA polymerase, connection, and ribonuclease H (RNase H) domains.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.30439823865890503,
    0.6864521503448486,
    0.00914959516376257
  ],
  "Almost all known RT inhibitor resistance mutations identified to date map to the polymerase domain of the enzyme.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.22927303612232208,
    0.7467314004898071,
    0.02399558387696743
  ],
  "However, the connection and RNase H domains are not routinely analysed in clinical samples and none of the genotyping assays available for patient management sequence the entire RT coding region.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.060085657984018326,
    0.9233541488647461,
    0.016560187563300133
  ],
  "The British Columbia Centre for Excellence in HIV/AIDS (the Centre) genotypes clinical isolates up to codon 400 in RT, and our retrospective statistical analyses of the Centre\u2019s database have identified an N348I mutation in the RT connection domain in treatment-experienced individuals.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.008324792608618736,
    0.9903163313865662,
    0.0013589519076049328
  ],
  "The objective of this multidisciplinary study was to establish the in vivo relevance of this mutation and its role in drug resistance.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.011211761273443699,
    0.9717357754707336,
    0.017052480950951576
  ],
  "Methods and Findings The prevalence of N348I in clinical isolates, the time taken for it to emerge under selective drug pressure, and its association with changes in viral load, specific drug treatment, and known drug resistance mutations was analysed from genotypes, viral loads, and treatment histories from the Centre\u2019s database.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.015988433733582497,
    0.9793137907981873,
    0.004697747062891722
  ],
  "N348I increased in prevalence from below 1% in 368 treatmentnao \u00a8ve individuals to 12.1% in 1,009 treatment-experienced patients (p \u00bc 7.7 3 10 \ufffd 12 ).||N348I mutations cause resistance to zidovudine (AZT).": [
    0.01750117540359497,
    0.979800820350647,
    0.002698038937523961
  ],
  "N348I appeared early in therapy and was highly associated with thymidine analogue mutations (TAMs) M41L and T215Y/F (p , 0.001), the lamivudine resistance mutations M184V/I (p , 0.001), and non-nucleoside RTI (NNRTI) resistance mutations K103N and Y181C/I (p , 0.001).||N348I mutations cause resistance to zidovudine (AZT).": [
    0.294554740190506,
    0.6412652134895325,
    0.06418004631996155
  ],
  "The association with TAMs and NNRTI resistance mutations was consistent with the selection of N348I in patients treated with regimens that included both zidovudine and nevirapine (odds ratio 2.62, 95% confidence interval 1.43\u20134.81).||N348I mutations cause resistance to zidovudine (AZT).": [
    0.09377231448888779,
    0.4482123851776123,
    0.4580152630805969
  ],
  "The appearance of N348I was associated with a significant increase in viral load (p , 0.001), which was as large as the viral load increases observed for any of the TAMs.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.12411358952522278,
    0.8708226084709167,
    0.00506378710269928
  ],
  "However, this analysis did not account for the simultaneous selection of other RT or protease inhibitor resistance mutations on viral load.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.1687363237142563,
    0.8212369084358215,
    0.010026838630437851
  ],
  "To delineate the role of this mutation in RT inhibitor resistance, N348I was introduced into HIV-1 molecular clones containing different genetic backbones.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.30465880036354065,
    0.6604950428009033,
    0.03484613075852394
  ],
  "N348I decreased zidovudine susceptibility 2- to 4-fold in the context of wildtype HIV-1 or when combined with TAMs.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.5768917798995972,
    0.4034918248653412,
    0.019616402685642242
  ],
  "N348I also decreased susceptibility to nevirapine (7.4fold) and efavirenz (2.5-fold) and significantly potentiated resistance to these drugs when combined with K103N.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.08870319277048111,
    0.8365679979324341,
    0.07472878694534302
  ],
  "Biochemical analyses of recombinant RT containing N348I provide supporting evidence for the role of this mutation in zidovudine and NNRTI resistance and give some insight into the molecular mechanism of resistance.||N348I mutations cause resistance to zidovudine (AZT).": [
    0.04273483529686928,
    0.3515293002128601,
    0.6057358384132385
  ],
  "Conclusions||N348I mutations cause resistance to zidovudine (AZT).": [
    0.10665526986122131,
    0.862951397895813,
    0.030393358319997787
  ],
  "Successful pregnancy requires coordination of an array of signals and factors from multiple tissues.||NR5A2 does not play a role in development of endometrial tissues.": [
    0.70372074842453,
    0.2917342185974121,
    0.004545043688267469
  ],
  "One such element, liver receptor homolog-1 (Lrh-1), is an orphan nuclear receptor that regulates metabolism and hormone synthesis.||NR5A2 does not play a role in development of endometrial tissues.": [
    0.22587265074253082,
    0.756323516368866,
    0.01780378818511963
  ],
  "It is strongly expressed in granulosa cells of ovarian follicles and in the corpus luteum of rodents and humans.||NR5A2 does not play a role in development of endometrial tissues.": [
    0.9946945309638977,
    0.0043172151781618595,
    0.0009882156737148762
  ],
  "Germline ablation of Nr5a2 (also called Lrh-1), the gene coding for Lrh-1, in mice is embryonically lethal at gastrulation.||NR5A2 does not play a role in development of endometrial tissues.": [
    0.12489384412765503,
    0.8617531657218933,
    0.013353000394999981
  ],
  "Depletion of Lrh-1 in the ovarian follicle shows that it regulates genes required for both steroid synthesis and ovulation.||NR5A2 does not play a role in development of endometrial tissues.": [
    0.7319273352622986,
    0.2616358697414398,
    0.006436777766793966
  ],
  "To study the effects of Lrh-1 on mouse gestation, we genetically disrupted its expression in the corpus luteum, resulting in luteal insufficiency.||NR5A2 does not play a role in development of endometrial tissues.": [
    0.6375607848167419,
    0.33908259868621826,
    0.023356586694717407
  ],
  "Hormone replacement permitted embryo implantation but was followed by gestational failure with impaired endometrial decidualization, compromised placental formation, fetal growth retardation and fetal death.||NR5A2 does not play a role in development of endometrial tissues.": [
    0.7845621109008789,
    0.19162830710411072,
    0.02380954660475254
  ],
  "Lrh-1 is also expressed in the mouse and human endometrium, and in a primary culture of human endometrial stromal cells, reduction of NR5A2 transcript abundance by RNA interference abrogated decidualization.||NR5A2 does not play a role in development of endometrial tissues.": [
    0.8966475129127502,
    0.09515678137540817,
    0.008195648901164532
  ],
  "These findings show that Lrh-1 is necessary for maintenance of the corpus luteum, for promotion of decidualization and for formation of the placenta.||NR5A2 does not play a role in development of endometrial tissues.": [
    0.1999257355928421,
    0.7841933965682983,
    0.015880823135375977
  ],
  "It therefore has multiple, indispensible roles in establishing and sustaining pregnancy.||NR5A2 does not play a role in development of endometrial tissues.": [
    0.9891085624694824,
    0.010129565373063087,
    0.0007618279778398573
  ],
  "Successful pregnancy requires coordination of an array of signals and factors from multiple tissues.||NR5A2 is important in reverse cholesterol transport in humans.": [
    0.039637088775634766,
    0.80484938621521,
    0.1555134803056717
  ],
  "One such element, liver receptor homolog-1 (Lrh-1), is an orphan nuclear receptor that regulates metabolism and hormone synthesis.||NR5A2 is important in reverse cholesterol transport in humans.": [
    0.5856965184211731,
    0.3948063552379608,
    0.019497118890285492
  ],
  "It is strongly expressed in granulosa cells of ovarian follicles and in the corpus luteum of rodents and humans.||NR5A2 is important in reverse cholesterol transport in humans.": [
    0.004807597957551479,
    0.9576876163482666,
    0.03750482574105263
  ],
  "Germline ablation of Nr5a2 (also called Lrh-1), the gene coding for Lrh-1, in mice is embryonically lethal at gastrulation.||NR5A2 is important in reverse cholesterol transport in humans.": [
    0.27227815985679626,
    0.7229143381118774,
    0.004807536490261555
  ],
  "Depletion of Lrh-1 in the ovarian follicle shows that it regulates genes required for both steroid synthesis and ovulation.||NR5A2 is important in reverse cholesterol transport in humans.": [
    0.42124342918395996,
    0.5127378106117249,
    0.06601878255605698
  ],
  "To study the effects of Lrh-1 on mouse gestation, we genetically disrupted its expression in the corpus luteum, resulting in luteal insufficiency.||NR5A2 is important in reverse cholesterol transport in humans.": [
    0.5258371829986572,
    0.42481327056884766,
    0.04934949055314064
  ],
  "Hormone replacement permitted embryo implantation but was followed by gestational failure with impaired endometrial decidualization, compromised placental formation, fetal growth retardation and fetal death.||NR5A2 is important in reverse cholesterol transport in humans.": [
    0.15186011791229248,
    0.6090677380561829,
    0.23907218873500824
  ],
  "Lrh-1 is also expressed in the mouse and human endometrium, and in a primary culture of human endometrial stromal cells, reduction of NR5A2 transcript abundance by RNA interference abrogated decidualization.||NR5A2 is important in reverse cholesterol transport in humans.": [
    0.013738680630922318,
    0.975732684135437,
    0.010528694838285446
  ],
  "These findings show that Lrh-1 is necessary for maintenance of the corpus luteum, for promotion of decidualization and for formation of the placenta.||NR5A2 is important in reverse cholesterol transport in humans.": [
    0.44423797726631165,
    0.5345674753189087,
    0.021194549277424812
  ],
  "It therefore has multiple, indispensible roles in establishing and sustaining pregnancy.||NR5A2 is important in reverse cholesterol transport in humans.": [
    0.11046423017978668,
    0.7176664471626282,
    0.17186926305294037
  ],
  "Successful pregnancy requires coordination of an array of signals and factors from multiple tissues.||NR5A2 is important in development of endometrial tissues.": [
    0.0065605673007667065,
    0.9600040912628174,
    0.03343529254198074
  ],
  "One such element, liver receptor homolog-1 (Lrh-1), is an orphan nuclear receptor that regulates metabolism and hormone synthesis.||NR5A2 is important in development of endometrial tissues.": [
    0.5169750452041626,
    0.47499585151672363,
    0.008029098622500896
  ],
  "It is strongly expressed in granulosa cells of ovarian follicles and in the corpus luteum of rodents and humans.||NR5A2 is important in development of endometrial tissues.": [
    0.00264909490942955,
    0.7099319100379944,
    0.28741905093193054
  ],
  "Germline ablation of Nr5a2 (also called Lrh-1), the gene coding for Lrh-1, in mice is embryonically lethal at gastrulation.||NR5A2 is important in development of endometrial tissues.": [
    0.17053966224193573,
    0.8197208642959595,
    0.009739406406879425
  ],
  "Depletion of Lrh-1 in the ovarian follicle shows that it regulates genes required for both steroid synthesis and ovulation.||NR5A2 is important in development of endometrial tissues.": [
    0.25244927406311035,
    0.6673952341079712,
    0.08015547692775726
  ],
  "To study the effects of Lrh-1 on mouse gestation, we genetically disrupted its expression in the corpus luteum, resulting in luteal insufficiency.||NR5A2 is important in development of endometrial tissues.": [
    0.37849143147468567,
    0.4838477671146393,
    0.13766078650951385
  ],
  "Hormone replacement permitted embryo implantation but was followed by gestational failure with impaired endometrial decidualization, compromised placental formation, fetal growth retardation and fetal death.||NR5A2 is important in development of endometrial tissues.": [
    0.039480287581682205,
    0.8566081523895264,
    0.10391156375408173
  ],
  "Lrh-1 is also expressed in the mouse and human endometrium, and in a primary culture of human endometrial stromal cells, reduction of NR5A2 transcript abundance by RNA interference abrogated decidualization.||NR5A2 is important in development of endometrial tissues.": [
    0.0038665246684104204,
    0.9435655474662781,
    0.052567947655916214
  ],
  "These findings show that Lrh-1 is necessary for maintenance of the corpus luteum, for promotion of decidualization and for formation of the placenta.||NR5A2 is important in development of endometrial tissues.": [
    0.45197269320487976,
    0.5322681069374084,
    0.015759184956550598
  ],
  "It therefore has multiple, indispensible roles in establishing and sustaining pregnancy.||NR5A2 is important in development of endometrial tissues.": [
    0.014444761909544468,
    0.894115149974823,
    0.09144005924463272
  ],
  "BACKGROUND Genetic and epidemiological evidence suggests an inverse association between B-type natriuretic peptide (BNP) levels in blood and risk of type 2 diabetes (T2D), but the prospective association of BNP with T2D is uncertain, and it is unclear whether the association is confounded.   \n||Natriuretic peptides increase susceptibility to diabetes.": [
    0.9310591220855713,
    0.04678719490766525,
    0.022153634577989578
  ],
  "METHODS AND FINDINGS We analysed the association between levels of the N-terminal fragment of pro-BNP (NT-pro-BNP) in blood and risk of incident T2D in a prospective case-cohort study and genotyped the variant rs198389 within the BNP locus in three T2D case-control studies.||Natriuretic peptides increase susceptibility to diabetes.": [
    0.05951555445790291,
    0.6368698477745056,
    0.30361461639404297
  ],
  "We combined our results with existing data in a meta-analysis of 11 case-control studies.||Natriuretic peptides increase susceptibility to diabetes.": [
    0.17364591360092163,
    0.7446406483650208,
    0.08171341568231583
  ],
  "Using a Mendelian randomization approach, we compared the observed association between rs198389 and T2D to that expected from the NT-pro-BNP level to T2D association and the NT-pro-BNP difference per C allele of rs198389.||Natriuretic peptides increase susceptibility to diabetes.": [
    0.06784333288669586,
    0.8167008757591248,
    0.11545582860708237
  ],
  "In participants of our case-cohort study who were free of T2D and cardiovascular disease at baseline, we observed a 21% (95% CI 3%-36%) decreased risk of incident T2D per one standard deviation (SD) higher log-transformed NT-pro-BNP levels in analysis adjusted for age, sex, body mass index, systolic blood pressure, smoking, family history of T2D, history of hypertension, and levels of triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.||Natriuretic peptides increase susceptibility to diabetes.": [
    0.7175909280776978,
    0.26102176308631897,
    0.02138727530837059
  ],
  "The association between rs198389 and T2D observed in case-control studies (odds ratio = 0.94 per C allele, 95% CI 0.91-0.97) was similar to that expected (0.96, 0.93-0.98) based on the pooled estimate for the log-NT-pro-BNP level to T2D association derived from a meta-analysis of our study and published data (hazard ratio = 0.82 per SD, 0.74-0.90) and the difference in NT-pro-BNP levels (0.22 SD, 0.15-0.29) per C allele of rs198389.||Natriuretic peptides increase susceptibility to diabetes.": [
    0.06614429503679276,
    0.7954013347625732,
    0.1384543776512146
  ],
  "No significant associations were observed between the rs198389 genotype and potential confounders.   \n||Natriuretic peptides increase susceptibility to diabetes.": [
    0.16989177465438843,
    0.810498058795929,
    0.019610203802585602
  ],
  "CONCLUSIONS Our results provide evidence for a potential causal role of the BNP system in the aetiology of T2D.||Natriuretic peptides increase susceptibility to diabetes.": [
    0.04510629177093506,
    0.8766494989395142,
    0.07824425399303436
  ],
  "Further studies are needed to investigate the mechanisms underlying this association and possibilities for preventive interventions.||Natriuretic peptides increase susceptibility to diabetes.": [
    0.08822987973690033,
    0.865990936756134,
    0.04577920585870743
  ],
  "Please see later in the article for the Editors' Summary.||Natriuretic peptides increase susceptibility to diabetes.": [
    0.08701562881469727,
    0.8388611078262329,
    0.07412319630384445
  ],
  "BACKGROUND Genetic and epidemiological evidence suggests an inverse association between B-type natriuretic peptide (BNP) levels in blood and risk of type 2 diabetes (T2D), but the prospective association of BNP with T2D is uncertain, and it is unclear whether the association is confounded.   \n||Natriuretic peptides protect against diabetes.": [
    0.9020747542381287,
    0.08791124075651169,
    0.01001389417797327
  ],
  "METHODS AND FINDINGS We analysed the association between levels of the N-terminal fragment of pro-BNP (NT-pro-BNP) in blood and risk of incident T2D in a prospective case-cohort study and genotyped the variant rs198389 within the BNP locus in three T2D case-control studies.||Natriuretic peptides protect against diabetes.": [
    0.5415610074996948,
    0.4115937650203705,
    0.04684525728225708
  ],
  "We combined our results with existing data in a meta-analysis of 11 case-control studies.||Natriuretic peptides protect against diabetes.": [
    0.20431388914585114,
    0.6023154258728027,
    0.19337067008018494
  ],
  "Using a Mendelian randomization approach, we compared the observed association between rs198389 and T2D to that expected from the NT-pro-BNP level to T2D association and the NT-pro-BNP difference per C allele of rs198389.||Natriuretic peptides protect against diabetes.": [
    0.18438297510147095,
    0.6846819519996643,
    0.13093511760234833
  ],
  "In participants of our case-cohort study who were free of T2D and cardiovascular disease at baseline, we observed a 21% (95% CI 3%-36%) decreased risk of incident T2D per one standard deviation (SD) higher log-transformed NT-pro-BNP levels in analysis adjusted for age, sex, body mass index, systolic blood pressure, smoking, family history of T2D, history of hypertension, and levels of triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.||Natriuretic peptides protect against diabetes.": [
    0.20705197751522064,
    0.5820964574813843,
    0.21085159480571747
  ],
  "The association between rs198389 and T2D observed in case-control studies (odds ratio = 0.94 per C allele, 95% CI 0.91-0.97) was similar to that expected (0.96, 0.93-0.98) based on the pooled estimate for the log-NT-pro-BNP level to T2D association derived from a meta-analysis of our study and published data (hazard ratio = 0.82 per SD, 0.74-0.90) and the difference in NT-pro-BNP levels (0.22 SD, 0.15-0.29) per C allele of rs198389.||Natriuretic peptides protect against diabetes.": [
    0.33249205350875854,
    0.5712283253669739,
    0.09627960622310638
  ],
  "No significant associations were observed between the rs198389 genotype and potential confounders.   \n||Natriuretic peptides protect against diabetes.": [
    0.24398283660411835,
    0.5850312113761902,
    0.17098593711853027
  ],
  "CONCLUSIONS Our results provide evidence for a potential causal role of the BNP system in the aetiology of T2D.||Natriuretic peptides protect against diabetes.": [
    0.6950069665908813,
    0.27804747223854065,
    0.026945577934384346
  ],
  "Further studies are needed to investigate the mechanisms underlying this association and possibilities for preventive interventions.||Natriuretic peptides protect against diabetes.": [
    0.09618827700614929,
    0.7750532031059265,
    0.128758504986763
  ],
  "Please see later in the article for the Editors' Summary.||Natriuretic peptides protect against diabetes.": [
    0.08067059516906738,
    0.643559455871582,
    0.275769978761673
  ],
  "BACKGROUND Genetic and epidemiological evidence suggests an inverse association between B-type natriuretic peptide (BNP) levels in blood and risk of type 2 diabetes (T2D), but the prospective association of BNP with T2D is uncertain, and it is unclear whether the association is confounded.   \n||High levels of copeptin decrease risk of diabetes.": [
    0.6996396780014038,
    0.26748019456863403,
    0.03288009390234947
  ],
  "METHODS AND FINDINGS We analysed the association between levels of the N-terminal fragment of pro-BNP (NT-pro-BNP) in blood and risk of incident T2D in a prospective case-cohort study and genotyped the variant rs198389 within the BNP locus in three T2D case-control studies.||High levels of copeptin decrease risk of diabetes.": [
    0.34236016869544983,
    0.6358049511909485,
    0.021834861487150192
  ],
  "We combined our results with existing data in a meta-analysis of 11 case-control studies.||High levels of copeptin decrease risk of diabetes.": [
    0.11031951010227203,
    0.8072973489761353,
    0.08238319307565689
  ],
  "Using a Mendelian randomization approach, we compared the observed association between rs198389 and T2D to that expected from the NT-pro-BNP level to T2D association and the NT-pro-BNP difference per C allele of rs198389.||High levels of copeptin decrease risk of diabetes.": [
    0.08168233931064606,
    0.877889096736908,
    0.04042850807309151
  ],
  "In participants of our case-cohort study who were free of T2D and cardiovascular disease at baseline, we observed a 21% (95% CI 3%-36%) decreased risk of incident T2D per one standard deviation (SD) higher log-transformed NT-pro-BNP levels in analysis adjusted for age, sex, body mass index, systolic blood pressure, smoking, family history of T2D, history of hypertension, and levels of triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.||High levels of copeptin decrease risk of diabetes.": [
    0.09772510081529617,
    0.5504705905914307,
    0.35180428624153137
  ],
  "The association between rs198389 and T2D observed in case-control studies (odds ratio = 0.94 per C allele, 95% CI 0.91-0.97) was similar to that expected (0.96, 0.93-0.98) based on the pooled estimate for the log-NT-pro-BNP level to T2D association derived from a meta-analysis of our study and published data (hazard ratio = 0.82 per SD, 0.74-0.90) and the difference in NT-pro-BNP levels (0.22 SD, 0.15-0.29) per C allele of rs198389.||High levels of copeptin decrease risk of diabetes.": [
    0.08714523166418076,
    0.865942656993866,
    0.04691218212246895
  ],
  "No significant associations were observed between the rs198389 genotype and potential confounders.   \n||High levels of copeptin decrease risk of diabetes.": [
    0.1331762820482254,
    0.8444757461547852,
    0.022347964346408844
  ],
  "CONCLUSIONS Our results provide evidence for a potential causal role of the BNP system in the aetiology of T2D.||High levels of copeptin decrease risk of diabetes.": [
    0.16027946770191193,
    0.8228648900985718,
    0.01685563288629055
  ],
  "Further studies are needed to investigate the mechanisms underlying this association and possibilities for preventive interventions.||High levels of copeptin decrease risk of diabetes.": [
    0.061226967722177505,
    0.8938664793968201,
    0.04490659758448601
  ],
  "Please see later in the article for the Editors' Summary.||High levels of copeptin decrease risk of diabetes.": [
    0.07139170169830322,
    0.8246532082557678,
    0.10395514965057373
  ],
  "The TLX1 and TLX3 transcription factor oncogenes have a key role in the pathogenesis of T cell acute lymphoblastic leukemia (T-ALL).||Normal expression of RUNX1 causes tumorsupressing effects.": [
    0.123125359416008,
    0.8290947079658508,
    0.04777992516756058
  ],
  "Here we used reverse engineering of global transcriptional networks to decipher the oncogenic regulatory circuit controlled by TLX1 and TLX3.||Normal expression of RUNX1 causes tumorsupressing effects.": [
    0.025621721521019936,
    0.9253614544868469,
    0.049016837030649185
  ],
  "This systems biology analysis defined T cell leukemia homeobox 1 (TLX1) and TLX3 as master regulators of an oncogenic transcriptional circuit governing T-ALL.||Normal expression of RUNX1 causes tumorsupressing effects.": [
    0.015249521471560001,
    0.9261943697929382,
    0.05855617672204971
  ],
  "Notably, a network structure analysis of this hierarchical network identified RUNX1 as a key mediator of the T-ALL induced by TLX1 and TLX3 and predicted a tumor-suppressor role for RUNX1 in T cell transformation.||Normal expression of RUNX1 causes tumorsupressing effects.": [
    0.916114330291748,
    0.0666690394282341,
    0.01721658930182457
  ],
  "Consistent with these results, we identified recurrent somatic loss-of-function mutations in RUNX1 in human T-ALL.||Normal expression of RUNX1 causes tumorsupressing effects.": [
    0.23444540798664093,
    0.7610076665878296,
    0.004546962212771177
  ],
  "Overall, these results place TLX1 and TLX3 at the top of an oncogenic transcriptional network controlling leukemia development, show the power of network analyses to identify key elements in the regulatory circuits governing human cancer and identify RUNX1 as a tumor-suppressor gene in T-ALL.||Normal expression of RUNX1 causes tumorsupressing effects.": [
    0.8431035280227661,
    0.12959185242652893,
    0.02730461396276951
  ],
  "The TLX1 and TLX3 transcription factor oncogenes have a key role in the pathogenesis of T cell acute lymphoblastic leukemia (T-ALL).||RUNX1 is downregulated or mutated in TLX1 T-ALL.": [
    0.13981996476650238,
    0.83046954870224,
    0.029710453003644943
  ],
  "Here we used reverse engineering of global transcriptional networks to decipher the oncogenic regulatory circuit controlled by TLX1 and TLX3.||RUNX1 is downregulated or mutated in TLX1 T-ALL.": [
    0.20742449164390564,
    0.7773957252502441,
    0.015179810114204884
  ],
  "This systems biology analysis defined T cell leukemia homeobox 1 (TLX1) and TLX3 as master regulators of an oncogenic transcriptional circuit governing T-ALL.||RUNX1 is downregulated or mutated in TLX1 T-ALL.": [
    0.04432278499007225,
    0.9323976039886475,
    0.023279573768377304
  ],
  "Notably, a network structure analysis of this hierarchical network identified RUNX1 as a key mediator of the T-ALL induced by TLX1 and TLX3 and predicted a tumor-suppressor role for RUNX1 in T cell transformation.||RUNX1 is downregulated or mutated in TLX1 T-ALL.": [
    0.8968004584312439,
    0.0956517681479454,
    0.007547779940068722
  ],
  "Consistent with these results, we identified recurrent somatic loss-of-function mutations in RUNX1 in human T-ALL.||RUNX1 is downregulated or mutated in TLX1 T-ALL.": [
    0.0036011580377817154,
    0.09853313118219376,
    0.8978657722473145
  ],
  "Overall, these results place TLX1 and TLX3 at the top of an oncogenic transcriptional network controlling leukemia development, show the power of network analyses to identify key elements in the regulatory circuits governing human cancer and identify RUNX1 as a tumor-suppressor gene in T-ALL.||RUNX1 is downregulated or mutated in TLX1 T-ALL.": [
    0.7834845185279846,
    0.19330787658691406,
    0.023207644000649452
  ],
  "The TLX1 and TLX3 transcription factor oncogenes have a key role in the pathogenesis of T cell acute lymphoblastic leukemia (T-ALL).||Normal expression of RUNX1 has tumor-promoting effects.": [
    0.01792953722178936,
    0.47588393092155457,
    0.5061865448951721
  ],
  "Here we used reverse engineering of global transcriptional networks to decipher the oncogenic regulatory circuit controlled by TLX1 and TLX3.||Normal expression of RUNX1 has tumor-promoting effects.": [
    0.1644071489572525,
    0.5530036687850952,
    0.28258922696113586
  ],
  "This systems biology analysis defined T cell leukemia homeobox 1 (TLX1) and TLX3 as master regulators of an oncogenic transcriptional circuit governing T-ALL.||Normal expression of RUNX1 has tumor-promoting effects.": [
    0.0041408599354326725,
    0.3827509582042694,
    0.6131081581115723
  ],
  "Notably, a network structure analysis of this hierarchical network identified RUNX1 as a key mediator of the T-ALL induced by TLX1 and TLX3 and predicted a tumor-suppressor role for RUNX1 in T cell transformation.||Normal expression of RUNX1 has tumor-promoting effects.": [
    0.9961889386177063,
    0.003122210269793868,
    0.0006888746866025031
  ],
  "Consistent with these results, we identified recurrent somatic loss-of-function mutations in RUNX1 in human T-ALL.||Normal expression of RUNX1 has tumor-promoting effects.": [
    0.5764603018760681,
    0.4173652231693268,
    0.006174408830702305
  ],
  "Overall, these results place TLX1 and TLX3 at the top of an oncogenic transcriptional network controlling leukemia development, show the power of network analyses to identify key elements in the regulatory circuits governing human cancer and identify RUNX1 as a tumor-suppressor gene in T-ALL.||Normal expression of RUNX1 has tumor-promoting effects.": [
    0.9894288182258606,
    0.009309260174632072,
    0.0012619257904589176
  ],
  "BACKGROUND The main associations of body-mass index (BMI) with overall and cause-specific mortality can best be assessed by long-term prospective follow-up of large numbers of people.||Obesity decreases life quality.": [
    0.0032935799099504948,
    0.7375243902206421,
    0.25918203592300415
  ],
  "The Prospective Studies Collaboration aimed to investigate these associations by sharing data from many studies.   \n||Obesity decreases life quality.": [
    0.02317637950181961,
    0.8899794220924377,
    0.08684419095516205
  ],
  "METHODS Collaborative analyses were undertaken of baseline BMI versus mortality in 57 prospective studies with 894 576 participants, mostly in western Europe and North America (61% [n=541 452] male, mean recruitment age 46 [SD 11] years, median recruitment year 1979 [IQR 1975-85], mean BMI 25 [SD 4] kg/m(2)).||Obesity decreases life quality.": [
    0.003822985338047147,
    0.8101972341537476,
    0.18597978353500366
  ],
  "The analyses were adjusted for age, sex, smoking status, and study.||Obesity decreases life quality.": [
    0.009775570593774319,
    0.8748849630355835,
    0.11533944308757782
  ],
  "To limit reverse causality, the first 5 years of follow-up were excluded, leaving 66 552 deaths of known cause during a mean of 8 (SD 6) further years of follow-up (mean age at death 67 [SD 10] years): 30 416 vascular; 2070 diabetic, renal or hepatic; 22 592 neoplastic; 3770 respiratory; 7704 other.   \n||Obesity decreases life quality.": [
    0.004550552926957607,
    0.9512996673583984,
    0.0441497303545475
  ],
  "FINDINGS In both sexes, mortality was lowest at about 22.5-25 kg/m(2).||Obesity decreases life quality.": [
    0.02883218787610531,
    0.9441872239112854,
    0.02698056772351265
  ],
  "Above this range, positive associations were recorded for several specific causes and inverse associations for none, the absolute excess risks for higher BMI and smoking were roughly additive, and each 5 kg/m(2) higher BMI was on average associated with about 30% higher overall mortality (hazard ratio per 5 kg/m(2) [HR] 1.29 [95% CI 1.27-1.32]): 40% for vascular mortality (HR 1.41 [1.37-1.45]); 60-120% for diabetic, renal, and hepatic mortality (HRs 2.16 [1.89-2.46], 1.59 [1.27-1.99], and 1.82 [1.59-2.09], respectively); 10% for neoplastic mortality (HR 1.10 [1.06-1.15]); and 20% for respiratory and for all other mortality (HRs 1.20 [1.07-1.34] and 1.20 [1.16-1.25], respectively).||Obesity decreases life quality.": [
    0.003631506348028779,
    0.6538538932800293,
    0.3425145447254181
  ],
  "Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer.||Obesity decreases life quality.": [
    0.11691104620695114,
    0.7915976643562317,
    0.09149132668972015
  ],
  "These inverse associations were much stronger for smokers than for non-smokers, despite cigarette consumption per smoker varying little with BMI.   \n||Obesity decreases life quality.": [
    0.00730590894818306,
    0.9704082608222961,
    0.02228585071861744
  ],
  "INTERPRETATION Although other anthropometric measures (eg, waist circumference, waist-to-hip ratio) could well add extra information to BMI, and BMI to them, BMI is in itself a strong predictor of overall mortality both above and below the apparent optimum of about 22.5-25 kg/m(2).||Obesity decreases life quality.": [
    0.0023810977581888437,
    0.4624217748641968,
    0.5351971387863159
  ],
  "The progressive excess mortality above this range is due mainly to vascular disease and is probably largely causal.||Obesity decreases life quality.": [
    0.0030778672080487013,
    0.7846077084541321,
    0.2123144567012787
  ],
  "At 30-35 kg/m(2), median survival is reduced by 2-4 years; at 40-45 kg/m(2), it is reduced by 8-10 years (which is comparable with the effects of smoking).||Obesity decreases life quality.": [
    0.002266911556944251,
    0.5639726519584656,
    0.43376049399375916
  ],
  "The definite excess mortality below 22.5 kg/m(2) is due mainly to smoking-related diseases, and is not fully explained.||Obesity decreases life quality.": [
    0.0028421843890100718,
    0.5841073989868164,
    0.4130503833293915
  ],
  "BACKGROUND The main associations of body-mass index (BMI) with overall and cause-specific mortality can best be assessed by long-term prospective follow-up of large numbers of people.||Obesity raises life quality.": [
    0.9583655595779419,
    0.03825462609529495,
    0.003379801055416465
  ],
  "The Prospective Studies Collaboration aimed to investigate these associations by sharing data from many studies.   \n||Obesity raises life quality.": [
    0.6279028058052063,
    0.3639160990715027,
    0.008181151933968067
  ],
  "METHODS Collaborative analyses were undertaken of baseline BMI versus mortality in 57 prospective studies with 894 576 participants, mostly in western Europe and North America (61% [n=541 452] male, mean recruitment age 46 [SD 11] years, median recruitment year 1979 [IQR 1975-85], mean BMI 25 [SD 4] kg/m(2)).||Obesity raises life quality.": [
    0.6861135363578796,
    0.30576565861701965,
    0.008120798505842686
  ],
  "The analyses were adjusted for age, sex, smoking status, and study.||Obesity raises life quality.": [
    0.7182495594024658,
    0.2719355523586273,
    0.009814905002713203
  ],
  "To limit reverse causality, the first 5 years of follow-up were excluded, leaving 66 552 deaths of known cause during a mean of 8 (SD 6) further years of follow-up (mean age at death 67 [SD 10] years): 30 416 vascular; 2070 diabetic, renal or hepatic; 22 592 neoplastic; 3770 respiratory; 7704 other.   \n||Obesity raises life quality.": [
    0.6654318571090698,
    0.32211044430732727,
    0.012457696720957756
  ],
  "FINDINGS In both sexes, mortality was lowest at about 22.5-25 kg/m(2).||Obesity raises life quality.": [
    0.5206702351570129,
    0.4657999873161316,
    0.013529801741242409
  ],
  "Above this range, positive associations were recorded for several specific causes and inverse associations for none, the absolute excess risks for higher BMI and smoking were roughly additive, and each 5 kg/m(2) higher BMI was on average associated with about 30% higher overall mortality (hazard ratio per 5 kg/m(2) [HR] 1.29 [95% CI 1.27-1.32]): 40% for vascular mortality (HR 1.41 [1.37-1.45]); 60-120% for diabetic, renal, and hepatic mortality (HRs 2.16 [1.89-2.46], 1.59 [1.27-1.99], and 1.82 [1.59-2.09], respectively); 10% for neoplastic mortality (HR 1.10 [1.06-1.15]); and 20% for respiratory and for all other mortality (HRs 1.20 [1.07-1.34] and 1.20 [1.16-1.25], respectively).||Obesity raises life quality.": [
    0.9434679746627808,
    0.04939776286482811,
    0.00713421031832695
  ],
  "Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer.||Obesity raises life quality.": [
    0.403787225484848,
    0.5253753662109375,
    0.07083733379840851
  ],
  "These inverse associations were much stronger for smokers than for non-smokers, despite cigarette consumption per smoker varying little with BMI.   \n||Obesity raises life quality.": [
    0.4601123332977295,
    0.5344648957252502,
    0.005422757938504219
  ],
  "INTERPRETATION Although other anthropometric measures (eg, waist circumference, waist-to-hip ratio) could well add extra information to BMI, and BMI to them, BMI is in itself a strong predictor of overall mortality both above and below the apparent optimum of about 22.5-25 kg/m(2).||Obesity raises life quality.": [
    0.995376706123352,
    0.0037115043960511684,
    0.000911820912733674
  ],
  "The progressive excess mortality above this range is due mainly to vascular disease and is probably largely causal.||Obesity raises life quality.": [
    0.8049969673156738,
    0.18303123116493225,
    0.011971780098974705
  ],
  "At 30-35 kg/m(2), median survival is reduced by 2-4 years; at 40-45 kg/m(2), it is reduced by 8-10 years (which is comparable with the effects of smoking).||Obesity raises life quality.": [
    0.9807683825492859,
    0.015819914638996124,
    0.003411761252209544
  ],
  "The definite excess mortality below 22.5 kg/m(2) is due mainly to smoking-related diseases, and is not fully explained.||Obesity raises life quality.": [
    0.8971379995346069,
    0.09430170804262161,
    0.008560292422771454
  ],
  "Synaptic long-term potentiation (LTP) at spinal neurons directly communicating pain-specific inputs from the periphery to the brain has been proposed to serve as a trigger for pain hypersensitivity in pathological states.||PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.22034181654453278,
    0.771500825881958,
    0.008157329633831978
  ],
  "Previous studies have functionally implicated the NMDA receptor-NO pathway and the downstream second messenger, cGMP, in these processes.||PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.3536287248134613,
    0.5669913291931152,
    0.07937993854284286
  ],
  "Because cGMP can broadly influence diverse ion-channels, kinases, and phosphodiesterases, pre- as well as post-synaptically, the precise identity of cGMP targets mediating spinal LTP, their mechanisms of action, and their locus in the spinal circuitry are still unclear.||PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.4704947769641876,
    0.4721742868423462,
    0.057330939918756485
  ],
  "Here, we found that Protein Kinase G1 (PKG-I) localized presynaptically in nociceptor terminals plays an essential role in the expression of spinal LTP.||PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.26359039545059204,
    0.7320655584335327,
    0.004344083368778229
  ],
  "Using the Cre-lox P system, we generated nociceptor-specific knockout mice lacking PKG-I specifically in presynaptic terminals of nociceptors in the spinal cord, but not in post-synaptic neurons or elsewhere (SNS-PKG-I(-/-) mice).||PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.09828674793243408,
    0.7670075297355652,
    0.13470570743083954
  ],
  "Patch clamp recordings showed that activity-induced LTP at identified synapses between nociceptors and spinal neurons projecting to the periaqueductal grey (PAG) was completely abolished in SNS-PKG-I(-/-) mice, although basal synaptic transmission was not affected.||PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.43001148104667664,
    0.4680279791355133,
    0.10196059942245483
  ],
  "Analyses of synaptic failure rates and paired-pulse ratios indicated a role for presynaptic PKG-I in regulating the probability of neurotransmitter release.||PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.3380002975463867,
    0.652642548084259,
    0.00935710035264492
  ],
  "Inositol 1,4,5-triphosphate receptor 1 and myosin light chain kinase were recruited as key phosphorylation targets of presynaptic PKG-I in nociceptive neurons.||PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.3952651619911194,
    0.5805040597915649,
    0.024230727925896645
  ],
  "Finally, behavioural analyses in vivo showed marked defects in SNS-PKG-I(-/-) mice in several models of activity-induced nociceptive hypersensitivity, and pharmacological studies identified a clear contribution of PKG-I expressed in spinal terminals of nociceptors.||PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.1747862696647644,
    0.8132827877998352,
    0.011930950917303562
  ],
  "Our results thus indicate that presynaptic mechanisms involving an increase in release probability from nociceptors are operational in the expression of synaptic LTP on spinal-PAG projection neurons and that PKG-I localized in presynaptic nociceptor terminals plays an essential role in this process to regulate pain sensitivity.||PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.3166678249835968,
    0.6788190603256226,
    0.004513062071055174
  ],
  "Synaptic long-term potentiation (LTP) at spinal neurons directly communicating pain-specific inputs from the periphery to the brain has been proposed to serve as a trigger for pain hypersensitivity in pathological states.||PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.21274253726005554,
    0.7718828916549683,
    0.01537457387894392
  ],
  "Previous studies have functionally implicated the NMDA receptor-NO pathway and the downstream second messenger, cGMP, in these processes.||PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.3541075885295868,
    0.572155237197876,
    0.07373718917369843
  ],
  "Because cGMP can broadly influence diverse ion-channels, kinases, and phosphodiesterases, pre- as well as post-synaptically, the precise identity of cGMP targets mediating spinal LTP, their mechanisms of action, and their locus in the spinal circuitry are still unclear.||PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.40799325704574585,
    0.544794499874115,
    0.04721224680542946
  ],
  "Here, we found that Protein Kinase G1 (PKG-I) localized presynaptically in nociceptor terminals plays an essential role in the expression of spinal LTP.||PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.1958470642566681,
    0.7976914644241333,
    0.0064614941366016865
  ],
  "Using the Cre-lox P system, we generated nociceptor-specific knockout mice lacking PKG-I specifically in presynaptic terminals of nociceptors in the spinal cord, but not in post-synaptic neurons or elsewhere (SNS-PKG-I(-/-) mice).||PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.06510157138109207,
    0.7165281772613525,
    0.21837028861045837
  ],
  "Patch clamp recordings showed that activity-induced LTP at identified synapses between nociceptors and spinal neurons projecting to the periaqueductal grey (PAG) was completely abolished in SNS-PKG-I(-/-) mice, although basal synaptic transmission was not affected.||PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.32100731134414673,
    0.5288457274436951,
    0.15014703571796417
  ],
  "Analyses of synaptic failure rates and paired-pulse ratios indicated a role for presynaptic PKG-I in regulating the probability of neurotransmitter release.||PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.3203307092189789,
    0.6681867837905884,
    0.01148255355656147
  ],
  "Inositol 1,4,5-triphosphate receptor 1 and myosin light chain kinase were recruited as key phosphorylation targets of presynaptic PKG-I in nociceptive neurons.||PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.25134044885635376,
    0.723588228225708,
    0.025071337819099426
  ],
  "Finally, behavioural analyses in vivo showed marked defects in SNS-PKG-I(-/-) mice in several models of activity-induced nociceptive hypersensitivity, and pharmacological studies identified a clear contribution of PKG-I expressed in spinal terminals of nociceptors.||PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.19655710458755493,
    0.7890146374702454,
    0.014428273774683475
  ],
  "Our results thus indicate that presynaptic mechanisms involving an increase in release probability from nociceptors are operational in the expression of synaptic LTP on spinal-PAG projection neurons and that PKG-I localized in presynaptic nociceptor terminals plays an essential role in this process to regulate pain sensitivity.||PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.3547664284706116,
    0.6407109498977661,
    0.004522617440670729
  ],
  "Synaptic long-term potentiation (LTP) at spinal neurons directly communicating pain-specific inputs from the periphery to the brain has been proposed to serve as a trigger for pain hypersensitivity in pathological states.||PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.18535511195659637,
    0.8057650327682495,
    0.008879810571670532
  ],
  "Previous studies have functionally implicated the NMDA receptor-NO pathway and the downstream second messenger, cGMP, in these processes.||PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.3085986375808716,
    0.6616118550300598,
    0.029789485037326813
  ],
  "Because cGMP can broadly influence diverse ion-channels, kinases, and phosphodiesterases, pre- as well as post-synaptically, the precise identity of cGMP targets mediating spinal LTP, their mechanisms of action, and their locus in the spinal circuitry are still unclear.||PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.6264684796333313,
    0.3512391149997711,
    0.02229241468012333
  ],
  "Here, we found that Protein Kinase G1 (PKG-I) localized presynaptically in nociceptor terminals plays an essential role in the expression of spinal LTP.||PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.8699018359184265,
    0.11186876893043518,
    0.018229350447654724
  ],
  "Using the Cre-lox P system, we generated nociceptor-specific knockout mice lacking PKG-I specifically in presynaptic terminals of nociceptors in the spinal cord, but not in post-synaptic neurons or elsewhere (SNS-PKG-I(-/-) mice).||PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.2958385646343231,
    0.6900460720062256,
    0.01411533635109663
  ],
  "Patch clamp recordings showed that activity-induced LTP at identified synapses between nociceptors and spinal neurons projecting to the periaqueductal grey (PAG) was completely abolished in SNS-PKG-I(-/-) mice, although basal synaptic transmission was not affected.||PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.6460790038108826,
    0.3184455931186676,
    0.03547539934515953
  ],
  "Analyses of synaptic failure rates and paired-pulse ratios indicated a role for presynaptic PKG-I in regulating the probability of neurotransmitter release.||PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.8282663822174072,
    0.1654909998178482,
    0.0062426915392279625
  ],
  "Inositol 1,4,5-triphosphate receptor 1 and myosin light chain kinase were recruited as key phosphorylation targets of presynaptic PKG-I in nociceptive neurons.||PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.8592839241027832,
    0.1300661414861679,
    0.010649941861629486
  ],
  "Finally, behavioural analyses in vivo showed marked defects in SNS-PKG-I(-/-) mice in several models of activity-induced nociceptive hypersensitivity, and pharmacological studies identified a clear contribution of PKG-I expressed in spinal terminals of nociceptors.||PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.6059515476226807,
    0.3795948028564453,
    0.014453659765422344
  ],
  "Our results thus indicate that presynaptic mechanisms involving an increase in release probability from nociceptors are operational in the expression of synaptic LTP on spinal-PAG projection neurons and that PKG-I localized in presynaptic nociceptor terminals plays an essential role in this process to regulate pain sensitivity.||PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.": [
    0.8824371099472046,
    0.10800119489431381,
    0.009561623446643353
  ],
  "Synaptic long-term potentiation (LTP) at spinal neurons directly communicating pain-specific inputs from the periphery to the brain has been proposed to serve as a trigger for pain hypersensitivity in pathological states.||PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.5262811779975891,
    0.4560440480709076,
    0.017674745991826057
  ],
  "Previous studies have functionally implicated the NMDA receptor-NO pathway and the downstream second messenger, cGMP, in these processes.||PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.37025436758995056,
    0.6106331944465637,
    0.019112443551421165
  ],
  "Because cGMP can broadly influence diverse ion-channels, kinases, and phosphodiesterases, pre- as well as post-synaptically, the precise identity of cGMP targets mediating spinal LTP, their mechanisms of action, and their locus in the spinal circuitry are still unclear.||PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.5620970129966736,
    0.40418416261672974,
    0.033718742430210114
  ],
  "Here, we found that Protein Kinase G1 (PKG-I) localized presynaptically in nociceptor terminals plays an essential role in the expression of spinal LTP.||PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.8795915842056274,
    0.11009331047534943,
    0.010315004736185074
  ],
  "Using the Cre-lox P system, we generated nociceptor-specific knockout mice lacking PKG-I specifically in presynaptic terminals of nociceptors in the spinal cord, but not in post-synaptic neurons or elsewhere (SNS-PKG-I(-/-) mice).||PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.3009761571884155,
    0.6902251243591309,
    0.008798744529485703
  ],
  "Patch clamp recordings showed that activity-induced LTP at identified synapses between nociceptors and spinal neurons projecting to the periaqueductal grey (PAG) was completely abolished in SNS-PKG-I(-/-) mice, although basal synaptic transmission was not affected.||PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.6318535208702087,
    0.34200984239578247,
    0.02613663859665394
  ],
  "Analyses of synaptic failure rates and paired-pulse ratios indicated a role for presynaptic PKG-I in regulating the probability of neurotransmitter release.||PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.8141732811927795,
    0.1812993437051773,
    0.004527400713413954
  ],
  "Inositol 1,4,5-triphosphate receptor 1 and myosin light chain kinase were recruited as key phosphorylation targets of presynaptic PKG-I in nociceptive neurons.||PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.8239709734916687,
    0.1671953797340393,
    0.008833710104227066
  ],
  "Finally, behavioural analyses in vivo showed marked defects in SNS-PKG-I(-/-) mice in several models of activity-induced nociceptive hypersensitivity, and pharmacological studies identified a clear contribution of PKG-I expressed in spinal terminals of nociceptors.||PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.5704191327095032,
    0.41701358556747437,
    0.012567304074764252
  ],
  "Our results thus indicate that presynaptic mechanisms involving an increase in release probability from nociceptors are operational in the expression of synaptic LTP on spinal-PAG projection neurons and that PKG-I localized in presynaptic nociceptor terminals plays an essential role in this process to regulate pain sensitivity.||PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.": [
    0.9001080989837646,
    0.09063165634870529,
    0.009260185062885284
  ],
  "Antigen-specific CD8+ T-cell tolerance, induced by myeloid-derived suppressor cells (MDSCs), is one of the main mechanisms of tumor escape.||Peroxynitrite is required for induction of T cell tolerance.": [
    0.289696604013443,
    0.7041109800338745,
    0.006192436441779137
  ],
  "Using in vivo models, we show here that MDSCs directly disrupt the binding of specific peptide\u2013major histocompatibility complex (pMHC) dimers to CD8-expressing T cells through nitration of tyrosines in a T-cell receptor (TCR)-CD8 complex.||Peroxynitrite is required for induction of T cell tolerance.": [
    0.4305112063884735,
    0.5388842225074768,
    0.03060455061495304
  ],
  "This process makes CD8-expressing T cells unable to bind pMHC and to respond to the specific peptide, although they retain their ability to respond to nonspecific stimulation.||Peroxynitrite is required for induction of T cell tolerance.": [
    0.37749260663986206,
    0.5541795492172241,
    0.0683279037475586
  ],
  "Nitration of TCR-CD8 is induced by MDSCs through hyperproduction of reactive oxygen species and peroxynitrite during direct cell-cell contact.||Peroxynitrite is required for induction of T cell tolerance.": [
    0.04731651395559311,
    0.8641108870506287,
    0.08857261389493942
  ],
  "Molecular modeling suggests specific sites of nitration that might affect the conformational flexibility of TCR-CD8 and its interaction with pMHC.||Peroxynitrite is required for induction of T cell tolerance.": [
    0.6013862490653992,
    0.38888978958129883,
    0.009723974391818047
  ],
  "These data identify a previously unknown mechanism of T-cell tolerance in cancer that is also pertinent to many pathological conditions associated with accumulation of MDSCs.||Peroxynitrite is required for induction of T cell tolerance.": [
    0.062378235161304474,
    0.9337722063064575,
    0.003849518485367298
  ],
  "Antigen-specific CD8+ T-cell tolerance, induced by myeloid-derived suppressor cells (MDSCs), is one of the main mechanisms of tumor escape.||NOX2-independent pathways can generate peroxynitrite by reacting with nitrogen intermediates.": [
    0.3502223789691925,
    0.5567600131034851,
    0.09301761537790298
  ],
  "Using in vivo models, we show here that MDSCs directly disrupt the binding of specific peptide\u2013major histocompatibility complex (pMHC) dimers to CD8-expressing T cells through nitration of tyrosines in a T-cell receptor (TCR)-CD8 complex.||NOX2-independent pathways can generate peroxynitrite by reacting with nitrogen intermediates.": [
    0.2619566321372986,
    0.5082499980926514,
    0.22979336977005005
  ],
  "This process makes CD8-expressing T cells unable to bind pMHC and to respond to the specific peptide, although they retain their ability to respond to nonspecific stimulation.||NOX2-independent pathways can generate peroxynitrite by reacting with nitrogen intermediates.": [
    0.3674582242965698,
    0.5109568238258362,
    0.12158500403165817
  ],
  "Nitration of TCR-CD8 is induced by MDSCs through hyperproduction of reactive oxygen species and peroxynitrite during direct cell-cell contact.||NOX2-independent pathways can generate peroxynitrite by reacting with nitrogen intermediates.": [
    0.26040810346603394,
    0.6449340581893921,
    0.09465781599283218
  ],
  "Molecular modeling suggests specific sites of nitration that might affect the conformational flexibility of TCR-CD8 and its interaction with pMHC.||NOX2-independent pathways can generate peroxynitrite by reacting with nitrogen intermediates.": [
    0.10538119822740555,
    0.7627821564674377,
    0.13183671236038208
  ],
  "These data identify a previously unknown mechanism of T-cell tolerance in cancer that is also pertinent to many pathological conditions associated with accumulation of MDSCs.||NOX2-independent pathways can generate peroxynitrite by reacting with nitrogen intermediates.": [
    0.09977538138628006,
    0.7782757878303528,
    0.12194887548685074
  ],
  "Antigen-specific CD8+ T-cell tolerance, induced by myeloid-derived suppressor cells (MDSCs), is one of the main mechanisms of tumor escape.||Peroxynitrite is required for nitration of TCR/CD8.": [
    0.17924189567565918,
    0.8126916289329529,
    0.008066454902291298
  ],
  "Using in vivo models, we show here that MDSCs directly disrupt the binding of specific peptide\u2013major histocompatibility complex (pMHC) dimers to CD8-expressing T cells through nitration of tyrosines in a T-cell receptor (TCR)-CD8 complex.||Peroxynitrite is required for nitration of TCR/CD8.": [
    0.19346283376216888,
    0.7999964952468872,
    0.006540645379573107
  ],
  "This process makes CD8-expressing T cells unable to bind pMHC and to respond to the specific peptide, although they retain their ability to respond to nonspecific stimulation.||Peroxynitrite is required for nitration of TCR/CD8.": [
    0.08481103181838989,
    0.8765908479690552,
    0.038598086684942245
  ],
  "Nitration of TCR-CD8 is induced by MDSCs through hyperproduction of reactive oxygen species and peroxynitrite during direct cell-cell contact.||Peroxynitrite is required for nitration of TCR/CD8.": [
    0.026397673413157463,
    0.37745073437690735,
    0.59615159034729
  ],
  "Molecular modeling suggests specific sites of nitration that might affect the conformational flexibility of TCR-CD8 and its interaction with pMHC.||Peroxynitrite is required for nitration of TCR/CD8.": [
    0.04496839642524719,
    0.9526529312133789,
    0.002378690056502819
  ],
  "These data identify a previously unknown mechanism of T-cell tolerance in cancer that is also pertinent to many pathological conditions associated with accumulation of MDSCs.||Peroxynitrite is required for nitration of TCR/CD8.": [
    0.3530087471008301,
    0.6058683395385742,
    0.0411229245364666
  ],
  "Paraneoplastic thrombocytosis is associated with many solid tumors and often correlates with reduced survival.||Pro-inflammatory cytokines are up repressed during tumor development.": [
    0.33269527554512024,
    0.6477603316307068,
    0.01954437606036663
  ],
  "Recent studies suggest that a pathogenic feed back loop may be operative between platelets and tumor cells, with reciprocal interactions between tumor growth/metastasis and thrombocytosis/platelet activation.||Pro-inflammatory cytokines are up repressed during tumor development.": [
    0.4569266140460968,
    0.5131018757820129,
    0.029971493408083916
  ],
  "Specific molecular pathways have been identified in which tumors can stimulate platelet production and activation; activated platelets can, in turn, promote tumor growth and metastasis.||Pro-inflammatory cytokines are up repressed during tumor development.": [
    0.8653908967971802,
    0.11264457553625107,
    0.02196456305682659
  ],
  "Taken together, these findings provide exciting new potential targets for therapeutic intervention.||Pro-inflammatory cytokines are up repressed during tumor development.": [
    0.29483675956726074,
    0.6617488861083984,
    0.04341433569788933
  ],
  "Paraneoplastic thrombocytosis is associated with many solid tumors and often correlates with reduced survival.||Tumor development occurs in conjunction with suppression of pro-inflammatory cytokines.": [
    0.29136306047439575,
    0.6816325783729553,
    0.027004322037100792
  ],
  "Recent studies suggest that a pathogenic feed back loop may be operative between platelets and tumor cells, with reciprocal interactions between tumor growth/metastasis and thrombocytosis/platelet activation.||Tumor development occurs in conjunction with suppression of pro-inflammatory cytokines.": [
    0.2625514566898346,
    0.3394734263420105,
    0.3979750871658325
  ],
  "Specific molecular pathways have been identified in which tumors can stimulate platelet production and activation; activated platelets can, in turn, promote tumor growth and metastasis.||Tumor development occurs in conjunction with suppression of pro-inflammatory cytokines.": [
    0.8133163452148438,
    0.15522295236587524,
    0.03146063908934593
  ],
  "Taken together, these findings provide exciting new potential targets for therapeutic intervention.||Tumor development occurs in conjunction with suppression of pro-inflammatory cytokines.": [
    0.711098849773407,
    0.2731693387031555,
    0.0157318115234375
  ],
  "Paraneoplastic thrombocytosis is associated with many solid tumors and often correlates with reduced survival.||Tumor development occurs in conjunction with upregulation of pro-inflammatory cytokines.": [
    0.0178547203540802,
    0.8979091048240662,
    0.08423622697591782
  ],
  "Recent studies suggest that a pathogenic feed back loop may be operative between platelets and tumor cells, with reciprocal interactions between tumor growth/metastasis and thrombocytosis/platelet activation.||Tumor development occurs in conjunction with upregulation of pro-inflammatory cytokines.": [
    0.1461358517408371,
    0.5444077253341675,
    0.30945637822151184
  ],
  "Specific molecular pathways have been identified in which tumors can stimulate platelet production and activation; activated platelets can, in turn, promote tumor growth and metastasis.||Tumor development occurs in conjunction with upregulation of pro-inflammatory cytokines.": [
    0.06743151694536209,
    0.31510746479034424,
    0.6174610257148743
  ],
  "Taken together, these findings provide exciting new potential targets for therapeutic intervention.||Tumor development occurs in conjunction with upregulation of pro-inflammatory cytokines.": [
    0.07310599833726883,
    0.8218894600868225,
    0.10500457882881165
  ],
  "G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.||Pyridostatin decreases telomere fragility in BRCA2-deficient cells.": [
    0.07042048871517181,
    0.9264945983886719,
    0.003084939904510975
  ],
  "Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.||Pyridostatin decreases telomere fragility in BRCA2-deficient cells.": [
    0.1507510244846344,
    0.7851499319076538,
    0.06409908086061478
  ],
  "We have previously shown that HR facilitates telomere replication.||Pyridostatin decreases telomere fragility in BRCA2-deficient cells.": [
    0.32570138573646545,
    0.6322446465492249,
    0.04205397889018059
  ],
  "Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.||Pyridostatin decreases telomere fragility in BRCA2-deficient cells.": [
    0.37811172008514404,
    0.5507033467292786,
    0.0711849257349968
  ],
  "Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.||Pyridostatin decreases telomere fragility in BRCA2-deficient cells.": [
    0.997670590877533,
    0.0012466582702472806,
    0.001082763192243874
  ],
  "Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.||Pyridostatin decreases telomere fragility in BRCA2-deficient cells.": [
    0.4306216239929199,
    0.5545415282249451,
    0.014836860820651054
  ],
  "PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.||Pyridostatin decreases telomere fragility in BRCA2-deficient cells.": [
    0.7202441096305847,
    0.25472137331962585,
    0.025034457445144653
  ],
  "Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.||Pyridostatin decreases telomere fragility in BRCA2-deficient cells.": [
    0.06001218780875206,
    0.8624828457832336,
    0.07750497758388519
  ],
  "G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.||Pyridostatin deregulates G2/M progression.": [
    0.27716943621635437,
    0.717202365398407,
    0.005628171842545271
  ],
  "Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.||Pyridostatin deregulates G2/M progression.": [
    0.5757094025611877,
    0.390077143907547,
    0.034213464707136154
  ],
  "We have previously shown that HR facilitates telomere replication.||Pyridostatin deregulates G2/M progression.": [
    0.7166685461997986,
    0.23534691333770752,
    0.04798456281423569
  ],
  "Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.||Pyridostatin deregulates G2/M progression.": [
    0.2712475657463074,
    0.6982964873313904,
    0.030455948784947395
  ],
  "Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.||Pyridostatin deregulates G2/M progression.": [
    0.6601743698120117,
    0.28928840160369873,
    0.05053724721074104
  ],
  "Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.||Pyridostatin deregulates G2/M progression.": [
    0.14334449172019958,
    0.6484699845314026,
    0.20818550884723663
  ],
  "PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.||Pyridostatin deregulates G2/M progression.": [
    0.564152717590332,
    0.3718232810497284,
    0.06402398645877838
  ],
  "Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.||Pyridostatin deregulates G2/M progression.": [
    0.18294885754585266,
    0.7971185445785522,
    0.019932560622692108
  ],
  "G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.||Pyridostatin encourages proliferation of homologous recombination - defective cells.": [
    0.7772669196128845,
    0.21719950437545776,
    0.005533603951334953
  ],
  "Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.||Pyridostatin encourages proliferation of homologous recombination - defective cells.": [
    0.7573915719985962,
    0.23720626533031464,
    0.005402139388024807
  ],
  "We have previously shown that HR facilitates telomere replication.||Pyridostatin encourages proliferation of homologous recombination - defective cells.": [
    0.9378604292869568,
    0.05906737595796585,
    0.0030722394585609436
  ],
  "Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.||Pyridostatin encourages proliferation of homologous recombination - defective cells.": [
    0.567662239074707,
    0.4148663580417633,
    0.01747138611972332
  ],
  "Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.||Pyridostatin encourages proliferation of homologous recombination - defective cells.": [
    0.5793244242668152,
    0.34321558475494385,
    0.07745996117591858
  ],
  "Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.||Pyridostatin encourages proliferation of homologous recombination - defective cells.": [
    0.9570053219795227,
    0.04032383859157562,
    0.0026708210352808237
  ],
  "PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.||Pyridostatin encourages proliferation of homologous recombination - defective cells.": [
    0.5480616092681885,
    0.3800477981567383,
    0.07189059257507324
  ],
  "Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.||Pyridostatin encourages proliferation of homologous recombination - defective cells.": [
    0.9570281505584717,
    0.03920578956604004,
    0.003766121808439493
  ],
  "G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.||Pyridostatin induces checkpoint activation.": [
    0.2898918390274048,
    0.5670642256736755,
    0.14304392039775848
  ],
  "Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.||Pyridostatin induces checkpoint activation.": [
    0.4734326899051666,
    0.4210412800312042,
    0.10552596300840378
  ],
  "We have previously shown that HR facilitates telomere replication.||Pyridostatin induces checkpoint activation.": [
    0.6678870320320129,
    0.260334312915802,
    0.07177860289812088
  ],
  "Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.||Pyridostatin induces checkpoint activation.": [
    0.279556542634964,
    0.5463466048240662,
    0.17409682273864746
  ],
  "Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.||Pyridostatin induces checkpoint activation.": [
    0.6113349199295044,
    0.35001927614212036,
    0.03864573314785957
  ],
  "Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.||Pyridostatin induces checkpoint activation.": [
    0.4367712736129761,
    0.37055814266204834,
    0.19267062842845917
  ],
  "PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.||Pyridostatin induces checkpoint activation.": [
    0.799343466758728,
    0.1755882203578949,
    0.02506830543279648
  ],
  "Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.||Pyridostatin induces checkpoint activation.": [
    0.1773194521665573,
    0.7890517711639404,
    0.033628784120082855
  ],
  "G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.||Pyridostatin induces double-strand breaks accumulation.": [
    0.47114813327789307,
    0.49255871772766113,
    0.03629326447844505
  ],
  "Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.||Pyridostatin induces double-strand breaks accumulation.": [
    0.7791931629180908,
    0.21276342868804932,
    0.008043329231441021
  ],
  "We have previously shown that HR facilitates telomere replication.||Pyridostatin induces double-strand breaks accumulation.": [
    0.8010560870170593,
    0.18314726650714874,
    0.015796639025211334
  ],
  "Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.||Pyridostatin induces double-strand breaks accumulation.": [
    0.44347554445266724,
    0.49367648363113403,
    0.06284797936677933
  ],
  "Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.||Pyridostatin induces double-strand breaks accumulation.": [
    0.503451943397522,
    0.42059919238090515,
    0.07594887912273407
  ],
  "Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.||Pyridostatin induces double-strand breaks accumulation.": [
    0.4867822825908661,
    0.4163086414337158,
    0.09690910577774048
  ],
  "PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.||Pyridostatin induces double-strand breaks accumulation.": [
    0.3671756684780121,
    0.5104215145111084,
    0.12240279465913773
  ],
  "Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.||Pyridostatin induces double-strand breaks accumulation.": [
    0.5505791306495667,
    0.42892441153526306,
    0.020496437326073647
  ],
  "G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.||Pyridostatin prevents double-strand breaks accumulation.": [
    0.39191991090774536,
    0.5648400783538818,
    0.04324006289243698
  ],
  "Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.||Pyridostatin prevents double-strand breaks accumulation.": [
    0.5110106468200684,
    0.47105672955513,
    0.017932631075382233
  ],
  "We have previously shown that HR facilitates telomere replication.||Pyridostatin prevents double-strand breaks accumulation.": [
    0.5885085463523865,
    0.3791923522949219,
    0.03229903429746628
  ],
  "Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.||Pyridostatin prevents double-strand breaks accumulation.": [
    0.4005047380924225,
    0.5201988220214844,
    0.07929643988609314
  ],
  "Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.||Pyridostatin prevents double-strand breaks accumulation.": [
    0.35505959391593933,
    0.5722532868385315,
    0.07268711924552917
  ],
  "Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.||Pyridostatin prevents double-strand breaks accumulation.": [
    0.5565882921218872,
    0.3871900737285614,
    0.056221604347229004
  ],
  "PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.||Pyridostatin prevents double-strand breaks accumulation.": [
    0.7361912727355957,
    0.23894904553890228,
    0.02485969103872776
  ],
  "Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.||Pyridostatin prevents double-strand breaks accumulation.": [
    0.11809220165014267,
    0.8553038239479065,
    0.02660396136343479
  ],
  "G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.||Pyridostatin reduces proliferation of homologous recombination - defective cells.": [
    0.11273251473903656,
    0.8385821580886841,
    0.04868536442518234
  ],
  "Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.||Pyridostatin reduces proliferation of homologous recombination - defective cells.": [
    0.7057454586029053,
    0.2862965166568756,
    0.007957961410284042
  ],
  "We have previously shown that HR facilitates telomere replication.||Pyridostatin reduces proliferation of homologous recombination - defective cells.": [
    0.4617694616317749,
    0.5107996463775635,
    0.02743092179298401
  ],
  "Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.||Pyridostatin reduces proliferation of homologous recombination - defective cells.": [
    0.19010670483112335,
    0.6697068214416504,
    0.14018651843070984
  ],
  "Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.||Pyridostatin reduces proliferation of homologous recombination - defective cells.": [
    0.5485119223594666,
    0.4004323184490204,
    0.05105578526854515
  ],
  "Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.||Pyridostatin reduces proliferation of homologous recombination - defective cells.": [
    0.7822891473770142,
    0.19198985397815704,
    0.025720953941345215
  ],
  "PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.||Pyridostatin reduces proliferation of homologous recombination - defective cells.": [
    0.4061141610145569,
    0.5270615816116333,
    0.06682422012090683
  ],
  "Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.||Pyridostatin reduces proliferation of homologous recombination - defective cells.": [
    0.014743083156645298,
    0.9545104503631592,
    0.030746500939130783
  ],
  "G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.||Pyridostatin stabilizes the G - quadruplex in the telomeric region.": [
    0.05675734952092171,
    0.9400344491004944,
    0.003208209527656436
  ],
  "Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.||Pyridostatin stabilizes the G - quadruplex in the telomeric region.": [
    0.5717505812644958,
    0.40683311223983765,
    0.021416332572698593
  ],
  "We have previously shown that HR facilitates telomere replication.||Pyridostatin stabilizes the G - quadruplex in the telomeric region.": [
    0.5067619681358337,
    0.44516536593437195,
    0.04807266220450401
  ],
  "Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.||Pyridostatin stabilizes the G - quadruplex in the telomeric region.": [
    0.18355070054531097,
    0.8046161532402039,
    0.011833125725388527
  ],
  "Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.||Pyridostatin stabilizes the G - quadruplex in the telomeric region.": [
    0.028363971039652824,
    0.4206853210926056,
    0.5509507060050964
  ],
  "Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.||Pyridostatin stabilizes the G - quadruplex in the telomeric region.": [
    0.40265020728111267,
    0.565705418586731,
    0.03164441138505936
  ],
  "PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.||Pyridostatin stabilizes the G - quadruplex in the telomeric region.": [
    0.850630521774292,
    0.13717897236347198,
    0.012190471403300762
  ],
  "Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.||Pyridostatin stabilizes the G - quadruplex in the telomeric region.": [
    0.0030670014675706625,
    0.9955877065658569,
    0.0013452575076371431
  ],
  "G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.||Pyridostatin destabilizes the G - quadruplex in the telomeric region.": [
    0.31877169013023376,
    0.6774206161499023,
    0.0038076876662671566
  ],
  "Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.||Pyridostatin destabilizes the G - quadruplex in the telomeric region.": [
    0.8776910901069641,
    0.11680439114570618,
    0.005504483822733164
  ],
  "We have previously shown that HR facilitates telomere replication.||Pyridostatin destabilizes the G - quadruplex in the telomeric region.": [
    0.9186525940895081,
    0.07689686864614487,
    0.004450598731637001
  ],
  "Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.||Pyridostatin destabilizes the G - quadruplex in the telomeric region.": [
    0.36865586042404175,
    0.6241032481193542,
    0.007240848615765572
  ],
  "Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.||Pyridostatin destabilizes the G - quadruplex in the telomeric region.": [
    0.9890121221542358,
    0.006922481581568718,
    0.0040654283948242664
  ],
  "Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.||Pyridostatin destabilizes the G - quadruplex in the telomeric region.": [
    0.2405681014060974,
    0.7098442316055298,
    0.04958770424127579
  ],
  "PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.||Pyridostatin destabilizes the G - quadruplex in the telomeric region.": [
    0.15295642614364624,
    0.6935698390007019,
    0.15347369015216827
  ],
  "Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.||Pyridostatin destabilizes the G - quadruplex in the telomeric region.": [
    0.8096494078636169,
    0.1821560561656952,
    0.008194572292268276
  ],
  "The target of rapamycin (TOR) pathway is a major nutrient-sensing pathway that, when genetically downregulated, increases life span in evolutionarily diverse organisms including mammals.||Rapamycin delays aging in fruit flies.": [
    0.6146175265312195,
    0.368602454662323,
    0.016779975965619087
  ],
  "The central component of this pathway, TOR kinase, is the target of the inhibitory drug rapamycin, a highly specific and well-described drug approved for human use.||Rapamycin delays aging in fruit flies.": [
    0.027478333562612534,
    0.9674896001815796,
    0.005032065790146589
  ],
  "We show here that feeding rapamycin to adult Drosophila produces the life span extension seen in some TOR mutants.||Rapamycin delays aging in fruit flies.": [
    0.32540562748908997,
    0.2332748919725418,
    0.4413195550441742
  ],
  "Increase in life span by rapamycin was associated with increased resistance to both starvation and paraquat.||Rapamycin delays aging in fruit flies.": [
    0.011979201808571815,
    0.9416238069534302,
    0.04639703035354614
  ],
  "Analysis of the underlying mechanisms revealed that rapamycin increased longevity specifically through the TORC1 branch of the TOR pathway, through alterations to both autophagy and translation.||Rapamycin delays aging in fruit flies.": [
    0.022616934031248093,
    0.9583781361579895,
    0.019004996865987778
  ],
  "Rapamycin could increase life span of weak insulin/Igf signaling (IIS) pathway mutants and of flies with life span maximized by dietary restriction, indicating additional mechanisms.||Rapamycin delays aging in fruit flies.": [
    0.008880719542503357,
    0.9860257506370544,
    0.00509356614202261
  ],
  "The target of rapamycin (TOR) pathway is a major nutrient-sensing pathway that, when genetically downregulated, increases life span in evolutionarily diverse organisms including mammals.||Rapamycin increases the concentration of triacylglycerols in fruit flies.": [
    0.13270355761051178,
    0.8606130480766296,
    0.006683375686407089
  ],
  "The central component of this pathway, TOR kinase, is the target of the inhibitory drug rapamycin, a highly specific and well-described drug approved for human use.||Rapamycin increases the concentration of triacylglycerols in fruit flies.": [
    0.2581785321235657,
    0.7383384108543396,
    0.003483109176158905
  ],
  "We show here that feeding rapamycin to adult Drosophila produces the life span extension seen in some TOR mutants.||Rapamycin increases the concentration of triacylglycerols in fruit flies.": [
    0.23866882920265198,
    0.6338897347450256,
    0.12744148075580597
  ],
  "Increase in life span by rapamycin was associated with increased resistance to both starvation and paraquat.||Rapamycin increases the concentration of triacylglycerols in fruit flies.": [
    0.13495604693889618,
    0.8184453248977661,
    0.04659861698746681
  ],
  "Analysis of the underlying mechanisms revealed that rapamycin increased longevity specifically through the TORC1 branch of the TOR pathway, through alterations to both autophagy and translation.||Rapamycin increases the concentration of triacylglycerols in fruit flies.": [
    0.09103379398584366,
    0.869024932384491,
    0.03994126245379448
  ],
  "Rapamycin could increase life span of weak insulin/Igf signaling (IIS) pathway mutants and of flies with life span maximized by dietary restriction, indicating additional mechanisms.||Rapamycin increases the concentration of triacylglycerols in fruit flies.": [
    0.052676357328891754,
    0.9397841095924377,
    0.0075395493768155575
  ],
  "The target of rapamycin (TOR) pathway is a major nutrient-sensing pathway that, when genetically downregulated, increases life span in evolutionarily diverse organisms including mammals.||Rapamycin decreases the concentration of triacylglycerols in fruit flies.": [
    0.08443320542573929,
    0.9075210094451904,
    0.00804578885436058
  ],
  "The central component of this pathway, TOR kinase, is the target of the inhibitory drug rapamycin, a highly specific and well-described drug approved for human use.||Rapamycin decreases the concentration of triacylglycerols in fruit flies.": [
    0.007694001775234938,
    0.9893102645874023,
    0.002995788585394621
  ],
  "We show here that feeding rapamycin to adult Drosophila produces the life span extension seen in some TOR mutants.||Rapamycin decreases the concentration of triacylglycerols in fruit flies.": [
    0.22954684495925903,
    0.6704508066177368,
    0.10000231862068176
  ],
  "Increase in life span by rapamycin was associated with increased resistance to both starvation and paraquat.||Rapamycin decreases the concentration of triacylglycerols in fruit flies.": [
    0.10423734784126282,
    0.8458624482154846,
    0.049900226294994354
  ],
  "Analysis of the underlying mechanisms revealed that rapamycin increased longevity specifically through the TORC1 branch of the TOR pathway, through alterations to both autophagy and translation.||Rapamycin decreases the concentration of triacylglycerols in fruit flies.": [
    0.3066164553165436,
    0.6660304665565491,
    0.027353037148714066
  ],
  "Rapamycin could increase life span of weak insulin/Igf signaling (IIS) pathway mutants and of flies with life span maximized by dietary restriction, indicating additional mechanisms.||Rapamycin decreases the concentration of triacylglycerols in fruit flies.": [
    0.12853696942329407,
    0.8631425499916077,
    0.008320415392518044
  ],
  "Aberrant epigenetic reprogramming often results in developmental defects in somatic cell nuclear transfer (SCNT) embryos during embryonic genome activation (EGA).||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.": [
    0.027489451691508293,
    0.9562078714370728,
    0.01630271039903164
  ],
  "Bovine eight-cell SCNT embryos exhibit global hypermethylation of histone H3 lysine 9 tri- and di-methylation (H3K9me3/2), but the intrinsic reason for this remains elusive.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.": [
    0.052702222019433975,
    0.9423627853393555,
    0.004935021512210369
  ],
  "Here, we provide evidence that two H3K9 demethylase genes, lysine-specific demethylase 4D (KDM4D) and 4E (KDM4E), are related to active H3K9me3/2 demethylation in in vitro fertilized (IVF) embryos and are deficiently expressed in cloned embryos at the time of EGA.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.": [
    0.029240239411592484,
    0.9503881931304932,
    0.02037154696881771
  ],
  "Moreover, KDM4E plays a more crucial role in IVF and SCNT embryonic development, and overexpression of KDM4E can restore the global transcriptome, improve blastocyst formation and increase the cloning efficiency of SCNT embryos.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.": [
    0.4028771221637726,
    0.5912961959838867,
    0.005826715379953384
  ],
  "Our results thereby indicate that KDM4E can function as a crucial epigenetic regulator of EGA and as an internal defective factor responsible for persistent H3K9me3/2 barriers to SCNT-mediated reprogramming.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.": [
    0.06126467138528824,
    0.9263734221458435,
    0.012361855246126652
  ],
  "Furthermore, we show that interactions between RNA and KDM4E are essential for H3K9 demethylation during EGA.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.": [
    0.19331015646457672,
    0.7963083982467651,
    0.010381479747593403
  ],
  "These observations advance the understanding of incomplete nuclear reprogramming and are of great importance for transgenic cattle procreation.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.": [
    0.08127520233392715,
    0.9061058163642883,
    0.012619022279977798
  ],
  "Aberrant epigenetic reprogramming often results in developmental defects in somatic cell nuclear transfer (SCNT) embryos during embryonic genome activation (EGA).||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.": [
    0.05237070098519325,
    0.9455421566963196,
    0.002087182365357876
  ],
  "Bovine eight-cell SCNT embryos exhibit global hypermethylation of histone H3 lysine 9 tri- and di-methylation (H3K9me3/2), but the intrinsic reason for this remains elusive.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.": [
    0.043333977460861206,
    0.9548974633216858,
    0.0017686157952994108
  ],
  "Here, we provide evidence that two H3K9 demethylase genes, lysine-specific demethylase 4D (KDM4D) and 4E (KDM4E), are related to active H3K9me3/2 demethylation in in vitro fertilized (IVF) embryos and are deficiently expressed in cloned embryos at the time of EGA.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.": [
    0.013862041756510735,
    0.97540682554245,
    0.010731089860200882
  ],
  "Moreover, KDM4E plays a more crucial role in IVF and SCNT embryonic development, and overexpression of KDM4E can restore the global transcriptome, improve blastocyst formation and increase the cloning efficiency of SCNT embryos.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.": [
    0.01975543424487114,
    0.9064260721206665,
    0.07381848245859146
  ],
  "Our results thereby indicate that KDM4E can function as a crucial epigenetic regulator of EGA and as an internal defective factor responsible for persistent H3K9me3/2 barriers to SCNT-mediated reprogramming.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.": [
    0.025504620745778084,
    0.9726741313934326,
    0.0018212295835837722
  ],
  "Furthermore, we show that interactions between RNA and KDM4E are essential for H3K9 demethylation during EGA.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.": [
    0.010603329166769981,
    0.9699418544769287,
    0.019454818218946457
  ],
  "These observations advance the understanding of incomplete nuclear reprogramming and are of great importance for transgenic cattle procreation.||Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.": [
    0.00693530822172761,
    0.9857922196388245,
    0.007272480987012386
  ],
  "Aberrant epigenetic reprogramming often results in developmental defects in somatic cell nuclear transfer (SCNT) embryos during embryonic genome activation (EGA).||Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.": [
    0.036245107650756836,
    0.9620758891105652,
    0.0016789741348475218
  ],
  "Bovine eight-cell SCNT embryos exhibit global hypermethylation of histone H3 lysine 9 tri- and di-methylation (H3K9me3/2), but the intrinsic reason for this remains elusive.||Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.": [
    0.0735546201467514,
    0.9238858222961426,
    0.002559604123234749
  ],
  "Here, we provide evidence that two H3K9 demethylase genes, lysine-specific demethylase 4D (KDM4D) and 4E (KDM4E), are related to active H3K9me3/2 demethylation in in vitro fertilized (IVF) embryos and are deficiently expressed in cloned embryos at the time of EGA.||Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.": [
    0.040316443890333176,
    0.9497917294502258,
    0.009891818277537823
  ],
  "Moreover, KDM4E plays a more crucial role in IVF and SCNT embryonic development, and overexpression of KDM4E can restore the global transcriptome, improve blastocyst formation and increase the cloning efficiency of SCNT embryos.||Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.": [
    0.0598134808242321,
    0.9215941429138184,
    0.01859242096543312
  ],
  "Our results thereby indicate that KDM4E can function as a crucial epigenetic regulator of EGA and as an internal defective factor responsible for persistent H3K9me3/2 barriers to SCNT-mediated reprogramming.||Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.": [
    0.009514952078461647,
    0.9867644309997559,
    0.0037205980625003576
  ],
  "Furthermore, we show that interactions between RNA and KDM4E are essential for H3K9 demethylation during EGA.||Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.": [
    0.004663418512791395,
    0.9762998223304749,
    0.019036779180169106
  ],
  "These observations advance the understanding of incomplete nuclear reprogramming and are of great importance for transgenic cattle procreation.||Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.": [
    0.030097389593720436,
    0.9619317054748535,
    0.00797095987945795
  ],
  "BACKGROUND Transmission of dengue viruses (DENV), the leading cause of arboviral disease worldwide, is known to vary through time and space, likely owing to a combination of factors related to the human host, virus, mosquito vector, and environment.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.0015443179290741682,
    0.9974952936172485,
    0.0009604468941688538
  ],
  "An improved understanding of variation in transmission patterns is fundamental to conducting surveillance and implementing disease prevention strategies.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.006864206865429878,
    0.9914074540138245,
    0.0017283466877415776
  ],
  "To test the hypothesis that DENV transmission is spatially and temporally focal, we compared geographic and temporal characteristics within Thai villages where DENV are and are not being actively transmitted.   \n||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.01339652482420206,
    0.9792630076408386,
    0.007340473122894764
  ],
  "METHODS AND FINDINGS Cluster investigations were conducted within 100 m of homes where febrile index children with (positive clusters) and without (negative clusters) acute dengue lived during two seasons of peak DENV transmission.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.0015550056705251336,
    0.9964501857757568,
    0.001994810998439789
  ],
  "Data on human infection and mosquito infection/density were examined to precisely (1) define the spatial and temporal dimensions of DENV transmission, (2) correlate these factors with variation in DENV transmission, and (3) determine the burden of inapparent and symptomatic infections.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.011230174452066422,
    0.9790240526199341,
    0.009745785035192966
  ],
  "Among 556 village children enrolled as neighbors of 12 dengue-positive and 22 dengue-negative index cases, all 27 DENV infections (4.9% of enrollees) occurred in positive clusters (p < 0.01; attributable risk [AR] = 10.4 per 100; 95% confidence interval 1-19.8 per 100].||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.0017409530701115727,
    0.9962291121482849,
    0.002029954455792904
  ],
  "In positive clusters, 12.4% of enrollees became infected in a 15-d period and DENV infections were aggregated centrally near homes of index cases.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.002445672173053026,
    0.994358479976654,
    0.0031958993058651686
  ],
  "As only 1 of 217 pairs of serologic specimens tested in positive clusters revealed a recent DENV infection that occurred prior to cluster initiation, we attribute the observed DENV transmission subsequent to cluster investigation to recent DENV transmission activity.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.010459423065185547,
    0.9740724563598633,
    0.015468084253370762
  ],
  "Of the 1,022 female adult Ae.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.022828685119748116,
    0.6290284395217896,
    0.3481428921222687
  ],
  "aegypti collected, all eight (0.8%) dengue-infected mosquitoes came from houses in positive clusters; none from control clusters or schools.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.0016824482008814812,
    0.9968448877334595,
    0.0014726558001711965
  ],
  "Distinguishing features between positive and negative clusters were greater availability of piped water in negative clusters (p < 0.01) and greater number of Ae.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.031242696568369865,
    0.8535307049751282,
    0.11522659659385681
  ],
  "aegypti pupae per person in positive clusters (p = 0.04).||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.02200791984796524,
    0.7936710715293884,
    0.18432094156742096
  ],
  "During primarily DENV-4 transmission seasons, the ratio of inapparent to symptomatic infections was nearly 1:1 among child enrollees.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.004427996464073658,
    0.9935710430145264,
    0.002000942127779126
  ],
  "Study limitations included inability to sample all children and mosquitoes within each cluster and our reliance on serologic rather than virologic evidence of interval infections in enrollees given restrictions on the frequency of blood collections in children.   \n||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.008357892744243145,
    0.9764116406440735,
    0.015230495482683182
  ],
  "CONCLUSIONS Our data reveal the remarkably focal nature of DENV transmission within a hyperendemic rural area of Thailand.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.0024296496994793415,
    0.9943417310714722,
    0.003228637855499983
  ],
  "These data suggest that active school-based dengue case detection prompting local spraying could contain recent virus introductions and reduce the longitudinal risk of virus spread within rural areas.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.07597772777080536,
    0.9204608798027039,
    0.0035614483058452606
  ],
  "Our results should prompt future cluster studies to explore how host immune and behavioral aspects may impact DENV transmission and prevention strategies.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.011735920794308186,
    0.9852938055992126,
    0.002970305271446705
  ],
  "Cluster methodology could serve as a useful research tool for investigation of other temporally and spatially clustered infectious diseases.||Rising temperatures caused by global warming increases risk of dengue fever transmission.": [
    0.01677936129271984,
    0.9747979044914246,
    0.00842268206179142
  ],
  "BACKGROUND Transmission of dengue viruses (DENV), the leading cause of arboviral disease worldwide, is known to vary through time and space, likely owing to a combination of factors related to the human host, virus, mosquito vector, and environment.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.05202610418200493,
    0.9468480348587036,
    0.0011258432641625404
  ],
  "An improved understanding of variation in transmission patterns is fundamental to conducting surveillance and implementing disease prevention strategies.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.23949281871318817,
    0.757571816444397,
    0.0029353590216487646
  ],
  "To test the hypothesis that DENV transmission is spatially and temporally focal, we compared geographic and temporal characteristics within Thai villages where DENV are and are not being actively transmitted.   \n||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.27353477478027344,
    0.7230209112167358,
    0.0034443442709743977
  ],
  "METHODS AND FINDINGS Cluster investigations were conducted within 100 m of homes where febrile index children with (positive clusters) and without (negative clusters) acute dengue lived during two seasons of peak DENV transmission.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.12859167158603668,
    0.8693503141403198,
    0.0020580096170306206
  ],
  "Data on human infection and mosquito infection/density were examined to precisely (1) define the spatial and temporal dimensions of DENV transmission, (2) correlate these factors with variation in DENV transmission, and (3) determine the burden of inapparent and symptomatic infections.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.4323127567768097,
    0.5641903877258301,
    0.00349684851244092
  ],
  "Among 556 village children enrolled as neighbors of 12 dengue-positive and 22 dengue-negative index cases, all 27 DENV infections (4.9% of enrollees) occurred in positive clusters (p < 0.01; attributable risk [AR] = 10.4 per 100; 95% confidence interval 1-19.8 per 100].||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.32036805152893066,
    0.6766868829727173,
    0.0029450359288603067
  ],
  "In positive clusters, 12.4% of enrollees became infected in a 15-d period and DENV infections were aggregated centrally near homes of index cases.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.31805822253227234,
    0.6786431074142456,
    0.0032986896112561226
  ],
  "As only 1 of 217 pairs of serologic specimens tested in positive clusters revealed a recent DENV infection that occurred prior to cluster initiation, we attribute the observed DENV transmission subsequent to cluster investigation to recent DENV transmission activity.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.4842377007007599,
    0.5115137696266174,
    0.004248527344316244
  ],
  "Of the 1,022 female adult Ae.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.47536540031433105,
    0.44525715708732605,
    0.07937745749950409
  ],
  "aegypti collected, all eight (0.8%) dengue-infected mosquitoes came from houses in positive clusters; none from control clusters or schools.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.2720012962818146,
    0.7250035405158997,
    0.002995141549035907
  ],
  "Distinguishing features between positive and negative clusters were greater availability of piped water in negative clusters (p < 0.01) and greater number of Ae.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.6169484853744507,
    0.37176069617271423,
    0.011290788650512695
  ],
  "aegypti pupae per person in positive clusters (p = 0.04).||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.40625932812690735,
    0.5565673112869263,
    0.037173300981521606
  ],
  "During primarily DENV-4 transmission seasons, the ratio of inapparent to symptomatic infections was nearly 1:1 among child enrollees.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.23087891936302185,
    0.7668256759643555,
    0.002295438200235367
  ],
  "Study limitations included inability to sample all children and mosquitoes within each cluster and our reliance on serologic rather than virologic evidence of interval infections in enrollees given restrictions on the frequency of blood collections in children.   \n||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.3826013505458832,
    0.6118496656417847,
    0.005548956338316202
  ],
  "CONCLUSIONS Our data reveal the remarkably focal nature of DENV transmission within a hyperendemic rural area of Thailand.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.3234671950340271,
    0.6739845871925354,
    0.0025482000783085823
  ],
  "These data suggest that active school-based dengue case detection prompting local spraying could contain recent virus introductions and reduce the longitudinal risk of virus spread within rural areas.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.2805594801902771,
    0.7146144509315491,
    0.0048260996118187904
  ],
  "Our results should prompt future cluster studies to explore how host immune and behavioral aspects may impact DENV transmission and prevention strategies.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.34002935886383057,
    0.656926155090332,
    0.0030445046722888947
  ],
  "Cluster methodology could serve as a useful research tool for investigation of other temporally and spatially clustered infectious diseases.||Rising temperatures caused by global warming lowers the risk of dengue fever transmission.": [
    0.4189460277557373,
    0.5759027600288391,
    0.00515122851356864
  ],
  "BACKGROUND Transmission of dengue viruses (DENV), the leading cause of arboviral disease worldwide, is known to vary through time and space, likely owing to a combination of factors related to the human host, virus, mosquito vector, and environment.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.0017207203200086951,
    0.9961084723472595,
    0.0021708186250180006
  ],
  "An improved understanding of variation in transmission patterns is fundamental to conducting surveillance and implementing disease prevention strategies.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.0060316454619169235,
    0.9860821962356567,
    0.007886144332587719
  ],
  "To test the hypothesis that DENV transmission is spatially and temporally focal, we compared geographic and temporal characteristics within Thai villages where DENV are and are not being actively transmitted.   \n||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.04138021171092987,
    0.9243438243865967,
    0.03427590802311897
  ],
  "METHODS AND FINDINGS Cluster investigations were conducted within 100 m of homes where febrile index children with (positive clusters) and without (negative clusters) acute dengue lived during two seasons of peak DENV transmission.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.0034684438724070787,
    0.9353758692741394,
    0.06115570291876793
  ],
  "Data on human infection and mosquito infection/density were examined to precisely (1) define the spatial and temporal dimensions of DENV transmission, (2) correlate these factors with variation in DENV transmission, and (3) determine the burden of inapparent and symptomatic infections.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.02654675953090191,
    0.9058231711387634,
    0.06763006001710892
  ],
  "Among 556 village children enrolled as neighbors of 12 dengue-positive and 22 dengue-negative index cases, all 27 DENV infections (4.9% of enrollees) occurred in positive clusters (p < 0.01; attributable risk [AR] = 10.4 per 100; 95% confidence interval 1-19.8 per 100].||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.011475474573671818,
    0.8987851142883301,
    0.08973940461874008
  ],
  "In positive clusters, 12.4% of enrollees became infected in a 15-d period and DENV infections were aggregated centrally near homes of index cases.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.0027634394355118275,
    0.8481550812721252,
    0.14908146858215332
  ],
  "As only 1 of 217 pairs of serologic specimens tested in positive clusters revealed a recent DENV infection that occurred prior to cluster initiation, we attribute the observed DENV transmission subsequent to cluster investigation to recent DENV transmission activity.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.007913097739219666,
    0.9164074659347534,
    0.0756794661283493
  ],
  "Of the 1,022 female adult Ae.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.0586523562669754,
    0.6150884032249451,
    0.32625919580459595
  ],
  "aegypti collected, all eight (0.8%) dengue-infected mosquitoes came from houses in positive clusters; none from control clusters or schools.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.0026754974387586117,
    0.8198301792144775,
    0.1774943470954895
  ],
  "Distinguishing features between positive and negative clusters were greater availability of piped water in negative clusters (p < 0.01) and greater number of Ae.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.00555817736312747,
    0.9322144389152527,
    0.06222740188241005
  ],
  "aegypti pupae per person in positive clusters (p = 0.04).||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.03386107459664345,
    0.7773336172103882,
    0.18880526721477509
  ],
  "During primarily DENV-4 transmission seasons, the ratio of inapparent to symptomatic infections was nearly 1:1 among child enrollees.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.009521069005131721,
    0.9741911292076111,
    0.01628776639699936
  ],
  "Study limitations included inability to sample all children and mosquitoes within each cluster and our reliance on serologic rather than virologic evidence of interval infections in enrollees given restrictions on the frequency of blood collections in children.   \n||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.007431706879287958,
    0.9116814732551575,
    0.08088681101799011
  ],
  "CONCLUSIONS Our data reveal the remarkably focal nature of DENV transmission within a hyperendemic rural area of Thailand.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.7569848895072937,
    0.22828051447868347,
    0.014734608121216297
  ],
  "These data suggest that active school-based dengue case detection prompting local spraying could contain recent virus introductions and reduce the longitudinal risk of virus spread within rural areas.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.9333959817886353,
    0.05743339657783508,
    0.009170557372272015
  ],
  "Our results should prompt future cluster studies to explore how host immune and behavioral aspects may impact DENV transmission and prevention strategies.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.005723890848457813,
    0.9835303425788879,
    0.010745706968009472
  ],
  "Cluster methodology could serve as a useful research tool for investigation of other temporally and spatially clustered infectious diseases.||Urbanization is an important risk factor related to the transmission of dengue fever.": [
    0.006919198203831911,
    0.9832730293273926,
    0.009807746857404709
  ],
  "OBJECTIVES To investigate the association between antidepressant treatment and risk of several potential adverse outcomes in older people with depression and to examine risks by class of antidepressant, duration of use, and dose.   \n||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.5533650517463684,
    0.44252705574035645,
    0.0041078850626945496
  ],
  "DESIGN Cohort study of people aged 65 and over diagnosed as having depression.   \n||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.6625264286994934,
    0.33034664392471313,
    0.007126898970454931
  ],
  "SETTING 570 general practices in the United Kingdom supplying data to the QResearch primary care database.   \n||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.6505862474441528,
    0.32968243956565857,
    0.019731387495994568
  ],
  "PARTICIPANTS 60,746 patients diagnosed as having a new episode of depression between the ages of 65 and 100 years from 1 January 1996 to 31 December 2007 and followed up until 31 December 2008.   \n||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.7747777104377747,
    0.21887899935245514,
    0.006343328393995762
  ],
  "MAIN OUTCOME MEASURES Hazard ratios associated with antidepressant use for all cause mortality, attempted suicide/self harm, myocardial infarction, stroke/transient ischaemic attack, falls, fractures, upper gastrointestinal bleeding, epilepsy/seizures, road traffic accidents, adverse drug reactions, and hyponatraemia, adjusted for a range of potential confounding variables.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.7715891599655151,
    0.2254781574010849,
    0.0029326602816581726
  ],
  "Hazard ratios were calculated for antidepressant class (tricyclic and related antidepressants, selective serotonin reuptake inhibitors, other antidepressants), dose, and duration of use and for commonly prescribed individual drugs.   \n||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.6537114977836609,
    0.3419095575809479,
    0.00437889015302062
  ],
  "RESULTS 54,038 (89.0%) patients received at least one prescription for an antidepressant during follow-up.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.30772024393081665,
    0.6788532137870789,
    0.013426564633846283
  ],
  "A total of 1,398,359 antidepressant prescriptions were issued: 764,659 (54.7%) for selective serotonin reuptake inhibitors, 442,192 (31.6%) for tricyclic antidepressants, 2203 (0.2%) for monoamine oxidase inhibitors, and 189,305 (13.5%) for the group of other antidepressants.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.38876011967658997,
    0.5963801741600037,
    0.014859769493341446
  ],
  "The associations with the adverse outcomes differed significantly between the antidepressant classes for seven outcomes.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.29329049587249756,
    0.7028692364692688,
    0.003840304911136627
  ],
  "Selective serotonin reuptake inhibitors were associated with the highest adjusted hazard ratios for falls (1.66, 95% confidence interval 1.58 to 1.73) and hyponatraemia (1.52, 1.33 to 1.75) compared with when antidepressants were not being used.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.8277634978294373,
    0.1679656058549881,
    0.004270894918590784
  ],
  "The group of other antidepressants was associated with the highest adjusted hazard ratios for all cause mortality (1.66, 1.56 to 1.77), attempted suicide/self harm (5.16, 3.90 to 6.83), stroke/transient ischaemic attack (1.37, 1.22 to 1.55), fracture (1.64, 1.46 to 1.84), and epilepsy/seizures (2.24, 1.60 to 3.15), compared with when antidepressants were not being used.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.95103520154953,
    0.046609826385974884,
    0.0023549289908260107
  ],
  "Tricyclic antidepressants did not have the highest hazard ratio for any of the outcomes.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.005348446778953075,
    0.8582332730293274,
    0.13641828298568726
  ],
  "Significantly different associations also existed between the individual drugs for the same seven outcomes; trazodone (tricyclic antidepressant), mirtazapine, and venlafaxine (both in the group of other antidepressants) were associated with the highest rates for some of these outcomes.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.5790218114852905,
    0.41562098264694214,
    0.005357254296541214
  ],
  "Absolute risks over 1 year for all cause mortality were 7.04% for patients while not taking antidepressants, 8.12% for those taking tricyclic antidepressants, 10.61% for selective serotonin reuptake inhibitors, and 11.43% for other antidepressants.   \n||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.9236459732055664,
    0.07429131120443344,
    0.0020627512130886316
  ],
  "CONCLUSIONS Selective serotonin reuptake inhibitors and drugs in the group of other antidepressants were associated with an increased risk of several adverse outcomes compared with tricyclic antidepressants.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.3138120770454407,
    0.6816095113754272,
    0.004578359425067902
  ],
  "Among individual drugs, trazodone, mirtazapine, and venlafaxine were associated with the highest risks for some outcomes.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.8735906481742859,
    0.1239466592669487,
    0.002462729113176465
  ],
  "As this is an observational study, it is susceptible to confounding by indication, channelling bias, and residual confounding, so differences in characteristics between patients prescribed different antidepressant drugs that could account for some of the associations between the drugs and the adverse outcomes may remain.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.43309035897254944,
    0.5633987784385681,
    0.0035108423326164484
  ],
  "Further research is needed to confirm these findings, but the risks and benefits of different antidepressants should be carefully evaluated when these drugs are prescribed to older people.||Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.": [
    0.40203920006752014,
    0.5938108563423157,
    0.004149988759309053
  ],
  "OBJECTIVES To investigate the association between antidepressant treatment and risk of several potential adverse outcomes in older people with depression and to examine risks by class of antidepressant, duration of use, and dose.   \n||Side effects associated with antidepressants increases risk of stroke.": [
    0.005021163262426853,
    0.9936657547950745,
    0.001313089276663959
  ],
  "DESIGN Cohort study of people aged 65 and over diagnosed as having depression.   \n||Side effects associated with antidepressants increases risk of stroke.": [
    0.062011998146772385,
    0.9297016859054565,
    0.008286370895802975
  ],
  "SETTING 570 general practices in the United Kingdom supplying data to the QResearch primary care database.   \n||Side effects associated with antidepressants increases risk of stroke.": [
    0.0556727796792984,
    0.9004417657852173,
    0.04388546571135521
  ],
  "PARTICIPANTS 60,746 patients diagnosed as having a new episode of depression between the ages of 65 and 100 years from 1 January 1996 to 31 December 2007 and followed up until 31 December 2008.   \n||Side effects associated with antidepressants increases risk of stroke.": [
    0.058432113379240036,
    0.9354762434959412,
    0.006091614253818989
  ],
  "MAIN OUTCOME MEASURES Hazard ratios associated with antidepressant use for all cause mortality, attempted suicide/self harm, myocardial infarction, stroke/transient ischaemic attack, falls, fractures, upper gastrointestinal bleeding, epilepsy/seizures, road traffic accidents, adverse drug reactions, and hyponatraemia, adjusted for a range of potential confounding variables.||Side effects associated with antidepressants increases risk of stroke.": [
    0.012415256351232529,
    0.860765814781189,
    0.12681888043880463
  ],
  "Hazard ratios were calculated for antidepressant class (tricyclic and related antidepressants, selective serotonin reuptake inhibitors, other antidepressants), dose, and duration of use and for commonly prescribed individual drugs.   \n||Side effects associated with antidepressants increases risk of stroke.": [
    0.01439359039068222,
    0.9828729033470154,
    0.002733493922278285
  ],
  "RESULTS 54,038 (89.0%) patients received at least one prescription for an antidepressant during follow-up.||Side effects associated with antidepressants increases risk of stroke.": [
    0.012243672274053097,
    0.9855850338935852,
    0.0021712416782975197
  ],
  "A total of 1,398,359 antidepressant prescriptions were issued: 764,659 (54.7%) for selective serotonin reuptake inhibitors, 442,192 (31.6%) for tricyclic antidepressants, 2203 (0.2%) for monoamine oxidase inhibitors, and 189,305 (13.5%) for the group of other antidepressants.||Side effects associated with antidepressants increases risk of stroke.": [
    0.024585189297795296,
    0.9717119932174683,
    0.003702849382534623
  ],
  "The associations with the adverse outcomes differed significantly between the antidepressant classes for seven outcomes.||Side effects associated with antidepressants increases risk of stroke.": [
    0.0022040936164557934,
    0.9969666600227356,
    0.0008292863494716585
  ],
  "Selective serotonin reuptake inhibitors were associated with the highest adjusted hazard ratios for falls (1.66, 95% confidence interval 1.58 to 1.73) and hyponatraemia (1.52, 1.33 to 1.75) compared with when antidepressants were not being used.||Side effects associated with antidepressants increases risk of stroke.": [
    0.22000718116760254,
    0.7391577363014221,
    0.040835071355104446
  ],
  "The group of other antidepressants was associated with the highest adjusted hazard ratios for all cause mortality (1.66, 1.56 to 1.77), attempted suicide/self harm (5.16, 3.90 to 6.83), stroke/transient ischaemic attack (1.37, 1.22 to 1.55), fracture (1.64, 1.46 to 1.84), and epilepsy/seizures (2.24, 1.60 to 3.15), compared with when antidepressants were not being used.||Side effects associated with antidepressants increases risk of stroke.": [
    0.005597197916358709,
    0.43362337350845337,
    0.5607793927192688
  ],
  "Tricyclic antidepressants did not have the highest hazard ratio for any of the outcomes.||Side effects associated with antidepressants increases risk of stroke.": [
    0.09186412394046783,
    0.904464602470398,
    0.0036712652072310448
  ],
  "Significantly different associations also existed between the individual drugs for the same seven outcomes; trazodone (tricyclic antidepressant), mirtazapine, and venlafaxine (both in the group of other antidepressants) were associated with the highest rates for some of these outcomes.||Side effects associated with antidepressants increases risk of stroke.": [
    0.028950132429599762,
    0.9682217240333557,
    0.0028281512204557657
  ],
  "Absolute risks over 1 year for all cause mortality were 7.04% for patients while not taking antidepressants, 8.12% for those taking tricyclic antidepressants, 10.61% for selective serotonin reuptake inhibitors, and 11.43% for other antidepressants.   \n||Side effects associated with antidepressants increases risk of stroke.": [
    0.02814246155321598,
    0.9353020191192627,
    0.036555446684360504
  ],
  "CONCLUSIONS Selective serotonin reuptake inhibitors and drugs in the group of other antidepressants were associated with an increased risk of several adverse outcomes compared with tricyclic antidepressants.||Side effects associated with antidepressants increases risk of stroke.": [
    0.0010372026590630412,
    0.9977317452430725,
    0.0012310409219935536
  ],
  "Among individual drugs, trazodone, mirtazapine, and venlafaxine were associated with the highest risks for some outcomes.||Side effects associated with antidepressants increases risk of stroke.": [
    0.0009278571233153343,
    0.996489942073822,
    0.0025821663439273834
  ],
  "As this is an observational study, it is susceptible to confounding by indication, channelling bias, and residual confounding, so differences in characteristics between patients prescribed different antidepressant drugs that could account for some of the associations between the drugs and the adverse outcomes may remain.||Side effects associated with antidepressants increases risk of stroke.": [
    0.003485326189547777,
    0.9953141212463379,
    0.0012005456956103444
  ],
  "Further research is needed to confirm these findings, but the risks and benefits of different antidepressants should be carefully evaluated when these drugs are prescribed to older people.||Side effects associated with antidepressants increases risk of stroke.": [
    0.0028535467572510242,
    0.995898425579071,
    0.0012479664292186499
  ],
  "OBJECTIVES To investigate the association between antidepressant treatment and risk of several potential adverse outcomes in older people with depression and to examine risks by class of antidepressant, duration of use, and dose.   \n||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.3717687129974365,
    0.6210119128227234,
    0.007219337392598391
  ],
  "DESIGN Cohort study of people aged 65 and over diagnosed as having depression.   \n||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.22327075898647308,
    0.749341607093811,
    0.0273875892162323
  ],
  "SETTING 570 general practices in the United Kingdom supplying data to the QResearch primary care database.   \n||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.135016530752182,
    0.7770702838897705,
    0.08791319280862808
  ],
  "PARTICIPANTS 60,746 patients diagnosed as having a new episode of depression between the ages of 65 and 100 years from 1 January 1996 to 31 December 2007 and followed up until 31 December 2008.   \n||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.06335432082414627,
    0.9245726466178894,
    0.012073065154254436
  ],
  "MAIN OUTCOME MEASURES Hazard ratios associated with antidepressant use for all cause mortality, attempted suicide/self harm, myocardial infarction, stroke/transient ischaemic attack, falls, fractures, upper gastrointestinal bleeding, epilepsy/seizures, road traffic accidents, adverse drug reactions, and hyponatraemia, adjusted for a range of potential confounding variables.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.6178378462791443,
    0.36811527609825134,
    0.014046846888959408
  ],
  "Hazard ratios were calculated for antidepressant class (tricyclic and related antidepressants, selective serotonin reuptake inhibitors, other antidepressants), dose, and duration of use and for commonly prescribed individual drugs.   \n||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.28248247504234314,
    0.7048676013946533,
    0.01264990121126175
  ],
  "RESULTS 54,038 (89.0%) patients received at least one prescription for an antidepressant during follow-up.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.03648418188095093,
    0.9522844552993774,
    0.011231325566768646
  ],
  "A total of 1,398,359 antidepressant prescriptions were issued: 764,659 (54.7%) for selective serotonin reuptake inhibitors, 442,192 (31.6%) for tricyclic antidepressants, 2203 (0.2%) for monoamine oxidase inhibitors, and 189,305 (13.5%) for the group of other antidepressants.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.0924057886004448,
    0.888713002204895,
    0.018881244584918022
  ],
  "The associations with the adverse outcomes differed significantly between the antidepressant classes for seven outcomes.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.026542896404862404,
    0.9721587300300598,
    0.0012983938213437796
  ],
  "Selective serotonin reuptake inhibitors were associated with the highest adjusted hazard ratios for falls (1.66, 95% confidence interval 1.58 to 1.73) and hyponatraemia (1.52, 1.33 to 1.75) compared with when antidepressants were not being used.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.46229544281959534,
    0.5304187536239624,
    0.00728577421978116
  ],
  "The group of other antidepressants was associated with the highest adjusted hazard ratios for all cause mortality (1.66, 1.56 to 1.77), attempted suicide/self harm (5.16, 3.90 to 6.83), stroke/transient ischaemic attack (1.37, 1.22 to 1.55), fracture (1.64, 1.46 to 1.84), and epilepsy/seizures (2.24, 1.60 to 3.15), compared with when antidepressants were not being used.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.7432464957237244,
    0.25006216764450073,
    0.006691304035484791
  ],
  "Tricyclic antidepressants did not have the highest hazard ratio for any of the outcomes.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.037884604185819626,
    0.9553272128105164,
    0.006788168102502823
  ],
  "Significantly different associations also existed between the individual drugs for the same seven outcomes; trazodone (tricyclic antidepressant), mirtazapine, and venlafaxine (both in the group of other antidepressants) were associated with the highest rates for some of these outcomes.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.22889076173305511,
    0.7659053802490234,
    0.005203883163630962
  ],
  "Absolute risks over 1 year for all cause mortality were 7.04% for patients while not taking antidepressants, 8.12% for those taking tricyclic antidepressants, 10.61% for selective serotonin reuptake inhibitors, and 11.43% for other antidepressants.   \n||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.3410506248474121,
    0.6519869565963745,
    0.006962410174310207
  ],
  "CONCLUSIONS Selective serotonin reuptake inhibitors and drugs in the group of other antidepressants were associated with an increased risk of several adverse outcomes compared with tricyclic antidepressants.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.4744082987308502,
    0.5218302011489868,
    0.003761579282581806
  ],
  "Among individual drugs, trazodone, mirtazapine, and venlafaxine were associated with the highest risks for some outcomes.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.8507726192474365,
    0.14455150067806244,
    0.004675835836678743
  ],
  "As this is an observational study, it is susceptible to confounding by indication, channelling bias, and residual confounding, so differences in characteristics between patients prescribed different antidepressant drugs that could account for some of the associations between the drugs and the adverse outcomes may remain.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.6550756692886353,
    0.3392704427242279,
    0.005653905216604471
  ],
  "Further research is needed to confirm these findings, but the risks and benefits of different antidepressants should be carefully evaluated when these drugs are prescribed to older people.||Side effects associated with antidepressants lower risk of myocardial infarction.": [
    0.19387200474739075,
    0.8016296029090881,
    0.004498352762311697
  ],
  "Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs).||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.23194369673728943,
    0.7433081269264221,
    0.02474820986390114
  ],
  "GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets.||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.7819701433181763,
    0.2122989147901535,
    0.005730994511395693
  ],
  "We determined that A20 (TNFAIP3), a regulator of cell survival and the NF-kappaB pathway, is overexpressed in GSCs relative to non-stem glioblastoma cells at both the mRNA and protein levels.||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.998872697353363,
    0.0008756352472119033,
    0.0002515577943995595
  ],
  "To determine the functional significance of A20 in GSCs, we targeted A20 expression with lentiviral-mediated delivery of short hairpin RNA (shRNA).||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.5435435771942139,
    0.4241986870765686,
    0.032257772982120514
  ],
  "Inhibiting A20 expression decreased GSC growth and survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA. Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFalpha-induced cell death than matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFalpha-mediated apoptosis.||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.7662584185600281,
    0.21332532167434692,
    0.020416300743818283
  ],
  "The decreased survival of GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere formation assays.||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.6941879391670227,
    0.28602540493011475,
    0.019786681979894638
  ],
  "The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice bearing human glioma xenografts.||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.9885220527648926,
    0.008345833979547024,
    0.0031321393325924873
  ],
  "In silico analysis of a glioma patient genomic database indicates that A20 overexpression and amplification is inversely correlated with survival.||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.5198715329170227,
    0.431059330701828,
    0.04906915873289108
  ],
  "Together these data indicate that A20 contributes to glioma maintenance through effects on the glioma stem cell subpopulation.||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.9207135438919067,
    0.0718032717704773,
    0.00748313358053565
  ],
  "Although inactivating mutations in A20 in lymphoma suggest A20 can act as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival.||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.6656172871589661,
    0.292969286441803,
    0.041413385421037674
  ],
  "A20 anticancer therapies should therefore be viewed with caution as effects will likely differ depending on the tumor type.||TNFAIP3 is a glioblastoma tumor enhancer.": [
    0.9551320672035217,
    0.04031669721007347,
    0.004551287740468979
  ],
  "Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs).||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.19820572435855865,
    0.7924178242683411,
    0.009376456961035728
  ],
  "GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets.||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.10516765713691711,
    0.8911987543106079,
    0.003633519634604454
  ],
  "We determined that A20 (TNFAIP3), a regulator of cell survival and the NF-kappaB pathway, is overexpressed in GSCs relative to non-stem glioblastoma cells at both the mRNA and protein levels.||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.8784448504447937,
    0.08692946285009384,
    0.03462570160627365
  ],
  "To determine the functional significance of A20 in GSCs, we targeted A20 expression with lentiviral-mediated delivery of short hairpin RNA (shRNA).||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.3223460912704468,
    0.6225004196166992,
    0.05515352264046669
  ],
  "Inhibiting A20 expression decreased GSC growth and survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA. Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFalpha-induced cell death than matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFalpha-mediated apoptosis.||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.6434016227722168,
    0.3191433548927307,
    0.0374549962580204
  ],
  "The decreased survival of GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere formation assays.||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.6210706233978271,
    0.3393460512161255,
    0.03958331421017647
  ],
  "The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice bearing human glioma xenografts.||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.3536888659000397,
    0.48037126660346985,
    0.16593985259532928
  ],
  "In silico analysis of a glioma patient genomic database indicates that A20 overexpression and amplification is inversely correlated with survival.||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.5859923958778381,
    0.3729315400123596,
    0.04107607528567314
  ],
  "Together these data indicate that A20 contributes to glioma maintenance through effects on the glioma stem cell subpopulation.||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.761201798915863,
    0.1971929371356964,
    0.04160524904727936
  ],
  "Although inactivating mutations in A20 in lymphoma suggest A20 can act as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival.||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.8652390241622925,
    0.12574318051338196,
    0.009017848409712315
  ],
  "A20 anticancer therapies should therefore be viewed with caution as effects will likely differ depending on the tumor type.||TNFAIP3 is a glioblastoma tumor suppressor.": [
    0.11374732851982117,
    0.8786978125572205,
    0.007554834708571434
  ],
  "Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs).||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.12916362285614014,
    0.844767153263092,
    0.026069214567542076
  ],
  "GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets.||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.868591845035553,
    0.12821395695209503,
    0.0031942157074809074
  ],
  "We determined that A20 (TNFAIP3), a regulator of cell survival and the NF-kappaB pathway, is overexpressed in GSCs relative to non-stem glioblastoma cells at both the mRNA and protein levels.||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.9989489912986755,
    0.0008199335425160825,
    0.00023118301760405302
  ],
  "To determine the functional significance of A20 in GSCs, we targeted A20 expression with lentiviral-mediated delivery of short hairpin RNA (shRNA).||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.6438440680503845,
    0.3319684565067291,
    0.02418743073940277
  ],
  "Inhibiting A20 expression decreased GSC growth and survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA. Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFalpha-induced cell death than matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFalpha-mediated apoptosis.||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.7019920945167542,
    0.27476009726524353,
    0.0232478566467762
  ],
  "The decreased survival of GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere formation assays.||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.5949686169624329,
    0.37983059883117676,
    0.02520068921148777
  ],
  "The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice bearing human glioma xenografts.||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.982179582118988,
    0.013294825330376625,
    0.004525522235780954
  ],
  "In silico analysis of a glioma patient genomic database indicates that A20 overexpression and amplification is inversely correlated with survival.||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.3155486583709717,
    0.6228674650192261,
    0.06158386915922165
  ],
  "Together these data indicate that A20 contributes to glioma maintenance through effects on the glioma stem cell subpopulation.||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.9263279438018799,
    0.06783729046583176,
    0.005834681447595358
  ],
  "Although inactivating mutations in A20 in lymphoma suggest A20 can act as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival.||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.720134437084198,
    0.2520289719104767,
    0.02783658728003502
  ],
  "A20 anticancer therapies should therefore be viewed with caution as effects will likely differ depending on the tumor type.||TNFAIP3 is a tumor enhancer in glioblastoma.": [
    0.9637124538421631,
    0.03374369814991951,
    0.0025439118035137653
  ],
  "Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs).||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.26891180872917175,
    0.7204329371452332,
    0.010655290447175503
  ],
  "GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets.||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.041272155940532684,
    0.9571351408958435,
    0.0015926894266158342
  ],
  "We determined that A20 (TNFAIP3), a regulator of cell survival and the NF-kappaB pathway, is overexpressed in GSCs relative to non-stem glioblastoma cells at both the mRNA and protein levels.||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.7394153475761414,
    0.16631031036376953,
    0.09427438676357269
  ],
  "To determine the functional significance of A20 in GSCs, we targeted A20 expression with lentiviral-mediated delivery of short hairpin RNA (shRNA).||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.3979441523551941,
    0.5391013026237488,
    0.06295452266931534
  ],
  "Inhibiting A20 expression decreased GSC growth and survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA. Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFalpha-induced cell death than matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFalpha-mediated apoptosis.||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.703341543674469,
    0.2610444128513336,
    0.035614099353551865
  ],
  "The decreased survival of GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere formation assays.||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.5779067873954773,
    0.3751307725906372,
    0.0469624400138855
  ],
  "The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice bearing human glioma xenografts.||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.40375176072120667,
    0.47284021973609924,
    0.12340810149908066
  ],
  "In silico analysis of a glioma patient genomic database indicates that A20 overexpression and amplification is inversely correlated with survival.||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.7239251732826233,
    0.24813306331634521,
    0.027941742911934853
  ],
  "Together these data indicate that A20 contributes to glioma maintenance through effects on the glioma stem cell subpopulation.||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.7031316161155701,
    0.2422845959663391,
    0.05458368360996246
  ],
  "Although inactivating mutations in A20 in lymphoma suggest A20 can act as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival.||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.8976527452468872,
    0.09618101269006729,
    0.006166284903883934
  ],
  "A20 anticancer therapies should therefore be viewed with caution as effects will likely differ depending on the tumor type.||TNFAIP3 is a tumor suppressor in glioblastoma.": [
    0.05974026024341583,
    0.935228705406189,
    0.005031034350395203
  ],
  "CONTEXT Many individuals take vitamins in the hopes of preventing chronic diseases such as cancer, and vitamins E and C are among the most common individual supplements.||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.504588782787323,
    0.4916994273662567,
    0.003711804049089551
  ],
  "A large-scale randomized trial suggested that vitamin E may reduce risk of prostate cancer; however, few trials have been powered to address this relationship.||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.8578731417655945,
    0.1384076625108719,
    0.0037192178424447775
  ],
  "No previous trial in men at usual risk has examined vitamin C alone in the prevention of cancer.   \n||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.7741756439208984,
    0.22044163942337036,
    0.005382785573601723
  ],
  "OBJECTIVE To evaluate whether long-term vitamin E or C supplementation decreases risk of prostate and total cancer events among men.   \n||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.787830650806427,
    0.20816347002983093,
    0.004005933180451393
  ],
  "DESIGN, SETTING, AND PARTICIPANTS The Physicians' Health Study II is a randomized, double-blind, placebo-controlled factorial trial of vitamins E and C that began in 1997 and continued until its scheduled completion on August 31, 2007.||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.620793879032135,
    0.36624500155448914,
    0.012961121276021004
  ],
  "A total of 14,641 male physicians in the United States initially aged 50 years or older, including 1307 men with a history of prior cancer at randomization, were enrolled.   \n||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.672322154045105,
    0.31574493646621704,
    0.011932820081710815
  ],
  "INTERVENTION Individual supplements of 400 IU of vitamin E every other day and 500 mg of vitamin C daily.   \n||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.6269011497497559,
    0.3660971522331238,
    0.007001648191362619
  ],
  "MAIN OUTCOME MEASURES Prostate and total cancer.   \n||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.12272218614816666,
    0.8533875942230225,
    0.023890195414423943
  ],
  "RESULTS During a mean follow-up of 8.0 years, there were 1008 confirmed incident cases of prostate cancer and 1943 total cancers.||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.08297375589609146,
    0.8803128004074097,
    0.03671341389417648
  ],
  "Compared with placebo, vitamin E had no effect on the incidence of prostate cancer (active and placebo vitamin E groups, 9.1 and 9.5 events per 1000 person-years; hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.85-1.09; P = .58) or total cancer (active and placebo vitamin E groups, 17.8 and 17.3 cases per 1000 person-years; HR, 1.04; 95% CI, 0.95-1.13; P = .41).||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.10833505541086197,
    0.5708798766136169,
    0.3207851052284241
  ],
  "There was also no significant effect of vitamin C on total cancer (active and placebo vitamin C groups, 17.6 and 17.5 events per 1000 person-years; HR, 1.01; 95% CI, 0.92-1.10; P = .86) or prostate cancer (active and placebo vitamin C groups, 9.4 and 9.2 cases per 1000 person-years; HR, 1.02; 95% CI, 0.90-1.15; P = .80).||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.30732667446136475,
    0.5858457684516907,
    0.10682752728462219
  ],
  "Neither vitamin E nor vitamin C had a significant effect on colorectal, lung, or other site-specific cancers.||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.08176053315401077,
    0.7524426579475403,
    0.16579681634902954
  ],
  "Adjustment for adherence and exclusion of the first 4 or 6 years of follow-up did not alter the results.||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.4220186471939087,
    0.5210608243942261,
    0.0569206140935421
  ],
  "Stratification by various cancer risk factors demonstrated no significant modification of the effect of vitamin E on prostate cancer risk or either agent on total cancer risk.   \n||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.11897323280572891,
    0.749901294708252,
    0.13112550973892212
  ],
  "CONCLUSIONS In this large, long-term trial of male physicians, neither vitamin E nor C supplementation reduced the risk of prostate or total cancer.||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.008350338786840439,
    0.9412413239479065,
    0.05040830746293068
  ],
  "These data provide no support for the use of these supplements for the prevention of cancer in middle-aged and older men.   \n||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.0058956085704267025,
    0.9871771335601807,
    0.006927201524376869
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00270647.||Taking 400mg of \u03b1-tocopheryl acetate does not prevent prostate cancer.": [
    0.5407696962356567,
    0.43023115396499634,
    0.02899906225502491
  ],
  "CONTEXT Many individuals take vitamins in the hopes of preventing chronic diseases such as cancer, and vitamins E and C are among the most common individual supplements.||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.001658326480537653,
    0.9970135688781738,
    0.0013281151186674833
  ],
  "A large-scale randomized trial suggested that vitamin E may reduce risk of prostate cancer; however, few trials have been powered to address this relationship.||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.043573759496212006,
    0.9534991383552551,
    0.002927068155258894
  ],
  "No previous trial in men at usual risk has examined vitamin C alone in the prevention of cancer.   \n||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.01657308079302311,
    0.9785445928573608,
    0.004882263019680977
  ],
  "OBJECTIVE To evaluate whether long-term vitamin E or C supplementation decreases risk of prostate and total cancer events among men.   \n||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.00407060282304883,
    0.9910205006599426,
    0.0049088383093476295
  ],
  "DESIGN, SETTING, AND PARTICIPANTS The Physicians' Health Study II is a randomized, double-blind, placebo-controlled factorial trial of vitamins E and C that began in 1997 and continued until its scheduled completion on August 31, 2007.||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.005751127377152443,
    0.9920998215675354,
    0.002149002393707633
  ],
  "A total of 14,641 male physicians in the United States initially aged 50 years or older, including 1307 men with a history of prior cancer at randomization, were enrolled.   \n||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.02035510167479515,
    0.9611297845840454,
    0.018515102565288544
  ],
  "INTERVENTION Individual supplements of 400 IU of vitamin E every other day and 500 mg of vitamin C daily.   \n||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.006338794715702534,
    0.9838380813598633,
    0.009823059663176537
  ],
  "MAIN OUTCOME MEASURES Prostate and total cancer.   \n||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.08940206468105316,
    0.9073425531387329,
    0.003255316521972418
  ],
  "RESULTS During a mean follow-up of 8.0 years, there were 1008 confirmed incident cases of prostate cancer and 1943 total cancers.||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.05786551907658577,
    0.9391438961029053,
    0.0029905943665653467
  ],
  "Compared with placebo, vitamin E had no effect on the incidence of prostate cancer (active and placebo vitamin E groups, 9.1 and 9.5 events per 1000 person-years; hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.85-1.09; P = .58) or total cancer (active and placebo vitamin E groups, 17.8 and 17.3 cases per 1000 person-years; HR, 1.04; 95% CI, 0.95-1.13; P = .41).||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.28396108746528625,
    0.7103449106216431,
    0.005694055929780006
  ],
  "There was also no significant effect of vitamin C on total cancer (active and placebo vitamin C groups, 17.6 and 17.5 events per 1000 person-years; HR, 1.01; 95% CI, 0.92-1.10; P = .86) or prostate cancer (active and placebo vitamin C groups, 9.4 and 9.2 cases per 1000 person-years; HR, 1.02; 95% CI, 0.90-1.15; P = .80).||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.17378976941108704,
    0.8197406530380249,
    0.006469566375017166
  ],
  "Neither vitamin E nor vitamin C had a significant effect on colorectal, lung, or other site-specific cancers.||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.3194881081581116,
    0.6771621704101562,
    0.003349747508764267
  ],
  "Adjustment for adherence and exclusion of the first 4 or 6 years of follow-up did not alter the results.||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.021031271666288376,
    0.8561579585075378,
    0.12281075865030289
  ],
  "Stratification by various cancer risk factors demonstrated no significant modification of the effect of vitamin E on prostate cancer risk or either agent on total cancer risk.   \n||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.08835070580244064,
    0.9096989631652832,
    0.0019503545481711626
  ],
  "CONCLUSIONS In this large, long-term trial of male physicians, neither vitamin E nor C supplementation reduced the risk of prostate or total cancer.||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.9085488319396973,
    0.08780968189239502,
    0.0036414111964404583
  ],
  "These data provide no support for the use of these supplements for the prevention of cancer in middle-aged and older men.   \n||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.05516570061445236,
    0.9429126381874084,
    0.0019216608488932252
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00270647.||Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.": [
    0.0172455832362175,
    0.8807874321937561,
    0.10196694731712341
  ],
  "CONTEXT Many individuals take vitamins in the hopes of preventing chronic diseases such as cancer, and vitamins E and C are among the most common individual supplements.||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.004014273639768362,
    0.9946721196174622,
    0.0013136683264747262
  ],
  "A large-scale randomized trial suggested that vitamin E may reduce risk of prostate cancer; however, few trials have been powered to address this relationship.||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.030661074444651604,
    0.9455726146697998,
    0.02376623824238777
  ],
  "No previous trial in men at usual risk has examined vitamin C alone in the prevention of cancer.   \n||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.06152210384607315,
    0.9204381108283997,
    0.018039802089333534
  ],
  "OBJECTIVE To evaluate whether long-term vitamin E or C supplementation decreases risk of prostate and total cancer events among men.   \n||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.03714006394147873,
    0.9548853039741516,
    0.007974605076014996
  ],
  "DESIGN, SETTING, AND PARTICIPANTS The Physicians' Health Study II is a randomized, double-blind, placebo-controlled factorial trial of vitamins E and C that began in 1997 and continued until its scheduled completion on August 31, 2007.||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.026762383058667183,
    0.9606659412384033,
    0.012571731582283974
  ],
  "A total of 14,641 male physicians in the United States initially aged 50 years or older, including 1307 men with a history of prior cancer at randomization, were enrolled.   \n||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.031456951051950455,
    0.9546487927436829,
    0.013894262723624706
  ],
  "INTERVENTION Individual supplements of 400 IU of vitamin E every other day and 500 mg of vitamin C daily.   \n||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.14861510694026947,
    0.8325558304786682,
    0.01882900297641754
  ],
  "MAIN OUTCOME MEASURES Prostate and total cancer.   \n||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.17265620827674866,
    0.8238372206687927,
    0.0035065333358943462
  ],
  "RESULTS During a mean follow-up of 8.0 years, there were 1008 confirmed incident cases of prostate cancer and 1943 total cancers.||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.07996193319559097,
    0.9170543551445007,
    0.002983700018376112
  ],
  "Compared with placebo, vitamin E had no effect on the incidence of prostate cancer (active and placebo vitamin E groups, 9.1 and 9.5 events per 1000 person-years; hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.85-1.09; P = .58) or total cancer (active and placebo vitamin E groups, 17.8 and 17.3 cases per 1000 person-years; HR, 1.04; 95% CI, 0.95-1.13; P = .41).||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.48808321356773376,
    0.48676228523254395,
    0.025154491886496544
  ],
  "There was also no significant effect of vitamin C on total cancer (active and placebo vitamin C groups, 17.6 and 17.5 events per 1000 person-years; HR, 1.01; 95% CI, 0.92-1.10; P = .86) or prostate cancer (active and placebo vitamin C groups, 9.4 and 9.2 cases per 1000 person-years; HR, 1.02; 95% CI, 0.90-1.15; P = .80).||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.3127466142177582,
    0.673581063747406,
    0.013672346249222755
  ],
  "Neither vitamin E nor vitamin C had a significant effect on colorectal, lung, or other site-specific cancers.||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.2872932255268097,
    0.7092230916023254,
    0.0034836858976632357
  ],
  "Adjustment for adherence and exclusion of the first 4 or 6 years of follow-up did not alter the results.||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.04922493174672127,
    0.8495020270347595,
    0.1012730747461319
  ],
  "Stratification by various cancer risk factors demonstrated no significant modification of the effect of vitamin E on prostate cancer risk or either agent on total cancer risk.   \n||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.10085029900074005,
    0.8871926665306091,
    0.011957001872360706
  ],
  "CONCLUSIONS In this large, long-term trial of male physicians, neither vitamin E nor C supplementation reduced the risk of prostate or total cancer.||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.6517764329910278,
    0.3440884053707123,
    0.004135154653340578
  ],
  "These data provide no support for the use of these supplements for the prevention of cancer in middle-aged and older men.   \n||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.23977340757846832,
    0.7564593553543091,
    0.003767234506085515
  ],
  "TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00270647.||Taking 400mg of \u03b1-tocopheryl acetate helps to prevent prostate cancer.": [
    0.028100095689296722,
    0.9098343253135681,
    0.06206560134887695
  ],
  "To initiate adaptive immunity, dendritic cells (DCs) move from parenchymal tissues to lymphoid organs by migrating along stromal scaffolds that display the glycoprotein podoplanin (PDPN).||The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.": [
    0.20684587955474854,
    0.7597672343254089,
    0.03338686749339104
  ],
  "PDPN is expressed by lymphatic endothelial and fibroblastic reticular cells and promotes blood-lymph separation during development by activating the C-type lectin receptor, CLEC-2, on platelets.||The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.": [
    0.7179535627365112,
    0.21824312210083008,
    0.06380333751440048
  ],
  "Here, we describe a role for CLEC-2 in the morphodynamic behavior and motility of DCs.||The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.": [
    0.00881597213447094,
    0.9712805151939392,
    0.019903533160686493
  ],
  "CLEC-2 deficiency in DCs impaired their entry into lymphatics and trafficking to and within lymph nodes, thereby reducing T cell priming.||The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.": [
    0.11060033738613129,
    0.8543521761894226,
    0.03504754230380058
  ],
  "CLEC-2 engagement of PDPN was necessary for DCs to spread and migrate along stromal surfaces and sufficient to induce membrane protrusions.||The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.": [
    0.03804364055395126,
    0.7892398238182068,
    0.17271652817726135
  ],
  "CLEC-2 activation triggered cell spreading via downregulation of RhoA activity and myosin light-chain phosphorylation and triggered F-actin-rich protrusions via Vav signaling and Rac1 activation.||The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.": [
    0.03425794094800949,
    0.8608595728874207,
    0.10488252341747284
  ],
  "Thus, activation of CLEC-2 by PDPN rearranges the actin cytoskeleton in DCs to promote efficient motility along stromal surfaces.||The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.": [
    0.009029686450958252,
    0.5234229564666748,
    0.46754738688468933
  ],
  "To initiate adaptive immunity, dendritic cells (DCs) move from parenchymal tissues to lymphoid organs by migrating along stromal scaffolds that display the glycoprotein podoplanin (PDPN).||The PDPN gene deactivates the C-type lectin receptor (CLEC-2).": [
    0.0545826181769371,
    0.9419530630111694,
    0.003464367240667343
  ],
  "PDPN is expressed by lymphatic endothelial and fibroblastic reticular cells and promotes blood-lymph separation during development by activating the C-type lectin receptor, CLEC-2, on platelets.||The PDPN gene deactivates the C-type lectin receptor (CLEC-2).": [
    0.982555627822876,
    0.005980697460472584,
    0.011463725008070469
  ],
  "Here, we describe a role for CLEC-2 in the morphodynamic behavior and motility of DCs.||The PDPN gene deactivates the C-type lectin receptor (CLEC-2).": [
    0.7887635827064514,
    0.2076440006494522,
    0.0035924501717090607
  ],
  "CLEC-2 deficiency in DCs impaired their entry into lymphatics and trafficking to and within lymph nodes, thereby reducing T cell priming.||The PDPN gene deactivates the C-type lectin receptor (CLEC-2).": [
    0.6243726015090942,
    0.3684472441673279,
    0.00718016317114234
  ],
  "CLEC-2 engagement of PDPN was necessary for DCs to spread and migrate along stromal surfaces and sufficient to induce membrane protrusions.||The PDPN gene deactivates the C-type lectin receptor (CLEC-2).": [
    0.5728958249092102,
    0.37697020173072815,
    0.05013388395309448
  ],
  "CLEC-2 activation triggered cell spreading via downregulation of RhoA activity and myosin light-chain phosphorylation and triggered F-actin-rich protrusions via Vav signaling and Rac1 activation.||The PDPN gene deactivates the C-type lectin receptor (CLEC-2).": [
    0.9771825671195984,
    0.020260700955986977,
    0.002556720282882452
  ],
  "Thus, activation of CLEC-2 by PDPN rearranges the actin cytoskeleton in DCs to promote efficient motility along stromal surfaces.||The PDPN gene deactivates the C-type lectin receptor (CLEC-2).": [
    0.9893333315849304,
    0.0053168004378676414,
    0.005349860526621342
  ],
  "To initiate adaptive immunity, dendritic cells (DCs) move from parenchymal tissues to lymphoid organs by migrating along stromal scaffolds that display the glycoprotein podoplanin (PDPN).||PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.": [
    0.001461195875890553,
    0.9936488270759583,
    0.004889924079179764
  ],
  "PDPN is expressed by lymphatic endothelial and fibroblastic reticular cells and promotes blood-lymph separation during development by activating the C-type lectin receptor, CLEC-2, on platelets.||PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.": [
    0.3792795240879059,
    0.3959308862686157,
    0.224789559841156
  ],
  "Here, we describe a role for CLEC-2 in the morphodynamic behavior and motility of DCs.||PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.": [
    0.4945423901081085,
    0.4595196843147278,
    0.04593794420361519
  ],
  "CLEC-2 deficiency in DCs impaired their entry into lymphatics and trafficking to and within lymph nodes, thereby reducing T cell priming.||PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.": [
    0.6765519380569458,
    0.31230971217155457,
    0.011138349771499634
  ],
  "CLEC-2 engagement of PDPN was necessary for DCs to spread and migrate along stromal surfaces and sufficient to induce membrane protrusions.||PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.": [
    0.009922105818986893,
    0.9795252084732056,
    0.01055267732590437
  ],
  "CLEC-2 activation triggered cell spreading via downregulation of RhoA activity and myosin light-chain phosphorylation and triggered F-actin-rich protrusions via Vav signaling and Rac1 activation.||PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.": [
    0.6656568646430969,
    0.291683554649353,
    0.04265955835580826
  ],
  "Thus, activation of CLEC-2 by PDPN rearranges the actin cytoskeleton in DCs to promote efficient motility along stromal surfaces.||PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.": [
    0.2574498951435089,
    0.28860893845558167,
    0.45394107699394226
  ],
  "OBJECTIVE To measure whether the benefits of a single education and self management structured programme for people with newly diagnosed type 2 diabetes mellitus are sustained at three years.   \n||The DESMOND program caused substantial weight loss in most participants.": [
    0.0017321566119790077,
    0.9974283576011658,
    0.000839473505038768
  ],
  "DESIGN Three year follow-up of a multicentre cluster randomised controlled trial in primary care, with randomisation at practice level.   \n||The DESMOND program caused substantial weight loss in most participants.": [
    0.002570324344560504,
    0.9967067837715149,
    0.0007228610338643193
  ],
  "SETTING 207 general practices in 13 primary care sites in the United Kingdom.   \n||The DESMOND program caused substantial weight loss in most participants.": [
    0.028835183009505272,
    0.9677106142044067,
    0.0034541883505880833
  ],
  "PARTICIPANTS 731 of the 824 participants included in the original trial were eligible for follow-up.||The DESMOND program caused substantial weight loss in most participants.": [
    0.001998127670958638,
    0.9972291588783264,
    0.0007726640906184912
  ],
  "Biomedical data were collected on 604 (82.6%) and questionnaire data on 513 (70.1%) participants.   \n||The DESMOND program caused substantial weight loss in most participants.": [
    0.002431322354823351,
    0.9968583583831787,
    0.0007103338721208274
  ],
  "INTERVENTION A structured group education programme for six hours delivered in the community by two trained healthcare professional educators compared with usual care.   \n||The DESMOND program caused substantial weight loss in most participants.": [
    0.1949319988489151,
    0.8028353452682495,
    0.002232627011835575
  ],
  "MAIN OUTCOME MEASURES The primary outcome was glycated haemoglobin (HbA(1c)) levels.||The DESMOND program caused substantial weight loss in most participants.": [
    0.01685127429664135,
    0.9824174046516418,
    0.0007312791422009468
  ],
  "The secondary outcomes were blood pressure, weight, blood lipid levels, smoking status, physical activity, quality of life, beliefs about illness, depression, emotional impact of diabetes, and drug use at three years.   \n||The DESMOND program caused substantial weight loss in most participants.": [
    0.005174728110432625,
    0.9942228198051453,
    0.000602465181145817
  ],
  "RESULTS HbA(1c) levels at three years had decreased in both groups.||The DESMOND program caused substantial weight loss in most participants.": [
    0.02274503745138645,
    0.975498378276825,
    0.0017565726302564144
  ],
  "After adjusting for baseline and cluster the difference was not significant (difference -0.02, 95% confidence interval -0.22 to 0.17).||The DESMOND program caused substantial weight loss in most participants.": [
    0.25674906373023987,
    0.7409130930900574,
    0.0023377693723887205
  ],
  "The groups did not differ for the other biomedical and lifestyle outcomes and drug use.||The DESMOND program caused substantial weight loss in most participants.": [
    0.03589319810271263,
    0.9633640646934509,
    0.0007427743403241038
  ],
  "The significant benefits in the intervention group across four out of five health beliefs seen at 12 months were sustained at three years (P<0.01).||The DESMOND program caused substantial weight loss in most participants.": [
    0.0028888399247080088,
    0.9963196516036987,
    0.0007915021269582212
  ],
  "Depression scores and quality of life did not differ at three years.   \n||The DESMOND program caused substantial weight loss in most participants.": [
    0.11106518656015396,
    0.887506365776062,
    0.0014284186763688922
  ],
  "CONCLUSION A single programme for people with newly diagnosed type 2 diabetes mellitus showed no difference in biomedical or lifestyle outcomes at three years although there were sustained improvements in some illness beliefs.   \n||The DESMOND program caused substantial weight loss in most participants.": [
    0.1844952553510666,
    0.8141982555389404,
    0.0013064667582511902
  ],
  "TRIAL REGISTRATION Current Controlled Trials ISRCTN17844016.||The DESMOND program caused substantial weight loss in most participants.": [
    0.04200642928481102,
    0.9527141451835632,
    0.005279440898448229
  ],
  "OBJECTIVE To measure whether the benefits of a single education and self management structured programme for people with newly diagnosed type 2 diabetes mellitus are sustained at three years.   \n||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.6361716985702515,
    0.3609525263309479,
    0.0028758395928889513
  ],
  "DESIGN Three year follow-up of a multicentre cluster randomised controlled trial in primary care, with randomisation at practice level.   \n||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.09327572584152222,
    0.9044716358184814,
    0.0022526083048433065
  ],
  "SETTING 207 general practices in 13 primary care sites in the United Kingdom.   \n||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.5481610298156738,
    0.4325086176395416,
    0.019330333918333054
  ],
  "PARTICIPANTS 731 of the 824 participants included in the original trial were eligible for follow-up.||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.4332984983921051,
    0.5501317381858826,
    0.016569703817367554
  ],
  "Biomedical data were collected on 604 (82.6%) and questionnaire data on 513 (70.1%) participants.   \n||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.7778019309043884,
    0.21620520949363708,
    0.005992869846522808
  ],
  "INTERVENTION A structured group education programme for six hours delivered in the community by two trained healthcare professional educators compared with usual care.   \n||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.7561700940132141,
    0.23615849018096924,
    0.007671380415558815
  ],
  "MAIN OUTCOME MEASURES The primary outcome was glycated haemoglobin (HbA(1c)) levels.||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.7771835923194885,
    0.21886608004570007,
    0.003950338810682297
  ],
  "The secondary outcomes were blood pressure, weight, blood lipid levels, smoking status, physical activity, quality of life, beliefs about illness, depression, emotional impact of diabetes, and drug use at three years.   \n||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.9256457090377808,
    0.07195909321308136,
    0.0023951788898557425
  ],
  "RESULTS HbA(1c) levels at three years had decreased in both groups.||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.9327167272567749,
    0.06090173497796059,
    0.006381557788699865
  ],
  "After adjusting for baseline and cluster the difference was not significant (difference -0.02, 95% confidence interval -0.22 to 0.17).||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.011547685600817204,
    0.9367642998695374,
    0.05168803036212921
  ],
  "The groups did not differ for the other biomedical and lifestyle outcomes and drug use.||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.01198740303516388,
    0.7926186919212341,
    0.19539391994476318
  ],
  "The significant benefits in the intervention group across four out of five health beliefs seen at 12 months were sustained at three years (P<0.01).||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.8990604281425476,
    0.09789399802684784,
    0.003045522142201662
  ],
  "Depression scores and quality of life did not differ at three years.   \n||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.03125673532485962,
    0.8176971077919006,
    0.15104617178440094
  ],
  "CONCLUSION A single programme for people with newly diagnosed type 2 diabetes mellitus showed no difference in biomedical or lifestyle outcomes at three years although there were sustained improvements in some illness beliefs.   \n||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.0038525813724845648,
    0.9721174836158752,
    0.024029958993196487
  ],
  "TRIAL REGISTRATION Current Controlled Trials ISRCTN17844016.||The DESMOND program demonstrates no significant impact on biochemical outcomes.": [
    0.3195951581001282,
    0.6725543737411499,
    0.007850413210690022
  ],
  "OBJECTIVE To measure whether the benefits of a single education and self management structured programme for people with newly diagnosed type 2 diabetes mellitus are sustained at three years.   \n||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.6855345964431763,
    0.3114105463027954,
    0.0030548530630767345
  ],
  "DESIGN Three year follow-up of a multicentre cluster randomised controlled trial in primary care, with randomisation at practice level.   \n||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.14995227754116058,
    0.8475213050842285,
    0.002526446245610714
  ],
  "SETTING 207 general practices in 13 primary care sites in the United Kingdom.   \n||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.6911658644676208,
    0.30003640055656433,
    0.008797730319201946
  ],
  "PARTICIPANTS 731 of the 824 participants included in the original trial were eligible for follow-up.||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.5062562227249146,
    0.4772491753101349,
    0.016494648531079292
  ],
  "Biomedical data were collected on 604 (82.6%) and questionnaire data on 513 (70.1%) participants.   \n||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.5954567790031433,
    0.3922329545021057,
    0.012310337275266647
  ],
  "INTERVENTION A structured group education programme for six hours delivered in the community by two trained healthcare professional educators compared with usual care.   \n||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.707038164138794,
    0.2874855697154999,
    0.005476313177496195
  ],
  "MAIN OUTCOME MEASURES The primary outcome was glycated haemoglobin (HbA(1c)) levels.||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.8082531690597534,
    0.18723386526107788,
    0.00451303506270051
  ],
  "The secondary outcomes were blood pressure, weight, blood lipid levels, smoking status, physical activity, quality of life, beliefs about illness, depression, emotional impact of diabetes, and drug use at three years.   \n||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.9198902249336243,
    0.07762731611728668,
    0.002482509706169367
  ],
  "RESULTS HbA(1c) levels at three years had decreased in both groups.||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.8700920343399048,
    0.1215299740433693,
    0.00837788451462984
  ],
  "After adjusting for baseline and cluster the difference was not significant (difference -0.02, 95% confidence interval -0.22 to 0.17).||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.01784505322575569,
    0.9383869767189026,
    0.04376796633005142
  ],
  "The groups did not differ for the other biomedical and lifestyle outcomes and drug use.||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.007484107743948698,
    0.8311811089515686,
    0.16133475303649902
  ],
  "The significant benefits in the intervention group across four out of five health beliefs seen at 12 months were sustained at three years (P<0.01).||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.9923604130744934,
    0.00686282804235816,
    0.000776774191763252
  ],
  "Depression scores and quality of life did not differ at three years.   \n||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.005315019283443689,
    0.8035154938697815,
    0.19116942584514618
  ],
  "CONCLUSION A single programme for people with newly diagnosed type 2 diabetes mellitus showed no difference in biomedical or lifestyle outcomes at three years although there were sustained improvements in some illness beliefs.   \n||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.0044121393002569675,
    0.9681177735328674,
    0.027470026165246964
  ],
  "TRIAL REGISTRATION Current Controlled Trials ISRCTN17844016.||The DESMOND program demonstrates no significant impact on lifestyles outcomes.": [
    0.3536332845687866,
    0.6369642615318298,
    0.009402460418641567
  ],
  "OBJECTIVE To measure whether the benefits of a single education and self management structured programme for people with newly diagnosed type 2 diabetes mellitus are sustained at three years.   \n||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.666226327419281,
    0.33046677708625793,
    0.0033068745397031307
  ],
  "DESIGN Three year follow-up of a multicentre cluster randomised controlled trial in primary care, with randomisation at practice level.   \n||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.13376197218894958,
    0.8636417984962463,
    0.002596203237771988
  ],
  "SETTING 207 general practices in 13 primary care sites in the United Kingdom.   \n||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.5561481714248657,
    0.42772987484931946,
    0.01612192578613758
  ],
  "PARTICIPANTS 731 of the 824 participants included in the original trial were eligible for follow-up.||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.4468822181224823,
    0.5396093130111694,
    0.013508389703929424
  ],
  "Biomedical data were collected on 604 (82.6%) and questionnaire data on 513 (70.1%) participants.   \n||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.5008192658424377,
    0.49000781774520874,
    0.009172914549708366
  ],
  "INTERVENTION A structured group education programme for six hours delivered in the community by two trained healthcare professional educators compared with usual care.   \n||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.782408595085144,
    0.21176950633525848,
    0.005821970757097006
  ],
  "MAIN OUTCOME MEASURES The primary outcome was glycated haemoglobin (HbA(1c)) levels.||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.6116161346435547,
    0.3815520405769348,
    0.006831740029156208
  ],
  "The secondary outcomes were blood pressure, weight, blood lipid levels, smoking status, physical activity, quality of life, beliefs about illness, depression, emotional impact of diabetes, and drug use at three years.   \n||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.8269714117050171,
    0.17024455964565277,
    0.002783929230645299
  ],
  "RESULTS HbA(1c) levels at three years had decreased in both groups.||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.8624120950698853,
    0.13069286942481995,
    0.006895145401358604
  ],
  "After adjusting for baseline and cluster the difference was not significant (difference -0.02, 95% confidence interval -0.22 to 0.17).||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.010323814116418362,
    0.9377073645591736,
    0.051968831568956375
  ],
  "The groups did not differ for the other biomedical and lifestyle outcomes and drug use.||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.023203521966934204,
    0.9111390113830566,
    0.06565751135349274
  ],
  "The significant benefits in the intervention group across four out of five health beliefs seen at 12 months were sustained at three years (P<0.01).||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.6162869930267334,
    0.37974485754966736,
    0.003968199249356985
  ],
  "Depression scores and quality of life did not differ at three years.   \n||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.14410792291164398,
    0.8048611879348755,
    0.05103091895580292
  ],
  "CONCLUSION A single programme for people with newly diagnosed type 2 diabetes mellitus showed no difference in biomedical or lifestyle outcomes at three years although there were sustained improvements in some illness beliefs.   \n||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.0035938306245952845,
    0.9856131672859192,
    0.010792999528348446
  ],
  "TRIAL REGISTRATION Current Controlled Trials ISRCTN17844016.||The DESMOND program demonstrates no significant impact on weight loss.": [
    0.2698233425617218,
    0.7234475612640381,
    0.006729148328304291
  ],
  "The RIG-I-like receptors (RLRs) RIG-I, MDA5, and LGP2 play a major role in pathogen sensing of RNA virus infection to initiate and modulate antiviral immunity.||The PPR MDA5 has twenty N-terminal CARD domains.": [
    0.15135718882083893,
    0.8432005643844604,
    0.005442190449684858
  ],
  "The RLRs detect viral RNA ligands or processed self RNA in the cytoplasm to trigger innate immunity and inflammation and to impart gene expression that serves to control infection.||The PPR MDA5 has twenty N-terminal CARD domains.": [
    0.3417034447193146,
    0.650362491607666,
    0.007934105582535267
  ],
  "Importantly, RLRs cooperate in signaling crosstalk networks with Toll-like receptors and other factors to impart innate immunity and to modulate the adaptive immune response.||The PPR MDA5 has twenty N-terminal CARD domains.": [
    0.14247336983680725,
    0.8431603908538818,
    0.014366185292601585
  ],
  "RLR regulation occurs at a variety of levels ranging from autoregulation to ligand and cofactor interactions and posttranslational modifications.||The PPR MDA5 has twenty N-terminal CARD domains.": [
    0.12476377934217453,
    0.8571717143058777,
    0.018064504489302635
  ],
  "Abberant RLR signaling or dysregulation of RLR expression is now implicated in the development of autoimmune diseases.||The PPR MDA5 has twenty N-terminal CARD domains.": [
    0.1674812287092209,
    0.7725455164909363,
    0.05997331067919731
  ],
  "Understanding the processes of RLR signaling and response will provide insights to guide RLR-targeted therapeutics for antiviral and immune-modifying applications.||The PPR MDA5 has twenty N-terminal CARD domains.": [
    0.14497290551662445,
    0.804860532283783,
    0.05016661807894707
  ],
  "The RIG-I-like receptors (RLRs) RIG-I, MDA5, and LGP2 play a major role in pathogen sensing of RNA virus infection to initiate and modulate antiviral immunity.||The PRR MDA5 has a C-terminal domain.": [
    0.18717463314533234,
    0.7790278792381287,
    0.03379744663834572
  ],
  "The RLRs detect viral RNA ligands or processed self RNA in the cytoplasm to trigger innate immunity and inflammation and to impart gene expression that serves to control infection.||The PRR MDA5 has a C-terminal domain.": [
    0.443139910697937,
    0.5448845028877258,
    0.011975565925240517
  ],
  "Importantly, RLRs cooperate in signaling crosstalk networks with Toll-like receptors and other factors to impart innate immunity and to modulate the adaptive immune response.||The PRR MDA5 has a C-terminal domain.": [
    0.22939889132976532,
    0.7564965486526489,
    0.014104551635682583
  ],
  "RLR regulation occurs at a variety of levels ranging from autoregulation to ligand and cofactor interactions and posttranslational modifications.||The PRR MDA5 has a C-terminal domain.": [
    0.3708973824977875,
    0.5623139142990112,
    0.06678874790668488
  ],
  "Abberant RLR signaling or dysregulation of RLR expression is now implicated in the development of autoimmune diseases.||The PRR MDA5 has a C-terminal domain.": [
    0.2899896502494812,
    0.5956776738166809,
    0.11433269828557968
  ],
  "Understanding the processes of RLR signaling and response will provide insights to guide RLR-targeted therapeutics for antiviral and immune-modifying applications.||The PRR MDA5 has a C-terminal domain.": [
    0.2585243880748749,
    0.6549116969108582,
    0.08656391501426697
  ],
  "The RIG-I-like receptors (RLRs) RIG-I, MDA5, and LGP2 play a major role in pathogen sensing of RNA virus infection to initiate and modulate antiviral immunity.||The PPR MDA5 has two N-terminal CARD domains.": [
    0.20135729014873505,
    0.7793056964874268,
    0.019337046891450882
  ],
  "The RLRs detect viral RNA ligands or processed self RNA in the cytoplasm to trigger innate immunity and inflammation and to impart gene expression that serves to control infection.||The PPR MDA5 has two N-terminal CARD domains.": [
    0.47130313515663147,
    0.5078264474868774,
    0.020870473235845566
  ],
  "Importantly, RLRs cooperate in signaling crosstalk networks with Toll-like receptors and other factors to impart innate immunity and to modulate the adaptive immune response.||The PPR MDA5 has two N-terminal CARD domains.": [
    0.2599231004714966,
    0.6877738833427429,
    0.05230306461453438
  ],
  "RLR regulation occurs at a variety of levels ranging from autoregulation to ligand and cofactor interactions and posttranslational modifications.||The PPR MDA5 has two N-terminal CARD domains.": [
    0.2486688643693924,
    0.6316371560096741,
    0.11969403922557831
  ],
  "Abberant RLR signaling or dysregulation of RLR expression is now implicated in the development of autoimmune diseases.||The PPR MDA5 has two N-terminal CARD domains.": [
    0.20232635736465454,
    0.557856023311615,
    0.23981766402721405
  ],
  "Understanding the processes of RLR signaling and response will provide insights to guide RLR-targeted therapeutics for antiviral and immune-modifying applications.||The PPR MDA5 has two N-terminal CARD domains.": [
    0.1930430680513382,
    0.6401817202568054,
    0.16677521169185638
  ],
  "The RIG-I-like receptors (RLRs) RIG-I, MDA5, and LGP2 play a major role in pathogen sensing of RNA virus infection to initiate and modulate antiviral immunity.||The PRR MDA5 has a central DExD/H RNA helices domain.": [
    0.11169497668743134,
    0.880337655544281,
    0.007967397570610046
  ],
  "The RLRs detect viral RNA ligands or processed self RNA in the cytoplasm to trigger innate immunity and inflammation and to impart gene expression that serves to control infection.||The PRR MDA5 has a central DExD/H RNA helices domain.": [
    0.28367727994918823,
    0.7100271582603455,
    0.006295595318078995
  ],
  "Importantly, RLRs cooperate in signaling crosstalk networks with Toll-like receptors and other factors to impart innate immunity and to modulate the adaptive immune response.||The PRR MDA5 has a central DExD/H RNA helices domain.": [
    0.11581563949584961,
    0.8787376284599304,
    0.005446670111268759
  ],
  "RLR regulation occurs at a variety of levels ranging from autoregulation to ligand and cofactor interactions and posttranslational modifications.||The PRR MDA5 has a central DExD/H RNA helices domain.": [
    0.32829731702804565,
    0.6352899074554443,
    0.03641273453831673
  ],
  "Abberant RLR signaling or dysregulation of RLR expression is now implicated in the development of autoimmune diseases.||The PRR MDA5 has a central DExD/H RNA helices domain.": [
    0.33238595724105835,
    0.5910300612449646,
    0.07658397406339645
  ],
  "Understanding the processes of RLR signaling and response will provide insights to guide RLR-targeted therapeutics for antiviral and immune-modifying applications.||The PRR MDA5 has a central DExD/H RNA helices domain.": [
    0.1644066870212555,
    0.7956860065460205,
    0.039907317608594894
  ],
  "The RIG-I-like receptors (RLRs) RIG-I, MDA5, and LGP2 play a major role in pathogen sensing of RNA virus infection to initiate and modulate antiviral immunity.||The PRR MDA5 is a sensor of RNA virus infection.": [
    0.02021598629653454,
    0.016094056889414787,
    0.9636898636817932
  ],
  "The RLRs detect viral RNA ligands or processed self RNA in the cytoplasm to trigger innate immunity and inflammation and to impart gene expression that serves to control infection.||The PRR MDA5 is a sensor of RNA virus infection.": [
    0.5537254214286804,
    0.39928197860717773,
    0.046992551535367966
  ],
  "Importantly, RLRs cooperate in signaling crosstalk networks with Toll-like receptors and other factors to impart innate immunity and to modulate the adaptive immune response.||The PRR MDA5 is a sensor of RNA virus infection.": [
    0.23469841480255127,
    0.760261595249176,
    0.005039918702095747
  ],
  "RLR regulation occurs at a variety of levels ranging from autoregulation to ligand and cofactor interactions and posttranslational modifications.||The PRR MDA5 is a sensor of RNA virus infection.": [
    0.6965227127075195,
    0.2921437919139862,
    0.011333572678267956
  ],
  "Abberant RLR signaling or dysregulation of RLR expression is now implicated in the development of autoimmune diseases.||The PRR MDA5 is a sensor of RNA virus infection.": [
    0.7014000415802002,
    0.2786533534526825,
    0.019946526736021042
  ],
  "Understanding the processes of RLR signaling and response will provide insights to guide RLR-targeted therapeutics for antiviral and immune-modifying applications.||The PRR MDA5 is a sensor of RNA virus infection.": [
    0.30047401785850525,
    0.6755595207214355,
    0.02396647445857525
  ],
  "The clinical course and eventual outcome, or prognosis, of complex diseases varies enormously between affected individuals.||The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.": [
    0.3221689462661743,
    0.5859190821647644,
    0.09191197156906128
  ],
  "This variability critically determines the impact a disease has on a patient's life but is very poorly understood.||The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.": [
    0.03452569246292114,
    0.9624870419502258,
    0.002987195271998644
  ],
  "Here, we exploit existing genome-wide association study data to gain insight into the role of genetics in prognosis.||The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.": [
    0.06729517132043839,
    0.8638626933097839,
    0.06884206086397171
  ],
  "We identify a noncoding polymorphism in FOXO3A (rs12212067: T > G) at which the minor (G) allele, despite not being associated with disease susceptibility, is associated with a milder course of Crohn's disease and rheumatoid arthritis and with increased risk of severe malaria.||The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.": [
    0.1674290895462036,
    0.8193625211715698,
    0.013208410702645779
  ],
  "Minor allele carriage is shown to limit inflammatory responses in monocytes via a FOXO3-driven pathway, which through TGF\u03b21 reduces production of proinflammatory cytokines, including TNF\u03b1, and increases production of anti-inflammatory cytokines, including IL-10.||The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.": [
    0.007290865294635296,
    0.8956543207168579,
    0.09705480933189392
  ],
  "Thus, we uncover a shared genetic contribution to prognosis in distinct diseases that operates via a FOXO3-driven pathway modulating inflammatory responses.||The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.": [
    0.0031556442845612764,
    0.9798398613929749,
    0.01700454391539097
  ],
  "The clinical course and eventual outcome, or prognosis, of complex diseases varies enormously between affected individuals.||The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.": [
    0.011313633993268013,
    0.9822831749916077,
    0.006403173319995403
  ],
  "This variability critically determines the impact a disease has on a patient's life but is very poorly understood.||The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.": [
    0.0018591369735077024,
    0.997078537940979,
    0.00106240704189986
  ],
  "Here, we exploit existing genome-wide association study data to gain insight into the role of genetics in prognosis.||The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.": [
    0.002204288262873888,
    0.9945675134658813,
    0.0032282653264701366
  ],
  "We identify a noncoding polymorphism in FOXO3A (rs12212067: T > G) at which the minor (G) allele, despite not being associated with disease susceptibility, is associated with a milder course of Crohn's disease and rheumatoid arthritis and with increased risk of severe malaria.||The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.": [
    0.0013274032389745116,
    0.007399400230497122,
    0.9912732243537903
  ],
  "Minor allele carriage is shown to limit inflammatory responses in monocytes via a FOXO3-driven pathway, which through TGF\u03b21 reduces production of proinflammatory cytokines, including TNF\u03b1, and increases production of anti-inflammatory cytokines, including IL-10.||The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.": [
    0.06271098554134369,
    0.932461678981781,
    0.0048273405991494656
  ],
  "Thus, we uncover a shared genetic contribution to prognosis in distinct diseases that operates via a FOXO3-driven pathway modulating inflammatory responses.||The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.": [
    0.001174170058220625,
    0.9974260926246643,
    0.0013996772468090057
  ],
  "The clinical course and eventual outcome, or prognosis, of complex diseases varies enormously between affected individuals.||The minor G allele of FOXO3 up-regulates IL-10.": [
    0.27225029468536377,
    0.5035601854324341,
    0.22418951988220215
  ],
  "This variability critically determines the impact a disease has on a patient's life but is very poorly understood.||The minor G allele of FOXO3 up-regulates IL-10.": [
    0.054350096732378006,
    0.9404249787330627,
    0.005224866326898336
  ],
  "Here, we exploit existing genome-wide association study data to gain insight into the role of genetics in prognosis.||The minor G allele of FOXO3 up-regulates IL-10.": [
    0.07658126205205917,
    0.8181667327880859,
    0.1052519753575325
  ],
  "We identify a noncoding polymorphism in FOXO3A (rs12212067: T > G) at which the minor (G) allele, despite not being associated with disease susceptibility, is associated with a milder course of Crohn's disease and rheumatoid arthritis and with increased risk of severe malaria.||The minor G allele of FOXO3 up-regulates IL-10.": [
    0.11021551489830017,
    0.8862079381942749,
    0.003576552029699087
  ],
  "Minor allele carriage is shown to limit inflammatory responses in monocytes via a FOXO3-driven pathway, which through TGF\u03b21 reduces production of proinflammatory cytokines, including TNF\u03b1, and increases production of anti-inflammatory cytokines, including IL-10.||The minor G allele of FOXO3 up-regulates IL-10.": [
    0.024208776652812958,
    0.6349077224731445,
    0.3408834934234619
  ],
  "Thus, we uncover a shared genetic contribution to prognosis in distinct diseases that operates via a FOXO3-driven pathway modulating inflammatory responses.||The minor G allele of FOXO3 up-regulates IL-10.": [
    0.002158795716241002,
    0.995826780796051,
    0.0020144530571997166
  ],
  "The clinical course and eventual outcome, or prognosis, of complex diseases varies enormously between affected individuals.||The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.": [
    0.005942482501268387,
    0.9905130863189697,
    0.003544385312125087
  ],
  "This variability critically determines the impact a disease has on a patient's life but is very poorly understood.||The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.": [
    0.0016020725015550852,
    0.9972834587097168,
    0.0011144746094942093
  ],
  "Here, we exploit existing genome-wide association study data to gain insight into the role of genetics in prognosis.||The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.": [
    0.019018929451704025,
    0.9774981737136841,
    0.0034828679636120796
  ],
  "We identify a noncoding polymorphism in FOXO3A (rs12212067: T > G) at which the minor (G) allele, despite not being associated with disease susceptibility, is associated with a milder course of Crohn's disease and rheumatoid arthritis and with increased risk of severe malaria.||The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.": [
    0.9982925057411194,
    0.0010583262192085385,
    0.0006491416716016829
  ],
  "Minor allele carriage is shown to limit inflammatory responses in monocytes via a FOXO3-driven pathway, which through TGF\u03b21 reduces production of proinflammatory cytokines, including TNF\u03b1, and increases production of anti-inflammatory cytokines, including IL-10.||The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.": [
    0.18933136761188507,
    0.8077461123466492,
    0.0029225493781268597
  ],
  "Thus, we uncover a shared genetic contribution to prognosis in distinct diseases that operates via a FOXO3-driven pathway modulating inflammatory responses.||The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.": [
    0.51012122631073,
    0.48698556423187256,
    0.0028931922279298306
  ],
  "Human astrocytes are larger and more complex than those of infraprimate mammals, suggesting that their role in neural processing has expanded with evolution.||Transplanted human glial progenitor cells can mature in their host animal.": [
    0.027392340824007988,
    0.5578758120536804,
    0.41473186016082764
  ],
  "To assess the cell-autonomous and species-selective properties of human glia, we engrafted human glial progenitor cells (GPCs) into neonatal immunodeficient mice.||Transplanted human glial progenitor cells can mature in their host animal.": [
    0.00432091997936368,
    0.7050532102584839,
    0.2906258702278137
  ],
  "Upon maturation, the recipient brains exhibited large numbers and high proportions of both human glial progenitors and astrocytes.||Transplanted human glial progenitor cells can mature in their host animal.": [
    0.0024407703895121813,
    0.0586867518723011,
    0.9388723969459534
  ],
  "The engrafted human glia were gap-junction-coupled to host astroglia, yet retained the size and pleomorphism of hominid astroglia, and propagated Ca2+ signals 3-fold faster than their hosts.||Transplanted human glial progenitor cells can mature in their host animal.": [
    0.012581990100443363,
    0.22481882572174072,
    0.7625992298126221
  ],
  "Long-term potentiation (LTP) was sharply enhanced in the human glial chimeric mice, as was their learning, as assessed by Barnes maze navigation, object-location memory, and both contextual and tone fear conditioning.||Transplanted human glial progenitor cells can mature in their host animal.": [
    0.012882237322628498,
    0.2441353052854538,
    0.7429825067520142
  ],
  "Mice allografted with murine GPCs showed no enhancement of either LTP or learning.||Transplanted human glial progenitor cells can mature in their host animal.": [
    0.5657780766487122,
    0.29231807589530945,
    0.1419038623571396
  ],
  "These findings indicate that human glia differentially enhance both activity-dependent plasticity and learning in mice.||Transplanted human glial progenitor cells can mature in their host animal.": [
    0.008761164732277393,
    0.38561302423477173,
    0.6056258082389832
  ],
  "Human astrocytes are larger and more complex than those of infraprimate mammals, suggesting that their role in neural processing has expanded with evolution.||Transplanted human glial cells can differentiate within the host animal.": [
    0.01007133163511753,
    0.3592382073402405,
    0.6306905150413513
  ],
  "To assess the cell-autonomous and species-selective properties of human glia, we engrafted human glial progenitor cells (GPCs) into neonatal immunodeficient mice.||Transplanted human glial cells can differentiate within the host animal.": [
    0.005901299882680178,
    0.4121840000152588,
    0.5819147229194641
  ],
  "Upon maturation, the recipient brains exhibited large numbers and high proportions of both human glial progenitors and astrocytes.||Transplanted human glial cells can differentiate within the host animal.": [
    0.003587515791878104,
    0.10660936683416367,
    0.8898031711578369
  ],
  "The engrafted human glia were gap-junction-coupled to host astroglia, yet retained the size and pleomorphism of hominid astroglia, and propagated Ca2+ signals 3-fold faster than their hosts.||Transplanted human glial cells can differentiate within the host animal.": [
    0.017394164577126503,
    0.24257323145866394,
    0.7400325536727905
  ],
  "Long-term potentiation (LTP) was sharply enhanced in the human glial chimeric mice, as was their learning, as assessed by Barnes maze navigation, object-location memory, and both contextual and tone fear conditioning.||Transplanted human glial cells can differentiate within the host animal.": [
    0.026129238307476044,
    0.31321537494659424,
    0.6606554388999939
  ],
  "Mice allografted with murine GPCs showed no enhancement of either LTP or learning.||Transplanted human glial cells can differentiate within the host animal.": [
    0.29764166474342346,
    0.4768243134021759,
    0.22553397715091705
  ],
  "These findings indicate that human glia differentially enhance both activity-dependent plasticity and learning in mice.||Transplanted human glial cells can differentiate within the host animal.": [
    0.0021493779495358467,
    0.14359569549560547,
    0.854254961013794
  ],
  "Human astrocytes are larger and more complex than those of infraprimate mammals, suggesting that their role in neural processing has expanded with evolution.||Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.": [
    0.9863887429237366,
    0.012910820543766022,
    0.0007004138315096498
  ],
  "To assess the cell-autonomous and species-selective properties of human glia, we engrafted human glial progenitor cells (GPCs) into neonatal immunodeficient mice.||Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.": [
    0.8949477076530457,
    0.10275895893573761,
    0.0022933422587811947
  ],
  "Upon maturation, the recipient brains exhibited large numbers and high proportions of both human glial progenitors and astrocytes.||Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.": [
    0.9334926009178162,
    0.06413339078426361,
    0.0023740679025650024
  ],
  "The engrafted human glia were gap-junction-coupled to host astroglia, yet retained the size and pleomorphism of hominid astroglia, and propagated Ca2+ signals 3-fold faster than their hosts.||Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.": [
    0.9966446161270142,
    0.0028840387240052223,
    0.00047128889127634466
  ],
  "Long-term potentiation (LTP) was sharply enhanced in the human glial chimeric mice, as was their learning, as assessed by Barnes maze navigation, object-location memory, and both contextual and tone fear conditioning.||Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.": [
    0.9943581223487854,
    0.005030523054301739,
    0.0006112898699939251
  ],
  "Mice allografted with murine GPCs showed no enhancement of either LTP or learning.||Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.": [
    0.4121917188167572,
    0.5364482402801514,
    0.05136002600193024
  ],
  "These findings indicate that human glia differentially enhance both activity-dependent plasticity and learning in mice.||Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.": [
    0.9981847405433655,
    0.0015901225851848722,
    0.0002251873374916613
  ],
  "OBJECTIVE To determine whether ultrasound imaging can reduce the risk of failed lumbar punctures or epidural catheterisations, when compared with standard palpation methods, and whether ultrasound imaging can reduce traumatic procedures, insertion attempts, and needle redirections.   \n||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.023467492312192917,
    0.9694757461547852,
    0.007056704722344875
  ],
  "DESIGN Systematic review and meta-analysis of randomised controlled trials.   \n||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.3209995627403259,
    0.6475094556808472,
    0.0314909927546978
  ],
  "DATA SOURCES Ovid Medline, Embase, and Cochrane Central Register of Controlled Trials up to May 2012, without restriction by language or publication status.   ||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.07493731379508972,
    0.9155521988868713,
    0.009510435163974762
  ],
  "REVIEW METHODS Randomised trials that compared ultrasound imaging with standard methods (no imaging) in the performance of a lumbar puncture or epidural catheterisation were identified.   \n||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.0064789000898599625,
    0.9924744963645935,
    0.001046591205522418
  ],
  "RESULTS 14 studies with a total of 1334 patients were included (674 patients assigned to the ultrasound group, 660 to the control group).||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.002040412975475192,
    0.9970356225967407,
    0.0009239270002581179
  ],
  "Five studies evaluated lumbar punctures and nine evaluated epidural catheterisations.||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.03357267379760742,
    0.9654409289360046,
    0.0009863858576864004
  ],
  "Six of 624 procedures conducted in the ultrasound group failed; 44 of 610 procedures in the control group failed.||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.01997360959649086,
    0.9772979021072388,
    0.0027284654788672924
  ],
  "Ultrasound imaging reduced the risk of failed procedures (risk ratio 0.21 (95% confidence interval 0.10 to 0.43), P<0.001).||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.0014291922561824322,
    0.9968569278717041,
    0.0017138747498393059
  ],
  "Risk reduction was similar when subgroup analysis was performed for lumbar punctures (risk ratio 0.19 (0.07 to 0.56), P=0.002) or epidural catheterisations (0.23 (0.09 to 0.60), P=0.003).||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.06691964715719223,
    0.923322856426239,
    0.009757534600794315
  ],
  "Ultrasound imaging also significantly reduced the risk of traumatic procedures (risk ratio 0.27 (0.11 to 0.67), P=0.005), the number of insertion attempts (mean difference -0.44 (-0.64 to -0.24), P<0.001), and the number of needle redirections (mean difference -1.00 (-1.24 to -0.75), P<0.001).   \n||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.003789405571296811,
    0.06529295444488525,
    0.9309176802635193
  ],
  "CONCLUSIONS Ultrasound imaging can reduce the risk of failed or traumatic lumbar punctures and epidural catheterisations, as well as the number of needle insertions and redirections.||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.0026818932965397835,
    0.5139676332473755,
    0.4833504557609558
  ],
  "Ultrasound may be a useful adjunct for these procedures.||Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.": [
    0.0012619212502613664,
    0.9977390766143799,
    0.0009989571990445256
  ],
  "OBJECTIVE To determine whether ultrasound imaging can reduce the risk of failed lumbar punctures or epidural catheterisations, when compared with standard palpation methods, and whether ultrasound imaging can reduce traumatic procedures, insertion attempts, and needle redirections.   \n||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.025411177426576614,
    0.9701569676399231,
    0.004431800451129675
  ],
  "DESIGN Systematic review and meta-analysis of randomised controlled trials.   \n||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.18431879580020905,
    0.777851939201355,
    0.037829313427209854
  ],
  "DATA SOURCES Ovid Medline, Embase, and Cochrane Central Register of Controlled Trials up to May 2012, without restriction by language or publication status.   ||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.067286916077137,
    0.9184224605560303,
    0.014290586113929749
  ],
  "REVIEW METHODS Randomised trials that compared ultrasound imaging with standard methods (no imaging) in the performance of a lumbar puncture or epidural catheterisation were identified.   \n||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.006940316408872604,
    0.9920652508735657,
    0.0009944047778844833
  ],
  "RESULTS 14 studies with a total of 1334 patients were included (674 patients assigned to the ultrasound group, 660 to the control group).||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.0025641454849392176,
    0.9965103268623352,
    0.0009255486656911671
  ],
  "Five studies evaluated lumbar punctures and nine evaluated epidural catheterisations.||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.0268398504704237,
    0.9722183346748352,
    0.0009417926776222885
  ],
  "Six of 624 procedures conducted in the ultrasound group failed; 44 of 610 procedures in the control group failed.||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.0033563452307134867,
    0.9951549768447876,
    0.0014886336866766214
  ],
  "Ultrasound imaging reduced the risk of failed procedures (risk ratio 0.21 (95% confidence interval 0.10 to 0.43), P<0.001).||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.0010084917303174734,
    0.997654139995575,
    0.00133744056802243
  ],
  "Risk reduction was similar when subgroup analysis was performed for lumbar punctures (risk ratio 0.19 (0.07 to 0.56), P=0.002) or epidural catheterisations (0.23 (0.09 to 0.60), P=0.003).||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.1306993067264557,
    0.8572313785552979,
    0.01206936128437519
  ],
  "Ultrasound imaging also significantly reduced the risk of traumatic procedures (risk ratio 0.27 (0.11 to 0.67), P=0.005), the number of insertion attempts (mean difference -0.44 (-0.64 to -0.24), P<0.001), and the number of needle redirections (mean difference -1.00 (-1.24 to -0.75), P<0.001).   \n||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.009868987835943699,
    0.11267010122537613,
    0.8774610161781311
  ],
  "CONCLUSIONS Ultrasound imaging can reduce the risk of failed or traumatic lumbar punctures and epidural catheterisations, as well as the number of needle insertions and redirections.||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.006219995208084583,
    0.5772565603256226,
    0.41652345657348633
  ],
  "Ultrasound may be a useful adjunct for these procedures.||Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.": [
    0.002011991338804364,
    0.9971686005592346,
    0.0008194532128982246
  ],
  "OBJECTIVE To determine whether ultrasound imaging can reduce the risk of failed lumbar punctures or epidural catheterisations, when compared with standard palpation methods, and whether ultrasound imaging can reduce traumatic procedures, insertion attempts, and needle redirections.   \n||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.9979585409164429,
    0.0016648350283503532,
    0.0003766578738577664
  ],
  "DESIGN Systematic review and meta-analysis of randomised controlled trials.   \n||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.4049893319606781,
    0.5796487331390381,
    0.01536194421350956
  ],
  "DATA SOURCES Ovid Medline, Embase, and Cochrane Central Register of Controlled Trials up to May 2012, without restriction by language or publication status.   ||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.2770492732524872,
    0.7080007791519165,
    0.014949950389564037
  ],
  "REVIEW METHODS Randomised trials that compared ultrasound imaging with standard methods (no imaging) in the performance of a lumbar puncture or epidural catheterisation were identified.   \n||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.3309481143951416,
    0.6661326289176941,
    0.002919229445978999
  ],
  "RESULTS 14 studies with a total of 1334 patients were included (674 patients assigned to the ultrasound group, 660 to the control group).||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.048570144921541214,
    0.9495164752006531,
    0.001913403975777328
  ],
  "Five studies evaluated lumbar punctures and nine evaluated epidural catheterisations.||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.161185622215271,
    0.8359915018081665,
    0.002822846407070756
  ],
  "Six of 624 procedures conducted in the ultrasound group failed; 44 of 610 procedures in the control group failed.||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.06568833440542221,
    0.9313927888870239,
    0.0029187952168285847
  ],
  "Ultrasound imaging reduced the risk of failed procedures (risk ratio 0.21 (95% confidence interval 0.10 to 0.43), P<0.001).||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.9867429733276367,
    0.012189801782369614,
    0.0010672489879652858
  ],
  "Risk reduction was similar when subgroup analysis was performed for lumbar punctures (risk ratio 0.19 (0.07 to 0.56), P=0.002) or epidural catheterisations (0.23 (0.09 to 0.60), P=0.003).||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.9723009467124939,
    0.025691138580441475,
    0.0020079815294593573
  ],
  "Ultrasound imaging also significantly reduced the risk of traumatic procedures (risk ratio 0.27 (0.11 to 0.67), P=0.005), the number of insertion attempts (mean difference -0.44 (-0.64 to -0.24), P<0.001), and the number of needle redirections (mean difference -1.00 (-1.24 to -0.75), P<0.001).   \n||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.9982105493545532,
    0.00113086705096066,
    0.0006586491945199668
  ],
  "CONCLUSIONS Ultrasound imaging can reduce the risk of failed or traumatic lumbar punctures and epidural catheterisations, as well as the number of needle insertions and redirections.||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.9992550015449524,
    0.0005234979325905442,
    0.00022148812422528863
  ],
  "Ultrasound may be a useful adjunct for these procedures.||Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.": [
    0.6336314678192139,
    0.3630675971508026,
    0.003300958313047886
  ],
  "OBJECTIVE To assess the effect of 25-hydroxyvitamin D (25-OHD) levels on pregnancy outcomes and birth variables.   \n||Vitamin D deficiency effects birth weight.": [
    0.021562421694397926,
    0.9174084067344666,
    0.061029188334941864
  ],
  "DESIGN Systematic review and meta-analysis.   \n||Vitamin D deficiency effects birth weight.": [
    0.06251049786806107,
    0.6917847394943237,
    0.2457047551870346
  ],
  "DATA SOURCES Medline (1966 to August 2012), PubMed (2008 to August 2012), Embase (1980 to August 2012), CINAHL (1981 to August 2012), the Cochrane database of systematic reviews, and the Cochrane database of registered clinical trials.   ||Vitamin D deficiency effects birth weight.": [
    0.044943053275346756,
    0.7329217195510864,
    0.2221352458000183
  ],
  "STUDY SELECTION Studies reporting on the association between serum 25-OHD levels during pregnancy and the outcomes of interest (pre-eclampsia, gestational diabetes, bacterial vaginosis, caesarean section, small for gestational age infants, birth weight, birth length, and head circumference).   \n||Vitamin D deficiency effects birth weight.": [
    0.05176973342895508,
    0.9229048490524292,
    0.02532537281513214
  ],
  "DATA EXTRACTION Two authors independently extracted data from original research articles, including key indicators of study quality.||Vitamin D deficiency effects birth weight.": [
    0.07975262403488159,
    0.6816080212593079,
    0.23863938450813293
  ],
  "We pooled the most adjusted odds ratios and weighted mean differences.||Vitamin D deficiency effects birth weight.": [
    0.03387904912233353,
    0.6549221873283386,
    0.31119877099990845
  ],
  "Associations were tested in subgroups representing different patient characteristics and study quality.   \n||Vitamin D deficiency effects birth weight.": [
    0.061634376645088196,
    0.7138016223907471,
    0.22456404566764832
  ],
  "RESULTS 3357 studies were identified and reviewed for eligibility.||Vitamin D deficiency effects birth weight.": [
    0.03236115351319313,
    0.6534364223480225,
    0.3142023980617523
  ],
  "31 eligible studies were included in the final analysis.||Vitamin D deficiency effects birth weight.": [
    0.03537926822900772,
    0.6297252774238586,
    0.33489546179771423
  ],
  "Insufficient serum levels of 25-OHD were associated with gestational diabetes (pooled odds ratio 1.49, 95% confidence interval 1.18 to 1.89), pre-eclampsia (1.79, 1.25 to 2.58), and small for gestational age infants (1.85, 1.52 to 2.26).||Vitamin D deficiency effects birth weight.": [
    0.2323242425918579,
    0.5787385702133179,
    0.18893718719482422
  ],
  "Pregnant women with low serum 25-OHD levels had an increased risk of bacterial vaginosis and low birthweight infants but not delivery by caesarean section.   \n||Vitamin D deficiency effects birth weight.": [
    0.045638710260391235,
    0.7831358313560486,
    0.17122547328472137
  ],
  "CONCLUSION Vitamin D insufficiency is associated with an increased risk of gestational diabetes, pre-eclampsia, and small for gestational age infants.||Vitamin D deficiency effects birth weight.": [
    0.013098690658807755,
    0.17113454639911652,
    0.8157667517662048
  ],
  "Pregnant women with low 25-OHD levels had an increased risk of bacterial vaginosis and lower birth weight infants, but not delivery by caesarean section.||Vitamin D deficiency effects birth weight.": [
    0.025746790692210197,
    0.6174055933952332,
    0.3568475842475891
  ],
  "OBJECTIVE To assess the effect of 25-hydroxyvitamin D (25-OHD) levels on pregnancy outcomes and birth variables.   \n||Vitamin D deficiency effects the term of delivery.": [
    0.027276471257209778,
    0.8616043925285339,
    0.11111915111541748
  ],
  "DESIGN Systematic review and meta-analysis.   \n||Vitamin D deficiency effects the term of delivery.": [
    0.0691305547952652,
    0.7335389256477356,
    0.197330504655838
  ],
  "DATA SOURCES Medline (1966 to August 2012), PubMed (2008 to August 2012), Embase (1980 to August 2012), CINAHL (1981 to August 2012), the Cochrane database of systematic reviews, and the Cochrane database of registered clinical trials.   ||Vitamin D deficiency effects the term of delivery.": [
    0.041718315333127975,
    0.8332523703575134,
    0.12502937018871307
  ],
  "STUDY SELECTION Studies reporting on the association between serum 25-OHD levels during pregnancy and the outcomes of interest (pre-eclampsia, gestational diabetes, bacterial vaginosis, caesarean section, small for gestational age infants, birth weight, birth length, and head circumference).   \n||Vitamin D deficiency effects the term of delivery.": [
    0.06095324084162712,
    0.821654200553894,
    0.11739252507686615
  ],
  "DATA EXTRACTION Two authors independently extracted data from original research articles, including key indicators of study quality.||Vitamin D deficiency effects the term of delivery.": [
    0.06888870149850845,
    0.6808856725692749,
    0.250225692987442
  ],
  "We pooled the most adjusted odds ratios and weighted mean differences.||Vitamin D deficiency effects the term of delivery.": [
    0.04495170712471008,
    0.6761763691902161,
    0.27887195348739624
  ],
  "Associations were tested in subgroups representing different patient characteristics and study quality.   \n||Vitamin D deficiency effects the term of delivery.": [
    0.08229078352451324,
    0.7615686058998108,
    0.15614062547683716
  ],
  "RESULTS 3357 studies were identified and reviewed for eligibility.||Vitamin D deficiency effects the term of delivery.": [
    0.04576348885893822,
    0.7211486101150513,
    0.2330879420042038
  ],
  "31 eligible studies were included in the final analysis.||Vitamin D deficiency effects the term of delivery.": [
    0.04178295284509659,
    0.7043058276176453,
    0.25391116738319397
  ],
  "Insufficient serum levels of 25-OHD were associated with gestational diabetes (pooled odds ratio 1.49, 95% confidence interval 1.18 to 1.89), pre-eclampsia (1.79, 1.25 to 2.58), and small for gestational age infants (1.85, 1.52 to 2.26).||Vitamin D deficiency effects the term of delivery.": [
    0.19125139713287354,
    0.605614960193634,
    0.20313362777233124
  ],
  "Pregnant women with low serum 25-OHD levels had an increased risk of bacterial vaginosis and low birthweight infants but not delivery by caesarean section.   \n||Vitamin D deficiency effects the term of delivery.": [
    0.04646764695644379,
    0.833175539970398,
    0.12035684287548065
  ],
  "CONCLUSION Vitamin D insufficiency is associated with an increased risk of gestational diabetes, pre-eclampsia, and small for gestational age infants.||Vitamin D deficiency effects the term of delivery.": [
    0.15944595634937286,
    0.6621367335319519,
    0.17841725051403046
  ],
  "Pregnant women with low 25-OHD levels had an increased risk of bacterial vaginosis and lower birth weight infants, but not delivery by caesarean section.||Vitamin D deficiency effects the term of delivery.": [
    0.04621847718954086,
    0.7140475511550903,
    0.23973394930362701
  ],
  "OBJECTIVE To assess the effect of 25-hydroxyvitamin D (25-OHD) levels on pregnancy outcomes and birth variables.   \n||Vitamin D deficiency is unrelated to birth weight.": [
    0.7660066485404968,
    0.22854307293891907,
    0.005450261756777763
  ],
  "DESIGN Systematic review and meta-analysis.   \n||Vitamin D deficiency is unrelated to birth weight.": [
    0.72906494140625,
    0.2408481240272522,
    0.030086949467658997
  ],
  "DATA SOURCES Medline (1966 to August 2012), PubMed (2008 to August 2012), Embase (1980 to August 2012), CINAHL (1981 to August 2012), the Cochrane database of systematic reviews, and the Cochrane database of registered clinical trials.   ||Vitamin D deficiency is unrelated to birth weight.": [
    0.7762354016304016,
    0.20706789195537567,
    0.01669677160680294
  ],
  "STUDY SELECTION Studies reporting on the association between serum 25-OHD levels during pregnancy and the outcomes of interest (pre-eclampsia, gestational diabetes, bacterial vaginosis, caesarean section, small for gestational age infants, birth weight, birth length, and head circumference).   \n||Vitamin D deficiency is unrelated to birth weight.": [
    0.7821745872497559,
    0.21450771391391754,
    0.003317712340503931
  ],
  "DATA EXTRACTION Two authors independently extracted data from original research articles, including key indicators of study quality.||Vitamin D deficiency is unrelated to birth weight.": [
    0.787186861038208,
    0.19927284121513367,
    0.013540280051529408
  ],
  "We pooled the most adjusted odds ratios and weighted mean differences.||Vitamin D deficiency is unrelated to birth weight.": [
    0.7260379791259766,
    0.24314895272254944,
    0.030813096091151237
  ],
  "Associations were tested in subgroups representing different patient characteristics and study quality.   \n||Vitamin D deficiency is unrelated to birth weight.": [
    0.7206031084060669,
    0.2553996741771698,
    0.02399723045527935
  ],
  "RESULTS 3357 studies were identified and reviewed for eligibility.||Vitamin D deficiency is unrelated to birth weight.": [
    0.6761202216148376,
    0.29097995162010193,
    0.03289983421564102
  ],
  "31 eligible studies were included in the final analysis.||Vitamin D deficiency is unrelated to birth weight.": [
    0.7174670696258545,
    0.2528519034385681,
    0.02968106046319008
  ],
  "Insufficient serum levels of 25-OHD were associated with gestational diabetes (pooled odds ratio 1.49, 95% confidence interval 1.18 to 1.89), pre-eclampsia (1.79, 1.25 to 2.58), and small for gestational age infants (1.85, 1.52 to 2.26).||Vitamin D deficiency is unrelated to birth weight.": [
    0.6650621891021729,
    0.32850074768066406,
    0.00643713166937232
  ],
  "Pregnant women with low serum 25-OHD levels had an increased risk of bacterial vaginosis and low birthweight infants but not delivery by caesarean section.   \n||Vitamin D deficiency is unrelated to birth weight.": [
    0.8340014219284058,
    0.1617041826248169,
    0.0042943404987454414
  ],
  "CONCLUSION Vitamin D insufficiency is associated with an increased risk of gestational diabetes, pre-eclampsia, and small for gestational age infants.||Vitamin D deficiency is unrelated to birth weight.": [
    0.8566433191299438,
    0.137776717543602,
    0.0055798920802772045
  ],
  "Pregnant women with low 25-OHD levels had an increased risk of bacterial vaginosis and lower birth weight infants, but not delivery by caesarean section.||Vitamin D deficiency is unrelated to birth weight.": [
    0.8902960419654846,
    0.1059819757938385,
    0.0037219671066850424
  ],
  "Monitoring cancer and aging in vivo remains experimentally challenging.||p16INK4A degradation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.07335785776376724,
    0.9045132398605347,
    0.022128906100988388
  ],
  "Here, we describe a luciferase knockin mouse (p16(LUC)), which faithfully reports expression of p16(INK4a), a tumor suppressor and aging biomarker.||p16INK4A degradation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.7098483443260193,
    0.2864511013031006,
    0.0037005410995334387
  ],
  "Lifelong assessment of luminescence in p16(+/LUC) mice revealed an exponential increase with aging, which was highly variable in a cohort of contemporaneously housed, syngeneic mice.||p16INK4A degradation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.20511934161186218,
    0.7858698964118958,
    0.009010780602693558
  ],
  "Expression of p16(INK4a) with aging did not predict cancer development, suggesting that the accumulation of senescent cells is not a principal determinant of cancer-related death.||p16INK4A degradation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.20303712785243988,
    0.7915596961975098,
    0.005403205286711454
  ],
  "In 14 of 14 tested tumor models, expression of p16(LUC) was focally activated by early neoplastic events, enabling visualization of tumors with sensitivity exceeding other imaging modalities.||p16INK4A degradation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.5880330801010132,
    0.40542182326316833,
    0.006545165553689003
  ],
  "Activation of p16(INK4a) was noted in the emerging neoplasm and surrounding stromal cells.||p16INK4A degradation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.9613999724388123,
    0.03660259023308754,
    0.001997428247705102
  ],
  "This work suggests that p16(INK4a) activation is a characteristic of all emerging cancers, making the p16(LUC) allele a sensitive, unbiased reporter of neoplastic transformation.||p16INK4A degradation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.9723033308982849,
    0.02531057596206665,
    0.002386026317253709
  ],
  "Monitoring cancer and aging in vivo remains experimentally challenging.||p16INK4A degradation is encoded by CDKN2A.": [
    0.3707226514816284,
    0.5202983617782593,
    0.10897904634475708
  ],
  "Here, we describe a luciferase knockin mouse (p16(LUC)), which faithfully reports expression of p16(INK4a), a tumor suppressor and aging biomarker.||p16INK4A degradation is encoded by CDKN2A.": [
    0.7288548350334167,
    0.2647736072540283,
    0.006371505092829466
  ],
  "Lifelong assessment of luminescence in p16(+/LUC) mice revealed an exponential increase with aging, which was highly variable in a cohort of contemporaneously housed, syngeneic mice.||p16INK4A degradation is encoded by CDKN2A.": [
    0.5885571837425232,
    0.399303138256073,
    0.012139593251049519
  ],
  "Expression of p16(INK4a) with aging did not predict cancer development, suggesting that the accumulation of senescent cells is not a principal determinant of cancer-related death.||p16INK4A degradation is encoded by CDKN2A.": [
    0.2934446930885315,
    0.700620710849762,
    0.005934595130383968
  ],
  "In 14 of 14 tested tumor models, expression of p16(LUC) was focally activated by early neoplastic events, enabling visualization of tumors with sensitivity exceeding other imaging modalities.||p16INK4A degradation is encoded by CDKN2A.": [
    0.7050347328186035,
    0.2870907187461853,
    0.007874608039855957
  ],
  "Activation of p16(INK4a) was noted in the emerging neoplasm and surrounding stromal cells.||p16INK4A degradation is encoded by CDKN2A.": [
    0.8566417694091797,
    0.13839852809906006,
    0.004959706217050552
  ],
  "This work suggests that p16(INK4a) activation is a characteristic of all emerging cancers, making the p16(LUC) allele a sensitive, unbiased reporter of neoplastic transformation.||p16INK4A degradation is encoded by CDKN2A.": [
    0.7469721436500549,
    0.24966022372245789,
    0.003367640543729067
  ],
  "Monitoring cancer and aging in vivo remains experimentally challenging.||p16INK4A accumulation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.0802619606256485,
    0.9060556292533875,
    0.013682412914931774
  ],
  "Here, we describe a luciferase knockin mouse (p16(LUC)), which faithfully reports expression of p16(INK4a), a tumor suppressor and aging biomarker.||p16INK4A accumulation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.1430419683456421,
    0.8517805337905884,
    0.005177525337785482
  ],
  "Lifelong assessment of luminescence in p16(+/LUC) mice revealed an exponential increase with aging, which was highly variable in a cohort of contemporaneously housed, syngeneic mice.||p16INK4A accumulation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.08463869988918304,
    0.9086641073226929,
    0.0066971867345273495
  ],
  "Expression of p16(INK4a) with aging did not predict cancer development, suggesting that the accumulation of senescent cells is not a principal determinant of cancer-related death.||p16INK4A accumulation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.22541573643684387,
    0.7700150012969971,
    0.0045692953281104565
  ],
  "In 14 of 14 tested tumor models, expression of p16(LUC) was focally activated by early neoplastic events, enabling visualization of tumors with sensitivity exceeding other imaging modalities.||p16INK4A accumulation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.3311830163002014,
    0.6475834846496582,
    0.021233495324850082
  ],
  "Activation of p16(INK4a) was noted in the emerging neoplasm and surrounding stromal cells.||p16INK4A accumulation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.039412934333086014,
    0.9496278762817383,
    0.0109592629596591
  ],
  "This work suggests that p16(INK4a) activation is a characteristic of all emerging cancers, making the p16(LUC) allele a sensitive, unbiased reporter of neoplastic transformation.||p16INK4A accumulation is  linked to an abnormal wound response caused by the microinvasive step of advanced Oral Potentially Malignant Lesions (OPMLs).": [
    0.16631093621253967,
    0.8148365020751953,
    0.01885257102549076
  ],
  "Allergic asthma is a T helper type 2 (T(H)2)-dominated disease of the lung.||CX3CR1 on the Th2 cells impairs T cell survival": [
    0.05384863168001175,
    0.933210551738739,
    0.012940876185894012
  ],
  "In people with asthma, a fraction of CD4(+) T cells express the CX3CL1 receptor, CX3CR1, and CX3CL1 expression is increased in airway smooth muscle, lung endothelium and epithelium upon allergen challenge.||CX3CR1 on the Th2 cells impairs T cell survival": [
    0.3430452346801758,
    0.6351649165153503,
    0.02178989350795746
  ],
  "Here we found that untreated CX3CR1-deficient mice or wild-type (WT) mice treated with CX3CR1-blocking reagents show reduced lung disease upon allergen sensitization and challenge.||CX3CR1 on the Th2 cells impairs T cell survival": [
    0.06409860402345657,
    0.9219629168510437,
    0.013938406482338905
  ],
  "Transfer of WT CD4(+) T cells into CX3CR1-deficient mice restored the cardinal features of asthma, and CX3CR1-blocking reagents prevented airway inflammation in CX3CR1-deficient recipients injected with WT T(H)2 cells.||CX3CR1 on the Th2 cells impairs T cell survival": [
    0.16263769567012787,
    0.7660620212554932,
    0.07130030542612076
  ],
  "We found that CX3CR1 signaling promoted T(H)2 survival in the inflamed lungs, and injection of B cell leukemia/lymphoma-2 protein (BCl-2)-transduced CX3CR1-deficient T(H)2 cells into CX3CR1-deficient mice restored asthma.||CX3CR1 on the Th2 cells impairs T cell survival": [
    0.9837473034858704,
    0.013661578297615051,
    0.0025911154225468636
  ],
  "CX3CR1-induced survival was also observed for T(H)1 cells upon airway inflammation but not under homeostatic conditions or upon peripheral inflammation.||CX3CR1 on the Th2 cells impairs T cell survival": [
    0.9529423117637634,
    0.042870741337537766,
    0.004186905920505524
  ],
  "Therefore, CX3CR1 and CX3CL1 may represent attractive therapeutic targets in asthma.||CX3CR1 on the Th2 cells impairs T cell survival": [
    0.18025469779968262,
    0.8104064464569092,
    0.0093388631939888
  ],
  "Allergic asthma is a T helper type 2 (T(H)2)-dominated disease of the lung.||CX3CR1 on the Th2 cells promotes T cell survival": [
    0.04640359804034233,
    0.9362152814865112,
    0.017381101846694946
  ],
  "In people with asthma, a fraction of CD4(+) T cells express the CX3CL1 receptor, CX3CR1, and CX3CL1 expression is increased in airway smooth muscle, lung endothelium and epithelium upon allergen challenge.||CX3CR1 on the Th2 cells promotes T cell survival": [
    0.02372795343399048,
    0.942736804485321,
    0.03353526443243027
  ],
  "Here we found that untreated CX3CR1-deficient mice or wild-type (WT) mice treated with CX3CR1-blocking reagents show reduced lung disease upon allergen sensitization and challenge.||CX3CR1 on the Th2 cells promotes T cell survival": [
    0.3458293080329895,
    0.6446133255958557,
    0.009557378478348255
  ],
  "Transfer of WT CD4(+) T cells into CX3CR1-deficient mice restored the cardinal features of asthma, and CX3CR1-blocking reagents prevented airway inflammation in CX3CR1-deficient recipients injected with WT T(H)2 cells.||CX3CR1 on the Th2 cells promotes T cell survival": [
    0.16966471076011658,
    0.7362533807754517,
    0.09408193826675415
  ],
  "We found that CX3CR1 signaling promoted T(H)2 survival in the inflamed lungs, and injection of B cell leukemia/lymphoma-2 protein (BCl-2)-transduced CX3CR1-deficient T(H)2 cells into CX3CR1-deficient mice restored asthma.||CX3CR1 on the Th2 cells promotes T cell survival": [
    0.034288838505744934,
    0.7100796103477478,
    0.25563156604766846
  ],
  "CX3CR1-induced survival was also observed for T(H)1 cells upon airway inflammation but not under homeostatic conditions or upon peripheral inflammation.||CX3CR1 on the Th2 cells promotes T cell survival": [
    0.20564115047454834,
    0.717536985874176,
    0.07682184875011444
  ],
  "Therefore, CX3CR1 and CX3CL1 may represent attractive therapeutic targets in asthma.||CX3CR1 on the Th2 cells promotes T cell survival": [
    0.09911125153303146,
    0.8944945931434631,
    0.006394172552973032
  ],
  "Allergic asthma is a T helper type 2 (T(H)2)-dominated disease of the lung.||CX3CR1 on the Th2 cells promotes airway inflammation.": [
    0.05149830877780914,
    0.9208207726478577,
    0.027680935338139534
  ],
  "In people with asthma, a fraction of CD4(+) T cells express the CX3CL1 receptor, CX3CR1, and CX3CL1 expression is increased in airway smooth muscle, lung endothelium and epithelium upon allergen challenge.||CX3CR1 on the Th2 cells promotes airway inflammation.": [
    0.7879860401153564,
    0.17485998570919037,
    0.037153907120227814
  ],
  "Here we found that untreated CX3CR1-deficient mice or wild-type (WT) mice treated with CX3CR1-blocking reagents show reduced lung disease upon allergen sensitization and challenge.||CX3CR1 on the Th2 cells promotes airway inflammation.": [
    0.17749188840389252,
    0.7835877537727356,
    0.03892035409808159
  ],
  "Transfer of WT CD4(+) T cells into CX3CR1-deficient mice restored the cardinal features of asthma, and CX3CR1-blocking reagents prevented airway inflammation in CX3CR1-deficient recipients injected with WT T(H)2 cells.||CX3CR1 on the Th2 cells promotes airway inflammation.": [
    0.9848928451538086,
    0.011075769551098347,
    0.004031435586512089
  ],
  "We found that CX3CR1 signaling promoted T(H)2 survival in the inflamed lungs, and injection of B cell leukemia/lymphoma-2 protein (BCl-2)-transduced CX3CR1-deficient T(H)2 cells into CX3CR1-deficient mice restored asthma.||CX3CR1 on the Th2 cells promotes airway inflammation.": [
    0.8457006812095642,
    0.08906994014978409,
    0.06522940844297409
  ],
  "CX3CR1-induced survival was also observed for T(H)1 cells upon airway inflammation but not under homeostatic conditions or upon peripheral inflammation.||CX3CR1 on the Th2 cells promotes airway inflammation.": [
    0.7989181876182556,
    0.14045795798301697,
    0.060623832046985626
  ],
  "Therefore, CX3CR1 and CX3CL1 may represent attractive therapeutic targets in asthma.||CX3CR1 on the Th2 cells promotes airway inflammation.": [
    0.7904391884803772,
    0.20368383824825287,
    0.0058770254254341125
  ],
  "Allergic asthma is a T helper type 2 (T(H)2)-dominated disease of the lung.||CX3CR1 on the Th2 cells suppresses airway inflammation.": [
    0.3592853248119354,
    0.6267836689949036,
    0.013931021094322205
  ],
  "In people with asthma, a fraction of CD4(+) T cells express the CX3CL1 receptor, CX3CR1, and CX3CL1 expression is increased in airway smooth muscle, lung endothelium and epithelium upon allergen challenge.||CX3CR1 on the Th2 cells suppresses airway inflammation.": [
    0.2448968142271042,
    0.41280364990234375,
    0.3422994613647461
  ],
  "Here we found that untreated CX3CR1-deficient mice or wild-type (WT) mice treated with CX3CR1-blocking reagents show reduced lung disease upon allergen sensitization and challenge.||CX3CR1 on the Th2 cells suppresses airway inflammation.": [
    0.31909990310668945,
    0.6228413581848145,
    0.05805877596139908
  ],
  "Transfer of WT CD4(+) T cells into CX3CR1-deficient mice restored the cardinal features of asthma, and CX3CR1-blocking reagents prevented airway inflammation in CX3CR1-deficient recipients injected with WT T(H)2 cells.||CX3CR1 on the Th2 cells suppresses airway inflammation.": [
    0.10310705751180649,
    0.1886124312877655,
    0.7082805037498474
  ],
  "We found that CX3CR1 signaling promoted T(H)2 survival in the inflamed lungs, and injection of B cell leukemia/lymphoma-2 protein (BCl-2)-transduced CX3CR1-deficient T(H)2 cells into CX3CR1-deficient mice restored asthma.||CX3CR1 on the Th2 cells suppresses airway inflammation.": [
    0.48290926218032837,
    0.266094446182251,
    0.25099626183509827
  ],
  "CX3CR1-induced survival was also observed for T(H)1 cells upon airway inflammation but not under homeostatic conditions or upon peripheral inflammation.||CX3CR1 on the Th2 cells suppresses airway inflammation.": [
    0.9419497847557068,
    0.04832029342651367,
    0.009729927405714989
  ],
  "Therefore, CX3CR1 and CX3CL1 may represent attractive therapeutic targets in asthma.||CX3CR1 on the Th2 cells suppresses airway inflammation.": [
    0.05356955900788307,
    0.9419586658477783,
    0.004471749532967806
  ],
  "Delayed T cell recovery and restricted T cell receptor (TCR) diversity after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are associated with increased risks of infection and cancer relapse.||Transferred UCB T cells acquire a memory-like phenotype in recipients.": [
    0.15496599674224854,
    0.8359606862068176,
    0.009073292836546898
  ],
  "Technical challenges have limited faithful measurement of TCR diversity after allo-HSCT.||Transferred UCB T cells acquire a memory-like phenotype in recipients.": [
    0.058973588049411774,
    0.8660044074058533,
    0.07502197474241257
  ],
  "Here we combined 5' rapid amplification of complementary DNA ends PCR with deep sequencing to quantify TCR diversity in 28 recipients of allo-HSCT using a single oligonucleotide pair.||Transferred UCB T cells acquire a memory-like phenotype in recipients.": [
    0.023115579038858414,
    0.9412478804588318,
    0.03563658148050308
  ],
  "Analysis of duplicate blood samples confirmed that we accurately determined the frequency of individual TCRs.||Transferred UCB T cells acquire a memory-like phenotype in recipients.": [
    0.14433062076568604,
    0.5847142934799194,
    0.2709551453590393
  ],
  "After 6 months, cord blood-graft recipients approximated the TCR diversity of healthy individuals, whereas recipients of T cell-depleted peripheral-blood stem cell grafts had 28-fold and 14-fold lower CD4(+) and CD8(+) T cell diversities, respectively.||Transferred UCB T cells acquire a memory-like phenotype in recipients.": [
    0.07614587247371674,
    0.8682054281234741,
    0.05564866214990616
  ],
  "After 12 months, these deficiencies had improved for the CD4(+) but not the CD8(+) T cell compartment.||Transferred UCB T cells acquire a memory-like phenotype in recipients.": [
    0.0645189881324768,
    0.919923722743988,
    0.015557288192212582
  ],
  "Overall, this method provides unprecedented views of T cell repertoire recovery after allo-HSCT and may identify patients at high risk of infection or relapse.||Transferred UCB T cells acquire a memory-like phenotype in recipients.": [
    0.02002423256635666,
    0.9681107401847839,
    0.011864961124956608
  ],
  "Delayed T cell recovery and restricted T cell receptor (TCR) diversity after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are associated with increased risks of infection and cancer relapse.||UCB T cells maintain high TCR diversity after transplantation.": [
    0.9477429986000061,
    0.050024934113025665,
    0.002232031198218465
  ],
  "Technical challenges have limited faithful measurement of TCR diversity after allo-HSCT.||UCB T cells maintain high TCR diversity after transplantation.": [
    0.5783502459526062,
    0.4161253869533539,
    0.005524314008653164
  ],
  "Here we combined 5' rapid amplification of complementary DNA ends PCR with deep sequencing to quantify TCR diversity in 28 recipients of allo-HSCT using a single oligonucleotide pair.||UCB T cells maintain high TCR diversity after transplantation.": [
    0.2065596878528595,
    0.7627821564674377,
    0.030658163130283356
  ],
  "Analysis of duplicate blood samples confirmed that we accurately determined the frequency of individual TCRs.||UCB T cells maintain high TCR diversity after transplantation.": [
    0.07101873308420181,
    0.9138582348823547,
    0.015123063698410988
  ],
  "After 6 months, cord blood-graft recipients approximated the TCR diversity of healthy individuals, whereas recipients of T cell-depleted peripheral-blood stem cell grafts had 28-fold and 14-fold lower CD4(+) and CD8(+) T cell diversities, respectively.||UCB T cells maintain high TCR diversity after transplantation.": [
    0.8060915470123291,
    0.1768358200788498,
    0.017072532325983047
  ],
  "After 12 months, these deficiencies had improved for the CD4(+) but not the CD8(+) T cell compartment.||UCB T cells maintain high TCR diversity after transplantation.": [
    0.5898630619049072,
    0.4029446840286255,
    0.007192237768322229
  ],
  "Overall, this method provides unprecedented views of T cell repertoire recovery after allo-HSCT and may identify patients at high risk of infection or relapse.||UCB T cells maintain high TCR diversity after transplantation.": [
    0.4387527108192444,
    0.5366071462631226,
    0.024640150368213654
  ],
  "Delayed T cell recovery and restricted T cell receptor (TCR) diversity after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are associated with increased risks of infection and cancer relapse.||UCB T cells reduce TCR diversity after transplantation.": [
    0.04304732009768486,
    0.8352150917053223,
    0.12173757702112198
  ],
  "Technical challenges have limited faithful measurement of TCR diversity after allo-HSCT.||UCB T cells reduce TCR diversity after transplantation.": [
    0.1709396094083786,
    0.7837415933609009,
    0.04531878978013992
  ],
  "Here we combined 5' rapid amplification of complementary DNA ends PCR with deep sequencing to quantify TCR diversity in 28 recipients of allo-HSCT using a single oligonucleotide pair.||UCB T cells reduce TCR diversity after transplantation.": [
    0.2856810986995697,
    0.7064026594161987,
    0.00791624654084444
  ],
  "Analysis of duplicate blood samples confirmed that we accurately determined the frequency of individual TCRs.||UCB T cells reduce TCR diversity after transplantation.": [
    0.07638690620660782,
    0.9146428108215332,
    0.00897026713937521
  ],
  "After 6 months, cord blood-graft recipients approximated the TCR diversity of healthy individuals, whereas recipients of T cell-depleted peripheral-blood stem cell grafts had 28-fold and 14-fold lower CD4(+) and CD8(+) T cell diversities, respectively.||UCB T cells reduce TCR diversity after transplantation.": [
    0.03054969012737274,
    0.26952481269836426,
    0.6999254822731018
  ],
  "After 12 months, these deficiencies had improved for the CD4(+) but not the CD8(+) T cell compartment.||UCB T cells reduce TCR diversity after transplantation.": [
    0.06618968397378922,
    0.8924731016159058,
    0.04133719205856323
  ],
  "Overall, this method provides unprecedented views of T cell repertoire recovery after allo-HSCT and may identify patients at high risk of infection or relapse.||UCB T cells reduce TCR diversity after transplantation.": [
    0.6064489483833313,
    0.3484521508216858,
    0.04509884864091873
  ]
}